0001356090-15-000066.txt : 20151110 0001356090-15-000066.hdr.sgml : 20151110 20151109163939 ACCESSION NUMBER: 0001356090-15-000066 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151109 DATE AS OF CHANGE: 20151109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTREXON CORP CENTRAL INDEX KEY: 0001356090 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36042 FILM NUMBER: 151216226 BUSINESS ADDRESS: STREET 1: 1750 KRAFT DRIVE STREET 2: SUITE 1400 CITY: BLACKSBURG STATE: VA ZIP: 24060 BUSINESS PHONE: 301-556-9809 MAIL ADDRESS: STREET 1: 1750 KRAFT DRIVE STREET 2: SUITE 1400 CITY: BLACKSBURG STATE: VA ZIP: 24060 10-Q 1 xon-20150930x10q.htm 10-Q 10-Q
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
FORM 10-Q
x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2015
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     .
Commission File Number: 001-36042
 INTREXON CORPORATION
(Exact name of registrant as specified in its charter)
Virginia
 
26-0084895
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification Number)
 
 
 
20374 Seneca Meadows Parkway
Germantown, Maryland
 
20876
(Address of principal executive offices)
 
(Zip Code)
(301) 556-9900
(Registrant's telephone number, including area code) 
(Former name, former address and former fiscal year, if changed since last report date) 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
 
x
  
Accelerated filer
 
¨
 
 
 
 
Non-accelerated filer
 
¨  (Do not check if a smaller reporting company)
  
Smaller reporting company
 
¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x
As of October 31, 2015, 116,397,980 shares of common stock, no par value per share, were outstanding.


INTREXON CORPORATION
FORM 10-Q
TABLE OF CONTENTS
 
Item No.
 
Page
1.
 
 
 
 
 
 
2.
3.
4.
 
1.
1A.
2.
6.
 
Intrexon®, Arctic®, UltraVector®, RheoSwitch Therapeutic System®, RTS®, Better DNA®, Trans Ova Genetics®, Multiply Success® and LEAP® are our and/or our affiliates’ registered trademarks in the United States and ActoBiotics™, BeyondBio™, AttSite™, mAbLogix™ and TopAct™ are our common law trademarks in the United States. This quarterly report and the information incorporated herein by reference contain references to trademarks, service marks and trade names owned by us or other companies. Solely for convenience, trademarks, service marks and trade names referred to in this quarterly report and the information incorporated herein, including logos, artwork, and other visual displays, may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks and trade names. We do not intend our use or display of other companies' trade names, service marks or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Other trademarks, trade names and service marks appearing in this quarterly report are the property of their respective owners.


2


Special Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Quarterly Report on Form 10-Q regarding our strategy, future events, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about:
 
•
our current and future exclusive channel collaborations ("ECCs"), license agreements and other collaborations and agreements;
•
developments concerning our collaborators and licensees;
•
our ability to successfully enter new markets or develop additional products, whether with our collaborators or independently;
•
competition from existing technologies and products or new technologies and products that may emerge;
•
actual or anticipated variations in our operating results;
•
actual or anticipated fluctuations in our competitors' or our collaborators' and licensees' operating results or changes in their respective growth rates;
•
our cash position;
•
market conditions in our industry;
•
our ability, and the ability of our collaborators and licensees, to protect our intellectual property and other proprietary rights and technologies;
•
our ability, and the ability of our collaborators and licensees, to adapt to changes in laws or regulations and policies;
•
the ability of our collaborators and licensees to secure any necessary regulatory approvals to commercialize any products developed under the ECCs and license agreements;
•
the rate and degree of market acceptance of any products developed by a collaborator under an ECC or through a joint venture or license under a license agreement;
•
our ability to retain and recruit key personnel;
•
our expectations related to the use of proceeds from our public offerings and other financing efforts; and
•
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.
Forward-looking statements may also concern our expectations relating to our subsidiaries and other affiliates. We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q.
We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q, particularly in Part II, Item 1A. "Risk Factors," that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.

3

You should read this Quarterly Report on Form 10-Q, the documents that we reference in this Quarterly Report on Form 10-Q, our Annual Report on Form 10-K for the year ended December 31, 2014 and the documents that we have filed as exhibits to our filings with the Securities and Exchange Commission completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


4

PART I. FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements

5

Intrexon Corporation and Subsidiaries
Consolidated Balance Sheets
(Unaudited) 
(Amounts in thousands, except share data)
September 30,
2015
 
December 31,
2014
Assets
 
 
 
Current assets
 
 
 
Cash and cash equivalents
$
125,433

 
$
27,466

Short-term investments
90,864

 
88,495

Receivables
 
 
 
Trade, net
25,153

 
14,582

Related parties
28,801

 
12,622

Note
—

 
1,501

Other
1,912

 
559

Inventory
22,338

 
25,789

Prepaid expenses and other
7,930

 
3,759

Total current assets
302,431

 
174,773

Long-term investments
136,266

 
27,113

Equity securities
76,623

 
164,889

Property, plant and equipment, net
42,201

 
38,000

Intangible assets, net
256,284

 
65,947

Goodwill
166,866

 
101,059

Investments in affiliates
3,790

 
3,220

Other assets
5,426

 
1,271

Total assets
$
989,887

 
$
576,272

Liabilities and Total Equity
 
 
 
Current liabilities
 
 
 
Accounts payable
$
4,546

 
$
6,267

Accrued compensation and benefits
14,475

 
7,736

Other accrued liabilities
7,918

 
5,731

Deferred revenue
32,006

 
16,522

Lines of credit
475

 
2,273

Current portion of long term debt
1,314

 
1,675

Current portion of deferred consideration
16,212

 
7,064

Related party payables
147

 
214

Total current liabilities
77,093

 
47,482

Long term debt, net of current portion
7,796

 
8,694

Deferred consideration, net of current portion
8,710

 
13,421

Deferred revenue, net of current portion
144,248

 
96,687

Deferred tax liabilities
21,550

 
—

Other long term liabilities
867

 
699

Total liabilities
260,264

 
166,983

Commitments and contingencies (Note 16)

 

Total equity
 
 
 
Common stock, no par value, 200,000,000 shares authorized as of September 30, 2015 and December 31, 2014; 116,359,041 and 100,557,932 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively
—

 
—

Additional paid-in capital
1,233,497

 
843,001

Accumulated deficit
(510,015
)
 
(458,236
)
Accumulated other comprehensive loss
(5,195
)
 
(4
)
Total Intrexon shareholders' equity
718,287

 
384,761

Noncontrolling interests
11,336

 
24,528

Total equity
729,623

 
409,289

Total liabilities and total equity
$
989,887

 
$
576,272

The accompanying notes are an integral part of these consolidated financial statements.

6

Intrexon Corporation and Subsidiaries
Consolidated Statements of Operations
(Unaudited)
 
(Amounts in thousands, except share and per share data)
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
2015
 
2014
 
2015
 
2014
Revenues
 
 
 
 
 
 
 
Collaboration and licensing revenues
$
34,726

 
$
12,656

 
$
66,690

 
$
32,257

Product revenues
9,446

 
4,115

 
32,645

 
4,124

Service revenues
8,945

 
4,261

 
32,157

 
4,261

Other revenues
250

 
165

 
615

 
196

Total revenues
53,367

 
21,197

 
132,107

 
40,838

Operating Expenses
 
 
 
 
 
 
 
Cost of products
11,215

 
4,224

 
31,654

 
4,310

Cost of services
5,451

 
2,316

 
17,316

 
2,316

Research and development
21,598

 
14,851

 
121,286

 
41,343

Selling, general and administrative
23,019

 
14,853

 
74,320

 
43,870

Total operating expenses
61,283

 
36,244

 
244,576

 
91,839

Operating loss
(7,916
)
 
(15,047
)
 
(112,469
)
 
(51,001
)
Other Income (Expense), Net
 
 
 
 
 
 
 
Unrealized and realized appreciation (depreciation) in fair value of equity securities
(30,453
)
 
(37,089
)
 
64,392

 
(48,944
)
Interest expense
(310
)
 
(230
)
 
(1,012
)
 
(309
)
Interest income
567

 
202

 
1,211

 
349

Other income (expense), net
589

 
(79
)
 
530

 
(110
)
Total other income (expense), net
(29,607
)
 
(37,196
)
 
65,121

 
(49,014
)
Equity in net loss of affiliates
(2,429
)
 
(1,619
)
 
(6,565
)
 
(3,510
)
Loss before income taxes
(39,952
)
 
(53,862
)
 
(53,913
)
 
(103,525
)
Income tax benefit (expense)
923

 
—

 
(806
)
 
(23
)
Net loss
$
(39,029
)
 
$
(53,862
)
 
$
(54,719
)
 
$
(103,548
)
Net loss attributable to the noncontrolling interests
816

 
1,137

 
2,940

 
2,895

Net loss attributable to Intrexon
$
(38,213
)
 
$
(52,725
)
 
$
(51,779
)
 
$
(100,653
)
Net loss attributable to Intrexon per share, basic and diluted
$
(0.34
)
 
$
(0.53
)
 
$
(0.47
)
 
$
(1.02
)
Weighted average shares outstanding, basic and diluted
112,244,129

 
99,888,203

 
109,244,641

 
98,711,564

The accompanying notes are an integral part of these consolidated financial statements.


7

Intrexon Corporation and Subsidiaries
Consolidated Statements of Comprehensive Loss
(Unaudited)
 
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
(Amounts in thousands)
2015
 
2014
 
2015
 
2014
Net loss
$
(39,029
)
 
$
(53,862
)
 
$
(54,719
)
 
$
(103,548
)
Other comprehensive income (loss):
 
 
 
 
 
 
 
Unrealized gain on investments
230

 
4

 
249

 
95

Foreign currency translation adjustments
(3,102
)
 
39

 
(5,374
)
 
(28
)
Comprehensive loss
(41,901
)
 
(53,819
)
 
(59,844
)
 
(103,481
)
Comprehensive loss attributable to the noncontrolling interests
778

 
1,111

 
2,874

 
2,874

Comprehensive loss attributable to Intrexon
$
(41,123
)
 
$
(52,708
)
 
$
(56,970
)
 
$
(100,607
)
The accompanying notes are an integral part of these consolidated financial statements.


8

Intrexon Corporation and Subsidiaries
Consolidated Statements of Shareholders' and Total Equity
(Unaudited)
 
(Amounts in thousands, except share data)
Common Stock
 
Additional
Paid-in
Capital
 
Accumulated
Other
Comprehensive
Loss
 
Accumulated
Deficit
 
Total
Intrexon
Shareholders'
Equity
 
Noncontrolling
Interests
 
Total
Equity
Shares
 
Amount
 
 
 
 
 
 
Balances at December 31, 2014
100,557,932

 
$
—

 
$
843,001

 
$
(4
)
 
$
(458,236
)
 
$
384,761

 
$
24,528

 
$
409,289

Stock-based compensation expense
—

 
—

 
26,388

 
—

 
—

 
26,388

 
161

 
26,549

Exercises of stock options and warrants
909,437

 
—

 
12,208

 
—

 
—

 
12,208

 
—

 
12,208

Shares issued to nonemployee members of the Board of Directors
10,106

 
—

 
480

 
—

 
—

 
480

 
—

 
480

Shares issued in public offerings, net of issuance costs
9,922,256

 
—

 
328,234

 
—

 
—

 
328,234

 
—

 
328,234

Shares issued as consideration of license agreement
2,100,085

 
—

 
59,579

 
—

 
—

 
59,579

 
—

 
59,579

Shares issued in acquisitions
2,552,151

 
—

 
126,863

 
—

 
—

 
126,863

 
—

 
126,863

Acquisition of noncontrolling interest
307,074

 
—

 
9,412

 
—

 
—

 
9,412

 
(10,978
)
 
(1,566
)
Adjustments for noncontrolling interests
—

 
—

 
(249
)
 
—

 
—

 
(249
)
 
499

 
250

Noncash dividend
—

 
—

 
(172,419
)
 
—

 
—

 
(172,419
)
 
—

 
(172,419
)
Net loss
—

 
—

 
—

 
—

 
(51,779
)
 
(51,779
)
 
(2,940
)
 
(54,719
)
Other comprehensive income (loss)
—

 
—

 
—

 
(5,191
)
 
—

 
(5,191
)
 
66

 
(5,125
)
Balances at September 30, 2015
116,359,041

 
$
—

 
$
1,233,497

 
$
(5,195
)
 
$
(510,015
)
 
$
718,287

 
$
11,336

 
$
729,623

The accompanying notes are an integral part of these consolidated financial statements


9

Intrexon Corporation and Subsidiaries
Consolidated Statements of Cash Flows
(Unaudited)
 
 
Nine Months Ended 
 September 30,
(Amounts in thousands)
2015
 
2014
Cash flows from operating activities
 
 
 
Net loss
$
(54,719
)
 
$
(103,548
)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
 
 
 
Depreciation and amortization
12,202

 
6,870

Loss on disposal of property, plant and equipment
519

 
170

Unrealized and realized (appreciation) depreciation on equity securities
(64,392
)
 
48,944

Amortization of discount/premium on investments
298

 
1,121

Equity in net loss of affiliates
6,565

 
3,510

Stock-based compensation expense
26,524

 
14,872

Contribution of services by shareholder
—

 
1,485

Shares issued to nonemployee members of the Board of Directors
480

 
486

Shares issued as consideration for license agreement
59,579

 
—

Provision for bad debts
1,562

 
74

Deferred income taxes
374

 
—

Other noncash items
305

 
244

Changes in operating assets and liabilities:
 
 
 
Receivables:
 
 
 
Trade
(12,014
)
 
3,443

Related parties
(11,182
)
 
(5,168
)
Note
1

 
—

Other
6,390

 
(41
)
Inventory
3,451

 
582

Prepaid expenses and other
(4,005
)
 
(679
)
Other assets
(3,817
)
 
89

Accounts payable
(3,560
)
 
(1,197
)
Accrued compensation and benefits
5,895

 
545

Other accrued liabilities
1,323

 
(820
)
Deferred revenue
52,400

 
18,636

Deferred consideration
(943
)
 
—

Related party payables
(67
)
 
(192
)
Other long term liabilities
168

 
(234
)
Net cash provided by (used in) operating activities
23,337

 
(10,808
)
The accompanying notes are an integral part of these consolidated financial statements.

10


Intrexon Corporation and Subsidiaries
Consolidated Statements of Cash Flows
(Unaudited)
 
 
Nine Months Ended 
 September 30,
(Amounts in thousands)
2015
 
2014
Cash flows from investing activities
 
 
 
Purchases of investments
(181,572
)
 
(60,478
)
Maturities of investments
70,000

 
98,245

Purchases of equity securities and warrants
(17,080
)
 
—

Acquisitions of businesses, net of cash received
(114,480
)
 
(67,117
)
Acquisition of noncontrolling interest
(1,566
)
 
—

Investments in affiliates
(4,699
)
 
(2,105
)
Purchases of property, plant and equipment
(9,841
)
 
(5,190
)
Proceeds from sale of property, plant and equipment
420

 
151

Proceeds from notes receivable
1,500

 
—

Net cash used in investing activities
(257,318
)
 
(36,494
)
Cash flows from financing activities
 
 
 
Proceeds from issuance of shares in a private placement
—

 
25,000

Proceeds from issuance of shares in public offerings, net of issuance costs
328,234

 
—

Advances from lines of credit
13,719

 
678

Repayments of advances from lines of credit
(15,517
)
 
(4,213
)
Proceeds from long term debt
81

 
268

Payments of long term debt
(1,032
)
 
(156
)
Payments of deferred consideration
(6,252
)
 
—

Proceeds from stock option exercises
12,208

 
1,274

Payment of stock issuance costs
—

 
(256
)
Net cash provided by financing activities
331,441

 
22,595

Effect of exchange rate changes on cash and cash equivalents
507

 
(98
)
Net increase (decrease) in cash and cash equivalents
97,967

 
(24,805
)
Cash and cash equivalents
 
 
 
Beginning of period
27,466

 
49,509

End of period
$
125,433

 
$
24,704

Supplemental disclosure of cash flow information
 
 
 
Cash paid during the period for interest
$
1,119

 
$
47

Cash paid during the period for income taxes
1,165

 
—

Significant noncash financing and investing activities
 
 
 
Note receivable as consideration for upfront fee from collaborator
$
5,000

 
$
10,000

Stock received as consideration for collaboration agreements
4,667

 
5,225

Stock issued in acquisitions, net
126,863

 
51,682

Stock issued to acquire noncontrolling interest
9,412

 
—

Noncash dividend to shareholders
172,419

 
—

Deferred consideration payable related to acquisition
11,440

 
20,115

Purchases of equipment included in accounts payable and other accrued liabilities
533

 
—

The accompanying notes are an integral part of these consolidated financial statements.

11

Intrexon Corporation and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
(Amounts in thousands, except share and per share data)
1. Organization and Basis of Presentation
Intrexon Corporation ("Intrexon"), a Virginia corporation, forms collaborations to create biologically based products and processes using synthetic biology. Intrexon has domestic operations in California, Florida, Maryland, and Virginia, and foreign operations in Belgium and Hungary. There have been no commercialized products derived from Intrexon's collaborations to date.
Trans Ova Genetics, L.C. and Subsidiaries ("Trans Ova"), a provider of bovine reproductive technologies and other genetic processes to cattle breeders and producers, is a wholly owned subsidiary of Intrexon with primary operations in Iowa, Maryland, Missouri, Oklahoma, and Texas (Note 3). ViaGen, L.C. ("ViaGen"), a provider of genetic preservation and cloning technologies, is a wholly owned subsidiary of Trans Ova. Exemplar Genetics, LLC ("Exemplar"), a provider of genetically engineered swine for medical and genetic research, is a wholly owned subsidiary through the combined investments of Intrexon, Trans Ova, and ViaGen.
Intrexon Produce Holdings, Inc. ("IPHI") is a wholly owned subsidiary of Intrexon. Okanagan Specialty Fruits, Inc. ("Okanagan"), a company which developed and received regulatory approval for the world's first non-browning apple without the use of any flavor-altering chemical or antioxidant additives, is a wholly owned subsidiary of IPHI with primary operations in Canada (Note 3). Fruit Orchard Holdings, Inc. ("FOHI") is a wholly owned subsidiary of IPHI with primary operations in Washington.
Oxitec Limited ("Oxitec"), a pioneering company in biological insect control solutions, is a wholly owned subsidiary of Intrexon with primary operations in England and Brazil (Note 3).
As of September 30, 2015, Intrexon owned approximately 63% of AquaBounty, a biotechnology company focused on improving productivity in commercial aquaculture.
At September 30, 2015, Intrexon owned approximately 51% of Biological & Popular Culture, Inc. ("BioPop").
Intrexon Corporation and its consolidated subsidiaries are hereinafter referred to as the "Company."
These consolidated financial statements are presented in United States dollars and are prepared under accounting principles generally accepted in the United States of America ("U.S. GAAP").
2. Summary of Significant Accounting Policies
Principles of Consolidation
The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.
Unaudited Financial Information
The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with U.S. GAAP. Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of September 30, 2015 and results of operations and cash flows for the interim periods ended September 30, 2015 and 2014. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2015, or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014.

12

Revenue Recognition
The Company generates revenue through contractual agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement, (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement, (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities, and (iv) royalties on sales of products arising from the collaboration or licensing agreement.
The Company's collaboration and licensing agreements typically contain multiple elements, or deliverables, including technology licenses, research and development services, and in certain cases manufacturing services. The Company identifies the deliverables within the agreements and evaluates which deliverables represent separate units of accounting. Analyzing the agreements to identify deliverables requires the use of judgment. A deliverable is considered a separate unit of accounting when the deliverable has value to the collaborator or licensee on a standalone basis based on the consideration of the relevant facts and circumstances for each agreement.
Consideration received is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. When available, the relative selling price for each deliverable is determined using vendor specific objective evidence ("VSOE") of the selling price or third-party evidence of the selling price, if VSOE does not exist. If neither VSOE nor third-party evidence of the selling price exists, the Company uses its best estimate of the selling price ("BESP") for the deliverable. The amount of allocable consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. The Company recognizes the revenue allocated to each unit of accounting as the Company delivers the related goods or services. If the Company determines that certain deliverables should be treated as a single unit of accounting, then the revenue is recognized using either a proportional performance or straight-line method, depending on whether the Company can reasonably estimate the level of effort required to complete its performance obligations under an arrangement and whether such performance obligations are provided on a best-efforts basis. As the Company cannot reasonably estimate its performance obligations related to its collaborators or licensees, the Company recognizes revenue on a straight-line basis over the period it expects to complete its performance obligations.
The terms of the Company's agreements may provide for milestone payments upon achievement of certain defined events. The Company applies the Milestone Method for recognizing milestone payments. Under the Milestone Method, the Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:
(1)
The consideration is commensurate with either the entity's performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the entity's performance to achieve the milestone;
(2)
The consideration relates solely to past performance; and
(3)
The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.
In the event that a milestone is not considered substantive, the Company recognizes the milestone consideration as revenue using the same method applied to upfront payments.
Research and development services are a deliverable satisfied by the Company in accordance with the terms of the collaboration and licensing agreements and the Company considers these services to be inseparable from the license to the core technology; therefore, reimbursements of services performed are recognized as revenue. Because reimbursement (i) is contingent upon performance of the services by the Company, (ii) does not include a profit component, and (iii) does not relate to any future deliverable, the revenue is recognized during the period in which the related services are performed and collection of such amounts is reasonably assured. Payments received for manufacturing services will be recognized when the earnings process related to the manufactured materials has been completed. Royalties to be received under the agreements will be recognized as earned.

13

From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. When no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue.
The Company also generates products and services revenue through sales of advanced reproductive technologies, including bovine embryos derived from the Company's embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock used in production. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) services have been rendered or delivery has occurred such that risk of loss has passed to the customer, (iii) the price is fixed or determinable, and (iv) collection from the customer is reasonably assured.
Research and Development
The Company considers that regulatory and other uncertainties inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, and the costs of consultants, certain in-licensed technology rights, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Indirect research and development costs include depreciation, amortization and other indirect overhead expenses.
The Company has research and development arrangements with third parties that include upfront and milestone payments and primarily relate to collaborations. At September 30, 2015 and December 31, 2014, the Company had research and development commitments with third parties that had not yet been incurred totaling $6,576 and $2,183, respectively. The commitments are generally cancellable by the Company at any time upon written notice.
Cash and Cash Equivalents
All highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions with high quality credit ratings. Recoverability of investments is dependent upon the performance of the issuer. At September 30, 2015 and December 31, 2014, the Company had cash equivalent investments in highly liquid money market accounts at major financial institutions of $93,158 and $16,598, respectively.
Short-term and Long-term Investments
At September 30, 2015, investments include short-term and long-term investments in U.S. government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company's written investment policy requires investments to be explicitly rated by two of the three following rating services: Standard & Poor's, Moody's and/or Fitch and to have a minimum rating of A1, P1 and/or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer.
Equity Securities
The Company holds equity securities received and/or purchased from certain collaborators. Other than investments accounted for using the equity method, the Company elected the fair value option to account for its equity securities held in these collaborators. These equity securities are recorded at fair value at each reporting date and are subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments are reported in the consolidated statement of operations. The fair value of these equity securities is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these collaborators. These equity securities are classified as noncurrent in the consolidated balance sheet since the Company does not intend to sell these equity securities within one year.
The Company records the fair value of securities received on the date the collaboration is consummated or the milestone is achieved using the closing, quoted price of the collaborator's security on that date, assuming the transfer of consideration is considered perfunctory. If the transfer of the consideration is not considered perfunctory, the Company considers the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluates whether

14

any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concludes that a discount should be applied, the fair value of the securities is adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.
Fair Value of Financial Instruments
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:
Level 1:
 
Quoted prices in active markets for identical assets and liabilities;
 
 
Level 2:
 
Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and
 
 
Level 3:
 
Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.
Concentrations of Risk
Due to the Company's mix of fixed and variable rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of September 30, 2015, gross unrealized losses on the Company's short-term and long-term investments were immaterial. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses.
Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of trade receivables. The Company controls credit risk through credit approvals, credit limits and monitoring procedures. The Company performs ongoing credit evaluations of its customers, but generally does not require collateral to support accounts receivable.
Equity Method Investments
The Company is party to three strategic joint ventures (Note 4). The Company accounts for its investments in these joint ventures and for its investment in Thrive Agrobiotics, Inc. ("Thrive Agrobiotics") (Note 5) using the equity method of accounting since the Company has the ability to exercise significant influence, but not control, over the operating activities of these entities.
The Company determined that it has significant influence over one of its collaborators, Oragenics, Inc. ("Oragenics"), as of September 30, 2015, and over two of its collaborators, Oragenics and ZIOPHARM Oncology, Inc. ("ZIOPHARM"), as of December 31, 2014, based on its ownership interests, representation on the board of directors of the collaborators and other qualitative factors. The Company accounts for its investments in Oragenics and ZIOPHARM using the fair value option.
The fair value of the Company's equity securities of Oragenics was $13,475 and $7,192 as of September 30, 2015 and December 31, 2014, respectively, and is included as equity securities in the respective consolidated balance sheets. The Company's ownership percentage of Oragenics was 24.2% and 24.4% at September 30, 2015 and December 31, 2014, respectively. Unrealized appreciation (depreciation) in the fair value of the Company's equity securities held in Oragenics was $2,404 and $(5,487) for the three months ended September 30, 2015 and 2014, respectively, and was $6,283 and $(11,890) for the nine months ended September 30, 2015 and 2014, respectively.
In June 2015, the Company distributed all of its holdings in ZIOPHARM to the Company's shareholders in the form of a special stock dividend (Note 13). Upon disposition, the Company realized a gain of $81,401 for the three months ended June 30, 2015. As of December 31, 2014, the Company's ownership percentage of ZIOPHARM was 15.7% and the fair value of the Company's equity securities of ZIOPHARM was $83,099 and is included as equity securities in the December 31, 2014 consolidated balance sheet. Unrealized depreciation in the fair value of the Company's equity securities held in ZIOPHARM was $22,783 and $27,864 for the three and nine months ended September 30, 2014, respectively.

15

Summarized unaudited financial data as of September 30, 2015 and December 31, 2014 and for the three and nine months ended September 30, 2015 and 2014, for the Company's equity method investments are as follows:
 
September 30,
2015
 
December 31, 2014
Current assets
$
12,225

 
$
63,627

Non-current assets
462

 
1,259

Total assets
12,687

 
64,886

Current liabilities
10,121

 
15,346

Non-current liabilities
—

 
570

Total liabilities
10,121

 
15,916

Net assets
$
2,566

 
$
48,970


 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Revenues
$
330

 
$
834

 
$
1,389

 
$
1,753

Operating expenses
7,020

 
17,052

 
114,023

 
46,266

Loss from operations
(6,690
)
 
(16,218
)
 
(112,634
)
 
(44,513
)
Other
(34
)
 
5,854

 
(33
)
 
11,543

Net loss
$
(6,724
)
 
$
(10,364
)
 
$
(112,667
)
 
$
(32,970
)
Variable Interest Entities
The Company identifies entities that (i) do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIE" or "VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE.
As of September 30, 2015 and December 31, 2014, the Company determined that certain of its collaborators and joint ventures were VIEs. As of September 30, 2015, the Company also determined that Harvest Intrexon Enterprise Fund I, LP ("Harvest") (Note 17) was a VIE. The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. The Company's aggregate investment balances of these VIEs as of September 30, 2015 was $1,909, which represents the Company's maximum risk of loss related to the identified VIEs. As of December 31, 2014, the Company did not hold any investment balances in the identified VIEs and therefore had no risk of loss as of that date.
Trade Receivables
Trade receivables consist of credit extended to the Company's customers and collaborators in the normal course of business and are reported net of an allowance for doubtful accounts. The Company reviews its customer accounts on a periodic basis and records bad debt expense for specific amounts the Company evaluates as uncollectible. Past due status is determined based upon contractual terms. Amounts are written off at the point when collection attempts have been exhausted. Management estimates uncollectible amounts considering such factors as current economic conditions and historic and anticipated customer performance. This estimate can fluctuate due to changes in economic, industry or specific customer conditions which may require adjustment to the allowance recorded by the Company. Management has included amounts believed to be uncollectible in the allowance for doubtful accounts.

16

The following table shows the activity in the allowance for doubtful accounts for the nine months ended September 30, 2015:
Balance at December 31, 2014
$
565

Charged to operating expenses
1,562

Write offs of accounts receivable
(112
)
Balance at September 30, 2015
$
2,015

Inventory
The Company's inventory primarily includes adult female cows which are used in certain production processes and are recorded at acquisition cost using the first-in, first-out method or at market, whichever is lower. Work-in-process inventory includes allocations of production costs and facility costs for products currently in production and is recorded at the lower of cost or market. Significant declines in the price of cows could result in unfavorable adjustments to inventory balances.
Property, Plant and Equipment
Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are generally expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets are as follows:
 
  
Years
Land improvements
 
4–20
Buildings and building improvements
  
3–23
Furniture and fixtures
  
1–7
Equipment
  
1–10
Computer hardware and software
  
1–7
Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to fourteen years.
Goodwill
Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized (Note 3). Goodwill is reviewed for impairment at least annually. The Company performs a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the two-step goodwill impairment test. If this is the case, the two-step goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the two-step goodwill impairment test is not required.
If the two-step goodwill impairment test is required, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, an indication of goodwill impairment exists for the reporting unit and the entity must perform step two of the impairment test. Under step two, an impairment loss is recognized for any excess of the carrying amount of the reporting unit's goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation and the residual fair value after this allocation is the implied fair value of the reporting unit goodwill. Fair value of the reporting unit is determined using a discounted cash flow analysis. If the fair value of the reporting unit exceeds its carrying amount, step two does not need to be performed.
The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review.
Intangible Assets
Intangible assets subject to amortization consist of patents, related technologies and know-how; customer relationships; trademarks; and a covenant not to compete acquired as a result of mergers and acquisitions (Note 3). These intangible assets are

17

subject to amortization, were recorded at fair value at the date of acquisition and are stated net of accumulated amortization. Indefinite-lived intangible assets consist of in-process research and development acquired in mergers and acquisitions (Note 3) and were recorded at fair value at the dates of the respective acquisitions.
The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible assets are expected to be realized. The intangible assets are amortized over their remaining estimated useful lives, ranging from two to eighteen years for the patents, related technologies and know-how; customer relationships; trademarks; and the covenant not to compete.
Impairment of Long-Lived Assets
Long-lived assets to be held and used, including property, plant and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.
Indefinite-lived intangible assets, including in-process research and development, are tested for impairment annually, or more frequently if events or circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of their fair value to carrying value, without consideration of any recoverability test. The Company monitors the progression of its in-process research and development, as the likelihood of success is contingent upon commercial development or regulatory approval.
Foreign Currency Translation
The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into United States dollars at the exchange rates in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in the consolidated statement of comprehensive loss. Revenue and expense amounts are translated at average rates during the period.
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.
Net Loss per Share
Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.
Segment Information
The Company has determined that it operates in one segment. The Company applies its technologies to create products and services which may be either sold directly to customers or developed through collaboration with third parties. As of

18

September 30, 2015 and December 31, 2014, the Company had $3,623 and $2,200, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $1,183 and $809 for the three months ended September 30, 2015 and 2014, respectively, and $3,446 and $1,178 for the nine months ended September 30, 2015 and 2014, respectively.
Recently Issued Accounting Pronouncements
In September 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-16, Business Combinations: Simplifying the Accounting for Measurement-Period Adjustments ("ASU 2015-16"). ASU 2015-16 eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Rather, the acquirer must recognize adjustments during the period in which the amounts are determined, including the effect on earnings of any amounts that would have been recorded in previous periods. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, with early adoption permitted. The Company elected to early adopt this guidance and there was no significant impact on the Company's consolidated financial statements.
In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330) - Simplifying the Measurement of Inventory ("ASU 2015-11"). The provisions of ASU 2015-11 provide guidance for simplifying the calculation for subsequent measurement of inventory measured using the first-in-first-out or average cost methods. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2016, and is effective for the Company for the year ending December 31, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.
In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810) - Amendments to the Consolidation Analysis ("ASU 2015-02"). The provisions of ASU 2015-02 provide guidance which changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. This guidance is effective for annual periods and interim periods within those annual periods, beginning after December 15, 2015, with early adoption permitted. The Company elected to early adopt this guidance and there was no significant impact on the Company's consolidated financial statements.
In May 2014, the FASB issued ASU 2014-9, Revenue from Contracts with Customers ("ASU 2014-9"). The FASB issued ASU 2014-9 to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance was originally effective for annual periods and interim periods within those annual periods beginning after December 15, 2016 and early adoption was not permitted. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606) - Deferral of the Effective Date ("ASU 2015-14"), which deferred the effective date of the guidance in ASU 2014-9 by one year to December 15, 2017 for interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016, and is effective for the Company for the year ending December 31, 2018. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.
Reclassifications
Certain insignificant reclassifications have been made to the prior interim period consolidated financial statements to conform to the current interim period presentation.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

19

3. Mergers and Acquisitions
Oxitec Acquisition
In September 2015, pursuant to a Stock Purchase Agreement (the “Oxitec Purchase Agreement”), the Company acquired 100% of the issued outstanding share capital of Oxitec, a pioneering company in biological insect control solutions, thereby expanding the Company’s capabilities to address a broad range of global environment, health and agricultural challenges. The aggregated consideration paid consisted of (i) 1,359,343 shares of the Company’s common stock (the “Stock Consideration”) and (ii) $90,199 in cash (the “Cash Consideration”), inclusive of net cash and working capital adjustments, as defined in the Oxitec Purchase Agreement, totaling $9,449 which are to be paid within eighty-five days of the September closing date. Stock Consideration totaling 480,422 shares and Cash Consideration totaling $1,991 were withheld as escrow at closing and are issuable and payable, respectively, eighteen months after closing, subject to reduction for satisfaction of any claims for indemnification made by the Company under the Oxitec Purchase Agreement. Cash Consideration related to the net cash and working capital adjustments, as well as the withheld cash, are included in deferred consideration as of September 30, 2015. The results of Oxitec’s operations subsequent to the acquisition date have been included in the consolidated financial statements.
The fair value of the total consideration transferred was $146,394. The acquisition date fair value of the Stock Consideration and Cash Consideration is presented below:
Cash
$
90,199

Common shares
56,195

 
$
146,394

The fair value of the shares of the Company common stock issued was based on the quoted closing price of the Company’s common stock as of the date of the acquisition. The preliminary estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:
Cash
$
3,780

Trade receivables
125

Other receivables
7,395

Prepaid expenses and other
121

Property, plant, and equipment
1,198

Intangible assets
96,854

Total assets acquired
109,473

Accounts payable
1,187

Accrued compensation and benefits
246

Other accrued liabilities
210

Deferred revenue
120

Deferred tax liabilities
12,584

Total liabilities assumed
14,347

Net assets acquired
95,126

Goodwill
51,268

Total consideration
$
146,394

The fair value of assets acquired and liabilities assumed at the acquisition date are considered preliminary and are subject to revision when the valuation of intangible assets is finalized. The acquired intangibles assets primarily include in-process research and development and the fair values of the acquired assets were determined using the multi-period excess earning method, which is a variation of the income approach that converts future cash flows to single discounted present value amounts. The in-process research and development are currently indefinite-lived intangible assets and, accordingly, are not being amortized. Goodwill, which is not expected to be deductible for tax purposes, represents the assembled workforce and the potential for future Oxitec products and technologies.

20

As of September 30, 2015, the Company had incurred $1,644 of acquisition related costs, all of which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations for the three and nine months ended September 30, 2015.
Okanagan Acquisition
In April 2015, pursuant to a Stock Purchase Agreement (the “Okanagan Purchase Agreement”), the Company acquired 100% of the outstanding shares of Okanagan, the pioneering agricultural company behind the world's first non-browning apple. In addition to supporting Okanagan's further commercialization and exploitation of its apple products, the Company expects to utilize its proprietary technologies to assist Okanagan in the development of further novel beneficial plant traits. Pursuant to the Okanagan Purchase Agreement, the former shareholders of Okanagan received an aggregate of 707,853 shares of the Company’s common stock, and $10,000 cash in exchange for all shares in Okanagan. The results of Okanagan's operations subsequent to the acquisition date have been included in the consolidated financial statements.
The fair value of the total consideration transferred was $40,933. The acquisition date fair value of each class of consideration transferred is presented below:
Cash
$
10,000

Common shares
30,933

 
$
40,933

The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock as of the date of the acquisition. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below along with subsequent adjustments during the measurement period to the fair value of assets acquired and liabilities assumed. The adjustments resulted from revisions to the valuation of intangible assets.
 
Initial Estimated Fair Value
 
Adjustments
 
Adjusted Fair Value
Cash
$
58

 
$
—

 
$
58

Trade receivables
16

 
—

 
16

Other receivables
49

 
—

 
49

Property, plant, and equipment
32

 
—

 
32

Intangible assets
33,800

 
2,700

 
36,500

Total assets acquired
33,955

 
2,700

 
36,655

Accounts payable
181

 
—

 
181

Deferred revenue
181

 
—

 
181

Deferred tax liabilities
8,145

 
702

 
8,847

Total liabilities assumed
8,507

 
702

 
9,209

Net assets acquired
25,448

 
1,998

 
27,446

Goodwill
15,485

 
(1,998
)
 
13,487

Total consideration
$
40,933

 
$
—

 
$
40,933

The acquired intangible assets primarily include developed technology, patents and know-how and the fair values of the acquired assets were determined using the with and without method, which is a variation of the income approach that utilizes estimated cash flows with all assets in place at the valuation date and estimated cash flows with all assets in place except the intangible assets at the valuation date. The intangible assets are being amortized over a useful life of fourteen years. Goodwill, which is not expected to be deductible for tax purposes, represents potential future applications of Okanagan's technology to other fruits, including additional apple varietals, and anticipated buyer-specific synergies arising from the combination of the Company's and Okanagan's technologies.
The Company incurred $341 of acquisition-related costs, of which $267 is included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the nine months ended September 30, 2015.

21

ActoGeniX Acquisition
In February 2015, the Company acquired 100% of the membership interests of ActoGeniX NV ("ActoGeniX"), a European clinical stage biopharmaceutical company, pursuant to a Stock Purchase Agreement (the "ActoGeniX Purchase Agreement"). ActoGeniX's platform technology complements our broad collection of technologies available for current and future collaborators. Pursuant to the ActoGeniX Purchase Agreement, the former members of ActoGeniX received an aggregate of 965,377 shares of the Company's common stock and $32,739 in cash in exchange for all membership interests of ActoGeniX. The results of ActoGeniX's operations subsequent to the acquisition date have been included in the consolidated financial statements.
The fair value of the total consideration transferred was $72,474. The acquisition date fair value of each class of consideration transferred is presented below:
Cash
$
32,739

Common shares
39,735

 
$
72,474

The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock as of the date of the acquisition. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below along with subsequent adjustments during the measurement period to the fair value of assets acquired and liabilities assumed. The adjustments resulted from the difference between estimated and actual accrued expenses.
 
Initial Estimated Fair Value
 
Adjustments
 
Adjusted Fair Value
Cash
$
3,180

 
$
—

 
$
3,180

Other receivables
305

 
—

 
305

Prepaid expenses and other
31

 
—

 
31

Property, plant and equipment
209

 
—

 
209

Intangible assets
68,100

 
—

 
68,100

Other assets
23

 
—

 
23

Total assets acquired
71,848

 
—

 
71,848

Accounts payable
230

 
—

 
230

Accrued compensation and benefits
624

 
(428
)
 
196

Other accrued liabilities
307

 
(54
)
 
253

Deferred revenue
732

 
—

 
732

Deferred tax liabilities
612

 
—

 
612

Total liabilities assumed
2,505

 
(482
)
 
2,023

Net assets acquired
69,343

 
482

 
69,825

Goodwill
3,131

 
(482
)
 
2,649

Total consideration
$
72,474

 
$
—

 
$
72,474

The acquired intangible assets primarily include in-process research and development, and the fair values of the acquired assets were determined using the multi-period excess earnings and with-and-without methods, which are both variations of the income approach that convert future cash flows to single discounted present value amounts. During the three months ended September 30, 2015, the Company re-evaluated the acquired in-process research and development and determined that it was no longer an indefinite-lived intangible asset. The Company assigned it a useful life of eighteen years and began amortization in August 2015. Goodwill, which is not expected to be deductible for tax purposes, represents the assembled workforce and anticipated buyer-specific synergies arising from the combination of the Company's and ActoGeniX's technologies.
The Company incurred $418 of acquisition-related costs, of which $381 is included in selling, general and administrative expenses in the accompanying consolidated statements of operations for the nine months ended September 30, 2015.

22

Trans Ova Acquisition
In August 2014, the Company acquired 100% of the membership interests of Trans Ova, a provider of bovine reproductive technologies, pursuant to an Amended and Restated Membership Interest Purchase Agreement (the "Trans Ova Purchase Agreement"). The Company and Trans Ova intend to build upon Trans Ova's current platform with new capabilities with a goal of achieving higher levels of delivered value to dairy and beef cattle producers. Pursuant to the Trans Ova Purchase Agreement, the former members of Trans Ova received an aggregate of 1,444,388 shares of the Company's common stock and $63,625 in cash, and will receive deferred cash consideration valued at $20,115 in exchange for all membership interests of Trans Ova. The deferred cash consideration is payable in three equal installments upon the first, second, and third anniversaries of the transaction date. The Trans Ova Purchase Agreement also provides for payment to the former members of Trans Ova a portion of certain cash proceeds in the event there is an award under certain litigation matters pending as of the transaction date to which Trans Ova is a party. The results of Trans Ova's operations subsequent to the acquisition date have been included in the consolidated financial statements, including revenues of $18,283 and $64,743 and net income (loss) of $(3,655) and $530 for the three and nine months ended September 30, 2015, respectively, and revenues of $8,502 and net loss of $481 for the three and nine months ended September 30, 2014.
The fair value of the total consideration transferred, including the noncontrolling interest in a majority-owned subsidiary of Trans Ova, was $127,875. The acquisition date fair value of each class of consideration transferred and noncontrolling interest is presented below:
Cash
$
63,625

Common shares
32,802

Deferred cash consideration
20,115

Total consideration transferred
116,542

Fair value of noncontrolling interest
11,333

Total
$
127,875

The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock as of the date of the acquisition. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown in the table below.
Cash
$
960

Trade receivables
18,693

Related party receivables
1,219

Inventory
18,476

Prepaid expenses and other
590

Property, plant and equipment
21,164

Intangible assets
23,700

Other assets
147

Total assets acquired
84,949

Accounts payable
3,317

Accrued compensation and benefits
913

Other accrued liabilities
271

Deferred revenue
4,458

Lines of credit
4,091

Related party payables
1,246

Long term debt
9,090

Total liabilities assumed
23,386

Net assets acquired
61,563

Goodwill
66,312

Total consideration and fair value of noncontrolling interest
$
127,875


23

The fair value of acquired inventory was determined using the cost approach, which establishes value based on the cost of reproducing or replacing the asset. The fair value of acquired property, plant and equipment was determined using the cost approach and the market approach. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets. The acquired intangible assets include various developed technologies and know-how, customer relationships, and trademarks, and the fair values of these assets were determined using the relief-from-royalty, multi-period excess earnings, and with-and-without methods, which are all variations of the income approach. The acquired intangible assets are being amortized over useful lives ranging from three to nine years. Goodwill, which will be deductible for tax purposes, represents the assembled workforce, potential future expansion of Trans Ova business lines and anticipated buyer-specific synergies arising from the combination of the Company's and Trans Ova's technologies.
In conjunction with a prior transaction associated with Trans Ova's subsidiary, ViaGen, in September 2012, the Company may be obligated to make certain future contingent payments to the former equity holders of ViaGen, up to a total of $6,000 if certain revenue targets, as defined in the share purchase agreement, are met.  The Company does not expect these revenue targets to be met and accordingly has assigned no value to this liability.
The Company incurred $713 of costs primarily for legal and due diligence services related to this acquisition, of which $372 and $684 is included in selling, general and administrative expenses in the accompanying consolidated statements of operations for the three and nine months ended September 30, 2014, respectively.
In February 2015, the Company acquired, through an exchange offer, the remaining outstanding membership interests of Trans Ova's majority-owned subsidiary, Exemplar, for $1,566 in cash and 307,074 shares of Company common stock.
Medistem Acquisition
In March 2014, the Company acquired 100% of the outstanding common stock and securities convertible into common stock of Medistem, Inc. ("Medistem"), an entity engaged in the development of Endometrial Regenerative Cells ("ERCs"), for a combination of cash and Company common stock. The acquisition allows the Company to employ its synthetic biology platforms to engineer a diverse array of cell-based therapeutic candidates using Medistem's multipotent ERCs. Pursuant to the terms of the merger agreement, Medistem equity holders received 714,144 shares of the Company's common stock and $4,920 in cash in exchange for the outstanding Medistem common stock and securities convertible into common stock. Additionally, Medistem had issued the Company two promissory notes in the amount of $707, including accrued interest, both of which were settled upon closing of the merger. Certain members of Medistem's management surrendered a total of 17,695 shares of their merger consideration to reimburse the Company for required payroll tax withholdings. The results of Medistem's operations subsequent to the acquisition date have been included in the consolidated financial statements.
The fair value of the total consideration transferred was $24,995. The acquisition date fair value of each class of consideration transferred is presented below:
 
Cash
$
4,920

Common shares
19,368

Settlement of promissory notes
707

 
$
24,995


24

The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock as of the date of the acquisition. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown in the table below.
Cash
$
8

Intangible assets
4,824

Total assets acquired
4,832

Accounts payable
644

Accrued compensation and benefits
67

Other accrued expenses
50

Total liabilities assumed
761

Net assets acquired
4,071

Goodwill
20,924

Total consideration
$
24,995

The fair value of acquired intangible assets was determined using the cost approach. The acquired intangible assets consist of in-process research and development, which is an indefinite-lived intangible asset. The goodwill consists of buyer-specific synergies between the Company's and Medistem's technologies present. The goodwill is not expected to be deductible for tax purposes.
The Company incurred $680 of acquisition-related costs, of which $310 is included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the nine months ended September 30, 2014.
Unaudited Condensed Pro Forma Financial Information
The results of operations of the 2015 acquisitions discussed above are included in the consolidated statements of operations beginning on the day after the acquisition date. The following unaudited condensed pro forma financial information for the three and nine months ended September 30, 2015 and 2014 is presented as if the acquisitions had been consummated on January 1, 2014:
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
 
Pro forma
Revenues
$
53,754

 
$
21,524

 
$
133,060

 
$
41,742

Loss before income taxes
(43,979
)
 
(58,972
)
 
(66,686
)
 
(117,811
)
Net loss
(43,057
)
 
(58,586
)
 
(66,319
)
 
(116,100
)
Net loss attributable to the noncontrolling interests
816

 
1,137

 
2,940

 
2,895

Net loss attributable to Intrexon
(42,241
)
 
(57,449
)
 
(63,379
)
 
(113,205
)

25

The results of operations of the 2014 acquisitions discussed above are included in the consolidated statements of operations beginning on the day after their respective acquisition dates. The following unaudited condensed pro forma financial information for the three and nine months ended September 30, 2014 is presented as if the acquisitions had been consummated on January 1, 2013:
 
Three Months Ended 
 September 30, 2014
 
Nine Months Ended 
 September 30, 2014
 
Pro forma
Revenues
$
31,507

 
$
88,629

Loss before income taxes
(51,864
)
 
(98,816
)
Net loss
(51,864
)
 
(98,839
)
Net loss attributable to the noncontrolling interests
1,200

 
3,260

Net loss attributable to Intrexon
(50,664
)
 
(95,580
)
4. Investments in Joint Ventures
Intrexon Energy Partners
In March 2014, the Company and certain investors (the "Investors"), including an affiliate of Third Security, LLC ("Third Security"), entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a joint venture formed to optimize and scale-up the Company's gas-to-liquid bioconversion platform for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to our technology for the use in bioconversion, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50%. In addition, Intrexon has committed to make additional capital contributions of up to $25,000, and the Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to $25,000, at the request of Intrexon Energy Partners' Board of Managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of September 30, 2015, the Company's remaining commitment was $20,426. The Company and the Investors have the right, but not the obligation, to make additional capital contributions above these limits when and if solicited by the Intrexon Energy Partners Board. Intrexon Energy Partners is governed by a board of managers which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members of the Intrexon Energy Partners Board are designated by a majority of the Investors.
See further discussion of the ECC at Note 5. See discussion of a concurrent private placement securities purchase made by the Investors at Note 13.
The Company's investment in Intrexon Energy Partners was $(1,591) and $(740) as of September 30, 2015 and December 31, 2014, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets.
OvaXon
In December 2013, the Company and OvaScience, Inc. ("OvaScience"), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, entered into a Limited Liability Company Agreement ("OvaXon LLC Agreement") to form OvaXon, LLC ("OvaXon"), a joint venture to create new applications for improving human and animal health. Both the Company and OvaScience made an initial capital contribution of $1,500 in January 2014 for a 50% membership interest in OvaXon. OvaXon is governed by the OvaXon board of managers ("OvaXon Board") which has four members, two each from the Company and OvaScience. In cases in which the OvaXon Board determines that additional capital contributions are necessary in order for OvaXon to conduct business and comply with its obligations, each of the Company and OvaScience have the right, but not the obligation, to make additional capital contributions to OvaXon subject to the OvaXon LLC Agreement.
Contemporaneously with the formation of the joint venture, the Company entered into an ECC with OvaXon (see Note 5).

26

The Company's investment in OvaXon was $242 and $(83) as of September 30, 2015 and December 31, 2014, respectively, and is included in investments in affiliates and other accrued liabilities, respectively, in the accompanying consolidated balance sheets.
S & I Ophthalmic
In September 2013, the Company entered into a Limited Liability Company Agreement ("Sun LLC Agreement") with Caraco Pharmaceutical Laboratories, Ltd. ("Sun Pharmaceutical Subsidiary"), an indirect subsidiary of Sun Pharmaceutical Industries Ltd. ("Sun Pharmaceutical"), an international specialty pharmaceutical company focused on chronic diseases, to form S & I Ophthalmic, LLC ("S & I Ophthalmic"). The Sun LLC Agreement governs the affairs and the conduct of business of S & I Ophthalmic. S & I Ophthalmic leverages experience and technology from both the Company and Sun Pharmaceutical. Both the Company and Sun Pharmaceutical Subsidiary made an initial capital contribution of $5,000 in October 2013 for a 50% membership interest in S & I Ophthalmic. S & I Ophthalmic is governed by a board of managers ("S & I Ophthalmic Board") which has four members, two each from the Company and Sun Pharmaceutical Subsidiary. In cases in which the S & I Ophthalmic Board determines that additional capital contributions are necessary in order for S & I Ophthalmic to conduct business and comply with its obligations, each of the Company and Sun Pharmaceutical Subsidiary have committed to making additional capital contributions to S & I Ophthalmic subject to certain limits defined in the agreement. Each has the right, but not the obligation, to make additional capital contributions above the defined limits when and if solicited by the S & I Ophthalmic Board.
Beginning on the seventh anniversary of the effective date of the Sun LLC Agreement, and upon the second anniversary thereafter, the Company, as well as Sun Pharmaceutical Subsidiary, may make a cash offer to purchase all of the other party's interest in S & I Ophthalmic. Upon receipt of such an offer, the other party must either agree to tender its interests at the offered price or submit a counteroffer at a price higher than the original offer. Such offer and counteroffer may continue until one party agrees to the other's price.
Contemporaneously with the formation of the joint venture, the Company entered into an ECC with S & I Ophthalmic (see Note 5).
The Company's investment in S & I Ophthalmic was $1,881 and $3,220 as of September 30, 2015 and December 31, 2014, respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets.
5. Collaboration and Licensing Revenue
The Company's collaborations and licensing agreements provide for multiple deliverables to be delivered by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, performance of certain research and development services and may include obligations for certain manufacturing services. The Company typically groups these deliverables into two units of accounting based on the nature of the deliverables and the separation criteria. The first deliverable ("Unit of Accounting 1") includes the license to the Company's technology platform, the Company's participation on the collaboration committees and any research and development services associated with its technology platforms. The deliverables for Unit of Accounting 1 are combined because they cannot be individually separated. If applicable, the second deliverable ("Unit of Accounting 2") includes manufacturing services to be provided for any Company materials in an approved product. These services have standalone value and are contingent due to uncertainties on whether an approved product will ever be developed thereby requiring manufacture by the Company at that time. All upfront consideration is allocated to Unit of Accounting 1. Unit of Accounting 2 is determined to be a contingent deliverable at the inception of the collaboration due to the uncertainties surrounding whether an approved product will ever be developed and require manufacturing by the Company. The upfront consideration allocated to Unit of Accounting 1 is recognized over the expected life of the Company's technology platform using a straight-line approach.
The Company recognizes the reimbursement payments received for research and development services in the period when the services are performed and collection is reasonably assured. At the inception of each collaboration and licensing agreement, the Company determines whether any milestone payments are substantive and can be recognized when earned. The milestone payments are typically not considered substantive. Royalties related to product sales will be recognized when earned since payments relate directly to products that have been fully developed and for which the Company has satisfied all of its obligations.
The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration or licensing agreements, collaborators or licensees either consolidated or accounted for using the equity method, or other qualitative factors.

27

Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation. The following table summarizes the amounts recorded in the consolidated statements of operations for each significant collaboration and licensing agreement for the three and nine months ended September 30, 2015 and 2014.
 
Three Months Ended September 30, 2015
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
645

 
$
4,006

 
$
4,651

Oragenics, Inc.
4,868

 
332

 
5,200

Fibrocell Science, Inc.
4,823

 
1,317

 
6,140

Genopaver, LLC
68

 
993

 
1,061

S & I Ophthalmic, LLC
—

 
1,193

 
1,193

OvaXon, LLC
—

 
549

 
549

Intrexon Energy Partners, LLC
625

 
3,185

 
3,810

Persea Bio, LLC
125

 
297

 
422

Ares Trading S.A.
1,597

 
260

 
1,857

Other
7,841

 
2,002

 
9,843

Total
$
20,592

 
$
14,134

 
$
34,726

 
Three Months Ended September 30, 2014
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
644

 
$
3,370

 
$
4,014

Oragenics, Inc.
261

 
3

 
264

Fibrocell Science, Inc.
449

 
1,014

 
1,463

Genopaver, LLC
68

 
360

 
428

S & I Ophthalmic, LLC
—

 
667

 
667

OvaXon, LLC
—

 
813

 
813

Intrexon Energy Partners, LLC
625

 
1,535

 
2,160

Other
443

 
2,404

 
2,847

Total
$
2,490

 
$
10,166

 
$
12,656

 
Nine Months Ended September 30, 2015
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
1,933

 
$
11,769

 
$
13,702

Oragenics, Inc.
5,437

 
408

 
5,845

Fibrocell Science, Inc.
5,719

 
4,500

 
10,219

Genopaver, LLC
205

 
2,460

 
2,665

S & I Ophthalmic, LLC
—

 
2,838

 
2,838

OvaXon, LLC
—

 
1,855

 
1,855

Intrexon Energy Partners, LLC
1,875

 
8,101

 
9,976

Persea Bio, LLC
375

 
553

 
928

Ares Trading S.A.
2,336

 
260

 
2,596

Other
9,446

 
6,620

 
16,066

Total
$
27,326

 
$
39,364

 
$
66,690


28

 
Nine Months Ended September 30, 2014
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
1,932

 
$
9,103

 
$
11,035

Oragenics, Inc.
784

 
588

 
1,372

Fibrocell Science, Inc.
1,345

 
2,759

 
4,104

Genopaver, LLC
205

 
1,204

 
1,409

S & I Ophthalmic, LLC
—

 
2,153

 
2,153

OvaXon, LLC
—

 
1,561

 
1,561

Intrexon Energy Partners, LLC
1,250

 
2,745

 
3,995

Other
1,373

 
5,255

 
6,628

Total
$
6,889

 
$
25,368

 
$
32,257

The following is a summary of the terms of the Company's significant collaborations and licensing agreements.
Merck Licensing Agreement
In March 2015, the Company signed a worldwide License and Collaboration Agreement ("Merck Agreement") with Ares Trading S.A. ("Ares Trading"), a subsidiary of the biopharmaceutical business of Merck KGaA, and ZIOPHARM through which the parties established a collaboration for the research and development and commercialization of certain products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. Pursuant to the Merck Agreement, the Company received a technology access fee of $115,000 as upfront consideration, of which $57,500 was paid to ZIOPHARM in accordance with the terms of the agreement. Upon the selection of the first two targets by Ares Trading, the Company is entitled to receive $10,000 payable in equal quarterly installments over two years, of which $6,250 is included in trade receivables and $3,750 in other long term assets on the consolidated balance sheet as of September 30, 2015. The Company will be entitled to receive a further $5,000 for each additional target selected by Ares Trading. The Company is also entitled to up to $413,000 of potential payments for substantive and non-substantive development and commercial milestones for each product, and royalties ranging from the lower-single digits to the low-teens of the net sales derived from the sale of products developed under the Merck Agreement. The Company may also receive up to $50,000 of further cash fees upon certain technical milestones as provided for in the agreement. The term of the Merck Agreement commenced in May 2015 and may be terminated by either party in the event of a material breach as defined in the agreement and may be terminated voluntarily by Ares Trading upon 90 days written notice to the Company. The Company will pay to ZIOPHARM 50% of all payments received for upfront fees, milestones, and royalties under the Merck Agreement. The remaining balance of deferred revenue associated with the upfront payment was $55,164 at September 30, 2015.
ZIOPHARM Collaborations
In January 2011, the Company entered into an ECC with ZIOPHARM, a related party. Pursuant to the ECC, ZIOPHARM received a license to the Company's technology platform within the field of oncology as defined more specifically in the agreement. Upon execution of the ECC, the Company received 3,636,926 shares of ZIOPHARM's common stock valued at $17,457 as upfront consideration. In addition to the deliverables discussed above, the Company transferred two clinical product candidates to ZIOPHARM that resulted in a separate unit of accounting for which $1,115 of the upfront consideration was allocated and recognized as collaboration revenue in 2011. The remaining $16,342 of upfront consideration was allocated to Unit of Accounting 1 discussed above. The Company is entitled to additional shares of common stock representing the lesser of (i) the original shares received or (ii) the number of shares representing 7.495% of ZIOPHARM's outstanding shares at the date of the dosing of the first patient in a Phase II clinical trial of a product candidate created, produced or developed by ZIOPHARM using the Company's technology ("ZIOPHARM Milestone"). In October 2012, the ZIOPHARM Milestone was achieved and the Company received 3,636,926 shares of ZIOPHARM's common stock valued at $18,330 as milestone consideration. Since the ZIOPHARM Milestone was not substantive, the Company allocated the ZIOPHARM Milestone to the applicable units of accounting and is recognizing it in a manner similar to these units of accounting. The remaining balance of deferred revenue associated with upfront and milestone payments was $21,260 and $23,193 at September 30, 2015 and December 31, 2014, respectively. The Company receives reimbursement payments for research and development services provided and manufacturing services for Company materials provided to ZIOPHARM during the ECC. Subject to certain expense allocations, ZIOPHARM will pay the Company 50% of the quarterly net profits derived from the sale of products developed from the ECC, as defined in the agreement. ZIOPHARM is responsible for conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of product candidates.

29

The term of the ECC commenced in January 2011 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by ZIOPHARM upon 90 days written notice to the Company. In March 2015, in conjunction with the Merck Agreement, the Company and ZIOPHARM amended their existing ECC. The amendment modifies the scope of the ECC in connection with the Merck Agreement and provides that the Company will pay to ZIOPHARM 50% of all payments received for upfront fees, milestones and royalties under the Merck Agreement.
In September 2015, the Company entered into its second ECC with ZIOPHARM ("ZIOPHARM ECC 2"). Pursuant to the ECC, ZIOPHARM received a license to the Company's technology platform to develop and commercialize novel biotherapeutics for the treatment of patients with graft-versus-host disease, or GvHD. Upon execution of ZIOPHARM ECC 2, the Company received a technology access fee of $10,000, all of which is included in deferred revenue at September 30, 2015. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to ZIOPHARM during the ECC. ZIOPHARM will pay the Company 50% of quarterly net profits derived from the sale of products developed from ZIOPHARM ECC 2, as defined in the agreement.
ZIOPHARM is responsible for funding the further development of ZIOPHARM ECC 2 products towards the goal of commercialization, conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of the ZIOPHARM ECC 2 commenced in September 2015 and may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by ZIOPHARM upon 90 days written notice to the Company.
See Notes 13 and 17 for further discussion related to ZIOPHARM.
Oragenics Collaborations
In June 2012, the Company entered into an ECC with Oragenics, a publicly traded company focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health for humans and pets and a related party. Pursuant to the ECC, at the transaction effective date, Oragenics received a license to the Company's technology platform within the field of lantibiotics for the treatment of infectious diseases in humans and companion animals as defined more specifically in the agreement. Upon execution of the ECC, the Company received a technology access fee of 4,392,425 shares of Oragenics' common stock valued at $6,588 as upfront consideration. The Company is entitled to receive additional shares of common stock, or at Oragenics' option, receive a cash payment based upon the fair market value of the shares, upon the separate achievement of certain regulatory milestones of the first product candidate developed from the ECC ("Oragenics ECC 1 Milestones"). The Oragenics ECC 1 Milestones include: (i) 1% of Oragenics' outstanding shares as defined in the ECC agreement at the date of the filing of the first Investigative New Drug Application with the U.S. FDA for a product candidate created, produced or developed using the Company's technology ("Oragenics ECC 1 Product"); (ii) 1.5% of Oragenics' outstanding shares as defined in the ECC agreement at the date of the dosing of the first patient in the first Phase II clinical trial of an Oragenics ECC 1 Product; (iii) 2% of Oragenics' outstanding shares as defined in the ECC agreement at the date of the dosing of the first patient in the first Phase III clinical trial of an Oragenics ECC 1 Product; (iv) 2.5% of Oragenics' outstanding shares as defined in the ECC agreement at the date of the first New Drug Application or Biologics License Application with the U.S. FDA for an Oragenics ECC 1 Product, or alternatively the first equivalent regulatory filing with a foreign agency; and (v) 3% of Oragenics' outstanding shares as defined in the ECC agreement at the date of the granting of the first regulatory approval of an Oragenics ECC 1 Product. The remaining balance of deferred revenue associated with the upfront payment was $4,758 and $5,171 at September 30, 2015 and December 31, 2014, respectively. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during the ECC. Oragenics will pay the Company 25% of the quarterly profits derived from the sale of products developed from the ECC, as defined in the agreement.
Oragenics is responsible for funding the further development of lantibiotics toward the goal of commercialization, conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of the ECC commenced in June 2012 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Oragenics upon 90 days written notice to the Company.
In September 2013, the Company entered into its second ECC with Oragenics ("Oragenics ECC 2"). Pursuant to Oragenics ECC 2, at the transaction effective date, Oragenics received a license to the Company's technology platform to develop and commercialize probiotics, specifically the direct administration to humans of genetically modified probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus as defined more specifically in the agreement. Upon execution of Oragenics ECC 2, the Company received a technology access fee of 1,348,000 shares of Oragenics' common stock valued at

30

$3,503 and a $1,956 convertible promissory note maturing on or before December 31, 2013 as upfront consideration. Prior to the maturity date, Oragenics had the right to convert the promissory note into shares of Oragenics' common stock subject to its shareholders' approval. The conversion price was equal to the closing price of Oragenics' common stock on the last trading day immediately prior to the date of conversion. In December 2013, Oragenics converted the promissory note into 698,241 shares of Oragenics' common stock. In September 2015, Oragenics and the Company mutually agreed to terminate Oragenics ECC 2 and accordingly, the Company recognized the remaining balance of the deferred revenue associated with the upfront payment.
In June 2015, the Company entered into its third ECC with Oragenics ("Oragenics ECC 3"). Pursuant to Oragenics ECC 3, at the transaction effective date, Oragenics received a license to the Company's technology platform within the field of biotherapeutics for use in certain treatments of oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus. Upon execution of Oragenics ECC 3, the Company received a technology access fee of a $5,000 convertible promissory note, which approximates fair value, maturing on or before December 31, 2015 as upfront consideration. Prior to the maturity date, Oragenics has the right to convert the promissory note into shares of Oragenics' common stock, subject to its shareholders' approval. The Company is also entitled to up to $22,000 of potential payments for development and commercial milestones for each Oragenics product developed from Oragenics ECC 3 and up to $10,000 of potential one-time payments for certain regulatory milestones under Oragenics ECC 3. The remaining balance of deferred revenue associated with the upfront payment was $4,815 at September 30, 2015. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during Oragenics ECC 3. Oragenics will pay the Company a royalty as a percentage in the low-teens of net sales derived from the sale of products developed from Oragenics ECC 3, as defined in the agreement.
Oragenics is responsible for funding the further development of Oragenics ECC 3 products towards the goal of commercialization, conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of Oragenics ECC 3 commenced in June 2015 and may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Oragenics upon 90 days written notice to the Company.
See Note 17 for a discussion of additional arrangements with Oragenics.
Fibrocell Science, Inc. Collaboration
In October 2012, the Company entered into an ECC with Fibrocell Science, Inc. ("Fibrocell"), a publicly traded, autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications and a related party. Pursuant to the ECC, at the transaction effective date, Fibrocell received a license to the Company's technology platform to develop and commercialize genetically modified and non-genetically modified autologous fibroblasts and autologous dermal cells in the United States of America. Upon execution of the ECC, the Company received a technology access fee of 1,317,520 shares of Fibrocell's common stock valued at $7,576 as upfront consideration. The number of shares received reflects a 1-for-25 reverse stock split of Fibrocell's common stock effective April 30, 2013. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Fibrocell during the ECC. On a quarterly basis, Fibrocell will pay the Company royalties of 7% of net sales up to $25,000 and 14% of net sales above $25,000 on each product developed from the ECC, as defined in the agreement. If Fibrocell uses the Company's technology platform to improve the production of a current or new Fibrocell product not developed from the ECC, Fibrocell will pay the Company a quarterly royalty equal to 33% of the cost of goods sold savings generated by the improvement, as defined in the agreement. Fibrocell is responsible for conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization and manufacturing of the product candidates. The term of the ECC commenced in October 2012 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Fibrocell upon 90 days written notice to the Company.
In June 2013, the Company entered into an amendment to the ECC with Fibrocell. The amendment expands the field of use defined in the ECC agreement. Under the terms of the amendment to the ECC, the Company received 1,243,781 shares of Fibrocell's common stock valued at $7,612 as a supplemental technology access fee. The Company allocated this additional consideration to the appropriate unit of accounting and is recognizing it consistent with the unit of accounting.
In January 2014, the Company entered into a second amendment to the ECC with Fibrocell. The second amendment further expanded the field of use defined in the ECC agreement. Under the terms of the second amendment to the ECC, the Company received 1,024,590 shares of Fibrocell's common stock valued at $5,225 as a technology access fee. The Company allocated this additional consideration to the appropriate unit of accounting. In September 2015, Fibrocell and the Company mutually agreed to terminate the second amendment to the ECC and accordingly, the Company recognized the remaining balance of

31

deferred revenue associated with the related upfront payment. The remaining balance of deferred revenue associated with Fibrocell was $11,772 and $17,491 at September 30, 2015 and December 31, 2014, respectively.
See Note 17 for further discussion related to Fibrocell.
Genopaver Collaboration
In March 2013, the Company entered into an ECC with Genopaver, LLC ("Genopaver"), an affiliate of Third Security (Note 17) and a related party. Genopaver was formed for the purpose of entering into the ECC and developing and commercializing products in the field of the fermentative production of alkaloids through genetically modified cell-lines and substrate feeds for use as active pharmaceutical ingredients or as commercially sold intermediates in the manufacture of active pharmaceutical ingredients. Upon execution of the ECC, the Company received a technology access fee of $3,000 as upfront consideration. The remaining balance of deferred revenue associated with the upfront payment was $2,318 and $2,523 at September 30, 2015 and December 31, 2014, respectively. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC. Genopaver will pay the Company a royalty as a percentage in the lower-double digits on the quarterly gross profits of product sales from products developed under the ECC, as defined in the agreement. Genopaver is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in March 2013 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Genopaver upon 90 days written notice to the Company.
AquaBounty Collaboration
In February 2013, the Company entered into an ECC with AquaBounty, a majority-owned consolidated subsidiary. The Company will be reimbursed for research and development services as provided for in the ECC agreement. In the event of product sales from a product developed from the ECC, the Company will receive 16.66% of quarterly gross profits for each product, as defined in the agreement. All revenues and expenses related to this ECC are eliminated in consolidation.
S & I Ophthalmic Collaboration
In September 2013, the Company entered into an ECC with S & I Ophthalmic, a joint venture between the Company and Sun Pharmaceutical Subsidiary, an indirect subsidiary of Sun Pharmaceutical, an international specialty pharmaceutical company focused on chronic diseases (Note 4). The ECC grants S & I Ophthalmic an exclusive license to the Company's technology platform to develop and commercialize therapies in humans for the treatment of ocular diseases defined more specifically in the agreement. The Company will be reimbursed for research and development services pursuant to the agreement and manufacturing services for Company materials provided to S & I Ophthalmic during the ECC. Subject to certain expense allocations, S & I Ophthalmic will pay the Company royalties with percentages ranging from mid-single digits and above of the net sales derived from the sale of products developed under the ECC, as defined in the agreement. The term of the ECC commenced in September 2013 and continues until terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by S & I Ophthalmic upon 90 days written notice to the Company.
BioPop Collaboration
In October 2013, the Company entered into an ECC with BioPop, a majority-owned consolidated subsidiary. The ECC grants BioPop an exclusive license to the Company's technology platform to develop and commercialize artwork, children's toys and novelty goods that are derived from living organisms or are enabled by synthetic biology. The Company will be reimbursed for research and development services and manufacturing services as provided for in the ECC agreement. The Company is entitled to royalties in the mid-single digits as a percentage of the net product sales of a product developed under the ECC, as defined in the agreement. All revenues and expenses related to this ECC are eliminated in consolidation.
OvaXon Collaboration
In December 2013, the Company entered into an ECC with OvaXon, a joint venture between the Company and OvaScience, a life sciences company focused on infertility treatments (Note 4) and a related party. The ECC grants OvaXon an exclusive license to the Company's technology platform to create new applications for improving human and animal health. OvaScience also licensed certain technology to OvaXon pursuant to a separate license agreement. The Company will be reimbursed for research and development services and manufacturing services as provided for in the ECC agreement. The term of the ECC commenced in December 2013 and continues until terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by OvaXon upon 90 days written notice to the Company.

32

Intrexon Energy Partners Collaboration
In March 2014, the Company entered into an ECC with Intrexon Energy Partners, a joint venture between the Company and certain investors, including an affiliate of Third Security (Note 4), and a related party. The ECC grants Intrexon Energy Partners an exclusive license to the Company's technology platform to optimize and scale-up the Company's gas-to-liquid bioconversion platform for the production of certain fuels and lubricants. Upon execution of the ECC, the Company received a technology access fee of $25,000 as upfront consideration. The remaining balance of deferred revenue associated with the upfront payment was $21,250 and $23,125 at September 30, 2015 and December 31, 2014, respectively. The Company will be reimbursed for research and development services as provided for in the ECC agreement. The term of the ECC commenced in March 2014 and continues until March 2034 unless terminated prior to that date by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Intrexon Energy Partners upon 90 days written notice to the Company.
Persea Bio Collaboration
In December 2014, the Company entered into an ECC with Persea Bio, LLC ("Persea Bio"), an affiliate of Third Security (Note 17) and a related party. Persea Bio was formed for the purpose of entering into the ECC and developing and commercializing a food program, as defined in the agreement. Upon execution of the ECC, the Company received a technology access fee of $5,000 as upfront consideration. The remaining balance of deferred revenue associated with the upfront payment was $4,625 and $5,000 at September 30, 2015 and December 31, 2014, respectively. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC. Persea Bio will pay the Company royalties as a percentage in the lower-double digits on the quarterly gross profits of product sales from products derived from the ECC, as defined in the agreement. Persea Bio is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in December 2014 and continues until terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Persea Bio upon 90 days written notice to the Company.
Thrive Agrobiotics Collaboration
In September 2015, the Company entered into an ECC with Thrive Agrobiotics, an affiliate of Harvest (Note 17) and a related party. Thrive Agrobiotics was formed for the purpose of entering into the ECC and developing and commercializing products to improve the overall growth and feed efficiency in piglets. Upon execution of the ECC, the Company received a technology access fee in the form of equity in Thrive Agrobiotics valued at $1,667 as upfront consideration, all of which is included in deferred revenue as of September 30, 2015. The Company is also entitled to up to $5,500 of potential payments for development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC. Thrive Agrobiotics will pay the Company a royalty as a percentage in the lower-double digits on the quarterly gross profits of product sales from products developed under the ECC, as defined in the agreement. Thrive Agrobiotics is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in September 2015 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Thrive Agrobiotics upon 90 days written notice to the Company.

33

Deferred Revenue
Deferred revenue primarily consists of consideration received for upfront and milestone payments in connection with the Company's collaborations and licensing agreements, prepayments for research and development services performed for collaborators and licensees and prepayments for product and service revenues. Deferred revenue consists of the following:
 
September 30,
2015
 
December 31,
2014
Upfront and milestone payments
$
159,069

 
$
107,228

Prepaid research and development services
11,099

 
1,045

Prepaid product and service revenues
5,292

 
4,365

Other
794

 
571

Total
$
176,254

 
$
113,209

Current portion of deferred revenue
$
32,006

 
$
16,522

Long-term portion of deferred revenue
144,248

 
96,687

Total
$
176,254

 
$
113,209

6. Short-term and Long-term Investments
The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of September 30, 2015:
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate
Fair Value
U.S. government debt securities
$
226,567

 
$
291

 
$
—

 
$
226,858

Certificates of deposit
272

 
—

 
—

 
272

Total
$
226,839

 
$
291

 
$
—

 
$
227,130

The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of December 31, 2014:
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate
Fair Value
U.S. government debt securities
$
115,293

 
$
54

 
$
(12
)
 
$
115,335

Certificates of deposit
273

 
—

 
—

 
273

Total
$
115,566

 
$
54

 
$
(12
)
 
$
115,608

For more information on the Company's method for determining the fair value of its assets, see Note 2 – "Fair Value of Financial Instruments".
The estimated fair value of available-for-sale investments classified by their contractual maturities as of September 30, 2015 was as follows:
Due within one year
$
90,864

After one year through three years
136,266

Total
$
227,130

Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's investments were primarily a result of unfavorable changes in interest rates subsequent to the initial purchase of these investments and have been in a loss position for less than 12 months.
As of September 30, 2015 and December 31, 2014, the Company did not consider any of its investments to be other-than-temporarily impaired. When evaluating its investments for other-than-temporary impairment, the Company reviews factors

34

such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer, the Company's ability and intent to hold the security and whether it is more likely than not that it will be required to sell the investment before recovery of its cost basis.
7. Fair Value Measurements
The carrying amount of cash and cash equivalents, receivables, prepaid expenses and other current assets, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments.
The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at September 30, 2015:
 
Quoted Prices in Active Markets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
September 30,
2015
Assets
 
 
 
 
 
 
 
U.S. government debt securities (Note 6)
$
—

 
$
226,858

 
$
—

 
$
226,858

Equity securities (Note 5)
61,747

 
14,876

 
—

 
76,623

Other
—

 
417

 
—

 
417

Total
$
61,747

 
$
242,151

 
$
—

 
$
303,898

The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at December 31, 2014:
 
Quoted Prices in Active Markets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
December 31,
2014
Assets
 
 
 
 
 
 
 
U.S. government debt securities (Note 6)
$
—

 
$
115,335

 
$
—

 
$
115,335

Equity securities (Note 5)
143,927

 
20,962

 
—

 
164,889

Other
—

 
273

 
—

 
273

Total
$
143,927

 
$
136,570

 
$
—

 
$
280,497

The carrying values of the Company's long term debt approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates. Financial liabilities measured on a recurring basis were not significant at September 30, 2015 and December 31, 2014.
The method used to estimate the fair value of the Level 1 assets in the tables above is based on observable market data as these equity securities are publicly-traded. The method used to estimate the fair value of the Level 2 short-term and long-term investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. The method used to estimate the fair value of the Level 2 equity securities in the tables above is based on the quoted market price of the publicly-traded security, adjusted for a discount for lack of marketability.
During the nine months ended September 30, 2015, $8,307 of certain equity securities have been transferred from Level 2 to Level 1 as a result of no longer needing to apply a discount for lack of marketability to these transferred equity securities.

35


8. Inventory
Inventory consists of the following:
 
September 30,
2015
 
December 31,
2014
Supplies, semen and embryos
$
1,368

 
$
1,184

Work in process
6,135

 
5,637

Livestock
12,753

 
16,996

Feed
2,082

 
1,972

Total inventory
$
22,338

 
$
25,789

9. Property, Plant and Equipment, net
Property, plant and equipment consist of the following:
 
September 30,
2015
 
December 31,
2014
Land and land improvements
$
9,085

 
$
7,565

Buildings and building improvements
7,311

 
7,265

Furniture and fixtures
1,608

 
1,236

Equipment
36,018

 
31,983

Leasehold improvements
6,998

 
6,382

Computer hardware and software
5,722

 
5,060

Construction and other assets in progress
1,927

 
1,002

 
68,669

 
60,493

Less: Accumulated depreciation and amortization
(26,468
)
 
(22,493
)
Property, plant and equipment, net
$
42,201

 
$
38,000

Depreciation expense was $1,987 and $1,807 for the three months ended September 30, 2015 and 2014, respectively, and $5,768 and $4,206 for the nine months ended September 30, 2015 and 2014, respectively.
10. Goodwill and Intangible Assets, net
The changes in the carrying amount of goodwill for the nine months ended September 30, 2015 are as follows:
Balance at December 31, 2014
$
101,059

Acquisitions
67,404

Foreign currency translation adjustment
(1,597
)
Balance at September 30, 2015
$
166,866

No goodwill or accumulated impairment losses existed as of September 30, 2015 and December 31, 2014.

36

Intangible assets consist of the following at September 30, 2015:
 
Weighted Average Useful Life (Years)
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net
Patents, related technologies and know-how
15.2
 
$
142,066

 
$
(15,141
)
 
$
126,925

Customer relationships
6.5
 
10,700

 
(2,255
)
 
8,445

Trademarks
8.4
 
5,900

 
(834
)
 
5,066

Covenant not to compete
2.0
 
395

 
(115
)
 
280

In-process research and development
 
 
115,568

 
—

 
115,568

Total
 
 
$
274,629

 
$
(18,345
)
 
$
256,284

Intangible assets consist of the following at December 31, 2014:
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net
Patents, related technologies and know-how
$
41,872

 
$
(10,849
)
 
$
31,023

Customer relationships
10,700

 
(806
)
 
9,894

Trademarks
5,900

 
(298
)
 
5,602

In-process research and development
19,428

 
—

 
19,428

Total
$
77,900

 
$
(11,953
)
 
$
65,947

Amortization expense was $2,857 and $1,290 for the three months ended September 30, 2015 and 2014, respectively and $6,434 and $2,664 for the nine months ended September 30, 2015 and 2014, respectively.
11. Lines of Credit and Long Term Debt
Lines of Credit
Trans Ova has a $6,000 revolving line of credit with First National Bank of Omaha which matures on May 1, 2016. The line of credit bears interest at the greater of 2.95% above the London Interbank Offered Rate or 3.00% and was 3.15% at September 30, 2015. As of September 30, 2015, there were no amounts outstanding. The amount available under the line of credit is based on eligible accounts receivable and inventory or the maximum line of credit amount.
Trans Ova's revolving line of credit is collateralized by certain of its assets and contain certain restricted covenants that include maintaining minimum tangible net worth, maximum allowable annual capital expenditures and working capital. Trans Ova was in compliance with these covenants as of September 30, 2015.
Exemplar has a $700 revolving line of credit with American State Bank which matures on November 1, 2016. The line of credit bears interest at 4.50% per annum. As of September 30, 2015, there was an outstanding balance of $475.
Long Term Debt
Long term debt consists of the following:
 
September 30,
2015
 
December 31,
2014
Notes payable
$
6,773

 
$
7,653

Royalty-based financing
1,857

 
1,926

Other
480

 
790

Long term debt
9,110

 
10,369

Less current portion
1,314

 
1,675

Long term debt, less current portion
$
7,796

 
$
8,694


37


Trans Ova has a note payable to American State Bank which matures in April 2033 and has an outstanding principal balance of $5,694 as of September 30, 2015. Trans Ova pays monthly installments of $39, which includes interest at 3.95%. The note payable is collateralized by all of Trans Ova's assets.
Trans Ova has a note payable to the Iowa Economic Development Authority which matures in July 2016 and has an outstanding principal balance of $550 as of September 30, 2015. Trans Ova pays quarterly installments of $183. The note payable in collateralized by certain parcels of Trans Ova's real estate.
Exemplar has notes payable with outstanding principal balances totaling $529 as of September 30, 2015. Exemplar pays monthly installments ranging from $1 to $4 with interest rates ranging from 0% to 3.00%. These notes mature from September 2018 to May 2020 and are collateralized by certain of Exemplar's real estate or letters of credit of certain of its members.
AquaBounty has a royalty-based financing grant from the Atlantic Canada Opportunities Agency ("ACOA"), a Canadian government agency, to provide funding of a research and development project. The total amount available under the award was $2,142, which AquaBounty claimed over a five year period. All amounts claimed by AquaBounty must be repaid in the form of a 10% royalty on any products commercialized out of this research and development project until fully paid. Because the timing of commercialization is subject to regulatory approval, the timing of repayment is uncertain. As of the acquisition date, AquaBounty had claimed $1,952 of the available funds and this amount was recorded at its acquisition date fair value of $1,107. The Company accretes the difference of $845 between the face value of amounts drawn and the acquisition date fair value over the expected period of repayment. Since the acquisition date, AquaBounty has claimed the remaining balance available under the grant, resulting in total long term debt of $1,857 as of September 30, 2015.
Future maturities of long term debt are as follows:
2015
$
506

2016
929

2017
382

2018
525

2019
340

2020
309

Thereafter
4,262

Total
$
7,253

The AquaBounty royalty-based financing grant is not included in the table above due to the uncertainty of the timing of repayment.
12. Income Taxes
Tax provisions for interim periods are calculated using an estimate of actual taxable income or loss for the respective period, rather than estimating the Company's annual effective income tax rate, as the Company is currently unable to reliably estimate its income for the full year. For the three months ended September 30, 2015, the Company had U.S. taxable loss of approximately $15,865, which resulted in an income tax benefit of $318 that was recognized to offset income tax expense recognized during the six months ended June 30, 2015. For the nine months ended September 30, 2015, the Company had U.S. taxable income of approximately $22,935, which, after offset of available loss carryforwards, resulted in $459 of current income tax expense due to the corporate alternative minimum tax. For the three and nine months ended September 30, 2015, the Company recognized $27 of current foreign income tax benefit. For the three months ended September 30, 2014, the Company had U.S. taxable loss of approximately $600, and no income tax benefit was recognized. For the nine months ended September 30, 2014, the Company had U.S. taxable income of approximately $600, which, after offset by available loss carryforwards, resulted in $23 of current income tax expense due to the corporate alternative minimum tax. For the three months ended September 30, 2015, the Company recorded deferred tax benefit of $578. For the nine months ended September 30, 2015, the Company recorded deferred tax expense of $374. There was no deferred tax expense for the three and nine months ended September 30, 2014. The Company's net deferred tax assets, excluding certain deferred tax liabilities totaling $21,550, are offset by a valuation allowance due to the Company's history of net losses combined with an inability to confirm recovery of the tax benefits of the Company's losses and other net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the

38


periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.
At September 30, 2015, the Company has loss carryforwards for U.S. federal income tax purposes of approximately $227,100 available to offset future taxable income and federal and state research and development tax credits of approximately $6,800, prior to consideration of annual limitations that may be imposed under Section 382. These carryforwards will begin to expire in 2022. Of these loss carryforwards, approximately $29,300 relates to benefits from stock compensation deductions that will be recorded as a component of paid-in capital when realized. The Company's direct foreign subsidiaries have foreign loss carryforwards of approximately $116,700, most of which do not expire.
13. Shareholders' Equity
Issuances of Common Stock
In August 2015, the Company closed a public offering of 5,609,756 shares of its common stock, inclusive of 731,707 shares of common stock sold by the Company pursuant to the full exercise of an overallotment option granted to the underwriters in connection with the offering, at a public offering price of $41.00 per share. The aggregate proceeds of the offering were $218,193, net of underwriting discounts of $11,500 and offering expenses paid by the Company of approximately $306, all of which were capitalized.
In January 2015, the Company closed a public offering of 4,312,500 shares of its common stock, inclusive of 562,500 shares of common stock sold by the Company pursuant to the full exercise of an overallotment option granted to the underwriters in connection with the offering and 555,556 shares of common stock purchased by affiliates of Third Security (Note 17), at a public offering price of $27.00 per share. The aggregate proceeds of the offering were $110,041, net of underwriting discounts and commissions of $6,086 and offering expenses paid by the Company of approximately $311, all of which were capitalized.
In March 2014 and concurrent with the formation of Intrexon Energy Partners, the Company entered into securities purchase agreements with each of the Investors in Intrexon Energy Partners for the private placement of 972,004 shares of the Company's common stock at a price per share of $25.72 for gross proceeds of $25,000. Each Investor purchased an amount proportionate to its investment in Intrexon Energy Partners, including 243,001 shares, or $6,250, purchased by an affiliate of Third Security (Note 17).
Dividend to Shareholders
In June 2015, the Company distributed to its shareholders 17,830,305 shares of ZIOPHARM common stock, representing all of the equity interests of ZIOPHARM held by the Company and resulting in a realized gain of $81,401. The distribution constituted a dividend to shareholders of record as of June 4, 2015. In connection with the distribution, pursuant to the terms of the Company's equity incentive plans, the conversion terms of all outstanding options for shares of the Company's stock as of June 4, 2015 were adjusted to reflect the value of the distribution with respect to shares of the Company's common stock.
Components of Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive loss were as follows:
 
September 30,
2015
 
December 31,
2014
Unrealized gain on investments
$
291

 
$
42

Foreign currency translation adjustments
(5,486
)
 
(46
)
Total accumulated other comprehensive loss
$
(5,195
)
 
$
(4
)

39


14. Stock Option Plans
The Company records the fair value of stock options issued to employees and non-employees as of the grant date as stock-based compensation expense. Stock-based compensation expense for employees and non-employees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the consolidated statements of operations are presented below:
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Cost of products
$
21

 
$
5

 
$
76

 
$
5

Cost of services
98

 
50

 
301

 
50

Research and development
2,234

 
1,514

 
6,141

 
3,226

Selling, general and administrative
6,032

 
2,681

 
20,006

 
11,591

Total
$
8,385

 
$
4,250

 
$
26,524

 
$
14,872

Intrexon Stock Option Plans
In April 2008, Intrexon adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Intrexon's board of directors may grant share based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of September 30, 2015, there are 1,439,637 stock options outstanding under the 2008 Plan.
In July 2013, the Company adopted the 2013 Plan for employees and nonemployees pursuant to which Intrexon's board of directors may grant share based awards, including stock options and shares of common stock, to employees, officers, consultants, advisors and nonemployee directors. The 2013 Plan became effective upon the closing of the Company's initial public offering in August 2013, and as of September 30, 2015, there were 13,000,000 shares authorized for issuance under the 2013 Plan, of which 9,220,403 stock options were outstanding and 3,219,354 shares were available for grant.
Stock option activity under Intrexon's award plans was as follows:
 
Number of Shares
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2014
8,323,544

 
$
22.59

 
8.64
Granted
4,282,000

 
47.89

 
 
Adjustment due to dividend (Note 13)
312,795

 
25.40

 
 
Exercised
(790,265
)
 
(16.89
)
 
 
Forfeited
(1,467,488
)
 
(25.77
)
 
 
Expired
(546
)
 
(17.72
)
 
 
Balances at September 30, 2015
10,660,040

 
32.07

 
8.53
Exercisable at September 30, 2015
2,502,418

 
18.18

 
6.73
Vested and Expected to Vest at September 30, 2015(1)
8,803,769

 
30.69

 
8.37
(1)
The number of stock options expected to vest takes into account an estimate of expected forfeitures.
Total unrecognized compensation costs related to nonvested awards at September 30, 2015 and December 31, 2014 were $112,205 and $62,281, respectively, and are expected to be recognized over a weighted-average period of approximately three years.
Intrexon currently uses authorized and unissued shares to satisfy share award exercises.

40


Other Plans
As of September 30, 2015, there were 5,382,000 options outstanding under the AquaBounty 2006 Equity Incentive Plan ("AquaBounty Plan") at a weighted average exercise price of $0.26 per share of which 4,320,333 were exercisable. As of December 31, 2014 , there were 7,347,000 options outstanding under the AquaBounty Plan at a weighted average exercise price of $0.31 per share of which 6,171,520 were exercisable.
15. License Agreement
In January 2015, the Company and ZIOPHARM jointly entered into a license agreement with the University of Texas System Board of Regents on behalf of the University of Texas MD Anderson Cancer Center ("MD Anderson") whereby the Company received an exclusive license to certain research and development technologies owned and licensed by MD Anderson, including technologies relating to novel chimeric antigen receptor (CAR) T-cell therapies, as well as co-licenses and non-exclusive licenses to certain other related technologies. ZIOPHARM shall receive access to these technologies pursuant to the terms of the Company's ECC with ZIOPHARM. The Company issued 2,100,085 shares of its common stock valued at $59,579 to MD Anderson as consideration, which is included in research and development expenses in the accompanying consolidated statement of operations for the nine months ended September 30, 2015. Subject to certain exceptions, the license agreement expires on the last to occur of (i) the expiration of all patents licensed thereunder, or (ii) the twentieth anniversary of the date of the license agreement.
In connection with the license agreement, the Company, ZIOPHARM, and MD Anderson entered into a research and development agreement which governs certain operational activities between the parties and pursuant to which ZIOPHARM will provide funding for certain research and development activities of MD Anderson for a period of three years, in an amount between $15,000 and $20,000 per year. The Company and ZIOPHARM are obligated to reimburse MD Anderson for out of pocket expenses for maintaining patents covering the licensed technologies.
16. Commitments and Contingencies
Operating Leases
The Company leases facilities and certain equipment under noncancelable operating leases. The equipment leases are renewable at the option of the Company. At September 30, 2015, future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:
2015
$
739

2016
4,161

2017
3,381

2018
2,067

2019
1,889

2020
1,941

Thereafter
1,587

Total
$
15,765

Rent expense, including other facility expenses, was $2,167 and $2,518 for the three months ended September 30, 2015 and 2014, respectively, and $6,548 and $5,249 for the nine months ended September 30, 2015 and 2014, respectively.
The Company maintains subleases for certain of its facilities. Rental income under sublease agreements was $334 and $270 for the three months ended September 30, 2015 and 2014, respectively, and $1,153 and $532 for the nine months ended September 30, 2015 and 2014, respectively. Future rental income approximates $182 for 2015, $741 for 2016, and $96 for 2017.
Contingencies
In March 2012, Trans Ova was named as a defendant in a licensing and patent infringement suit brought by XY, Inc. alleging that certain of Trans Ova's activities breach a licensing agreement and infringe on patents that XY, Inc. allegedly owns. Trans Ova is reviewing, defending and filing counter claims in the case. The matter is scheduled to go to trial in the first half of 2016. Based on advice from legal counsel, Trans Ova believes that XY, Inc.'s complaints are without merit; however, no assurances can be given that this matter will be resolved in Trans Ova's favor.

41

The Company may become subject to claims and assessments from time to time in the ordinary course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of September 30, 2015 and December 31, 2014, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.
17. Related Party Transactions
Third Security and Affiliates
The Company reimburses Third Security for certain administrative services and out-of-pocket expenses incurred on the Company's behalf. The total amount of expenses incurred by the Company for the three months ended September 30, 2015 and 2014 was $142 and $85, respectively and $294 and $173 for the nine months ended September 30, 2015 and 2014, respectively.
The Manager of Third Security is also the Chief Executive Officer ("CEO") and Chairman of the Board of Directors of the Company. Prior to 2015, the CEO did not receive compensation for his services as CEO, and as a result, the Company recorded $508 and $1,485 in compensation expense for the three and nine months ended September 30, 2014, respectively, based on the estimated salary and benefits appropriate for the role. The Company anticipates that the CEO will participate in the Company's executive annual incentive compensation plan beginning in 2015.
See additional discussion related to Third Security and the Company's CEO at Note 19.
Transactions with ECC Parties
In addition to entities controlled by Third Security, any entity in which the Company holds equity securities, including securities received as upfront or milestone consideration, and which also are party to a collaboration with the Company are considered to be related parties.
In July 2015, the Company purchased 375,868 shares of common stock of Fibrocell at $5.80 per share.
In March 2015, the Company purchased 278,788 shares of common stock of AmpliPhi Biosciences Corporation ("AmpliPhi"), a collaborator, and 69,696 warrants for $2,300. Of the total purchase price, $1,979 was allocated to the value of the shares of common stock and $321 was allocated to the value of the warrants. The number of shares and warrants received reflects a 1-for-50 reverse stock split of AmpliPhi's common stock effective August 7, 2015. The AmpliPhi warrants have been included in other assets on the consolidated balance sheet with a value of $145 as of September 30, 2015.
Between February 2011 and February 2015, the Company purchased $43,582 of ZIOPHARM securities. See Note 13 for additional discussion related to the Company's investment in ZIOPHARM.
The Company entered into an ECC with Histogenics Corporation ("Histogenics") in September 2014 and received a $10,000 convertible promissory note as upfront consideration. The note originally matured in September 2015 and accrued interest at 6.0% per annum. Upon the closing of Histogenics' IPO in December 2014, the note, with accrued interest, was converted to Histogenics common stock. Additionally, the Company purchased 1,772,364 shares of Histogenics common stock at $11.00 per share in the IPO.
In conjunction with the ECC with Oragenics (Note 5), the Company is entitled to, at its election, purchase up to 30% of securities offerings that may be conducted by Oragenics in the future, subject to certain conditions and limitations. In November 2013, the Company purchased 1,100,000 shares of Oragenics common stock at $2.50 per share. In September 2013, the Company purchased 1,300,000 shares of Oragenics common stock at $3.00 per share in a private transaction. In connection with Oragenics ECC 3 (Note 5), the Company agreed to purchase additional common stock in a qualified financing, as defined in the agreement, during the sixteen months following the effective date of the Oragenics ECC 3 in an amount up to the lesser of (i) the amount that is the proportion of such financing equal to the Company's pro rata equity holdings in Oragenics as of the effective date and (ii) $10,000, subject to certain conditions.
The Company recognized $31,740 and $11,295 of collaboration revenues from related parties in the three months ended September 30, 2015 and 2014, respectively, and $59,775 and $29,613 for the nine months ended September 30, 2015 and 2014, respectively.

42

Other Related Parties
In June 2015, the Company entered into an agreement with Harvest, an investment fund sponsored by Harvest Capital Strategies, LLC, and a related party based on ownership in the fund by affiliates of Third Security. Harvest was established to invest in life science research and development opportunities that Intrexon offers to Harvest. These will be investment proposals that are suitable for pursuit by a startup venture, characterized by the agreement as "start-up opportunities." For such start-up opportunities, the Company will provide Harvest with exclusive rights of first-look and first negotiation. For any opportunities it decides to pursue, Harvest would establish new collaboration entities which would enter into an ECC with the Company in a designated field. The terms of such ECCs would be negotiated between the Company and Harvest. In addition, the agreement provides the Company the right to present to Harvest the opportunity to invest in other ventures, including investment opportunities with respect to the Company's existing collaborations. Any such opportunities would be presented at the Company's discretion on a non-exclusive basis. The agreement with Harvest does not limit the Company's ability to execute other collaborations and joint ventures with third parties. As consideration for providing exclusive rights of first look and first negotiation for start-up opportunities, the Company receives a portion of the management fee collected by Harvest. These fees are included in other income in the accompanying consolidated statements of operations and totaled $697 for the three and nine months ended September 30, 2015.
18. Net Loss per Share
The following table presents the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2015 and 2014:
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Historical net loss per share:
 
 
 
 
 
 
 
Numerator:
 
 
 
 
 
 
 
Net loss attributable to Intrexon
$
(38,213
)
 
$
(52,725
)
 
$
(51,779
)
 
$
(100,653
)
Denominator:
 
 
 
 
 
 
 
Weighted average shares outstanding, basic and diluted
112,244,129

 
99,888,203

 
109,244,641

 
98,711,564

Net loss attributable to Intrexon per share, basic and diluted
$
(0.34
)
 
$
(0.53
)
 
$
(0.47
)
 
$
(1.02
)
The following potentially dilutive securities have been excluded from the above computations of diluted weighted average shares outstanding for the three and nine months ended September 30, 2015 and 2014, as they would have been anti-dilutive:
 
September 30,
 
2015
 
2014
Options
10,660,040

 
8,194,650

Warrants
194,719

 
373,102

Total
10,854,759

 
8,567,752

19. Subsequent Events
In November 2015, the Company entered into a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security will provide the Company with certain professional, administrative, and other support services in exchange for a fee of $800 per month to be paid in the form of fully-vested shares of the Company's common stock. The payments made by the Company under the Services Agreement constitute, in the aggregate, an award under the 2013 Plan and will be subject to the terms of the 2013 Plan.
In November 2015, the Company entered into a compensation arrangement with the Company's CEO. Previously, the CEO did not receive compensation for his services as CEO of the Company. Under the new compensation arrangement, the CEO will

43

receive compensation of $200 per month in the form of fully-vested shares of the Company's common stock. The shares of common stock will be issued pursuant to the terms of a Restricted Stock Unit Agreement under the 2013 Plan.

44

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following "Management's Discussion and Analysis of Financial Condition and Results of Operations" should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K.
The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements and you are cautioned not to place undue reliance on forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report on Form 10-Q, particularly in "Special Note Regarding Forward-Looking Statements" and "Risk Factors." The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date hereof.
Overview
We believe we are a leader in the field of synthetic biology, an emerging and rapidly evolving discipline that applies engineering principles to biological systems. Using our suite of proprietary and complementary technologies, we design, build and regulate gene programs, which are DNA sequences that consist of key genetic components. A single gene program or a complex, multi-genic program are fabricated and stored within a DNA vector. Vectors are segments of DNA used as a vehicle to transmit genetic information. DNA vectors can, in turn, be introduced into cells in order to generate a simple or complex cellular system, which are the basic and complex cellular activities that take place within a cell and the interaction of those systems in the greater cellular environment. It is these genetically modified cell systems that can be used to produce proteins, produce small molecules, or serve as cell-based products, which enable the development of new and improved products and manufacturing processes across a variety of end markets, including health, food, energy, environment, and consumer. Our synthetic biology capabilities include the ability to precisely control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.
We have devised our business model to bring many different commercial products to market through the formation of agreements, including exclusive channel collaborations, or ECCs, with collaborators that have expertise within specific industry sectors. Through our collaborations, we provide expertise in the engineering, creation and modification of gene programs and cellular systems, and our collaborators are responsible for providing market and product development expertise, as well as regulatory, sales and marketing capabilities. Generally, our collaborators compensate us through payment of technology access fees, royalties, milestones and reimbursement of certain costs. This business model allows us to leverage our capabilities and capital across a broader landscape of product opportunities and end markets than we would be capable of addressing on our own. Alternatively, where a collaborator wishes to work with us to develop an early-stage program, we may execute a research collaboration pursuant to which we receive reimbursement for our development costs but the exclusive license rights, and related access fee, are deferred until completion of an initial research program.
In certain strategic circumstances, we may enter into a joint venture with an ECC collaborator. In that event, we will enter into an ECC with a joint venture entity and may contribute access to our technology, cash or both into the joint venture which we will jointly control with our ECC collaborator. Pursuant to a joint venture agreement, we may be required to contribute additional capital to the joint venture, and we may be able to receive a higher financial return than we would normally receive from an ECC to the extent that we and our ECC collaborator are successful in developing one or more products. We currently are party to several such joint venture agreements including: S & I Ophthalmic, LLC, or S & I Ophthalmic, which is a joint venture with Caraco Pharmaceutical Laboratories, Ltd., or Sun Pharmaceutical Subsidiary, an indirect subsidiary of Sun Pharmaceutical Industries Ltd., or Sun Pharmaceutical, an international specialty pharmaceutical company focused on chronic diseases; OvaXon, LLC, or OvaXon, which is a joint venture with OvaScience, Inc., or OvaScience, a life sciences company focused on the discovery, development and commercialization of new treatments for infertility; and Intrexon Energy Partners, LLC, or Intrexon Energy Partners, a joint venture with a select group of external investors, to optimize and scale-up our gas-to-liquid bioconversion platform for the production of certain fuels and lubricants.
In 2011, we entered into our first collaboration and have added new collaborations since then, either by entering into new agreements or expanding or adding fields to existing ECCs. To date, we have entered into 36 such agreements and expansions with 28 different counterparties, of which 29 remain active. We have 26 active ECCs, including two expansions, and three research collaborations that we anticipate could, if successful, become commercial agreements. Under the ECCs, we are developing products in the fields of healthcare, food, energy, environment and consumer goods.
In June 2015, we entered into an agreement with Harvest Intrexon Enterprise Fund I, LP, or Harvest, an investment fund sponsored by Harvest Capital Strategies, LLC, and a related party based on ownership in the fund by affiliates of Third

45

Security, LLC. Harvest was established to invest in life science research and development opportunities that we offer to Harvest. These will be investment proposals that are suitable for pursuit by a startup venture, characterized by the agreement as "start-up opportunities." For such start-up opportunities, we will provide Harvest with exclusive rights of first-look and first negotiation. For any opportunities it decides to pursue, Harvest would establish new collaboration entities which would enter into an ECC with us in a designated field. The terms of such ECCs would be negotiated between us and Harvest.  In addition, the agreement provides us the right to present to Harvest the opportunity to invest in other ventures, including investment opportunities with respect to our existing collaborations. Any such opportunities would be presented at our discretion on a non-exclusive basis. The agreement with Harvest does not limit our ability to execute other collaborations and joint ventures with third parties. As consideration for providing exclusive rights of first look and first negotiation for start-up opportunities, we receive a portion of the management fee collected by Harvest.
As part of our ECC business model, we sometimes receive equity in lieu of cash for technology access fees and milestones and also may participate in capital raises to allow earlier-stage collaborators to focus their resources on product development. However, when such a collaborator develops greater operational or financial resources, its shares become a financial asset within Intrexon that is independent of our operational or collaborative purposes. In June 2015, we provided our shareholders the opportunity to participate directly in the value generated by our ECC with ZIOPHARM by distributing all of our shares in ZIOPHARM to our shareholders as a special stock dividend.
Mergers, acquisitions, and technology in-licensing
We may augment our suite of proprietary technologies through mergers or acquisitions of technologies which then become available to new or existing collaborators. Among other things, we seek to ensure that these acquired technologies are complementary to our existing technologies and that these mergers and acquisitions meet our desired return on investment and other economic criteria. In certain cases, such technologies may already be applied in the production of innovative products or services and in these cases, we seek to ensure that the target will achieve the creation of a new market or enable a disruptive position within an existing market for their existing products or services and that there is an opportunity for expansion of that unique position when complemented by our technology.
In September 2015, we acquired 100 percent of Oxitec Limited, or Oxitec, thereby expanding our capabilities to address a broad range of global environment, health and agricultural challenges. The aggregated consideration paid consisted of (i) 1,359,343 shares of our common stock, or the Stock Consideration, and (ii) $90.2 million in cash, or the Cash Consideration, inclusive of net cash and working capital adjustments, as defined in the agreement, totaling $9.4 million which are to be paid within eighty-five days of the September closing date. Stock Consideration totaling 480,422 shares and Cash Consideration totaling $2.0 million were withheld as escrow at closing and are issuable and payable, respectively, eighteen months after closing, subject to reduction for satisfaction of any claims for indemnification made by us under the agreement. We began consolidating Oxitec’s results of operations and financial position beginning in September 2015.
In April 2015, we acquired 100 percent of Okanagan Specialty Fruits Inc., or Okanagan, a company which developed and received regulatory approval for the world's first non-browning apple without the use of any flavor-altering chemical or antioxidant additives, for $10.0 million in cash and 707,853 shares of our common stock. In addition to supporting Okanagan's further commercialization and exploitation of its apple products, we expect to utilize our proprietary technologies to assist Okanagan in the development of further novel beneficial plant traits. We began consolidating Okanagan's results of operations and financial position beginning in April 2015.
In February 2015, we acquired 100 percent of ActoGeniX NV, or ActoGeniX, a European clinical stage biopharmaceutical company, for $32.7 million in cash and 965,377 shares of our common stock. ActoGeniX's platform technology complements our broad collection of technologies available for current and future collaborations. We began consolidating ActoGeniX's results of operations and financial position beginning in February 2015.
In January 2015, we and ZIOPHARM jointly entered into a license agreement with the University of Texas System Board of Regents on behalf of the University of Texas MD Anderson Cancer Center ("MD Anderson") whereby we received an exclusive license to certain research and development technologies owned and licensed by MD Anderson, including technologies relating to novel chimeric antigen receptor (CAR) T-cell therapies, as well as co-licenses and non-exclusive licenses to certain other related technologies. ZIOPHARM also received access to these technologies pursuant to the terms of our ECC with ZIOPHARM. We issued 2,100,085 shares of our common stock valued at $59.6 million to MD Anderson as consideration. Subject to certain exceptions, the license agreement expires on the last to occur of (i) the expiration of all patents licensed thereunder, or (ii) the twentieth anniversary of the date of the license agreement.

46

In August 2014, we acquired 100 percent of the membership interests of Trans Ova Genetics, L.C., or Trans Ova, a provider of bovine reproductive technologies. Intrexon and Trans Ova intend to build upon Trans Ova's current platform with new capabilities with a goal of achieving higher levels of delivered value to dairy and beef cattle producers. The consideration paid for all the membership interests in Trans Ova consisted of $63.6 million in cash and the issuance of an aggregate of 1,444,388 shares of the Company's common stock. In addition, deferred cash valued at $20.1 million is payable to the former members of Trans Ova in three equal installments upon the first, second, and third anniversaries of the closing date. The agreement also provides for the payment to the former members of Trans Ova of a portion of certain cash proceeds in the event there is an award under certain litigation matters pending as of closing to which Trans Ova is a party. We began consolidating Trans Ova's results of operations and financial position beginning in August 2014.
Financial overview
We have incurred significant losses since our inception. We anticipate that we may continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability. We have never generated any royalty revenues from sales of products by our collaborators and may never be profitable.
We expect our future capital requirements will be substantial, particularly as we continue to develop our business and expand our synthetic biology technology platform. We believe that our existing cash and cash equivalents, short-term and long-term investments, and cash expected to be received through our current collaborators and for sales of products and services provided by our consolidated subsidiaries will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.
Sources of revenue
We derive our revenues through the execution of ECCs and license and collaboration agreements for the development and commercialization of products enabled by our technologies. Generally, the terms of our collaborations provide that we receive some or all of the following: (i) technology access fees upon signing; (ii) reimbursements of costs incurred by us for our research and development and/or manufacturing efforts related to the specific application provided for in the collaboration; (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities; and (iv) royalties on sales of products arising from the collaboration.
Our technology access fees and milestone payments may be in the form of cash or securities of the collaborator. Our collaborations contain multiple arrangements and we typically defer revenues from the technology access fees and milestone payments received and recognize such revenues in the future over the anticipated performance period. We are also entitled to sublicensing revenues in those situations where our collaborators choose to license our technologies to other parties.
We also generate products and services revenue through sales of advanced reproductive technologies, including bovine embryos derived from our embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock used in production.  Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) services have been rendered or delivery has occurred such that risk of loss has passed to the customer, (iii) the price is fixed or determinable, and (iv) collection from the customer is reasonably assured.
In future periods, our revenues will depend on the number of collaborations to which we are party, the advancement and creation of programs within our collaborations and the extent to which our collaborators bring products enabled by our technologies to market. Our revenues will also depend upon our ability to maintain or improve the volume and pricing of our current product and service offerings and to develop new offerings, including those arising from the Okanagan and Oxitec acquisitions and those which may incorporate our technologies. Our revenues will also depend upon the ability of AquaBounty to receive regulatory approval and establish successful commercialization of its AquAdvantage® Salmon products. Our future revenues may also include additional revenue streams we may acquire through mergers and acquisitions. In light of our limited operating history and experience in consummating new collaborations and also the limited experience with our consolidated subsidiaries, there can be no assurance as to the timing, magnitude and predictability of revenues to which we might be entitled.
Cost of products and services revenues
Cost of products and services revenues includes primarily labor and related costs, drugs and supplies used primarily in the embryo transfer and in vitro fertilization processes, livestock and feed used in production, and facility charges, including rent and depreciation.  Fluctuations in the price of livestock and feed have not had a significant impact on our operating margins and no derivative financial instruments are used to mitigate the price risk.

47

Research and development expenses
We recognize research and development expenses as they are incurred. Our research and development expenses consist primarily of:
•
salaries and benefits, including stock-based compensation expense, for personnel in research and development functions;
•
fees paid to consultants and contract research organizations who perform research on our behalf and under our direction;
•
costs related to laboratory supplies used in our research and development efforts;
•
costs related to certain in-licensed technology rights;
•
depreciation of leasehold improvements and laboratory equipment;
•
amortization of patents and related technologies acquired in mergers and acquisitions; and
•
rent and utility costs for our research and development facilities.
We have no individually significant research and development projects and our research and development expenses primarily relate to either the costs incurred to expand or otherwise improve our multiple platform technologies or the costs incurred to develop a specific application of our technologies in support of current or prospective collaborators. Research and development expenses typically do not include significant development, including preclinical or clinical development, activities since they are the responsibility of our collaborators. Research and development expenses incurred for programs we support pursuant to an ECC agreement are typically reimbursed by the collaborator at cost and all other research and development programs may be terminated or otherwise deferred at our discretion. The amount of our research and development expenses may be impacted by, among other things, the number of collaborations and the number and size of programs we may support on behalf of a collaboration.
The table below summarizes our research and development expenses incurred to expand or otherwise improve our multiple platform technologies or the costs incurred to develop a specific application of our technologies in support of current or prospective collaborators and licensees for the three and nine months ended September 30, 2015 and 2014. Other research and development expenses for these periods include indirect salaries and overhead expenses that are not allocated to either expanding or improving our multiple platform technologies or specific applications of our technologies in support of current or prospective collaborators and licensees.
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
 
(In thousands)
Expansion or improvement of our platform technologies
$
3,641

 
$
3,134

 
$
72,168

 
$
10,185

Specific applications of our technologies in support of current and prospective collaborators and licensees
10,608

 
7,015

 
28,686

 
19,198

Other
7,349

 
4,702

 
20,432

 
11,960

Total research and development expenses
$
21,598

 
$
14,851

 
$
121,286

 
$
41,343

We expect that our research and development expenses will increase as we continue to enter into collaborations and as we expand our offerings across additional market sectors. We believe these increases will likely include increased costs related to the hiring of additional personnel in research and development functions, increased costs paid to consultants and contract research organizations and increased costs related to laboratory supplies. Research and development expenses may also increase as a result of ongoing research and development operations which we might assume through mergers and acquisitions.

48

Selling, general and administrative expenses
Selling, general and administrative expenses consist primarily of salaries and related costs, including stock-based compensation expense, for employees in executive, operational, finance, sales and marketing, information technology and legal functions. Other significant selling, general and administrative expenses include rent and utilities, advertising, insurance, legal services and expenses associated with obtaining and maintaining our intellectual property.
We expect that our selling, general and administrative expenses will increase as we continue to operate as a public company and expand our operations. We believe that these increases will likely include costs related to the hiring of additional personnel and increased fees for outside consultants, lawyers and accountants, including costs to comply with corporate governance, internal controls and similar requirements applicable to public companies. Selling, general and administrative expenses may also increase as a result of ongoing operations which we might assume through mergers and acquisitions.
Other income (expense), net
We hold equity securities received and/or purchased from certain collaborators. Other than investments accounted for using the equity method discussed below, we elected the fair value option to account for our equity securities held in these collaborators. These equity securities are recorded at fair value at each reporting date. Unrealized appreciation (depreciation) resulting from fair value adjustments are reported as other income (expense) in the consolidated statements of operations. As such, we bear the risk that fluctuations in the securities' share prices may significantly impact our results of operations. In June 2015, we recorded a realized gain related to the distribution of all of our shares of ZIOPHARM to our shareholders as a special stock dividend.
Interest income consists of interest earned on our cash and cash equivalents and short-term and long-term investments.
Interest expense pertains to deferred consideration payable to the former members of Trans Ova and long term debt.
As consideration for providing exclusive rights of first-look and first negotiation, we receive a portion of the management fee collected by Harvest for our obligation to provide Harvest with investment proposals that are suitable for pursuit by a startup. These fees are included in other income.
Equity in net loss of affiliates
Equity in net income or loss of affiliates is our pro-rata share of our equity method investments' operating results, adjusted for accretion of basis difference. We account for investments in our joint ventures and startup entities backed by Harvest using the equity method of accounting since we have the ability to exercise significant influence, but not control, over the operating activities of these joint ventures.

49

Results of operations
Comparison of the three months ended September 30, 2015 and the three months ended September 30, 2014
The following table summarizes our results of operations for the three months ended September 30, 2015 and 2014, together with the changes in those items in dollars and as a percentage:
 
Three Months Ended 
 September 30,
 
Dollar
Change
 
Percent
Change
 
2015
 
2014
 
 
(In thousands)
 
 
Revenues
 
 
 
 
 
 
 
Collaboration and licensing revenues
$
34,726

 
$
12,656

 
$
22,070

 
174.4
 %
Product revenues
9,446

 
4,115

 
5,331

 
129.6
 %
Service revenues
8,945

 
4,261

 
4,684

 
109.9
 %
Other revenues
250

 
165

 
85

 
51.5
 %
Total revenues
53,367

 
21,197

 
32,170

 
151.8
 %
Operating expenses
 
 
 
 
 
 


Cost of products
11,215

 
4,224

 
6,991

 
165.5
 %
Cost of services
5,451

 
2,316

 
3,135

 
135.4
 %
Research and development
21,598

 
14,851

 
6,747

 
45.4
 %
Selling, general and administrative
23,019

 
14,853

 
8,166

 
55.0
 %
Total operating expenses
61,283

 
36,244

 
25,039

 
69.1
 %
Operating loss
(7,916
)
 
(15,047
)
 
7,131

 
(47.4
)%
Total other expense, net
(29,607
)
 
(37,196
)
 
7,589

 
(20.4
)%
Equity in loss of affiliates
(2,429
)
 
(1,619
)
 
(810
)
 
50.0
 %
Loss before income taxes
(39,952
)
 
(53,862
)
 
13,910

 
(25.8
)%
Income tax benefit
923

 
—

 
923

 
N/A

Net loss
(39,029
)
 
(53,862
)
 
14,833

 
(27.5
)%
Net loss attributable to noncontrolling interests
816

 
1,137

 
(321
)
 
(28.2
)%
Net loss attributable to Intrexon
$
(38,213
)
 
$
(52,725
)
 
$
14,512

 
(27.5
)%
Collaboration and licensing revenues
The following table shows the collaboration and licensing revenue recognized for upfront and milestone payments received from our collaborators and reimbursements received for research and development services provided to our collaborators for the three months ended September 30, 2015 and 2014, together with the changes in those items:

50

 
Upfront and Milestone Payments
 
Research and Development Services
 
Total
 
Three Months Ended 
 September 30,
 
Dollar
Change
 
Three Months Ended 
 September 30,
 
Dollar
Change
 
Three Months Ended 
 September 30,
 
Dollar
Change
 
2015
 
2014
 
2015
 
2014
 
2015
 
2014
 
 
(In thousands)
ZIOPHARM Oncology, Inc.
$
645

 
$
644

 
$
1

 
$
4,006

 
$
3,370

 
$
636

 
$
4,651

 
$
4,014

 
$
637

Oragenics, Inc.
4,868

 
261

 
4,607

 
332

 
3

 
329

 
5,200

 
264

 
4,936

Fibrocell Science, Inc.
4,823

 
449

 
4,374

 
1,317

 
1,014

 
303

 
6,140

 
1,463

 
4,677

Genopaver, LLC
68

 
68

 
—

 
993

 
360

 
633

 
1,061

 
428

 
633

S & I Ophthalmic, LLC
—

 
—

 
—

 
1,193

 
667

 
526

 
1,193

 
667

 
526

OvaXon, LLC
—

 
—

 
—

 
549

 
813

 
(264
)
 
549

 
813

 
(264
)
Intrexon Energy Partners, LLC
625

 
625

 
—

 
3,185

 
1,535

 
1,650

 
3,810

 
2,160

 
1,650

Persea Bio, LLC
125

 
—

 
125

 
297

 
—

 
297

 
422

 
—

 
422

Ares Trading S.A.
1,597

 
—

 
1,597

 
260

 
—

 
260

 
1,857

 
—

 
1,857

Other
7,841

 
443

 
7,398

 
2,002

 
2,404

 
(402
)
 
9,843

 
2,847

 
6,996

Total
$
20,592

 
$
2,490

 
$
18,102

 
$
14,134

 
$
10,166

 
$
3,968

 
$
34,726

 
$
12,656

 
$
22,070

Collaboration and licensing revenues increased $22.1 million over the three months ended September 30, 2014 due to (i) the recognition of deferred revenue for upfront payments received from our license and collaboration agreement with Ares Trading S.A, or Ares Trading, which became effective in May 2015, and from other collaborations signed by us between October 1, 2014 and September 30, 2015; (ii) increased research and development services for both new collaborations and for the expansion or addition of new programs with previously existing collaborators, including ZIOPHARM, Genopaver, LLC, or Genopaver, and our joint venture with Intrexon Energy Partners; and (iii) the recognition of previously deferred revenue related to collaboration agreements for which we satisfied all of our obligations or which were terminated during the three months ended September 30, 2015.
Product and service revenues and cost of products and services
For the three months ended September 30, 2015, product revenue includes $8.3 million from the sale of pregnant cows, live calves and livestock used in production and service revenue includes $7.3 million from the provision of in vitro fertilization and embryo transfer services. For the three months ended September 30, 2014, these amounts were $3.8 million and $3.1 million, respectively. For the three months ended September 30, 2015, costs of products and services include $16.5 million related to the production of such products and services which primarily consist of employee compensation costs, livestock, feed, drug supplies, recipient costs and facility charges; this amount was $6.4 million for the three months ended September 30, 2014. These increases relate primarily to the inclusion of a full three months of results for Trans Ova in 2015 versus approximately one and a half months of results for 2014 since the acquisition occurred in August 2014.
Research and development expenses
Research and development expenses were $21.6 million for the three months ended September 30, 2015 compared to $14.9 million for the three months ended September 30, 2014, an increase of $6.7 million, or 45 percent. Salaries, benefits and other personnel costs increased $3.1 million due to (i) increases in research and development headcount to support new and expanded collaborations and from our 2015 acquisitions and (ii) additional compensation expenses related to performance and retention incentives for research and development employees. Lab supplies and consultants expenses increased $1.5 million as a result of the increased level of research and development services provided to our collaborators. Depreciation and amortization increased $1.3 million primarily as a result of acquiring property and equipment and intangible assets in connection with our acquisitions of ActoGeniX and Okanagan in 2015.
Selling, general and administrative expenses
Selling, general and administrative expenses were $23.0 million for the three months ended September 30, 2015 compared to $14.9 million for the three months ended September 30, 2014, an increase of $8.1 million, or 55 percent. Salaries, benefits and other personnel costs increased $4.1 million due to (i) the inclusion of selling, general and administrative employees of Trans

51

Ova for the full three months in 2015 compared to approximately one and a half months in 2014 and (ii) additional compensation expenses related to performance and retention incentives for selling, general and administrative employees. Legal and professional expenses increased $1.4 million primarily due to costs associated with the Oxitec acquisition in 2015.
Total other expense, net
Total other expense, net, was $29.6 million for the three months ended September 30, 2015 compared to $37.2 million for the three months ended September 30, 2014, a decrease of $7.6 million or 20 percent. Unrealized depreciation in fair value of equity securities decreased from $37.1 million for the three months ended September 30, 2014 to $30.5 million for the three months ended September 30, 2015 due to market changes in our equity securities portfolio.
Equity in net loss of affiliates
Equity in net loss of affiliates for the three months ended September 30, 2015 and 2014 includes our pro-rata share of the net losses of our investments we account for using the equity method of accounting. The $0.8 million increase in net loss of affiliates is primarily due to higher net losses incurred by Intrexon Energy Partners in 2015.
Comparison of the nine months ended September 30, 2015 and the nine months ended September 30, 2014
The following table summarizes our results of operations for the nine months ended September 30, 2015 and 2014, together with the changes in those items in dollars and as a percentage:
 
Nine Months Ended 
 September 30,
 
Dollar
Change
 
Percent
Change
 
2015
 
2014
 
 
(In thousands)
 
 
Revenues
 
 
 
 
 
 
 
Collaboration and licensing revenues
$
66,690

 
$
32,257

 
$
34,433

 
106.7
 %
Product revenues
32,645

 
4,124

 
28,521

 
>200%

Service revenues
32,157

 
4,261

 
27,896

 
>200%

Other revenues
615

 
196

 
419

 
>200%

Total revenues
132,107

 
40,838

 
91,269

 
>200%

Operating expenses
 
 
 
 
 
 


Cost of products
31,654

 
4,310

 
27,344

 
>200%

Cost of services
17,316

 
2,316

 
15,000

 
>200%

Research and development
121,286

 
41,343

 
79,943

 
193.4
 %
Selling, general and administrative
74,320

 
43,870

 
30,450

 
69.4
 %
Total operating expenses
244,576

 
91,839

 
152,737

 
166.3
 %
Operating loss
(112,469
)
 
(51,001
)
 
(61,468
)
 
120.5
 %
Total other income (expense), net
65,121

 
(49,014
)
 
114,135


>200%

Equity in loss of affiliates
(6,565
)
 
(3,510
)
 
(3,055
)
 
87.0
 %
Loss before income taxes
(53,913
)
 
(103,525
)
 
49,612

 
(47.9
)%
Income tax expense
(806
)
 
(23
)
 
(783
)
 
>200%

Net loss
(54,719
)
 
(103,548
)
 
48,829

 
(47.2
)%
Net loss attributable to noncontrolling interests
2,940

 
2,895

 
45

 
1.6
 %
Net loss attributable to Intrexon
$
(51,779
)
 
$
(100,653
)
 
$
48,874

 
(48.6
)%
Collaboration and licensing revenues
The following table shows the collaboration and licensing revenue recognized for upfront and milestone payments received from our collaborators and reimbursements received for research and development services provided to our collaborators for the nine months ended September 30, 2015 and 2014, together with the changes in those items:

52

 
Upfront and Milestone Payments
 
Research and Development Services
 
Total
 
Nine Months Ended 
 September 30,
 
Dollar
Change
 
Nine Months Ended 
 September 30,
 
Dollar
Change
 
Nine Months Ended 
 September 30,
 
Dollar
Change
 
2015
 
2014
 
2015
 
2014
 
2015
 
2014
 
 
(In thousands)
ZIOPHARM Oncology, Inc.
$
1,933

 
$
1,932

 
$
1

 
$
11,769

 
$
9,103

 
$
2,666

 
$
13,702

 
$
11,035

 
$
2,667

Oragenics, Inc.
5,437

 
784

 
4,653

 
408

 
588

 
(180
)
 
5,845

 
1,372

 
4,473

Fibrocell Science, Inc.
5,719

 
1,345

 
4,374

 
4,500

 
2,759

 
1,741

 
10,219

 
4,104

 
6,115

Genopaver, LLC
205

 
205

 
—

 
2,460

 
1,204

 
1,256

 
2,665

 
1,409

 
1,256

S & I Ophthalmic, LLC
—

 
—

 
—

 
2,838

 
2,153

 
685

 
2,838

 
2,153

 
685

OvaXon, LLC
—

 
—

 
—

 
1,855

 
1,561

 
294

 
1,855

 
1,561

 
294

Intrexon Energy Partners, LLC
1,875

 
1,250

 
625

 
8,101

 
2,745

 
5,356

 
9,976

 
3,995

 
5,981

Persea Bio, LLC
375

 
—

 
375

 
553

 
—

 
553

 
928

 
—

 
928

Ares Trading S.A.
2,336

 
—

 
2,336

 
260

 
—

 
260

 
2,596

 
—

 
2,596

Other
9,446

 
1,373

 
8,073

 
6,620

 
5,255

 
1,365

 
16,066

 
6,628

 
9,438

Total
$
27,326

 
$
6,889

 
$
20,437

 
$
39,364

 
$
25,368

 
$
13,996

 
$
66,690

 
$
32,257

 
$
34,433

Collaboration and licensing revenues increased $34.4 million over the nine months ended September 30, 2014 due to (i) the recognition of deferred revenue for upfront payments received from our license and collaboration agreement with Ares Trading, which became effective in May 2015, and from other collaborations signed by us between January 1, 2014 and September 30, 2015; (ii) increased research and development services for both new collaborations and for the expansion or addition of new programs with previously existing collaborators, including ZIOPHARM; Fibrocell Science, Inc., or Fibrocell; Genopaver and our joint venture with Intrexon Energy Partners; and (iii) the recognition of previously deferred revenue related to collaboration agreements for which we satisfied all of our obligations or which were terminated during the nine months ended September 30, 2015.
Product and service revenues and cost of products and services
For the nine months ended September 30, 2015, product revenue includes $28.4 million from the sale of pregnant cows, live calves and livestock used in production and service revenue includes $27.2 million from the provision of in vitro fertilization and embryo transfer services. For the nine months ended September 30, 2014, these amounts were $3.8 million and $3.1 million, respectively. For the nine months ended September 30, 2015, costs of products and services include $48.6 million related to the production of such products and services which primarily consist of employee compensation costs, livestock, feed, drug supplies, recipient costs and facility charges; this amount was $6.4 million for the nine months ended September 30, 2014. These increases relate primarily to the inclusion of nine months of results for Trans Ova in 2015 versus approximately one and one half months of results in 2014 since the acquisition occurred in August 2014.
Research and development expenses
Research and development expenses were $121.3 million for the nine months ended September 30, 2015 compared to $41.3 million for the nine months ended September 30, 2014, an increase of $80.0 million, or 193 percent. In January 2015, we issued 2,100,085 shares of our common stock valued at $59.6 million to the University of Texas MD Anderson Cancer Center, or MD Anderson, in exchange for an exclusive license to certain technologies owned by MD Anderson. Salaries, benefits and other personnel costs increased $9.0 million due to (i) increases in research and development headcount to support new and expanded collaborations and from our 2015 acquisitions and (ii) additional compensation expenses related to performance and retention incentives for research and development employees. Lab supplies and consultants expenses increased $5.6 million as a result of the increased level of research and development services provided to our collaborators. Depreciation and amortization expense increased $2.2 million primarily as a result of acquiring property and equipment and intangible assets in connection with our acquisitions of ActoGeniX and Okanagan in 2015.

53

Selling, general and administrative expenses
Selling, general and administrative expenses were $74.3 million for the nine months ended September 30, 2015 compared to $43.9 million for the nine months ended September 30, 2014, an increase of $30.4 million, or 69 percent. Salaries, benefits and other personnel costs increased $17.5 million due to (i) the inclusion of selling, general and administrative employees of Trans Ova for a full nine months in 2015 compared to approximately one and a half months in 2014 and (ii) additional compensation expenses related to performance and retention incentives for general and administrative employees. Legal and professional expenses increased $4.1 million primarily due to costs associated with the acquisitions of Oxitec, ActoGeniX, Okanagan and Exemplar, the license agreement with MD Anderson and other business development activity. Depreciation and amortization associated with Trans Ova increased $2.0 million due to the inclusion of such amounts for nine months in 2015 compared to one and one half months in 2014.
Total other income (expense), net
Total other income (expense), net, was $65.1 million for the nine months ended September 30, 2015 compared to $(49.0) million for the nine months ended September 30, 2014, an increase of $114.1 million or 233 percent. This increase was primarily related to the $81.4 million realized gain recognized upon the special stock dividend of all of our shares of ZIOPHARM to our shareholders in June 2015 and offset by unrealized depreciation in fair value of equity securities of $17.0 million for the nine months ended September 30, 2015 compared to $48.9 million for the nine months ended September 30, 2014 due to market changes in our equity securities portfolio.
Equity in net loss of affiliates
Equity in net loss of affiliates for the nine months ended September 30, 2015 and 2014 includes our pro-rata share of the net losses of our investments we account for using the equity method of accounting. The $3.1 million increase in net loss of affiliates is primarily due to higher net losses incurred by Intrexon Energy Partners in 2015.
Liquidity and capital resources
Sources of liquidity
We have incurred losses from operations since our inception and as of September 30, 2015, we had an accumulated deficit of $510.0 million. From our inception through September 30, 2015, we have funded our operations principally with the proceeds received from the sale of $509.5 million of our preferred stock, net proceeds from our IPO of $168.3 million and net proceeds from our subsequent public offerings of $328.2 million. As of September 30, 2015, we had cash and cash equivalents of $125.4 million and short-term and long-term investments of $227.1 million. Cash in excess of immediate requirements is invested primarily in money market funds, certificates of deposits and U.S. government debt securities in order to maintain liquidity and capital preservation.
Cash flows
The following table sets forth the significant sources and uses of cash for the periods set forth below: 
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
(In thousands)
Net cash provided by (used in):
 
 
 
Operating activities
$
23,337

 
$
(10,808
)
Investing activities
(257,318
)
 
(36,494
)
Financing activities
331,441

 
22,595

Effect of exchange rate changes on cash and cash equivalents
507

 
(98
)
Net increase (decrease) in cash and cash equivalents
$
97,967

 
$
(24,805
)
Cash flows from operating activities:
Net cash provided by operating activities was $23.3 million for the nine months ended September 30, 2015 compared to $10.8 million net cash used in operating activities for the nine months ended September 30, 2014. During the nine months ended

54

September 30, 2015, we received a $115.0 million technology access fee, of which $57.5 million was paid to ZIOPHARM, from our license and collaboration agreement with Ares Trading, offset by our net loss of $54.7 million which includes noncash items of (i) $64.4 million of unrealized appreciation and realized gains on our equity securities, (ii) $59.6 million of common stock issued to MD Anderson recorded as research and development expense, (iii) $26.5 million of stock-based compensation expense, and (iv) $12.2 million of depreciation and amortization expense. Net cash used in operating activities during the nine months ended September 30, 2014 was primarily composed of our $103.5 million net loss, which includes noncash items of (i) $48.9 million of unrealized depreciation on our equity securities, (ii) $14.9 million of stock compensation expense, and (iii) $6.9 million of depreciation and amortization expense, offset by the receipt of a $25.0 million technology access fee from our ECC with Intrexon Energy Partners.
Cash flows from investing activities:
Net cash used in investing activities was $257.3 million for the nine months ended September 30, 2015 compared to $36.5 million for the nine months ended September 30, 2014. During the nine months ended September 30, 2015, we used $114.5 million, net of cash received, for the acquisitions of ActoGeniX, Okanagan, and Oxitec; $181.6 million for the purchase of short-term and long-term investments; $17.1 million for the purchase of equity securities and warrants of three of our collaborators; and $9.8 million for purchases of property, plant and equipment. These cash outflows were offset by $70.0 million of proceeds from the maturity of short-term and long-term investments. During the nine months ended September 30, 2014, we received proceeds from the maturity of short-term and long-term investments of $98.3 million. These proceeds were offset by cash outflows of $67.1 million for the acquisitions of Trans Ova and Medistem, Inc., net of cash received; $60.5 million of purchases of short-term and long-term investments; and $5.2 million in purchases of property and equipment.
Cash flows from financing activities:
Net cash provided by financing activities was $331.4 million for the nine months ended September 30, 2015 compared to $22.6 million for the nine months ended September 30, 2014. During the nine months ended September 30, 2015, we received $328.2 million of net proceeds from our public offerings in January and August. During the nine months ended September 30, 2014, we received $25.0 million of proceeds from the private placement of our common stock which closed in March and $1.3 million from stock option exercises.
Future capital requirements
We established our current strategy and business model of commercializing our technologies through collaborators with development expertise in 2010 and we consummated our first collaboration in January 2011. We believe that we will continue to consummate collaborations with new companies across our various market sectors, which will result in additional upfront, milestone and cost recovery payments in the future.
We believe that our existing cash and cash equivalents, short-term and long-term investments, and cash expected to be received from our current collaborators and for sales of products and services provided by our consolidated subsidiaries will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.
We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:
 
•
progress in our research and development programs, as well as the magnitude of these programs;
•
the timing, receipt and amount of upfront, milestone and other payments, if any, from present and future collaborators, if any;
•
the timing, receipt and amount of sales and royalties, if any, from our potential products;
•
our ability to maintain or improve the volume and pricing of our current product offerings and to develop new offerings, including those which may incorporate new technologies;
•
the timing, receipt and amount of funding under future government contracts, if any;
•
our ability to maintain and establish additional collaborative arrangements and/or new business initiatives;

55

•
the timing of regulatory approval of products of our operations and those of AquaBounty;
•
the resources, time and cost required for the preparation, filing, prosecution, maintenance and enforcement of patent claims;
•
investments we may make in current and future collaborators, including joint ventures;
•
strategic mergers and acquisitions, including both the upfront acquisition cost as well as the cost to integrate, maintain, and expand the strategic target; and
•
the costs associated with legal activities, including litigation, arising in the course of our business activities and our ability to prevail in any such legal disputes.
Until such time, if ever, as we can generate positive operating cash flows, we may finance our cash needs through a combination of equity offerings, debt financings, government or other third-party funding, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common shareholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.
Contractual obligations and commitments
The following table summarizes our significant contractual obligations and commercial commitments at September 30, 2015 and the effects such obligations are expected to have on our liquidity and cash flows in future periods:
 
Total
 
Less Than 1 Year
 
1 - 3 Years
 
3 - 5 Years
 
More Than 5 Years
 
(In thousands)
Operating leases
$
15,765

 
$
3,909

 
$
5,969

 
$
3,806

 
$
2,081

Deferred consideration
24,922

 
16,212

 
8,710

 
—

 
—

Long term debt
7,253

 
1,314

 
940

 
661

 
4,338

 
$
47,940

 
$
21,435

 
$
15,619

 
$
4,467

 
$
6,419

In addition to the obligations in the table above, as of September 30, 2015 we also have the significant contractual obligations described below.
We acquired 100 percent of the outstanding capital stock of Immunologix in October 2011. The transaction included a contingent consideration arrangement which may require us to pay the selling shareholders 50 percent, subject to a maximum of $2.0 million, of revenue generated from Immunologix's technology applied towards a specific target as defined in the agreement up to a maximum of $2.0 million. This amount is not included in the table above due to the uncertainty of whether, if ever, we will pay this contingent consideration.
We are also party to in-licensed research and development agreements with various academic and commercial institutions where we could be required to make future payments for annual maintenance fees as well as for milestones and royalties we might receive upon commercial sales of products which incorporate their technologies. These agreements are generally subject to termination by us and therefore no amounts are included in the tables above. At September 30, 2015, we had research and development commitments with third parties totaling $6.6 million that had not yet been incurred.
In January 2009, AquaBounty was awarded a grant to provide funding of a research and development project from the Atlantic Canada Opportunities Agency, a Canadian government agency. The total amount available under the award was USD$2.1 million, which AquaBounty claimed over a five year period. All amounts claimed by AquaBounty must be repaid in the form of a 10 percent royalty on any products commercialized out of this research and development project until fully paid. Because the

56

timing of commercialization is subject to regulatory approval, the timing of repayment is uncertain. As of the acquisition date, AquaBounty had claimed $2.0 million of the available funds and this amount was recorded on our audited consolidated balance sheet at its acquisition date fair value of $1.1 million. The Company accretes the difference of $0.9 million between the face value of amounts drawn and the acquisition date fair value over the expected period of repayment. Since the acquisition date, AquaBounty claimed the remaining balance available under the grant, resulting in total long-term debt of $1.9 million as of September 30, 2015. This amount is not included in the table above due to the uncertainty of the timing of repayment.
In conjunction with the formation of a joint venture with an indirect subsidiary of Sun Pharmaceutical Industries, Ltd. in September 2013, we committed to making future capital contributions to the joint venture, subject to certain conditions and limitations, in order to comply with the obligations of the joint venture. In cases in which the board of managers of the joint venture determines that additional capital contributions are necessary, we have committed to making additional capital contributions subject to certain limitations. These future capital contributions are not included in the table above due to the uncertainty of the timing and amounts of such contributions.
In conjunction with the formation of a joint venture with OvaScience in December 2013, we may make future capital contributions to the joint venture. In cases in which the board of the joint venture determines that additional capital contributions are necessary, we have the option of making additional capital contributions subject to certain limitations. These future capital contributions are not included in the table above due to the uncertainty of the timing and amounts of such contributions.
In conjunction with the formation of a joint venture with Intrexon Energy Partners in March 2014, we committed to making future capital contributions to the joint venture in the amount of $25.0 million at the request of the board of managers of Intrexon Energy Partners and subject to certain conditions and limitations. As of September 30, 2015, our remaining commitment was $20.4 million. These future capital contributions are not included in the table above due to the uncertainty of the timing and amounts of such contributions.
In August 2014, we acquired all of the membership interests of Trans Ova and agreed to pay a portion of certain cash proceeds in the event there is an award under certain litigation matters pending as of closing to which Trans Ova is a party. These amounts are not included in the table above due to the uncertainty of whether any amounts may be due.
In conjunction with a prior transaction associated with Trans Ova's subsidiary, ViaGen, in September 2012, the Company may be obligated to make certain future contingent payments to the former equity holders of ViaGen, up to a total of $6.0 million if certain revenue targets, as defined in the share purchase agreement, are met. This amount is not included in the table above due to the uncertainty of when the Company will make any of these future payments, if ever.
In January 2015, we and ZIOPHARM jointly entered into a license agreement with MD Anderson whereby we received an exclusive license to certain technologies owned by MD Anderson. ZIOPHARM shall receive access to these technologies pursuant to the terms of our ECC. We and ZIOPHARM are obligated to reimburse MD Anderson for out of pocket expenses for maintaining patents covering the licensed technologies. These reimbursements are not included in the table above due to the uncertainty of the timing and amounts of such reimbursements.
In June 2015, we and Oragenics, Inc., or Oragenics, entered into an ECC. In conjunction with this ECC, we agreed to purchase additional common stock in a qualified financing, as defined in the agreement, during the sixteen months following the effective date of the ECC in an amount up to the lesser of (i) the amount that is the proportion of such financing equal to the Company's pro rata equity holdings in Oragenics as of the effective date and (ii) $10,000, subject to certain conditions. This amount is not included in the table above due to the uncertainty of the timing of this payment.
Net operating losses
As of September 30, 2015, we had net operating loss carryforwards of approximately $227.1 million for U.S. federal income tax purposes available to offset future taxable income and U.S. federal and state research and development tax credits of $6.8 million, prior to consideration of annual limitations that may be imposed under Section 382 of the Internal Revenue Code of 1986, as amended, or Section 382. These carryforwards begin to expire in 2022. Our direct foreign subsidiaries have foreign loss carryforwards of approximately $116.7 million, most of which do not expire.
Our past issuances of stock and mergers and acquisitions have resulted in ownership changes within the meaning of Section 382. As a result, the utilization of portions of our net operating losses may be subject to annual limitations. As of September 30, 2015, approximately $16.4 million of our net operating losses generated prior to 2008 are limited by Section 382 to annual usage limits of approximately $1.5 million. As of September 30, 2015, approximately $19.1 million of domestic net

57

operating losses were inherited via acquisition and are limited based on the value of the target at the time of the transaction. Future changes in stock ownership may also trigger an ownership change and, consequently, a Section 382 limitation.
Off-balance sheet arrangements
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, other than operating leases as mentioned above, as defined under Securities and Exchange Commission, or SEC, rules.
Critical accounting policies and estimates
Our management's discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.
There have been no material changes to our critical accounting policies from those described in "Management's discussion and analysis of financial condition and results of operations" included in our Annual report on Form 10-K for the year ended December 31, 2014.
Recent accounting pronouncements
For information with respect to recent accounting pronouncements and the impact of these pronouncement on our consolidated financial statements, see Note 2 – "Summary of Significant Accounting Policies" in the notes to the consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
The following sections provide quantitative information on our exposure to interest rate risk, stock price risk, and foreign currency exchange risk. We make use of sensitivity analyses which are inherently limited in estimating actual losses in fair value that can occur from changes in market conditions.
Interest rate risk
We had cash, cash equivalents and short-term and long-term investments of $352.6 million and $143.1 million at September 30, 2015 and December 31, 2014, respectively. Our cash and cash equivalents and short-term and long-term investments consist of cash, money market funds, U.S. government debt securities and certificates of deposit. The primary objective of our investment activities is to preserve principal, maintain liquidity and maximize income without significantly increasing risk. Our investments consist of U.S. government debt securities and certificates of deposit which may be subject to market risk due to changes in prevailing interest rates that may cause the fair values of our investments to fluctuate. We believe that a hypothetical 100 basis point increase in interest rates would not materially affect the fair value of our interest-sensitive financial instruments and any such losses would only be realized if we sold the investments prior to maturity.
Investments in publicly traded companies
We have common stock investments in several publicly traded companies that are subject to market price volatility. We have adopted the fair value method of accounting for these investments, except for our investment in AquaBounty as further described below, and therefore, have recorded them at fair value at the end of each reporting period with the unrealized gain or loss recorded as a separate component of other income (expense), net for the period. As of September 30, 2015 and December 31, 2014 the original aggregate cost basis of these investments was $102.6 million and $173.9 million, respectively, and the market value was $76.6 million and $164.9 million, respectively. The fair value of these investments is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these companies. The fair value of these investments as of September 30, 2015 would be approximately $84.3 million and $61.3 million, respectively, based on a hypothetical 10 percent increase or 20 percent decrease in the value of

58


the investments. The fair value of these investments as of December 31, 2014 would be approximately $181.4 million and $131.9 million, respectively, based on a hypothetical 10 percent increase or 20 percent decrease in the value of the investments.
In November 2012, we acquired 47.56 percent of the outstanding common stock of AquaBounty and we accounted for this investment under the equity method of accounting for the period from acquisition date through March 15, 2013. On March 15, 2013, we acquired 18,714,814 additional shares of AquaBounty common stock for $4.9 million, thereby increasing our aggregate ownership to 53.82 percent upon closing. Accordingly, effective upon closing of the acquisition of the additional shares, we consolidated the assets and operating results of AquaBounty in our consolidated financial statements. On March 20, 2014, we acquired 19,040,366 additional shares of AquaBounty common stock for $10.0 million, and on June 30, 2015, we acquired 12,728,044 additional shares for $3.0 million, thereby increasing our aggregate ownership to 62.96 percent upon closing. The common stock of AquaBounty is traded on the London Stock Exchange and the fair value of our investment in AquaBounty at September 30, 2015 and December 31, 2014 was $18.8 million and $22.8 million, respectively. The fair value of our investment in AquaBounty as of September 30, 2015 would be approximately $20.7 million and $15.0 million, respectively, based on a hypothetical 10 percent increase or 20 percent decrease in the share price of AquaBounty. The fair value of our investment in AquaBounty as of December 31, 2014 would be approximately $25.1 million and $18.2 million, respectively, based on a hypothetical 10 percent increase or 20 percent decrease in the share price of AquaBounty.
Foreign currency exchange risk
Because the common stock of AquaBounty is traded on the London Stock Exchange, the fair value of our holdings is subject to fluctuations in foreign currency rates. In addition, some of our subsidiaries' assets and current expenses are denominated in foreign currencies. We do not hedge our foreign currency exchange rate risk. The effect of a hypothetical 10 percent change in foreign currency exchange rates applicable to our business would not have a material impact on our consolidated financial statements.
Item 4. Controls and Procedures
Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), we carried out an evaluation, under supervision and with the participation of our management, including our Chief Executive Officer ("CEO"), who is our principal executive officer, and our Chief Financial Officer ("CFO"), who is our principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined under Rule 13a-15(e) and 15(d)-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, as of the end of the period covered by this report, our CEO and CFO concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.
In August 2014, we completed the acquisition of Trans Ova Genetics, L.C. (Trans Ova). Accordingly, our assessment of internal controls over financial reporting for the year ended December 31, 2014 excluded Trans Ova from the scope of our report. Under guidelines established by the SEC, companies are permitted to exclude acquisitions from their assessment of internal control over financial reporting during the first year of an acquisition while integrating the acquired company. During the integration period management is developing additional controls to ensure the financial information provided by Trans Ova is complete and accurate in all material respects. We expect this effort to be completed during 2015.
There has been no change in our internal control over financial reporting during the quarter ended September 30, 2015, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

59

PART II. OTHER INFORMATION 
Item 1. Legal Proceedings
We are involved in litigation or legal matters incidental to our business activities. While the outcome of these matters cannot be predicted with certainty, we are vigorously defending them and do not currently expect that any of them will have a material adverse effect on our business or financial position. However, should one or more of these matters be resolved in a manner adverse to our current expectation, the effect on our results of operations for a particular fiscal reporting period could be material.
Item 1A. Risk Factors
As disclosed in "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2014, there are a number of risks and uncertainties that can have a material effect on the operating results of our business and our financial condition. There are no additional material updates or changes to our risk factors since the filing of our Annual Report on Form 10-K for the year ended December 31, 2014, except as follows:
We may encounter difficulties in connection with our acquisition of Oxitec.
In September 2015, we acquired Oxitec Limited, or Oxitec. We cannot be certain that this acquisition will be successful or that we will realize the anticipated benefits of the acquisition. In particular, we may not be able to realize the strategic and operational benefits and objectives we anticipate. In addition, we may face increased competition in the markets for Oxitec’s products. Any of the following factors may have a material adverse effect on our business, operating results and financial condition. These factors may include:
•
the potential disruption of our ongoing business and diversion of management resources;
•
unanticipated expenses related to Oxitec's operations;
•
the impairment of relationships with Oxitec's customers;
•
the impairment of relationships with key suppliers and their ability to meet our demand;
•
potential unknown liabilities associated with the acquired business and technology;
•
potential liabilities related to litigation involving Oxitec;
•
potential periodic impairment of goodwill and intangible assets acquired; and
•
potential inability to retain, integrate and motivate key personnel.
AquaBounty will need additional capital.
In order for AquaBounty Technologies, Inc., or AquaBounty, to execute on its business plan as announced by its management, AquaBounty will have future capital requirements, and we may be asked to invest additional funds in AquaBounty. On June 30, 2015, we invested an additional $3.0 million into AquaBounty. If we fail to invest additional funds, we may not retain control over AquaBounty. We have been advised by the management of AquaBounty that as of September 30, 2015, AquaBounty held $3.1 million of cash and cash equivalents and had a working capital balance of $2.6 million and that the proceeds from Intrexon’s $3.0 million investment will provide AquaBounty with sufficient cash resources to continue operating to early 2016 at its current rate of spending. We have no contractual obligation to provide funds to AquaBounty and therefore we do not know whether, or to what extent, we will be required to invest additional funds in AquaBounty.
In evaluating our risks, readers should carefully consider these risk factors and the risk factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2014, which could materially affect our business, financial condition or operating results, in addition to the other information set forth in this report and in our other filings with the Securities and Exchange Commission.


60


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(a) Sales of Unregistered Securities
From July 1, 2015 through September 30, 2015, we consummated the following transaction involving the issuance of unregistered securities:
•
the issuance of 878,921 unregistered shares of our common stock on September 4, 2015 in connection with our acquisition of all of the outstanding equity of Oxitec Limited as previously discussed in our Current Reports on Form 8-K filed on August 12, 2015 and September 8, 2015.
(b) Use of Proceeds
On August 7, 2013, our registration statement on Form S-1 (File No. 333-189853) was declared effective by the Securities and Exchange Commission for our initial public offering pursuant to which we sold an aggregate of 11,499,998 shares of our common stock (inclusive of 1,499,999 shares of common stock sold by us pursuant to the full exercise of an overallotment option granted to the underwriters in connection with the offering) at a price to the public of $16.00 per share for aggregate gross offering proceeds of approximately $184.0 million. J.P. Morgan Securities LLC and Barclays Capital Inc. acted as joint book-running managers. On August 13, 2013, we closed the sale of such shares, resulting in net proceeds to us of approximately $168.3 million after deducting underwriting discounts and commissions of approximately $12.9 million and other offering expenses of approximately $2.8 million. No payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates. We invested the funds received in cash equivalents and other short-term and long-term investments in accordance with our investment policy. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus, dated August 7, 2013, and filed with the Securities and Exchange Commission on August 8, 2013 pursuant to Rule 424(b).
On January 27, 2015, we closed a public offering of 4,312,500 shares of our common stock (inclusive of 562,500 shares of common stock sold by us pursuant to the full exercise of an option granted to the underwriters in connection with the offering) at a public offering price of $27.00 per share for aggregate gross offering proceeds of approximately $116.4 million. J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporate acted as joint book-running managers. Net proceeds to us were approximately $110.0 million after deducting underwriting discounts and commissions of approximately $6.1 million and other offering expenses of approximately $0.3 million. No payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates. We invested the funds received in cash equivalents and other short-term and long-term investments in accordance with our investment policy. There has been no material change in the planned use of proceeds from this offering as described in our final prospectus, dated January 21, 2015, and filed with the Securities and Exchange Commission on January 22, 2015 pursuant to Rule 424(b).
On August 26, 2015, we closed a public offering of 5,609,756 shares of our common stock (inclusive of 731,707 shares of common stock sold by us pursuant to the full exercise of an option granted to the underwriters in connection with the offering) at a public offering price of $41.00 per share for aggregate gross offering proceeds of approximately $230.0 million. JMP Securities LLC acted as sole book-running manager. Stifel, Nicolaus & Company, Incorporated acted as lead manager. Griffin Securities, Inc. and Wunderlich Securities, Inc. acted as co-managers. Net proceeds to us were approximately $218.2 million after deducting underwriting discounts and commissions of approximately $11.5 million and other offering expenses of approximately $0.3 million. No payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates. We invested the funds received in cash equivalents and other short-term and long-term investments in accordance with our investment policy. There has been no material change in the planned use of proceeds from this offering as described in our final prospectus, dated August 21, 2015, and filed with the Securities and Exchange Commission on August 25, 2015 pursuant to Rule 424(b).
(c) Issuer Purchases of Equity Securities
Not applicable.

61


Item 6. Exhibits
Exhibit
No.
 
Description
1.1*
 
Underwriting Agreement, dated August 21, 2015, by and among the Company and JMP Securities LLC, as representative of the several underwriters named therein (incorporated by reference to Exhibit 1.1 to Intrexon Corporation’s Current Report on Form 8-K, filed on August 21, 2015 with the Securities and Exchange Commission)
 
 
2.1*
 
Agreement for the Acquisition of the Entire Issued and To Be Issued Share Capital of Oxitec Limited, dated August 7, 2015, by and among Intrexon Corporation, the Sellers named therein, the Warrantors (as defined therein) and 3729th Single Member Shelf Trading Company Limited (incorporated by reference to Exhibit 2.1 to Intrexon Corporation’s Current Report on Form 8-K, filed on August 12, 2015 with the Securities and Exchange Commission)
 
 
31.1
 
Certification of Randal J. Kirk, Chairman and Chief Executive Officer (Principal Executive Officer) of Intrexon Corporation, pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
31.2
 
Certification of Rick L. Sterling, Chief Financial Officer (Principal Financial Officer) of Intrexon Corporation, pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
32.1**
 
Certification of Randal J. Kirk, Chairman and Chief Executive Officer (Principal Executive Officer) of Intrexon Corporation, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
32.2**
 
Certification of Rick L. Sterling, Chief Financial Officer (Principal Financial Officer) of Intrexon Corporation, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
101.0**
 
Interactive Data File (Quarterly Report on Form 10-Q, for the quarterly period ended September 30, 2015, formatted in XBRL (eXtensible Business Reporting Language)).
 
Attached as Exhibit 101.0 to this Quarterly Report on Form 10-Q are the following documents formatted in XBRL: (i) the Consolidated Balance Sheets at September 30, 2015 and December 31, 2014, (ii) the Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and 2014, (iii) the Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2015 and 2014, (iv) the Consolidated Statements of Shareholders' and Total Equity for the nine months ended September 30, 2015, (v) the Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 and 2014, and (vi) the Notes to Consolidated Financial Statements.
*    Previously filed.
**
Furnished herewith.


62


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
Intrexon Corporation
 
 
(Registrant)
 
 
 
Date: November 9, 2015
 
By:
 
/s/  Rick L. Sterling        
 
 
 
 
Rick L. Sterling
 
 
 
 
Chief Financial Officer
 
 
 
 
(Principal Financial and Accounting Officer)


63
 EX-31.1 2 xon-20150930xexx311.htm EX 31.1 Exhibit


Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Randal J. Kirk, certify that:
 
1.
I have reviewed this quarterly report on Form 10-Q of Intrexon Corporation;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 9, 2015
 
/s/ RANDAL J. KIRK
Randal J. Kirk
Chairman and Chief Executive Officer
(Principal Executive Officer)


 EX-31.2 3 xon-20150930xexx312.htm EX 31.2 Exhibit


Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Rick L. Sterling, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Intrexon Corporation;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 Date: November 9, 2015
 
/s/ RICK L. STERLING
Rick L. Sterling
Chief Financial Officer
(Principal Financial Officer)


 EX-32.1 4 xon-20150930xexx321.htm EX 32.1 Exhibit


Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
I, Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon Corporation (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
•
the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2015 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
•
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 9, 2015
 
/s/ RANDAL J. KIRK
Randal J. Kirk
Chairman and Chief Executive Officer
(Principal Executive Officer)
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.



 EX-32.2 5 xon-20150930xexx322.htm EX 32.2 Exhibit


Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
I, Rick L. Sterling, Chief Financial Officer of Intrexon Corporation (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
•
the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2015 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
•
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 9, 2015
 
/s/ RICK L. STERLING
Rick L. Sterling
Chief Financial Officer
(Principal Financial Officer)
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.



 EX-101.INS 6 xon-20150930.xml XBRL INSTANCE DOCUMENT 0001356090 2015-01-01 2015-09-30 0001356090 xon:OkanaganSpecialtyFruitsIncMember 2015-01-01 2015-09-30 0001356090 xon:TransOvaGeneticsLcMember 2015-01-01 2015-09-30 0001356090 xon:ActoGeniXNVMember 2015-01-01 2015-09-30 0001356090 xon:A2014BusinessAcquisitionsMember 2015-01-01 2015-09-30 0001356090 xon:OxitecLimitedMember 2015-01-01 2015-09-30 0001356090 xon:MedistemIncMember 2015-01-01 2015-09-30 0001356090 xon:A2015BusinessAcquisitionsMember 2015-01-01 2015-09-30 0001356090 2015-10-31 0001356090 2014-12-31 0001356090 2015-09-30 0001356090 2014-01-01 2014-09-30 0001356090 2014-07-01 2014-09-30 0001356090 2015-07-01 2015-09-30 0001356090 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-09-30 0001356090 us-gaap:CommonStockMember 2015-09-30 0001356090 us-gaap:RetainedEarningsMember 2014-12-31 0001356090 us-gaap:ParentMember 2015-01-01 2015-09-30 0001356090 us-gaap:ParentMember 2014-12-31 0001356090 us-gaap:CommonStockMember 2015-01-01 2015-09-30 0001356090 us-gaap:AdditionalPaidInCapitalMember 2015-09-30 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-09-30 0001356090 us-gaap:NoncontrollingInterestMember 2015-01-01 2015-09-30 0001356090 us-gaap:NoncontrollingInterestMember 2014-12-31 0001356090 us-gaap:RetainedEarningsMember 2015-01-01 2015-09-30 0001356090 us-gaap:CommonStockMember 2014-12-31 0001356090 us-gaap:NoncontrollingInterestMember 2015-09-30 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-09-30 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0001356090 us-gaap:RetainedEarningsMember 2015-09-30 0001356090 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001356090 us-gaap:ParentMember 2015-09-30 0001356090 2014-09-30 0001356090 2013-12-31 0001356090 xon:AquaBountyMember 2015-09-30 0001356090 xon:BioPopMember 2015-09-30 0001356090 us-gaap:EquitySecuritiesMember xon:ZiopharmMember 2014-07-01 2014-09-30 0001356090 us-gaap:EquitySecuritiesMember xon:OragenicsMember 2015-09-30 0001356090 us-gaap:MinimumMember 2015-01-01 2015-09-30 0001356090 us-gaap:EquitySecuritiesMember xon:ZiopharmMember 2014-01-01 2014-09-30 0001356090 us-gaap:EquitySecuritiesMember xon:OragenicsMember 2014-07-01 2014-09-30 0001356090 us-gaap:LeaseholdImprovementsMember us-gaap:MaximumMember 2015-01-01 2015-09-30 0001356090 us-gaap:EquitySecuritiesMember xon:OragenicsMember 2014-12-31 0001356090 us-gaap:LeaseholdImprovementsMember us-gaap:MinimumMember 2015-01-01 2015-09-30 0001356090 us-gaap:EquitySecuritiesMember xon:OragenicsMember 2015-07-01 2015-09-30 0001356090 us-gaap:NonUsMember 2015-07-01 2015-09-30 0001356090 us-gaap:NonUsMember 2014-12-31 0001356090 xon:ZiopharmMember 2014-12-31 0001356090 us-gaap:EquitySecuritiesMember xon:ZiopharmMember 2014-12-31 0001356090 us-gaap:EquitySecuritiesMember xon:OragenicsMember 2014-01-01 2014-09-30 0001356090 xon:ZiopharmMember 2015-04-01 2015-06-30 0001356090 us-gaap:EquitySecuritiesMember xon:OragenicsMember 2015-01-01 2015-09-30 0001356090 xon:OragenicsMember 2015-09-30 0001356090 us-gaap:NonUsMember 2015-01-01 2015-09-30 0001356090 us-gaap:NonUsMember 2015-09-30 0001356090 us-gaap:MaximumMember 2015-01-01 2015-09-30 0001356090 us-gaap:NonUsMember 2014-07-01 2014-09-30 0001356090 xon:OragenicsMember 2014-12-31 0001356090 us-gaap:NonUsMember 2014-01-01 2014-09-30 0001356090 us-gaap:EquityMethodInvestmentsMember 2014-07-01 2014-09-30 0001356090 us-gaap:EquityMethodInvestmentsMember 2015-01-01 2015-09-30 0001356090 us-gaap:EquityMethodInvestmentsMember 2014-01-01 2014-09-30 0001356090 us-gaap:EquityMethodInvestmentsMember 2015-07-01 2015-09-30 0001356090 us-gaap:EquityMethodInvestmentsMember 2014-12-31 0001356090 us-gaap:EquityMethodInvestmentsMember 2015-09-30 0001356090 us-gaap:EquipmentMember us-gaap:MinimumMember 2015-01-01 2015-09-30 0001356090 us-gaap:EquipmentMember us-gaap:MaximumMember 2015-01-01 2015-09-30 0001356090 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MaximumMember 2015-01-01 2015-09-30 0001356090 xon:ComputerHardwareandSoftwareMember us-gaap:MaximumMember 2015-01-01 2015-09-30 0001356090 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2015-01-01 2015-09-30 0001356090 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2015-01-01 2015-09-30 0001356090 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MinimumMember 2015-01-01 2015-09-30 0001356090 us-gaap:LandImprovementsMember us-gaap:MinimumMember 2015-01-01 2015-09-30 0001356090 us-gaap:LandImprovementsMember us-gaap:MaximumMember 2015-01-01 2015-09-30 0001356090 xon:ComputerHardwareandSoftwareMember us-gaap:MinimumMember 2015-01-01 2015-09-30 0001356090 xon:TransOvaGeneticsLcMember 2015-09-30 0001356090 xon:ActoGeniXNVMember 2015-02-01 2015-02-28 0001356090 xon:TransOvaGeneticsLcMember 2014-07-01 2014-09-30 0001356090 xon:TransOvaGeneticsLcMember us-gaap:MinimumMember 2014-08-01 2014-08-31 0001356090 xon:OxitecLimitedMember 2015-09-01 2015-09-30 0001356090 xon:ActoGeniXNVMember 2015-02-28 0001356090 xon:TransOvaGeneticsLcMember 2014-08-01 2014-08-31 0001356090 xon:MedistemIncMember 2014-03-31 0001356090 xon:ExemplarGeneticsLLCMember 2015-02-01 2015-02-28 0001356090 xon:TransOvaGeneticsLcMember 2014-08-31 0001356090 xon:OkanaganSpecialtyFruitsIncMember 2015-04-01 2015-04-30 0001356090 xon:TransOvaGeneticsLcMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-07-01 2014-09-30 0001356090 xon:TransOvaGeneticsLcMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-01-01 2014-09-30 0001356090 xon:TransOvaGeneticsLcMember us-gaap:MaximumMember 2014-08-01 2014-08-31 0001356090 xon:MedistemIncMember 2014-03-01 2014-03-31 0001356090 xon:TransOvaGeneticsLcMember 2015-07-01 2015-09-30 0001356090 xon:OxitecLimitedMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-07-01 2015-09-30 0001356090 xon:OkanaganSpecialtyFruitsIncMember 2015-04-30 0001356090 xon:OxitecLimitedMember 2015-09-30 0001356090 xon:TransOvaGeneticsLcMember 2014-01-01 2014-09-30 0001356090 xon:ActoGeniXNVMember 2015-08-01 2015-08-31 0001356090 xon:MedistemIncMember xon:PromissoryNotesMember 2014-03-01 2014-03-31 0001356090 xon:OkanaganSpecialtyFruitsIncMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-09-30 0001356090 xon:MedistemIncMember 2014-01-01 2014-09-30 0001356090 xon:ActoGeniXNVMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-09-30 0001356090 xon:TransOvaGeneticsLcMember 2012-09-30 0001356090 xon:MedistemIncMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-01-01 2014-09-30 0001356090 xon:OkanaganSpecialtyFruitsIncMember us-gaap:ScenarioAdjustmentMember 2015-04-30 0001356090 xon:OkanaganSpecialtyFruitsIncMember us-gaap:ScenarioActualMember 2015-04-30 0001356090 xon:OkanaganSpecialtyFruitsIncMember us-gaap:ScenarioPlanMember 2015-04-30 0001356090 xon:A2015BusinessAcquisitionsMember us-gaap:ProFormaMember 2015-07-01 2015-09-30 0001356090 xon:A2015BusinessAcquisitionsMember us-gaap:ProFormaMember 2015-01-01 2015-09-30 0001356090 xon:A2015BusinessAcquisitionsMember us-gaap:ProFormaMember 2014-01-01 2014-09-30 0001356090 xon:A2015BusinessAcquisitionsMember us-gaap:ProFormaMember 2014-07-01 2014-09-30 0001356090 xon:ActoGeniXNVMember us-gaap:ScenarioPlanMember 2015-02-28 0001356090 xon:ActoGeniXNVMember us-gaap:ScenarioActualMember 2015-02-28 0001356090 xon:ActoGeniXNVMember us-gaap:ScenarioAdjustmentMember 2015-02-28 0001356090 xon:OxitecLimitedMember us-gaap:ScenarioPlanMember 2015-09-30 0001356090 xon:A2014BusinessAcquisitionsMember us-gaap:ProFormaMember 2014-07-01 2014-09-30 0001356090 xon:A2014BusinessAcquisitionsMember us-gaap:ProFormaMember 2014-01-01 2014-09-30 0001356090 xon:OxitecLimitedMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-09-30 0001356090 xon:InvestmentsInAffiliatesMember xon:SIOphthalmicMember 2015-09-30 0001356090 us-gaap:InvestorMember xon:IntrexonEnergyPartnersMember 2014-03-31 0001356090 xon:IntrexonEnergyPartnersMember 2015-09-30 0001356090 xon:InvestmentsInAffiliatesMember xon:SIOphthalmicMember 2014-12-31 0001356090 xon:OtherAccruedLiabilitiesMember xon:IntrexonEnergyPartnersMember 2014-12-31 0001356090 xon:IntrexonEnergyPartnersMember 2014-03-31 0001356090 xon:InvestmentsInAffiliatesMember xon:OvaXonMember 2015-09-30 0001356090 xon:OvaXonMember 2015-09-30 0001356090 xon:OvaXonMember 2014-01-31 0001356090 xon:OtherAccruedLiabilitiesMember xon:OvaXonMember 2014-12-31 0001356090 xon:SIOphthalmicMember 2013-10-31 0001356090 xon:OvaXonMember 2014-01-01 2014-01-31 0001356090 xon:OtherAccruedLiabilitiesMember xon:IntrexonEnergyPartnersMember 2015-09-30 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2014-03-01 2014-03-31 0001356090 us-gaap:InvestorMember xon:IntrexonEnergyPartnersMember 2014-03-01 2014-03-31 0001356090 xon:SIOphthalmicMember 2015-09-30 0001356090 xon:SIOphthalmicMember 2013-10-01 2013-10-31 0001356090 xon:MilestoneOneMember xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmOncologyEccOneMember 2012-10-01 2012-10-31 0001356090 xon:IntrexonEnergyPartnersMember 2014-03-01 2014-03-31 0001356090 xon:AquaBountyMember 2013-02-01 2013-02-28 0001356090 xon:SIOphthalmicMember 2013-09-01 2013-09-30 0001356090 xon:OragenicsThirdEccMember 2015-06-01 2015-06-30 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2014-03-01 2014-03-31 0001356090 xon:OragenicsEccMember 2012-06-30 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2012-10-01 2012-10-31 0001356090 xon:PrepaidResearchAndDevelopmentServicesMember xon:AresTradingS.A.Member 2015-05-31 0001356090 xon:AresTradingS.A.Member 2015-09-30 0001356090 xon:FibrocellMember 2012-10-01 2012-10-31 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:OragenicsThirdEccMember 2015-06-01 2015-06-30 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:OragenicsEccMember 2012-06-01 2012-06-30 0001356090 xon:ZiopharmOncologyEccOneMember 2011-01-01 2011-01-31 0001356090 xon:PrepaidResearchAndDevelopmentServicesMember xon:AresTradingS.A.Member 2015-05-01 2015-05-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmOncologyEccOneMember 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:PerseaBioLLCMember 2014-12-31 0001356090 xon:AresTradingS.A.Member 2015-05-01 2015-05-31 0001356090 xon:OragenicsEccMember 2012-06-01 2012-06-30 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmOncologyEccOneMember 2011-01-01 2011-01-31 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:PerseaBioLLCMember 2014-12-01 2014-12-31 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:GenopaverEccMember 2013-03-01 2013-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:AresTradingS.A.Member 2015-09-30 0001356090 xon:ZiopharmOncologyEccTwoMember 2015-09-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OragenicsEccMember 2014-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2014-12-31 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:OragenicsSecondEccMember 2013-09-01 2013-09-30 0001356090 xon:ZiopharmOncologyEccOneMember 2011-01-31 0001356090 xon:ZiopharmMember xon:AresTradingS.A.Member 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2014-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OragenicsEccMember 2015-09-30 0001356090 xon:OvaXonMember 2013-12-01 2013-12-31 0001356090 xon:FibrocellMember 2013-04-30 2013-04-30 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmOncologyEccUnitOfAccountingOneMember 2011-01-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:PerseaBioLLCMember 2015-09-30 0001356090 xon:SupplementalUpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2014-01-01 2014-01-31 0001356090 xon:SupplementalUpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2013-06-01 2013-06-30 0001356090 xon:ThriveAgrobioticsInc.Member 2015-09-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2015-09-30 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmOncologyEccSeparateUnitOfAccountingMember 2011-01-01 2011-01-31 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:OragenicsSecondEccMember 2013-12-01 2013-12-31 0001356090 xon:GenopaverEccMember 2013-03-01 2013-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmOncologyEccOneMember 2014-12-31 0001356090 xon:FibrocellMember 2012-10-31 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:AresTradingS.A.Member 2015-05-01 2015-05-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:GenopaverEccMember 2014-12-31 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:ThriveAgrobioticsInc.Member 2015-09-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OragenicsThirdEccMember 2015-09-30 0001356090 xon:ZiopharmMember xon:AresTradingS.A.Member 2015-07-01 2015-09-30 0001356090 xon:PerseaBioLLCMember 2014-12-01 2014-12-31 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmOncologyEccTwoMember 2015-09-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:GenopaverEccMember 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:SIOphthalmicMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:IntrexonEnergyPartnersMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OvaXonMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:PerseaBioLLCMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OvaXonMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:SIOphthalmicMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:AresTradingS.A.Member 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:FibrocellMember 2015-07-01 2015-09-30 0001356090 xon:OtherCollaborationsMember 2015-07-01 2015-09-30 0001356090 xon:IntrexonEnergyPartnersMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:GenopaverEccMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:PerseaBioLLCMember 2015-07-01 2015-09-30 0001356090 xon:OragenicsMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OragenicsMember 2015-07-01 2015-09-30 0001356090 xon:PerseaBioLLCMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OtherCollaborationsMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2015-07-01 2015-09-30 0001356090 xon:SIOphthalmicMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:ZiopharmMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:AresTradingS.A.Member 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OtherCollaborationsMember 2015-07-01 2015-09-30 0001356090 xon:OvaXonMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:GenopaverEccMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OragenicsMember 2015-07-01 2015-09-30 0001356090 xon:FibrocellMember 2015-07-01 2015-09-30 0001356090 xon:ZiopharmMember 2015-07-01 2015-09-30 0001356090 xon:GenopaverEccMember 2015-07-01 2015-09-30 0001356090 xon:AresTradingS.A.Member 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember 2015-09-30 0001356090 xon:PrepaidResearchAndDevelopmentServicesMember 2014-12-31 0001356090 xon:DeferredRevenueOtherMember 2014-12-31 0001356090 xon:PrepaidResearchAndDevelopmentServicesMember 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember 2014-12-31 0001356090 xon:PrepaidProductAndServiceRevenuesMember 2014-12-31 0001356090 xon:PrepaidProductAndServiceRevenuesMember 2015-09-30 0001356090 xon:DeferredRevenueOtherMember 2015-09-30 0001356090 xon:OragenicsMember 2015-01-01 2015-09-30 0001356090 xon:AresTradingS.A.Member 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:GenopaverEccMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2015-01-01 2015-09-30 0001356090 xon:FibrocellMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:SIOphthalmicMember 2015-01-01 2015-09-30 0001356090 xon:ZiopharmMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:PerseaBioLLCMember 2015-01-01 2015-09-30 0001356090 xon:SIOphthalmicMember 2015-01-01 2015-09-30 0001356090 xon:GenopaverEccMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:SIOphthalmicMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember 2015-01-01 2015-09-30 0001356090 xon:OvaXonMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OragenicsMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OtherCollaborationsMember 2015-01-01 2015-09-30 0001356090 xon:OtherCollaborationsMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:AresTradingS.A.Member 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:IntrexonEnergyPartnersMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OragenicsMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:PerseaBioLLCMember 2015-01-01 2015-09-30 0001356090 xon:IntrexonEnergyPartnersMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:GenopaverEccMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:ZiopharmMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OvaXonMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OtherCollaborationsMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OvaXonMember 2015-01-01 2015-09-30 0001356090 xon:PerseaBioLLCMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:AresTradingS.A.Member 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:FibrocellMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:IntrexonEnergyPartnersMember 2014-07-01 2014-09-30 0001356090 xon:OvaXonMember 2014-07-01 2014-09-30 0001356090 xon:OragenicsMember 2014-07-01 2014-09-30 0001356090 xon:SIOphthalmicMember 2014-07-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OragenicsMember 2014-07-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember 2014-07-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OvaXonMember 2014-07-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:SIOphthalmicMember 2014-07-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:ZiopharmMember 2014-07-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OtherCollaborationsMember 2014-07-01 2014-09-30 0001356090 xon:OtherCollaborationsMember 2014-07-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2014-07-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:GenopaverEccMember 2014-07-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmMember 2014-07-01 2014-09-30 0001356090 xon:GenopaverEccMember 2014-07-01 2014-09-30 0001356090 xon:FibrocellMember 2014-07-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OtherCollaborationsMember 2014-07-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:SIOphthalmicMember 2014-07-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2014-07-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:FibrocellMember 2014-07-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OvaXonMember 2014-07-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OragenicsMember 2014-07-01 2014-09-30 0001356090 xon:ZiopharmMember 2014-07-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember 2014-07-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:GenopaverEccMember 2014-07-01 2014-09-30 0001356090 xon:IntrexonEnergyPartnersMember 2014-07-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember 2014-01-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:FibrocellMember 2014-01-01 2014-09-30 0001356090 xon:IntrexonEnergyPartnersMember 2014-01-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:ZiopharmMember 2014-01-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OvaXonMember 2014-01-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:SIOphthalmicMember 2014-01-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:SIOphthalmicMember 2014-01-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OragenicsMember 2014-01-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:GenopaverEccMember 2014-01-01 2014-09-30 0001356090 xon:OtherCollaborationsMember 2014-01-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OtherCollaborationsMember 2014-01-01 2014-09-30 0001356090 xon:OvaXonMember 2014-01-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember 2014-01-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2014-01-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:IntrexonEnergyPartnersMember 2014-01-01 2014-09-30 0001356090 xon:GenopaverEccMember 2014-01-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OragenicsMember 2014-01-01 2014-09-30 0001356090 xon:FibrocellMember 2014-01-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OvaXonMember 2014-01-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmMember 2014-01-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OtherCollaborationsMember 2014-01-01 2014-09-30 0001356090 xon:OragenicsMember 2014-01-01 2014-09-30 0001356090 xon:ZiopharmMember 2014-01-01 2014-09-30 0001356090 xon:SIOphthalmicMember 2014-01-01 2014-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:GenopaverEccMember 2014-01-01 2014-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2014-01-01 2014-09-30 0001356090 us-gaap:CertificatesOfDepositMember 2014-12-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember 2014-12-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember 2015-09-30 0001356090 us-gaap:CertificatesOfDepositMember 2015-09-30 0001356090 us-gaap:EquitySecuritiesMember 2015-09-30 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2014-12-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2014-12-31 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel1Member 2014-12-31 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel3Member 2014-12-31 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2014-12-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2014-12-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember 2014-12-31 0001356090 us-gaap:FairValueInputsLevel2Member 2014-12-31 0001356090 us-gaap:FairValueInputsLevel1Member 2014-12-31 0001356090 us-gaap:FairValueInputsLevel3Member 2014-12-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2014-12-31 0001356090 us-gaap:EquitySecuritiesMember 2014-12-31 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel2Member 2014-12-31 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2014-12-31 0001356090 xon:OtherFinancialAssetsMember 2014-12-31 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2015-09-30 0001356090 xon:OtherFinancialAssetsMember 2015-09-30 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel3Member 2015-09-30 0001356090 us-gaap:FairValueInputsLevel3Member 2015-09-30 0001356090 us-gaap:FairValueInputsLevel2Member 2015-09-30 0001356090 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2015-09-30 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel1Member 2015-09-30 0001356090 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2015-09-30 0001356090 us-gaap:USGovernmentDebtSecuritiesMember 2015-09-30 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2015-09-30 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2015-09-30 0001356090 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2015-09-30 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel2Member 2015-09-30 0001356090 us-gaap:FairValueInputsLevel1Member 2015-09-30 0001356090 xon:LivestockMember 2015-09-30 0001356090 xon:SuppliesSemenAndEmbryosMember 2015-09-30 0001356090 xon:WorkInProcessMember 2014-12-31 0001356090 xon:FeedMember 2014-12-31 0001356090 xon:FeedMember 2015-09-30 0001356090 xon:SuppliesSemenAndEmbryosMember 2014-12-31 0001356090 xon:LivestockMember 2014-12-31 0001356090 xon:WorkInProcessMember 2015-09-30 0001356090 xon:CovenantNotToCompeteMember 2015-09-30 0001356090 us-gaap:IntellectualPropertyMember 2015-09-30 0001356090 xon:CovenantNotToCompeteMember us-gaap:WeightedAverageMember 2015-01-01 2015-09-30 0001356090 us-gaap:IntellectualPropertyMember us-gaap:WeightedAverageMember 2015-01-01 2015-09-30 0001356090 us-gaap:CustomerRelationshipsMember 2015-09-30 0001356090 us-gaap:CustomerRelationshipsMember us-gaap:WeightedAverageMember 2015-01-01 2015-09-30 0001356090 us-gaap:TrademarksMember 2015-09-30 0001356090 us-gaap:TrademarksMember us-gaap:WeightedAverageMember 2015-01-01 2015-09-30 0001356090 us-gaap:InProcessResearchAndDevelopmentMember 2015-09-30 0001356090 us-gaap:CustomerRelationshipsMember 2014-12-31 0001356090 us-gaap:IntellectualPropertyMember 2014-12-31 0001356090 us-gaap:TrademarksMember 2014-12-31 0001356090 us-gaap:InProcessResearchAndDevelopmentMember 2014-12-31 0001356090 xon:AquaBountyMember xon:AtlanticCanadaOpportunitiesAgencyMember xon:RoyaltybasedFinancingMember 2013-03-15 0001356090 xon:TransOvaGeneticsLcMember xon:IowaEconomicDevelopmentAuthorityMember us-gaap:NotesPayableOtherPayablesMember 2015-01-01 2015-09-30 0001356090 xon:TransOvaGeneticsLcMember us-gaap:RevolvingCreditFacilityMember xon:FirstNationalBankofOmahaMember 2015-01-01 2015-09-30 0001356090 xon:TransOvaGeneticsLcMember xon:AmericanStateBankMember us-gaap:NotesPayableToBanksMember 2015-09-30 0001356090 xon:ExemplarGeneticsLLCMember us-gaap:NotesPayableOtherPayablesMember us-gaap:MinimumMember 2015-09-30 0001356090 xon:AquaBountyMember xon:AtlanticCanadaOpportunitiesAgencyMember xon:RoyaltybasedFinancingMember 2015-01-01 2015-09-30 0001356090 xon:AquaBountyMember xon:AtlanticCanadaOpportunitiesAgencyMember xon:RoyaltybasedFinancingMember 2015-09-30 0001356090 xon:TransOvaGeneticsLcMember us-gaap:RevolvingCreditFacilityMember xon:FirstNationalBankofOmahaMember 2015-09-30 0001356090 xon:ExemplarGeneticsLLCMember us-gaap:RevolvingCreditFacilityMember xon:AmericanStateBankMember 2015-09-30 0001356090 xon:ExemplarGeneticsLLCMember us-gaap:NotesPayableOtherPayablesMember us-gaap:MinimumMember 2015-01-01 2015-09-30 0001356090 xon:TransOvaGeneticsLcMember xon:AmericanStateBankMember us-gaap:NotesPayableToBanksMember 2015-01-01 2015-09-30 0001356090 xon:ExemplarGeneticsLLCMember us-gaap:NotesPayableOtherPayablesMember us-gaap:MaximumMember 2015-01-01 2015-09-30 0001356090 xon:ExemplarGeneticsLLCMember us-gaap:NotesPayableOtherPayablesMember us-gaap:MaximumMember 2015-09-30 0001356090 xon:TransOvaGeneticsLcMember xon:IowaEconomicDevelopmentAuthorityMember us-gaap:NotesPayableOtherPayablesMember 2015-09-30 0001356090 xon:TransOvaGeneticsLcMember us-gaap:RevolvingCreditFacilityMember xon:FirstNationalBankofOmahaMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-01-01 2015-09-30 0001356090 xon:ExemplarGeneticsLLCMember us-gaap:NotesPayableOtherPayablesMember 2015-09-30 0001356090 xon:RoyaltybasedFinancingMember 2015-09-30 0001356090 us-gaap:NotesPayableOtherPayablesMember 2014-12-31 0001356090 xon:OtherLongTermDebtMember 2014-12-31 0001356090 us-gaap:NotesPayableOtherPayablesMember 2015-09-30 0001356090 xon:RoyaltybasedFinancingMember 2014-12-31 0001356090 xon:OtherLongTermDebtMember 2015-09-30 0001356090 us-gaap:DomesticCountryMember 2015-09-30 0001356090 us-gaap:DomesticCountryMember xon:ShareBasedCompensationMember 2015-09-30 0001356090 us-gaap:DomesticCountryMember 2015-01-01 2015-09-30 0001356090 us-gaap:DomesticCountryMember 2014-07-01 2014-09-30 0001356090 us-gaap:DomesticCountryMember 2015-07-01 2015-09-30 0001356090 us-gaap:ForeignCountryMember 2015-07-01 2015-09-30 0001356090 us-gaap:DomesticCountryMember 2014-01-01 2014-09-30 0001356090 us-gaap:ForeignCountryMember 2015-09-30 0001356090 us-gaap:ForeignCountryMember 2015-01-01 2015-09-30 0001356090 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-09-30 0001356090 us-gaap:AccumulatedTranslationAdjustmentMember 2015-09-30 0001356090 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-12-31 0001356090 us-gaap:AccumulatedTranslationAdjustmentMember 2014-12-31 0001356090 2014-03-01 2014-03-31 0001356090 2015-01-01 2015-01-31 0001356090 2015-08-01 2015-08-31 0001356090 2015-08-31 0001356090 xon:AffiliatesOfThirdSecurityMember 2014-03-01 2014-03-31 0001356090 xon:OverallotmentOptionExerciseByUnderwritersMember 2015-08-01 2015-08-31 0001356090 xon:OverallotmentOptionExerciseByUnderwritersMember 2015-01-01 2015-01-31 0001356090 2014-03-31 0001356090 2015-01-31 0001356090 xon:AffiliatesOfThirdSecurityMember 2015-01-01 2015-01-31 0001356090 xon:ZiopharmMember 2015-06-01 2015-06-30 0001356090 xon:CostOfServicesMember 2014-07-01 2014-09-30 0001356090 us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-07-01 2014-09-30 0001356090 xon:CostOfProductsMember 2014-07-01 2014-09-30 0001356090 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-01-01 2014-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-07-01 2015-09-30 0001356090 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001356090 xon:CostOfProductsMember 2014-01-01 2014-09-30 0001356090 xon:CostOfServicesMember 2014-01-01 2014-09-30 0001356090 xon:CostOfProductsMember 2015-07-01 2015-09-30 0001356090 xon:CostOfServicesMember 2015-01-01 2015-09-30 0001356090 xon:CostOfServicesMember 2015-07-01 2015-09-30 0001356090 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001356090 xon:CostOfProductsMember 2015-01-01 2015-09-30 0001356090 xon:IntrexonStockOptionPlanMember 2015-01-01 2015-09-30 0001356090 xon:IntrexonStockOptionPlanMember 2015-09-30 0001356090 xon:IntrexonStockOptionPlanMember 2014-01-01 2014-12-31 0001356090 xon:IntrexonStockOptionPlanMember 2014-12-31 0001356090 xon:IntrexonStockOptionPlan2013PlanMember 2015-09-30 0001356090 xon:AquaBountyStockOptionPlanMember 2014-12-31 0001356090 xon:AquaBountyStockOptionPlanMember 2015-09-30 0001356090 xon:IntrexonStockOptionPlan2008PlanMember 2015-09-30 0001356090 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-01-31 0001356090 us-gaap:MaximumMember xon:ZiopharmMember 2015-09-30 0001356090 xon:ZiopharmMember 2015-01-01 2015-09-30 0001356090 us-gaap:MinimumMember xon:ZiopharmMember 2015-09-30 0001356090 xon:OragenicsMember 2015-09-30 0001356090 xon:AmpliPhiBiosciencesCorpMember 2015-03-01 2015-03-31 0001356090 xon:ThirdSecurityMember 2014-01-01 2014-09-30 0001356090 us-gaap:ChiefExecutiveOfficerMember 2014-07-01 2014-09-30 0001356090 xon:RelatedPartiesAggregatedMember 2014-01-01 2014-09-30 0001356090 us-gaap:ChiefExecutiveOfficerMember 2014-01-01 2014-09-30 0001356090 xon:ThirdSecurityMember 2015-07-01 2015-09-30 0001356090 xon:HistogenicsCorporationMember 2014-12-31 0001356090 xon:OragenicsThirdEccMember 2015-06-01 2015-06-30 0001356090 xon:ThirdSecurityMember 2014-07-01 2014-09-30 0001356090 xon:FibrocellMember 2015-07-31 0001356090 xon:SharePurchaseRightsPlanMember xon:OragenicsMember 2013-11-30 0001356090 us-gaap:WarrantMember xon:AmpliPhiBiosciencesCorpMember 2015-03-01 2015-03-31 0001356090 xon:RelatedPartiesAggregatedMember 2015-07-01 2015-09-30 0001356090 us-gaap:MaximumMember xon:OragenicsMember 2015-09-30 0001356090 xon:AmpliPhiBiosciencesCorpMember 2015-08-07 2015-08-07 0001356090 xon:RelatedPartiesAggregatedMember 2014-07-01 2014-09-30 0001356090 xon:ThirdSecurityMember 2015-01-01 2015-09-30 0001356090 xon:ZiopharmMember 2011-02-01 2015-02-28 0001356090 us-gaap:CommonStockMember xon:AmpliPhiBiosciencesCorpMember 2015-03-01 2015-03-31 0001356090 xon:RelatedPartiesAggregatedMember 2015-01-01 2015-09-30 0001356090 xon:FibrocellMember 2015-07-01 2015-07-31 0001356090 xon:HistogenicsCorporationMember 2014-12-01 2014-12-31 0001356090 xon:OragenicsMember 2013-09-30 0001356090 xon:OragenicsMember 2013-09-01 2013-09-30 0001356090 xon:SharePurchaseRightsPlanMember xon:OragenicsMember 2013-11-01 2013-11-30 0001356090 xon:HistogenicsCorporationMember 2014-09-30 0001356090 us-gaap:OtherNonoperatingIncomeExpenseMember xon:HarvestIntrexonEnterpriseFundILPMember 2015-07-01 2015-09-30 0001356090 us-gaap:OtherAssetsMember us-gaap:WarrantMember xon:AmpliPhiBiosciencesCorpMember 2015-09-30 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:HistogenicsCorporationMember 2014-09-01 2014-09-30 0001356090 us-gaap:OtherNonoperatingIncomeExpenseMember xon:HarvestIntrexonEnterpriseFundILPMember 2015-01-01 2015-09-30 0001356090 us-gaap:StockOptionMember 2014-01-01 2014-09-30 0001356090 us-gaap:WarrantMember 2014-01-01 2014-09-30 0001356090 us-gaap:StockOptionMember 2015-01-01 2015-09-30 0001356090 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001356090 xon:ThirdSecurityMember us-gaap:SubsequentEventMember 2015-11-01 2015-11-09 0001356090 us-gaap:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2015-11-01 2015-11-09 xbrli:shares xon:note iso4217:USD xon:segment xon:entity xon:joint_venture xon:installment iso4217:USD xbrli:shares xon:board_seat xbrli:pure xon:target false --12-31 Q3 2015 2015-09-30 10-Q 0001356090 116397980 Large Accelerated Filer INTREXON CORP XON 559000 1912000 6267000 4546000 14582000 25153000 6250000 -1121000 -298000 22493000 26468000 -4000 42000 -46000 -5195000 291000 -5486000 P9Y P3Y P14Y P18Y 843001000 1233497000 26549000 26388000 161000 26388000 311000 306000 200000 4250000 1514000 2681000 5000 50000 14872000 3226000 11591000 5000 50000 8385000 2234000 6032000 21000 98000 26524000 6141000 20006000 76000 301000 565000 2015000 112000 1290000 2664000 2857000 6434000 8567752 8194650 373102 10854759 10660040 194719 576272000 989887000 174773000 302431000 280497000 164889000 143927000 20962000 0 7192000 83099000 115335000 0 115335000 0 273000 0 273000 0 143927000 136570000 0 303898000 145000 76623000 61747000 14876000 0 13475000 226858000 0 226858000 0 417000 0 417000 0 61747000 242151000 0 54000 0 54000 291000 0 291000 12000 0 12000 0 0 0 115566000 273000 115293000 226839000 272000 226567000 136266000 90864000 115608000 273000 115335000 227130000 272000 226858000 27113000 136266000 7265000 7311000 714144 1444388 707853 965377 1359343 1.00 1 1 1 1 -50664000 -57449000 -95580000 -113205000 -42241000 -63379000 31507000 21524000 88629000 41742000 53754000 133060000 11333000 372000 680000 310000 713000 684000 1644000 418000 381000 341000 267000 1644000 24995000 707000 116542000 40933000 72474000 146394000 19368000 32802000 30933000 39735000 56195000 20115000 20115000 11440000 0 4832000 109473000 84949000 71848000 0 71848000 36655000 2700000 33955000 8000 3780000 960000 3180000 0 3180000 58000 0 58000 121000 590000 31000 0 31000 125000 18693000 16000 0 16000 644000 1187000 3317000 230000 0 230000 181000 0 181000 50000 210000 271000 253000 -54000 307000 12584000 612000 0 612000 8847000 702000 8145000 4824000 96854000 23700000 68100000 0 68100000 36500000 2700000 33800000 18476000 761000 14347000 23386000 2023000 -482000 2505000 9209000 702000 8507000 4071000 95126000 61563000 69825000 482000 69343000 27446000 1998000 25448000 1107000 147000 23000 0 23000 1198000 21164000 209000 0 209000 32000 0 32000 24995000 146394000 127875000 72474000 0 72474000 40933000 0 40933000 0 533000 49509000 24704000 27466000 125433000 -24805000 97967000 17830305 200000000 200000000 100557932 116359041 100557932 100557932 116359041 116359041 0 0 -52708000 -100607000 -41123000 -56970000 -1111000 -2874000 -778000 -2874000 -53819000 -103481000 -41901000 -59844000 1002000 1927000 4224000 4310000 11215000 31654000 2316000 2316000 5451000 17316000 0 23000 -318000 -27000 459000 -27000 698241 0.0295 0.045 0.03 0 0.0395 0.03 4000 1000 39000 183000 0 0 -578000 374000 113209000 571000 4365000 1045000 107228000 17491000 2523000 23125000 5171000 5000000 23193000 176254000 794000 5292000 11099000 159069000 55164000 11772000 2318000 21250000 4758000 4815000 4625000 21260000 16342000 10000000 16522000 32006000 96687000 144248000 6800000 21550000 0 21550000 1807000 4206000 1987000 5768000 6870000 12202000 0 172419000 172419000 172419000 12622000 28801000 214000 147000 -0.53 -1.02 -0.34 -0.47 -98000 507000 7736000 14475000 P3Y P3Y 62281000 112205000 0.5 0.5 0.244 0.157 0.242 0.5 0.5 64886000 12687000 63627000 12225000 15346000 10121000 15916000 10121000 -10364000 -32970000 -6724000 -112667000 1259000 462000 570000 0 834000 1753000 330000 1389000 3220000 3220000 -740000 -83000 3790000 242000 1881000 -1591000 6086000 11500000 8307000 P6Y6M P15Y2M12D P8Y4M24D P2Y P18Y P2Y 11953000 806000 0 10849000 298000 18345000 2255000 0 15141000 834000 115000 77900000 10700000 19428000 41872000 5900000 274629000 10700000 115568000 142066000 5900000 395000 65947000 9894000 19428000 31023000 5602000 256284000 8445000 115568000 126925000 5066000 280000 1236000 1608000 -170000 -519000 20924000 101059000 166866000 51268000 66312000 2649000 -482000 3131000 13487000 -1998000 15485000 67404000 0 0 -1597000 -53862000 -51864000 -58972000 -103525000 -98816000 -117811000 -39952000 -43979000 -53913000 -66686000 -1619000 -3510000 -2429000 -6565000 0 23000 -923000 806000 0 1165000 -1197000 -3560000 -3443000 12014000 18636000 52400000 5168000 11182000 -192000 -67000 545000 5895000 -582000 -3451000 0 -1000 -820000 1323000 -234000 168000 -89000 3817000 41000 -6390000 679000 4005000 65947000 256284000 230000 309000 310000 1012000 47000 1119000 25789000 1972000 16996000 1184000 5637000 22338000 2082000 12753000 1368000 6135000 202000 349000 567000 1211000 7565000 9085000 2518000 5249000 2167000 6548000 6382000 6998000 166983000 260264000 576272000 989887000 47482000 77093000 475000 0 0.0315 700000 6000000 2273000 475000 10369000 7653000 790000 1926000 9110000 1857000 529000 5694000 550000 6773000 480000 1857000 1675000 1314000 340000 525000 382000 929000 506000 8694000 7796000 31983000 36018000 697000 697000 24528000 11336000 1566000 -9412000 10978000 -9412000 0.63 0.51 16598000 93158000 22595000 331441000 -36494000 -257318000 -10808000 23337000 -52725000 -100653000 -38213000 -51779000 -1137000 -1200000 -1137000 -2895000 -3260000 -2895000 -816000 -816000 -2940000 -2940000 2200000 3623000 -37196000 -49014000 -29607000 65121000 1501000 0 1 36244000 17052000 91839000 46266000 61283000 7020000 244576000 114023000 -15047000 -51001000 -7916000 -112469000 15765000 4161000 1941000 1889000 2067000 3381000 1587000 96000 741000 182000 739000 270000 532000 334000 1153000 227100000 29300000 116700000 5731000 7918000 1271000 5426000 3750000 4000 95000 230000 249000 39000 -28000 -3102000 -5374000 -5125000 -5191000 66000 -5191000 699000 867000 164889000 76623000 -244000 -305000 -79000 -110000 589000 530000 165000 196000 250000 615000 10000000 5000000 256000 0 0 1566000 4920000 63625000 10000000 32739000 90199000 67117000 114480000 5000000 1500000 25000000 2105000 4699000 60478000 181572000 1979000 321000 2300000 0 17080000 5190000 9841000 3759000 7930000 0 1500000 268000 81000 25000000 6250000 25000000 0 678000 13719000 98245000 70000000 151000 420000 1274000 12208000 800000 85000 173000 142000 294000 -53862000 -51864000 -58586000 -481000 -103548000 -98839000 -116100000 -481000 -39029000 -43057000 -3655000 -54719000 -66319000 530000 -2940000 -51779000 -51779000 60493000 68669000 38000000 42201000 P23Y P3Y P10Y P1Y P7Y P1Y P20Y P4Y P14Y P1Y P7Y P1Y 74000 1562000 81401000 4213000 15517000 156000 1032000 14851000 41343000 21598000 121286000 -458236000 -510015000 21197000 8502000 809000 40838000 8502000 1178000 53367000 18283000 1183000 132107000 64743000 3446000 4115000 4124000 9446000 32645000 4261000 4261000 8945000 32157000 14853000 43870000 23019000 74320000 14872000 26524000 13000000 3219354 546 1467488 4282000 312795 7347000 8323544 5382000 1439637 9220403 10660040 0.31 22.59 0.26 32.07 6171520 4320333 2502418 18.18 8803769 30.69 16.89 17.72 25.77 47.89 25.40 25.72 27.00 41.00 P8Y7M21D P8Y6M11D P6Y8M23D P8Y4M13D 88495000 90864000 2552151 972004 243001 4312500 555556 562500 5609756 731707 9922256 790265 909437 51682000 126863000 126863000 126863000 110041000 218193000 328234000 328234000 328234000 12208000 12208000 0 12208000 384761000 718287000 409289000 -4000 843001000 24528000 384761000 -458236000 729623000 -5195000 1233497000 11336000 718287000 -510015000 0.04 0.02 1-for-25 1-for-50 0 1909000 99888203 98711564 112244129 109244641 845000 P16M 10000 250000 -249000 499000 -249000 2142000 1952000 20000000 15000000 P3Y P85D 9449000 3 480422 1991000 127875000 P18M 6000000 1219000 67000 246000 913000 196000 -428000 624000 7395000 305000 0 305000 49000 0 49000 4091000 1246000 120000 4458000 732000 0 732000 181000 0 181000 9090000 P90D P90D P90D P90D P90D P90D P90D P90D P90D P90D P90D P90D 1115000 12656000 10166000 1014000 360000 1535000 3000 2404000 813000 667000 3370000 2490000 449000 68000 625000 261000 443000 0 0 644000 1463000 428000 2160000 264000 2847000 813000 667000 4014000 32257000 25368000 2759000 1204000 2745000 588000 5255000 1561000 2153000 9103000 6889000 1345000 205000 1250000 784000 1373000 0 0 1932000 4104000 1409000 3995000 1372000 6628000 1561000 2153000 11035000 34726000 14134000 260000 1317000 993000 3185000 332000 2002000 549000 297000 1193000 4006000 20592000 1597000 4823000 68000 625000 4868000 7841000 0 125000 0 645000 1857000 6140000 1061000 3810000 5200000 9843000 549000 422000 1193000 4651000 66690000 39364000 260000 4500000 2460000 8101000 408000 6620000 1855000 553000 2838000 11769000 27326000 2336000 5719000 205000 1875000 5437000 9446000 0 375000 0 1933000 2596000 10219000 2665000 9976000 5845000 16066000 1855000 928000 2838000 13702000 0.5 11295000 29613000 31740000 59775000 5000000 0.01 0.07495 0.03 0.025 0.02 0.015 P2Y 2 3636926 4392425 3636926 1317520 1243781 1348000 1024590 17457000 6588000 18330000 7576000 3000000 7612000 3503000 5225000 25000000 25000000 5000000 115000000 1667000 10000000 1956000 10000000 5000000 25000000 0.07 0.14 0.1666 0.5 0.25 0.5 0.33 5060000 5722000 1566000 307074 508000 1485000 1485000 0 7064000 16212000 13421000 8710000 48970000 2566000 -16218000 -44513000 -6690000 -112634000 5854000 11543000 -34000 -33000 -37089000 -5487000 -22783000 -48944000 -11890000 -27864000 -30453000 2404000 64392000 6283000 P5Y P3M 0 -943000 25000000 25000000 20426000 4262000 309000 7253000 50000000 10000 413000 22000 5500000 0.30 0.06 2 1 3 2 3 2 2 2 2 2 2022 59579000 0 6252000 57500000 0 328234000 0.1 2183000 6576000 0 59579000 1300000 1100000 1772364 278788 375868 43582000 3.00 11.00 2.50 5.80 17695 307074 2100085 2100085 10106 486000 480000 0 9412000 59579000 59579000 59579000 480000 480000 480000 5225000 4667000 -600000 600000 -15865000 22935000 69696 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,130</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,566</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,608</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Unaudited Financial Information</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with U.S. GAAP. Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and results of operations and cash flows for the interim periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">. These interim financial results are not necessarily indicative of the results to be expected for the year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following unaudited condensed pro forma financial information for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> is presented as if the acquisitions had been consummated on January&#160;1, 2014:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pro forma</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,524</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,742</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,979</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,972</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,686</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(117,811</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(116,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to the noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">816</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,137</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,940</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,895</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(57,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(113,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following unaudited condensed pro forma financial information for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> is presented as if the acquisitions had been consummated on January&#160;1, 2013:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="61%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September 30, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pro forma</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,864</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(98,816</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(98,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to the noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,260</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50,664</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(95,580</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All highly liquid investments with an original maturity of </font><font style="font-family:inherit;font-size:10pt;">three months</font><font style="font-family:inherit;font-size:10pt;"> or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions with high quality credit ratings. Recoverability of investments is dependent upon the performance of the issuer.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration and Licensing Revenue</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's collaborations and licensing agreements provide for multiple deliverables to be delivered by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, performance of certain research and development services and may include obligations for certain manufacturing services. The Company typically groups these deliverables into two units of accounting based on the nature of the deliverables and the separation criteria. The first deliverable ("Unit of Accounting 1") includes the license to the Company's technology platform, the Company's participation on the collaboration committees and any research and development services associated with its technology platforms. The deliverables for Unit of Accounting 1 are combined because they cannot be individually separated. If applicable, the second deliverable ("Unit of Accounting 2") includes manufacturing services to be provided for any Company materials in an approved product. These services have standalone value and are contingent due to uncertainties on whether an approved product will ever be developed thereby requiring manufacture by the Company at that time. All upfront consideration is allocated to Unit of Accounting 1. Unit of Accounting 2 is determined to be a contingent deliverable at the inception of the collaboration due to the uncertainties surrounding whether an approved product will ever be developed and require manufacturing by the Company. The upfront consideration allocated to Unit of Accounting 1 is recognized over the expected life of the Company's technology platform using a straight-line approach.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes the reimbursement payments received for research and development services in the period when the services are performed and collection is reasonably assured. At the inception of each collaboration and licensing agreement, the Company determines whether any milestone payments are substantive and can be recognized when earned. The milestone payments are typically not considered substantive. Royalties related to product sales will be recognized when earned since payments relate directly to products that have been fully developed and for which the Company has satisfied all of its obligations.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration or licensing agreements, collaborators or licensees either consolidated or accounted for using the equity method, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation. The following table summarizes the amounts recorded in the consolidated statements of operations for each significant collaboration and licensing agreement for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="43%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognized From</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Upfront&#160;and Milestone Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,868</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,317</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">993</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,061</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S &amp; I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">297</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,841</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,002</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,843</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,592</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,726</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="43%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognized From</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Upfront&#160;and Milestone Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">428</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S &amp; I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">813</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">813</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">443</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,404</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,847</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,490</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,166</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="43%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognized From</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Upfront&#160;and Milestone Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">408</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,845</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,460</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,665</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S &amp; I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">928</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,446</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,066</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,326</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="43%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognized From</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Upfront&#160;and Milestone Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,932</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,372</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,204</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,409</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S &amp; I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,561</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,561</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,373</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,255</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,628</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,368</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,257</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the terms of the Company's significant collaborations and licensing agreements.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Merck Licensing Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2015, the Company signed a worldwide License and Collaboration Agreement ("Merck Agreement") with Ares Trading S.A. ("Ares Trading"), a subsidiary of the biopharmaceutical business of Merck KGaA, and ZIOPHARM through which the parties established a collaboration for the research and development and commercialization of certain products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. Pursuant to the Merck Agreement, the Company received a technology access fee of </font><font style="font-family:inherit;font-size:10pt;">$115,000</font><font style="font-family:inherit;font-size:10pt;"> as upfront consideration, of which </font><font style="font-family:inherit;font-size:10pt;">$57,500</font><font style="font-family:inherit;font-size:10pt;"> was paid to ZIOPHARM in accordance with the terms of the agreement. Upon the selection of the first </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> targets by Ares Trading, the Company is entitled to receive </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;"> payable in equal quarterly installments over </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> years, of which </font><font style="font-family:inherit;font-size:10pt;">$6,250</font><font style="font-family:inherit;font-size:10pt;"> is included in trade receivables and </font><font style="font-family:inherit;font-size:10pt;">$3,750</font><font style="font-family:inherit;font-size:10pt;"> in other long term assets on the consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The Company will be entitled to receive a further </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;"> for each additional target selected by Ares Trading. The Company is also entitled to up to </font><font style="font-family:inherit;font-size:10pt;">$413,000</font><font style="font-family:inherit;font-size:10pt;"> of potential payments for substantive and non-substantive development and commercial milestones for each product, and royalties ranging from the lower-single digits to the low-teens of the net sales derived from the sale of products developed under the Merck Agreement. The Company may also receive up to </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;"> of further cash fees upon certain technical milestones as provided for in the agreement. The term of the Merck Agreement commenced in May 2015 and may be terminated by either party in the event of a material breach as defined in the agreement and may be terminated voluntarily by Ares Trading upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company. The Company will pay to ZIOPHARM </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of all payments received for upfront fees, milestones, and royalties under the Merck Agreement. The remaining balance of deferred revenue associated with the upfront payment was </font><font style="font-family:inherit;font-size:10pt;">$55,164</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ZIOPHARM Collaborations</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January&#160;2011, the Company entered into an ECC with ZIOPHARM, a related party. Pursuant to the ECC, ZIOPHARM received a license to the Company's technology platform within the field of oncology as defined more specifically in the agreement. Upon execution of the ECC, the Company received </font><font style="font-family:inherit;font-size:10pt;">3,636,926</font><font style="font-family:inherit;font-size:10pt;"> shares of ZIOPHARM's common stock valued at </font><font style="font-family:inherit;font-size:10pt;">$17,457</font><font style="font-family:inherit;font-size:10pt;"> as upfront consideration. In addition to the deliverables discussed above, the Company transferred two clinical product candidates to ZIOPHARM that resulted in a separate unit of accounting for which </font><font style="font-family:inherit;font-size:10pt;">$1,115</font><font style="font-family:inherit;font-size:10pt;"> of the upfront consideration was allocated and recognized as collaboration revenue in 2011. The remaining </font><font style="font-family:inherit;font-size:10pt;">$16,342</font><font style="font-family:inherit;font-size:10pt;"> of upfront consideration was allocated to Unit of Accounting 1 discussed above. The Company is entitled to additional shares of common stock representing the lesser of (i)&#160;the original shares received or (ii)&#160;the number of shares representing </font><font style="font-family:inherit;font-size:10pt;">7.495%</font><font style="font-family:inherit;font-size:10pt;"> of ZIOPHARM's outstanding shares at the date of the dosing of the first patient in a Phase II clinical trial of a product candidate created, produced or developed by ZIOPHARM using the Company's technology ("ZIOPHARM Milestone"). In October&#160;2012, the ZIOPHARM Milestone was achieved and the Company received </font><font style="font-family:inherit;font-size:10pt;">3,636,926</font><font style="font-family:inherit;font-size:10pt;"> shares of ZIOPHARM's common stock valued at </font><font style="font-family:inherit;font-size:10pt;">$18,330</font><font style="font-family:inherit;font-size:10pt;"> as milestone consideration. Since the ZIOPHARM Milestone was not substantive, the Company allocated the ZIOPHARM Milestone to the applicable units of accounting and is recognizing it in a manner similar to these units of accounting. The remaining balance of deferred revenue associated with upfront and milestone payments was </font><font style="font-family:inherit;font-size:10pt;">$21,260</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$23,193</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company receives reimbursement payments for research and development services provided and manufacturing services for Company materials provided to ZIOPHARM during the ECC. Subject to certain expense allocations, ZIOPHARM will pay the Company </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of the quarterly net profits derived from the sale of products developed from the ECC, as defined in the agreement. ZIOPHARM is responsible for conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of product candidates. The term of the ECC commenced in January 2011 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by ZIOPHARM upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company. In March 2015, in conjunction with the Merck Agreement, the Company and ZIOPHARM amended their existing ECC. The amendment modifies the scope of the ECC in connection with the Merck Agreement and provides that the Company will pay to ZIOPHARM </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of all payments received for upfront fees, milestones and royalties under the Merck Agreement.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, the Company entered into its second ECC with ZIOPHARM ("ZIOPHARM ECC 2"). Pursuant to the ECC, ZIOPHARM received a license to the Company's technology platform to develop and commercialize novel biotherapeutics for the treatment of patients with graft-versus-host disease, or GvHD. Upon execution of ZIOPHARM ECC 2, the Company received a technology access fee of </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;">, all of which is included in deferred revenue at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to ZIOPHARM during the ECC. ZIOPHARM will pay the Company </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of quarterly net profits derived from the sale of products developed from ZIOPHARM ECC 2, as defined in the agreement.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM is responsible for funding the further development of ZIOPHARM ECC 2 products towards the goal of commercialization, conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of the ZIOPHARM ECC 2 commenced in September 2015 and may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by ZIOPHARM upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Notes </font><font style="font-family:inherit;font-size:10pt;">13</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:10pt;"> for further discussion related to ZIOPHARM.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Oragenics Collaborations</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June&#160;2012, the Company entered into an ECC with Oragenics, a publicly traded company focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health for humans and pets and a related party. Pursuant to the ECC, at the transaction effective date, Oragenics received a license to the Company's technology platform within the field of lantibiotics for the treatment of infectious diseases in humans and companion animals as defined more specifically in the agreement. Upon execution of the ECC, the Company received a technology access fee of </font><font style="font-family:inherit;font-size:10pt;">4,392,425</font><font style="font-family:inherit;font-size:10pt;"> shares of Oragenics' common stock valued at </font><font style="font-family:inherit;font-size:10pt;">$6,588</font><font style="font-family:inherit;font-size:10pt;"> as upfront consideration. The Company is entitled to receive additional shares of common stock, or at Oragenics' option, receive a cash payment based upon the fair market value of the shares, upon the separate achievement of certain regulatory milestones of the first product candidate developed from the ECC ("Oragenics ECC 1 Milestones"). The Oragenics ECC 1 Milestones include: (i)&#160;</font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> of Oragenics' outstanding shares as defined in the ECC agreement at the date of the filing of the first Investigative New Drug Application with the U.S. FDA for a product candidate created, produced or developed using the Company's technology ("Oragenics ECC 1 Product"); (ii)&#160;</font><font style="font-family:inherit;font-size:10pt;">1.5%</font><font style="font-family:inherit;font-size:10pt;"> of Oragenics' outstanding shares as defined in the ECC agreement at the date of the dosing of the first patient in the first Phase II clinical trial of an Oragenics ECC 1 Product; (iii)&#160;</font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;"> of Oragenics' outstanding shares as defined in the ECC agreement at the date of the dosing of the first patient in the first Phase III clinical trial of an Oragenics ECC 1 Product; (iv)&#160;</font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;"> of Oragenics' outstanding shares as defined in the ECC agreement at the date of the first New Drug Application or Biologics License Application with the U.S. FDA for an Oragenics ECC 1 Product, or alternatively the first equivalent regulatory filing with a foreign agency; and (v)&#160;</font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> of Oragenics' outstanding shares as defined in the ECC agreement at the date of the granting of the first regulatory approval of an Oragenics ECC 1 Product. The remaining balance of deferred revenue associated with the upfront payment was </font><font style="font-family:inherit;font-size:10pt;">$4,758</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5,171</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during the ECC. Oragenics will pay the Company </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> of the quarterly profits derived from the sale of products developed from the ECC, as defined in the agreement.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics is responsible for funding the further development of lantibiotics toward the goal of commercialization, conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of the ECC commenced in June 2012 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Oragenics upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September&#160;2013, the Company entered into its second ECC with Oragenics ("Oragenics ECC 2"). Pursuant to Oragenics ECC 2, at the transaction effective date, Oragenics received a license to the Company's technology platform to develop and commercialize probiotics, specifically the direct administration to humans of genetically modified probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus as defined more specifically in the agreement. Upon execution of Oragenics ECC 2, the Company received a technology access fee of </font><font style="font-family:inherit;font-size:10pt;">1,348,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Oragenics' common stock valued at </font><font style="font-family:inherit;font-size:10pt;">$3,503</font><font style="font-family:inherit;font-size:10pt;"> and a </font><font style="font-family:inherit;font-size:10pt;">$1,956</font><font style="font-family:inherit;font-size:10pt;"> convertible promissory note maturing on or before December&#160;31, 2013 as upfront consideration. Prior to the maturity date, Oragenics had the right to convert the promissory note into shares of Oragenics' common stock subject to its shareholders' approval. The conversion price was equal to the closing price of Oragenics' common stock on the last trading day immediately prior to the date of conversion. In December&#160;2013, Oragenics converted the promissory note into </font><font style="font-family:inherit;font-size:10pt;">698,241</font><font style="font-family:inherit;font-size:10pt;"> shares of Oragenics' common stock. In September 2015, Oragenics and the Company mutually agreed to terminate Oragenics ECC 2 and accordingly, the Company recognized the remaining balance of the deferred revenue associated with the upfront payment.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2015, the Company entered into its third ECC with Oragenics ("Oragenics ECC 3"). Pursuant to Oragenics ECC 3, at the transaction effective date, Oragenics received a license to the Company's technology platform within the field of biotherapeutics for use in certain treatments of oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus. Upon execution of Oragenics ECC 3, the Company received a technology access fee of a </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;"> convertible promissory note, which approximates fair value, maturing on or before December 31, 2015 as upfront consideration. Prior to the maturity date, Oragenics has the right to convert the promissory note into shares of Oragenics' common stock, subject to its shareholders' approval. The Company is also entitled to up to </font><font style="font-family:inherit;font-size:10pt;">$22,000</font><font style="font-family:inherit;font-size:10pt;"> of potential payments for development and commercial milestones for each Oragenics product developed from Oragenics ECC 3 and up to </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;"> of potential one-time payments for certain regulatory milestones under Oragenics ECC 3. The remaining balance of deferred revenue associated with the upfront payment was </font><font style="font-family:inherit;font-size:10pt;">$4,815</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during Oragenics ECC 3. Oragenics will pay the Company a royalty as a percentage in the low-teens of net sales derived from the sale of products developed from Oragenics ECC 3, as defined in the agreement.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics is responsible for funding the further development of Oragenics ECC 3 products towards the goal of commercialization, conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of Oragenics ECC 3 commenced in June 2015 and may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Oragenics upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note </font><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:10pt;"> for a discussion of additional arrangements with Oragenics.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fibrocell Science, Inc. Collaboration</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October&#160;2012, the Company entered into an ECC with Fibrocell Science, Inc. ("Fibrocell"), a publicly traded, autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications and a related party. Pursuant to the ECC, at the transaction effective date, Fibrocell received a license to the Company's technology platform to develop and commercialize genetically modified and non-genetically modified autologous fibroblasts and autologous dermal cells in the United States of America. Upon execution of the ECC, the Company received a technology access fee of </font><font style="font-family:inherit;font-size:10pt;">1,317,520</font><font style="font-family:inherit;font-size:10pt;"> shares of Fibrocell's common stock valued at </font><font style="font-family:inherit;font-size:10pt;">$7,576</font><font style="font-family:inherit;font-size:10pt;"> as upfront consideration. The number of shares received reflects a </font><font style="font-family:inherit;font-size:10pt;">1-for-25</font><font style="font-family:inherit;font-size:10pt;"> reverse stock split of Fibrocell's common stock effective April&#160;30, 2013. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Fibrocell during the ECC. On a quarterly basis, Fibrocell will pay the Company royalties of </font><font style="font-family:inherit;font-size:10pt;">7%</font><font style="font-family:inherit;font-size:10pt;"> of net sales up to </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">14%</font><font style="font-family:inherit;font-size:10pt;"> of net sales above </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;"> on each product developed from the ECC, as defined in the agreement. If Fibrocell uses the Company's technology platform to improve the production of a current or new Fibrocell product not developed from the ECC, Fibrocell will pay the Company a quarterly royalty equal to </font><font style="font-family:inherit;font-size:10pt;">33%</font><font style="font-family:inherit;font-size:10pt;"> of the cost of goods sold savings generated by the improvement, as defined in the agreement. Fibrocell is responsible for conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization and manufacturing of the product candidates. The term of the ECC commenced in October&#160;2012 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Fibrocell upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June&#160;2013, the Company entered into an amendment to the ECC with Fibrocell. The amendment expands the field of use defined in the ECC agreement. Under the terms of the amendment to the ECC, the Company received </font><font style="font-family:inherit;font-size:10pt;">1,243,781</font><font style="font-family:inherit;font-size:10pt;"> shares of Fibrocell's common stock valued at </font><font style="font-family:inherit;font-size:10pt;">$7,612</font><font style="font-family:inherit;font-size:10pt;"> as a supplemental technology access fee. The Company allocated this additional consideration to the appropriate unit of accounting and is recognizing it consistent with the unit of accounting.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January&#160;2014, the Company entered into a second amendment to the ECC with Fibrocell. The second amendment further expanded the field of use defined in the ECC agreement. Under the terms of the second amendment to the ECC, the Company received </font><font style="font-family:inherit;font-size:10pt;">1,024,590</font><font style="font-family:inherit;font-size:10pt;"> shares of Fibrocell's common stock valued at </font><font style="font-family:inherit;font-size:10pt;">$5,225</font><font style="font-family:inherit;font-size:10pt;"> as a technology access fee. The Company allocated this additional consideration to the appropriate unit of accounting. In September 2015, Fibrocell and the Company mutually agreed to terminate the second amendment to the ECC and accordingly, the Company recognized the remaining balance of deferred revenue associated with the related upfront payment. The remaining balance of deferred revenue associated with Fibrocell was </font><font style="font-family:inherit;font-size:10pt;">$11,772</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$17,491</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note </font><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:10pt;"> for further discussion related to Fibrocell.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Genopaver Collaboration</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2013, the Company entered into an ECC with Genopaver, LLC ("Genopaver"), an affiliate of Third Security (Note </font><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:10pt;">) and a related party. Genopaver was formed for the purpose of entering into the ECC and developing and commercializing products in the field of the fermentative production of alkaloids through genetically modified cell-lines and substrate feeds for use as active pharmaceutical ingredients or as commercially sold intermediates in the manufacture of active pharmaceutical ingredients. Upon execution of the ECC, the Company received a technology access fee of </font><font style="font-family:inherit;font-size:10pt;">$3,000</font><font style="font-family:inherit;font-size:10pt;"> as upfront consideration. The remaining balance of deferred revenue associated with the upfront payment was </font><font style="font-family:inherit;font-size:10pt;">$2,318</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,523</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC. Genopaver will pay the Company a royalty as a percentage in the lower-double digits on the quarterly gross profits of product sales from products developed under the ECC, as defined in the agreement. Genopaver is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in March&#160;2013 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Genopaver upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">AquaBounty Collaboration</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February&#160;2013, the Company entered into an ECC with AquaBounty, a majority-owned consolidated subsidiary. The Company will be reimbursed for research and development services as provided for in the ECC agreement. In the event of product sales from a product developed from the ECC, the Company will receive </font><font style="font-family:inherit;font-size:10pt;">16.66%</font><font style="font-family:inherit;font-size:10pt;"> of quarterly gross profits for each product, as defined in the agreement. All revenues and expenses related to this ECC are eliminated in consolidation.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">S &amp; I Ophthalmic Collaboration</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September&#160;2013, the Company entered into an ECC with S &amp; I Ophthalmic, a joint venture between the Company and Sun Pharmaceutical Subsidiary, an indirect subsidiary of Sun Pharmaceutical, an international specialty pharmaceutical company focused on chronic diseases (Note </font><font style="font-family:inherit;font-size:10pt;">4</font><font style="font-family:inherit;font-size:10pt;">). The ECC grants S &amp; I Ophthalmic an exclusive license to the Company's technology platform to develop and commercialize therapies in humans for the treatment of ocular diseases defined more specifically in the agreement. The Company will be reimbursed for research and development services pursuant to the agreement and manufacturing services for Company materials provided to S &amp; I Ophthalmic during the ECC. Subject to certain expense allocations, S &amp; I Ophthalmic will pay the Company royalties with percentages ranging from mid-single digits and above of the net sales derived from the sale of products developed under the ECC, as defined in the agreement. The term of the ECC commenced in September&#160;2013 and continues until terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by S &amp; I Ophthalmic upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">BioPop Collaboration</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October&#160;2013, the Company entered into an ECC with BioPop, a majority-owned consolidated subsidiary. The ECC grants BioPop an exclusive license to the Company's technology platform to develop and commercialize artwork, children's toys and novelty goods that are derived from living organisms or are enabled by synthetic biology. The Company will be reimbursed for research and development services and manufacturing services as provided for in the ECC agreement. The Company is entitled to royalties in the mid-single digits as a percentage of the net product sales of a product developed under the ECC, as defined in the agreement. All revenues and expenses related to this ECC are eliminated in consolidation.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">OvaXon Collaboration</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December&#160;2013, the Company entered into an ECC with OvaXon, a joint venture between the Company and OvaScience, a life sciences company focused on infertility treatments (Note </font><font style="font-family:inherit;font-size:10pt;">4</font><font style="font-family:inherit;font-size:10pt;">) and a related party. The ECC grants OvaXon an exclusive license to the Company's technology platform to create new applications for improving human and animal health. OvaScience also licensed certain technology to OvaXon pursuant to a separate license agreement. The Company will be reimbursed for research and development services and manufacturing services as provided for in the ECC agreement. The term of the ECC commenced in December&#160;2013 and continues until terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by OvaXon upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intrexon Energy Partners Collaboration</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2014, the Company entered into an ECC with Intrexon Energy Partners, a joint venture between the Company and certain investors, including an affiliate of Third Security (Note </font><font style="font-family:inherit;font-size:10pt;">4</font><font style="font-family:inherit;font-size:10pt;">), and a related party. The ECC grants Intrexon Energy Partners an exclusive license to the Company's technology platform to optimize and scale-up the Company's gas-to-liquid bioconversion platform for the production of certain fuels and lubricants. Upon execution of the ECC, the Company received a technology access fee of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;"> as upfront consideration. The remaining balance of deferred revenue associated with the upfront payment was </font><font style="font-family:inherit;font-size:10pt;">$21,250</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$23,125</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company will be reimbursed for research and development services as provided for in the ECC agreement. The term of the ECC commenced in March&#160;2014 and continues until March&#160;2034 unless terminated prior to that date by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Intrexon Energy Partners upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Persea Bio Collaboration</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December&#160;2014, the Company entered into an ECC with Persea Bio, LLC ("Persea Bio"), an affiliate of Third Security (Note </font><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:10pt;">) and a related party. Persea Bio was formed for the purpose of entering into the ECC and developing and commercializing a food program, as defined in the agreement. Upon execution of the ECC, the Company received a technology access fee of </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;"> as upfront consideration. The remaining balance of deferred revenue associated with the upfront payment was </font><font style="font-family:inherit;font-size:10pt;">$4,625</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC. Persea Bio will pay the Company royalties as a percentage in the lower-double digits on the quarterly gross profits of product sales from products derived from the ECC, as defined in the agreement. Persea Bio is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in December&#160;2014 and continues until terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Persea Bio upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Thrive Agrobiotics Collaboration</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September&#160;2015, the Company entered into an ECC with Thrive Agrobiotics, an affiliate of Harvest (Note </font><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:10pt;">) and a related party. Thrive Agrobiotics was formed for the purpose of entering into the ECC and developing and commercializing products to improve the overall growth and feed efficiency in piglets. Upon execution of the ECC, the Company received a technology access fee in the form of equity in Thrive Agrobiotics valued at </font><font style="font-family:inherit;font-size:10pt;">$1,667</font><font style="font-family:inherit;font-size:10pt;"> as upfront consideration, all of which is included in deferred revenue as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The Company is also entitled to up to </font><font style="font-family:inherit;font-size:10pt;">$5,500</font><font style="font-family:inherit;font-size:10pt;"> of potential payments for development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC. Thrive Agrobiotics will pay the Company a royalty as a percentage in the lower-double digits on the quarterly gross profits of product sales from products developed under the ECC, as defined in the agreement. Thrive Agrobiotics is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in September&#160;2015 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Thrive Agrobiotics upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Revenue</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue primarily consists of consideration received for upfront and milestone payments in connection with the Company's collaborations and licensing agreements, prepayments for research and development services performed for collaborators and licensees and prepayments for product and service revenues. Deferred revenue consists of the following:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="65%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront and milestone payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,099</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,045</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid product and service revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">571</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">176,254</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,209</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of deferred revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,006</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,522</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,248</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">176,254</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,209</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases facilities and certain equipment under noncancelable operating leases. The equipment leases are renewable at the option of the Company. At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,161</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,067</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,941</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,587</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,765</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense, including other facility expenses, was </font><font style="font-family:inherit;font-size:10pt;">$2,167</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,518</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$6,548</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5,249</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company maintains subleases for certain of its facilities. Rental income under sublease agreements was </font><font style="font-family:inherit;font-size:10pt;">$334</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$270</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$1,153</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$532</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively. Future rental income approximates </font><font style="font-family:inherit;font-size:10pt;">$182</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$741</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$96</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2012, Trans Ova was named as a defendant in a licensing and patent infringement suit brought by XY, Inc. alleging that certain of Trans Ova's activities breach a licensing agreement and infringe on patents that XY, Inc. allegedly owns. Trans Ova is reviewing, defending and filing counter claims in the case. The matter is scheduled to go to trial in the first half of 2016. Based on advice from legal counsel, Trans Ova believes that XY, Inc.'s complaints are without merit; however, no assurances can be given that this matter will be resolved in Trans Ova's favor.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may become subject to claims and assessments from time to time in the ordinary course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Risk</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the Company's mix of fixed and variable rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, gross unrealized losses on the Company's short-term and long-term investments were immaterial. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of trade receivables. The Company controls credit risk through credit approvals, credit limits and monitoring procedures. The Company performs ongoing credit evaluations of its customers, but generally does not require collateral to support accounts receivable.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Variable Interest Entities</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company identifies entities that (i)&#160;do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii)&#160;in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIE" or "VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii)&#160;have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lines of Credit and Long Term Debt</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lines of Credit</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trans Ova has a </font><font style="font-family:inherit;font-size:10pt;">$6,000</font><font style="font-family:inherit;font-size:10pt;"> revolving line of credit with First National Bank of Omaha which matures on May 1, 2016. The line of credit bears interest at the greater of </font><font style="font-family:inherit;font-size:10pt;">2.95%</font><font style="font-family:inherit;font-size:10pt;"> above the London Interbank Offered Rate or </font><font style="font-family:inherit;font-size:10pt;">3.00%</font><font style="font-family:inherit;font-size:10pt;"> and was </font><font style="font-family:inherit;font-size:10pt;">3.15%</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> amounts outstanding. The amount available under the line of credit is based on eligible accounts receivable and inventory or the maximum line of credit amount.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trans Ova's revolving line of credit is collateralized by certain of its assets and contain certain restricted covenants that include maintaining minimum tangible net worth, maximum allowable annual capital expenditures and working capital. Trans Ova was in compliance with these covenants as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exemplar has a </font><font style="font-family:inherit;font-size:10pt;">$700</font><font style="font-family:inherit;font-size:10pt;"> revolving line of credit with American State Bank which matures on November&#160;1, 2016. The line of credit bears interest at </font><font style="font-family:inherit;font-size:10pt;">4.50%</font><font style="font-family:inherit;font-size:10pt;"> per annum. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, there was an outstanding balance of </font><font style="font-family:inherit;font-size:10pt;">$475</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Long Term Debt</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt consists of the following:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="69%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,653</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty-based financing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,926</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,110</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,369</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt, less current portion</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,796</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,694</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trans Ova has a note payable to American State Bank which matures in April 2033 and has an outstanding principal balance of </font><font style="font-family:inherit;font-size:10pt;">$5,694</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. Trans Ova pays monthly installments of </font><font style="font-family:inherit;font-size:10pt;">$39</font><font style="font-family:inherit;font-size:10pt;">, which includes interest at </font><font style="font-family:inherit;font-size:10pt;">3.95%</font><font style="font-family:inherit;font-size:10pt;">. The note payable is collateralized by all of Trans Ova's assets.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trans Ova has a note payable to the Iowa Economic Development Authority which matures in July 2016 and has an outstanding principal balance of </font><font style="font-family:inherit;font-size:10pt;">$550</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. Trans Ova pays quarterly installments of </font><font style="font-family:inherit;font-size:10pt;">$183</font><font style="font-family:inherit;font-size:10pt;">. The note payable in collateralized by certain parcels of Trans Ova's real estate. </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exemplar has notes payable with outstanding principal balances totaling </font><font style="font-family:inherit;font-size:10pt;">$529</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. Exemplar pays monthly installments ranging from </font><font style="font-family:inherit;font-size:10pt;">$1</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$4</font><font style="font-family:inherit;font-size:10pt;"> with interest rates ranging from </font><font style="font-family:inherit;font-size:10pt;">0%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">3.00%</font><font style="font-family:inherit;font-size:10pt;">. These notes mature from September 2018 to May 2020 and are collateralized by certain of Exemplar's real estate or letters of credit of certain of its members.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AquaBounty has a royalty-based financing grant from the Atlantic Canada Opportunities Agency ("ACOA"), a Canadian government agency, to provide funding of a research and development project. The total amount available under the award was </font><font style="font-family:inherit;font-size:10pt;">$2,142</font><font style="font-family:inherit;font-size:10pt;">, which AquaBounty claimed over a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> year period. All amounts claimed by AquaBounty must be repaid in the form of a </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> royalty on any products commercialized out of this research and development project until fully paid. Because the timing of commercialization is subject to regulatory approval, the timing of repayment is uncertain. As of the acquisition date, AquaBounty had claimed </font><font style="font-family:inherit;font-size:10pt;">$1,952</font><font style="font-family:inherit;font-size:10pt;"> of the available funds and this amount was recorded at its acquisition date fair value of </font><font style="font-family:inherit;font-size:10pt;">$1,107</font><font style="font-family:inherit;font-size:10pt;">. The Company accretes the difference of </font><font style="font-family:inherit;font-size:10pt;">$845</font><font style="font-family:inherit;font-size:10pt;"> between the face value of amounts drawn and the acquisition date fair value over the expected period of repayment. Since the acquisition date, AquaBounty has claimed the remaining balance available under the grant, resulting in total long term debt of </font><font style="font-family:inherit;font-size:10pt;">$1,857</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future maturities of long term debt are as follows:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="84%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">506</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">929</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">525</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,253</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The AquaBounty royalty-based financing grant is not included in the table above due to the uncertainty of the timing of repayment.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue consists of the following:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="65%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront and milestone payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,099</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,045</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid product and service revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">571</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">176,254</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,209</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of deferred revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,006</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,522</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,248</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">176,254</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,209</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Option Plans</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records the fair value of stock options issued to employees and non-employees as of the grant date as stock-based compensation expense. Stock-based compensation expense for employees and non-employees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the consolidated statements of operations are presented below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="42%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,032</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,006</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,591</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,385</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,250</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,524</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,872</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intrexon Stock Option Plans</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April&#160;2008, Intrexon adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Intrexon's board of directors may grant share based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, there are </font><font style="font-family:inherit;font-size:10pt;">1,439,637</font><font style="font-family:inherit;font-size:10pt;"> stock options outstanding under the 2008 Plan.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July&#160;2013, the Company adopted the 2013 Plan for employees and nonemployees pursuant to which Intrexon's board of directors may grant share based awards, including stock options and shares of common stock, to employees, officers, consultants, advisors and nonemployee directors. The 2013 Plan became effective upon the closing of the Company's initial public offering in August 2013, and as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">13,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares authorized for issuance under the 2013 Plan, of which </font><font style="font-family:inherit;font-size:10pt;">9,220,403</font><font style="font-family:inherit;font-size:10pt;"> stock options were outstanding and </font><font style="font-family:inherit;font-size:10pt;">3,219,354</font><font style="font-family:inherit;font-size:10pt;"> shares were available for grant.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock option activity under Intrexon's award plans was as follows:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,323,544</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.64</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,282,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47.89</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment due to dividend (Note 13)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">312,795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(790,265</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16.89</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,467,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(546</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17.72</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,660,040</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.53</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable at September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,502,418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.73</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Vested and Expected to Vest at September&#160;30, 2015(1)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,803,769</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.37</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The number of stock options expected to vest takes into account an estimate of expected forfeitures.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total unrecognized compensation costs related to nonvested awards at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$112,205</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$62,281</font><font style="font-family:inherit;font-size:10pt;">, respectively, and are expected to be recognized over a weighted-average period of approximately </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon currently uses authorized and unissued shares to satisfy share award exercises.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Plans</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">5,382,000</font><font style="font-family:inherit;font-size:10pt;"> options outstanding under the AquaBounty 2006 Equity Incentive Plan ("AquaBounty Plan") at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.26</font><font style="font-family:inherit;font-size:10pt;"> per share of which </font><font style="font-family:inherit;font-size:10pt;">4,320,333</font><font style="font-family:inherit;font-size:10pt;"> were exercisable. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> , there were </font><font style="font-family:inherit;font-size:10pt;">7,347,000</font><font style="font-family:inherit;font-size:10pt;"> options outstanding under the AquaBounty Plan at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.31</font><font style="font-family:inherit;font-size:10pt;"> per share of which </font><font style="font-family:inherit;font-size:10pt;">6,171,520</font><font style="font-family:inherit;font-size:10pt;"> were exercisable.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Share</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss per Share</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the computation of basic and diluted net loss per share for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historical net loss per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,213</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52,725</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,779</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,653</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,244,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,888,203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,244,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,711,564</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.53</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.47</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.02</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following potentially dilutive securities have been excluded from the above computations of diluted weighted average shares outstanding for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, as they would have been anti-dilutive:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,660,040</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,194,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">194,719</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">373,102</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,854,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,567,752</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investments in Joint Ventures</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intrexon Energy Partners</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2014, the Company and certain investors (the "Investors"), including an affiliate of Third Security, LLC ("Third Security"), entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a joint venture formed to optimize and scale-up the Company's gas-to-liquid bioconversion platform for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to our technology for the use in bioconversion, as a result of which the Company received a technology access fee of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;"> while retaining a </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> membership interest in Intrexon Energy Partners. The Investors made initial capital contributions, totaling </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;"> in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">. In addition, Intrexon has committed to make additional capital contributions of up to </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">, and the Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">, at the request of Intrexon Energy Partners' Board of Managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company's remaining commitment was </font><font style="font-family:inherit;font-size:10pt;">$20,426</font><font style="font-family:inherit;font-size:10pt;">. The Company and the Investors have the right, but not the obligation, to make additional capital contributions above these limits when and if solicited by the Intrexon Energy Partners Board. Intrexon Energy Partners is governed by a board of managers which has five members. </font><font style="font-family:inherit;font-size:10pt;">Two</font><font style="font-family:inherit;font-size:10pt;"> members of the Intrexon Energy Partners Board are designated by the Company and </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> members of the Intrexon Energy Partners Board are designated by a majority of the Investors.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See further discussion of the ECC at Note </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">. See discussion of a concurrent private placement securities purchase made by the Investors at Note </font><font style="font-family:inherit;font-size:10pt;">13</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's investment in Intrexon Energy Partners was </font><font style="font-family:inherit;font-size:10pt;">$(1,591)</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$(740)</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">OvaXon</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December&#160;2013, the Company and OvaScience, Inc. ("OvaScience"), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, entered into a Limited Liability Company Agreement ("OvaXon LLC Agreement") to form OvaXon, LLC ("OvaXon"), a joint venture to create new applications for improving human and animal health. Both the Company and OvaScience made an initial capital contribution of </font><font style="font-family:inherit;font-size:10pt;">$1,500</font><font style="font-family:inherit;font-size:10pt;"> in January 2014 for a </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> membership interest in OvaXon. OvaXon is governed by the OvaXon board of managers ("OvaXon Board") which has four members, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> each from the Company and OvaScience. In cases in which the OvaXon Board determines that additional capital contributions are necessary in order for OvaXon to conduct business and comply with its obligations, each of the Company and OvaScience have the right, but not the obligation, to make additional capital contributions to OvaXon subject to the OvaXon LLC Agreement. </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contemporaneously with the formation of the joint venture, the Company entered into an ECC with OvaXon (see Note </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's investment in OvaXon was </font><font style="font-family:inherit;font-size:10pt;">$242</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$(83)</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, and is included in investments in affiliates and other accrued liabilities, respectively, in the accompanying consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">S &amp; I Ophthalmic</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September&#160;2013, the Company entered into a Limited Liability Company Agreement ("Sun LLC Agreement") with Caraco Pharmaceutical Laboratories, Ltd. ("Sun Pharmaceutical Subsidiary"), an indirect subsidiary of Sun Pharmaceutical Industries Ltd. ("Sun Pharmaceutical"), an international specialty pharmaceutical company focused on chronic diseases, to form S &amp; I Ophthalmic, LLC ("S &amp; I Ophthalmic"). The Sun LLC Agreement governs the affairs and the conduct of business of S &amp; I Ophthalmic. S &amp; I Ophthalmic leverages experience and technology from both the Company and Sun Pharmaceutical. Both the Company and Sun Pharmaceutical Subsidiary made an initial capital contribution of </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;"> in October 2013 for a </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> membership interest in S &amp; I Ophthalmic. S &amp; I Ophthalmic is governed by a board of managers ("S &amp; I Ophthalmic Board") which has four members, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> each from the Company and Sun Pharmaceutical Subsidiary. In cases in which the S&#160;&amp;&#160;I Ophthalmic Board determines that additional capital contributions are necessary in order for S &amp; I Ophthalmic to conduct business and comply with its obligations, each of the Company and Sun Pharmaceutical Subsidiary have committed to making additional capital contributions to S &amp; I Ophthalmic subject to certain limits defined in the agreement. Each has the right, but not the obligation, to make additional capital contributions above the defined limits when and if solicited by the S&#160;&amp;&#160;I Ophthalmic Board.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning on the seventh anniversary of the effective date of the Sun LLC Agreement, and upon the second anniversary thereafter, the Company, as well as Sun Pharmaceutical Subsidiary, may make a cash offer to purchase all of the other party's interest in S&#160;&amp;&#160;I Ophthalmic. Upon receipt of such an offer, the other party must either agree to tender its interests at the offered price or submit a counteroffer at a price higher than the original offer. Such offer and counteroffer may continue until one party agrees to the other's price.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contemporaneously with the formation of the joint venture, the Company entered into an ECC with S &amp; I Ophthalmic (see Note </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's investment in S &amp; I Ophthalmic was </font><font style="font-family:inherit;font-size:10pt;">$1,881</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3,220</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Method Investments</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is party to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> strategic joint ventures (Note </font><font style="font-family:inherit;font-size:10pt;">4</font><font style="font-family:inherit;font-size:10pt;">). The Company accounts for its investments in these joint ventures and for its investment in Thrive Agrobiotics, Inc. ("Thrive Agrobiotics") (Note </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">) using the equity method of accounting since the Company has the ability to exercise significant influence, but not control, over the operating activities of these entities.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized unaudited financial data as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, for the Company's equity method investments are as follows:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="71%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,259</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,886</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,121</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,346</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,121</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,916</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,566</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">834</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,389</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,052</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,266</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,854</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,543</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,724</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,667</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in Active Markets</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other Observable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Unobservable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities (Note 6)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,858</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,858</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities (Note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,747</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242,151</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,898</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in Active Markets<br clear="none"/>(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other Observable Inputs<br clear="none"/>(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Unobservable Inputs<br clear="none"/>(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities (Note 6)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,335</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,335</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities (Note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,927</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">280,497</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amount of cash and cash equivalents, receivables, prepaid expenses and other current assets, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in Active Markets</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other Observable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Unobservable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities (Note 6)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,858</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,858</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities (Note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,747</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242,151</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,898</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in Active Markets<br clear="none"/>(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other Observable Inputs<br clear="none"/>(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Unobservable Inputs<br clear="none"/>(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities (Note 6)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,335</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,335</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities (Note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,927</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">280,497</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying values of the Company's long term debt approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates. Financial liabilities measured on a recurring basis were not significant at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The method used to estimate the fair value of the Level 1 assets in the tables above is based on observable market data as these equity securities are publicly-traded. The method used to estimate the fair value of the Level 2 short-term and long-term investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. The method used to estimate the fair value of the Level 2 equity securities in the tables above is based on the quoted market price of the publicly-traded security, adjusted for a discount for lack of marketability.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$8,307</font><font style="font-family:inherit;font-size:10pt;"> of certain equity securities have been transferred from Level 2 to Level 1 as a result of no longer needing to apply a discount for lack of marketability to these transferred equity securities.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</font></div><div style="line-height:120%;padding-top:16px;padding-left:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.1171875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="91%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted prices in active markets for identical assets and liabilities;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Translation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into United States dollars at the exchange rates in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in the consolidated statement of comprehensive loss. Revenue and expense amounts are translated at average rates during the period.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill and Intangible Assets, net</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in the carrying amount of goodwill for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisitions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,404</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,597</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,866</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> goodwill or accumulated impairment losses existed as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets consist of the following at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td width="37%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Useful Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents, related technologies and know-how</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,255</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,445</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademarks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(834</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Covenant not to compete</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(115</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">280</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,568</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,568</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274,629</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,345</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets consist of the following at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents, related technologies and know-how</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,872</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(806</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,894</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademarks</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,428</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,428</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,900</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,953</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,947</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense was </font><font style="font-family:inherit;font-size:10pt;">$2,857</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,290</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively and </font><font style="font-family:inherit;font-size:10pt;">$6,434</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,664</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized (Note </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">). Goodwill is reviewed for impairment at least annually. The Company performs a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the two-step goodwill impairment test. If this is the case, the two-step goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the two-step goodwill impairment test is not required.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the two-step goodwill impairment test is required, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, an indication of goodwill impairment exists for the reporting unit and the entity must perform step two of the impairment test. Under step two, an impairment loss is recognized for any excess of the carrying amount of the reporting unit's goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation and the residual fair value after this allocation is the implied fair value of the reporting unit goodwill. Fair value of the reporting unit is determined using a discounted cash flow analysis. If the fair value of the reporting unit exceeds its carrying amount, step two does not need to be performed.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets subject to amortization consist of patents, related technologies and know-how; customer relationships; trademarks; and a covenant not to compete acquired as a result of mergers and acquisitions (Note </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">). These intangible assets are subject to amortization, were recorded at fair value at the date of acquisition and are stated net of accumulated amortization. Indefinite-lived intangible assets consist of in-process research and development acquired in mergers and acquisitions (Note </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">) and were recorded at fair value at the dates of the respective acquisitions.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible assets are expected to be realized. The intangible assets are amortized over their remaining estimated useful lives, ranging from </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">eighteen years</font><font style="font-family:inherit;font-size:10pt;"> for the patents, related technologies and know-how; customer relationships; trademarks; and the covenant not to compete.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets, including in-process research and development, are tested for impairment annually, or more frequently if events or circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of their fair value to carrying value, without consideration of any recoverability test. The Company monitors the progression of its in-process research and development, as the likelihood of success is contingent upon commercial development or regulatory approval.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax provisions for interim periods are calculated using an estimate of actual taxable income or loss for the respective period, rather than estimating the Company's annual effective income tax rate, as the Company is currently unable to reliably estimate its income for the full year. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company had U.S. taxable loss of approximately </font><font style="font-family:inherit;font-size:10pt;">$15,865</font><font style="font-family:inherit;font-size:10pt;">, which resulted in an income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$318</font><font style="font-family:inherit;font-size:10pt;"> that was recognized to offset income tax expense recognized during the six months ended June 30, 2015. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company had U.S. taxable income of approximately </font><font style="font-family:inherit;font-size:10pt;">$22,935</font><font style="font-family:inherit;font-size:10pt;">, which, after offset of available loss carryforwards, resulted in </font><font style="font-family:inherit;font-size:10pt;">$459</font><font style="font-family:inherit;font-size:10pt;"> of current income tax expense due to the corporate alternative minimum tax. For the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$27</font><font style="font-family:inherit;font-size:10pt;"> of current foreign income tax benefit. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company had U.S. taxable loss of approximately </font><font style="font-family:inherit;font-size:10pt;">$600</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> income tax benefit was recognized. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company had U.S. taxable income of approximately </font><font style="font-family:inherit;font-size:10pt;">$600</font><font style="font-family:inherit;font-size:10pt;">, which, after offset by available loss carryforwards, resulted in </font><font style="font-family:inherit;font-size:10pt;">$23</font><font style="font-family:inherit;font-size:10pt;"> of current income tax expense due to the corporate alternative minimum tax. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded deferred tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$578</font><font style="font-family:inherit;font-size:10pt;">. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded deferred tax expense of </font><font style="font-family:inherit;font-size:10pt;">$374</font><font style="font-family:inherit;font-size:10pt;">. There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> deferred tax expense for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">. The Company's net deferred tax assets, excluding certain deferred tax liabilities totaling </font><font style="font-family:inherit;font-size:10pt;">$21,550</font><font style="font-family:inherit;font-size:10pt;">, are offset by a valuation allowance due to the Company's history of net losses combined with an inability to confirm recovery of the tax benefits of the Company's losses and other net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company has loss carryforwards for U.S. federal income tax purposes of approximately </font><font style="font-family:inherit;font-size:10pt;">$227,100</font><font style="font-family:inherit;font-size:10pt;"> available to offset future taxable income and federal and state research and development tax credits of approximately </font><font style="font-family:inherit;font-size:10pt;">$6,800</font><font style="font-family:inherit;font-size:10pt;">, prior to consideration of annual limitations that may be imposed under Section&#160;382. These carryforwards will begin to expire in </font><font style="font-family:inherit;font-size:10pt;">2022</font><font style="font-family:inherit;font-size:10pt;">. Of these loss carryforwards, approximately </font><font style="font-family:inherit;font-size:10pt;">$29,300</font><font style="font-family:inherit;font-size:10pt;"> relates to benefits from stock compensation deductions that will be recorded as a component of paid-in capital when realized. The Company's direct foreign subsidiaries have foreign loss carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$116,700</font><font style="font-family:inherit;font-size:10pt;">, most of which do not expire.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory consists of the following:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="69%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplies, semen and embryos</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,135</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,637</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Livestock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Feed</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,972</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,338</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,789</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's inventory primarily includes adult female cows which are used in certain production processes and are recorded at acquisition cost using the first-in, first-out method or at market, whichever is lower. Work-in-process inventory includes allocations of production costs and facility costs for products currently in production and is recorded at the lower of cost or market. Significant declines in the price of cows could result in unfavorable adjustments to inventory balances. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of available-for-sale investments classified by their contractual maturities as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> was as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due within one year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After one year through three years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,130</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Short-term and Long-term Investments</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,130</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,566</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,608</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For more information on the Company's method for determining the fair value of its assets, see Note </font><font style="font-family:inherit;font-size:10pt;">2</font><font style="font-family:inherit;font-size:10pt;"> &#8211; "Fair Value of Financial Instruments".</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of available-for-sale investments classified by their contractual maturities as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> was as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due within one year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After one year through three years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,130</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's investments were primarily a result of unfavorable changes in interest rates subsequent to the initial purchase of these investments and have been in a loss position for less than 12 months.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company did not consider any of its investments to be other-than-temporarily impaired. When evaluating its investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer, the Company's ability and intent to hold the security and whether it is more likely than not that it will be required to sell the investment before recovery of its cost basis.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-term and Long-term Investments</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, investments include short-term and long-term investments in U.S. government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company's written investment policy requires investments to be explicitly rated by two of the three following rating services: Standard&#160;&amp; Poor's, Moody's and/or Fitch and to have a minimum rating of A1, P1 and/or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mergers and Acquisitions</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Oxitec Acquisition</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, pursuant to a Stock Purchase Agreement (the &#8220;Oxitec Purchase Agreement&#8221;), the Company acquired </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the issued outstanding share capital of Oxitec, a pioneering company in biological insect control solutions, thereby expanding the Company&#8217;s capabilities to address a broad range of global environment, health and agricultural challenges. The aggregated consideration paid consisted of (i) </font><font style="font-family:inherit;font-size:10pt;">1,359,343</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock (the &#8220;Stock Consideration&#8221;) and (ii) </font><font style="font-family:inherit;font-size:10pt;">$90,199</font><font style="font-family:inherit;font-size:10pt;"> in cash (the &#8220;Cash Consideration&#8221;), inclusive of net cash and working capital adjustments, as defined in the Oxitec Purchase Agreement, totaling </font><font style="font-family:inherit;font-size:10pt;">$9,449</font><font style="font-family:inherit;font-size:10pt;"> which are to be paid within </font><font style="font-family:inherit;font-size:10pt;">eighty-five</font><font style="font-family:inherit;font-size:10pt;"> days of the September closing date. Stock Consideration totaling </font><font style="font-family:inherit;font-size:10pt;">480,422</font><font style="font-family:inherit;font-size:10pt;"> shares and Cash Consideration totaling </font><font style="font-family:inherit;font-size:10pt;">$1,991</font><font style="font-family:inherit;font-size:10pt;"> were withheld as escrow at closing and are issuable and payable, respectively, </font><font style="font-family:inherit;font-size:10pt;">eighteen</font><font style="font-family:inherit;font-size:10pt;"> months after closing, subject to reduction for satisfaction of any claims for indemnification made by the Company under the Oxitec Purchase Agreement. Cash Consideration related to the net cash and working capital adjustments, as well as the withheld cash, are included in deferred consideration as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The results of Oxitec&#8217;s operations subsequent to the acquisition date have been included in the consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the total consideration transferred was </font><font style="font-family:inherit;font-size:10pt;">$146,394</font><font style="font-family:inherit;font-size:10pt;">. The acquisition date fair value of the Stock Consideration and Cash Consideration is presented below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,195</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the shares of the Company common stock issued was based on the quoted closing price of the Company&#8217;s common stock as of the date of the acquisition. The preliminary estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant, and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,854</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,473</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,584</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,347</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,126</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of assets acquired and liabilities assumed at the acquisition date are considered preliminary and are subject to revision when the valuation of intangible assets is finalized. The acquired intangibles assets primarily include in-process research and development and the fair values of the acquired assets were determined using the multi-period excess earning method, which is a variation of the income approach that converts future cash flows to single discounted present value amounts. The in-process research and development are currently indefinite-lived intangible assets and, accordingly, are not being amortized. Goodwill, which is not expected to be deductible for tax purposes, represents the assembled workforce and the potential for future Oxitec products and technologies. </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of September 30, 2015, the Company had incurred </font><font style="font-family:inherit;font-size:10pt;">$1,644</font><font style="font-family:inherit;font-size:10pt;"> of acquisition related costs, all of which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Okanagan Acquisition</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, pursuant to a Stock Purchase Agreement (the &#8220;Okanagan Purchase Agreement&#8221;), the Company acquired </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding shares of Okanagan, the pioneering agricultural company behind the world's first non-browning apple. In addition to supporting Okanagan's further commercialization and exploitation of its apple products, the Company expects to utilize its proprietary technologies to assist Okanagan in the development of further novel beneficial plant traits. Pursuant to the Okanagan Purchase Agreement, the former shareholders of Okanagan received an aggregate of </font><font style="font-family:inherit;font-size:10pt;">707,853</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock, and </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;"> cash in exchange for all shares in Okanagan. The results of Okanagan's operations subsequent to the acquisition date have been included in the consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the total consideration transferred was </font><font style="font-family:inherit;font-size:10pt;">$40,933</font><font style="font-family:inherit;font-size:10pt;">. The acquisition date fair value of each class of consideration transferred is presented below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock as of the date of the acquisition. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below along with subsequent adjustments during the measurement period to the fair value of assets acquired and liabilities assumed. The adjustments resulted from revisions to the valuation of intangible assets.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Initial Estimated Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjusted Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant, and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,955</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,655</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,145</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">702</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,847</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,507</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">702</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,209</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,485</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,998</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,487</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquired intangible assets primarily include developed technology, patents and know-how and the fair values of the acquired assets were determined using the with and without method, which is a variation of the income approach that utilizes estimated cash flows with all assets in place at the valuation date and estimated cash flows with all assets in place except the intangible assets at the valuation date. The intangible assets are being amortized over a useful life of </font><font style="font-family:inherit;font-size:10pt;">fourteen years</font><font style="font-family:inherit;font-size:10pt;">. Goodwill, which is not expected to be deductible for tax purposes, represents potential future applications of Okanagan's technology to other fruits, including additional apple varietals, and anticipated buyer-specific synergies arising from the combination of the Company's and Okanagan's technologies.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurred </font><font style="font-family:inherit;font-size:10pt;">$341</font><font style="font-family:inherit;font-size:10pt;"> of acquisition-related costs, of which </font><font style="font-family:inherit;font-size:10pt;">$267</font><font style="font-family:inherit;font-size:10pt;"> is included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ActoGeniX Acquisition</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2015, the Company acquired </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the membership interests of ActoGeniX NV ("ActoGeniX"), a European clinical stage biopharmaceutical company, pursuant to a Stock Purchase Agreement (the "ActoGeniX Purchase Agreement"). ActoGeniX's platform technology complements our broad collection of technologies available for current and future collaborators. Pursuant to the ActoGeniX Purchase Agreement, the former members of ActoGeniX received an aggregate of </font><font style="font-family:inherit;font-size:10pt;">965,377</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock and </font><font style="font-family:inherit;font-size:10pt;">$32,739</font><font style="font-family:inherit;font-size:10pt;"> in cash in exchange for all membership interests of ActoGeniX. The results of ActoGeniX's operations subsequent to the acquisition date have been included in the consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the total consideration transferred was </font><font style="font-family:inherit;font-size:10pt;">$72,474</font><font style="font-family:inherit;font-size:10pt;">. The acquisition date fair value of each class of consideration transferred is presented below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,474</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock as of the date of the acquisition. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below along with subsequent adjustments during the measurement period to the fair value of assets acquired and liabilities assumed. The adjustments resulted from the difference between estimated and actual accrued expenses.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Initial Estimated Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjusted Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">305</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">305</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,848</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,848</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">307</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">612</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">612</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,505</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(482</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,343</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">482</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,825</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,474</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,474</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquired intangible assets primarily include in-process research and development, and the fair values of the acquired assets were determined using the multi-period excess earnings and with-and-without methods, which are both variations of the income approach that convert future cash flows to single discounted present value amounts. During the three months ended September 30, 2015, the Company re-evaluated the acquired in-process research and development and determined that it was no longer an indefinite-lived intangible asset. The Company assigned it a useful life of </font><font style="font-family:inherit;font-size:10pt;">eighteen years</font><font style="font-family:inherit;font-size:10pt;"> and began amortization in August 2015. Goodwill, which is not expected to be deductible for tax purposes, represents the assembled workforce and anticipated buyer-specific synergies arising from the combination of the Company's and ActoGeniX's technologies.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurred </font><font style="font-family:inherit;font-size:10pt;">$418</font><font style="font-family:inherit;font-size:10pt;"> of acquisition-related costs, of which </font><font style="font-family:inherit;font-size:10pt;">$381</font><font style="font-family:inherit;font-size:10pt;"> is included in selling, general and administrative expenses in the accompanying consolidated statements of operations for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Trans Ova Acquisition</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the Company acquired </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the membership interests of Trans Ova, a provider of bovine reproductive technologies, pursuant to an Amended and Restated Membership Interest Purchase Agreement (the "Trans Ova Purchase Agreement"). The Company and Trans Ova intend to build upon Trans Ova's current platform with new capabilities with a goal of achieving higher levels of delivered value to dairy and beef cattle producers. Pursuant to the Trans Ova Purchase Agreement, the former members of Trans Ova received an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,444,388</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock and </font><font style="font-family:inherit;font-size:10pt;">$63,625</font><font style="font-family:inherit;font-size:10pt;"> in cash, and will receive deferred cash consideration valued at </font><font style="font-family:inherit;font-size:10pt;">$20,115</font><font style="font-family:inherit;font-size:10pt;"> in exchange for all membership interests of Trans Ova. The deferred cash consideration is payable in </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> equal installments upon the first, second, and third anniversaries of the transaction date. The Trans Ova Purchase Agreement also provides for payment to the former members of Trans Ova a portion of certain cash proceeds in the event there is an award under certain litigation matters pending as of the transaction date to which Trans Ova is a party. The results of Trans Ova's operations subsequent to the acquisition date have been included in the consolidated financial statements, including revenues of </font><font style="font-family:inherit;font-size:10pt;">$18,283</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$64,743</font><font style="font-family:inherit;font-size:10pt;"> and net income (loss) of </font><font style="font-family:inherit;font-size:10pt;">$(3,655)</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$530</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and revenues of </font><font style="font-family:inherit;font-size:10pt;">$8,502</font><font style="font-family:inherit;font-size:10pt;"> and net loss of </font><font style="font-family:inherit;font-size:10pt;">$481</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the total consideration transferred, including the noncontrolling interest in a majority-owned subsidiary of Trans Ova, was </font><font style="font-family:inherit;font-size:10pt;">$127,875</font><font style="font-family:inherit;font-size:10pt;">. The acquisition date fair value of each class of consideration transferred and noncontrolling interest is presented below:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,802</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred cash consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration transferred</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,542</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock as of the date of the acquisition. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown in the table below.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,693</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Related party receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,476</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,164</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,949</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lines of credit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,091</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Related party payables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,090</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,563</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration and fair value of noncontrolling interest</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of acquired inventory was determined using the cost approach, which establishes value based on the cost of reproducing or replacing the asset. The fair value of acquired property, plant and equipment was determined using the cost approach and the market approach. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets. The acquired intangible assets include various developed technologies and know-how, customer relationships, and trademarks, and the fair values of these assets were determined using the relief-from-royalty, multi-period excess earnings, and with-and-without methods, which are all variations of the income approach. The acquired intangible assets are being amortized over useful lives ranging from </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> years. Goodwill, which will be deductible for tax purposes, represents the assembled workforce, potential future expansion of Trans Ova business lines and anticipated buyer-specific synergies arising from the combination of the Company's and Trans Ova's technologies.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with a prior transaction associated with Trans Ova's subsidiary, ViaGen, in September 2012, the Company may be obligated to make certain future contingent payments to the former equity holders of ViaGen, up to a total of </font><font style="font-family:inherit;font-size:10pt;">$6,000</font><font style="font-family:inherit;font-size:10pt;"> if certain revenue targets, as defined in the share purchase agreement, are met.&#160; The Company does not expect these revenue targets to be met and accordingly has assigned </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> value to this liability.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurred </font><font style="font-family:inherit;font-size:10pt;">$713</font><font style="font-family:inherit;font-size:10pt;"> of costs primarily for legal and due diligence services related to this acquisition, of which </font><font style="font-family:inherit;font-size:10pt;">$372</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$684</font><font style="font-family:inherit;font-size:10pt;"> is included in selling, general and administrative expenses in the accompanying consolidated statements of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2015, the Company acquired, through an exchange offer, the remaining outstanding membership interests of Trans Ova's majority-owned subsidiary, Exemplar, for </font><font style="font-family:inherit;font-size:10pt;">$1,566</font><font style="font-family:inherit;font-size:10pt;"> in cash and </font><font style="font-family:inherit;font-size:10pt;">307,074</font><font style="font-family:inherit;font-size:10pt;"> shares of Company common stock. </font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Medistem Acquisition</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2014, the Company acquired </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding common stock and securities convertible into common stock of Medistem, Inc. ("Medistem"), an entity engaged in the development of Endometrial Regenerative Cells ("ERCs"), for a combination of cash and Company common stock. The acquisition allows the Company to employ its synthetic biology platforms to engineer a diverse array of cell-based therapeutic candidates using Medistem's multipotent ERCs. Pursuant to the terms of the merger agreement, Medistem equity holders received </font><font style="font-family:inherit;font-size:10pt;">714,144</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock and </font><font style="font-family:inherit;font-size:10pt;">$4,920</font><font style="font-family:inherit;font-size:10pt;"> in cash in exchange for the outstanding Medistem common stock and securities convertible into common stock. Additionally, Medistem had issued the Company </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> promissory notes in the amount of </font><font style="font-family:inherit;font-size:10pt;">$707</font><font style="font-family:inherit;font-size:10pt;">, including accrued interest, both of which were settled upon closing of the merger. Certain members of Medistem's management surrendered a total of </font><font style="font-family:inherit;font-size:10pt;">17,695</font><font style="font-family:inherit;font-size:10pt;"> shares of their merger consideration to reimburse the Company for required payroll tax withholdings. The results of Medistem's operations subsequent to the acquisition date have been included in the consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the total consideration transferred was </font><font style="font-family:inherit;font-size:10pt;">$24,995</font><font style="font-family:inherit;font-size:10pt;">. The acquisition date fair value of each class of consideration transferred is presented below:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,920</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,368</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Settlement of promissory notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,995</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock as of the date of the acquisition. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown in the table below.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,824</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,832</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">644</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">761</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,071</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,995</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of acquired intangible assets was determined using the cost approach. The acquired intangible assets consist of in-process research and development, which is an indefinite-lived intangible asset. The goodwill consists of buyer-specific synergies between the Company's and Medistem's technologies present. The goodwill is not expected to be deductible for tax purposes.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurred </font><font style="font-family:inherit;font-size:10pt;">$680</font><font style="font-family:inherit;font-size:10pt;"> of acquisition-related costs, of which </font><font style="font-family:inherit;font-size:10pt;">$310</font><font style="font-family:inherit;font-size:10pt;"> is included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Unaudited Condensed Pro Forma Financial Information</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations of the 2015 acquisitions discussed above are included in the consolidated statements of operations beginning on the day after the acquisition date. The following unaudited condensed pro forma financial information for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> is presented as if the acquisitions had been consummated on January&#160;1, 2014:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pro forma</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,524</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,742</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,979</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,972</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,686</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(117,811</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(116,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to the noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">816</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,137</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,940</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,895</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(57,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(113,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations of the 2014 acquisitions discussed above are included in the consolidated statements of operations beginning on the day after their respective acquisition dates. The following unaudited condensed pro forma financial information for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> is presented as if the acquisitions had been consummated on January&#160;1, 2013:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="61%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September 30, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pro forma</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,864</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(98,816</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(98,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to the noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,260</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50,664</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(95,580</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-16, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations: Simplifying the Accounting for Measurement-Period Adjustments</font><font style="font-family:inherit;font-size:10pt;"> ("ASU 2015-16"). ASU 2015-16 eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Rather, the acquirer must recognize adjustments during the period in which the amounts are determined, including the effect on earnings of any amounts that would have been recorded in previous periods. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, with early adoption permitted. The Company elected to early adopt this guidance and there was no significant impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory (Topic 330) - Simplifying the Measurement of Inventory</font><font style="font-family:inherit;font-size:10pt;"> ("ASU 2015-11"). The provisions of ASU 2015-11 provide guidance for simplifying the calculation for subsequent measurement of inventory measured using the first-in-first-out or average cost methods. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2016, and is effective for the Company for the year ending December 31, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2015, the FASB issued ASU 2015-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Consolidation (Topic 810) - Amendments to the Consolidation Analysis</font><font style="font-family:inherit;font-size:10pt;"> ("ASU 2015-02"). The provisions of ASU 2015-02 provide guidance which changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. This guidance is effective for annual periods and interim periods within those annual periods, beginning after December 15, 2015, with early adoption permitted. The Company elected to early adopt this guidance and there was no significant impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-9, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> ("ASU 2014-9"). The FASB issued ASU 2014-9 to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance was originally effective for annual periods and interim periods within those annual periods beginning after December&#160;15, 2016 and early adoption was not permitted. In August 2015, the FASB issued ASU 2015-14, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606) - Deferral of the Effective Date </font><font style="font-family:inherit;font-size:10pt;">("ASU 2015-14"), which deferred the effective date of the guidance in ASU 2014-9 by one year to December 15, 2017 for interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016, and is effective for the Company for the year ending December&#160;31, 2018. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Corporation ("Intrexon"), a Virginia corporation, forms collaborations to create biologically based products and processes using synthetic biology. Intrexon has domestic operations in California, Florida, Maryland, and Virginia, and foreign operations in Belgium and Hungary. There have been no commercialized products derived from Intrexon's collaborations to date.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trans Ova Genetics, L.C. and Subsidiaries ("Trans Ova"), a provider of bovine reproductive technologies and other genetic processes to cattle breeders and producers, is a wholly owned subsidiary of Intrexon with primary operations in Iowa, Maryland, Missouri, Oklahoma, and Texas (Note </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">). ViaGen, L.C. ("ViaGen"), a provider of genetic preservation and cloning technologies, is a wholly owned subsidiary of Trans Ova. Exemplar Genetics, LLC ("Exemplar"), a provider of genetically engineered swine for medical and genetic research, is a wholly owned subsidiary through the combined investments of Intrexon, Trans Ova, and ViaGen.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Produce Holdings, Inc. ("IPHI") is a wholly owned subsidiary of Intrexon. Okanagan Specialty Fruits, Inc. ("Okanagan"), a company which developed and received regulatory approval for the world's first non-browning apple without the use of any flavor-altering chemical or antioxidant additives, is a wholly owned subsidiary of IPHI with primary operations in Canada (Note </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">). Fruit Orchard Holdings, Inc. ("FOHI") is a wholly owned subsidiary of IPHI with primary operations in Washington.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oxitec Limited ("Oxitec"), a pioneering company in biological insect control solutions, is a wholly owned subsidiary of Intrexon with primary operations in England and Brazil (Note </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, Intrexon owned approximately </font><font style="font-family:inherit;font-size:10pt;">63%</font><font style="font-family:inherit;font-size:10pt;"> of AquaBounty, a biotechnology company focused on improving productivity in commercial aquaculture.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, Intrexon owned approximately </font><font style="font-family:inherit;font-size:10pt;">51%</font><font style="font-family:inherit;font-size:10pt;"> of Biological&#160;&amp; Popular Culture, Inc. ("BioPop").</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Corporation and its consolidated subsidiaries are hereinafter referred to as the "Company."</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements are presented in United States dollars and are prepared under accounting principles generally accepted in the United States of America ("U.S. GAAP").</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain insignificant reclassifications have been made to the prior interim period consolidated financial statements to conform to the current interim period presentation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property, Plant and Equipment, net</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment consist of the following:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="69%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land and land improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings and building improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,311</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,265</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,018</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,983</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,722</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,060</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction and other assets in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,669</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,493</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,468</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,493</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,201</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense was </font><font style="font-family:inherit;font-size:10pt;">$1,987</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,807</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$5,768</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4,206</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are generally expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="86%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4&#8211;20</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings and building improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3&#8211;23</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#8211;7</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#8211;10</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#8211;7</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">fourteen years</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment consist of the following:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="69%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land and land improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings and building improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,311</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,265</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,018</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,983</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,722</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,060</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction and other assets in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,669</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,493</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,468</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,493</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,201</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Trade Receivables</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade receivables consist of credit extended to the Company's customers and collaborators in the normal course of business and are reported net of an allowance for doubtful accounts. The Company reviews its customer accounts on a periodic basis and records bad debt expense for specific amounts the Company evaluates as uncollectible. Past due status is determined based upon contractual terms. Amounts are written off at the point when collection attempts have been exhausted. Management estimates uncollectible amounts considering such factors as current economic conditions and historic and anticipated customer performance. This estimate can fluctuate due to changes in economic, industry or specific customer conditions which may require adjustment to the allowance recorded by the Company. Management has included amounts believed to be uncollectible in the allowance for doubtful accounts.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third Security and Affiliates</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company reimburses Third Security for certain administrative services and out-of-pocket expenses incurred on the Company's behalf. The total amount of expenses incurred by the Company for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$142</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$85</font><font style="font-family:inherit;font-size:10pt;">, respectively and </font><font style="font-family:inherit;font-size:10pt;">$294</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$173</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Manager of Third Security is also the Chief Executive Officer ("CEO") and Chairman of the Board of Directors of the Company. Prior to 2015, the CEO did not receive compensation for his services as CEO, and as a result, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$508</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,485</font><font style="font-family:inherit;font-size:10pt;"> in compensation expense for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, based on the estimated salary and benefits appropriate for the role. The Company anticipates that the CEO will participate in the Company's executive annual incentive compensation plan beginning in 2015.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See additional discussion related to Third Security and the Company's CEO at Note </font><font style="font-family:inherit;font-size:10pt;">19</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Transactions with ECC Parties</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to entities controlled by Third Security, any entity in which the Company holds equity securities, including securities received as upfront or milestone consideration, and which also are party to a collaboration with the Company are considered to be related parties. </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the Company purchased </font><font style="font-family:inherit;font-size:10pt;">375,868</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of Fibrocell at </font><font style="font-family:inherit;font-size:10pt;">$5.80</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2015, the Company purchased </font><font style="font-family:inherit;font-size:10pt;">278,788</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of AmpliPhi Biosciences Corporation ("AmpliPhi"), a collaborator, and </font><font style="font-family:inherit;font-size:10pt;">69,696</font><font style="font-family:inherit;font-size:10pt;"> warrants for </font><font style="font-family:inherit;font-size:10pt;">$2,300</font><font style="font-family:inherit;font-size:10pt;">. Of the total purchase price, </font><font style="font-family:inherit;font-size:10pt;">$1,979</font><font style="font-family:inherit;font-size:10pt;"> was allocated to the value of the shares of common stock and </font><font style="font-family:inherit;font-size:10pt;">$321</font><font style="font-family:inherit;font-size:10pt;"> was allocated to the value of the warrants. The number of shares and warrants received reflects a </font><font style="font-family:inherit;font-size:10pt;">1-for-50</font><font style="font-family:inherit;font-size:10pt;"> reverse stock split of AmpliPhi's common stock effective August 7, 2015. The AmpliPhi warrants have been included in other assets on the consolidated balance sheet with a value of </font><font style="font-family:inherit;font-size:10pt;">$145</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Between February 2011 and February 2015, the Company purchased </font><font style="font-family:inherit;font-size:10pt;">$43,582</font><font style="font-family:inherit;font-size:10pt;"> of ZIOPHARM securities. See Note </font><font style="font-family:inherit;font-size:10pt;">13</font><font style="font-family:inherit;font-size:10pt;"> for additional discussion related to the Company's investment in ZIOPHARM.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into an ECC with Histogenics Corporation ("Histogenics") in September 2014 and received a </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;"> convertible promissory note as upfront consideration. The note originally matured in September&#160;2015 and accrued interest at </font><font style="font-family:inherit;font-size:10pt;">6.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum. Upon the closing of Histogenics' IPO in December 2014, the note, with accrued interest, was converted to Histogenics common stock. Additionally, the Company purchased </font><font style="font-family:inherit;font-size:10pt;">1,772,364</font><font style="font-family:inherit;font-size:10pt;"> shares of Histogenics common stock at </font><font style="font-family:inherit;font-size:10pt;">$11.00</font><font style="font-family:inherit;font-size:10pt;"> per share in the IPO.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the ECC with Oragenics (Note </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">), the Company is entitled to, at its election, purchase up to </font><font style="font-family:inherit;font-size:10pt;">30%</font><font style="font-family:inherit;font-size:10pt;"> of securities offerings that may be conducted by Oragenics in the future, subject to certain conditions and limitations. In November&#160;2013, the Company purchased </font><font style="font-family:inherit;font-size:10pt;">1,100,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Oragenics common stock at </font><font style="font-family:inherit;font-size:10pt;">$2.50</font><font style="font-family:inherit;font-size:10pt;"> per share. In September&#160;2013, the Company purchased </font><font style="font-family:inherit;font-size:10pt;">1,300,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Oragenics common stock at </font><font style="font-family:inherit;font-size:10pt;">$3.00</font><font style="font-family:inherit;font-size:10pt;"> per share in a private transaction. In connection with Oragenics ECC 3 (Note </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">), the Company agreed to purchase additional common stock in a qualified financing, as defined in the agreement, during the </font><font style="font-family:inherit;font-size:10pt;">sixteen</font><font style="font-family:inherit;font-size:10pt;"> months following the effective date of the Oragenics ECC 3 in an amount up to the lesser of (i) the amount that is the proportion of such financing equal to the Company's pro rata equity holdings in Oragenics as of the effective date and (ii) </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;">, subject to certain conditions.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized </font><font style="font-family:inherit;font-size:10pt;">$31,740</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$11,295</font><font style="font-family:inherit;font-size:10pt;"> of collaboration revenues from related parties in the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$59,775</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$29,613</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Related Parties</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2015, the Company entered into an agreement with Harvest, an investment fund sponsored by Harvest Capital Strategies, LLC, and a related party based on ownership in the fund by affiliates of Third Security. Harvest was established to invest in life science research and development opportunities that Intrexon offers to Harvest. These will be investment proposals that are suitable for pursuit by a startup venture, characterized by the agreement as "start-up opportunities." For such start-up opportunities, the Company will provide Harvest with exclusive rights of first-look and first negotiation. For any opportunities it decides to pursue, Harvest would establish new collaboration entities which would enter into an ECC with the Company in a designated field. The terms of such ECCs would be negotiated between the Company and Harvest.&#160;In addition, the agreement provides the Company the right to present to Harvest the opportunity to invest in other ventures, including investment opportunities with respect to the Company's existing collaborations. Any such opportunities would be presented at the Company's discretion on a non-exclusive basis. The agreement with Harvest does not limit the Company's ability to execute other collaborations and joint ventures with third parties. As consideration for providing exclusive rights of first look and first negotiation for start-up opportunities, the Company receives a portion of the management fee collected by Harvest. These fees are included in other income in the accompanying consolidated statements of operations and totaled </font><font style="font-family:inherit;font-size:10pt;">$697</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers that regulatory and other uncertainties inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, and the costs of consultants, certain in-licensed technology rights, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Indirect research and development costs include depreciation, amortization and other indirect overhead expenses.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has research and development arrangements with third parties that include upfront and milestone payments and primarily relate to collaborations. At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company had research and development commitments with third parties that had not yet been incurred totaling </font><font style="font-family:inherit;font-size:10pt;">$6,576</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,183</font><font style="font-family:inherit;font-size:10pt;">, respectively. The commitments are generally cancellable by the Company at any time upon written notice.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generates revenue through contractual agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i)&#160;upfront payments upon consummation of the agreement, (ii)&#160;reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement, (iii)&#160;milestone payments upon the achievement of specified development, regulatory and commercial activities, and (iv)&#160;royalties on sales of products arising from the collaboration or licensing agreement.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's collaboration and licensing agreements typically contain multiple elements, or deliverables, including technology licenses, research and development services, and in certain cases manufacturing services. The Company identifies the deliverables within the agreements and evaluates which deliverables represent separate units of accounting. Analyzing the agreements to identify deliverables requires the use of judgment. A deliverable is considered a separate unit of accounting when the deliverable has value to the collaborator or licensee on a standalone basis based on the consideration of the relevant facts and circumstances for each agreement.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consideration received is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. When available, the relative selling price for each deliverable is determined using vendor specific objective evidence ("VSOE") of the selling price or third-party evidence of the selling price, if VSOE does not exist. If neither VSOE nor third-party evidence of the selling price exists, the Company uses its best estimate of the selling price ("BESP") for the deliverable. The amount of allocable consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. The Company recognizes the revenue allocated to each unit of accounting as the Company delivers the related goods or services. If the Company determines that certain deliverables should be treated as a single unit of accounting, then the revenue is recognized using either a proportional performance or straight-line method, depending on whether the Company can reasonably estimate the level of effort required to complete its performance obligations under an arrangement and whether such performance obligations are provided on a best-efforts basis. As the Company cannot reasonably estimate its performance obligations related to its collaborators or licensees, the Company recognizes revenue on a straight-line basis over the period it expects to complete its performance obligations.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The terms of the Company's agreements may provide for milestone payments upon achievement of certain defined events. The Company applies the Milestone Method for recognizing milestone payments. Under the Milestone Method, the Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration is commensurate with either the entity's performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the entity's performance to achieve the milestone;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration relates solely to past performance; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event that a milestone is not considered substantive, the Company recognizes the milestone consideration as revenue using the same method applied to upfront payments.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development services are a deliverable satisfied by the Company in accordance with the terms of the collaboration and licensing agreements and the Company considers these services to be inseparable from the license to the core technology; therefore, reimbursements of services performed are recognized as revenue. Because reimbursement (i)&#160;is contingent upon performance of the services by the Company, (ii)&#160;does not include a profit component, and (iii)&#160;does not relate to any future deliverable, the revenue is recognized during the period in which the related services are performed and collection of such amounts is reasonably assured. Payments received for manufacturing services will be recognized when the earnings process related to the manufactured materials has been completed. Royalties to be received under the agreements will be recognized as earned.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. When no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also generates products and services revenue through sales of advanced reproductive technologies, including bovine embryos derived from the Company's embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock used in production. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) services have been rendered or delivery has occurred such that risk of loss has passed to the customer, (iii) the price is fixed or determinable, and (iv) collection from the customer is reasonably assured.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of accumulated other comprehensive loss were as follows:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="69%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain on investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,486</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,195</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following potentially dilutive securities have been excluded from the above computations of diluted weighted average shares outstanding for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, as they would have been anti-dilutive:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,660,040</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,194,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">194,719</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">373,102</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,854,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,567,752</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the total consideration transferred was </font><font style="font-family:inherit;font-size:10pt;">$24,995</font><font style="font-family:inherit;font-size:10pt;">. The acquisition date fair value of each class of consideration transferred is presented below:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,920</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,368</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Settlement of promissory notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,995</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the total consideration transferred was </font><font style="font-family:inherit;font-size:10pt;">$40,933</font><font style="font-family:inherit;font-size:10pt;">. The acquisition date fair value of each class of consideration transferred is presented below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the total consideration transferred was </font><font style="font-family:inherit;font-size:10pt;">$72,474</font><font style="font-family:inherit;font-size:10pt;">. The acquisition date fair value of each class of consideration transferred is presented below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,474</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the total consideration transferred, including the noncontrolling interest in a majority-owned subsidiary of Trans Ova, was </font><font style="font-family:inherit;font-size:10pt;">$127,875</font><font style="font-family:inherit;font-size:10pt;">. The acquisition date fair value of each class of consideration transferred and noncontrolling interest is presented below:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,802</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred cash consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration transferred</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,542</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the total consideration transferred was </font><font style="font-family:inherit;font-size:10pt;">$146,394</font><font style="font-family:inherit;font-size:10pt;">. The acquisition date fair value of the Stock Consideration and Cash Consideration is presented below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,195</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt consists of the following:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="69%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,653</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty-based financing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,926</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,110</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,369</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt, less current portion</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,796</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,694</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the computation of basic and diluted net loss per share for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historical net loss per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,213</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52,725</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,779</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,653</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,244,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,888,203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,244,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,711,564</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.53</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.47</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.02</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation costs included in the consolidated statements of operations are presented below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="42%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,032</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,006</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,591</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,385</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,250</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,524</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,872</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets consist of the following at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td width="37%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Useful Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents, related technologies and know-how</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,255</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,445</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademarks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(834</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Covenant not to compete</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(115</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">280</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,568</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,568</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274,629</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,345</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets consist of the following at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents, related technologies and know-how</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,872</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(806</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,894</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademarks</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,428</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,428</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,900</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,953</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,947</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,161</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,067</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,941</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,587</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,765</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in the carrying amount of goodwill for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisitions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,404</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,597</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,866</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory consists of the following:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="69%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplies, semen and embryos</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,135</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,637</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Livestock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Feed</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,972</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,338</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,789</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future maturities of long term debt are as follows:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="84%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">506</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">929</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">525</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,253</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preliminary estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant, and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,854</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,473</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,584</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,347</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,126</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown in the table below.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,693</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Related party receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,476</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,164</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,949</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lines of credit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,091</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Related party payables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,090</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,563</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration and fair value of noncontrolling interest</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown in the table below.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="85%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,824</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,832</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">644</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">761</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,071</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,995</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below along with subsequent adjustments during the measurement period to the fair value of assets acquired and liabilities assumed. The adjustments resulted from the difference between estimated and actual accrued expenses.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Initial Estimated Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjusted Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">305</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">305</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,848</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,848</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">307</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">612</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">612</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,505</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(482</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,343</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">482</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,825</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,474</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,474</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below along with subsequent adjustments during the measurement period to the fair value of assets acquired and liabilities assumed. The adjustments resulted from revisions to the valuation of intangible assets.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Initial Estimated Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjusted Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant, and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,955</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,655</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,145</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">702</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,847</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,507</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">702</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,209</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,485</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,998</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,487</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock option activity under Intrexon's award plans was as follows:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,323,544</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.64</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,282,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47.89</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment due to dividend (Note 13)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">312,795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(790,265</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16.89</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,467,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(546</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17.72</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,660,040</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.53</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable at September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,502,418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.73</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Vested and Expected to Vest at September&#160;30, 2015(1)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,803,769</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.37</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The number of stock options expected to vest takes into account an estimate of expected forfeitures.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has determined that it operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment. The Company applies its technologies to create products and services which may be either sold directly to customers or developed through collaboration with third parties. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Unaudited Financial Information</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with U.S. GAAP. Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and results of operations and cash flows for the interim periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">. These interim financial results are not necessarily indicative of the results to be expected for the year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generates revenue through contractual agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i)&#160;upfront payments upon consummation of the agreement, (ii)&#160;reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement, (iii)&#160;milestone payments upon the achievement of specified development, regulatory and commercial activities, and (iv)&#160;royalties on sales of products arising from the collaboration or licensing agreement.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's collaboration and licensing agreements typically contain multiple elements, or deliverables, including technology licenses, research and development services, and in certain cases manufacturing services. The Company identifies the deliverables within the agreements and evaluates which deliverables represent separate units of accounting. Analyzing the agreements to identify deliverables requires the use of judgment. A deliverable is considered a separate unit of accounting when the deliverable has value to the collaborator or licensee on a standalone basis based on the consideration of the relevant facts and circumstances for each agreement.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consideration received is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. When available, the relative selling price for each deliverable is determined using vendor specific objective evidence ("VSOE") of the selling price or third-party evidence of the selling price, if VSOE does not exist. If neither VSOE nor third-party evidence of the selling price exists, the Company uses its best estimate of the selling price ("BESP") for the deliverable. The amount of allocable consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. The Company recognizes the revenue allocated to each unit of accounting as the Company delivers the related goods or services. If the Company determines that certain deliverables should be treated as a single unit of accounting, then the revenue is recognized using either a proportional performance or straight-line method, depending on whether the Company can reasonably estimate the level of effort required to complete its performance obligations under an arrangement and whether such performance obligations are provided on a best-efforts basis. As the Company cannot reasonably estimate its performance obligations related to its collaborators or licensees, the Company recognizes revenue on a straight-line basis over the period it expects to complete its performance obligations.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The terms of the Company's agreements may provide for milestone payments upon achievement of certain defined events. The Company applies the Milestone Method for recognizing milestone payments. Under the Milestone Method, the Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration is commensurate with either the entity's performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the entity's performance to achieve the milestone;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration relates solely to past performance; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event that a milestone is not considered substantive, the Company recognizes the milestone consideration as revenue using the same method applied to upfront payments.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development services are a deliverable satisfied by the Company in accordance with the terms of the collaboration and licensing agreements and the Company considers these services to be inseparable from the license to the core technology; therefore, reimbursements of services performed are recognized as revenue. Because reimbursement (i)&#160;is contingent upon performance of the services by the Company, (ii)&#160;does not include a profit component, and (iii)&#160;does not relate to any future deliverable, the revenue is recognized during the period in which the related services are performed and collection of such amounts is reasonably assured. Payments received for manufacturing services will be recognized when the earnings process related to the manufactured materials has been completed. Royalties to be received under the agreements will be recognized as earned.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. When no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also generates products and services revenue through sales of advanced reproductive technologies, including bovine embryos derived from the Company's embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock used in production. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) services have been rendered or delivery has occurred such that risk of loss has passed to the customer, (iii) the price is fixed or determinable, and (iv) collection from the customer is reasonably assured.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers that regulatory and other uncertainties inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, and the costs of consultants, certain in-licensed technology rights, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Indirect research and development costs include depreciation, amortization and other indirect overhead expenses.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has research and development arrangements with third parties that include upfront and milestone payments and primarily relate to collaborations. At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company had research and development commitments with third parties that had not yet been incurred totaling </font><font style="font-family:inherit;font-size:10pt;">$6,576</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,183</font><font style="font-family:inherit;font-size:10pt;">, respectively. The commitments are generally cancellable by the Company at any time upon written notice.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All highly liquid investments with an original maturity of </font><font style="font-family:inherit;font-size:10pt;">three months</font><font style="font-family:inherit;font-size:10pt;"> or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions with high quality credit ratings. Recoverability of investments is dependent upon the performance of the issuer. At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company had cash equivalent investments in highly liquid money market accounts at major financial institutions of </font><font style="font-family:inherit;font-size:10pt;">$93,158</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$16,598</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-term and Long-term Investments</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, investments include short-term and long-term investments in U.S. government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company's written investment policy requires investments to be explicitly rated by two of the three following rating services: Standard&#160;&amp; Poor's, Moody's and/or Fitch and to have a minimum rating of A1, P1 and/or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Securities</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company holds equity securities received and/or purchased from certain collaborators. Other than investments accounted for using the equity method, the Company elected the fair value option to account for its equity securities held in these collaborators. These equity securities are recorded at fair value at each reporting date and are subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments are reported in the consolidated statement of operations. The fair value of these equity securities is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these collaborators. These equity securities are classified as noncurrent in the consolidated balance sheet since the Company does not intend to sell these equity securities within one year.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records the fair value of securities received on the date the collaboration is consummated or the milestone is achieved using the closing, quoted price of the collaborator's security on that date, assuming the transfer of consideration is considered perfunctory. If the transfer of the consideration is not considered perfunctory, the Company considers the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluates whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concludes that a discount should be applied, the fair value of the securities is adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</font></div><div style="line-height:120%;padding-top:16px;padding-left:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.1171875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="91%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted prices in active markets for identical assets and liabilities;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Risk</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the Company's mix of fixed and variable rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, gross unrealized losses on the Company's short-term and long-term investments were immaterial. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of trade receivables. The Company controls credit risk through credit approvals, credit limits and monitoring procedures. The Company performs ongoing credit evaluations of its customers, but generally does not require collateral to support accounts receivable.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Method Investments</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is party to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> strategic joint ventures (Note </font><font style="font-family:inherit;font-size:10pt;">4</font><font style="font-family:inherit;font-size:10pt;">). The Company accounts for its investments in these joint ventures and for its investment in Thrive Agrobiotics, Inc. ("Thrive Agrobiotics") (Note </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">) using the equity method of accounting since the Company has the ability to exercise significant influence, but not control, over the operating activities of these entities.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that it has significant influence over </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> of its collaborators, Oragenics, Inc. ("Oragenics"), as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and over </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> of its collaborators, Oragenics and ZIOPHARM Oncology, Inc. ("ZIOPHARM"), as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, based on its ownership interests, representation on the board of directors of the collaborators and other qualitative factors. The Company accounts for its investments in Oragenics and ZIOPHARM using the fair value option. </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Company's equity securities of Oragenics was </font><font style="font-family:inherit;font-size:10pt;">$13,475</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7,192</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, and is included as equity securities in the respective consolidated balance sheets. The Company's ownership percentage of Oragenics was </font><font style="font-family:inherit;font-size:10pt;">24.2%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">24.4%</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively. Unrealized appreciation (depreciation) in the fair value of the Company's equity securities held in Oragenics was </font><font style="font-family:inherit;font-size:10pt;">$2,404</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$(5,487)</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, and was </font><font style="font-family:inherit;font-size:10pt;">$6,283</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$(11,890)</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2015, the Company distributed all of its holdings in ZIOPHARM to the Company's shareholders in the form of a special stock dividend (Note </font><font style="font-family:inherit;font-size:10pt;">13</font><font style="font-family:inherit;font-size:10pt;">). Upon disposition, the Company realized a gain of </font><font style="font-family:inherit;font-size:10pt;">$81,401</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended June 30, 2015. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company's ownership percentage of ZIOPHARM was </font><font style="font-family:inherit;font-size:10pt;">15.7%</font><font style="font-family:inherit;font-size:10pt;"> and the fair value of the Company's equity securities of ZIOPHARM was </font><font style="font-family:inherit;font-size:10pt;">$83,099</font><font style="font-family:inherit;font-size:10pt;"> and is included as equity securities in the December 31, 2014 consolidated balance sheet. Unrealized depreciation in the fair value of the Company's equity securities held in ZIOPHARM was </font><font style="font-family:inherit;font-size:10pt;">$22,783</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$27,864</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized unaudited financial data as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, for the Company's equity method investments are as follows:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="71%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,259</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,886</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,121</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,346</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,121</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,916</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,566</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">834</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,389</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,052</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,266</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,854</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,543</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,724</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,667</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Variable Interest Entities</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company identifies entities that (i)&#160;do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii)&#160;in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIE" or "VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii)&#160;have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that certain of its collaborators and joint ventures were VIEs. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company also determined that Harvest Intrexon Enterprise Fund I, LP ("Harvest") (Note </font><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:10pt;">) was a VIE. The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. The Company's aggregate investment balances of these VIEs as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$1,909</font><font style="font-family:inherit;font-size:10pt;">, which represents the Company's maximum risk of loss related to the identified VIEs. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company did not hold any investment balances in the identified VIEs and therefore had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> risk of loss as of that date.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Trade Receivables</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade receivables consist of credit extended to the Company's customers and collaborators in the normal course of business and are reported net of an allowance for doubtful accounts. The Company reviews its customer accounts on a periodic basis and records bad debt expense for specific amounts the Company evaluates as uncollectible. Past due status is determined based upon contractual terms. Amounts are written off at the point when collection attempts have been exhausted. Management estimates uncollectible amounts considering such factors as current economic conditions and historic and anticipated customer performance. This estimate can fluctuate due to changes in economic, industry or specific customer conditions which may require adjustment to the allowance recorded by the Company. Management has included amounts believed to be uncollectible in the allowance for doubtful accounts.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows the activity in the allowance for doubtful accounts for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="81%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charged to operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,562</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Write offs of accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's inventory primarily includes adult female cows which are used in certain production processes and are recorded at acquisition cost using the first-in, first-out method or at market, whichever is lower. Work-in-process inventory includes allocations of production costs and facility costs for products currently in production and is recorded at the lower of cost or market. Significant declines in the price of cows could result in unfavorable adjustments to inventory balances. </font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are generally expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="86%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4&#8211;20</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings and building improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3&#8211;23</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#8211;7</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#8211;10</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#8211;7</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">fourteen years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized (Note </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">). Goodwill is reviewed for impairment at least annually. The Company performs a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the two-step goodwill impairment test. If this is the case, the two-step goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the two-step goodwill impairment test is not required.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the two-step goodwill impairment test is required, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, an indication of goodwill impairment exists for the reporting unit and the entity must perform step two of the impairment test. Under step two, an impairment loss is recognized for any excess of the carrying amount of the reporting unit's goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation and the residual fair value after this allocation is the implied fair value of the reporting unit goodwill. Fair value of the reporting unit is determined using a discounted cash flow analysis. If the fair value of the reporting unit exceeds its carrying amount, step two does not need to be performed.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets subject to amortization consist of patents, related technologies and know-how; customer relationships; trademarks; and a covenant not to compete acquired as a result of mergers and acquisitions (Note </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">). These intangible assets are subject to amortization, were recorded at fair value at the date of acquisition and are stated net of accumulated amortization. Indefinite-lived intangible assets consist of in-process research and development acquired in mergers and acquisitions (Note </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">) and were recorded at fair value at the dates of the respective acquisitions.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible assets are expected to be realized. The intangible assets are amortized over their remaining estimated useful lives, ranging from </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">eighteen years</font><font style="font-family:inherit;font-size:10pt;"> for the patents, related technologies and know-how; customer relationships; trademarks; and the covenant not to compete.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets, including in-process research and development, are tested for impairment annually, or more frequently if events or circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of their fair value to carrying value, without consideration of any recoverability test. The Company monitors the progression of its in-process research and development, as the likelihood of success is contingent upon commercial development or regulatory approval.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Translation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into United States dollars at the exchange rates in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in the consolidated statement of comprehensive loss. Revenue and expense amounts are translated at average rates during the period.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Share</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has determined that it operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment. The Company applies its technologies to create products and services which may be either sold directly to customers or developed through collaboration with third parties. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$3,623</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,200</font><font style="font-family:inherit;font-size:10pt;">, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling </font><font style="font-family:inherit;font-size:10pt;">$1,183</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$809</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$3,446</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,178</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-16, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations: Simplifying the Accounting for Measurement-Period Adjustments</font><font style="font-family:inherit;font-size:10pt;"> ("ASU 2015-16"). ASU 2015-16 eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Rather, the acquirer must recognize adjustments during the period in which the amounts are determined, including the effect on earnings of any amounts that would have been recorded in previous periods. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, with early adoption permitted. The Company elected to early adopt this guidance and there was no significant impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory (Topic 330) - Simplifying the Measurement of Inventory</font><font style="font-family:inherit;font-size:10pt;"> ("ASU 2015-11"). The provisions of ASU 2015-11 provide guidance for simplifying the calculation for subsequent measurement of inventory measured using the first-in-first-out or average cost methods. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2016, and is effective for the Company for the year ending December 31, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2015, the FASB issued ASU 2015-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Consolidation (Topic 810) - Amendments to the Consolidation Analysis</font><font style="font-family:inherit;font-size:10pt;"> ("ASU 2015-02"). The provisions of ASU 2015-02 provide guidance which changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. This guidance is effective for annual periods and interim periods within those annual periods, beginning after December 15, 2015, with early adoption permitted. The Company elected to early adopt this guidance and there was no significant impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-9, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> ("ASU 2014-9"). The FASB issued ASU 2014-9 to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance was originally effective for annual periods and interim periods within those annual periods beginning after December&#160;15, 2016 and early adoption was not permitted. In August 2015, the FASB issued ASU 2015-14, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606) - Deferral of the Effective Date </font><font style="font-family:inherit;font-size:10pt;">("ASU 2015-14"), which deferred the effective date of the guidance in ASU 2014-9 by one year to December 15, 2017 for interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016, and is effective for the Company for the year ending December&#160;31, 2018. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain insignificant reclassifications have been made to the prior interim period consolidated financial statements to conform to the current interim period presentation.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders' Equity</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Issuances of Common Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2015, the Company closed a public offering of </font><font style="font-family:inherit;font-size:10pt;">5,609,756</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock, inclusive of </font><font style="font-family:inherit;font-size:10pt;">731,707</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock sold by the Company pursuant to the full exercise of an overallotment option granted to the underwriters in connection with the offering, at a public offering price of </font><font style="font-family:inherit;font-size:10pt;">$41.00</font><font style="font-family:inherit;font-size:10pt;"> per share. The aggregate proceeds of the offering were </font><font style="font-family:inherit;font-size:10pt;">$218,193</font><font style="font-family:inherit;font-size:10pt;">, net of underwriting discounts of </font><font style="font-family:inherit;font-size:10pt;">$11,500</font><font style="font-family:inherit;font-size:10pt;"> and offering expenses paid by the Company of approximately </font><font style="font-family:inherit;font-size:10pt;">$306</font><font style="font-family:inherit;font-size:10pt;">, all of which were capitalized.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, the Company closed a public offering of </font><font style="font-family:inherit;font-size:10pt;">4,312,500</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock, inclusive of </font><font style="font-family:inherit;font-size:10pt;">562,500</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock sold by the Company pursuant to the full exercise of an overallotment option granted to the underwriters in connection with the offering and </font><font style="font-family:inherit;font-size:10pt;">555,556</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock purchased by affiliates of Third Security (Note </font><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:10pt;">), at a public offering price of </font><font style="font-family:inherit;font-size:10pt;">$27.00</font><font style="font-family:inherit;font-size:10pt;"> per share. The aggregate proceeds of the offering were </font><font style="font-family:inherit;font-size:10pt;">$110,041</font><font style="font-family:inherit;font-size:10pt;">, net of underwriting discounts and commissions of </font><font style="font-family:inherit;font-size:10pt;">$6,086</font><font style="font-family:inherit;font-size:10pt;"> and offering expenses paid by the Company of approximately </font><font style="font-family:inherit;font-size:10pt;">$311</font><font style="font-family:inherit;font-size:10pt;">, all of which were capitalized.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2014 and concurrent with the formation of Intrexon Energy Partners, the Company entered into securities purchase agreements with each of the Investors in Intrexon Energy Partners for the private placement of </font><font style="font-family:inherit;font-size:10pt;">972,004</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$25.72</font><font style="font-family:inherit;font-size:10pt;"> for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">. Each Investor purchased an amount proportionate to its investment in Intrexon Energy Partners, including </font><font style="font-family:inherit;font-size:10pt;">243,001</font><font style="font-family:inherit;font-size:10pt;"> shares, or </font><font style="font-family:inherit;font-size:10pt;">$6,250</font><font style="font-family:inherit;font-size:10pt;">, purchased by an affiliate of Third Security (Note </font><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Dividend to Shareholders</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2015, the Company distributed to its shareholders </font><font style="font-family:inherit;font-size:10pt;">17,830,305</font><font style="font-family:inherit;font-size:10pt;"> shares of ZIOPHARM common stock, representing all of the equity interests of ZIOPHARM held by the Company and resulting in a realized gain of </font><font style="font-family:inherit;font-size:10pt;">$81,401</font><font style="font-family:inherit;font-size:10pt;">. The distribution constituted a dividend to shareholders of record as of June 4, 2015. In connection with the distribution, pursuant to the terms of the Company's equity incentive plans, the conversion terms of all outstanding options for shares of the Company's stock as of June 4, 2015 were adjusted to reflect the value of the distribution with respect to shares of the Company's common stock.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Components of Accumulated Other Comprehensive Loss</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of accumulated other comprehensive loss were as follows:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="69%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain on investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,486</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,195</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the Company entered into a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security will provide the Company with certain professional, administrative, and other support services in exchange for a fee of </font><font style="font-family:inherit;font-size:10pt;">$800</font><font style="font-family:inherit;font-size:10pt;"> per month to be paid in the form of fully-vested shares of the Company's common stock. The payments made by the Company under the Services Agreement constitute, in the aggregate, an award under the 2013 Plan and will be subject to the terms of the 2013 Plan.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the Company entered into a compensation arrangement with the Company's CEO. Previously, the CEO did not receive compensation for his services as CEO of the Company. Under the new compensation arrangement, the CEO will receive compensation of </font><font style="font-family:inherit;font-size:10pt;">$200</font><font style="font-family:inherit;font-size:10pt;"> per month in the form of fully-vested shares of the Company's common stock. The shares of common stock will be issued pursuant to the terms of a Restricted Stock Unit Agreement under the 2013 Plan.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows the activity in the allowance for doubtful accounts for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="81%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charged to operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,562</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Write offs of accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the amounts recorded in the consolidated statements of operations for each significant collaboration and licensing agreement for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="43%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognized From</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Upfront&#160;and Milestone Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,868</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,317</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">993</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,061</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S &amp; I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">297</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,841</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,002</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,843</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,592</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,726</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="43%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognized From</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Upfront&#160;and Milestone Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">428</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S &amp; I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">813</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">813</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">443</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,404</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,847</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,490</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,166</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="43%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognized From</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Upfront&#160;and Milestone Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">408</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,845</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,460</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,665</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S &amp; I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">928</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,446</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,066</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,326</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="43%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognized From</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Upfront&#160;and Milestone Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,932</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,372</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,204</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,409</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S &amp; I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,561</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,561</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,373</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,255</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,628</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,368</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,257</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Securities</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company holds equity securities received and/or purchased from certain collaborators. Other than investments accounted for using the equity method, the Company elected the fair value option to account for its equity securities held in these collaborators. These equity securities are recorded at fair value at each reporting date and are subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments are reported in the consolidated statement of operations. The fair value of these equity securities is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these collaborators. These equity securities are classified as noncurrent in the consolidated balance sheet since the Company does not intend to sell these equity securities within one year.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records the fair value of securities received on the date the collaboration is consummated or the milestone is achieved using the closing, quoted price of the collaborator's security on that date, assuming the transfer of consideration is considered perfunctory. If the transfer of the consideration is not considered perfunctory, the Company considers the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluates whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concludes that a discount should be applied, the fair value of the securities is adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">License Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, the Company and ZIOPHARM jointly entered into a license agreement with the University of Texas System Board of Regents on behalf of the University of Texas MD Anderson Cancer Center ("MD Anderson") whereby the Company received an exclusive license to certain research and development technologies owned and licensed by MD Anderson, including technologies relating to novel chimeric antigen receptor (CAR) T-cell therapies, as well as co-licenses and non-exclusive licenses to certain other related technologies. ZIOPHARM shall receive access to these technologies pursuant to the terms of the Company's ECC with ZIOPHARM. The Company issued </font><font style="font-family:inherit;font-size:10pt;">2,100,085</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock valued at </font><font style="font-family:inherit;font-size:10pt;">$59,579</font><font style="font-family:inherit;font-size:10pt;"> to MD Anderson as consideration, which is included in research and development expenses in the accompanying consolidated statement of operations for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">. Subject to certain exceptions, the license agreement expires on the last to occur of (i) the expiration of all patents licensed thereunder, or (ii) the twentieth anniversary of the date of the license agreement. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the license agreement, the Company, ZIOPHARM, and MD Anderson entered into a research and development agreement which governs certain operational activities between the parties and pursuant to which ZIOPHARM will provide funding for certain research and development activities of MD Anderson for a period of </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">, in an amount between </font><font style="font-family:inherit;font-size:10pt;">$15,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$20,000</font><font style="font-family:inherit;font-size:10pt;"> per year. The Company and ZIOPHARM are obligated to reimburse MD Anderson for out of pocket expenses for maintaining patents covering the licensed technologies.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated useful lives of these assets are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="86%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4&#8211;20</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings and building improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3&#8211;23</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#8211;7</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#8211;10</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#8211;7</font></div></td></tr></table></div></div></div> The number of stock options expected to vest takes into account an estimate of expected forfeitures. EX-101.SCH 7 xon-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2112100 - Disclosure - Collaboration and Licensing Revenue link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Collaboration and Licensing Revenue - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Collaboration and Licensing Revenue - Summarized Amount of Collaboration and Licensing Revenue Recorded in Consolidated Statements of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Collaboration and Licensing Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2425403 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2425402 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments Under Noncancelable Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2325301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Shareholders' and Total Equity link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Goodwill and Intangible Assets, net link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Goodwill and Intangible Assets, net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Changes in Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2419404 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Goodwill and Intangible Assets, net (Tables) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2421401 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Inventory - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Investments in Joint Ventures link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - Investments in Joint Ventures - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - License Agreement link:presentationLink link:calculationLink link:definitionLink 2424401 - Disclosure - License Agreement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Lines of Credit and Long Term Debt link:presentationLink link:calculationLink link:definitionLink 2420403 - Disclosure - Lines of Credit and Long Term Debt - Components of Long Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Lines of Credit and Long Term Debt - Lines of Credit - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2420404 - Disclosure - Lines of Credit and Long Term Debt - Long Term Debt - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2420405 - Disclosure - Lines of Credit and Long Term Debt - Schedule of Future Maturities of Long Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Lines of Credit and Long Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Mergers and Acquisitions link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Mergers and Acquisitions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Mergers and Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Mergers and Acquisitions - Fair Value of Consideration Transferred (Details) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - Mergers and Acquisitions - Pro Forma Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Mergers and Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2127100 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 2427402 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2427403 - Disclosure - Net Loss per Share - Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2327301 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Organization and Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Property, Plant and Equipment, net link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - Property, Plant and Equipment, net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Property, Plant and Equipment, net - Schedule of Property Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Property, Plant and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 2126100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2426401 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2422402 - Disclosure - Shareholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2422403 - Disclosure - Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 2322301 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Short-term and Long-term Investments link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Short-term and Long-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Short-term and Long-term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Short-term and Long-term Investments - Summary of Estimated Fair Value of Available-for-Sale Investments Classified by Contractual Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Short-term and Long-term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Stock Option Plans link:presentationLink link:calculationLink link:definitionLink 2423402 - Disclosure - Stock Option Plans - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2423404 - Disclosure - Stock Option Plans - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2423403 - Disclosure - Stock Option Plans - Stock Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2323301 - Disclosure - Stock Option Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2128100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2428401 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Summary of Significant Accounting Policies - Summarized Financial Data (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Summary of Significant Accounting Policies - Trade Receivables - Rollforward of Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 xon-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 xon-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 xon-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Investments, Debt and Equity Securities [Abstract] Due within one year Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value After one year through three years Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value Aggregate Fair Value Available-for-sale Securities, Debt Securities Accounting Policies [Abstract] Allowance for Doubtful Accounts Receivable Allowance for Doubtful Accounts Receivable [Roll Forward] December 31, 2014 Allowance for Doubtful Accounts Receivable Charged to operating expenses Provision for Doubtful Accounts Write offs of accounts receivable Allowance for Doubtful Accounts Receivable, Write-offs September 30, 2015 Equity [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Unrealized gain on investments Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Fair Value Disclosures [Abstract] Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Third Security Third Security [Member] Third Security, LLC Chief Executive Officer Chief Executive Officer [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Monthly service fee Professional and Contract Services Expense Monthly compensation, in the form of equity Allocated Share-based Compensation Expense Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments Available-for-sale Securities [Table Text Block] Investments Classified by Contractual Maturity Date Investments Classified by Contractual Maturity Date [Table Text Block] Equity Method Investments and Joint Ventures [Abstract] Investments in Joint Ventures Equity Method Investments and Joint Ventures Disclosure [Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Oxitec Limited Oxitec Limited [Member] Oxitec Limited [Member] Okanagan Specialty Fruits Inc Okanagan Specialty Fruits Inc [Member] Okanagan Specialty Fruits Inc [Member] ActoGeniX NV ActoGeniX NV [Member] ActoGeniX NV [Member] Trans Ova Genetics, LC Trans Ova Genetics Lc [Member] Trans Ova Genetics LC [Member] Exemplar Genetics, LLC Exemplar Genetics, LLC [Member] Exemplar Genetics, LLC [Member] Medistem, Inc. Medistem Inc [Member] Medistem, Inc. Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Selling, general and administrative Selling, General and Administrative Expenses [Member] Noncash or Part Noncash Acquisitions by Unique Description [Axis] Noncash or Part Noncash Acquisitions by Unique Description [Axis] Noncash or Part Noncash Acquisition, Name [Domain] Noncash or Part Noncash Acquisition, Name [Domain] Settlement of Promissory Notes Promissory Notes [Member] Promissory notes settled upon closing of the merger Business Acquisition [Line Items] Business Acquisition [Line Items] Percentage of outstanding common stock acquired Business Acquisition, Percentage of Voting Interests Acquired Consideration transferred, shares issued or issuable Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Cash Payments to Acquire Businesses, Gross Cash and working capital adjustments Business Acquisition, Consideration Transferred, Cash and Working Capital Adjustments Amount of consideration transferred in a business combination related to cash and working capital adjustments. Payment of cash and working capital adjustments, number of days after closing Business Acquisition, Consideration Transferred, Cash And Working Capital Adjustments, Transfer Period After Closing Time period following the closing date of the business acquisition during which cash and working capital adjustments are due to be paid by the entity. Consideration transferred, shares issuable withheld as escrow Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Withheld as Escrow Number of shares of equity interests issued or issuable to acquire entity which were withheld as escrow. Consideration transferred, cash withheld as escrow Business Combination, Cash Consideration Withheld as Escrow Portion of cash consideration in a business combination withheld as escrow. Transfer of cash withheld as escrow, number of months after closing Business Combination, Consideration Withheld as Escrow, Transfer Period After Closing Period following the closing date of a business combination at which time consideration withheld as escrow is due to be paid by the entity. Total consideration transferred Business Combination, Consideration Transferred Business combination, acquisition related cost Business Combination, Acquisition Related Costs Intangible assets, useful life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Deferred cash consideration Business Combination, Consideration Transferred, Liabilities Incurred Deferred cash consideration, number of payment installments Business Acquisition, Consideration Transferred, Liabilities Incurred, Number Of Payment Installments Number of installments payable for deferred consideration associated with the business acquisition. Revenues Revenues Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Total consideration transferred, including the noncontrolling interest Business Combination, Consideration Transferred and Noncontrolling Interest Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer combined with noncontrolling interest. Possible future contingent payments to former equity holders Business Combination, Contingent Consideration, Future Payments To Equity Holders, Maximum Business Combination, Contingent Consideration, Future Payments To Equity Holders, Maximum Possible future contingent payments to former equity holders, current valuation Business Combination, Contingent Consideration, Liability, Current Cash paid to acquire noncontrolling interest Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Purchase of Interest by Parent, Cash Portion Represents the cash portion of the purchase by the parent of an additional equity interest in a subsidiary during the period, thereby effecting a change in total (consolidated) equity attributable to the parent. The purchase of the additional equity interest represented by this element increases the parent's controlling interest in the subsidiary. Shares issued to acquire noncontrolling interest Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Purchase of Interest by Parent, Shares Issued by Parent Represents the shares issued by the parent for purchase by the parent of an additional equity interest in a subsidiary during the period, thereby effecting a change in total (consolidated) equity attributable to the parent. The purchase of the additional equity interest represented by this element increases the parent's controlling interest in the subsidiary. Number of promissory notes settled upon the closing of the merger Number Of Promissory Notes Settled Number of promissory notes settled upon the closing of the merger. Shares of merger consideration surrendered by acquiree management to reimburse for required payroll tax withholdings Shares Surrendered To Pay Withholding Taxes Shares Number of shares surrendered by former management of acquiree to reimburse the entity for required payroll tax withholdings. Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] U.S. government debt securities US Government Debt Securities [Member] Certificates of deposit Certificates of Deposit [Member] Schedule of Available-for-sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Amortized Cost Available-for-sale Debt Securities, Amortized Cost Basis Gross Unrealized Gains Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Losses Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax Aggregate Fair Value Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Changes in Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Cost of products Cost Of Products [Member] Cost Of Products [Member] Cost of services Cost Of Services [Member] Cost Of Services [Member] Research and development Research and Development Expense [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Stock based compensation cost Goodwill Goodwill [Roll Forward] December 31, 2014 Goodwill Acquisitions Goodwill, Acquired During Period Foreign currency translation adjustment Goodwill, Translation Adjustments September 30, 2015 Inventory Disclosure [Abstract] Inventory Inventory Disclosure [Text Block] Earnings Per Share [Abstract] Net Loss per Share Earnings Per Share [Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Total Intrexon Shareholders' Equity Parent [Member] Noncontrolling Interests Noncontrolling Interest [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balances (in shares) Common Stock, Shares, Outstanding Balances Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Stock-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Exercises of stock options and warrants (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercises of stock options and warrants Stock Issued During Period, Value, Stock Options Exercised Shares issued to nonemployee members of the Board of Directors (in shares) Stock Issued During Period Shares Nonemployee Director Number of shares of new stock issued during the period as compensation paid to nonemployee members of the Board of Directors. Shares issued to nonemployee members of the Board of Directors Stock Issued During Period Value Nonemployee Director Equity impact of the value of new stock issued during the period as compensation paid to nonemployee members of the Board of Directors. Shares issued in public offerings, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Shares issued in public offerings, net of issuance costs Stock Issued During Period, Value, New Issues Shares issued as consideration of license agreement (in shares) Stock Issued During Period, Shares, Issued for License Agreement Number of shares issued in lieu of cash for license agreement entered into by the entity. Shares issued as consideration of license agreement Stock Issued During Period, Value, Issued for License Agreement Value of stock issued in lieu of cash for license agreement entered into by the entity. Shares issued in acquisitions (in shares) Stock Issued During Period, Shares, Acquisitions Shares issued in acquisitions Stock Issued During Period, Value, Acquisitions Acquisition of noncontrolling interest (in shares) Stock Issued During Period, Shares, Acquisitions of Noncontrolling Interests Number of shares of stock issued during the period for acquisitions of noncontrolling interests. Acquisition of noncontrolling interest Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Adjustments for noncontrolling interests Adjustments for noncontrolling interests Increase in noncontrolling interest balance because of current period activity, including business combinations and subsidiary equity issuances. Noncash dividend Dividends, Common Stock, Paid-in-kind Net loss Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Balances (in shares) Balances Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Table] Organization Consolidation And Presentation Of Financial Statements Disclosure [Table] Organization Consolidation And Presentation Of Financial Statements Disclosure [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] AquaBounty Technologies, Inc. Aqua Bounty [Member] Aqua Bounty Technologies, Inc. Biological & Popular Culture, Inc. Bio Pop [Member] Biological & Popular Culture, Inc. Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items] Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Parent ownership interest Noncontrolling Interest, Ownership Percentage by Parent Debt Disclosure [Abstract] Lines of Credit and Long Term Debt Debt Disclosure [Text Block] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Stock Option Plans Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Commitments and Contingencies Disclosure [Abstract] Future Minimum Lease Payments Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] 2015 Operating Leases, Future Minimum Payments, Remainder of Fiscal Year 2016 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2017 Operating Leases, Future Minimum Payments, Due in Two Years 2018 Operating Leases, Future Minimum Payments, Due in Three Years 2019 Operating Leases, Future Minimum Payments, Due in Four Years 2020 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total Operating Leases, Future Minimum Payments Due Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Oragenics, Inc. Oragenics [Member] Oragenics, Inc. ZIOPHARM Oncology, Inc. Ziopharm [Member] ZIOPHARM Oncology, Inc. Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Equity Securities Equity Securities [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Foreign Countries Non-US [Member] Organization And Significant Accounting Policies [Line Items] Organization And Significant Accounting Policies [Line Items] Organization And Significant Accounting Policies [Line Items] Research and development commitments with third parties not incurred Research And Development Commitments Not Yet Incurred Portion of commitments related to research and development arrangements with third parties which has not yet been incurred. Maturity period of liquid investment Highly Liquid Investment Maximum Maturity Period Original maturity period for highly liquid investments to be considered cash equivalent, maximum Cash equivalent investments in highly liquid money market accounts Money Market Funds, at Carrying Value Number of strategic joint ventures Number Of Joint Ventures In Which The Company Participates Number Of Joint Ventures In Which The Company Participates Number of collaborators over which the Company has significant influence Number Of Collaborators, Equity Method Investments Number of collaborators over which the entity has significant influence, as it relates to determination of equity method investments. Fair value of financial assets measured at fair value on a recurring basis Assets, Fair Value Disclosure Company's ownership percentage Equity Method Investment, Ownership Percentage Unrealized and realized appreciation (depreciation) in fair value of equity securities Equity Securities Unrealized and Realized Appreciation Depreciation The amounts of gains and losses from fair value changes and disposition of equity securities included in earnings. Realized gain on equity securities Realized Investment Gains (Losses) Variable interest entities, risk of loss Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount Intangible assets, useful life Finite-Lived Intangible Asset, Useful Life Number of segments Number of Operating Segments Long-lived assets Long-Lived Assets Schedule Of Investments In Joint Venture [Table] Schedule Of Investments In Joint Venture [Table] Schedule Of Investments In Joint Venture [Table] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Upfront Upfront [Member] Upfront consideration for collaboration Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Upfront and Milestone Payments Upfront And Milestone Payments [Member] Upfront and milestone payments received as collaboration for the entity's collaborations Intrexon Energy Partners, LLC Intrexon Energy Partners [Member] Intrexon Energy Partners, LLC OvaXon, LLC Ova Xon [Member] OvaXon, LLC S & I Ophthalmic, LLC S I Ophthalmic [Member] S & I Ophthalmic, LLC Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other Accrued Liabilities Other Accrued Liabilities [Member] Other Accrued Liabilities [Member] Investments In Affiliates Investments In Affiliates [Member] Investments In Affiliates [Member] Investors Investor [Member] Schedule Of Investments In Joint Venture [Line Items] Schedule Of Investments In Joint Venture [Line Items] Schedule Of Investments In Joint Venture [Line Items] Collaborative arrangement consideration received, value Collaborative Arrangement Consideration Received Value Value of consideration received by the entity for collaboration Membership interest Initial capital contribution Payments to Acquire Interest in Joint Venture Maximum additional capital contribution committed Joint Venture Additional Capital Contributions Committed Amount of additional capital contributions to the joint venture for which the entity is committed, maximum. Additional capital contributions committed, remaining commitment Joint Venture Additional Capital Contributions Committed, Remaining Commitment Remaining amount of additional capital contributions to the joint venture for which the entity is committed. Number of board members designated by the Company Number Of Seats Selected By Company Number of seats on the governing board selected by the Company. Number of board members not designated by the Company Number Of Seats Not Selected By Company Number of seats on the governing board not selected by the Company. Investment Equity Method Investments Mergers and Acquisitions Mergers, Acquisitions and Dispositions Disclosures [Text Block] Statement of Comprehensive Income [Abstract] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized gain on investments Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss attributable to the noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive loss attributable to Intrexon Comprehensive Income (Loss), Net of Tax, Attributable to Parent Organization and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Notes payable Notes Payable, Other Payables [Member] Royalty-based financing Royalty-based Financing [Member] Royalty-based Financing [Member] Other Other Long-Term Debt [Member] Other Long-Term Debt [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Long-term debt Long-term Debt Current portion of long term debt Long-term Debt, Current Maturities Long term debt, net of current portion Long-term Debt, Excluding Current Maturities Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table] Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table] 2015 Business Acquisitions 2015 Business Acquisitions [Member] 2015 Business Acquisitions [Member] 2014 Business Acquisitions 2014 Business Acquisitions [Member] 2014 Business Acquisitions [Member] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Pro Forma Pro Forma [Member] Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items] Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items] Revenues Business Acquisition, Pro Forma Revenue Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Net loss attributable to the noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Net loss attributable to Intrexon Business Acquisition, Pro Forma Net Income (Loss) Principles of Consolidation Consolidation, Policy [Policy Text Block] Unaudited Financial Information Basis of Accounting, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Research and Development Research and Development Expense, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Short-term and Long-term Investments Marketable Securities, Policy [Policy Text Block] Equity Securities Equity Securities Policy [Policy Text Block] Disclosure of accounting policy for equity securities received and/or purchased from certain collaborators. Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Concentrations of Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Equity Method Investments Equity Method Investments, Policy [Policy Text Block] Variable Interest Entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] Trade Receivables Receivables, Policy [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Net Loss per Share Earnings Per Share, Policy [Policy Text Block] Segment Information Segment Reporting, Policy [Policy Text Block] Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Reclassifications Reclassification, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Fair Value Measurements Fair Value Disclosures [Text Block] Schedule of Capitalization, Equity [Table] Schedule of Capitalization, Equity [Table] Overallotment Option Exercise By Underwriters Overallotment Option Exercise By Underwriters [Member] Overallotment option granted to and exercised by the underwriters in conjunction with the completion of the entity's initial public offering. Affiliates of Third Security Affiliates Of Third Security [Member] Affiliates of Third Security, LLC Schedule of Capitalization, Equity [Line Items] Schedule of Capitalization, Equity [Line Items] Shares of common stock issued Price per share of common stock (in usd per share) Share Price Underwriting discounts and commissions Expense Related to Distribution or Servicing and Underwriting Fees Offering expenses capitalized by the Company Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Proceeds from issuance of shares in a private placement Proceeds from Issuance of Private Placement Noncash dividend, shares Common Stock Dividends, Shares Future Minimum Lease Payments Under Noncancelable Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] License Agreement [Abstract] License Agreement [Abstract] License Agreement License Agreement [Text Block] The entire disclosure for significant arrangements with third parties under license agreements. Descriptions may include identification of the specific license, period of time covered, minimum quantities and amounts, and cancellation rights. Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Goodwill accumulated impairment losses Goodwill, Impaired, Accumulated Impairment Loss Amortization expense Amortization of Intangible Assets Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Options Equity Option [Member] Warrants Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Acquisition Date Fair Value Consideration Transferred Schedule of Business Acquisitions, by Acquisition [Table Text Block] Estimated Fair Value of Assets Acquired and Liabilities Assumed at Acquisition Date Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Condensed Pro forma Financial Information Business Acquisition, Pro Forma Information [Table Text Block] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Weighted Average Weighted Average [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Patents, related technologies and know-how Intellectual Property [Member] Customer relationships Customer Relationships [Member] Trademarks Trademarks [Member] Covenant not to compete Covenant Not To Compete [Member] Covenant Not To Compete [Member] In-process research and development In Process Research and Development [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Weighted Average Useful Life (Years) Gross Carrying Amount Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Finite-Lived Intangible Assets, Net Summarized Collaboration and Licensing Revenue Collaboration and Licensing Revenue [Table Text Block] Tabular disclosure of summarized revenues recognized for each significant collaboration and licensing agreement and aggregated nonsignificant collaborations and licensing agreements. Summary of Deferred Revenue Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Intrexon Stock Option Plans Intrexon Stock Option Plan [Member] Stock option plans for Intrexon Corporation Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Balances at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Adjustment due to dividend (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period Exercised (in shares) Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Balances at end of period (in shares) Exercisable at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Vested and Expected to Vest at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Balances at beginning of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Adjustment due to dividend (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Forfeited (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expired (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Balances at period end (in usd per share) Exercisable, weighted average exercise price, at end of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Vested and Expected to Vest, weighted average exercise price at end of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Balances, weighted average remaining contractual period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable at period end, weighted average remaining contractual period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Vested and Expected to Vest at period end, weighted average remaining contractual period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Income Statement [Abstract] Revenues Revenues [Abstract] Collaboration and licensing revenues Collaboration And Licensing Revenue Revenue from contractual agreements with collaborators whereby the collaborators obtain exclusive access to the entity's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use as well as revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Includes revenue recognized from upfront payments received upon consummation of the agreement, reimbursements for costs incurred by the entity for research and development efforts, and milestone payments received upon achievement of specified development, regulatory and commercial activities as defined in the collaboration and licensing agreements. Product revenues Sales Revenue, Goods, Net Service revenues Sales Revenue, Services, Net Other revenues Other Revenue, Net Total revenues Operating Expenses Operating Expenses [Abstract] Cost of products Cost of Goods Sold Cost of services Cost of Services Research and development Research and Development Expense Selling, general and administrative Selling, General and Administrative Expense Total operating expenses Operating Expenses Operating loss Operating Income (Loss) Other Income (Expense), Net Nonoperating Income (Expense) [Abstract] Interest expense Interest Expense Interest income Investment Income, Nonoperating Other income (expense), net Other Nonoperating Income (Expense) Total other income (expense), net Nonoperating Income (Expense) Equity in net loss of affiliates Income (Loss) from Equity Method Investments Loss before income taxes Income tax benefit (expense) Income Tax Expense (Benefit) Net loss Net loss attributable to the noncontrolling interests Net loss attributable to Intrexon Net Income (Loss) Attributable to Parent Net loss attributable to Intrexon per share, basic and diluted (usd per share) Earnings Per Share, Basic and Diluted Weighted average shares outstanding, basic and diluted Weighted Average Number of Shares Outstanding, Basic and Diluted Summarized Unaudited Financial Information for the Equity Method Investments Equity Method Investments [Table Text Block] Allowance for Doubtful Accounts Allowance for Doubtful Accounts Table Text Block [Table Text Block] [Table Text Block] for Schedule detailing changes to the allowance for doubtful accounts during the period, including provisions, write-offs, and recoveries. Estimated Useful Lives Schedule Of Property Plant And Equipment Estimated Useful Lives [Table Text Block] Tabular disclosure of estimated useful lives of property plant and equipment used in the normal conduct of business. Statement of Cash Flows [Abstract] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Loss on disposal of property, plant and equipment Gain (Loss) on Disposition of Property Plant Equipment Unrealized and realized (appreciation) depreciation on equity securities Amortization of discount/premium on investments Accretion (Amortization) of Discounts and Premiums, Investments Equity in net loss of affiliates Stock-based compensation expense Share-based Compensation Contribution of services by shareholder Contribution Of Services By Shareholder Compensation expense recognized for value of services contributed by a shareholder Shares issued to nonemployee members of the Board of Directors Stock Issued During Period To Nonemployee Director Expense Amount of expense that relates to stock issued during the period as compensation paid to nonemployee members of the Board of Directors. Shares issued as consideration for license agreement Shares Issued As Consideration For License Agreement, Value Fair value of shares issued as consideration for license agreement. Provision for bad debts Deferred income taxes Deferred Income Tax Expense (Benefit) Other noncash items Other Noncash Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Receivables: Increase (Decrease) in Receivables [Abstract] Trade Increase (Decrease) in Accounts Receivable Related parties Increase (Decrease) in Due from Related Parties, Current Note Increase (Decrease) in Notes Receivable, Current Other Increase (Decrease) in Other Receivables Inventory Increase (Decrease) in Inventories Prepaid expenses and other Increase (Decrease) in Prepaid Expense and Other Assets Other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued compensation and benefits Increase (Decrease) in Employee Related Liabilities Other accrued liabilities Increase (Decrease) in Other Accrued Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Deferred consideration Increase (Decrease) in Deferred Consideration The increase (decrease) during the reporting period in the liability reflecting deferred consideration resulting from a business combination. Related party payables Increase (Decrease) in Due to Related Parties, Current Other long term liabilities Increase (Decrease) in Other Noncurrent Liabilities Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Purchases of investments Payments to Acquire Investments Maturities of investments Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities Purchases of equity securities and warrants Payments to Acquire Other Investments Acquisitions of businesses, net of cash received Payments to Acquire Businesses, Net of Cash Acquired Acquisition of noncontrolling interest Payments to Acquire Additional Interest in Subsidiaries Investments in affiliates Payments to Acquire Interest in Subsidiaries and Affiliates Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from notes receivable Proceeds from Collection of Notes Receivable Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Proceeds from issuance of shares in public offerings, net of issuance costs Proceeds from Issuance of Common Stock, Net of Issuance Costs The cash inflow from the additional capital contribution to the entity, net of the cash outflows for costs incurred directly with the issuance of an equity security. Advances from lines of credit Proceeds from Lines of Credit Repayments of advances from lines of credit Repayments of Lines of Credit Proceeds from long term debt Proceeds from Issuance of Long-term Debt Payments of long term debt Repayments of Long-term Debt Payments of deferred consideration Payments Of Deferred Consideration Cash outflows representing payments for deferred consideration from a business combination. Proceeds from stock option exercises Proceeds from Stock Options Exercised Payment of stock issuance costs Payments of Stock Issuance Costs Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents Cash and Cash Equivalents [Abstract] Beginning of period Cash and Cash Equivalents, at Carrying Value End of period Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Cash paid during the period for interest Interest Paid Cash paid during the period for income taxes Income Taxes Paid Significant noncash financing and investing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Note receivable as consideration for upfront fee from collaborator Other Significant Noncash Transaction, Value of Consideration Received Stock received as consideration for collaboration agreements Stock Received As Consideration For Collaboration Agreements Fair value of stock received from collaborative partners as consideration for collaboration agreements. Stock issued in acquisitions, net Stock issued to acquire noncontrolling interest Stock Issued During Period, Value, Acquisition Of Noncontrolling Interests Value of stock issued to acquire noncontrolling interests during the period. Noncash dividend to shareholders Deferred consideration payable related to acquisition Purchases of equipment included in accounts payable and other accrued liabilities Capital Expenditures Incurred but Not yet Paid Maturities of Long-term Debt [Abstract] Maturities of Long-term Debt [Abstract] 2015 Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year 2016 Long-term Debt, Maturities, Repayments of Principal in Year Two 2017 Long-term Debt, Maturities, Repayments of Principal in Year Three 2018 Long-term Debt, Maturities, Repayments of Principal in Year Four 2019 Long-term Debt, Maturities, Repayments of Principal in Year Five 2020 Long Term Debt, Maturities, Repayments Of Principal In Year Six Long Term Debt, Maturities, Repayments Of Principal In Year Six Thereafter Long Term Debt, Maturities, Repayments Of Principal After Year Six Long Term Debt, Maturities, Repayments Of Principal After Year Six Long-term Debt Long Term Debt, Total, Excluding Royalty-based Financing Long Term Debt, Total, Excluding Royalty-based Financing Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Research and Development Services Research And Development Services [Member] Research and development services provided by the entity Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Fibrocell Science, Inc. Fibrocell [Member] Fibrocell Science, Inc. Genopaver, LLC Genopaver Ecc [Member] First ECC with Genopaver, LLC Persea Bio, LLC Persea Bio, LLC [Member] Persea Bio, LLC Ares Trading S.A. Ares Trading S.A. [Member] Ares Trading S.A., a subsidiary of Merck Serono S.A. [Member] Other Collaborations Other Collaborations [Member] Aggregate of other collaborations not separately disclosed Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaboration And Licensing Revenue Computation of Basic and Diluted Net Loss per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Other Commitments [Table] Other Commitments [Table] Other Commitments [Line Items] Other Commitments [Line Items] Payment of license fees Payment Of License Fees License fee paid upon execution of agreement Annual funding commitment, term Annual Funding Commitment Term Term for the annual funding commitment in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Annual funding commitment, amount Annual Funding Commitment Amount of annual funding commitment. Subsequent Events Subsequent Events [Text Block] Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets Assets, Current [Abstract] Cash and cash equivalents Short-term investments Short-term Investments Receivables Receivables, Net, Current [Abstract] Trade, net Accounts Receivable, Net, Current Related parties Due from Related Parties, Current Note Notes, Loans and Financing Receivable, Gross, Current Other Accounts and Other Receivables, Net, Current Inventory Inventory, Gross Prepaid expenses and other Prepaid Expense and Other Assets, Current Total current assets Assets, Current Long-term investments Available-for-sale Securities, Noncurrent Equity securities Other Marketable Securities, Noncurrent Property, plant and equipment, net Property, Plant and Equipment, Net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Goodwill Investments in affiliates Other assets Other Assets, Noncurrent Total assets Assets Liabilities and Total Equity Liabilities and Equity [Abstract] Current liabilities Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued compensation and benefits Employee-related Liabilities, Current Other accrued liabilities Other Accrued Liabilities, Current Deferred revenue Deferred Revenue, Current Lines of credit Line of Credit, Current Current portion of deferred consideration Deferred Consideration, Current Carrying value as of the balance sheet date of the portion of deferred consideration resulting from a business combination that is expected to be repaid within one year or the normal operating cycle, if longer. Related party payables Due to Related Parties, Current Total current liabilities Liabilities, Current Deferred consideration, net of current portion Deferred Consideration, Noncurrent Carrying value as of the balance sheet date of the portion of deferred consideration resulting from a business combination, excluding current portion. Deferred revenue, net of current portion Deferred Revenue, Noncurrent Deferred tax liabilities Deferred Tax Liabilities, Net, Noncurrent Other long term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 16) Commitments and Contingencies Total equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Common stock, no par value, 200,000,000 shares authorized as of September 30, 2015 and December 31, 2014; 116,359,041 and 100,557,932 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively Common Stock, Value, Outstanding Additional paid-in capital Additional Paid in Capital Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Total Intrexon shareholders' equity Stockholders' Equity Attributable to Parent Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Total equity Total liabilities and total equity Liabilities and Equity Collaboration and Licensing Agreements [Table] Collaboration and Licensing Agreements [Table] Collaboration and Licensing Agreements [Table] Prepaid Research and Development Services Prepaid Research And Development Services [Member] Research and development services ZIOPHARM Oncology ECC 1 Ziopharm Oncology Ecc One [Member] First ECC with ZIOPHARM Oncology, Inc. ZIOPHARM Oncology ECC Separate Unit of Accounting Ziopharm Oncology Ecc Separate Unit Of Accounting [Member] Separate unit of accounting for ECC with ZIOPHARM Oncology, Inc. ZIOPHARM Oncology ECC Unit of Accounting One Ziopharm Oncology Ecc Unit Of Accounting One [Member] Unit of accounting one for ECC with ZIOPHARM Oncology, Inc. ZIOPHARM Oncology ECC 2 Ziopharm Oncology Ecc Two [Member] Second ECC with ZIOPHARM Oncology, Inc. Oragenics ECC 1 Oragenics Ecc [Member] First ECC with Oragenics, Inc. Oragenics ECC 2 Oragenics Second Ecc [Member] Second ECC with Oragenics, Inc. Oragenics ECC 3 Oragenics Third Ecc [Member] Third ECC with Oragenics, Inc. Thrive Agrobiotics, Inc. Thrive Agrobiotics, Inc. [Member] Thrive Agrobiotics, Inc. [Member] Supplemental Upfront Supplemental Upfront [Member] Supplemental upfront consideration received for expansion of collaboration Milestone One Milestone One [Member] First collaboration milestone Collaboration and Licensing Agreements [Line Items] Collaboration and Licensing Agreements [Line Items] [Line Items] for Collaboration and Licensing Agreements [Table] Related party payables Payments To Related Parties Cash outflows for payments made to related parties. Number of targets selected Collaborative Arrangement, Consideration Receivable, Minimum Targets Required The number of targets selected by a collaborator under a collaboration agreement which result in consideration owed to the entity. Deferred revenue Deferred Revenue Collection period for the receivable after target selection Collaborative Arrangement, Consideration Receivable, Collection Period The period over which the consideration is owed to the entity under a collaboration agreement. Collaborative agreement additional target fee Collaborative Agreement Additional Target Fee Value of consideration to be received from the licensee if the licensee selects an additional target. Maximum milestone payments required upon successful achievement, per product Maximum Milestone Payments Required Upon Successful Achievement, Per Product Amount of potential future milestone payments to be received under agreement per product, maximum Maximum milestone payments required upon successful achievement, one-time Maximum Milestone Payments Required Upon Successful Achievement, One-Time Amount of potential future milestone payments to be received under agreement one-time, maximum Required notice period for voluntary termination of collaborative agreement Collaboration Agreement Termination Notice Period Notice period required for voluntary termination of collaboration. Collaboration arrangement, percent of collaboration payments Collaboration Arrangement, Percent Of Collaboration Payments Percent of collaboration payments received pursuant to a collaboration agreement for upfront fees, milestones and royalties which will be paid to another party. Collaborative arrangement consideration received, shares Collaborative Arrangement Consideration Received Shares Number of shares of common stock of a collaborator received by the entity as consideration Percent of shares outstanding at the date of achievement of future milestone Collaborative Arrangement Additional Consideration Receivable As Percentage Of Outstanding Shares Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone. Royalty rate as a percentage of net profit Collaborative Arrangement Royalty Rate As Percentage Of Net Profit Percentage of net profit, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled. Percentage of shares outstanding at the date of achievement of future milestone 2 Collaborative Arrangement Additional Consideration Receivable As Percentage Of Outstanding Shares Two Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone 2. Percentage of shares outstanding at the date of achievement of future milestone 3 Collaborative Arrangement Additional Consideration Receivable As Percentage Of Outstanding Shares Three Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone 3. Percentage of shares outstanding at the date of achievement of future milestone 4 Collaborative Arrangement Additional Consideration Receivable As Percentage Of Outstanding Shares Four Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone 4. Percentage of shares outstanding at the date of achievement of future milestone 5 Collaborative Arrangement Additional Consideration Receivable As Percentage Of Outstanding Shares Five Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone 5. Collaborative arrangement consideration received, value of convertible promissory note Collaborative Arrangement Consideration Received Value Of Convertible Promissory Note Value of promissory note received as consideration of collaboration agreement which can be settled in cash or common stock. Conversion of promissory note into common stock (in shares) Debt Conversion, Converted Instrument, Shares Issued Reverse stock split ratio Stockholders' Equity, Reverse Stock Split Reverse stock split, conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Royalty rate as a percentage of net sales, tier 1 Collaborative Arrangement Royalties As Percentage Of Net Sales Tier One Percentage of net sales, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled, tier 1. Level of net sales at which royalty rate changes to tier 2 Collaborative Arrangement Net Sales At Which Royalty Rate Changes To Tier Two Level of net sales, as defined in the collaboration agreement, at which the royalty rate changes to tier 2. Royalty rate as a percentage of net sales, tier 2 Collaborative Arrangement Royalties As Percentage Of Net Sales Tier Two Percentage of net sales, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled, tier 2. Royalty rate of savings from improvement Collaborative Arrangement Royalty Rate As Percentage Of Savings From Improvement Percentage of cost of goods sold, as defined in the collaboration agreement, savings generated by production improvements used to calculate royalty payments to which the entity is entitled. Royalty rate as a percentage of gross profit Collaborative Arrangement Royalty Rate As Percentage Of Gross Profit Percentage of gross profit, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled. Line of Credit Facility [Table] Line of Credit Facility [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Line of Credit Revolving Credit Facility [Member] Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] First National Bank of Omaha First National Bank of Omaha [Member] First National Bank of Omaha [Member] American State Bank American State Bank [Member] American State Bank [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Line of credit, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Minimum interest rate Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum Actual interest rate at period end Line of Credit Facility, Interest Rate at Period End Line of credit, outstanding balance Long-term Line of Credit Interest rate Debt Instrument, Interest Rate, Stated Percentage Components of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Property, Plant and Equipment [Abstract] Depreciation expense Depreciation Notes payable to banks Notes Payable to Banks [Member] Iowa Economic Development Authority Iowa Economic Development Authority [Member] Iowa Economic Development Authority [Member] Atlantic Canada Opportunities Agency Atlantic Canada Opportunities Agency [Member] Atlantic Canada Opportunities Agency [Member] Outstanding principal balance Periodic payment amount Debt Instrument, Periodic Payment Periodic principal payment amount Debt Instrument, Periodic Payment, Principal Amount available under financial grant for research and development Amount Available Under Financial Grant For Research And Development Amount available under research and development grant Period to claim funding from government award Government Award, Claim Period Length of period during which amounts can be claimed under research and development grant Royalty rate to be paid Rate Of Royalty Agreed To Be Paid Percentage of royalty on products commercialized under research and development grant Amount claimed under financial grant Amount Claimed Under Financial Grant Amount claimed under research and development grant to date Long term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Accreted difference between face value of amount drawn and acquisition date fair value Accreted Difference Between Face Value Of Amount Drawn And Acquisition Date Fair Value Accreted Difference Between Face Value Of Amount Drawn And Acquisition Date Fair Value Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Property, Plant and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Initial estimated fair value Scenario, Plan [Member] Adjustments Scenario, Adjustment [Member] Adjusted fair value Scenario, Actual [Member] Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Trade receivables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Related party receivables Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Related Party Receivables Amount due from related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Other receivables Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Receivables Amount of other receivables acquired at the acquisition date. Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Prepaid expenses and other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Accrued compensation and benefits Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Compensation And Benefits Amount of accrued compensation and benefits assumed at the acquisition date. Other accrued liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Deferred revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Revenue Amount of deferred revenue assumed at the acquisition date. Deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent Lines of credit Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Lines of Credit Balance outstanding of lines of credit due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Related party payables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Related Party Payables Amount of liabilities due to related parties assumed at the acquisition date. Long term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long Term Debt Amount of long-term debt assumed at the acquisition date, including both current and noncurrent maturities. Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Net assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Total consideration Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Land and land improvements Land and Land Improvements Buildings and building improvements Buildings and Improvements, Gross Furniture and fixtures Furniture and Fixtures, Gross Equipment Machinery and Equipment, Gross Leasehold improvements Leasehold Improvements, Gross Computer hardware and software Computer Hardware and Software Amount before accumulated depreciation and amortization of computer hardware and purchased software. Construction and other assets in progress Construction in Progress, Gross Property, plant and equipment, gross Property, Plant and Equipment, Gross Less: Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Other Assets Other Assets [Member] AmpliPhi Biosciences Corp AmpliPhi Biosciences Corp [Member] AmpliPhi Biosciences Corp [Member] Other Nonoperating Income Other Nonoperating Income (Expense) [Member] Histogenics Corporation Histogenics Corporation [Member] Histogenics Corporation [Member] Related Parties, Aggregated Related Parties, Aggregated [Member] Related Parties, Aggregated [Member] Harvest Intrexon Enterprise Fund I, LP Harvest Intrexon Enterprise Fund I, LP [Member] Harvest Intrexon Enterprise Fund I, LP [Member] Investment [Axis] Investment [Axis] Investment [Domain] Investment [Domain] Share Purchase Rights Plan Share Purchase Rights Plan [Member] Entity's right to purchase shares, subject to certain conditions and limitations Related Party Transaction [Line Items] Related Party Transaction [Line Items] Total amount of expenses reimbursed Compensation expense Common stock purchased from collaborative partners (in shares) Shares Purchased From Collaborative Partners Number of shares of common stock purchased from collaborator Price per share of common shares (in usd per share) Shares Purchased Price Per Share Price per share of collaborator's common stock purchased Warrants purchased from collaborative partners (in shares) Warrants Purchased From Collaborative Partners Number of warrants purchased from collaborator Purchases of equity securities and warrants Common stock purchased from collaborative partners, value Shares Purchased From Collaborative Partners Value Value of common stock purchased from collaborator Note receivable, stated interest rate Note Receivable Interest Rate Interest rate per annum of the note receivable. Maximum percentage of shares of future securities offerings of collaborative partners to which the entity is entitled to purchase Maximum Percentage Of Shares Entitled To Purchase Percentage of shares that the entity is entitled to purchase in securities offerings conducted by collaborator, maximum. Commitment period for purchase of additional common stock after effective date Additional Common Stock Purchase Agreement, Commitment Period After Effective Date The commitment period following the effective date of an agreement during which the entity is obligated to purchase additional common stock. Common stock purchase commitment Additional Shares Value Agreed To Purchase Value of additional common stock for which the entity has committed to purchasing from collaborator, original Collaboration revenue Collaboration Revenues Revenue from contractual agreements with collaborators whereby the collaborators obtain exclusive access to the entity's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Includes revenue recognized from upfront payments received upon consummation of the agreement, reimbursements for costs incurred by the entity for research and development efforts, and milestone payments received upon achievement of specified development, regulatory and commercial activities as defined in the collaboration agreements. Management fees revenue Management Fees Revenue Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value of assets transferred from Level 2 to Level 1 Fair Value, Assets, Level 2 to Level 1 Transfers, Amount Goodwill and Intangible Assets, net Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Equity Method Investments Equity Method Investments [Member] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Current assets Equity Method Investment, Summarized Financial Information, Current Assets Non-current assets Equity Method Investment, Summarized Financial Information, Noncurrent Assets Total assets Equity Method Investment, Summarized Financial Information, Assets Current liabilities Equity Method Investment, Summarized Financial Information, Current Liabilities Non-current liabilities Equity Method Investment, Summarized Financial Information, Noncurrent Liabilities Total liabilities Equity Method Investment, Summarized Financial Information, Liabilities Net assets Equity Method Investment Summarized Financial Information Assets Liabilities Net Equity Method Investment Summarized Financial Information Assets Liabilities Net Revenues Equity Method Investment, Summarized Financial Information, Revenue Operating expenses Loss from operations Equity Method Investment Summarized Financial Information Operating Income Loss The amount of operating income (loss) reported by an equity method investment of the entity. Other Equity Method Investment Summarized Financial Information Other Nonoperating Income Expense The amount of nonoperating income (expense) reported by an equity method investment of the entity. Net loss Equity Method Investment, Summarized Financial Information, Net Income (Loss) Schedule of Employee Service Share-based Compensation Allocation Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Stock Option Activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Inventory, Current [Table] Inventory, Current [Table] Inventory [Axis] Inventory [Axis] Inventory [Domain] Inventory [Domain] Supplies, semen and embryos Supplies, Semen And Embryos [Member] Supplies, Semen And Embryos [Member] Work in process Work In Process [Member] Work In Process [Member] Livestock Livestock [Member] Livestock [Member] Feed Feed [Member] Feed [Member] Inventory [Line Items] Inventory [Line Items] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Prepaid Product and Service Revenues Prepaid Product And Service Revenues [Member] Prepaid Product And Service Revenues [Member] Other Deferred Revenue Other [Member] Other deferred revenue Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Current portion of deferred revenue Long-term portion of deferred revenue Total Common shares Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair value of noncontrolling interest Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Total Rent expense Operating Leases, Rent Expense Rental income under sublease agreement Operating Leases, Income Statement, Sublease Revenue Future Rental Income Operating Leases, Future Minimum Payments Receivable [Abstract] 2015 Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year 2016 Operating Leases, Future Minimum Payments Receivable, in Two Years 2017 Operating Leases, Future Minimum Payments Receivable, in Three Years Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Domestic Tax Authority Domestic Tax Authority [Member] Foreign Tax Authority Foreign Tax Authority [Member] Operating Loss Carryforwards [Axis] Operating Loss Carryforwards [Axis] Information by specific operating losses related to unused operating loss carryforwards. Operating Loss Carryforwards [Domain] Operating Loss Carryforwards [Domain] Operating Loss Carryforwards [Domain] Stock Compensation Deductions Share Based Compensation [Member] Share Based Compensation [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Taxable income (loss) Taxable Income Loss Taxable income (loss) Current income tax expense (benefit) Current Income Tax Expense (Benefit) Deferred income tax expense (benefit) Deferred tax liabilities Deferred Tax Liabilities, Net Operating loss carryforwards Operating Loss Carryforwards Federal and state research and development tax credits Deferred Tax Assets, Tax Credit Carryforwards, Research Expiration date of U.S. federal income tax loss carryforwards Operating Loss Carryforwards Expiration Year Range Start Expiration date range for Federal income tax loss carryforwards, start Historical net loss per share: Earnings Per Share, Basic and Diluted [Abstract] Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Net loss attributable to Intrexon Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Short-term and Long-term Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Common stock, no par value (in usd per share) Common Stock, No Par Value Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Intrexon Stock Option Plan - 2008 Plan Intrexon Stock Option Plan 2008 Plan [Member] Intrexon Stock Option Plan - 2008 Equity Incentive Plan Intrexon Stock Option Plan - 2013 Plan Intrexon Stock Option Plan 2013 Plan [Member] Intrexon Stock Option Plan - 2013 Omnibus Incentive Plan Aqua Bounty Stock Option Plan Aqua Bounty Stock Option Plan [Member] Stock option plan for AquaBounty Technologies, Inc. Options outstanding (in shares) Number of shares authorized for issuance Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Remaining shares available to grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Unrecognized compensation costs related to nonvested awards Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Recognized over weighted-average period Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Weighted average price of option (in usd per share) Shares exercisable at end of period Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Schedule of Long-term Debt Instruments Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Future Maturities of Long-term Debt Schedule of Maturities of Long-term Debt [Table Text Block] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Other Other Financial Assets [Member] Other Financial Assets [Member] Assets Assets, Fair Value Disclosure [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Land improvements Land Improvements [Member] Buildings and building improvements Building and Building Improvements [Member] Furniture and fixtures Furniture and Fixtures [Member] Equipment Equipment [Member] Computer hardware and software Computer Hardware and Software [Member] Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and purchased software applications. Leasehold Improvements Leasehold Improvements [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property plant and equipment, useful life Property, Plant and Equipment, Useful Life Collaboration and Licensing Revenue Collaborative Arrangement Disclosure [Text Block] EX-101.PRE 11 xon-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R39.htm IDEA: XBRL DOCUMENT v3.3.0.814
Commitments and Contingencies (Tables)
 9 Months Ended
Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]  
Future Minimum Lease Payments Under Noncancelable Operating Leases
At September 30, 2015, future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:
2015
$
739

2016
4,161

2017
3,381

2018
2,067

2019
1,889

2020
1,941

Thereafter
1,587

Total
$
15,765
XML 13 R54.htm IDEA: XBRL DOCUMENT v3.3.0.814
Short-term and Long-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Short-term and Long-term Investments (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost $ 226,839 $ 115,566
Gross Unrealized Gains 291 54
Gross Unrealized Losses 0 (12)
Aggregate Fair Value 227,130 115,608
U.S. government debt securities    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 226,567 115,293
Gross Unrealized Gains 291 54
Gross Unrealized Losses 0 (12)
Aggregate Fair Value 226,858 115,335
Certificates of deposit    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 272 273
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Aggregate Fair Value $ 272 $ 273
XML 14 R48.htm IDEA: XBRL DOCUMENT v3.3.0.814
Mergers and Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Apr. 30, 2015
Feb. 28, 2015
Dec. 31, 2014
Aug. 31, 2014
Mar. 31, 2014
Business Acquisition [Line Items]            
Goodwill $ 166,866     $ 101,059    
Oxitec Limited | Initial estimated fair value            
Business Acquisition [Line Items]            
Cash 3,780          
Trade receivables 125          
Other receivables 7,395          
Prepaid expenses and other 121          
Property, plant and equipment 1,198          
Intangible assets 96,854          
Total assets acquired 109,473          
Accounts payable 1,187          
Accrued compensation and benefits 246          
Other accrued liabilities 210          
Deferred revenue 120          
Deferred tax liabilities 12,584          
Total liabilities assumed 14,347          
Net assets acquired 95,126          
Goodwill 51,268          
Total consideration $ 146,394          
Okanagan Specialty Fruits Inc | Initial estimated fair value            
Business Acquisition [Line Items]            
Cash   $ 58        
Trade receivables   16        
Other receivables   49        
Property, plant and equipment   32        
Intangible assets   33,800        
Total assets acquired   33,955        
Accounts payable   181        
Deferred revenue   181        
Deferred tax liabilities   8,145        
Total liabilities assumed   8,507        
Net assets acquired   25,448        
Goodwill   15,485        
Total consideration   40,933        
Okanagan Specialty Fruits Inc | Adjustments            
Business Acquisition [Line Items]            
Cash   0        
Trade receivables   0        
Other receivables   0        
Property, plant and equipment   0        
Intangible assets   2,700        
Total assets acquired   2,700        
Accounts payable   0        
Deferred revenue   0        
Deferred tax liabilities   702        
Total liabilities assumed   702        
Net assets acquired   1,998        
Goodwill   (1,998)        
Total consideration   0        
Okanagan Specialty Fruits Inc | Adjusted fair value            
Business Acquisition [Line Items]            
Cash   58        
Trade receivables   16        
Other receivables   49        
Property, plant and equipment   32        
Intangible assets   36,500        
Total assets acquired   36,655        
Accounts payable   181        
Deferred revenue   181        
Deferred tax liabilities   8,847        
Total liabilities assumed   9,209        
Net assets acquired   27,446        
Goodwill   13,487        
Total consideration   $ 40,933        
ActoGeniX NV | Initial estimated fair value            
Business Acquisition [Line Items]            
Cash     $ 3,180      
Other receivables     305      
Prepaid expenses and other     31      
Property, plant and equipment     209      
Intangible assets     68,100      
Other assets     23      
Total assets acquired     71,848      
Accounts payable     230      
Accrued compensation and benefits     624      
Other accrued liabilities     307      
Deferred revenue     732      
Deferred tax liabilities     612      
Total liabilities assumed     2,505      
Net assets acquired     69,343      
Goodwill     3,131      
Total consideration     72,474      
ActoGeniX NV | Adjustments            
Business Acquisition [Line Items]            
Cash     0      
Other receivables     0      
Prepaid expenses and other     0      
Property, plant and equipment     0      
Intangible assets     0      
Other assets     0      
Total assets acquired     0      
Accounts payable     0      
Accrued compensation and benefits     (428)      
Other accrued liabilities     (54)      
Deferred revenue     0      
Deferred tax liabilities     0      
Total liabilities assumed     (482)      
Net assets acquired     482      
Goodwill     (482)      
Total consideration     0      
ActoGeniX NV | Adjusted fair value            
Business Acquisition [Line Items]            
Cash     3,180      
Other receivables     305      
Prepaid expenses and other     31      
Property, plant and equipment     209      
Intangible assets     68,100      
Other assets     23      
Total assets acquired     71,848      
Accounts payable     230      
Accrued compensation and benefits     196      
Other accrued liabilities     253      
Deferred revenue     732      
Deferred tax liabilities     612      
Total liabilities assumed     2,023      
Net assets acquired     69,825      
Goodwill     2,649      
Total consideration     $ 72,474      
Trans Ova Genetics, LC            
Business Acquisition [Line Items]            
Cash         $ 960  
Trade receivables         18,693  
Related party receivables         1,219  
Inventory         18,476  
Prepaid expenses and other         590  
Property, plant and equipment         21,164  
Intangible assets         23,700  
Other assets         147  
Total assets acquired         84,949  
Accounts payable         3,317  
Accrued compensation and benefits         913  
Other accrued liabilities         271  
Deferred revenue         4,458  
Lines of credit         4,091  
Related party payables         1,246  
Long term debt         9,090  
Total liabilities assumed         23,386  
Net assets acquired         61,563  
Goodwill         66,312  
Total consideration         $ 127,875  
Medistem, Inc.            
Business Acquisition [Line Items]            
Cash           $ 8
Intangible assets           4,824
Total assets acquired           4,832
Accounts payable           644
Accrued compensation and benefits           67
Other accrued liabilities           50
Total liabilities assumed           761
Net assets acquired           4,071
Goodwill           20,924
Total consideration           $ 24,995
EXCEL 15 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`"R,:4?G]9[`0P(``"DO```3````6T-O;G1E;G1?5'EP97-= M+GAM;,W:W6[3,!0'\%>I`&3N$W4)+9LK^O>'CO=$%0% M;;!*_YNFZ;'/.]_O;H;5P2H;JZ_[&T(?6L7'X^!DGM=&>^'OC&I=Q/9 M3^U)UJ7;;/K&MJZY'_.6.N72]EV.5XL[$])G,^84Y#"0.7#\I'6)D[!QO/U3]&GBO?VHVY']*K"C_=NSK885X3N]X_E?ITR%EB_FU= MY6A\4873C7_KK!_+T/RT_6U'.?_':SFYB?MQN`WFH3\IL+_8F,JQ'DT_G1O5 M@PN[[\[MWO(QL>6J6MLN?<@+0^K//"5Y\5V.1I)3_U?MYR>E<<&^J&!9>,&7 MHC/!ME]3R/,]_V[\NN!R?92YSM__-/0Y&,E\N"`2K^J#@?3!0?H0('U(D#X4 M2!\:I(\KD#[>@_1!5RB-H(A*44BE**92%%0IBJH4A56*XBI%@96BR,I09&4H MLC(461F*K`Q%5H8B*T.1E:'(RE!D92BRQW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6: ME((C-Z."N[_8_`)02P,$%`````@`+(QI1\`AU&6!`@``[2\``!H```!X;"]? M%>=-"%@;.Q80D8_JO/`L6G/C?K+^GTZ7+#\.8^OGN?I@N79E_3H=Z[+;OW2'5TC16 M3[=SJN>G/V>O7G>;:GK=N6KUM9L.J6RJ[\/TGH\IE5Q?O]S#O,!\^V-,_[/\ ML-^?MNEEV'Z[I+[\HZ+^M4!5+P?)AQ.>B1$N0:(&/#24)8<[1V@&O'\=H!L!U';`?(=ARS'4#; M<=1V@&W'<=L!N!U';@?H=AR['<#;M='#-D=O`7H+1V\! M>@M';P%Z"T=O`7H+1V\!>@M';P%Z"T=O`7H+1V\%>BM';P5Z*T=O!7HK::\$ M;99P]%:@MW+T5J"W5'+T#T#MP]`Y`[\#1.P"]`T?O M`/0.'+T-Z&TAM'+T-Z&TAMI+,FZ+`)1V\#>AM' M;P-Z&T=O`WH;1^\(](X*=77S[O_FUVG_@RI_SK9__P)4$L#!!0````(`"R, M:4?2:VD2!`0```$3```0````9&]C4')O<',O87!P+GAM;+U877/:.!3]*QI> M-CL3:@J$9C/4,S3)[F:GV3"%IL^*?0%-9(E*,@W]]7LE`S%!4C$/FY?8\CW2 M_3CG7INAT)VKL9)+4(:!)B\%%_H*%S^V%L8LKY)$9PLHJ'Z')@*?SJ0JJ,%; M-4_D;,8RN)%968`P2;?3&23P8D#DD+>7NTU;Z=">,EHN.E]=?E5-Y0`W74_H-J]P55D..A>[OO%IW-WVN,DUOL]8**.>1UV\.' MVUP\@M(VTO?==QW\VZ5@NU[M#31G8CZF3.ETN#)7*\B,5)LRKPGWG9;U;'5JKOF2VU4^DVJ9[T`,'J8[!;= M9=VV?LWZZ67'6>#5OF6RBRS=I&TO;KLR98:#?IB-J3+_4RI<3-M$7'9:M>BW M6Q`J/26[JVLIM.0L1W+EY!/E5&1`)@G(WIKS$3 M@_^LEYK(&7E`(C;%6.$TQ5AU-#Z'ZH47\Z#F5+"?+JDNUY^H9@XR5F`UYL%, MRJ*@:NU\87/!L.1(,C+*,EEBI;R8>U!SU)T[8I1]+YEF]DA_8>[$"K2IG&>" M_",9;O^(MR7Z%`B=<_HDU6L0>J$9_G)?!*`0*:.U]NAD)ZW,RYG3+<\S+TFYX3KR8OZ3,?S#. MG?&=,-COV!,',M(:.7ONQ6#/A8H"V%*9V85*IC;4FX#GF2R`3.E+(-VN02\D MS[&DOSFWC3_*B9'9,RK#E<4&ZM^O*A8&,E?@,AHHI[E<>N^;R&7CVB]DL[7ZO;E^>OWF^NE=--=/;W"T/.+1 M'.HD;A^5`CD[DMWQ,Z*CH>\O>)3`_>X)F-X)&'_UXQA_]8/B:I-1GC<;=8BQ M>FB.Z3<4?AL+)/T3)#I92;MYL[CP\R".\?,@C@GP(-:4+@(\B&+\/`@ULC9Q MK&J(L=3QC[C7YH<[XVMV7F)[0L)NUIMWPHL_FF,&_@$0[9X#/P_B&#\/XA@_ M#Z)=>N#G01QSPC08^*=!'.-_$:B_@6T)@ZJ@O/H(.G[JO&*;8.QGB100P!S. MJKJ'QV.JQ>`GD!^S$\5Q+Y+[R3MAEH9Z8@3SP<^#\,NH<_+8F5U5IS2V31Z/ M&4N#SC+*`_5Y^TI+@C4]^"GAS0\'R?X/7NE_4$L#!!0````(`"R,:4?^^5-_ M/@$``&D#```1````9&]C4')O<',O8V]R92YX;6S-DTU/PS`,AO\*ZKU+LPHF MHJX'0)R8A,00B%M(O"VL^5#BJ>N_)\M*RX#+;MSJVN_CUW%2"<>$]?#HK0./ M"L+%7C.UO=X*0:\V_DFP:0@T(`&@X'0"259_6RVQK:F(J.^KJ+C MA@=<6*E6"N1--Y;]3L7."%Z'HQSDT#[]_=-#RI"LK]P'-52U;3MIRU07!Z;D M=?'PE,XF5R8@-P*B*BB&G8-Y]M7YI;R]6]YG];2@ESFE>7&]I#-6EHS.W@Z3 MG?@;#>M^B'_K^,M@VBXJ;.#,W2:-3,M-GPDD(0BO'"IKSL(ES#=Q@H7=^P<( M/!_4"]-EVT+76B]#G>[7&!U>3ES9VOKNF/H1G;RJ^A-02P,$%`````@`+(QI M1YE&UL[5I;<]HX%'[O MK]!X9_9M"\8V@;:T$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J; M/`0LZ?O.14?GZ#AY\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL M:$#05%%:;U\@M.4?,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP M&U@@?\YOI^1.6HCA5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C. M=GSVQ.V?C,K:=#1M&N#C\7@XMLO2BW`A(5M>5`TR``6'!VULS2`Y9>*?IUE!K9';O=05SP6.XY MB1'^QL4$UFG2&98T1G*=D`4.`#?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB! M]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95 MO-RCEU@5`9<8WS2J-2S%UGB5P/&MG#P=$Q+-E`L&08:7)"82J3E^34@3_BNE MVOZKR2.FJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PU MDSY@R.S-D77.UI$.$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;] MN'Z&U3-L+([W1]072N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E M>G@*-Y;&O%"N@GL!_]':-\*K^(+`.7\N?<^E[[GT/:'2MSAD6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^ M+,_Y/%_GM,T+,T.WF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1 M^^?!4;"C[SR6'<>(\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L M%.!D8"V@!X.O40+R4E5@,5O&`RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9 M;2)2.<)IF!-GJ\K>9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F M2J+S&5.^YRM)Q%4XOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M M#`DL6XA9$N)-7>W5YYNTB42%(JP#`4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG! M/3-R0]A4)?.NVB8+A=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH`1JV*^NJ]/^26<.[1[ M\8$@F_S6VZ3VW>`,?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY M@%CS#*%F.-^'19H:,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\ MW/[O#;#"Q([A[8N_`5!+`P04````"``LC&E'H6QEAJ&T8A,-C*H/G0;T6V94>@ M%T^6,[N_?GKQ2QP(Z;*N-%]T>G3WW'-GY>RH5AW%#UN,%6@9Y74,MTI57SRO MSK:8H7HI*LSU22$D0TIO9>G5E<0HKTT0H][*]T./(<)A$O&&K9FJ028:KF*X M&B'@XN]$CF/X=/'Q5R/4[0?@UL6GQ<)_NKP]Q"_LP24$CN-;'L,@O(;>RTF7 M_G%>?79`'1IJKZ\AB0K!YZ48((GJ9[!#5/L'QCT35$B@=*^T!HMPQ+#SN$.4 MI)(8L$",T,[!*P/8]O9^C'`A;6Z7X3#/TI\RR3*-H=__7IXNG=CM8LHCE,[+ MTT`254@I+/E:;T!O;[I*%\<%QTZD]3OA74K4!:OKO0"[Z+RID#F68^8`#E`2 M45PH'2!)N36K$I61+I023!LY0:7@B!K*(:(W-&V&*7TPE_FQF'&W!7`^YAG[ M$!@5@ZD;T9O3-;!-]?;9'/<^K7\6+VB+,8&.1E5%NZ^4E)QA)]9!:]'O3M$' M1^B3"`VL8"LD>=;^YB)D&L`2@AV6BF3[R&^)J@UN57^#O;8XIO#KSZ4=F_YWP0.;;WIHS)+Q"<\R[Y]U* M"]^KM*N;?U3F]=-W;\3/!OR(@K0A5!$^2$#FE7QO9-/9[)V&N^;,VVFNVU.% M4OU!-,NBR7);P_U]7Z]5*_U?=J,Z M^FUI72M[.G2K?;MS#-N&@F!7)?H#==O7,B=HV:@L[7VO_[^Z'1#1J*0?3GU-C;^][E,S3 M/$W++2/\[4*K:X_`<$+(NM=7ZEQ>'B6S1,BAMQ^UZ95[+WOUR=EAH[L5L1*Q MU,[WB]#=\9^M[G2K?X5VTY%?V^N_K=._;-=+LZB=-6:\*OPP7D1W\'=GJ(V] MKB=_[.7EM_`DCI)R1L`K[?6E-KJ_.4K&[T:%GNP_Z,HX_/??1#<.SNTC%K)K MQ(>N)XHXZ;8/CX8FM('^?-*,-W:'FKZXDV:^'2H$O2,QK-$-C44CWDHCNUJ) ML3L>("E`TF=!Q(LS":`,0-G_@!8]?81.>F&7XNM&.0#E`,J?!7IGVPV`"@`5 MSP(MUA);5`*H?%Z+I%\#J`)0]1CTU:UDIW^-SWE\_&^EUR/GS"FO`'0`H(/' MH,70MM+=C%W1JTY3=$@RZKBN[4!&`>@5@%X]!GU6;D53[$/U934R[H<*!.(6CB,RNT,?+2NOOQ.:5([#Q-?X246CPG%'X5'=J:[Y3M#+/E%_IV:KT7)-J8B1A!*0J:,H(NADNO?@QA M*?MP]6!*I*ADRB@93;"T0A0JF3)*QE$'B$(E4T;)I^)0O*`*P4Q&!RU-&4NC M89;-<&%%83-.V%B897-$H;T98^\38;;K'S[!#%W.&)?O0NWVXC_QZDFUP`@< M3;,TM%TRTI$H>`9)SB34NQ(H=X9I_>CN&(QJ';& MJ!V-'O$"4:AVQJC].#:X%N6H=AXSC@>1Z'C^:0F9AR/H]#Q'!W/&<>?S+@]<=PT6#OFZ'C..!Y!A:!!%%J> M,Y9'43F&>(ZFY\\)\3T2RV+AE*/I.6-ZM+05>_@N@K87C.W1]:!`VPNTO7AN MG5R@[07:7K`%20R%MA=H>\'9'ENE"K2]0-L+SO8H"FTO)N^`C.U/+7A[8IQ2 MB$+;"\;VIU%AWF`=6*#M!6/[_=I)[:C7JAEHO:*YO3N/*+2]8&R/+J3%*T2A M[05C>Q158LE2HNTE8WMT32[1]A)M+QG;XRBTO43;2\;V.`IM+]'VDK$]6BF4 M:'N)MI>,[7$4VEZB[>5SZY<2ZY=RLN?!V!Y'88%>HNTE:_O]B][M;*&XD6:[ M[X4HM+WD-CZXJNH>B2BTO?S-UTA"A3TFVRE$56A[]5MOE)-N(@IMK[A*AD-M M3S[8_:K0]HJK9%C47=H@"FVO6-L?O/1.'R.BT/:*W=Z+U:&XI%9H>\5N\$50 M%=I>H>T58_O3[]-C3Q$UV>-C;&>JXZU50Q]6642A[15C.XLZLSWU6$LS\0IM MKSC;'[ZLBZ<4/4#;#V:[C>WQYW$ONU%+BH8F[/3[\3:U-'78_J>/^=J=6AO_MR+<;_F_^`U!+`P04````"``LC&E' M0CNXBE8"``#U!P``&````'AL+W=O:6EK-H+A`Z^R_7S[4X@2]$<'W/<\! M/%`,E'WP&F/A?;:DXP>_%J+?!P&O:MPB_D)[W,DO5\I:)&27W0+>,XPNVM22 M`(9A&K2HZ?RRT&-OK"SH79"FPV_,X_>V1>S?$1,Z''S@3P/OS:T6:B`HBV#V M79H6=[RAG"_@OT)Q$JB%;\;/'#KW5/)GRG]4)V?EX,?JAPPP950(9!L M'OB$"5&1)/GO&/3)5$;[?8K^74]7IG]&')\H^=-<1"VS#7WO@J_H3L0['7[@ M<0Z)"EA1PO73J^Y-,0C89H-IBE M"TQF>E[?D$!EP>C@,;,9/5)[#O:17+G*XWJ0F>62,^-R]%&&1?!0848%U(JC MK0"S(I"Q9P!T`48[M.S0!3C9BL@-B%R`R,P@LNRQVQZ[[+&QQY8]6>9G%$=; MD;H!R08@L>R9$V`K=FY`N@%(+7ON!-@*$+H)V08AL_U@B4@,PD@ZL\TA2-R0 MW09D9T.^_"FI@2PD*[]*OH'(;7_L7*J%9&46ZG189:B/SPBI$[+49"L49]E. ME$55[IQ;,FJZ<;F2-,Q7]AXX"WA"V?4)W#_80@/7*,XJGBAV&4/@IBPT<(6R M5>S`KF48N9;M-&K&90-IE&?Y[NN4`NN4;3&[Z=N'>Q6]=_JRLT;G&^X5ZE/Z M*2^+'MWP+\1N3<>],Q7RK-<'\Y52@64NX8O,J99W\-PA^"K4:Z:2-;>2Z0C: M3Y?L?-.7_P%02P,$%`````@`+(QI1V>K,!T[!0``PAH``!@```!X;"]W;W)K M]=_'[9M.RY^'/;'X6ZY M'<>7F]5J>-BVAV;XTKVTQ^F?IZX_-.-TV3^OAI>^;1Y/08?]"JHJK`[-[KA< MWY[N?>W7M]WKN-\=VZ_]8G@]')K^OTV[[][OEFYYO?%M][P=YQNK]>WJ(^YQ M=VB/PZX[+OKVZ6[YJ[NI*YG(L$3I*-D&B*6BC\AV0UU?]A`C03>#8!/#[H\:C% MTSD>>7R4%N.Y$6?)\21QX`E1D]5L+'>NYEZS'AT);`HO'2FU+X#WFG4>U+5SER"?0O<2"E\B].-5+Y%Y2 MJE15'<50"&!X204OB7L!U4MBM:@]5W.%\\RLL)$+-C*WH7;\)O-*LE.]UESD MO3%.9B::3N8_?UI1Q_/FHKD\'D!4)TT?EV]4-!QP&W0WP>BH@?8S70NDL=A+&`9*^L@A=\)FB8:C$8\>!3#J0G6!M",D:0D)7NG')**AAJH?,Q0#264%`1?4WZ.*+)RAI+6`6.5=*Q"AR7Y'55+503Z(SY M`"6D`DR4"@!%3A020,,5;^1N4:`JLQ1A*)`5.4J^3%`0A MT>E@EZH0K5E5HBAPBGJ=HB!RUP!&7BEDL6+['&FGA%'@&-5W%QL0@-3G7BU$ MX`PO6((HHU[-<%%ENS/JD$JH4LM4[ M)1PCQ['7<8P"C`>>QU'N,G'H,.REKH\I3'&`L$EHB, MG,A>)S*2&*1>1U,M9$9R@B4>(^>QUWF,7HP)?58)4BI7829R=06<5<2@Z0*2LCSHA3(25=7I")7P2 MQZ>^,]D0!^,OWDTUZ8F`%,Y'7%;:1B6($H>H/N@$DV)TS3J-"5.26VC=YGT0J=N]%;L;<-+\]S^U?3/ MN^.PN._&L3N-BWSZ-\\\X=\#Y%KF^, M/EY;K?\'4$L#!!0````(`"R,:4?`37;7W0$``&8%```8````>&PO=V]R:W-H M965T&ULC91=;]L@%(;_"O(/*/["42/'4N-JVBXF5;W8KDF, M8ZM@/"!Q]^_'A^/ABEKUA8'#^Y[S`()RXN)-=H0H\,[H(`]1I]2XAU">.\*P M?.`C&?1,RP7#2@_%!,",MP/457:V(NH2GY5M!_(BP#RRA@6 M?X^$\ND0)=$]\-I?.F4"L"KAXFMZ1@;9\P$(TAZBIV1?%T9A!;]Z,DFO#PS[ MB?,W,_C1'*+8(!!*SLIDP+JYD9I0:A+IPG_FG/]+&J/?OV?_9E>KZ4]8DIK3 MWWVC.@T;1Z`A+;Y2]`C()SYQ*^P?GJU2 MF=316[5+2G@S>69):B5'7Y*&%/5*@18)U/47B#0$D3F(U(=(P_XLY,^=/_/] MV1K128Z^I$A#DOH3R8HBWZ#(?8I\70(Y"B<9W$;%\Q=2UMO*%1/:8$(^$PHR M(:]2DA09>HSS),BT4L8Q0KO'[)-]*C:8"I^I"#(57V8JOL`$O2LQX@OYB<6E M'R0X<:5OE[T*+>>*Z'SQ@\[;Z4=O&5#2*M/=F8+N'7`#Q&PO=V]R:W-H965T&ULC9E-<^,V#(;_BL?WQ`3X(3+C>&8MJ=,>.K.SA_:L.$KL6E+-DA-*"ZESB6'X!X"9*`I/6E;KZW^[+L%C^KXZE]7NZ[[ORT6K6[?5D5 M[6-]+D_^E[>ZJ8K.?VW>5^VY*8O7JU%U7*$09E45A]-RL[Y>^]ILUO5'=SR< MRJ_-HOVHJJ+Y=UL>Z\OS$I:W"]\.[_NNO[#:K%=WN]=#59[:0WU:-.7;\_(+ M/.7H>N1*_'4H+VWP_Z(/_J6NO_=?_GA]7HH^AO)8[KK>1>$_?I1I>3SVGOS( M_XQ./\?L#1RN6B]?RK?@X=M_JR^_EJ$'W M#G?UL;W^7>P^VJZN;B;+157\'#X/I^OG9?C%BM&,-\#1`.\&]W%X`SD:R$\# M-6N@1@/UJR/HT4!/1E@-VJ\SEQ5=L5DW]671#.D^%_VJ@B?M<[-;M->+S9`0 M/W>MO_ICDR3KU8_>SXC@%=D2Q')(%B)P)U9^_'L0R`4QCH"!.7(#I"&1.#:& M_W621YR0,"47IASF2@;V5O#VBK-7@[T*[8&&F`PS,2"G*R)5@H:CTI`"-)JE MLI`RQCC!43D9$5$GO"X]HTN'NB93KP==.AC%*64X*`TA!:`Y*-,D7J-8*J>N M4/&BS(PH$XJ2K"@3#&(='TD:0@H-L*(,$04Z845%71%1R8RH)!2E6%%),`AJ MP6H*&3!\GD+&\+G,B1]G>#UV1H\-];!C;&TPAI;2L%.;AA0".);*0@I\G@2? MIQ!3PDK+"W,S1XT+A44FIB^#T9GI?_STP,:Y'9E1#R"?I91@"I%=-QFAI%\5 M+)939Q(BQRBP->NF+2PWUO+:(,R[TNR^2PF%/FI>6DA!$L'RN#,JC:V$-VEA MC;*.EX9DL6K'SD!*,%"6GX*,8@AH(^J0'*E2R8@\MH+>Y(4E=%J0;O(DF48! M["RD!.OEL6=T1K!$260'S0FFI$UBZW*NOD-8X!T[W5L@5=G/-AMV2C!I4$4V M78AY2">1Y(6<`RLCW0_,E7D(Z[SCZSR$A?9`1SBC) MIR:G[I1O6")=$`82?`-S9;#*NRYM=9 M2J"'Z5W8*(MZXI.:4T\0:P)PK@G`L`G@2^`6@2PQ9_B&+:6<3(#/?D8XHWW6 M>'G$G7("(CL-YUH!#%L!Q[<"B$2@PDCF"`:&+ZD9Q?QM)=^U4TSJ:/KF.@$, M.P%_7//R)!G).7/*@9`:=43C7#^`BFCD&P(DI1GY M4D`@_J`DR(,5?"-`*8R4.)QK`U`357P?@)IF3L16IO[%S%%.)?P2SBG79TY% M[KYP[N8?#='(W_XCN?^/=#H$`I!\GT,H="IR;!+*NMB:G&M0,"'*)AW*^!0* M:>=A<;I/QN=0E-.8H.:X;,)!,BT>X[,HROE3P>C8"IWK4=`2C9.8[*B1=`SB M42H.2Z?8M%>SH\()-NUG[2B0=C./P>ZA\N;Z%'1$'M^H(&DOP-^U*XCMP1!U MSEJ+_(K/J%/AO%.C(C60.+4)@#;3*K@*'E579?-^?4G0+G;UQZGK>_+@ZOU% MQ!?L'W5/KF_A*07F>@9/^?":X=/]9GTNWLL_B^;]<&H7+W77U=7U:?A;77>E M#]WG>+G8E\7K_V_"R8?C2U>?;NY/["YS-?U!+`P04````"``L MC&E'RJ3)B,4"``#R"0``&````'AL+W=OC&5/=A7MFSQQKKR/NFKDRC\I=5X&@=R=>,WD@SCS1O\YB+9F2B_;8R#/ M+6?[SJFN`AR&BZ!F9>/G66=[:O-,7%15-ORI]>2EKEG[>\TK<5WYR+\9GLOC M21E#D&?!Z+RP\K_Q$MMR@TD`[QL^17:7U[)OE7(=[,XOM^Y8><&KRC#IR+\&TL^8QM'^OK%_[>3J]%^9Y(6H7LJ].NEL0]_; M\P.[5.I97+_Q04-L"'>BDMW3VUVD$O7-Q?=J]M&_RZ9[7_L_%`UNL`,>'/#H M,,:!':+!(?IT('<=R.!`_C="/#C$DPA!K[VKW(8IEF>MN'IMW^XS,[L*+6/= MFYTG.V/;-T373FKK>XY"F@7OAFC`X`ZSMC$T@2`;AV9$!#J!,0L,93%$P)8[ MA@(4-H*F8`[_)-G.D#AI1E":45^LR"E6`A,0B(#T!,0AF"1)^UKTF*;#?(G2 M$*<0K'!@<90L0+:-"R,4@6Q;!X;"*"8SZN([Y8D==3/U7=PIS\(F0*&;:=R7 M9V%EBB,04]@8`B$V#@M)(44,=-0A40YUF_[4E!CTV*@*3W5!W M.U!0]M9!X9D6)WEI.$BS,6BF]1L;A).9ALV"'$WF0IP597Y:J@AXZ`R@ ML6D(1^"IX^)B3,,$/'8FN$5*0_#<<7%(#S'6'=1K#*P+K>;ML1LEI+<3ET:9 MH\>RCN/*(S87XL2^1LL"`?:-&6^Z"_23/L_.[,A_L/98-M)[%4I?P]V=>1!" M<9UY^*`[=-(#V+BH^$&93VI:UX\D_4*)\VW"&L>\_`]02P,$%`````@`+(QI M1QSEXA$B!```DQ,``!@```!X;"]W;W)K59R`B)PCP]GF:+>7?O>[F8%Q]U=CS9[V50?>1Y6OZ_M%EQ>9G1 MV?7&C^/[H6YOA(MY>+/;'7-[JH[%*2CM_F7VE3XGC+=(1_P\VDOE_`[:X-^* MXG=[\=_N94;:&&QFMW4[1-I\?=J5S;)VI,;SGV'0N\_6T/U]'7W3I=N$_Y96 M=E5DOXZ[^M!$2V;!SN[3CZS^45P2.^0@VP&W159UG\'VHZJ+_&HR"_+T;_]] M/'7?E_X?308SW(`-!NQF0*G7@`\&_&[`O09B,!`W`Z:\!G(PD#<#[C>(!H/H M[L&?M!H,U-U#Y#70@X&^>^AF(^RGHYO,=5JGBWE97(*R7X'GM%WH]%DWRV4; M5-W-LE\CS716S=W/!:5R'GZV`PT,ZY@E9"*,64%&8R+US.GGB%$2F4XP\B5GP1!<4]0 M'`0EH"O5!\4=5X(8I@V&K5U,"TX(Q;!7%WM"'6X@(C7C$<;%+L>U4!'J,7$Q M)B33>)D$5B;>ETF`,DE\`.FILP0#1.CD2S?.2`J#46M(<:TQ*IY$)2Y%G>J! MM")/6A%(2Z$K-7*<&&($5[@?Y?&C@!\TF:5RDV&,H-1Z$A5/HA*7(GA2VI.4 M!DFAL[W2X#&G),+=&(\;X[KA!*V=<1]QC3+K"4P\QH!@VTW":+3MGTZX%*W* M``UKRC#&Y$AA*-K.KKZ`IN-"NQR@0658(T8"+<]$+O9Q,'1?,Z&@FW"TFZRH MVR18TR6('I$NZNL1%#0)/*TE=556FJ8=X56:A,4>#,:-BO8U;J#:7.(U$FZ- MI&14CN@@]>D[!0+_V*^N-0)ZRR(=H?.VGLC%/@Z&[M-P"D2<*D%T!/#=P+Q)"H!E#!C#Y*O@U#00@3>0J@!-51,/&[(K\E-!&,O"+?= MOH["0$+[O8QQ4ST>.X;SDZ`:PZ'7!B%@:\`;.LN,6SSB#6',12,88!4,XWZ36"` MS8;C<2Y#YTW".7VWW]+R_7BJ@K>BKHN\>X.P+XK:-H.1+\U<'&RZNUUD=E^W M/U4[2?T[H_ZB+L[75V"W]W"+?U!+`P04````"``LC&E'$BH`7B`'``"Z*``` M&````'AL+W=O8B M7!PO_+E\>N[W%^:WU_-3N8?ENMWLEMUFMFT?;RX^AJN[/$I&Q5_+]FU7_#W; MF__2=5_W'WY_N+FH]A[:57O?[ZM8#+^^M7?M:K6O:;CS/X=*?]QS7[#\^UC[ MKV-S!_M?%KOVKEO]O7SHGP>WU<7LH7UO MN[Y;'XME4.I&I*3ZS>Z5-3W(F:VC)4RD*@8/K9\\XTM/_GR5&C M=])!K$MN21-@!JF71+)4&YX6Q" M`)26'Y6Q1S\`68ZZ'RX?!XM)`!!F>_X'C]H!L,U)MU3B.&9[9,L[.L@C=@!D M,^MN2AC'RI[]I8X<0`:5VH=U,0"VV5@8@P?9@)35E\90\O,R4!7L;BZE,:5H MMHP\U%*)VJCC@RIP%4)M#D>4DIL3*2!\#+9ZR-YE*62LE&?KA1A?+#=0:60:WL=(H^R5%(VZG.6(*8. M(]NA*@%[&>@QVNJE263N6/-12B=JDIP@2L,1B#R?! MF=EDVY6'7"J1:\1V@I1<-_;#`V&RDP1Y09E*Y!JYG#\-LV`+C0VG**'\%@BG/7G%B$`B_F&`[I+BG:BB!["(P1ERU.)9HHQVAT5 MH:.JNK(7WJAR_+BQ`6E9K"H\ZD8(N*)GB@C8#?60B,Q0@5JI4G8:Y\$W0LX5 M/5;$DJGC6[[IJU0V-3FHBQY](P1>,:9,A@[+E?W>!%++D,?>"'%7](`1@:DA M).=-#K620[`7JN@1.$**C@;K,$6SB.FK^7E/)8^]J61OT@=4`O0F:/O@GHF_6]H:3O'D";2@GQ&:#1CX?=!-C-^CJ58)^!ZK,%'WR]`[O)PVX" M[&:#)IAYM2\%CGY*I3AK9O*(FX"X65^AM2;]36* M2Z#6)N!`1LZ>!7O49:!NUJG+F&BK:*:>,R7;;P?L09Q.,8A@-D#O)02<6,'"_80SH#P6D@>*U3G$LT M-[FQWSA!>4E#IG6ZRMLRYA+FE(T://(RD+?6EP.&+^9RLK,N*-,P`NP=+/'` M*P#>6E\0I()IR2F:&PX@I90K>PJ+BM]#APO@MTY&%1XK!5A9ZP07")[!7G]! MF.P7'O%P*8#+6L>W``2#_5VHO".@BK<](,#)VAC6XK%-@&VUCEIA8(@=N4$8 MSM_6T95[<`')IA-72F(-4\VD"`B9R&:(>&P38%NCXU;@6,*07L2>:GC009S- M?O&"JD!0;73F2AD_FQ3L8Q[U.P:E!TH!4#8Z*`5V6S,E9^*^8U<@>XC,@,A& M1V0&1(;QJTGCW`D0L@K!'D[9"Z@9"-F<1>;#H:-NFWY_!*JZ>CN-]I/V1LK/KG\+5W72H[D^>SF> M%#P=5[S]#U!+`P04````"``LC&E'T68>TJ(!``"Q`P``&````'AL+W=OZ89>"R^B[5PHL+)@,Z\6"K05J(F!YD@?-X?3+B`BX+>`T2YB$KR?$5]# M\K,^TBQ8``F5"PK<+Q=X`BF#D&_\=])\;QF(R_BJ_CU.Z]V?N84GE']$[3IO M-J.DAH8/TKW@^`.F$?9!L$)IXY=4@W6HKA1*%']+J]!Q'=.?+]E$6R?D$R'_ M0&"I4;3YC3M>%@9'8M+6]CR<6^5J+B9XOZ/DZ?;M&WR:'VQN']^L"NS6!71+8?39BPIQN,0\? MFK#%GBHP;;PZEE0XZ'A1%]7Y=C[F\4S>X671\Q9^<=,*;`P-H@-O M(KO;4]+Y]S,G$AH7P@6B?O3"`%9LAMEG2OZ\O+"$5Z@OV#.><.6./ MBPG-J^T`''G7JK='VCDW'!BS50=:V!L#;&CUL+\.8'"Z4AW])IXD6WG0H*5!5MXM=306XD] M,=`:!0N@H')!0?CE`H^@5!#RA=]F MS8^2@;C>7]6_Q6Z]^[.P\(CJMZQ=Y\UFE-30B%&Y%YR^P]S";1"L4-GX)=5H M'>HKA1(MWM,J^[A.Z4^^GVG;!#X3^$*XRZ+Q5"C:?!).E(7!B9ATM(,(-[@[ M<'\0%;$Q:5+WWJCUV4NYN[\KV"4(S1@>,:=/F`7!O/I2@F^5F.E\1>?;]/T6 M?9\<[C\YO-\6R+<$\B20_Z_%A#FM,7YL_RG"5F>JP;1Q="RI<.SCH*ZRRW0^ M\'@G'_"R&$0+/X5I96_)&9V_V7@-#:(#;R*[N:6D\^]G"10T+FR_^KU)(Y4" MA\/U@2ROM/P+4$L#!!0````(`"R,:4=B`T6OH@$``+$#```9````>&PO=V]R M:W-H965T&,"*[2&V6=*_KR\L2RK:%SPSG'/FC"_EA.;5]@".O"NI[9'VS@T'QFS= M@^+V#@?0_D^+1G'G4],Q.QC@320IR?(L^\04%YI69:P]FZK$T4FAX=D0.RK% MS>\32)R.=$>OA1?1]2X46%6RA=<(!=H*U,1`>Z0/N\-I'Q`1\%/`9%X3X(UBAM_))ZM`[5E4*)XN]I%3JN4_I3%#-MFY#/ MA'PA?,FB\=0HVOS*':]*@Q,Q:6L''DYP=\C]1M3$QJ))TWNCUE`PM MH@-O(KN[IZ3W[V=))+0NA)]];-*52HG#X?I`EE=:_0%02P,$%`````@`+(QI M1^NCYH"C`0``L0,``!D```!X;"]W;W)K&UL?5/; MCILP$/T5RQ^P)H2D5420-EM5[4.EU3ZTSPX,8*WMH;8)V[^O+X1E*]07/#.< M<^:,+^6$YM7V`(Z\*:GMF?;.#2?&;-V#XO8!!]#^3XM&<>=3TS$[&.!-)"G) M\BP[,L6%IE49:\^F*G%T4FAX-L2.2G'SYP(2IS/=T7OA172]"P56E6SA-4*! MM@(U,=">Z>/N="D"(@)^"ICL*B;!^Q7Q-23?FS/-@@604+N@P/UR@R>0,@CY MQK]GS?>6@;B.[^I?X[3>_95;>$+Y2S2N]V8S2AIH^2C="T[?8![A$`1KE#9^ M23U:A^I.H43QM[0*'==T)9&UL?5/;;J0P#/V5*!_0,,STLB,&J=/5JGU8 MJ>I#]SD#!J(F,9N$H?OWS86AM$+[0FQSSK$=.\6(YLUV`(Z\*ZGM@7;.]7O& M;-6!XO8*>]#^3X-&<>==TS+;&^!U)"G)\BR[88H+3#@I-#P;(@= ME.+FWQ$DC@>ZH9?`BV@[%P*L+-C,JX4";05J8J`YT/O-_K@+B`AX%3#:A4U" M[2?$M^`\U0>:A1)`0N6"`O?'&1Y`RB#D$_^=-#]3!N+2OJC_BMWZZD_#X"%,+UT&P0FGCEU2#=:@N%$H4?T^GT/$RSR[+=@Y M"$V8/&*.2\QF1C"O/J?(UU),]'R98IV^7:-O4X7;9?8?-^L"NS6!71+8_:_% MA#E^Q=Q]2\(6=ZK`M'%U+*EPT'%1%]%Y.^_S.)-/>%GTO(7?W+1"6W)"YR<; MQ]`@.O!%9%?7E'3^_7%8N4352U#Y6B/+3/7AC`BLT0VRSIW]<7EI`*]07; MPSEGSGC&Q83FQ78`CKQIU=L3[9P;CHS9J@,M[!T.T/L_#1HMG#^:EMG!@*@C M22O&L^P3TT+VM"QB[,F4!8Y.R1Z>#+&CUL+\.8/"Z41S>@L\R[9S(<#*@BV\ M6FKHK<2>&&A.]#X_GO:!0N@H')!0?CE"@^@ M5!#RB5]GS?>4@;C>W]2_Q6J]^XNP\(#JMZQ=Y\UFE-30B%&Y9YR^PUS"(0A6 MJ&S\DFJT#O6-0HD6;VF5?5RG].>0S[1M`I\)?"%\R:+QE"C:?!1.E(7!B9AT MM8,('/"]K/? MFS12Z>!PN#V0Y966?P%02P,$%`````@`+(QI1YQHESJB`0``L0,``!D```!X M;"]W;W)K&UL?5/;;IPP$/T5RQ\0@R%MM6*1LHFJ MYB%2E(?VV0L#6/&%VF9)_[Z^L(1$*"]X9CCGS!E?JEF;5SL`./0FA;)'/#@W M'@BQS0"2V1L]@O)_.FTD M#;*3E,S\.X'0\Q'G^%IXX?W@0H'4%5EY+9>@+-<*&>B.^"X_G,J`B(#?'&:[ MB5'P?M;Z-22/[1%GP0((:%Q08'ZYP#T($81\X[^+YGO+0-S&5_6?<5KO_LPL MW&OQA[=N\&8SC%KHV"3TLK5W&=TY^B M7&C[!+H0Z$KXD47CJ5&T^<`: MYK0BER"T8&C$G+:8?$40K[ZVH'LM%CK=MMBG%WOT(CDL/C@L]@7*/8$R"91? MC9@PIX^8\E,3LME3"::/5\>B1D\J7M1-=;V==S2>R3N\KD;6PQ,S/5<6G;7S M)QN/H=/:@3>1W=QB-/CWLR8".A?"[SXVZ4JEQ.GQ^D#65UK_!U!+`P04```` M"``LC&E'<7"47:0!``"O`P``&0```'AL+W=O3SC'M\`+[P<7`J2N MR(IKN01EN5;(0'?"#_GQ7(:,F/"+PVPW-@K:+UJ_!N='>\)9D``"&A<8F#^N M\`A"!")?^&WA_"@9@%O[QOXM=NO57YB%1RU^\]8-7FR&40L=FX1[T?-W6%HX M!,)&"QN_J)FLT_(&P4BR]W1R%<\Y_2GH`ML'T`5`5\#7+`I/A:+,)^9871D] M(Y.N=F1A@OF1^HMHD(U!D[KW0JV/7NNBK,@U\"PI-*:)('%%IX?]@G*/8(R$93_Z3"EG,M/->[_J4$V-RK!]'%Q+&KT MI.*:;J+K;C[$$9*/]+H:60\_F>FYLNBBG9]K'$*GM0,O(KL[8#3XU[,Z`CH7 MS"_>-FFADN/T>'L>ZQNM_P)02P,$%`````@`+(QI1S?^\&"C`0``L0,``!D` M``!X;"]W;W)K&UL?5/);J0P$/T5RQ\0@YLLTZ*1 MTHFBY#!2E,/,V0T%6/%";--D_GZ\T(2,T%QP5?'>JU=>RDF;=]L#./0IA;(' MW#LW[`FQ=0^2V2L]@/)_6FTDL^=4R$-?Q1?TI3NO= MGYB%!RU^\\;UWFR&40,M&X5[T],SS"-&UL?5/+;MLP$/P50A\0RK3=!H8L($X1-(<`00[MF996$A&2JY"4E?Y] M^)`5I5![$7=7,[.S?!0CFE?;`3CRKJ2VQZQSKC]0:JL.%+49J:/@@W0N. M/V$:81\$*Y0V?DDU6(?J2LF(XN]I%3JN8_JSWTZT=0*;"&PFW.;1>&H4;?[@ MCI>%P9&8M+4]#R>X.3"_$16QL6C2]-ZH]=5+R5A>T$L0FC`L8DY+S&9&4*\^ MMV!K+28Z6[98IV_7Z-OD%T*0(B M`GYSF.PF1L'[5>N7D/QLSC@+%D!`[8("\\L-'D"((.0;O\Z:[RT#<1LOZH]Q M6N_^RBP\:/&'-Z[W9C.,&FC9*-RSGG[`/,(Q"-9:V/A%]6B=E@L%(\G>TLI5 M7*?T)U]H^P0Z$^A*^)9%XZE1M/F=.5:51D_(I*T=6#C!PXGZC:B1C463IO=& MK:_>*DKSDMR"T(RA$7/98@XK@GCUM07=:S'3Z;;%/CW?H^?)8?[!8;$O4.P) M%$F@^-^("7/YB#E^:D(V>RK!=/'J6%3K4<6+NJFNM_.>QC-YAU?EP#KXQ4S' ME457[?S)QF-HM7;@361W1XQZ_W[61$#K0OC5QR9=J90X/2P/9'VEU3]02P,$ M%`````@`+(QI1Z@';'"C`0``L0,``!D```!X;"]W;W)K&UL?5/;;IPP$/T5BP^(6;.Y:,4B91-5[4.E*`_MLQ<&L&)[B&V6]._K M"TM(A?J"9X9SSISQI9S0O-D>P)$/);4]9KUSPX%26_>@N+W!`;3_TZ)1W/G4 M=-0.!G@324I2EN=W5'&ALZJ,M1=3E3@Z*32\&&)'I;CY;9Z2!EH_2O>+T M'>81;H-@C=+&+ZE'ZU!=*1E1_".M0L=U2G^*8J9M$]A,8`OA(8_&4Z-H\YD[ M7I4&)V+2U@X\G.#NP/Q&U,3&HDG3>Z/65R\58WI+ M"[;58J:S=8MM>K%%+Y+#XHO#^VV!_9;`/@GL_S=BPIR^8A[^:4)7>ZK`=/'J M6%+CJ.-%7567V_G(XIE\PJMRX!W\Y*83VI(S.G^R\1A:1`?>1'YSFY'>OY\E MD="Z$-[[V*0KE1*'P_6!+*^T^@M02P,$%`````@`+(QI1XQ+U^.C`0``L0,` M`!D```!X;"]W;W)K&UL?5/;;IPP$/T5RQ\0@]GT MLF*1LJFJ]J%2E(?VV0L#6+$9:ILE_?OZPA)2H;Y@>SCGS!G/N)S1O-@>P)%7 MK09[HKUSXY$Q6_>@A;W#$0;_IT6CA?-'TS$[&A!-)&G%>)9]8%K(@59EC#V9 MJL3)*3G`DR%VTEJ8/V=0.)]H3F^!9]GU+@185;*5UT@-@Y4X$`/MB3[DQ_,A M("+@IX39;O8D>+\@OH3#]^9$LV`!%-0N*`B_7.$1E`I"/O'O1?,M92!N]S?U MK[%:[_XB+#RB^B4;UWNS&24-M&)2[AGG;["4T MRB&N<_K#\X6V3^`+@:^$3UDTGA)%FU^$$U5I<"8F7>TH0@?S(_<741,;@R95 M[XU:'[U6G'\NV34(+1@>,>BH7.MRGVZ<4>O4@.BRV]R/8% M#GL"AR1P^%^)"7-^ARG^+9)M[E2#Z>+H6%+C-,1!W437Z7S@L2=O\*H<10<_ MA.GD8,D%G>]L;$.+Z,";R.[N*>G]^UD/"EH7MA_]WJ212@>'X^V!K*^T^@M0 M2P,$%`````@`+(QI1QQ&UL?5/;;IPP$/T5BP^(64.::L4B95-5[4.E*`_MLQ<&L&)[J&V6 M]._K"TM(A?J"9X9SSISQI9K1O-H!P)$W);4]98-SXY%2VPR@N+W#$;3_TZ%1 MW/G4]-2.!G@;24I2EN>?J.)"9W45:\^FKG!R4FAX-L1.2G'SYPP2YU-VR&Z% M%]$/+A1H7=&5UPH%V@K4Q$!WRAX/QW,9$!'P4\!L-S$)WB^(KR'YWIZR/%@` M"8T+"MPO5W@"*8.0;_Q[T7QO&8C;^*;^-4[KW5^XA2>4OT3K!F\VST@+'9^D M>\'Y&RPCW`?!!J6-7]),UJ&Z43*B^%M:A8[KG/X\E`MMG\`6`EL)G_-H/#6* M-K]PQ^O*X$Q,VMJ1AQ,\')G?B(;86#1I>F_4^NJU9@6KZ#4(+1@6,>I$<%A\<%OL"Y9Y`F03*_XV8,.>/F/*?)G2SIPI, M'Z^.)0U..E[4376]G8\LGLD[O*Y&WL,/;GJA+;F@\R<;CZ%#=.!-Y'?W&1G\ M^UD3"9T+X8./3;I2*7$XWA[(^DKKOU!+`P04````"``LC&E'!&IH]:0!``"Q M`P``&0```'AL+W=O/M'6N/S!FRQ:TL#?80^?_U&BT<#XU#;.]`5%%DE:,9]DMTT)VM,AC M[#+&#UL*\GT#A>*0;>BT\RZ9UH<"*G,V\2FKHK,2.&*B/]&%S M..T"(@+^2!CM(B;!^QGQ-22_JB/-@@504+J@(/QR@4=0*@CYQG\GS<^6@;B, MK^H_XK3>_5E8>$3U(BO7>K,9)1748E#N&<>?,(VP#X(E*AN_I!RL0WVE4*+% M6UIE%]'W$VV=P"<"GPG?LF@\-8HVOPLGBMS@2$S:VEZ$$]P' MM^L"NS6!71+8_6_$A#E]Q=S]TX0M]E2#:>+5L:3$H8L7=5&=;^<#CV?R"2_R M7C3P6YA&=I:]:D`0``L0,``!D```!X;"]W;W)K&UL?5/;;IPP$/T5RQ\0LUZV35P=#M#[ M/PT:+9Q/3UH6L?9DR@)'IV0/3X;846MA_IY!X72B M.WHK/,NV`S@2^$^RP: M3XVBS:_"B;(P.!&3MG80X01W1^XWHB(V%DV:WANUOGHM^?Z^8-<@-&-XQ)S7 MF-V"8%Y]:<&W6LQTOFZQ3=]OT??)X?Z=PR_;`OF60)X$\O^-F##G=Y@\^]"$ MK?94@VGCU;&DPK&/%W5576[G0SQ$]@8OBT&T\%.85O:67-#YDXW'T"`Z\":R MNP,EG7\_2Z*@<2'\[&.3KE1*'`ZW![*\TO(?4$L#!!0````(`"R,:4?@ZYA# MH@$``+$#```9````>&PO=V]R:W-H965TVF#>N6%/B*U[D,S>Z`&4_]-J(YGSJ>F('0RP)I*D(#3+[HAD M7.&JC+5G4Y5Z=((K>#;(CE(R\^\(0D\'O,.7P@OO>A<*I"K)PFNX!&6Y5LA` M>\`/N_VQ"(@(^,UALJL8!>\GK5]#\M0< M6P;B.KZH_XC3>O:%@)-E;6KF*ZY3^Y/K]^UD2`:T+X3&UL?5/;;IPP$/T5RQ\0LRR;5BL6*9NH:A\J17EHG[TP M@!7;0VRSI']?7UA"*M07/#.<<^:,+^6$YM7V`(Z\*ZGMB?;.#4?&;-V#XO8. M!]#^3XM&<>=3TS$[&.!-)"G)\BR[9XH+3:LRUIY-5>+HI-#P;(@=E>+FSQDD M3B>ZH[?"B^AZ%PJL*MG":X0";05J8J`]T8?=\5P$1`3\$C#954R"]POB:TA^ M-">:!0L@H79!@?OE"H\@91#RC=]FS8^6@;B.;^K?XK3>_85;>$3Y6S2N]V8S M2AIH^2C="T[?81[A$`1KE#9^23U:A^I&H43Q][0*'=8W8)@7GUID6^UF.GYNL4V?;]%WR>'^T\.#]L"Q99`D02*_XV8,.?/F/M_ MFK#5GBHP7;PZEM0XZGA15]7E=C[D\4P^X%4Y\`Y^`PMH@-O M(KL[4-+[][,D$EH7PB\^-NE*I<3A<'L@RRNM_@)02P,$%`````@`+(QI1]*C M$G>D`0``L0,``!D```!X;"]W;W)K&UL?5/+;MLP M$/P5@A\0RK32)(8L($Y1M(<"00[MF996#X3DJB1EI7]?/F1%"81>Q-W5S.PL M'\6$YM5V`(Z\*:GMD7;.#0?&;-6!$O8&!]#^3X-&">=3TS([&!!U)"G)>)9] M84KTFI9%K#V;LL#1R5[#LR%V5$J8OR>0.!WICEX++WW;N5!@9<$67MTKT+9' M30PT1_JX.YSR@(B`7SU,=A63X/V,^!J2'_619L$"2*A<4!!^N<`32!F$?.,_ ML^9[RT!X38(5BAM_))J MM`[5E4*)$F]I[75&H4;7X53I2%P8F8M+6#"">X M.W"_$16QL6C2]-ZH]=5+R?.[@EV"T(SA$7-:8W8+@GGUI07?:C'3^;K%-GV_ M1=\GA_L/#N^W!?(M@3P)Y/\;,6%.'S$/GYJPU9XJ,&V\.I94..IX45?5Y78^ M\G@F[_"R&$0+/X5I>VW)&9T_V7@,#:(#;R*[N:6D\^]G220T+H1W/C;I2J7$ MX7!](,LK+?\!4$L#!!0````(`"R,:4?&PO=V]R M:W-H965T,B&F@WAFUCYUY$V_"+ZKN1 MO8A`7H:!BG];UO/K)DS">>*U.YZ4F8C:)EKJ]MW`1MGQ,1#LL`F?DL_^GVZJ17&X?!GAWHI5>O_/J#W?:0FX8[WDO[-]A=I.+# M7!(&`_VMT@QDD`IG"HV[C; MR6(>KEH0E.8.E#IX4*?./,"J18;S0%#NX$'M.O,`OQ8%S@-!I8,']?7,DX(6 M%8:G,\"0TJ4V7Q8DP.BE0VT0Y%`;\:4!`4:O M<+7=@5R_J;XT(,#H%:ZV.Y!#;<27!@08G>!I`$&50V[$EP8$&#W#90U!E2/= MB"\-"#!ZY=@/!#GT1GQI0(#1*UQO=R"7WGQI0(#3:X?>(,BE-U\<$.#TVJ$W M"+K76[0ZF@Y,'.T)7`8[?AGM@7\UNYSRGX@]VG[!V^9,C^P7%<=NE,$;5_J` M;$^S!\X5TZN('_1;/>GOD&70LX,RMZ6^%]/)?!HH?IX_-):OG?8_4$L#!!0` M```(`"R,:4?%%"D&PP$``'L$```9````>&PO=V]R:W-H965T??PB% MRNI-;!^^OT-\R$>IWG0+8-"[X)T^)ZTQ_0EC7;8@J'Z0/73V22V5H,8>58-U MKX!6GB0X)FF:84%9EQ2YK[VH(I>#X:R#%X7T(`15_R[`Y7A.-LF]\,J:UK@" M+G(\\RHFH--,=DA!?4Z>-J=+YA`>\)O!J!=[Y+)?I7QSAY_5.4E=!.!0&J=` M[7*#9^#<"5GCOY/FAZ4C+O=W]>^^6YO^2C4\2_Z'5::U8=,$55#3@9M7.?Z` MJ86]$RPEU_X7E8,V4MPI"1+T/:RL\^L8GAP.$RU.(!.!S(3'U`;4_=/[@Y$?LB2J1]487N;5!MJ[>"''-O"+JH9U&EVEL7?47ZA:2@,V1/I@6VWMEV`^<*B-VQ[L7H7A"`&ULC59=;Z,P$/PKB!]0V,T7J0A2T]/I[N&DJ@]WST[B M)*B`<[:3]/[]V0;2N+)=OP0PLS/KB<9L>67\31PIE M:4O$`SO13KW9,]X2J1[Y(1,G3LG.%+5-AGD^SUI2=VE5FK477I7L+)NZHR\\ M$>>V)?S?FC;LNDHA'1=>Z\-1ZH6L*K-;W:YN:2=JUB6<[E?I$SRNL=`0@_A= MTZNXNT]T\QO&WO3#S]TJS74/M*%;J2F(NESH,VT:S:24_PZD'YJZ\/Y^9/]N MMJO:WQ!!GUGSI][)H^HV3Y,=W9-S(U_9]0<=]C#3A%O6"/.;;,]"LG8L29.6 MO/?7NC/7:_^FR(JDF.93911,-]3WF`Y$I]IL$NB2&A@&>&EC5FZ173BO"KZY9=NVB#(/3K.](PZ5GS`$PYPIF-P M%##&4@@E!"81IMH@\.0(G$$:=:8QKEH@\.TGE#>PP@13#X4S3:.K\RA70UF! M18RK%@@\N0=GI$:=(L95"P1SCTXH>6#%"CRG!SIC-;B*>8RK&$H,0H2K-@@\ MYQ0Z8S7J8(2K-@@\)PV&LH=6K-!SB&#H^X11'R@,)0:MQ""X=VN#/"<`ACY2 M:,4*?:TZ8S7N=A&UVU!BL(C9K0WZ?(AD=V-22_G!3(,BV;)S9X;/N]7;Q/F$ M9LSZ@%?EB1SH+\(/=2>2#9-J6#.3U9XQ2547^8/R_*AFXMM#0_=2WR[4/>^G MQ/Y!LM,X]-XF[^H_4$L#!!0````(`"R,:4<@\_K*L0$``!8$```9````>&PO M=V]R:W-H965TU# MI2@/[;,'+HMB^U+;#.G?UPM#($)YP?;E;!?;9`/J-],`6/(NA3*GI+&V.U)J MB@8D-W?8@7)O*M226[?4-36=!EX&DA24I>F!2MZJ),]"[47G&?96M`I>-#&] ME%S_.X/`X91LDEOAM:T;ZPLTS^C$*UL)RK2HB(;JE#QMCN>]1P3`[Q8&,YL3 MG_V"^.87/\M3DOH((*"P7H&[X0K/((07/"I@DIH>*]L*\X_("QA9"P0&'"DQ2]L2AOE(1(_A['5H5QB&\>TI&V M3F`C@7TBT&@48G[CEN>9QH'H^&D[[G=P`V_N*Y;9<@%K3L^8:\K1`LN1'KG4C3NDDX+`97UTWLWU_'>%6Q`0``%@0``!D```!X;"]W;W)K&UL?53+;J0P$/P5BP^(P_9` M`U;\(+89LG\?/Q@"$!)?FF'36]@>,3=6!H.9& M]2#=3J.TH-8M=8M-KX'6@20X)FGZ`PO*9%(6(?:DRT(-EC,)3QJ900BJ_Y^` MJ_&89,DU\,S:SOH`+@L\\VHF0!JF)-+0').[['#:>T0`_&4PFL4<>>]GI5[\ MXG=]3%)O`3A4UBM0-US@'CCW0B[QZZ3YD=(3E_.K^F.HUKD_4P/WBO]CM>V< MV31!-31TX/99C;]@*B$XK!0WX8NJP5@EKI0$"?H61R;#.,:=VW2B;1/(1""? M"#@F"C8?J*5EH=6(=#S:GOH;S`[$'42%3`CJ6+TS:EST4N9Y6N"+%YHP)&!. M2TPV([!3GU.0K103G2SH9)N>;]'SZ#!?TK-T6V"W);"+`KM5B=FZQ(@YK3%? MN-Q_DV2_$L@WDZPQNT])\.+B!.@VO$^#*C7(T`V+Z-P"=R1<_`>\+'K:PA^J M6R8-.BOKGD^XZT8I"\Y$>N-<=*Y)YP6'QOKI3S?7\=W&A57]M0OG7T'Y#E!+ M`P04````"``LC&E';6QM(Z0!``"Q`P``&0```'AL+W=O,"3R!$$/*)_\Z:7RD#<6U?U7_&;GWU9V;A28L_O'&]+S;#J(&6C<*] MZ^D%YA;V0;#6PL8OJD?KM+Q2,)+L,YUQ+<@E",X9&S&F-R1<$\>I+ M"KJ58J;3%9UNTXLM>I$J+-;TO-@6V&T)[)+`[J;%^]L6$^9TBWGXEH2L[E2" MZ>+J6%3K4<5%7467[7RD<29?\*H<6`>_F.FXLNBLG9]L'$.KM0-?1':WQZCW M[V=Q!+0NF`_>-FFEDN/T<'T@RRNM_@-02P,$%`````@`+(QI1Z%D6EZG`0`` ML0,``!D```!X;"]W;W)K&UL;5/;;IPP$/T5RQ\0 M@V';=,4B95-5[4.E*`_MLQ<&L.(+MP)#\Z-1T)L,X!D]D&/H/R?3AO)G#^:GMC1`&LC20I"L^P3D8PK7%;8=1"QR;A7O7\'982#D&PT<+&+VHFZ[2\43"2 M[#VM7,5U3G\*NM#V"70AT)7PF$7C*5&T^94Y5E=&S\BDJQU9Z&!^I/XB&F1C MT*3JO5'KH]>Z*!XK<@U""X9&S'F+R5<$\>IK"KJ78J'3#9WNTXL]>I$<%EMZ M?M@7*/<$RB10WI7XY;[$A#G?8KP] MD/65UO\`4$L#!!0````(`"R,:4?M<0`MI0$``+$#```9````>&PO=V]R:W-H M965T&<,V<\XVK6YMT.``Y]2*'L$0_.C0=";#.`9/9! MCZ#\GTX;R9P_FI[8T0!K(TD*0K/L"Y&,*UQ7,?9JZDI/3G`%KP;924IF_IU` MZ/F(Q1\'[6^CT< M?K9'G`4+(*!Q08'YY0(O($00\HG_+IJWE(&XW5_5O\=JO?LSL_"BQ1_>NL&; MS3!JH6.3<&]Z_@%+"8]!L-'"QB]J)NNTO%(PDNPCK5S%=4Y_RG*A[1/H0J`K MX2F+QE.B:/,;A>BH5.-W2Z3R_VZ$5R6&SI^=.^0+DG4":!\JY$>E]BPISN M,<6G)&1SIQ),'T?'HD9/*@[J)KI.YS.-/;G!ZVID/?QBIN?*HK-VOK.Q#9W6 M#KR)[.$1H\&_G_4@H'-A^]7O31JI='!ZO#Z0]976_P%02P,$%`````@`+(QI M1VXV7HVR`0``%@0``!D```!X;"]W;W)K&UL?53+ M;IPP%/T5BP^(&0-)-&*0,JFJ=E$IRJ)=>^`"5OR@MAG2OZ\?#(&(=H/MRWE= M;%-.2K^9'L"B=\&E.26]M<,18U/W(*BY4P-(]Z956E#KEKK#9M!`FT`2'),T MO<>",IE49:B]Z*I4H^5,PHM&9A2"ZC]GX&HZ)8?D5GAE76]]`5R%G M_'O6_+#TQ/7\IOXU=.O27ZB!9\5_L<;V+FR:H`9:.G+[JJ9O,+<0$M:*F_!$ M]6BL$C=*@@1]CR.389SBFR*;:?L$,A/(0GA,0_!H%&)^H996I583TO'3#M3O MX.%(W(>HD0E%';MW08VK7JLLSTM\]4(SA@3,>8TY+`CLU!<+LF9^WZ3XCTFQ$7C8-=EB'C^9X-7& M"=!=.)\&U6J4X3:LJLL5>")AXS_@53G0#GY0W3%IT$59=WS"7K=*67`ATCN7 MHG>7=%EP:*V?/KBYCN&UL?53;;IPP$/T5 MBP^(6<.VZ8I%RJ:*VH=*41[:9R\,8,5FB&V6]._K"TO8BO8%V^-SSIRQ/103 MZE?3`5CRKF1OCDEG[7"@U%0=*&[N<(#>[32H%;=NJ5MJ!@V\#B0E*4O33U1Q MT2=E$6+/NBQPM%+T\*R)&97B^O<))$['9)=<`R^B[:P/T+*@"Z\6"GHCL"<: MFF/RL#N<]AX1`#\%3&8U)][[&?'5+[[7QR3U%D!"9;T"=\,%'D%*+^02O\V: M'RD]<3V_JC^%:IW[,S?PB/*7J&WGS*8)J:'AH[0O.'V#N83@L$)IPI=4H[&H MKI2$*/X>1]&'<8H[^?U,VR:PF<`6PGT:C,=$P>97;GE9:)R(CD<[<'^#NP-S M!U$1$X(Z5N^,&A>]E%G^I:`7+S1C6,"8?Q2Y_T^2_8T`VTQRB\G^2D)7%Z=` MM^%]&E+AV(=N6$67%GA@X>(_X&4Q\!9^<-V*WI`S6O=\PETWB!:A< MDRX+"8WUT\]NKN.[C0N+P[4+EU]!^0=02P,$%`````@`+(QI1T,$2].E`0`` ML0,``!D```!X;"]W;W)K&UL;5/+;J0P$/P5RQ\0 M\\Q&(P8IDU64/:P4Y;![]D`#5OQ@;3-D_SY^,(2)N&"[J:JN=K>K6>EW,P!8 M]"&X-$<\6#L>"#'-`(*:.S6"='\ZI06U[JA[8D8-M`TDP4F6)/=$4"9Q7878 MJZXK-5G.)+QJ9"8AJ/Y_`J[F(T[Q-?#&^L'Z`*DKLO):)D`:IB32T!WQ8WHX M%1X1`'\8S&:S1][[6:EW?_C5'G'B+0"'QGH%ZI8+/`'G7L@E_K=H?J7TQ.W^ MJOXKY'SZ/#?$O/ MDWV!8D^@B`+%38GE;8D1<[K%W']+0C9W*D#W870,:M0DPZ!NHNMT/F:A)U_P MNAII#[^I[IDTZ*RLZVQH0Z>4!6QY&*!ZO&ZP-9 M7VG]"5!+`P04````"``LC&E'#E"_HK8!```6!```&0```'AL+W=OP*! MXS'9)-?`*V\[ZP.T+.C,J[D$93@JHJ$Y)H^;PVGG$0'PF\-H%G/BO9\1W_SB M9WU,4F\!!%36*S`W7.`)A/!"+O'[I/F9TA.7\ZOZ3W&*^GB1=7)P$W8;W:4B%@PK=L(C.+?"8A8O_A)=% MSUKXQ73+E2%GM.[YA+MN$"TX$^F=<]&Y)IT7`AKKIWLWU_'=QH7%_MJ%\Z^@ M_`=02P,$%`````@`+(QI1PH-=K"F`0``L0,``!D```!X;"]W;W)K&UL;5/;;IPP$/T5RQ\0LX9LVA6+E$U4M0^5HCRTSUX8P(HO MQ#9+^O?UA25LQ`NVAW/.G/&,RTF;-]L#./0AA;)'W#LW'`BQ=0^2V3L]@/)_ M6FTD<_YH.F('`ZR))"D(S;(]D8PK7)4Q]F*J4H].<`4O!ME12F;^G4#HZ8AW M^!IXY5WO0H!4)5EX#9>@+-<*&6B/^'%W.!4!$0%_.$QVM4?!^UGKMW#XU1QQ M%BR`@-H%!>:7"SR!$$'()WZ?-3]3!N)Z?U7_$:OU[L_,PI,6?WGC>F\VPZB! MEHW"O>KI)\PEW`?!6@L;OZ@>K=/R2L%(LH^T M1'9WCU'OW\]R$-"ZL'WP>Y-&*AV<'JX/9'FEU7]02P,$%`````@`+(QI1RGK M1F*P`0``%@0``!D```!X;"]W;W)K&UL?53+;J,P M%/T5BP^HB1/23D20FHZJ=C%2U45G[<`%K/I!;1,Z?U\_"(4*S0;;E_.ZV"8? ME'XW+8!%GX)+!5H$D."9INL>" M,ID4>:B]Z")7O>5,PHM&IA>"ZG\GX&HX)IOD6GAE36M]`19PRCPB`-X8#&8V1S[[6:EWOWBNCDGJ(P"'TGH%ZH8+/`#G7L@9?XR: MWY:>.)]?U1]#MR[]F1IX4/POJVSKPJ8)JJ"F/;>O:GB"L860L%3V.5 MN%(2).AG')D,XQ#?W*4C;9U`1@+Y0<#1*,3\32TML"NS6!7138+5K<+UN,F-,2<[MNDOW')%L(W*V:+#&_?IC@V<8)T$TX MGP:5JI?A-LRJTQ6X)V'CO^%%WM$&_E#=,&G065EW?,)>UTI9<"'2&Y>B=9=T M6G"HK9_>NKF.YS8NK.JNMW#Z%11?4$L#!!0````(`"R,:4&PO=V]R:W-H965T]2]'H?=<8,.TIUW8%D^@$'Z.V;%I5DQJ;J1/6@@#6^20J:QO&62L;[J"I] M[5E5)9Z-X#T\*Z+/4C+UYP`"QWV41-?""S]UQA5H5=*YK^$2>LVQ)PK:??0U MV1T*A_"`7QQ&?1,3Y_V(^.J2'\T^BIT%$%`;Q\#L&WB?.?I&N\ MC:_LW_RTUOV1:7A$\9LWIK-FXX@TT+*S,"\X?H=IA(TCK%%H_R3U61N4UY:( M2/8>5M[[=0QOOL13VWI#.C6D^-!R-M\8H95I<*1J+"U`W-?,-FE=B-J MHGU1A>FM46VKERHKXI)>'-&$23WF<(M)9P2U[+-$NB:1!XET(9&L$V1K!%D@ MR!8$_W&0WW&0+PBRY9`!&ULC5C;DMHX$/T5%^^)=;-D40Q580!G'[8JE8?= M9P^(2\7&Q/8,V;]?7V1&;23AEV$PI[M/MUJG92UN1?FK.BE5!W_R[%*]S$YU M?9V'8;4[J3RMOA97=6E^.11EGM;-U_(85M=2I?O.*,]"@A`/\_1\F2T7W;,? MY7)1O-?9^:)^E$'UGN=I^=]*9<7M989GPX.?Y^.I;A^$RT5XM]N?'>E59 MUGIJ(O_63C]CMH;F_X/W;9=N0_\MK=1KD?U[WM>GABV:!7MU2-^S^F=Q^ZYT M#E'K<%=D5?"Z:U=\%5?>P[)>\69VJ>?JQI$(LPH_6D<:0#K,R,2*V038F!-\184/@ MSH+86.@(!+"PAGB%&&G#K`$F1E:J$(-MF.T$/PG$$'O2U)8T[4M/@0-J=\!L M#ECO@`$'#+(4?65[S*7#\$APA)`-MYF(2TP`>(1#-1C-A## M[4&X)P@'#H2U.MS(1E(@V0!&/YB!SJ:"(Q)1BYG&X!E*&8N@4. M^V87!L-+.N0)6Z>(GI\8C@B7"]^,P&!(N#:?J>F4D\>M-ZS_1&`"@*3==#2P0;>8P-BYE38`1QE[/"D,G0(C"T^C^*80-L<0X8X!@:T3 M8F@4.:51B$^D"0*-8I\RQ%1)P6T-H#?<9&0"D)BS&,HYS,"GO`0J;^1P815! M74=")M71IW`$''HEASDS74<($C;09@HH&8%B!V.?4!$H5-+APB=49))0$9]0 M$3ZE_\#ADS(1.?MO*C(!2('A$0'R]TD5,:5JK+,#?5,P"$/,)54`^"5BL7.P M`20G3O7;0I>-3DJW)A.?7!%3KIC3A4^NR"2YHCZYHNCY-DL`B"''@87Z1(5B MX(+8%N&5FH>O&#>1G*6EOC,8)2"8JR[>5^Y)[]S4IP>4/=^)"35?DYNNDV[1 MIKX791H]W39KC=&M2XBP=+D^QH^@(N;N8SSUR1'E8"F8PX55$8:E$).6PK?7 M*-QK]GN$$5+J_?\G4H6[_%:T\]Q?(_9>ZN`[WX?=+ M^>7_4$L#!!0````(`"R,:4=8_TS9EP,``(4/```9````>&PO=V]R:W-H965T MPM)2`B.YTP5F?:A,YT^M,^<1F4. MB`4\K]^^"40ON6[0%Y7XV\U_=V&7+"ZR?>F.0O3!6UTUW=/LV/>G>1AVVZ.H MB^ZS/(E&_;.7;5WTZK(]A-VI%<5N,*JK$$<1"^NB;&;+Q;#VHUTNY+FORD;\ M:(/N7-=%^W%G>3CV>B%<+L*;W:ZL1=.5L@E:L7^:?4'S''&- M#,2O4EPZZW>@Q3]+^:(OONV>9I'6("JQ[;6+0GV]BK6H*NU)[?S'.'W?4QO: MOZ_>\R%<)?^YZ,1:5K_+77]4:J-9L!/[XESU/^7EJS`Q4.UP*ZMN^`RVYZZ7 M]=5D%M3%V_A=-L/W9?R'1\8,-L#&`-\,;OO`!L08D'>#>-(@-@;QHSM08T`? MW8$9`_;!(!R3-:0Z*_IBN6CE)6C'^^-4Z-L0S9DJYC;HAL5VK*!*=J=67Y=Q ME"["5^W(,'A@5C:3<`C);`3=B%`)N*G`D`JS`[;,,;3!VB824&9VU\GFOI/< M<4+A2`@4"1GS2>Q\H@AV$$,.XM%![#A`KLAD3-?(-`/#$.8$HM8V11B.8XC* M;$HQ-&$0MK&Q%'&2PI'1B*>>I-]M0`0?8$X9YD.[.!@-#:@3@! MP\\<"!&>0M3&I1)*/'%-C0]$G6J`=5\9:-PHB;`G,NK(B2C<-%T,Q1$&G[.- MPZGNRGPW&SCKA7B#NU M2S#X/K9V,101!K^W?>!4[5@"@1L7)/C_KA):1X9:M(?A=-<%6WEN>OWR9:W> M3I!?L#YR?%A?H?D:`>L9FF_&\^&[^^7B5!S$]Z(]E$T7/,M>'72&4\E>REXH MX=%G5:*C.A/?+BJQ[_7/1-=N/"6.%[T\70^]MY/W\A]02P,$%`````@`+(QI M1[N9$][]`0``<@4``!D```!X;"]W;W)K&UL?51+ M;Z,P$/XK%O!%(7A@CXM\.*)^V41I=`Z_]N5,F$#=UO.". M/8-!]GQ``D[;Z#G=["N381/^]#!);X^,]P/G;^;PZ[B-$F,!*+3*,!"]?,`> M*#5$6OA]YKQ)&J"_O[+_L-5J]P3I)M.=:Y&T0>':I2N3.OK1Y&E9QQ^&:,[!-F?GYZ1+ M1JS9%PDSZB>P@I92"%S162K(JHP01XBR!U!OB)X7)NL7!DN M9[`Y15F$18H[(L5*Y&DM4CB1PA-)BQ*'G.S]I"H/&RGO&"E](S@)&BD]C6]I MBL,JU1V5:J62!GM:>2HX2;\V-?;^90;B;.^X1"V_#,K\/%YT&2//V-R%+_&= M'B]N&MQHFGHD9_A-Q+D?)#IPI6^:O18GSA5H=\F#[D6G!^!RH'!29EN9)KF9 MX`Z*C]<)MXS9YC]02P,$%`````@`+(QI1_K/XWOK`@``)`X``!D```!X;"]W M;W)K&ULC5?;CILP$/T5Q`)V)]I0\03N]!6W3DRWA"I+ODI$1=.R:$+:NH$TG2>-*1JX[+HUEYY6;"K MK*N6OO)(7)N&\#];6K/[)L[B<>&M.IVE7DC*(IGB#E5#6U&Q-N+TN(F?L_46 MEQK2(7Y6]"X>SB-=_(ZQ=WWQ_;")4UT#K>E>:@JB#C?Z0NM:,ZG,OP?2SYPZ M\/%\9/_:R57E[XB@+ZS^51WD656;QM&!'LFUEF_L_HT.&F::<,]JT?U&^ZN0 MK!E#XJ@A'_VQ:KOCO;^S3(

P`,`3`%]'F2/E%7YA%Y7R$:%:*=(+<18$^0&P2YG6#FJ6!F$,S,9]1CMB9F;D\R]R29&P0+.\'" M(W,1(G/IJ6`9(-/$+.U)5IXD*X-@92?0;G+JU#?_+S2SOO1#$5D6(-4$8>K( M8WWSQSQ@4#B\DUG?_E$M!JFUOO]C%7F(VCQ(K<\FF>$!=%@]LYI@5#L/4FNU MP5C%(D3M(DBMSRV9805T?)TR2*VO,<`J1*T!0D?[0)]CT#!#[C`#6LTPJ,4L1"WZ.@-" M@%H3E#O:!WJ')\,,N6O\\HU/�_H:\S8,@$98*<_ZW/,6B8(7=\D]$W16'0 M&(6^SH`A@Y0)RO_-DSQ,\0WEIVZS(J(]N[;=WNAA==H0/4.W"_B$E\6%G.@/ MPD]5*Z(=DVHOT0W^1\8D556D3^J9G]66;;JHZ5'JTX4ZY_TFIK^0[#+NR::- M8?D74$L#!!0````(`"R,:4<:2#N3WP8``.&PO=V]R:W-H965T M=V+=92JD:@*$2YBJJ7G8??:`@=0D M,6L;F/W[M6,[J#/=;?$`Q)Q6JZ4^IUO"\X^B_%6]Y'D]^;W;[JOSZ4M=OY[- M9M7#2[[+JB_%:[YO_O)4E+NL;CZ6S[/JM*NWFWW^O9Q4;[M=5OZWS+?%Q_E43(<'/S;/+W7[8+:8SXYVCYM=OJ\V MQ7Y2YD_GTZ_B[-[K%G)`_+W)/ZK@]TD[^9]%\:O]3;_*%NA\B: M'^_Y1;[=MB,UGO_M!_WTV1J&OP^CKP[A-M/_F57Y1;']9_-8OS2S3::3Q_PI M>]O6/XJ/F[R/P;0#/A3;ZO!]\O!6U<5N,)E.=MGO[N=F?_CYT?W%)[T9;B![ M`WDTD(XU4+V!.AH(S1KHWD#'>C"]@8DUL+V!/1HHSQJXWL!]&@C6P/<&_G-* MO$':&Z2Q!NV>=SN71)L<-UM$FPS;+>2)R:Q+K$-:7F9UMIB7Q<>D[+CTFK64 M%6>-53/XI#H\+;MT;S*S:IZ^+[0V\]E[.U*/D0?,$F(LAKD),/?IQ@2>C%+6$5.Z#8%2B/1/H.F" M#(%"29%0R'6(U(EO=I>*TG)16K#R%@W3!J[^4FDB4V)2MP!IE+>26)$[B-1. M4&.N`5(DRF@Z5,>%ZD":2GP$SR6ZCTGTE)M#"I;[1-0ZS!)B/(:YB<#<41@P MV[9ZT=-M_QJ,D6(;M.Q!0]*:5&EB:01>FP9GH/!8-&^6/:ASEB8B3Y5J.BY< M4@9W'KA+B3%P4>EE2:0QNB19IDO`=(?7.PF8;K6FU)T%PEFQDB`%B(S0,(D3 MO5\=*:-6A^6O5..Z?7D"HB;+\E?J<<&]E"%_7>*\H8)B^2O-N-Y>2L#?I/LB MO+$$EG:<5YUHTN'8EFI?$R2^E!O!'VP4"PQ53JN`!5I>-5M[-6"O()13X^P=8M91,;/$U&9<`58G M(&J3659J.ZX`*QVR4C0%17G*&4M*[<8E8*5#4EIE)7VEHEE2:C\N`2L=DE(( M:[2DW;&\U.EXFJY[4*\X@NXX#$M-`X_*Z&EH9<*^>.1NBBW!!I9@A2ZD"4LP MD?.&Y;D)>7YZ"6;Z2["0YL)+KZC;(8#T)OGSQUIHNXC#2N1AI7(X?HZE$CE*-ZN`7SX?WQ*K)0_&VK]LQ@J?'=]&^RO:%G)/G2W%V+9#G-^+L%GM^)\[6W8L] MGVX7\]?L.?^6E<^;?37Y6=1UL3N\RO-4%'7>1)-\:6CZDF>/QP_;_*EN?VWY M6W;OH74?ZN)U>*WN^&[?XG]02P,$%`````@`+(QI1Y_+.*NI`P``'A$``!D` M``!X;"]W;W)K&ULC9A;=Z>S#[C/5J$R!N("U^^^72Z!))XGTH4`X]Y,O(2YNO'ROSHS5SF>> M%=5R=J[KR]QUJ_V9Y4GUP"^L:-X<>9DG=?-8GMSJ4K+DT"GEF8N>%[AYDA:S MU:(;>RU7"WZML[1@KZ537?,\*?\]L8S?EC.8#0._TM.Y;@?/OPX+&=>&P/+V+YN323-Y8.M M69:UEAK/?X71+Y^MHGP_6-]VZ3;AOR456_/L3WJHSTVTWLPYL&-RS>I?_+9C M(HQDGA09&NAD7F09&"7< M)H(Q#-2%(5R@I(XZ!VM4`HUU,AM%)O9T,L^J#.ADMJJ,-IZ7NQ'O9(DPUM>$ MZ&I"^M8029]X1&^`Z@S0W@"5T_!]-3FHG2Z$'X.N#\2W! M^$HVJ#<06,H13"E':(D@E,L1:!-]"J5$8P]B0]LBBYM(F3Q$=>/W;B+)C1]` M;*AG;'$3*]E$VFQBN;DT(#'5^VG7>*.C]J54^,A@0KO(B-8!3.D=:!>((0J\ MW[VU$!()>\V?P9,6N\$3N=_`M1`J1$8Q,>5DXQ/H_1ZN06:/6CS9X`.%/C`L MT&###R;Q!S8`80*!&Y`1)!@2`X)@8Q`F0+@!F4(2A\1`(=@PA`D<;D`&,40: M&CA$&X>H<`@F$S8.<1*':.,0)W#XC#*'`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`:-,^0*F=`%[N8#) M[^#F)L-E5B]-WLY-R/OH?:G9SZR9(N52^6XLN!O+YL.7+^#`?+B:^?#@#GQ^ M!_[FX;O+A/ALI"9$5:X20)7`QAF*54(^G]D:8T4B*!)9D5@L$K,BP22A2@)5 M4C[CKE@DL9%0N<:)C<4BIU]F8TG%,D.CH0YE(^:%BBPS%LH1Z53Y^0^-+H62 MC\X*E8K('2MI5HG*E30#5;)!6-*$,$X,Y+YC$*B4G+%F#D&S4I$8UA@E\%(R$03@V-$GJ MC:&J,@C#1D^2>F-R;8]DI5F#[MU,H9*0M%J(%PR1>"01FBI`?&-W$&D8W M",LF(48?QYMC66`,BW!L506A6U51!<'84@6?6ZJH@E!L=06=6UU1!6'8F@HV MMSF&=9#(W,+-M:T@V%A5!U&`K3#FC67;]21MHQUB`3?MRQN7D\`G4`@1@8.^?*Q4 M000.$8'CEEP04(\F2>P1B7V')?94E]PC" MOL*2^RI+[A&&?84E]\R21^GPPR,Y]S66W.=RGK025K9'=.!K++GG/ M&,%76'+/",%8Z0#1P\-W:,F'0P=?:6_#+> MUC,LD_BZ`4$YJ&FR;4..92,=/`6$Y9!CN?PVH`W$QB-405`.%;Z\#3F6180% M!.50XEH0P[D0%':Q`<$Y.`G MI:,-GHU'FC;X&HV)>]&IM"'7=J^%$]F`Q#VP-VD">)BV2Q8Q(#8(C`V$59V3 M09"L2D1<$',N*`MA&W,J\"250500N3,OZF`;)WR)B@\B5O;BI:6-.!T';(*SLB!@A">1C%=N=E MX(R-ID<%`S&*"WE9]L96\#F1@G$8Q=A`#(>H(M;->)$<[*+ND8))%L5/RLL4 M.[::V@&2@G$657'@UHZM)C:!I&"D1>6@%D1P;(3W@:1@I$5Q32_3Q]AJ8BM( M"F9:%(>W]*AR?(/=(.&X&\^["?AF>3=I0T@3<3>N\0*^6>`-[`D))]Y8Y$W0 M1V*1-W%;2#CPQA-O99$D'GF3TJ:$(V\\\R:`BH?>G/BH(%?PV)NPU%GN3=P? M$@Z^L>2;()?$HF_B%I%P]HV'WP3-)!9_TTI>ZI`K;O)O$JARKO`I2L%;P@DX M%H&39)-%X+27WF\0C,"1YF:@>&C:$DO!@>TBP1@4$GC@KR!0_-26N=!^/%/RW* M4K,@EK3S5AP5!#K+VI659D$L:^>EA06C=L2S=D6A61`+VSF)NF#4CES%&[T% ML;!=\!+YP[P=N8IW>HNQU2@THGR6@WG76M-O]19CH^L1DKC488*/6(1/X*T% ML0R?/CK86]J:9W\Z_;[\VO]ON?NZ>MO/OFP/A^WFX?0GTR_;[:$_7DW]\O>OZ9W-1J@U^E475O&XN;7M]"J0GO@G5_?&^1YTP;]K M_;-[^79\W:`N!E6H0]NYR,SC0R6J*#I/9N;_K-//.3M#]_OH_<]>K@G_/6M4 MHHM_\V-[,=&B37!4I^Q6M#_T_2]E-?#.X4$73?\9'&Y-J\O19!.4V:_AF5?] M\S[\(I$U@PV(-2"3P30/;$"M`?TT8*L&S!JP9V?@UH#/9@@'[7WF]EF;[;:U MO@?UL-S7K-M5^(6;M3D$33]8#PMB8T8\=QW0;?G2.+$-ZYLUE(@DA>Q?! M$Q&:`*8H"!2%G8$XY@2:('&)*`9C>.@D77#BA4FA,.F0+.HEB\$.&.2`#0Z8 MFR:$_""C(1<#4_7,'S2..8&PQ,,XE0+$]C,LGB_Q@*4>AA'EA,/J^(HZ[JF; MQ<,'==Q7AT@,80E_H&[`]C[&(@QZ2_E<'9.P.K&B3GCJ**A..!-)+$!I+H,Q MC4!A+D1BAD!9'B3CA16+5C1%WH9><"!7*D(^4Q'Q2@2QXT"",M]B1R:G$6=@ M6EV*8$Y`:N]2F%(DX,RZ&,,1(["PKA$M*NM^7"YVJ\U"=FLR&L_/-JO.Y[B, M([@@?$X((<%-F/HXY'#L>Y\3@BY4 MO<]A+-Q%\#6"O6G42)XH?`NM5[X'+9:^1RW6OD\M%C\&V]FHC'K*9A5CVY&% MQM4CA&%8G,?QB+$8\K?W.4$IO.-3GS/9(FA)XUK'Q,PEV#W.*>8(W!ZIATG3&!?^Q^"U=R'E+H7"1*59_[*UP3'/2M:KO:<$:G:^)7TEU$ M9N-O^"7!P/C>7"N'2^"G^]WVFIW5WUE]SJLF>->MN?[T=Y63UJTR@:,O)J,7 M<_&=7@IU:KNO49?JX2HXO+3Z.MYLI^OU[G]02P,$%`````@`+(QI1W!T0`G) M`P``]1(``!D```!X;"]W;W)K&ULC5C+DILZ$/T5 MROL$U"U>4QY7Q79)6I;*X63.V;%,!Y``>)W\?'L*#'*E'LQB#.-U':O7I M!BUOLO[9G(5HO=]E437/BW/;7IY\O]F?19DU'^5%5-V3HZS+K.UNZY/?7&J1 M'0:CLO`A""*_S/)JL5H.8]_JU5)>VR*OQ+?::ZYEF=5_UJ*0M^<%6TP#W_/3 MN>T'_-72O]L=\E)432XKKQ;'Y\4G]K3CV$,&Q/^YN#6S:Z^?_(N4/_N;KX?G M1=#/011BW_8NLN[G56Q$4?2>.N9?RND;9V\XOYZ\[X;E=M-_R1JQD<6/_-"> MN]D&"^\@CMFU:+_+VQ>AUA#V#O>R:(;_WO[:M+*<3!9>F?T>?_-J^+V-3V)4 M9F8#4`9P-P!&&J`R0%<#K@RXJT&H#,*[`=(&D3*('AC\,5A#J+=9FZV6M;QY M]9@?EZQ/0_84=9NY]YIAL!YWL`MVTXV^KD(6+_W7WI'"P(!9SS&<1W>,W_F_ MDX")1#D`C20QD6QT3&K";#4,!";,9QW#3)B=C@'S@M"T(!RCAIH#-#O@)@=\ M=,`U!UR?93RN9,14`P;C-.C^3+B=A@/0<-J$0F)"H3:AT.P@(D(2N80D)F80 M:PXB?:DC9JUC8C-)0I`DFH/$%,]U,HLGA$%@#VA*,*4:4VK MAY1JT*'7;7&N&K+[(*4=C!SJ`$;O*Q2I'H>Q0QU0()J%4B!J"L34XL*HK"E+ M4I"X MID'.3"M>\WF#L[Q7^;-/]U+4I^&4I?'V\EJU_;?K;/1^DO,)^D__A_$U>]J. M1P)O;E;+2W82_V7U*:\:[T6VK2R'4X"CE*WHIAA\[#+V+++#_:80Q[:_C/M4 M'D]EQIM67J9#IOM)U^HO4$L#!!0````(`"R,:4?S#5^^=P<``)(O```9```` M>&PO=V]R:W-H965T[D?@]KW=?S^\ M-$TW^[G=[`YW-R]=]_IQ/C\\O#3;U>%#^]KL^O\\M?OMJNL_[I_GA]=]LWH\ M-MINYK:J8+Y=K7-ZV^P.ZW8WVS=/=S>?S,>EJ:I!#\7?LV'T MW]KV^_#AC\>[FVH81+-I'KJACU7_ZT>S:#:;H:O^U/^,O?XZZ="P_'OJ_;?C M?/OQ?UL=FD6[^7O]V+WTPZUN9H_-T^IMTWUMWW]OQDF$H<.'=G,X_IP]O!VZ M=CLUN9EM5S]/O]>[X^_WTW]2-3:C&]BQ@3TW.)^';N#&!NY7`R\V\&,#KSU# M&!N$BS/,3W,_.E>ONM7][;Y]G^U/W_?K:KBLS,?0?S'?JC M/^Z#M[?S'T-'H\8>-9]+34R4I"XEYJR8]P,XC\)2HQC/8(OFY!@6I2)F<@Q7 M.UDRG:!A.FJ8[F260V8YN@-/=>!/'7C4@<>#C"-\M$"I%J7*6`BD MJBY5`)`K2K5$9[0V1'IB09A8*";FJXKN``1K06-M%$80)6O#R=I83-1#,)1H M@425(7NJ2Y%QL;*4:HE4IG*!GE82II6*:;G,=)`%8[/&V"%1V2$,_[QJ[2@Z MS378JB*]12H+M+>XJ^0#Z2U2]5^!969&AM\T,YQ^C+N&3*[17F-5_I*I,HW" M:?QUY:UL/.-OJ3(>'&TP4E769-KA4N9-Y9FY28%G<.(!TP49+9/#0>4P&2[3 M*$#C,"!7@$X'I/(VT08#NLR!N8+1"7W%/)",E'H&Q9Y+3!=DPDS^)I6_9,9, MH\@:?S-*PTQ>FPND`HBTOZ7()D=^"TNL,H&9F96RSZ+LXP+G)>WJ!1,G0^8!$)@7Z\L6J`%S9)T6?1=%G.7O)A)GL]2I[ MI>+%!HV]H:R2DJ$#&*FL`5)5(U7.$6B#T1DS]_"W4O)9G'Q,96?)B)D,CBJ# MI2+&)HW!"24K65'52)0MDW=6"BN+PXKIPI&I,'%`I;'$2:6',PI+1M'Y1J33 M$*ELR,Q#UDD)XW#"<&PDPI&*CIQ4+3B1CR932ES)R=//$:2RR3/6(8R""N@[ MT6&.XBX[)X6,0R$3&$1R$B,Y%20YJ5YP&DQR);?8*F3R7EQ@F;^$R\EBI(KN MDF`TN^9)>@$:CS*/H"]Q5)J.15J.2EZL-K4,DC"&(NWNN:&FGZ(*>]Y43XY9\4>0%% M7N"ZD"@IJ"@I2#5,T%!2**F%KN&O2^KKDB4CP=.1@BZ@H`M,51`LHWM@WW1(/!14/!:E0"1H>"B7J@*5+!(VH M1B*3(IT#6&6Y"C5(Z190N@6F3@:)K4#%5B`5*J!A*S!XNJ1S2.0B$VP@I1*@ M5`I,70L268&*K$`J+D!#5H!H*&2:F9#*.L<$$TBI`BA5@%LO$A>,5#`$4D4` M&AB"$DSZRHY^+8Q4GF;2&HFR]S0)P<7:$CJBK2O`52.1?IQS12&1.!+MF1+)N*FYN46A&E%G!=2$@454@4I9HA M:I`H`O*.?F."1;2[")HJ>F4#B4+B+EYQN1QE'S`T%"4:BBH:BE*]$#4T%-'" MD3/D8VF!5>RZ?:GR@5ZF7B*5C=Q#.TGAEU#X`;?T+S%14C%1DJJ/I&&B5*)* M9A;FD,@Q"QM(9#VM6B*5L=S"(6/I&(7?C$*G;A,TFAEU#H`0-*20*EI`*E).Y^T8!2*L&%6_A$(F[A,V%0 M8A8^L8JMKI(4?`D%'U=^9`F4L@J4LE3!9`TH9<1`O2NDOTAERI7RTF"D2GU* MDP8CE8W-JP(#T;*EXSR)3)W& M3JKI3>WEIL-Q9^B%S%=D;S66`5AZ;RB6!?N_E[OS8K_QMMD_'W=Z'V8/[=NN M&TPJCIZWDW^RPW[EB^.?S<>%(8[7P_;SX_[F7]W?W[ZNGIL_5_OG]>XP^]9V M7;L];FE^:MNNZ<==?>@ODI=F]7C^L&F>NN'/`0CVIQWCIP]=^SKM@#]OP[__ M#U!+`P04````"``LC&E'ZMJ'SM[G/\^VJ?]\H.;AQ_WJ\T/#HX/ M#[IV=P]/L^?EP_QY;S'[?K3_+WIS2\EO,%O(OQ]FOY>]?^]M9O]U/O][\Y\/ M=T?[S682L\?9M]6FC^GZKU^SD]GCXZ:K]=#_;7O],^BF8?_?I??SK;WK^7^= M+FG_-$T<\MU\_!>J-WN]U4=[O=[78#%KEZ#[;:@]OU8/OS'+@H[D)A!WG> M0B@&XUW3-#7D.2#)FB8SR&MUGQ,9"88ZR5#77^S!4'YGJ.L-93QY^VI..^!Y M'TANO=T8X+6VQXD(!".]9*3O>]-6C?2]D;PS@?-E'T!#`Q>';N?6`(8;.KJSW>PM#&^,A:&24K(UB9ZCTD MB1B2AABR-(<\'B^YORS&OUZ5UB%*W$3"P<0WE2(_\\UOV2AH.:W%M)Z*_-RU MP(D(Q-G7"Y@R>\Q2OC;]LQ;41E/3"(/5\T<9#!-(J%EVUH)V@SGBJ8G$3$,6 MQHIUP^QKP[C11+HG!Z,-"A37CH:@S`PD4BYY!241L&E"7NAG.P`:GWF:))$G M"8@RYZ5T(\WJ&C%\C5'L/0/A&SR7R6\0V!!;D@&0;&RX^N<6D=18 MS[K6B.1A@#RR8?JH4T)9<:=:<3':C1^GE:L!B*$5(P:PP0"V]8$0Q%DDUAH& MHCS[^D!1%30B%1B@@AR8/NH17ER8-2ZT8O#:9MR%)P,0XT(K9G)+XRM[@B!N M9:U(`Q9H('-]U`.L75EK52LKYERKR+F75I5SK1B%UH\'Q^4`Q%315HQ"&\9= M>#D`<1:)46C[`1:&;%H&0A`Q`XE1:!/T8>H#(<@R`XG)V&;HP]4'0I"O#^3$ M>'8-]!&J`PU`3(@X,9X=01_,AG+BA8U3W=@X,1KZA;0Q;-IU M\J4)!FNU9C]UU7KQ(!2"[P5UH`;`R]O@QLJT1`.FKX&SXO,H'' M(,^U%7V+(.(&$IG``Q/0X*"1VX'Z9_3FKX;9)%Y,[=[`2%6ZOAB`&+KV(JEX M"WVX6J1?>"`5\=[!B[SB'8Q6S:L7`Q!3,'KY0M1#'[$^$((88OQ6K>)%5O(95/')`8,^>`'0FL;?(?9P)P7.<@B,[?(G` M^V:14T*?+FQD:JX@'O6#ZJ@?1"((&.-5;ON"(,,9+!)!@.K",L$0Q)-V4)VT M@QBY05$/?`RJ>B#(3PJJ-P5X*Z#,9;V;@&\%KR_ZRI-"'V>2Y7;\+0*EEZ$@ MGC`"D(MERIX@OBH$U;-"$'DCY'&_?AB`&+]&,7)CH_!K[-_:>\>5*#>`2\06 M/8"CY%E^0J!'9D0KQ5(DXOT!X]8H'DJBZE`21=J(=MRM[P8@SJUBZ1"=QJW] M(XE-Q%:S`#04V.<=`.8^4\2/`I*SRA)+#62&??XR0#$>#R)G)&`#CPW6;'42*I2(XFAED`V M41?!)'C!\[D)G+;E'*%--&PY>ZWIM=W1(U`T5RQXDJ;@25!V-#YSH7:#2%<1 M1Q0+`!@MJQ6Y!61(2;!4Y*X$M.2Y32HK*50U3Q)I)&5A@[5BBI0A>BF\?GXK MKM$B)S(2M2!B+94UM53&DB:SM2\`C;7\(W<663'#-8QA'@6S6/MD5>V311[+ MP&..:JQPEE$<)UZ>9+$"RD!YGDE*N4YYQ6RO,EODD:SAD0RA[+AZ^&:`8[NQ%!R2X7:$#%O.GB/2\@?: M:W6?$QDY$'"-*+C@DM9PTI-&O';9_GI\V:F1)5*-&8_NJX(J.E4G2/^HD752 M#5S%&E];[*N":L\9P89LF$M':F2E5`/WK'PO(J%L?ZU9;%FVU(3QQ;XHJ'+* MWI(`N]AB=&]_/;;8%P6E6FQ9#]7`TRKWWD^-*(/8_EJQV",Z21*S>MG9(&RD M7>;BQAM1-F*^9JX6B9$L%MM)E;%I1(P(:L1ZS7]%H$:D8!V?1&A$CD@89)S4 MD-$:=K;K@FQ$&TABD+6YI*!ZS[J"\7*0@9(P6+87,8D2J;(HC6@$29%'"ZB] M9HB>.\"=(](3KY-7]SF1D0-UKQSA(%0,EBD5258JDDZJ2+)6D8PBCUX2*`:# M3Y+M" M:K.:;P1EMZPA)*/(HA\+JNA&G>1;.8N"EC#8JL;_8T&5(X`7Q-2,[+`;#^X! M;?6H\Z&@VKV;DW%EGX2R3L^NO'P+X'2W`+)HDD`0R;&RQRM[X@]$B/0LFUVK^YS(R(&Q M\A4$*#?Y3^OU7U(#-Z\;)6Z".-.PHA`1.+!3)D"4A%KVDXWB9T((1*'"!I/) M"G2<#$%\+JCV,"*6/++DDT#.Z3U7/3-ZSLYVE7:"&$5G-Y>HVF]]8N'VVBAF MHL#<QTP4F%L.,[!*YBF4 MC'JNF&(THV6%@^ZJ5!:$4I"N2DN"""`-)_Y3_N<#J*5*+="Y3=OK9`0Z,%@F M+)2OLENJ3UB!+6ANQH&="7T@I3M`RK;*9`D*VN#87F2R##JRE!6JA!+5 M>J)X5U":#R$0(V?M!D0>X\IH1M#:&:_C,5FM2E%3AH%JU/%[Z1R1PT6"?:SM MDS1+EF6-@?]+Z,\67Z8_9ENOCQ\+S<^SI?K>9/1YOO8/P^GZ]FZ[Z:O]9= MW<^F=]U_'F??5YM_;GAFL?MBU]U_5O.7H_:+:KMORSW^/U!+`P04````"``L MC&E'UP)5W7T"```="0``&0```'AL+W=OC4I&S=+A[Z7+DO9751E0U\ZA]_KFG1_GVG%^J,+W*GCM;P5 M0G5X6>K-<9>RI@TO6>-T]'ITOX!##B(E&12_2MISX]E1\"?&WE3CQ^7H^HJ! M5O0L5`HB;P^:TZI2F>3(?\:D_\=4@>;SE/W;4*[$/Q%.J<[URP>@IQG9J\ZWO9#/=>OXG],

`,<`.`<` MM!D0C`'!AP!/DPUU?26"9&G'>J?3D]$2->?@$$CGS@X?.CMMEZR,R]Y'%J(H M]1XJT:B!@^;9U$";(E\H\"SQ),!,`6T4@::`"XK8GB"P)4`Z0;!(D"PA(UV& MUC2#)E!?LTV5FRH08@CM,&@#!IDPV%\.@S4,,H=!"!I%&[+6)??!!%M>3)NM:-(5QLER+K3+D0X^CC'GG&0 MM>1&?Y+N5C;<.3$AS\3A`+LR)JA,Y3])9PKYKS(W*GH5ZC%2]NO36S<$:Z>? MD?F/*/L'4$L#!!0````(`"R,:4>".?[_G@(``,$*```9````>&PO=V]R:W-H M965TJ:@^55GMHST[B M)&@!I]A9MF]?&YLLCHS#)6#SS_@;^]?$Q4#[-W8FA'L?;=.QK7_F_+()`K8_ MDQ:S)WHAG?ARI'V+N1CVIX!=>H(/8U#;!#`,4=#BNO/+8IQ[Z#\?\=R!%?&_Y*AQ]$UY#(A'O:L/'7VU\9I^T4XGLM M_E#/NAN?@_J2A3K,'@!U`+P%@-@9$.F`Z"X@4&1C7=\PQV71T\'KU6%'AM4BMV,-T9)E@;4C32Q@A6FUR.5:0[)H6V!M2Q,*7&%<+?KL*S-' M&3S0/*DH6FB4P-7H@-GI\H44UN:DW0OB-?8%KKX"DA4&!O.^`5-HWQ53M`3C MZBX`K3$O>FP8N\0$Z8]Z.I@OC[=9:_@=02P,$%`````@`+(QI1Z.;B7;'`0``A`0``!D```!X;"]W M;W)K&UL?53;;ILP&'X5Q`/4!P[)(H+49JJZBTE5 M+[9K!WX"JHV9[83N[><#821"N<'VSW?ZC4TQ2O6I6P`3?0G>ZWW<&C/L$-)5 M"X+I)SE`;]\T4@EF[%*=D!X4L-J3!$<4XQP)UO5Q6?C:NRH+>3:\Z^%=1?HL M!%-_7X#+<1^3^%KXZ$ZM<054%FCFU9V`7G>RCQ0T^_B9[`Z90WC`KPY&O9A' M+OM1RD^W^%'O8^PB`(?*.`5FAPL<@',G9(W_3)K_+1UQ.;^JO_IN;?HCTW"0 M_'=7F]:&Q7%40\/.W'S(\0VF%GS"2G+MGU%UUD:**R6.!/L*8]?[<0QOMGBB MK1/H1*`S@:0/"EABZACC<(+(9@FR`.05=2Y&$%'3))WA=(%D32(-` M&ULC5C;CM,P$/V5 MJ!]`8L_$3E;=2E"$X`$)\0#/V=;=1IO$)_)M=C(GOIE]R<^_[R$,?=X:SJHGNG+ZH9GIQT6Q?]<-D^Q]VE5<5Q M"JJKF">)B.NB;#:[[73O6[O;ZM>^*AOUK8VZU[HNVC\?5*6OCQNV66]\+Y_/ M_7@CWFWC6]RQK%73E;J)6G5ZW+QG#WO,1LB$^%&J:V><1R/Y)ZU?QHLOQ\=- M,G)0E3KT8XIB.+RIO:JJ,=/PR[^6I/]^F8\*"K;OH;'5Z[7M=KR":JB]_SL6RFXW5^DB5+ MF#N`+P'\%L"0#(`E`/X+B&=F4UT?B[[8;5M]C=KY95R*\9VS!QB4.T3==+.= MY1HJZX:[;SLA8!N_C8D6#)\P'TP,=R'V%B*]0>*!P(T%=[&`F06W6*`[`;@2 MX)P`C`20)S9).9M+,G2`E!$E#!!$$ M`T$)DLZ""+-2+K(T<\'V)HRQ%,#S@B5!1YH?B.#N!!DA2!8B2$XPR`,$R8U* MI1`^>J@69F#5X_G(F+/M5DDP2!)GXZTLTA!)4J-:P21Z1#%A#"'GGJ6$ M49W,A%64\*1P=M^JBPS2Q=E_*XLL1)?,*-@)V7L@-A&JCUENU>)1E#M[;YTV M28@"`V$:J/N3U!/4LT=S;>*H<(DH,:>UR&R"'-M1,Y2YE;$Q/'0*32)PS5R-R: MI-X4SA9%)2-A3`?2QI9TLFN MPH"U8F12N'6QK&R2^WP74!T-UDR5OA24F84@-PO4$(00/PNF4_4Y%0OD=2I` M=358X]2;@K*S$.1G@1J$$.)H(;^[U'H@]O\Z5"^C-4ZEIQ:DO"P&>5FDYA^& M>%GD=^7P0&PB5`>C-46E9RE"RL=BD(]%:OYAB(_%]+X<;HA-A.IDO9UV2!`PKXNFP,>R$PD-K9>+L6S^EJTSV7314^Z[W4];;F< MM.[5D"AY-^AZ5L7Q=E&I4S^>RE'X>;]IONCU9=T^N^WA[?X"4$L#!!0````( M`"R,:4??ZP<@E@$``'L#```9````>&PO=V]R:W-H965TP"'WJ50]HA[YX8#(;;I03+[I`=0_J331C+G0W,A=C#` MVDB2@M`LVQ')N,)U%7,OIJ[TU0FNX,4@>Y62F3\G$'H\X@V^)U[YI7J* MS+R62U"6:X4,=$?\>7,X%0$1`3\YC':Q1\'[6>NW$'QOCS@+%D!`XX("\\L- MGD&((.0+_YXT_Y4,Q.7^KOXU=NO=GYF%9RU^\=;UWFR&40L=NPKWJL=O,+6P M#8*-%C9^47.U3LL[!2/)WM/*55S'=++/)MHZ@4X$.A-H,IX*19M?F&-U9?2( M3!KMP,(-;@[4#Z)!-B9-ZMX;M3Y[JW=E69%;$)HP-&).2TRQS6<,\?IS$;I6 MI$A%Z$*`[NBZ0+XFD">!_,'E?EV@^(^#XD'@TV.;96HS853$[/.L_%"%+`8[ ML`O\8.;"E45G[?P=Q8%V6COP4MG3%J/>OX0Y$-"YL"W]WJ2?(P5.#_=??7YO M]5]02P,$%`````@`+(QI1_)\L,%$`@``]0<``!D```!X;"]W;W)K&ULC57;CILP%/P5Q`L6E))QK6>9R<=OX7\%R!6$,,XE=#!K&8>UK\ MGK%WO?AQW/FAUD`H.4A-@=5P)16A5#.I/_\92?__4RRW^L&/3F7&P.TD^ MIKD3X)@`YP00;2:@,0%]2@BL,E/75RQQ67`V>-P>1H_UF8-GI)P[>,($N;5+ M5294]%HF65@$5TTT8J#!O"PQT(6H5HAXA@1*P*P"NE0@JP*N5``W`7(11)8` M+0A0M-:8VBHLI+,:(4*9"U6M4'&:Y6XMT8:6:%4,=!/$&V[$C[B1;"A(-MR( MK1O)HDZ`DLP%JE8@D$5N)>F&DG15"G(39!M>9(]XD6\HR.][D2_*3`"*G5XL M07&"4K<2W3AN2M&;BV)NV`FK:N+D"KDFYT#^"\<9,KT4.N.._3;C@KW=FGC'6V.NK&E[U24J3O'=MKS?IR9CS*LOT M[B0[H1_46?9VY:"&3A@['(Z9/@]2[$>CKLT(0BSK1-.GV_4X]S1LU^IBVJ:7 M3T.B+UTGAG^/LE7738K3>>*Y.9Z,F\BVZ^QFMV\ZV>M&]!_QEFX M?XY7U.[<+M'CY."WRV:F[>S;EE5LG;TY1Y.&C)K'4$,@11TIBILDLP`W"@)1 M4$]!0GM85A6'*!9@R@@%W_[$,PC#.899(1"L"HU0+*%6$0D"4*HA2E`04U9$( M,02C\`44'J%0$(6'!X&3$D2)1`C=V1578^^RN,4`)@=A)E$_%R\&GO`ZEJ&< MWSDQ&*R3,U!4*'D!`^$@TA?"<@8?FT\ZIV\*&,OJ/$V.2AEI'6&'FR6)_MPN`U:>3"N M6[KT_57J!T:=YY?![7FR_0]02P,$%`````@`+(QI1VOF.V'^`0``;P4``!D` M``!X;"]W;W)K&ULC53;CML@$/T5Y`]8;,>)O9%C M:7.IVH=*JWUHGXDSB:T%XP*)MW]?+HY#(K;MBX'Q.6<.`TPYQ55 MR<^*MAV\"B3/C!'Q>PV4#ZLHB:Z!M_;4*!/`58DGWJ%ET,F6=TC`<16]),M= M9A`6\*.%07IS9+SO.7\WBV^'510;"T"A5D:!Z.$"&Z#4".G$OT;-6TI#].=7 M]2]VM]K]GDC8O,&YA;@1K3J7]HOHL%6=72H08 M^7!CV]EQ<'^*>*2%">E(2"?"E"=,F(V$V8V0_960C83L?S/,1\+\(0-V>[>5 MVQ)%JE+P`0EWVCTQERI9SO79U$C:H'`'HFLG=?12+9X7);X8H1&36LS:Q^1% M"++U(CAGR*[3T3N;,Y"-F>N6#,_0U*$ M!;*00.8$LKMJY_&PO=V]R:W-H965TV1\7[B_-TYA-005IQ*^XNJLU2<72$!8N3#K?U@U\E]V>(9M@Z(9T"\`&)GW`E9 MF\]$D;(0?$+"M78DYA^,]K%N1(6D#0I7O38J=?129KMM$5X,T9P3VYRCGQ,M M&:%F7R3B-8D9'GOP)-VL$VS6"#;.X\8G^(^!9`V?.'QR@_]28^Y,NIS!U8@C MG.[6==([.NE-+W>W.JG323V=+$]PLBZ3W9')/)D[(A[T66N'V-[FS_3RV(D+?PD MHNT'B4Y98#A4:9;6[ZX8;1'10?KT_+\KZ5_P!0 M2P,$%`````@`+(QI1R.J,)`@`@``=@8``!D```!X;"]W;W)K&ULC57+;J,P%/T5Q`?4QCS21@2I>6EF,5+5Q^-%SDZRJ5ORQ@-QHA3S?TO2L'X1 M1N$E\%X?*ZD#H,C!R-O7E+2B9FW`R6$1OD;S;:H1!O"[)KUPYH'VOF/L0R]^ M[A"LA08,,ICE!//L@ZQ=R%4$*`.C"^1S M,61`#AWY$JQ7'7TWQ'U!+`P04````"``LC&E'76*:!MT#``"4$P``&0```'AL M+W=OHU\!A('`2[ MAP!!#MFSQJ9M(9+HE>1Q\O?1TV'/DAU>1I94W:QNL8H<;N^Z_=Y=E.J#'W75 M=,^;2]]?G\*P.UQ4773O]%4UPYN3;NNB'V[;<]A=6U4JZ:']^4)6^/V]@LS[X6IXO_?@@W&W#1]RQK%73 ME;H)6G5ZWKR'I[T4(V1"?"O5O3-^!R/Y%ZV_CS?_')\WTK0CRF*X?*J M]JJJQDS#R/\M27^/.0::O]?LGZ9R!_HO1:?VNOJW//:7@6VT"8[J5-RJ_JN^ M_ZV6&N(QX4%7W?0W.-RZ7M=KR":HBQ_SM6RFZWU^DT5+F#T`EP!\!&#"!H@E M0#P"0$Z5SLRFNCX6?;';MOH>M//'N!;C-X&83&\/\!9F0 ML0VVIS#(8V&GDS!T$D(GL]))S.;$"6;22L>$)7$N4SN;E&&3$C:Y/4'&3);, M9[+D#(.X M*)..#H/55%9*X#%E%M#2(TQRM$]A@A,0H6,*@]6#5D:FQ:3@$"5P)@->+@.< MS0#K,VM?3`>!*#4,[$5AF5$?Y<%8#/EX#IHMD MTN%\!)5GN730X;P&B-F`8^T#SFW`RVZ`\QOP,1PPK23.79/&B:*K.>/`ZCW.!VB_(;OMM?BK#X7[;ELNN!%][VNIW.3D]:]&EA$[P8Q7%1Q?-Q4 MZM2//]/1[N9#H_FFU]?U#.QQ$+?[!5!+`P04````"``LC&E'&T7IHDD"``#6 M!P``&0```'AL+W=O4O?,* M8^%]-*3E>[\2HML%`2\KW"#^0#O\81B=MU)``AF$:-*AN M_2+7:Z^LR.E5D+K%K\SCUZ9![-\!$]KO?>"/"V_UI1)J(2CR8+([U0UN>4U; MC^'SWG\$NP-(%40C?M>XY[.QIYP_4OJN)C]/>S]4/F""2Z$HD/S<\!,F1#%) MY;\#Z:>F,IR/1_9G':YT_X@X?J+D3WT2E?0V]+T3/J,K$6^T?\%##(DB+"GA M^M\KKUS09C3QO09]F&_=ZF]O=C;A8.8V@(,!G`R@<=P(:3=_((&*G-'>8R:W M'5)'"'90)J+TN%YD)GKI*)>KMR*#,`]NBFC`0(TYS#%@0@22?9*`+HG!',[, MXR1R$T0N@MCX&%D^+A#$+H+($,060>PF2%8\2"R"Q,Y29L(TF%9CTE#_W$+I MBE!J":6VD,$N%?2:ZN[V6QU:F&/4+_;G_`B[]`%_T+L4K?<.U(A7W_]5)\I M%5AZ$3[(@"O99*<)P6>AAID<,]-VS$30;NRB4RLO_@-02P,$%`````@`+(QI M1X`_!55,`@``^0<``!D```!X;"]W;W)K&ULC971 MCIP@%(9?Q?@`JXB*3AR3KDW37C39[$5[S3C,:%;%`C-NW[X@:G&#[MRHX'\. M'S]PR`;*WGA%B'#>VZ;C1[<2HC]X'B\KTF+^1'O2R3\7REHL9)-=/=XS@L]C M4-MX@>_'7HOKSLVSL>^%Y1F]B:;NR`MS^*UM,?O[3!HZ'%W@SAVO];42JL/+ M,V^).]1R]']`@X%")5D5/RJR<"-;T?!GRA]4XT?YZ/K*P;2D%*H M%%B^[J0@3:,RR9'_3$G_CZD"S>\Y^[=QNA+_A#DI:/.[/HM*TOJN\<4';.<1U6ORNWW4WO@?])_&G,'M`,`4$2X!V8C,` M3@'P0X"GR<9Y?<4"YQFC@\/T8O18K3DX0.E) M)DTP:IY-36!3%"M%M$@\";!0!#8*J"F"%06R)X"V!*%.`%<)DC4DTM/0FF[4 MI`#X-E%ABH`/X]3.$NZPA`9+!-:C1!HE-$>!(+2)BI4H1ANV1CLDD4D264DB M8Q"$TMA*8HJ2.`WM)/$.2;Q:GPU3TR<7A`^4$6">RS"QEY&5"*4?U]@SBG2/K^0G M9M>ZX\Z)"EGOQ^)\H500F&@VY"/6)E/WZ9M(-0?OYHEUN^_P? M4$L#!!0````(`"R,:4?.VV8DB@,``.$0```9````>&PO=V]R:W-H965T.VE MJO+FWY,HY77M$W\9>"F.IVX8"+)5<+/;%Y6HVT+67B,.:_^1/&QI.D!&Q.]" M7%OEWAN2?Y7R;7CXN5_[X9"#*,6N&USD_>5=;$19#I[ZR']GI_>8@Z%ZOWC_ M/I;;I_^:MV(CRS_%OCOUV8:^MQ>'_%)V+_+Z0\PU\,'A3I;M^-_;7=I.5HN) M[U7YQW0MZO%ZG=XDX6R&&\!L`#>#6QS<@,X&]&[`K`9L-F"?#(*IE)&(;=[E MV:J15Z^99N^<#XN$/+">ZIW7CH/-Q&]/1=N/OF-`R+\"##CF.,,KQ4PJ0& M%ZALYYDCQ&7J""K+)0MP6-`S:"(UBF/Z945/L[S1@''$J9%_@JIT24J3*3/5 MA>ITH88Y46,3%N$.ZWH&S0N;A^:"40DNH30-L@0/%:G[16+AUB96HJO5M.Q0 M&2[<)D[W&8.P_89`.Q"ZTJ*`I- M!=E:'.@]SI0JJJV%UM2%5FK3#`T=NL(,6O8C'IN^RZ8QJFN,X=.@?D8"86".9>MV5!,CY^@" M_P0R?/90FV*IIE@>XW%T4&*(8Q,LU03+4XR[+8VUE3EWH\V"NCM]/\ M(XP'S#L\6YWSH_B5-\>B;KU7V?7'U/%,>9"R$WTBX;>^^)/(][>'4ARZX38> M6)E.X--#)\_+#PJW7S6R_U!+`P04````"``LC&E'[_MK=/P!```(!@``&0`` M`'AL+W=OJD MBMI%I2B+=NT!,Z`83&S/D+Y]?6&H43QL\.T__W=L[%/.E+WS#F/A?0YDY$>_ M$V(Z!`&O.SP@_D0G/,J5EK(!"3EDEX!/#*-&!PTD@`"DP8#ZT:]*/??*JI)> M!>E'_,H\?AT&Q/Z>,*'ST0_]^\1;?^F$F@BJ,ECCFG[`(^_IZ#'<'OUOX>$4 M`B71BM\]GKG5]U3R9TK?U>!G<_2!R@$37`ME@61SP\^8$.4DR1^+Z7^F"K3[ M=_<7O5V9_AEQ_$S)G[X1G/F;.=D/J%X0'*@Z@] MKB>9V;U,E,O96Y6E81G/!?"AY45D0!G\\N8"ZY%/Z()_(7;I1^Z= MJ9#U0C_NEE*!I1=XDKEWLBRO`X);H;J9VI0I5&8@Z'2ONVOQK_X!4$L#!!0` M```(`"R,:4?#Q)<0#`,``*0,```9````>&PO=V]R:W-H965T\BOMWMB)$.Y]-'7+EOZ)\_,B"-CN1)J2/=`S:?LG!]HU M)>^7W3%@YXZ4>VG4U`$,PR1HRJKUBUSN/75%3B^\KEKRU'GLTC1E]W=%:GI= M^L"?-IZKXXF+C:#(@]EN7S6D915MO8XT+\*Z5O M8O%SO_1#H8'49,<%1=E?WLF:U+5@ZCW_&4D_?0I#]7YB_R[#[>6_EHRL:?U2 M[?FI5QOZWIXD"C`;KQ$`RQR\QM2EX6>4>O7C>4 M^UR*4P46J*_-SF-RLQL*TN>.];OO!4Y0'KP+HA$#)6:E85(39*-"P(P(>@&S M"FA2,7J`BCDT.5BK")P9-7Q)LK60:#(CD\QH2%:D)2LQ$\0F@G@@B#4"K(O$ M0RX&3"LQWQ!.PS`TX=8JSHC8J(@(QQ:BK9E(BPDY8D)*3.CF=*`A)*1X@`"A M\#\I`W#C!&J*$H>B1,MR:B;`CCKC>^J<.A2D&D%F3$JJUAF@-$&6K*PU9!): MLZ?B(,PB&^%6!=[P:2%FCA`S-41L]+/*5.$1L![ES'Z4Q]!41(PRVU%683"R MQB7^0*R!B8=*9,`8V0B:S\U\#5[`"ZYW!H M;2R+'$5P(G59KHX'M):'D87"U?/`74T/N+H>2._H"4#K9A!;7QL'3I?DZE(@ M<]5K_,<%:ML`(,&.@KFA@[!`&<$:TAWE\,N\';VT7.1;V9T'[$%#G]E3_\DP+VIR MX.(6BY0/0_2PX/0\?1/,'R;%/U!+`P04````"``LC&E'FX+EPTX#``"8#0`` M&0```'AL+W=O?(JR)MQ&5U\NI+Q=)#2RIRCR`4>46: ME>YBUJZ]58L9OS9Y5K*WRJFO19%6_Y8LY[>YB]UNX5=V.C=RP5O,O)YWR`I6 MUADOG8H=Y^X+?MX1)"$MXG?&;K5Q[DCQ[YQ_R(L?A[F+I`:6LWTC3:3B\,E6 M+,^E)>'YKS9Z]RF)YGEG_;4-5\A_3VNVXOF?[-"Y[7[;^SO]8-+SJ*ZQ3IESIF97N\J3LQTC280#2!](3>#TSP-<&_$X)1 M0J`)P51"J`GA5$*D"='4&*@FT*F$6!/B!TF>*D=;S'7:I(M9Q6].I3KPDLI& MQ\^Q:)>]4[>+E>H14,F0P.+P[%=:VI^>06'".=`6K3NT'?^WL^;5L9%C&:K^I>"'R&_%A?8F? M-QA8WXI-B-HRW,TO9I?TQ'ZFU2DK:^>=-^++M/V,/'+>,"$&ULC51+CYLP&/PK%O>N>3\B M@M2EJMI#I=4>VK,#3D!K8VH[8?OOZP=A866A7+#],3/,-]@N)\;?1(>Q!.^4 M#.+H=5*.!PA%TV&*Q!,;\:#>G!FG2*HEOT`QH%W+[SVET[J`JQ*N/#:GN)!]&P`')^/WM?@ M4!<:80"_>SR)U1QH[R?&WO3B9WOT?&T!$]Q(K8#4<,,U)D0+J0__G34_/JF) MZ_E=_;OI5KD_(8%K1O[TK>R46=\#+3ZC*Y&O;/J!YQ82+=@P(LP3-%)<0S83H$P%:9Z:O;TBBJN1L`MS^BQ'I M7QX<(I5<`X0I5YC0A>BWB"2!0*5@<5%Z'(1 M61?AQD7N%HA<`K$5B#8"Q=9D9MNPF,%@OB1!D;A0]085NYW$.T[BE9,@\-T" MR4X6R2-9I#L.TKTL$IM%NNHR+`(7IEYCXM#M(]OQD6V2"-P"^4X2^2-)%#L. MB@=V1;'9%7&>.G?%!A6GGZS`U9D;T07_0OS2#P*W5?Q)_@(` M`*<+```9````>&PO=V]R:W-H965THNW*Z'O==^NV87T=0=?>T#?FG;JO_W0AMVW80X'#?>ZN-)J(UHNXYN M=ONZI1VO61?T]+`)G_%3":`@`^)W3:_<>@^4^'?&/M3BYWX3(J6!-G0GE(M* M/CYI29M&>9+,?XW3.ZCU89PK=>;XB;`SV(4K7RQT3204W&>"382C`<@!>"@>1^!F(CR'6@1)'(O@=Q#X' M1#N('0?$[R"949`X#F(WRD3G06,ZG>J8%"G)_$3I#%'J$$WD*IL)-5L2:CZC M(%\0:FZ%6@"@&$T0%3-$A4.4>HD*.Z<$#7]^)E7VDU3JH\65>;D,2),1P`5) MX@DN;U6.7&Y!Y1,NO!5ESA##DD/$>]O3*`<6W`H#TD0Q`40(\>?(!J8XPPD\ MYBBRYJ*6]L=A7N3!CEVZ83RU=F\SZ?,PDD9W^'9]KH[T5]4?ZXX'[TS(Z6P8 MI0Z,"2J5H)54=))3\VW1T(-0KYF2JN=(O1#L/([%M]E\^Q]02P,$%`````@` M+(QI1P#F([O,`@``U0H``!D```!X;"]W;W)K&UL MC5;!;J,P$/T5Q`<4;#"0B""U25:[AY6J'G;/;N(DJ(!3[#3=OU\;&VJB">42 ML'EOYLTS&2:_\O9-G!B3WF==-6+EGZ0\+X-`[$ZLIN*!GUFCGAQX6U.IENTQ M$.>6T7U'JJL`AV$2U+1L_"+O]I[;(N<7694->VX]<:EKVOY[8A6_KGSD]QLO MY?$D]490Y,'`VYB`.UZ)[M?;783D=4_QO9I^FFO9=->K>9*%E@83L"7@ M@3#D@0F1)41?A'B2$%M"/#<#L01RDR$PM7?.;:BD1=[RJ]>:XSY3_5:A)5%G ML_-$M]F:`U'>";7[461AG`!4C&(E/CA<$T!A-E M!`*M75",20B!-BX()P3'$&KKHE"Z@YZ5X%^^*V; M%F3*7&2@G2/,[3MJ#1UAHA`\E^V]0..:P#;7US3J4OV$9Z$F2_:7LL&^&] M&ULC9=1CYLX$(#_"LK[@3T&;%;92+>)JKN'2E4?>L]LXB2H@%,@F_;? MUP:2M=FQKR\!S,Q\8W"^Q.N;ZK[W9RF'Z&=3M_WSZCP,EZ.JFO*05]VIZ2_=+(\C$E-G0`A>=*45;O:K,>Q+]UFK:Y#7;7R2Q?UUZ8I MNU\OLE:WYQ5=W0>^5J?S8`:2S3IYY!VJ1K9]I=JHD\?GU=_T:0?"A(P1WRIY MZZWSR#3_JM1W<_'OX7E%3`^REOO!E"CUX4UN95V;2IK\8R[ZSC2)]OF]^J=Q MNKK]U[*76U7_5QV&L^Z6K**#/);7>OBJ;O_(>0Z9*;A7=3]^1OMK/ZCFGK** MFO+G=*S:\7B;[@@RI^$),"?`GR:P.8$]$B`+)J1S0KI(2*:IC`]B5P[E9MVI M6]1-;^]2FD5"GU+]J/=1/PYVT_/5CZ+7HV\;0?@Z>3.%YA@88[9V#,4B=G8$ M+]YC$MW!HPW`VI@18!4`%.%$9#B!800V390Y$Q5X@10KD$X%4J=`X3:93=.8 M8MHIA@'+TA0'90%09H,H04&9!4I!Z"\SP4%Y`)0[((J"<@O$*/#"\^AY@,,= M#J`<;G'^X@6!W`,2`9!P0`P%"1M$TYRGPK,8B@"I<$@I2BIL4I;F.,6XR8LQ M-RU.AG+FH`E$29X3DJ*K9N=$!M$\;SP-!3R"'5$0GTE0B:ACDI@\:[$W*[M$H`X\Y%" M*J&.2V#Q%2]FDB,3'@L?*>02ZL@$`"?ESIJ(?8LO)!/JV`08#G)T0G/_G$(Z MH8Y/(,51CE#TI#CWH$(^H8Y0(,-1CE$HCSG@*`@Y!1RG0(ZBP#8%@WCYST#, M/\KDSQ8IA'0"CDZ`XPW9.J$B]LD$0C(!QQ,@4)E`4";SMQ-LF3`2^U0"(96` MHQ+PE0BI!!R5,(+-:+L(HEC0;A'D6UDAVX!C&\;P9MP@CP(@Y!IP7,,R_#7F MH==X;\:MY/F)AH\^&MMXE\S'E)!70/Q_:R]N$%M*);'^YC>R.XW[I3[:JVL[ MF`5FC3[V9"]@M@G+<>!/6SV5CW=T"_K.N(U+WA&;]:4\R<]E=ZK:/GI5@]Z@ MC+N)HU*#U)V36+_AL]YI/BYJ>1S,*3>_Q-/>:[H8U.6^E7SL9S>_`5!+`P04 M````"``LC&E'3WESB5<"``#J!P``&0```'AL+W=O##C6]FV=J[97F&;GQMNGQ*W78K>L0_?>"6S*>7-^= M%]Z::\WE`L@SL,1538=[UI#>H?AR+/A+S+R<_J MY'I2`VYQR64*)(8[+G#;RDR"^>^4])-3!IK/<_;ORJZ0?T8,%Z3]TU2\%FH] MUZGP!=U:_D;&'WCR$,F$)6F9^G?*&^.DFT-FQZ-8YZ)X93F#T@F`*" M)6#AL0>$4T#X)0!H9K7)9PQL7K/ MTS#-P%TFFC"!PKR8&`AC&Z8P,?Z"`$+!(B.PR9@H`B,\2:PR"A,3V"E"&T6H MG88KIP=[`FA+`'4":%H,P[7&2/O0F%YK]#W/2R,[4;1#%)E*-X3&.T[C1YPF M.P(2,P'TUDX3[30QG$:'*#D(LW:F=(E;+P+A:.TROJN4PIR2W M7G4X8W5I:\^!NIH_X7DVH"O^A>BUZ9ES)EQ<\.HVOA#"L9#B/0G+M6B\RZ3% M%RX?$WG)Z%:D)YP,6RD"-8JJ,=>X/N)U\-N<,M"S;W1 MLB!WCKL!O5&'W?L>TK\7A,ET=H&[3+QWMY;+":\LO#6N[GHTL(X,#D7-V?T" M3A?@2XE2_.K0Q(R^(Y._$O(A!S_JL^O+'!!&%9<64#0/](HPEDZ"_&&G;KM!M9->R?PYS!X0S`'!&A#HQ#5(I?D53'6"R#2;PK1A3!/)H MY]!R&R;2F-RXJ6D26BFY28FSG3.3%6$7(Q=7#GB^:?-]GD4+*$WB)Y)G?.HC MO*&?D-ZZ@3E7PD754)]X0PA'PLQ_$:7[6D9P(``!X(```9````>&PO=V]R:W-H965T ML;?14FI=#Z;NA4KMY2R6WJ>*$K:$/'" M.MJJ-R?&&R+5EI\]T7%*C@.IJ;W`]V.O(57KYMD0>^5YQBZRKEKZRAUQ:1K" M_VYHS?J5B]QKX*TZEU('O#SS)MZQ:F@K*M8ZG)Y6[AHM]PN-&`"_*MH+Z]G1 MW@^,O>O-C^/*];4%6M-":@6BE@^ZI76MA53B/Z/F+:4FVL]7]6]#MF!".A/!&B)X2HI$0_6\&/!+P70;/U#YT;DH>; MT^Z(_JC0$JNS*1PQ!+DY$-4[H:(?>1HEF?>AA49,,&`V-B9)()78J/,-@3&X32 M`*SW$6;F)'WB))T[B4$G-BB)$.CD$6;F9/'$R6+N!/RN-S9H$8-?]0.(\>%9 MMU]#^7F8.\(IV*65^GBMZ#3:UH&^/>_B&[3<(B"^4Z/03*Z;?)YUY$Q_$GZN M6N$H_J796EJ]ZHR",:QS(JTLUV.I_UG_VLYK/RH\DWV^QG M-:D_BB*M_KO,\G)_,273\8-?F_=UTWT0S6?1P6ZU*;)MO2FWDRI[NYC^(.?/ M4G227O'/)MO7UNM)E_Q+6?[NWCRL+J9QET.69Z]-YR)M_WQF5UF>=Y[:R'^, MTZ^8G:']>O1^VY?;IO^2UME5F?^[637K-MMX.EEE;^E'WOPJ]_>9J:'/\+7, MZ_[_R>M'W93%:#*=%.G?X>]FV__=#]_HV)BY#:@QH`<#PE$#9@S8P8#A$;@Q MX*$1A#$0!P.J4`-I#.172KB!,@;J*P)!#;0QT*%%)\8@"37HKOEPY>+0I,CA M8I-@D_%R$QIL,EYPPH)-QDM.^)%)-+1OW_S7:9/.9U6YGU0#L;NTVQC(>6O5 M.I_4_:?5`%7;_W7[Z>=<"S*+/CM/1D-[S2744)?F"FJ82W-M:Y12+LT-],-= MFENH$2[-G:UA.G9I[J$?Z=(\0(TSYX6MX>[:'P/R>0KPLPSP\PQSU@=-U#;$ MH2NHLRO8T!44>$C<'IC3`Q\\,-N#/,I3#?4.FFVO<2J6MH)P+>(X=N?"L5RX ME0N11^LJAERX'4G%.K9#6<(E=R8-DA%8,L*^@(FS[%MAQ:`ZYHGZELV@7-A* M%C.=:$_>3[@2Y"^Q_"6XL,3M06'-I4*:2V,Y:)`#=:Z,!JU#/0OX:,M@?]F= M:JMHPGV]`6(JYEW@!"LN`<4QMX=NDOE7N/OV]!(3]V`P:1!RFN!'(QHJ%O'W MYC,<`QT*,G'O2V-2]L8DN/#X<.],X^*PH,5!=Q3"P>)P5S=<$7NK8$IHZ=F* M";IA$`%B'8T[;6+9>(LS7R"4;`+1EAX?*-LD"&Z"TDWTZ<6](0!)I97VU8S" M1B!MRATKL6+)I/WG&:EN*$TH&F-C:`#EQHA,6=T.X@.%HO12<);P^L`/`4&G M`(H>`R@\!VA7T<_4'O.<"4W]5:-84HBE+V,W;F/5(JAJE"0J3W?PK1&-TT)1 M9@EA,#=R8S"%[0_F1&%$)IAG:E,42PJP5$<;_2"Z.Q(1E^@Q1+3TBF#**-W4 MIILEGG'!T%G*@F8I0VEDY'0_/#`P(S'T&3HC&3W=#P]&9&:3)PQ^P`=D*^JZ MB(LC$7.)GKPBF`U*/@/D*P](#"6?!9'/4/)9`/GW#)!/L"N-DL]0\K4)9I-/ MSWP,H.@SFT49>R8M<[,XKFX2LKH<':$6#V^&1$\>_WKN:X#I2$T,1[PP.4(E'*IUP")4TD\=_V MEL`&5S%GSG;`'Y;!5 M>ZM&418`94T]/MR(C%7SH*KQYT\`$>UL[X40QU6[GRGY93`C%#@!9J;VS&Z! MWG>*H/M.@4XY`3C2PKTR]GVG=#R8&Y<&T<&<4"X%O#_U##.)GF!ET`E6H@-1 MVKS).($U#Z)+(-+:ERP*I010DJ-[@\0$LJ&,SV(/3!(%4D(@/3->HD#*("`E M"J0,>"*\D(`T[IW;F&[(*;)^(-JE[]DRK=XWVWKR4C9-6?2_"[V599.UWN*S MUMLZ2U>'-WGVUG0O5=?EPT^GPYNFW(V_!!]^CI[_#U!+`P04````"``LC&E' MS'4UE6H"``!Y!P``&0```'AL+W=OP,VYBLB2!N2JCU46NVA/3O$2=`"3FTGV?[[VI@0&WG37C`>WGOS M9HP\Q8VR=WXB1'@?7=OSE7\2XKP,`EZ?2(?Y@IY)+[\<*.NPD%MV#/B9$;P? M2%T;P#!,@@XWO5\60^R5E06]B+;IR2OS^*7K,/NS)BV]K7S@WP-OS?$D5"`H MBV#B[9N.]+RAO6_@.4V58@!\+,A-VZ\>\K[CM)WM?F^7_FALD!:4@NE M@.5R)15I6R4D$_\>-1\I%=%\OZM_':J5[G>8DXJVOYJ].$FSH>_MR0%?6O%& M;]_(6$*L!&O:\N'IU1G^%Z'/_3:],-ZTU^R<*2Y"7`DP(DPY7$3HI$0 M/0CH*0&-!/2_&>*1$,\R!+KVH7,;+'!9,'KSF#[M,U8_%5C&\FQJCP]!I@]$ M]H[+Z+7,LJP(KDIHQ,`!LS8QJ1.R,2%@0@32P.0"NER,&:!!AZX$E8E(' M?XIL/Q&Q;$8NFY%N5F0UZQ,!Y!)`6@"9;0J1;3+5O="8?L!\B3(((A>LLF`Q M3&'L@FUL&$CGO=.PK04#\BJ)(W=U\9/VQ&9[\M`MD#QI3V*U)[&=QKH]B>$4 M``@1`C!W(2L3F>?RYX9AY`)N+,DPEY()`B[DUI+,4@#B!+G+3)^4F5IESLXM MTV6FYH&$BPBY4-4,%4B/H^3[HIFE;_@502P,$%`````@`+(QI1TB@ MO0HF`@``=`8``!D```!X;"]W;W)K&ULC57;CILP M$/T5BP]8S!TB@K1)5;4/E5;[T#X[Q`EH;4QM)VS_OKX0`BLOFY<8C\\Y5G7_0*' M$*8^16WG5:6)O?"J9!=)V@Z_<"`NE"+^;X<)&[9>X-T"K^VYD3K@5Z4_\8XM MQ9UH60(] M)D0KJ!X[5*B![(5T MJ!4S)T(;R$67GCW6402/`ZG!'O#]Q&M@W;IE,8R]TK(@%X[K%KU2AUV:!M*_ M*X1)OW0#]S;P5I\K+@>\LO#NO&/=H);5I'4H.BW=;\%B%P`)&1"_:M0SH^W( MXO>$O,O.C^/2]64-"*,#EQ)0/*YHC3"62F+E/UKT50II#!@PJS$FM6'6)@;8$!L3 MD>8VR/:IR.Z!B">:*K MW$S+P(P6D1?TPU7DI+',@[,76.\@[30(YE@-K._UK0KP_+U<:9#>^/_<>L;- MV<$S^@GIN6Z9LR=<7,+#C7DBA",AY;^(\UZ)[_6]@]&)RV8JVE1]P52'D^[V M0;[_*RC_`5!+`P04````"``LC&E'*Z0]<77&```Y0P,`%````'AL+W-H87)E M9%-T&UL[+W9DMM6EBCZ?.Y7(!19QZD(9)H`9[NZ(M(:7.J6++5D M5_7ICGX`23`3-@FP`%`IUE/_P[DO-^+>G^LON6O:>Z^-@61J*+LJSH,M)@GL M8>VUUSS\OJKJX,-VDU?_].BNKG???/UUM;Q+MTEU7>S2''Y9%^4VJ>'/\O;K M:E>FR:JZ2]-ZN_DZ'@PF7V^3+'\4[//L+_OT2;'/ZW]Z-!\,'_WA]U7VA]_7 M?WA:+/?;-*^#)%\%S_(ZJP_!BYS'S(H\N`JJNZ1,J]]_7?_A]U_C._S>/'A5 MY/5=!>^LTE7SUW?I[CH8#L(@'D3CYH^OES7\&'7_:-=ST[V>_[A95'69+.O_ M['WSQ\,N;?X8#:[^M?G=#3R]HC>>;Y+;YJ_K9%.UAK%SO$G+K,`%KH*G2=UZ MSNS___H?_^/H)I]GU3+9!/\K3ILAE&'>'Y)M:WP*)+ M6/`+0(\/P;^DA^9S3_9EV01!'SBOKJ+X:ACU3/4\VZ1E\`3>NRW*UCPOD_(V M#6Z6RQ2>@F=6_'S?LHOM%K#L75TL?PF#=X3ZP>M]7=5P/P"4K5T4>55LLA4- M_%VR2?)E"J_!_:O@ZOST[FEP>?$XN`BR//CQKMA7,$K[C-.EO0^C/C`E505C MMGY-JCNZN4O\D/YEG[U/-O!XZ\%W=T597]5IN86EO$^K>MOUU-MTF<((BTW[ MOB,JI6&0IW7[I0WM?I>4==9^\8>B?9ZOZ[OV";R`=>5UQPF^*=-=DJV"]`,0 MO`K.`S=<=`WQ8U$#*BV/@NQED=^>!,0S@"1@0Y7"6%G7KMZ40'W+^A`&NTTB MU!/!O\/A.L'T(@<4NLT`MK*PSJ>^+XK5?;9IW=47;JV(2\EZG6TR`'MK803: MGJTS>'HP28`&HRY@Z*X]PQU"_E'!21\01SI^+_>`",MBBP?%]!H!LTCS=)VU MYY2URFM'9GZ:KE-8WBHH4\"1?6OFEUD.:%&L@R4\E+6`:O:V@SN`:X('-X`% M`6'!*EV<\\+*+&$)-SY;(2F!7X[=A8.!4\\Y+$]#_*6W2D(8VJ6_O%YH>4M] M\-L"ZP>_5R'@$DE/$$T> M-UY#<>J;:I%$QF\@+//``2"^""Z2N M<,#_B>P4)/L:Z&_V5X!.0G@*\D&=;A<`"",DT?J!$\BWP@V^#:)H$@['\W`P MBNB1"$8>CZ?A?!B;T;.JPOM#5-%QJ@?.%,)Y5[MT66?OTTUKOSE`!:&B9 M?D#`X\[OB@T@=_55SQG]4.2(#V6QV2`XLAS0#6CH:2PC`-5'3[^?Z5^^2?"6 MW*5U!F+-8Q`"+H*O>V3H=S6,0-(='-3S+(=Q,I3QBBH[(>OVXU]P"6>SKX`$ M`5QIVB;Z-UYNH>A9CS/.G?5H<:;T9*%!>/MZ)W3K?#EJ>+9*TI*RWC*MZR`P MFTVR*$K'RS;9$M$4$*KL>0=$@]5^6??^_@[H#0S2^SL3R+Y?&5M[WV6HP>J> MB;#4WE%%Z+;C5?;^7O$J.T3$"B3U)4N=*UC&IB"9I[U+NG9A`-0X144`GT]6 MVRPGS0+)3/?6"KN%M&<+;I-=E(+!]P+N_A8N@X#A<1C\T!:V?LI!6]XP6T9J[]Y/)?E*[ MGP[A40!X_@LBYL*>D,^?T^SV#I]+W@,*@UK:)I$=HSZ`:C[Q&"D=U[G4TV-&_CARG/WLZ'4'%S<( MB-!\_,V1JW>;P+(`L$?4L>>`<-EM+B+H\A"@;:+:"%5>_;SO>>_)2;FB_<0G MX=L9P_5AWI%3?>=).X@9?-/E^EX%\V#+G"]%SA=XUK>S$8#&[.'H9`\Y(A2^ M$:'PR6FAD'&EC:C'WGG:+4@VA$(?3,_.$0I?]!VD2'45B5-\2Q_#409';37V MI5,/PH4"]*_@=L!C](D8"T&YL8'@/]["6@.X`?=)N6K=/'KE"DA&4^_N83;/ M/J3E,JM86R8Y#1@NBUF(5S`'6OV\;7_D$&T+E%96X"+`G4JWNTUQ2--@2\H( MC8C7[;L"]HI_/,V`]=9%>71!GS;R\=%@UMU^`4(?O`/Z+>!,915B?(1$_R7( M3`]8X?EC'A\'%#Q/PR>[!HFG:9#6+`%M67]Y&$CTBVU: M8'_#5?50XV/3G3="F\)9UA*`T'.^V`'/H4%VE;T'<.8M#GZ27YY+CH[Z630Y M.OK@,8$"M_%\4]PK0:+3"+VF9]9EL542?(+FA&Y;HH(LW%BXBP"R##BD%43Q M'L-G@B,H*PC(5;`XH(A%"/.X^L@VS1?O773O,="4SPW"JK=D6% MLC0I2OV6WG,UBDNM4CP.M$J!\YW4(6[4HLD:F55DB_T:QMEF^^T)^>D)(BT* M(?*Z4>X0GLJ4\D#Z@#?B)(%X@T=7F<<7R8I,F?T6WF-J!5^;7"Y7!FAZS(/1 M0@5R89QG+.U2"QZ(B:=N"1_7\7?>[$'33H35'CG?5TDMB'/B06_`%M8=Y=\W MFK##VXM]A59W&,M9B'&+)9U`6VOQIG[0I0(46J;I2N`&US+]Q"'R`G1;66B7 M(\.>MASP66?5/-\UV_..GZ^W+,O[\8;*U0.:!3N%9=8I[G/9=\=.#O.1$L?- MZCWS$!IZ<]S/\C;=)0?+.I*'O.IOX;AWYHV:Y/PGSW/@-'!-2;<@48O/@[23EIR#+<_@[)8T3?H!KE)^FP;HT`[X,S&NY;G^8%Q$9K60E=9"SA[C MN_0VRW-<,UY'"DQH+3E?]?_X;K_;;0BA@=,B1P.^OR]32TGP,L&";.Q'YXTC MS_!JCSA-`CY/189**-(<0PC4F>7K\ZB%>28B^`W$8O ME+U6DU/2,@ZA'3SGL6SC;04@L-'`+(17?I(3$M_`L]_L5V;?OK_;Q1V5) M4>X,PEP^,E\_>AP"6_I35L+]SQ(X!OM0B(BVK7Q4(UD>"0P@_2(K-L4MNL8V MAX#-%L830>O9(?U%H2+8DY.E.H@O3=X\7+O%P?$%*[BI%?Y<.'\1V:$V&:P$ M5A>B]E("",/@55(>0%18A32363[_M18+HS_,=^GF%J5K?.*/^_P6!K@.?@0$ M2&%RT-D6:9JC]PWHQ1:9@TC[=D>`FW0=Z?J:=7_5!1[4O6!H-&L&K]\GP?=I MCKN&^_;R^LDU+>#=?@'8GB4E^;8?V6?Y-(29E"2:P<<<+X(L!-7+.EW>Y01[ M'4!#WAD$GX,[GE52UX#N"R`0>/_,PPO\HL[8#3 MVP.ZSVKD:' MWL40SJ!FBXR/)T MI34`?2"AVX>Y`P@]=:78=YD&?P3*RU+BBWR)<'[QYH\O'CT^^^BOX1B3/`%B M$[S;H::[P3B]$O0--Z1Y@N&%QI`D/\#@V?+..!:M&BULK4QOT2)A@$>Q)18<+U)GE?E%>P M0A*,`PRNI<.`<8'+9\4'(!ZH7Y"U^_TYV(+`.H;\3V#CJT1C-8$F>(TLJ5RU MH?_\]7G0/S'OGX'+PK@UG<\'T)^7P-W1;OBK M0E%4N'L`3&HOXL'G(`[/\ML-F6J0097)7[.-AM5-7UQ+Z`;GF0E'/L`,=0JK MF0Q_AR_>_&6??(=\_8`[A3U92G"PFUUC>"U&IX#JMZ6;#)"PQ%1W6($/`@_/7I\W1B0(9`?UC7%&YCPK0*E1[PDCYXP.*X?(<^K4G^TM94\ M*B=YX*@[EB18AOHISZQ1$;DU\#UA*/+H+L%)]_F*I2H\&`8V2&(97-O*!!`` MD.!W!"P-C`OT!\>SA0,!X`%\?KI^=QU\?W/S!D#4UCNV6\%&+<[?N-G?P"Z7 M_1&0^I$CPM;Y\P#=M=LE[ZL6^P#V!!DZ"[Z2IXX!#G.#]Q.!I*Z6^$#D6"V2 M:+P`]-UL6%(WE\&*P106A0P$%1L%R/6X+%)9'`0Q3ZL%"H1?(5#R/7*AKN6ZQ<'65F@G72%7*8#D$J3X5IV]_=#,7NQ` M<&7Y?XL\-.6@8W/JL&)9.7+.?4ET7'G)085#60]1$YDGA;-4VOOO[]`M95>( M!^5H:"$`#H@5/:%PSQH4Q$0F7-MLGM5OY<#N&AE=J4$3;&YY9N*$5,_:;C.C M`T0)BR1AV:!Y&NC=(B5WZ9(`+PL[8#Y"RI&4S6!)I.8(.)(0#B))K_=(H`T^ M&/.#W=IU/]X[C#Y]`RH0838848V^A16SH?SG?4XWDI$=5W_^@'QBK#&S711W MDP)4^G'^AO?X-L508&22SP';@FAP]2\M\*4=H:9PA!)O!_\N"Z",EBX8TL0T MGZVT_*21UO/)SL4C`GBV($+C)D?VQ8XM'YQHR0;: M6Y,XK]4TL@(1JAN,%8U`Q=U)W+/3/ZUI0.O57^/B4`-W&00:DG!!,/87.!2A M2;HAJQU,?4U:#G'?D-:`IE;#2+3;IS(*#_R0U!Z;$>D=M:GAG-AMS"=<` MP0+4H-MO@LOLL35Y63/R?E<0AE?(2LW&",'-Q"&\"&^"(+-=[,LJ=V)%O-("M!G+:"`&Q'6_1@@1!4W7\`XQ5VM?$J`M2<,@^H*DSMIU MV9C8L5Y8\#8#9@^2>-K8+#V\O,M@-=:H;(]&K3'TE"$/!Y3AD=6\R^P]0*@X M@(Z3L9T8G2B5CR1E1JA.I@H?N0GL9==UN-:7MFG7Z+]#]6$GVC#B(%Z2+9!B M%']`D#"\#F9<@5B!@7+HS0N%'GFZ^\'S`,V2-1X!"\9Z741YFH?,9#7%&%$B8D:I5:^A<8;D9)@2Y!:TC>WS3#PG M5D($<2Q/-H>_&BNU!F)AEG5HCDS6UTHKNC_O5[=\8#?Z8=36C!$5!2I_+?Y2 MD/+ES>V3#8Y#886L:9KHL`;)(=(KAK&NGSTIW>OGP%'D]WY,Q'/RLK5%2Z M'H8;N`YP,%#C2#;&B.:L`FB_6(.LE9$41+_G#QF6!ZE"CSKO\68BJ!<4.%W5 MI"=WOP_*\+-WH.=9V4-!3:2N+9X5'1N=/H+3QS4`[D8L(7CH6U9XB)6A-+G. M/K#H;D[`C;T\!].VA=S?8W>=Z1-A(',3=F:P^%,J06E99B@X)K0T>I:732AC M0:0G\JF9C/57(1%F"K=>,U8'$1#3@!E*0%TY;,:`W@(E><1+2TQ?K!NO"2(+ MC`U%]NB8$W5)EK+*;=;<&4%4LM!**ANJ-FE)^F#. MEP(U>@S5OD*W=;!-Z[MBA6+73C0"E+7O4AI([POT>Y3+JP(1Y.#PEN1"9$GD M;"(YPI!I@C8J!1N`":&\MY3%)KL5L4)L)$!$,$"#E3Z.V)"55'LXL[ZWV=PB M@@G18KQ:5T:H(6I,MK7&?O":=VWIV$J5A,1&J(:8;'A"X](KO#0'*$Q#'P;S MC>*]@%[\MEDM*EQU+CSY3FAY5FOUCL]NDX.5;9% MY+O+(']EAWU%V"8"*D,$4:X]+YI:5@*&YNN]D/7I%=T^%@(X<;+NE4(3M0*T MG]2HK->`P4#@$W=B(@J98\E%]L'OU/N5&1UQ$=7S=?L)-$O5:(%_WYH0Q1CO M627$Z-=(9`'4V%)J7I?>88DI*"#1XPZ*3H.#9`TJ"-%34C2%AN!(*=4-^,I' M,W(]T_X:VRK,2W?XG+:WV'PBQ<&0CX">3L8$#'9C`LB&"SX2Q_GW-04M\(^> M(/^@%7X;7,9=8.`KC3KUG.T((-J_>9?OZ5'BV#YN(`7KQH_>2^(?FK\7A>O,4(C=)EO#)C1' M;NJS:/@XH:4P4_6:_UJ+0W@?+P;&>$V9F6T9)^->_\`0T8POP9!3D M^4O$EXTH=6Y*Q%VXWN_-89G!C#=Y7Q)K."[$>;L0U3`O3K[,%T+$QH8SQTF' MSM+40]WX3ZP+A9M8->H]-$24354H:ZP7JV-1HVFCM=8E"0%=]8>B:+..A*VD MVT5Y*!K!,[YXQH^P,VI-VZ;K\CZK2X`B'&EF#:$NL(6\/#A6;VQ(E7Z@*[9- MF^]Y]CUSN[R8&78"X%67['?`PWO04_%?"P_[LXTL-F!!E_S;3L)`EPPI&V!% MM4\J3[LGK/,4`J--$R&S)^0\424:Y4NCS1)I.M!%+)9B**6]$2,ML^H7#K*M M^++NL':,O=7+/>QEFY;&I$FTBU3RK.I6F94Y4E$K9W*4`?OHE<<\GRKF^6,/ MY\(]^%92/J9]+O>>"$V6(V.BX#_/SM[BT9@XE-Z[2X!)',0?@#-PA":G/[+` M3G`D(_01MF]K&AE6`[@B#GKEF&%3-DS?NS1$C@)=&_I"52>2`YW%P4Y`MO8- MRD>`0TOK*[T2WK[2MM<2E3)X#"B[Q$"&BKC3A=J+A@-'6&"^"^(SBBG]^RB+ MGTF+4]?G/0"DV%>!)=`'V!GLD`P+H(]C(E__B-8-0.#5F3>AEPNDT",S@Z*6 M>8=^-G-,/G&\(Y&DSX?@+F5E9+.LM&6R1/6291E!$0?I4#`Y``]#9="7Z<0, MWXW5%WK26>\E\-G#7;(Z!D)79J=O)S@`RD"'M&9"8QTO5$D%T?%B$HZG$QK] M(@ZCV3#PB\X8@YJJZ0,,SX5_,$";Y+V*9(%G1Q!9^ MP-P%%,[W+)J+_.=C[8+D%XN!H!W#W;TE]HXZ-A']Q4'%L6A11PF5!XG"V$2AJ<).1&XULGB6B M0X"G8//R4S&^`7Y_*7D#+>"..[<=<_#&XFNVCB59AT;.^P9C MX?(5QI":\,&B_`K8\JNB6'&T$CFVGV>UD'F8E61#M)GDV7:_-4-B-!U1 M?>"UE*H!$>HFUYMZ+JNP,0#+M MML/XFFXXLHCLCJIT$#L=R1!'8W*X0-VUA3N,R&#IM$J;*_V1ONQ(YA3S2;EB M9Z>:VR!Q21$\I`7B/35AF=6>_(BX-B%W+-:_+]!PAW0;3<]>`9=*J`RI0PTC MI)Y81:'Q^G`!+L;(CU?5,6DNE(SOF5^$J>Z!`9N1S6;6FSV&N[!)DB#=!U*QP^*]Q""OMFNQ7%4M7%]W M7DAA[ROC(O-ME6+6I\@?5B7[G0CN(F+L)CD#_[(OJ!(G^[F;QE`DBV9-A\!X M0G`E(>F;6S.>M3&(*6,*.C\O$P[#U/:I^AFF@?KC,=HG(R71]030#@LNB)@E--RQGA1JXE$3"HXCY0K]' M&W$GI*)BK)A(5UB*$M'C74MB6$B`)<*(4W@%#.PJD4W3,A.%PN9&6D./FK$C ME"5AR>T*$*74&P7R5:+*?>!5PB(*Q";C@\KRW1[]RZ8,`=XS][*"B3!%-]QM M]E[&0"4&@VAD;/+=[7.+J9I,ZE$`KKV>H$(WG/*I&001Z6E7T3 M_.O'[%/C`&ST6QDN_D:+ATT(NJAI`Q;9H`TG4GLW,4OVZEF4"XV7F6U1F$[E M+%.;`[M;!63?@#C6!FC_V(Q1*-XQJ#4LA>BF'VI[U]I#FQ![&\]&(7?+-*]5 MKLE;M"0\=4,ZU6B;?<`'V$:,^T`3'_N&D1%IR=>FPODC>$I%6<-Y9P5+>Q61 M72FVIR0P6R6*/!E'T\AN2S1X[YV$*W)MT0R$/TO)OL=TX6QK+*,GW5)HUF&3 M`\'"#YK.ZI;6""+#RHG'@+PY%;"P?%='`PNI,H9JMFN"*$K9+EB?1XJZ>#G_ MU\%3/_`)!0=O$6KU=N5N;2Q)ZF7X3!BIL'5XH*^5H[)"V79H+GS/L5PK/I@I M/LCKW!6(QQG'N!M50$U/5M0FYAJC%2(P47HF7V)_Q>5@*2%5P:%A8I.\R,H; MR&8P\':ZY8@/)*#4I-2@7['>4X6&-76[#5AF7:"5MIM*KS"JI MA4\T`(DX5?]-;T%\_1F676,,*Z,?IWB.@L<-Z7.I),PF^EN=N#&6I/0WG@^H M_"5Z%8,;0";,_:3\;U%D5M*R<#3 M+B\PRT$_1:\>GY+H!HA'H0MWZZHTI11@#/7)FIBB!"1C\L4U=<[-,U&HTKH= MO!<&K[%L;:ZA9K^AU.%^HDKN%=H&F[..#4X/__N+UV_^>//V5?`Z7Y+#R4YI M?G$S=AE[K3!(D;;W@//57;:S?(`\^3NOG`:3]X4I$;FRQ2<[U$==1(%MW1S3 MA#J94>#/QN&>C3N,:]F->HP@VD?>TMSA$3?1/0#N(AJ&HRF;RR^F832/']@T M(&A:!,D1KX2@I&L=SLTJ;QXQ6%1-JZH[2+@)2+:QC')K9_'H.OX=YPR.KD>_ MDPJ('[,GS])UHC!XMXIX[$B,8:]Q+G$X&HSX6"['X6@V=<'MGL_I=+9DUP'1 M%),PG@UEBB@*9_.!FR.GH.>/FX+4[7_>PP#XE,_J5UCZ'K!5]T;ZV(V#`?S^8/N9WL; M_=?4NR5>=2AE-!+(@U?GW2PS0@M8(GMXKHF&ZNN/W%ZAWUDLN`BB.(SC,7R8#,-)/`U^ M*/(KOY=6,)K$013&XWF@>TGAFY/9-)B,PMEL8@?6)H)H$$9Q!#@=#D<3;V3] MU'__U_\=C*>#H-V2Q;T_CR;8R\$M.P['DPG\.YJ%#0/;JN`"1YS&^!A\!$@-)^8SCCJ9\A_#F.#S./B34;9MYXEG M(C?V)3T:N9+EQTN*>24!E7R'U7Z-Y=DIG,DTE+`BMPDCPXAQE$)9^^*8=-(0 MZ99QIH82:4VQGL35F`?MK2A77&5"Y[*+D@(WA6+>O+!9;STHM)'I.YA8'3YZ$\OGG$R.7RH'CWN MT=O(LYC1&DB4S*]8CW,*G"&5=F@*KW"[TQI&:T$--T#&\:DM58'(!JZ3O!8( M&3X:Y!(N[Y$2#^`IGV?JK>!UK"J3-NGF[4J3HKA?$)T)D\A`7=SC(X6(W!H1 MV'J+36F4OH(9(S"4J/*P+B2,Q@FGHT4D2/LQ(RHI4#:>EEROBZHH%\:^PQ>5 MUTK!;5*:&@WEMHF=.128E1?'!@QM9UCXBIV(,O`"P9AV[MQ^.IG/1OK[<&Z= MA1CUJ;H,KVMIZBO9F7KM6^<$QS151N,D[]+;:,"&_DTV+\:J(W8V/2,YF9K3 M_C$I\>*Z&D?/$+EAYP"XYVA:>A$&+]_`C9,'K;X>(?4`4 MGJOO""OU0+M6VQX::Y,/'!BBHX$;`?X*/?6IGT0S`TX0ZP/.:&EO M223(QA1&,.:,$@D_]->8"#B2VI577%'-$6.UDV^4'<^:^W1$2LVB6DLEL78U MFW_A+H6L6NKP`(TH.1/?65CSE1\"(?68D9:B!$=X@+BX*O:+>KW?6"M"T^7^ M/DOO*\_0YPP.E$!I@@3%?R4E]&\?AC@@,!<.K MT/$$'MONO%)+Z8>[A%Q;U\$K&Q1F\U8;2[8[;/GSQ(Y#QG*15/O"/.XRE"VD M9Q-FEJ&#D<*VS7&HJXV'!V"Q>;28,FSB4FPVXWI0"<8@T+T M9V3AB*LZH5\;RTD0!X:DYNM8#VHR^*_M@]P@_)G]WKDB,A/`D*PP)W2=;A.J M;7!OL(`JIHG[V#!QEW/2S')I1(PI)Q"%T6N#)%;9O,JPX"]]0EG=V,/+P#K< MA;FD[SFI`SW!Y77PYZ+\!=Z],MEB;F=N/UR,P'@QU)(YGI_4:\X[.,A7>/@V M-4/N+(%(ORT&$+U+XZ*6$)^*5`E>_K57N&^5+KF*OVG<$S6Y;Z:+MI%AUK$T6"6P@E%MUKQGJD M$0K>=@QB-NH6.P/3&FFS-2[8[);4E&7=)5EIXF\I?(S1VXO:E\M"X8_?=__>]X$'RWS\20B4\LY"__T2$^.@3AM'RNP' M%ILC^'6JCAW_C@9$`_98I!.KP]XG\E95K&OZ@]]ZB07\29#R)J2G&;:I@A5Y MKEUDF@7#.O7@9;0A59%D0RT#$#%"=I^B4QIQ1908XNA30 M_1=8X16&FURQZB)TRS>K)BIXC.JC(,FEDG,4QHQD,2E+JCTH<=<4DR.V&5RC MC7J\+ZY`AMI1+1?>OMLN2%&UQ#AFE8DQPV):X7GO,BCY#&F\L:)8<> M4X9UY6@N,=:>^:BN-RB!I$S=,-]3WP@G5+D-GORDC!BHB9JR!6RQ:3:"P#*I M5Z!R?>N42:[0`H/<9;OJ6XYV0HFXXJA#-)"_1V&/HU2DX!+66[*LN5&I!@:] M-782OT.DX[0_FK*^C4TV,E+T1D,V-/9GN2"(32:FUF9LI@M+S<;THL1E7SI^ MD5,=)]#SKC98T=-AO?]Y>*W=Q;("%'\[GA::(;%AQ M]&+?[L@0[HJ*[]#P4N8-9TM+AC.DOO-,;%N%+WA0',T61C1DD1W7X#D&.[L-#%OE)YBR[74/BMRTZX& M-%3KI,W*1A"]/2#Z)K0>[5:16Y,WI[+B62#69%H"@HWKKP!EIZID``XH/.=T M^'72L;*[@F-7JSV7)>\HG*5*2GME4,J@HQ'/-5:!IQY:'/^Q/'"WH8WJ^M"9 M54&9`/*J;D41Y*:/\WLX*#VW!$Y,2*UNUFZD5E+2AT'+ZD[FQ?B-I1'17 M3(C(O_AV$N5B42!"4PDBG]U6JQ89T@HJ+_@C]D0T?U"#1.;+?E:TJW'5SJ02 MJQU:`$W#F>1#'V8TKJ%ATF(SPA<1*$1&N%H&AQ>_B9J2Y88?W2;FJ MS@>/9/#8ZK9YPC(5O,6'J<4L-.-Q*'[R08)%Z"0%PU@44C)=09:^+;85*@\> M)#L%.*)AG*H+ZZTW1IB3.U+DKMC8D5UQ!([CJG8GOO9/*3UZ]39=TM75J<0: M`3"Q&8?63D`S7%,VI5P^XUV2[56(2!E<92G"Y=JFD#1,C=*Z-F14.V;,1\7< MCE@K+N;F2B^9JV:[KS@'KJI6F=K>L)UON"*K>*1J),0@9,9L=V/K$`H*Z*E. MV1E:X4*X_)8"?M>R-#H:QPJZS]`RRL`P]68]6]UX\#LSOYW6@>F)DREU$6SJ MFN=R0IE2K*74PI$BM`ZQ3$U\T+GA?"@SMN>`@R5*H7-K:&<-<86E.BB-AFK!V=)4&!!( M`8>P[X!ZMU-[SR6IMQOS`\51-SPLBP.'3"/D[<--:HK2`+:.T''8XC.^9VUJ M9?F(])T&>8NSU>-Q M!@*LO5)]R^E\WVS.>:VP?#D@ZN%*"DD(`WS.M4C@_CB5?=6_/;,WTLMT8^I* M@OJY;7M/G:F^'6"F$=-R\>Z[8GQN/DZ&Z5W90HJQ,A<4L-E$$H"2I]D]P;\1`*K.[EFQ(TS+*]IN[#MZE?*.;[<9TX&%'-A0S9J8Q MZ,BJTMM6=Q-;K)LJUVBC@&MNVUT=TX5C8'T?SNFMT$]G$WMQ!!M*1"433?=+ MU_5(UPYHUV#[Q'`_C)ZZP*!O$UT?QH-!*W>D6&L;D5$LEL5C(NH2APM:3:8?\X<&-CM:"2UZ&"6Z>PS);]@;&7LM\H1*N!7:Z,RV55KYJJ3E7P'26G73YZ?O/N.^H(VIS%/?K3CL2= MRT5]YJLO".Y@$+UXH M844R&SFH5.JQ&N!$/6:M2CF*XC4I\@1?6R%9%'ZOQ0C32EVCU8D`.S2_8?5+ M(7=\MVXQQSKG2JL\"6FU!$RRDQCB*/8^K\>>K:1.A;O\YQ?I;99STUSR&EG* M@?C)6,H5\!,L_I&LI(H5A_;73;'6EKXJ]`OLBK);L(&<$IGK)Z9RH&PK\_YD M8SO)0X,YU=V"2V.OC,7/*%0A5Y<_%CM@2,/AX'%PU;H3ZA+@0:K7%/I')N*? MND94)H1)/6#[25@84-1E8S+-@.GW_8)5W=J3?(NUBB=J:(,Z4NO*!6HAFH@@ M1/%.+)'\VJ@UL>FC_K2:49W3G7':4*UT,)C)K1#8V#!LTPL*RY!O74*PA#A4 MIJ@>>?_HGGXD0CY/%^4>-<@32#F(PT876$',642(>0-#KFP\&:]$/WTC;E6- MF(/X!&(.XC9B,L4S=GWV6,K04C/)N6>[O/Y]D2U2OD=!S88GUH<="\2;]!9+ M5*B<=DTV/C-ZAO]@I.]50D@VZD6RT=4\M%9"DOJ?2%"VY!D]L2*I12)XQ^!0 M]X@DRF(!Z_5!+-6VKW&SGTVI#)2$)23SLMJ\I8XC_+N]?#B`:N3[XYWZ#:@: MAV;:_E"^371;K%)N%>]2V0I3^BGQ)1V[,!V`MO1AXT?^5WLLOYT:>Q/E>YB@ M\:X&7N;\FRB-2&`*G"*Q^IM27[84^[AM4F44C@-JW>QO\8J?XJNCL]&+2=MD M,$'2QH;/Q+:%>6:A\-2*LV8&+`!A>BL:.YP5N_`5;?!SE"/7&+LXV%J&B!-- MN$REBR=#FB/\";#-.FUM$-O,$WK-PK`)9%MEDG'95?]8<&H+^25-V=OVUKX4 M&YW]5MDHJ%A>2=Y*]?36]+-L/>A"K0ZY^-6SQ2D"4S6;VON*@J[.LA+4]=:UU,4$8YT\BT_.90?79GZ"+&%E+7O_^Z_L/OOZZR/_P>_ZO_\$I% MZ-RH6)KF`K)2\Z9C)'X7`\#X>CH34OK]OK MUH98<-/B._LB-0MHO2=6B$J:W:-!=6G:']P7 MY2]T(G)BRN1!\0&F7:%X4'HQ)E16NGDX&LU5OI%$6R*,1"(A\_L!-%#B6P<+ M&8?/4K97$C4[`.+F&\T&X2B.#9!Q5VTX>$;$^3QB&S(NAP.G,`-O66(`:FWG M-D&!B.:/;XL,JH(H%-,Z4?P,S+HO[;_BQBT!HPA/EEJN" M\02^Q%Q"LZCN?742*)\X";'''7I-NJ70.:PW`Z&W3D@T?Q6`JQZ&^G`-MQ M\(8RX)04XDK"8;&:1M)>V`C%C."D9AU!W?,)U7KQ"NPH=@S4=CHTUOG*T"<< M;3;%K\M]VNCV1-EHQC,=CR:RGT2>U<"+HX&+/#&J:Q0/_'`4KS!/'(YGHXZ* M/>8<0`\S&0L_](=0^A/Q8B&QU0CH8T3U_2< M;6>N^Z%7KZ4=2TC-T'(=]:%BO\W#E7FZE=M[7C1YJTI8Y5VRTCGLB!&VTC/( M;H$1:L:9(DDUXK>PC2VD^"L*6E1Q1FNP$A1"`8&)Z2$'@'V?8H=I"=JRJ1\D MMHFQ1J6&"+4S8>VZ@=%9@"A3+_?W=*0G.J2YBRJN18(P6/V62#`..7>I@`H* M^%PCP&?%_-X6=\80&?'RJXJ3E8V/V\*3S(#A<6<3=`5E:!B!GG!\S]&LG='] M?N"VP]N6>Q#PE1L*O]2E`+6#[I"&VDG2@3X MR')JU\'K7U`K3O*F.G4#EVWSD:J4&?*CE:F6%L7"CXS+`R@5RE=4;"LOD*X9 M70"!-JNO*G;W8$^0*U"$[MD:M=MQN+=-[U;%??$!,RF^+BU(7>BO;H^'W8F* MS)EU*-0)1[<8V6A]XUJR[ZDGIW1DIV84:4VA=(U0"K38P`8L?`5=&FT8S3+S M`NN?V^H]&\EYP#1QI!IOU*&2P-Q_:I*IB?EAI1_CI$[%=4V@1JNF$`\\,1U, M@6N?J_E)#$(T"`>#`9-$U)),<+&)<)'!L#ZH+*`M++NC^_L0ED>#<#XK=\N9:Q3D\,(Y$.-->)H1P:SS\[@$AJ2/Z^P]L[!3 MC51T&,N-:8NA?A=,&L_@?UB@DCYV*`H3^C6:=*@+HSG]!O^K9M$=3&)GKS:>E+GF'X-TO=ZLH/-OS-C0)@EXJX.<1OZ75Z,J& MQ7ZTS"V\ME*T0HG=/,_&H@T&&6V2I-@ZJ#COQ!+7E[:Y)CN5\ M-L1PSOQ,FA5+>@N/?!YA70GC+(@W&X(K/JPZ)-N^X.MRG_GI=*JP*4M0>+0@ M$FW$_:'KB"WVA[2\LC6_J@-(V9R/JEW4S+M=P%R+V^"P7>ML16PZS6`XBAIZ MP55#+[`ZP44\F?Z-%(,>O>!,;>!F61??IWGV;TUUH",XYZ@$OZ6A_:8"%%!C M)_CA3^BO-G]2NX+@V1Y9`,B/F'A*?I"*RG\OLF('$L<6;M">FQ`)'!ZFF[CI M.AZAP$SS.Z``W->:/9@.9W'6C=&_]J7X4U3-/=R]EQ1M>@!Q8RQ3,!KK&HG* M[W4";Q_$O1+Y?#(.A]/I>6($/HW#T?1,:_9GD-`%Z@T)?0Y?HAE;%O-_)/2_+PF=HP-,NJ#-NW20X5(7 MY)4W=FB7R/0YQ/5A&,T&5@;DO]J"^7`P9H%[<-2:/V1I>-BRZ3?$=Y1M\4'\ MMRW`3T!@!H$<'Y"/8HCGG^,AOSOLD>JG$4C9,WI&/K9D^G@XD#$&9[@")O$H MN!S%)$_/CWD%AB"\7XZQIGP\'K:5A:EH+?AOK[(PB?@A_+=?48A!40`Q?S3# MXOT7 M-L]75F^X@@]7O@)1A$SLK;:;9E42U2:_]P MSG.+=.1[2;`MTD_J8WO:3]!(!:LPS@P?J]N:2*.P#-\XM!WZ%2Z],,J_I6_A M"RD66LXY1[,81;.S-8OA+/J570YGJA94\")X_3YI>1KL68\^0;&PPU-X%8?J M4PG/!7S,*?)-*MUB"0)U"`T5(N?\`6'#;U.I@O7*36L[@_2J&6ZKW6J&=U]@ M%O>\ZS-.)5*YU(C]^2M7;]MJ)R3CY.F]'_7%]H?@MN#`,^X%CD=+'6]+U2UV ME>*M1BC;ZBPKH,0'N9PI2*X)EBL0+T;:I:4Z=52HG`T&H7#V>P! M>@JUYQD;/45Z>G%I56Y5X4)PD&3[C(\@0#+F13P(HVC\(#W'[H@/^-A$F1-+ MZ/XAZ4__LIDXX%C20\)VS*O M(@[?FA@OK*6&"7[L#$QZ-XD+99*H;A.:!:G%9DOUU'?J;Z9Z:AN7#=6%Q5Q$ M,]=Q;C(*IR/^C&%H(GU<8MKW8WKXLN1+9\A-0&_9E::5]A([F5JYIT:'`) M#D_#7FG3\>=5Z`DCN%&A MM&^=410.AT;;PO9G#*?_8VO0M@:Y]UP%A`[SV@8@3CH#YF;A9#X$J8*%.>[^ MZST0QM%41A-1ATZ=SPD)YBG:$?65]6$TFP4SD%A M;.G5PW`8G1-<-X^&QX+KIAV>ME$X&L^"EY2\5MB>,Z-P,(\:,)3%$`!'$RH, M2678N7_+'-[H:IQG-6O8PVS2K4UC&XNA4Z$G$]ANW'G9R*I[UN4Z=I^4#F>0 MX#[IJ!G,#*>JK5YJM"-7FJF24;WKQDTQK$HL0_]4V9@I=?UK.YX)C`W*79EC5AO4GUG?#KTY*X`9(9 M21MD1&B;!^B>?KI!(&P[-BGEQE26=&*F+(3IY]R:;:&&=I*'4<5*4O5E*PI+"^</8AW0*' M++E=\45$_7B->HP['@ZFX6`Z4C)T5\;)=?`JQ0[AZ;9I/7M%QMTSC6=Z8RW; MB>HQ+=9MZ5:FZMMQ:;6U70V6AUE>!Y>/S!?DQ[>-4M/\-KEU=[`1J/HL7P'# MJ$NDL&]38=J(6D\`_;"RPK.W3RHIH(=@-KZ8^1P4L_6Y]6'X"#J^+Z6`:>-%$HFZXTLNJ@'_&N;2J^,8/I$779Y M149:SIA1?"N:@O8W]@\D*\W9-C1W3*;)M@MJC:F!P%4XC!2>'%"Y(-F&4@\+ M;K+5,G>I=?Y]!%K$@(SSSVR7.6)[8=3W32_1/!Q.9L"`$#,,S6KA'V+;12#+ M_3_FD3/-(UVY?:-P%O>E]L%OP[AM>\#4G#-\^=.&X<&*+N-C5H'I).HT"8R` M7T?.(A`/`'=&/8[T7KPXHA>=ISR?5*\>UG-%1]*>[?.U37]D+L*[7G5'%QCW MU1I%G3RU66YK8[('NW_[A.S);'"^FS4:_.8#.-&^_E.>`-?#`;$="#>7?%,6 M6%!WFZ@"FLTJL(I7J,F%='!93UV"`T,;]A5UKEP4[]-6HGN+0?3J`*XPD!"\ M%[!I\3^X=G8G\GI@\CRIL!46(6 M3N+Y$;0>1^%L@@%ZE_-9B#BE,=C_<3C_:&2-J"PT8!;[W^"/[$;;O/A9ZP$ON*NO_I5/%?_W2,EEX[.Z5;_ M#%GZ(7B3E'6.BM`Q,P1,[_HUX.C8J(?#9%Z8OQ\]]O2U'.MN@30FPNN/%.GP MCI5*4!-?OGP27#[RO\414CJ+%>N92?`RV]*%>&F[JY@UN;`'9NZW:'7.Q1"\ M7MN^S7B5]ESEWIIXBW4O&,S*^G[G%(>?":;O&:9L_)0.ZB"-4Z%EU*"7R2:] M0L.G)RO=)M5578!(!J>]0C,%J]=DD;8!0;;6OFOLK<(RUGN,^R&1?K\HJ1A< ML^D=AH+XL(2M/'G"]N)>'.#@$2IU^L$46"HQW(^L)Y@LH?(HS!JER*2WD[#9 M']$5EE95TR5B2`^:<*^F=4I8';C=DL\1GVHNI[_>7?5K5QR[X5U)A'NTI9.Q1E*SG7.B%1QRKH^JD MN$BGK50,.-:E(&R0`6>H9@A8ERM&K8WB2=".,/0.BZ%'F\8+ZHIJDHF/73F$ M.6>#E64A]I'0GBJN`$/%-M=8O2Y;9N*/Y:4<@]=U_^]8$9:H-8^5!`MS(EMS M(DPN$-?7"K<`)/>%MMR=7H;4KT@@ MPJ=R#R)=!@2F5JAH+<.G_:?0;I[;J-$R>T_-.#`7E4V5SE9K?6.ZL)I#&C-- M-/3QZZM*&+MTDNS?/Z'H)XYVW%I#-2]ZXTQ. MZN%>ESJ`_^OWR;^QI\6N!$77MI0##[Y;9NB*LTX1]Q7S?@J#K_B;RA8J61?+ MO3+X4=8`H#CLK!FNWRX\@D$FZ3UUT1&QC2OEK='HOB%QZ2/$(EHY[AH%&A6Y MC`2!9`S^V0@\_%>7>./:O^`JO;Q@:8&)4@.&)>^WB70>SK,MT![/LY4_$G.3$(CV-LQR:$K8G:3>6=++=V_#RE!B,BY"1 M@;F:+XG"5@X6=,26><33J:.Q91VP*=J0;Z=NGMUG9T/PH"Q9\5H%(0^=J6&N M-/#+TV)?F:V8H`0O#L/#ZT8AGSY966:]K(`H"X5^?)QTRAOB`1'__.5L^"5H M9.;K>E;ETM%5'12T.?*#">J[X'\FV]VWP8O@]>X.4'2#7;&;]7N'QT!\)@U[ MMV\3,*ZNGH#R6P1O_(SRER8-FS;YLEY=RQB-Y]Y9[[[XNK'A+C:K:H0:=[SZ M`BY1Q7V<>L>W@V(/\430G:SI&,$5=*?!:QZRO"N+'$`*?"1-*-;)4.TNR!L: MWO6;255I`;)78Q;K5Y?6W#5!#S)@<@HV8.'^G"43"Z^:VX%)Y:*+.;1!VL-% MCI[M^8S%*G>OEW5AT/KL/\!,YSU$`]3&C_G5\5M;4.-@SQ(YUB^BS-F)SU'I^L\=KE_3U%U1(M"= M2E^RJD]W?XH6"6*69A.D.#/*&P\96$KV=(^7>"6;CYYQ2-&-##,.B:%@,02D M"R/3DDO>#?4IXF90PC@=_4R'MH7)7T]3_Q.N:B5._A./(*=A`W"P?\4H#DEYK3M/SPKQB MZ9@Q'K,1E"/C,'V>,U,YK\,X^4VR:IN)4I4<*&^87< M,93BMB4/W>\M:N@])0US$R\"<:$CD7O2[6UX+OZ`M\4L4C$C+A)DHLQ`3\5B M^%PBP+SNF_;3%VH$XJ:T*V'BKP8QPEWE M>K$LRPQ;N4BV*Y=65>^`2/)3GA%E4]TR(^S+J?N//^2`FG90_[1L?DOWB8EQ MX7#."35BY+VNM@I?3)ZO@A/UX>K8MM31Q@!6BCVS38$/&"7*%95)D8!KL*<# M%4A36ZFU,9U0LP7%[T[".];P[L8HTY*"K^!*^FDYE0J=MQBBRP0HYP"D]^Q? M1E&+H%"I^',2C;B?T09Y@-2\R%>FF+C)!%AQ1+QMZ,X=[G/;"J]C,D[N0/V` MR8'K!$A]B&&T*,Y/O[2-`QVF_ M%$;6P!`?;(SMW9`Z"28$B.IU3&D^).V9("Y3(>0D$9!XN"1`%S9*O%>8==,( MBU..0I[2-->5B-JMEXABW8D<6WN*/`CGE20J6^G>D8\R-=Q!P*L*Q!$4BI:YN>I&!2MD@T5K^`$KNXU M8'6=9:I/#X?Q&H;;$O!TS5T(\WJ/J_-1'\^\[6%&G8K;T63X'$OY#=6QD3#4 MAOJYT@_'$&G:KSJUX?I4+S'+L),@WY,X"0O#*TM.6)4F3^&HNL$B-4UN4$)= M^<3'-$PTZEAKZ!#O*+8 MG(]WAEI"_SVP10ME\D5M8VW5RSHJ1:QS>@JCM^A0*;2$A/3 M=DTWI*[/COZB=IMXP?59GW79/SE\\;HKZJKC!2/2OW77\#F"E2.=?Q)&0/&[ MEB"\,;?RK2:C3Q49?6?(Y+^_>/WFCS=O7P6O\Z74#R:WV44P&8TI)'\PF-"_ MDW$4O$:#8)XM*WEJ%,XFLV`XC(,Q!5X]SQ88X0P7U7?"85#Y$+N/1=-@$D:C M0?!]FA<[;/',ID\893[')P:3Z(B%E`H^AQ$]B?_7'C#\;3R:TW_'@X.PO@.6 MV\/_SZ)!\`;SB)+@NZS@W[&A3CR?!MC"ZP9#KK"$`)[^N^N;ZP`]I],``\Q` M\QR;H/9I.!M%6`^.*DC/1JYH0SR`%V)J#Q-&0PP&'8[":3PYZ_Q'O^;YTUK# MX73`>`"+:9Y_#*3B.B=Z-PA"G\K7,?`B2QQ-_Q4Y],IO1?\\1G MT9#^.WWB<&Y#K#@>34RQA1&<4AR.!B.,:;45%R[PN_F`*_-'DPG5"0#LGW3$ M1/Z6[FLD)<6C*)Q.YA1S'&(]\^:9CX?P^W@\#.:`4^W;&X?#X81N;PS7TI24G%,M]TDXB6&O$R!"$X<,TW`8 M(Q(,,1$)KP0&8P-^G($-O^+M16Q`HC,'2`E6#`#]F\@PG8V"\0QKVF,B@V,D(YC M?@^?)6YEB/P(<`E/=&:/R$F.O=HI7LI-AM.OM4BBW:_\FPM MYVO[8EP^TM]Q&(GO2L7UM$N`:^\B3_8OWR$RT81.S*3JEO'U\E0XRG19C2" M4UDB6(0%>'>\IX_'RH/UD_/@Z!KJUJ*(ADM3;0&4%XTI_B:QISD*WOF&?KULEGL0=,!T/7"#: MQI8CDMR\HD-5\.SUIUJ"FET;5;EKZXF-&Q0?M=4YE`N082O09P51P[C5Y]Q$ MA]O9))QV!#P?Y\`465LVQ>KH:W8_>88&;,.EO^N_7L[@H/0FN6!2MLX9%?QR M,2G`_A[3$4U%WMO,51Z!GZZP&JW%2RQSQR8(P'JV")EA\&O)_^5[[:P(KN=L MXQ;ZP$.;/T'/G(]`;CPP@+/]Q:B8,&K4G(TN)(7N+E$^!8^D\BVW;1_QCW+[ MS"8;BV0X`^(1/K]*#DY;E.(N;-XN(Q3;&9`6`C932;B(BI MD6F+>5XFR5B:K]`Z.]GC,)P,)^$<9&Z7L6\VU,RQ5Z5BHVDX M`EFNCW&VF@NVG&N-G$)_=;J``?(EVQG%V$Q5E1&-W63ZM(T'J#*F<2F1)[#A M"'1FT(N(RDD*M+KM_8B(SN;/'@2K9B0-OZ]%\2PGU&O>B@O0>X:CF',S3L_6 MYV%H0+'%N3334@S0';5WOK8^F+%6PD%5;&W%=O9>>(0,8?$(0$F=Z8FE6".M M?4H-/+T>S<>_:^!91_-+\1#IB)B55Z*$A27TA$K40H)Q+7#I7KQP&,.5=HA, MMY!'XK17H:GS3-MP3`XHL44M9\+MO,N7C^R35K7$4,(77HB<%!)K/\K'306K M!;<^ZV6=@1I.4J[S8C2NZSOR+QQ9'+HWE.322`5PB-H]@JFT8CVZG8YYB04Q MUXK40UO@-L^Q#V<&.TA*&:_J'.93&-!>F0@Z/#XL/%E'R]>D+LJ`FD7%7WFX/Z?/N;%`B]HO M@.YN#FP&7G5E8RV`VF\-!I,+!33)9,76?":UJ$4@N<4%)K<)FJ,I@Q>YX;XR M1-1P/_,D85EI,V7I;_8.\).IU'XYSVXCO%17BO83,4(%Q<]IV]GHW7D]2%W%>]:NDD1%]HOPGIB"W# MFOM/V32(#<-D:CG%CHF@M"A!4,I9Q^1X'+4*?CB*5)]/AM M@ZR4Z>U^DU!S`R5R^;:,EH6B6\?!-&N+F?AWY'3MRF0P]C]AI(1OR*P3_:YQ M7EVVF!8-]+2%+EL-)FTT;35<6(%B"0'P/Z3WP=-R?QOI"(-<&NED@'7=LEML$`>"SN%;HON7`)WAEX$-Z#)LA_-@I5;'T?6GCO"+ M.(!&X70\8YO;.(RFT6_5Y/:WT7<23,.JT=+NI MFH[:[;[F9"9";>Y&9(A@$Z,9QUSWI!:&F]""ND^:(N!\A$1UK6U`IRSWW'+W M#!HZ/$Y#A[^BO:7+KB]56&V?0(XVE2-WPXJ4M,L.,12F5;V>&]_D`],"K5GB$\DY*-/P,EJSXW)0L?0LK. MB.N,XQ-AG0\,VW2;-W)@0Y!N8("4>:&U1(/V6F#T*\SC]A=UW,[$SKS&1%]( M59LAFORC^II:NE<+IB=TL$1**I`8+41Q?C3OX&E*>- MX;C#?P"&ZY"X9>S$R%!GQUPD559II.]DORZ^">`Y_9W/8_TZ^>1V'S4>X4J! MYA%$/969\W$6TA?J8+GE]UD7DRM)IYI9N?KG4OPIR+B&JM!OLJ/>I" MPRI8)D#2S_3L6$`/+XK">#0,I[/HP0QG@IC!N=,@/M""\`)V<;9FJQL7JX\Z ML*J,VFS&2IM!Y7E79CTI--TA^](:D51"JRNV7KYNY&>-CIVKK79Z[NFVGC=Z M"Q^V&-8^_;2/K*OWT`?Q*!S/'RIEC,,X'O.A_ZW/N=,.ZB[R@^R@)X#VZ7;1 MLTP71L)NV48_WB*BV"952HW"J6DWC^ER\T]S6C=UL..!@.HRV.(1;37+1L:? M(*GVCC4*45P^LE]("?K<2K$Q_EOJ8X+*U.&M'Y M:".LW1`FS:99)!"]K&D@IC\`09&(:@W.B%.;7Y)-D1&#X,H*GDVL<#2YGDP:22/^K>JHU7'LOMQL;,%* M":$PS;,5,RTE'F,[>* M$;%D9$KBXX8I$K+JAF:2JV:?G\^6R@;GS(OS[PS)@9V@@=HN_R%A-I_E'O8S MM4\R\W4"^V-SC[O[%QPW!Q*6.\[:**NSS5:-@CHDPY(QL/@\E71.<]>3_,^_ MV:=XX*_%RCI/YR%<[;NL>`.WZ)C;Z%RRQD,]E)DI(B%K^4)D`<[EOBA_"8%L M99M5F>8X2'&HQ,T"K\&YL8&5VPM1HTV%?9N,>@T6Y6V29]66-0MD(UB,FW&@ M.N3LH<)`&5S;YV+8_>3@/%ZN5]%,`++7UNA`[?O9D)35+?6%@F+=*1(\Y&)^ M9C8N+?%:^'VD&V=_\IZ4?#R74^N6GF=T[U1M-W40E66JW:I^XP[)?C_I#GUB MSTW5HI'"@F3ZE5^)C*>M;C_+C3K*0#P,^ZWR#P'^P]P' M/?UY^VUB1\W19W2'/__*&3AEKK.X*VI_EE$-+EIXUDWKA<,GW3U,J=P2NZ+( M!J"J5^A)]5Z]3:JKNKC:9'_99ROD-#JFV(RE"H]%Z:AU`@5SC[.%\_E^PT"W%?/G+??`9CO%KN%[+&8WYC02DH M0)NV)P2LSWG)?X4[/@JQ)KZD+]+L?^\&:XT?Q_7JOZ'%NJ%UGY;;U2Y^%7NU M=_%_J^*6`M+#:M&6%(]VZW+,CELBCZ6B:,K7'KA-[?Z8E"A+G21S'8O\TL[' M1N06%M_&*DZP@ON:[RCZ"S&B+R.%A`YZEX%F^SFE'>,"+1@[I2\1?-L!$5U* M,L2V(/WUTA]6C^J\>M]',C7&5)/]LR5JG#`"_$9(;Q?._ET[#3LV]*M0XXXJ M4O]('L0.,#^$GC\UU]=T67G:O,\@LF]Y-@D`DV!)'6[468@PZ2ZWVE,BT>F4 M9W8!P1(QZ4/OI6UFR'&EN@&TMH'K]N`T^!BJBSM4;YI M4$=/./SI./0N@F@\#P?-X%KS!=6:K,_:/'6SFU$QJ-+:O'=L6]H"9 MQU@+:F)ZPTSGHV`\C6Q'F&B*_21&U!]G&,:#>?!$PI1W16EN;XM+4.,8;HL6 M3<)Q'`BT2B,1[-@/@DGLVG_(IH=G]_=P:`\/.[33?;"]:5N MOJ-^PD-:,(B>,5,5G0MEX?^XH9B@9?V?'S-K;\MN;NZWW(`^(GD6\,W[)-N@ MC9]2"I!8G]OA#T#Z5W*`5'4HY'^?`PG:T-=4K(VO`/PB^.\22]I\I_<-X:;1I&P\%OZ@3:FN:O=`#8AB>>8]\LNI>740SB.G\]'(Z/ MG,!0G8!K`8COC:F37&NXR6`6/,>$OX+:CU(S<]U(VUTN[M`I0B3S5)L`Z8&: M74W8X2:$74F,)J+&_PX>*2A0C&^>Y"1[OLB!"NSI+![QK<2R:%MBV@\Z2'7E M.9$BHQP((C&8D"%9V**&=]\Z*CU?"596WP1/]ZG)HD=^@CV!L+/9()Q-1L'- MNL8D)O.]B8?DMIS4/BB(AD!@=4LW0?TG=Y@82%Q=ZNE1$`=J:24=+:+Q`L." M#QB7"9NC?N&^<9RW#:+).B'3)BS9;KNJ30H0MX!@+4W?'+DOA3>:]'AN/]7L M/Z97`(*SEG<2F9(BR?-U\K[@+M=+M^?&9M&C#$J7BGT&!&,%9@^,.:F,P[)J M7%V`CVONFV$&U(8$=*I5(&V\V)8*

`^]PC]3JXZ4.`/JN3UB5`B/8Z'`?X MI6!_XV1`!J6$F2M<`/"P+3!IAA*HO8#/2T@X9XMX5BOS/G4R)\6XPOAS1B<#3E/+`6/G@0K;<;G&3%*6!Q+8I*KVA20"3!S<9 MGV=FNR)IFY(9N-*E-C2"J9[V%0I]KE2&NO"6/W0+;=).A?%[MTF6K`8:HX[" MY@P4+Z`G-+C#6VG)9D-&MGP89./1#"@GRH8P9%,X70'5@HKH?@ MUN[V5DG/M;#'`OY-\*_[`F'YIC1]YV\XG/T5\8PJN'R)ZDH0/0[>J7Z0K'"\ M7J!60A!ZD>_V[NG8?_JGO.A[/ ML\F^PVQL$@S)'<3*QG91'@HR=$@G["B,9J/@ST7Y"_GV,%,3%+8)J,GC8!Q. MAM/@94:A8`"2"!N!#]'T.9]/@N?H&HS#P2S&GN/6[)399:.@`5QDQHVWI[.6 M>?--6>S@K`'#WFR2W!DJ=ZQ4Y6G]H#>.0/7T3(%[9&W0<@0/.X&7'-RY MPKK!*UU7HJ+^[(,9,MQI.)Z,@^_VV69%]2A(W)>__'>FX3"*X/\Q//]\7X*. MCJA$%K?L0TWJ3D1FI2B,AQ,%%V"S@VB&2YK/AG`]@""0PN>-CH/CT_X(@"A%*@-BJ-L5N$Y_NB6)%:CB^\R&M,(4$>=B/J9\?U M.O[*>03LC&E9P'/VJ+I;Y;XU(ST,/&7JV1"_DZ"I3A$=W5&`D>,Y8!\@2R4U M-"?3<#08H7F6BMZSXKZ49K`;P4IBBG2_+J-P/,>X#C57Q\K0:02*UV02_%"X MS16DS5O,=U8E8_QC@735;S7M$P85\.4Z]E&Q7@WXSRF6QH3);S`TY#8-?JK2 M]7X#/&&=!I?_"XVLC\4$_\0_KU(!C.Q[","(<#G04`?6489Z\WDST!,]:3Y+,U2T\Q*&].>P,I M:#2FO<7C21@#;W[8,7:IH5_V@("L`HFSL>4"\7SP>;@`#P@L;#B24&M@AJ,OPP1>9M+9YPE67*BM0S?X$74F M=`\WWR"7\5F4_O380?.1'Y&`8M($V5`2A`+R8="BBPTEQ6#-"M(!^'DI9D*- M4DR&[7=)3M+YZVUREXB=AA1Y=J>\2@X!H_Z$U:O&D`OR#%G%7DH7WE+*#M7$ MBZ^Q)S2K3Z1P%?F*0@3A]P7._7J]IFC`MQ3@!X=R/1C\C@WFL*GA=82O]]2< M[?5\D)T>P"U&`&C=J4RJ*;J_UQJGPIL9.M>Z7;C(A(<;H[*S6X@LP8KN@ MX3;YD&WWV^:@//VU.\FOJO[CRR0NIL:X0G)H+0Y6O?,F)C$?4K9QM MDR/@VE.@YXU%S<,H&B!O&H)R@EJ)]=F8Z!XLRSE"-0NVZ+\>!F7]]1(G4;A/^\WU"UD/`!^+G2U M!<$(-/$N^.1'*.8.A!Y,.VO`"J,%T&H(+S5(2^Y=%R(D1[>(3G-8)OYV,0:! M]!P2UH\H7M&"BXBBI$>\BH9=W7L2:!$6[R2F2A"J4MD('Q\_Y07(SO`-9/SQ M(.;T-0I".\9ZS/I]^`44L5#7F%'E2*:R20K3VM+4E5?4AA&T[*%!E/3H\D%N M:NHEM02I/$]62?!ZAP0#J]UE%+Q$ZN;EHYLGKV^X5#0]!]Q&NW6X&5N(FY?8 M;5L=G1+)>^5D>!IK5T@<,HG(1\2*A/IIB]^FKSRTV2880J+@[3J=#( M36$YP%:R8L5IZ4:F,0_#B:@AMGN,`<#8`'*@-[("$B#+O[-1Y&05.KA@;Z]2 MP0J1G/E*=D19$"!(-#5HM=CM!6:^#KY+.=Z')/UL*_!L!WAGE>[VT-&=+FP, M84-S\=5]+DAE&"[!VIDAI'"VAV$K"SMJ"!3;U^RQ(0*8;C"8K<#'BH>',1?E MBMVB)'@UIFKX&F"":#!MY#]@W$%:2W3@*B-!V)#&&>BM.JUXG<`/+GI,SGY5 M)O>YK*^]76\-[U/CD=N1FU5PR0/D=?`NPP6<`3N'=_AP.ZNN"_7IUC:"N/B^ M--R/###2%OMIYO,]T2\5"0=/-OV8#?.56([&H"<3MYH#688/TP#MM$3ZQO$8 M/\R#X6C`!'`XF..I`5VC$+E1&$]<4.@TC$%4PD-5T#E.M3+B)%X"C74TB:*D MW*P6KVT82=<-Z/"3P`5+@Q^3#VE'3+/Y[5PGBAN+WB+R6+DB#)0YM16$DI#E M9+,4:PCW:\4T=..**ZB4(=653CX(HZ8ID%^@<<4H[TX9E\%]-Z$,V&X'*^J( MJYTNX\-TQ"-#$T&F,I%$U`2RM<^-/%2FZ&^&K^S2.9Z-!C.+1%I'U/F:(E#/ M-VCX@6Y(CBC2P,"$((&@5Q2R:5\T1AOUG,I4JK(/_LZH>K/9E(/!F8[*HR`P:-$"0AR' M\Z$%`APG1Z_R5G1T+4.1S.%P7M2O)/1@=C$:SXD?B:;1`0=U&X'F8[PB]H)V M[5^5KORAB0-4S>?AD%"@OXBG>GVF=6S[H!^&?LTXT'/1;P+*-3M>\J(+VWP$ M>Q`ZG%Q2+SKPHKIP`?6A\W$A'GY!5'@X!I!\8=-?FG=Z/)T%GW3=NJ^B>VD`B8DB1O-P7M,!P4YE2N.0M0O M0^)'"AT"B4Y&J9<,6"BNJ(-UZP&1CVUXW"9"/$B`%`M*UN-FSG@555`#*,[K M#,0/'9/+[-V>7F?X5>5'M_:`@LI@XL?*-D'GZ':S`ITOI2&X!86'F_?82._J M[(CD"J^!S<@JC86!I-;V9!R]C"\OS.I,D!**?<1&9=&M%"\U2H99D6A&Q#53 M.B.)D-Q?0MY;LPC8H`^*61F1!##&A"!BNK<+.W=2-P8A\NLI5:A98%[5JRZP M$1=Q2^\I:R2 MXY?R9)V&\289K3HH']U9HJ[K%',X-YK<25I\%_VGI`^L1Q/G94M#)?L(9T7I;1,9/0L476/;#*FRUA(X1$DL6;;;%G9DTYG>2 M@@KBOS&.^%"22/Q;TE20WF647X2:00STZ[4)[.YB+4W(S<,A6:8W'/U8.'I` MA@R."O*"U045[1Y<7H!1/M%(@J\4N>08H\Y]A78O,<7?8T*&?PL=V9$X.R-3 MV&*(-CK,_-*!/QV2:30A-R10&VD0PW=N51`U8."U-)5W7DM'#I%M/B.!L\>2 M+-N#!"\J3.->BLN,>R^\(R`#$;W9WZ*%I%V=`O4A*J_`$7R(VZGI^X*^TWDX M'4]4@X>L]AL[2!`TE=N"GZ?#"(`R52]X72"H]OO"3^]OYI^3@I%^0&L)\V6T MK7)QB4*JQW(D->F7ZV;3`LF9G*Y5XGJ)';%TT_!K@A[J8ZBD]AE"DMD565"BM%E M/IM\&K)%T5G(UJZ99A0->PXJ;75]I/R@7H]73$<%]]ID0U>A>B@"QQ>F M+B$B1F\Q-%>[+WM/IV&32F"8^11S^$<*6WS)UL,=Q@(Z=7O6?/[CZVE,$]FJ M)/;`3>V^Z^`9+MVL62$B]88BRRRVNF$YE4*^BT;^X;%MZN05[-TT&)C>32'* MO!<3*N87-O#_W%ILU\'3#%T*.9?$5NSJ2,]NP-RZS!9[N//V58,ULBXB4*.6(`)0B-C8WK13<;T1&&+ M@'K-G1R"6@!@#1VR-(((+I=,5;*T;Q/LE-N/J2[?DKY+(-C?V@D3"IL00!9' M:AE)[WN)"AX0:<=B'+6@.W'YKNE[DA.YS:8*6&,W/OX.)X!55MZGE/G/H:7> M:SJZ4A(QO==(4N1M*;O[L6(G>0-]_(QP4VUA%)\;0%H%E^-P-,-(N,L1_I]M M]68<,G@Y"AZW!$TZR=?,:3'ZO65=5R9U%CN=./]6HO^P`@/6LL=3 M$R?!&U/L'M(=YW]#])VG`?7HB>I/UQ`+V(_)39@/5O;"/V'H^\UDP M1B=5A/^\[=.JXS`>8J3-&&:94,#O,(SC"5S,S8;$?S:LL(:>K-",218(O!D@ M(@UC&&$RBS`_$2OVH(P^=_5_9N&0LB]&Q"-AT5C.A^+!1Q3+:GEN!PZ_<`$X M@UGH'DU6@+'B7L2?K%9G"36^'USB[X_H`?S[T>-N_')?:+;`F&.F!(*Y*-`Y MCY8P-I(K=K[Y>7G96TPQ=0$W,A8 M.'+SOJ@6Y:TB`6?TQ/M$59[5P"4&6<17K);:OE$(@'BO6-F,BKZ1O"W3+SGJ MZZ^2L+@4HXJWUS*%U&E`<^`N0Y`!B\:ZTDLTR>#0@!5E\[086RV"Y0<7A4%Z M04GQ":HW3O]$GL!C473`038DR04P.#_:>MT?^6U!6L9+HV53JGGX_0<;[7"N M('DH.--D<3PW(6#1)`+@EWF1CD MG+GD&/%36+E9-(SB68(VB2E(+J!*C89V"O#$=#ZD)#<0A[()=O<,):FKBLJN MG\"QQOR<&>=_@1J&F3^;.*4!*HX9,)JN)P'^6#X11F M-2[,4#B\(=H.;2-Y.LIF238;P,_)8%HD/U>#?#%VR3*UY) MC(,\HI1\4%%J:^NA?6 MS*?6V+A@05DO83FA7ZS_&#,NN8![Y_VDHG5R%&A:A(LGZCD1+\B&818J,0ME M#7/.IC4<@'SEF3F8-8[@\(/27A0\XLH=#W,3MV`VF3E.TV(T/6Z.-)LC1EYD ML9&#X#@%P2\?AB,/LUFXT,29L3X=?*`S-:;Y;*?M%FG-FC"H4,?*BN61G`:_NF7%V9NSG6^.V+Y`PW MI<;*/\@_0=6FX0!]J>^`MK[@)C?L+0[PN:60A\KO:/&HZ60SKH&E@$[)P*.& MX8&XZ):<[D_.P#,-W3A8!6<04\"KOZ M0G6ET39Q*B-02F!S?K6>(&OML12Z@=MO(%E5UE%PL1W8@)Y03P.1A27,M=?N0"$0+NHG43!)/H(6D7I4U=;!9P/V!PSE9/C.AJDOEV"4D M;$JD=+1+;)%8'EEI3Y;2=/<%^7A%`1I\)$L7BW$IMWAT=*W6Q>!)C^NDECSX MOM6[VN`]K;NGF!'M.@>GU^X`F&TB\B%FHMX+*ZAGR7`F3F+0,D(JX8EBIC>ZM%93`6H/!B2QZW=P^BIU//`KG>UFZ(IB=DSPB",RS6J:EQ,ZEI<* MP_&<@,4QEV`9AMYV/MPO&K>[BW=,(C"#-UQ%5"_BBC^Z*A8 M10A@R`N\K5@'V]B.N1=!-[5MI.^2X`C7U1#X0JL^;)&3%#@1DOS9\+],;,7=L6V%@M^VA(U/BWF'#4^2K-) M)G'C(&]F'#F.&?53CAW/"+B+HL>S=#[*=/PX"%`:M!K1*\8@3SCFK2]@OO)D MP^XM_:8V?V0R-4G/8QC"8\)J3$`_G1F$C7PT?YR,:H\>S0FDQ`]#G(H)R17J MZ'5`"^5BE9@63&//U8GK4]B4\.DC)9NG)GT]&Q>R-D7^2"LC^0Q;;X8>$-O3 M;,8O,R!/4R`M^7LB4;E/YQ/S$::;^-Q!>Z'SM)&$NRYO3401QK&M+TMVF)8: M>A^O%>*5"+*,G)+OJWJ/N;`$&4Q!EO_ZO]"2NQC@I5U=,T,%9J`VUDM/5'<9 M543PW^D50S"O)>`QX=K4M__*ZA)D?I!UO:1'\BP@G"Q9O'F29E97C#M'VC[Z MAC"Y1<&IU!*3`!N!7V.NDHT`W"'^"`F15-3!I%I1GKW1#3B!^+E)($?KX$)R M[V"T!#B[AY.]TIMR4:V6U>>J,3]VZ]VM\.PPOT4)!>\YE,5WWRUNL",$6B)TB6GF5+L"DY5O>@6Q^"R M8\QM!@N!0^+',>SL#F,)%SN7LVG7)$S&0FA$'4Q,/ET]!HJFXW!9.)<7'/^( M:REWEI?X;M;TMKP4R"?LRGM$-@6('@06+]/D\EMQG3=5+4&X1$4\3/Q&3PCO M&K(E[LEMY@H"VMB;E*=!T8"EJUP"!(S%H\1:':*LFSU,8YC*)NJ^X4PC"9X` M@:_PW@TD+>,^?4]HO$2=)4=']G^R0[#J:-0(Z\#U/W.13[X75B31H)&^V!H. M-J\,+!#PZ>;JM"FQ+CE:Z#*RU&2`B&2?BIW2;]ZP+CSP5F14KU'.5\YL',5D MR>=R_6;3XA&E!X[)WD;";4P]*9K@S;*BO&2LIP5K_([=-,G)D_.7[YYPT;#S M&P2'*JUD:LT[+ZSWJ"FSOC=QQ\KL]/*=15$W=@?/[(M31U:KBW!"(^N6,;"* M+=D93\?#F1$[1K#4`I81]:N[K>R=A-$4<#R`2U>]H"Y7R*5+!9_-PLG=EH*? M;,K>9M5DK)B9O;QSD*]FT:2VU=9\;7B/BLVQVR=1W2Y*QUN"._:?@:"Q%O<7 MQPE]Q(6X9*8#K3$2<$^Q?]H('SG<_BAPK#!L]K3,#2Z!X0UTIZ"-Z+VHWIBA M(>\D5R$6-UM2WLAZ!ZLCM=G]MZ:)Q/))K3:'EVRC^#=8.2$`R/0\F"[ZSQD- M74$W5'EM,:%F=3?$:*%WT@&BJ`9B@V2P\*HQ!>6:!!V`^U/.!0>=3I*[<@,W M[+4NHJZ88G+CK"WT=(.E-BXP-!!-B&A$&\R\J%$MW[:^))_.TNFLZR5G"$7S M_F:)E1%MB?1SR?("25E`4BKZ=,Y>2]`_%X9,@XBPEO$3IRCRK$2@Y,9:*986EV>AV;8:#.Q2U>ZJD)[,-QV-6W[]9E,9P1 MU(/&W$2"=DPJ>GU356+?+W5&_FC?QW3&K=,5VUU-O^(>6V@$W+E3DW6ZANX(YN5 M\T82_&DK4#[-V&;'<9*4,X5R,0988]X<8;%TE^.E1S;;);!NDD`9E*2M:)\I MU*#!<28#'V[IITC4A)K6'Y+7[]\ES0JMO(LXF%0(I?$FMKC(/'E#]"KZ@99G M=B_Q0HW31Y9.I\`/)CIRNJU'+M#I)V"8RQ)F8RS6?P9MR.?0=L??H:N/^A7$ M>8S)UP-;UKH*9VI0+0B2WT33,IOB`IT%+#I%H2T<^`('G_CI5BCS[Q=2'-&- MPNC(I#6EGOXH(K)5%DQ5/IO.1=.UX%QA5)%>X\R/98$1NS$$*YP/QLW;Q*/! MCO<4Q[RG"#:RM+'U.R=:1!T1KEO("$ M@_JR-KD?L\-&X@#)$!5SS!>Z%KAL(48RHC0$*PL?\AA(RG-@2F.CO*63[+'4 M-H[CT`JV",HMB0_-FZOAI9<:T"DG7]N+$/U8"966W8BF:XI%GTLRY$>;5)LF M;]ZV;3P<*R)Z&VM#_)9B(@`:GRKJ@Q=8&UY&G<"GI M\3!D>.==@@B6Q)V!?Z#!I-H:X"^/%>`I>4)M3J&1-^+!$X(GH",9?\+?=L\K M:9>1DI9L8,`6PU=HWKK:;'X5`R[:6]?5]6:W%`$#7TXY6]XR+C&S?K&\ MY.`"FCI,TKYNLU]=NGVC4%K_.%J%3G*]N`%9C0-)R[MBUV19QW(D7`\0B^&Y MXL6UY5[0NI9N+RH[(PHO=XY>[1BU!*!4S[2Q2[*L/NP-*>RXH`QZ1F'LBJ+$ M>6<6[]XG89:_A4H\1511GK_TS;R5IK:_Y(A]O_HOR%/&:MGHS2R1"\`WU@65 MX5PCQI94@BP;429<(TV2#6,LQIE120!I=*Y@']A24=G,DJ!\,<4AV=4RU(&< MPVK(9XW@#U-P&/:-TQ);SD#2?@;8@MWCZ-F:YZ4NO;LCCX>%0,#R\CBUR@AT M#C[AP"B^NB)+R'>$?4Y?ESM.7C.`$?86>YJ<%+,TSQA"_&2@(KVB[$+X0=3A.J;%J#I&5`^ M1,T?PQ<858_EG^&W/,BE:<,_E2I1>;;BU7!!T9'5="G(: M<7>BND%QZ)$$%S:)BGRM-+Y=,WK4M@B,%=VTX'DUB,RO&]')GEL"_5'5Y^5F M7UM#TP.=48&CZR<[>Y:`X^-R+Z55B;Z14O@]6G@<`FBQ?UOUA^-R6X-\2TR6 M-(#XG%;T$TA&BDXB!!"BUU")=XHLU:4ESSAM!'GI>Y!M*/CFQ/P6)!6_9^3H ME4&J,?(0K-X1C[(8VRI9.3^\DK%TNKD2MOS5Y[B;7>WA`S$&,9E'%RZ"PN%L M[+2/3-U6*$>3_A,LY4_K$M0''*JNIVXA,8Y\/%P-`U-Z>%50OMK;[LNUOL"H M(K%8J+'[[:6K64!P6C^<@ M*U6#_9_1X;K!H<6)0U8Q]!44EIU@/E'IX9[3MTQQ

7`!]@IP2DEF9*0GG# MD:O:FSH-?UUA9"6>#F0ZE)/N19W[,W1#L17/.VLT14-(.*#5AI!80:8)47M8 MA&DNFQN>>;$),#+3I$+H(#\M.*A#)FB>YOM/YXW1UQ1O*F%HS9`>C*K`A3-6 M#+J`)=!(Z"%`WQVTT[VCZ,,GH+XQNO6V*B\%-BCT+_3OD'>,S6P,/X^SJ5WAA9,/3_Q$L7Q6MV15&^)`A%7HD`VR,JT0>\6RW@C]( M+G9^$F1D#'MD][ZD@C8Q=[1_&"X"+/9$U.U4>I2@UIA2XUD.TN3)R_/S)[C- M^$LM<2N1V,C:RQWRW[AKS1WP.MW>(2]S!E<_GUM MU7ECOTS]3`%!6_)1WC6Z02EU@K%:D"TU6^J5A".%QB+CFD`X&H1WPFC,'QBP MP`@^6OSR0X&=[.M;AYS-HQ;L:06+HPJHH.O!>#!=%/J=8-G@_:_-)A"73HMVD]0PY`Q!1/ND6<(Q"WT!,JMR.\\1+$ M&-2>L31P-%_NWB:PI>V;:43P5`*;G>.((N']338/-Y+/J++RU5+LNGI5]88,]Q_K^>7]Y+5"F^F&N;&-#BDI_+/Y0."BW,7U"/>58#XO7['BBHYI* M*MF3Z:-<(=ES^7`O#"X`&66NMX*%1+-HN3#@=;-J+%5EQ6R7_(4,]H_7(V7:'DV;&A#JC)V6!%P`?1U\N3GC^]>PHUF MPIF\-]&=M=Q>GK)/SK:*/0PG\"K!SIRUGEP)H'LC>VXU!?H'="0`&'[DR?/7WY\+X@T#?KTJL]QB_J,4Q7@L1\BN\(#;J*\($&@4=9*EK1\W0'*O$DCCDF.GKJT8S(619 M8PU/R,:[XS`BAEAK$<(5B/6F0:SX4:)-# M^^TIU:'C6O>I`&53L-/:HGKK>6&>023)0((L,)<;@\5)CC!L^M*4:5U54O?" M&PJG7Y)8P7:2TC=8<41I)49#V+.VUHR@)8()\6(\6J=&J!$7W5G=G`];N,(I M=8U424B-INWKJS/KTR`S\+DK^U:I=!2C0`M+CL.90/E\CXIW8Z)*&2V1<=8J_:U MZ1UI$17ZJ_`)-(,ARA,7EO%>B&*,]ZP28G0SDT=T6U&USHC>89GI=Q:_)K@9 M2+)>8S;33BQ0PD.P)PXF_X-/9H1H! M:@3\7^LL!MX2=_-S/I:"#+6"_%$C_#XYR6/+8.#4Z\V*@&DV0(5P,ZLNOV=5 MHVA91,M#E-0C\I4_:6;^G`%Y+\`:>$:UG.T8(!G^:9:?*Q.P5OJT@1PL3A^M MA\3?-'\NBM;WMCI$C9!B?$WH&[FISP[:D0.=HP`O=4_R8_2>9:C#1FRC@8ND MITK62,?PRS#4*G>*#6S+-0L8%-ED"$V!I?";MPH)Y/Y[-D4AU'W:5-[V^G8+[XK=>?V0"2'"S+P+P(A'\C9_1<688.5;4[&7A`4L"+,P(*U& ML?8>YT-"9(T6!C8AJITT0G],.`FJ:?B\TURI'IFHI2(#P$K"B&V(DQ%D]?F[ MY\Q,M%A;-%0KMEX%5@_[0ET40<9L-<+*A&ZX8N=>0+WK$CXSR8TU*8]B4.?[ M&L;TP9HI+'H6#TV5=M1FOV!0:.^#X5!1I&8V;`A@Y()(M8R"=SY#&8A2YUY) MQ>6!;S:JH1$[IDW?TM70+<1YLQ#5<+TYV)@/A(B-#>>1DPZCN"F:N_&?!K7! M%E.QA\L343!/R5ECM4W1D4;31FNM2^7E9YS$)5D[J"6Q?67CU&:="Q"R@-U6 MMQ?;^PUJNUNF2<-?5`@;/<+.KRN:-AV7S\O=%E814R2L(50H4JX4Z@NG@U5, MR0"S_>PX8UU]I2-V6S7;>?8]<[K<(XBJ0SN'1UW@*Q4&DUT/^S4JN#1DLRP8 M1_DARACHD"%G`ZJH]V7M:?=$=9Y"8+1I8F1VAYSO:HMF_*W19HDU<>T:@@7B M"Y)X#ERDVV5-B5H4EH//W&$:D#W5BSW,Y193X)D/$N\BE7Q9QU5F98Y4W,J9 M'*7#%GX5.A'47:HJ*/=]SB-T?>'AU'WC*N^NGP:_7.-]QIE!VCP?AA=?D7/? MGAV@.[Y6EE);UY8P((:+RT^VZPYI02<<4U>4-VJ2\PWW90OXYJI]:'<$X;-& M0(0&1&L'M+0S5-@7>)BL"^N4/0VQ?>XEK#)5>".INA,X@5\4(]CYS8*#H,./;--/D^]*3L*_*JS'`M?%8U-AF7D2^PDHI>2$+T%?9VD]?&;R47.8,2-8LL,%0#B0@D*F(QDQU=QCLTV@:@4.CRII1V_`7!+$%M MB\6UM3Y(X1PW<`)6Z+N`SR\]&'Y3Z\ZDZIFRN_<.Z4NB`ZGF-T5+LO(DYE&7 MAQ3+%B:7?>5&,^#Q72B\V=(:0EVBZD6Y_E4,(22:BO,&(9WH%D/5F'"H6-ST MJ=V'5T%E',[\-4D3J-+3'7-Q+ZL@:>6D)K,L<5O^&9WSUMF]E*`REQ2.J\F9 M55C2FXN?,V@5<5#"&E-U^_1RQXO?1?0%BG+:1HIJ`2,XI3K(N-EO-NMK_NNU M>DD;_I8W$,/&_0Y7MD/_80Z!4475J0JSBELUHBT%2DD"#)<_>!8"-N59-Q#+3WRS M75:W=RZOU4FWSMG&%VAC\#NV:/NYRGAHFBY,PP%T6@\&E-T[OYK>"QMO@C%G M"("Z+25H?_=E8ZB'#ZZS.0FDFI'.ODL^DEL,>.-_*V_OOD_>;S;;/\"M^':S MN>2H)')'OUKNA,O"6PU2C*"W29>8#0Z<^GUFVYQFS1PT$;I[)F*,RG'I7Q:D@"K$S\\AK;R,FUDK2-H'EN14EV MC:HQDB3,550;ID;]8A6=QN/#`;C8HSX(J7PN_0HKNY8U8&.QFQBM!R7@@A1&O-24[8)$Q)V+1S)E6C]*[0B`F%3!SQ*X: M%L8VC;6K8Q9;19^QU4NR\6H^[TQ:.U,(2D"#HP,0:ZO!:@P=B"TU<"('4F[5 M2^,(\RV28KRG^!Y6&-M=!>X@"NA`"O?^AE)*#:BV_P)DHV9,]XGQ=UQR`#JP MIUO3G[4DB"[3L/];,0I%`PS/`V7".C5U6[,O7ON&`5KUT2B&Z)>^-:;]MK@' MK$]@;N_@\F9YT%H0-S8816U8Q-*C0U;8J2@%TB3DF%SLVY+4Q*W$=3.!;T4) M8O<:%CY21P)Q75]G)0T)B(ZT[#[LP3L.CH\`/X"TK"5?&GV^G$XXE M/3P2I$=32.S@J$1F.37+>AGAR6+MW5GHTN#&?(7C^=F,1X=APP;L;V/Z1X\F MR2LW39OBOUQ(`-\7%Y@JQ]APC)(K8Q/0$>69[+0ASN+ZW0O8`%Y,V]6]#E2W M";;FVC'85'1?\.;=@C`(+)N%6Q+3SEBR2_7VX&9(+V*OT.VXJ+;=8Q4]8P53 M8@*2!"5X&N&0>"TD$!/7B,$L91G8I2*3IF&6ZA"8,VTM.^J-D9"7DF7%4R"U MK9XH,,`MZMCW/$HJRPST:'Q5R_7='OW08E1D-%?;6*V)7*NNN^OE9^D#U2@, MMI&^R<>W7UM:UXR6`TC9F,L+QI/E0"E,6#1P05L/Y_'D#<5`9-Z(GEEK$DC' MX0`V%V2CY4+7-$OII?![$7<^2=H4:F$]8-%E;&(/R\B^2_[G0^:I:0`F^KUT MEW^G!RYV?W2EP)&FC!T_WV>Z`2)8;%C)KXO:2F*H$/XN4 M1&Z2SE)?7'EU[P1K$:<#P,E>M@"J$+*\-?;3@SXO-.*PW8G6PH_(]JNXDH1! M6!P:$'_-]6+-=:]#C86_V9KH'@0KM#!@I="(:PRRG/_"CZJB.@QZ$&KT=N1N M;"S`ZF'X=S^R;NM-<6GWJ4P[-5RB95L&ZO)BH0X+#V.K+I$?P9B8)P3M$:SY^(]DY6 ME\UZB9GE%$&Y65274E9)O4-,8$B5UQL.DV$]GP49,Q6*[A*G#;SJ8K]3=E?E M%B?#"8M&.]*E4)B0%%>;SN8FW&8SD,@H95SK_6"CEHB#7>0;HQ;$FD430(*! MGT;)LP#%V`G$S6-C5?A&7YR8UGP>'_]TLR68/B#"BR6:GFL!V3YY$G[UY)F# MHVJS332B-D-]\$8".7UL#:Y05*L,R^4:U&ET-?+NBBJ#])>Z&#Q7)<`O6R'* MI0"Y!+OZL^'+KPWW?"F/]G^R+4S?O)0OIA.*TJ#1D]VLWB-,[9(\::8NL=T/ MX_C$&"<4&/E(6;0BI>H(*H!)J>FXG#3_??&`GLI4@5N/`N0=@>RZI9+!)++3Q$"ZQ%8 M/U8=)(QQA*[D?H!Q812#,2AIAX/%/"-"I=-E(T#(C'A1;[871F@@RYN!!#8( M0R8]W`((RZ;`6WEP?"OJR^O"/_4B4T$#6F.:N3-AZ?!S&YL6X!SZ>R'J)25Q M\[B`0%VI('Q3\]!_HFOP@[L&#SZ0?&K>G/:"U:;J'6 MVCCA1,T4L%"RR%V4E^P+TFC5+DO-YC4HN[6U^"""Z-J$95!^PWL,\42C*=IH M]W4C!865:).A9Y,R*?H0)&!Y%U5.$)_*YNK*Z/=W=#52;(N*!$&T?%".?=R5 MFY(TT($@DG/\@X2A-X9L9QBHW6A$HS*QM:F>V&K/O1'<'=Y2BZI]Z;9#G5?< MO&7MPN(Q`\`8H*W!62D*YJ54$0#ZVY*Z9G?(OD*-B;DG"NY&D'+V=4/$CL2L M+\!W=7NKA]S,ZI]FR<1/:US%_KJ:P-L#E-PXH$/%JVVB3442>$XQ&6F'"*\%0;)+YOMK]#VU$1# MNIFY^7"RC1&DU9`Y\(1D15./B#\2F#*.(7(E0/T)4R1<[3MRW=_9;5S&+;JF=,;[B_%.)G%@L]K=[CI32\3U, M*BK$!\_.GQ5V-"NS%5;V<#XN&\,E1@?$KUANC9N;O"Y\OWNQ*<*FZ8HTD2^D M$;>/ACP2Y6HA(UCNQ(#<%SPT%(LHLUY)#N6%!OK>K*NK,VK84&C MBLS)&R+`6]0^)89I])__\7_R8?)\OQ3L5WSB0O[R'RWPT2)YM=^NEP*_@'+S M5U:?,OAVJK8=_\Z&Q$#VB`H)4O'EEU):U9NK'?W!K:A*&YI[_!?2T[RVE5HK MLKPXAXY=AJO*6R\C>*ET/5?T+%6[C'XL5!Q`:B`$7RGHVZ3R'S:;2PIHMK_8 M).%:NS'MQ>4J1.CD;0^PG5BHG-`3*&.J].C1;A*#R6CA3Y)"LSK6"8">OIONKI($6:H")7X63#Q/^[7EI>0]I'X>9Z;7E%$IAFD> MDC?9(T:G+#R7SB=ZS+SDCFUSOH6C)]25K0D*C>W5B8MF-2-X9@?7YQ6=I""( MR)&,;+K\>4`T;MI12WLF6W) M7"S($1XS?7^##0@=YK8@3\>;E:SO]6:#FX9F'BSI=WW-ZAH[\"D;H78\E^[9 MEO<%%^GK]0X4+E)9Y05V=@JR:,J^I?;8LMV-"SO6FI2-+V.AV]A!E+3M"]>OUY0C MO=SAC<8U$9O#5&NNU*J.XLE.Z#F\.IQ#WV^NM3MH)J2RX:B;#D:)-0#E[JXKYQK0!('[NR MZ<9?J$`G0]]:0==<@+_'<>&0F^B!"=F"8QRP>!2L_8:VI(5)=#_.GZRD_)?9 M2%AL"N/$L:%=0N?5W'7KJ>L8;;0>3K9EQ&5L-*N128)!!ZC>HS-!^5%D(L8H MW*X6H4`&A'8HKG=)Q\7BK)P[@Y4*(&+0/I3BJX:,HB1ZEV5;A]8(BY+H8@LD M1L<)N!**DS9Z$+A<[YL*,^RECTC@%W=E:G#*5VJ&?9:/QTS M=;W=($;\E5E0*T*KQ3S,$OTZ``=9(M/+CK%?FQJ9*&(T;50LX"PSSC(#,R@B M\BC'1'')M;RK.&&JN1P\<:E3Q*\E1<$75SD`8GGX*F@DA;,16E`)-FO!]D5] MV#JCEMM&V(K=(/HDM9Z[`'[*Q+JJ!)*=P>%W$17L3;=%P8,C*2T*[`W+]-PZR4N2A!`&%`(FPS$G9R3$7$A55A74?S7 MKF<97"D:`D41.-)4X]FF#*`H1DD,H5J8CI?&R,'PE^HKH5YYL4H)IAO*7L1A M2T[3A"U'R.$*\8?I#K]$U\[6QAI:8&W.<48K/9?;E>_#I)'4IB.:"'B9JIW, M3JV2MHY:$>-@*#S2\;:Z0:B&SQ6=$9'>'A*Y6A12X0V'4&>YVD%``,1 ML9D@1#Z57RL4B.F/'?U!\H&?$^'RV,,H2#$^HB%3VB-Y,B6\JNX MUW5-$!;)E&RY(8/E+58GW-Y[*QD5)(D;S MG8EOM:#(.CUZ&RSMDF!KL:+`FMAH86O?H#<,*!):SJ+Q8,GT5.$H_I-Y MOWVM6Z9S)YUJH#N41U0\-W.**TFTZ@":D3]%5OYQ9VPMN%$VYO).5\<(A8"W=Z?2E:9W(>O M.#$1CI.S)'04'S)S(X5/RB;?.?9@"_?&<[W;9H!Q?,S:FQ5MU/LH8;A]9!>" MO\27HBR;S1GQJL_@4,FT;["?>M5=^F*$1$+6NI(898,K;RN1A1G9%9_W]HH& M\:"$2+L`LT'9:4TN.U_WS+G0RU=7UP$NLH7YH^Q9;?+`$T9,L@57QT5^8(XQ M1_G7Z,2TH?[8@XU:(K`54@9HA`8O/5)4W*N'%L*E+%CW>\VE/721C>UFO=D+ MO#K[^!S+)@=O<8_^=$=BP,F3 MLX\_P:/XBM-LDB;/C0/TW#E`,?^:+/M7]^;XJCZ1]-ZZ2^CT/=\W9TJFI[>8 M=V#PI/K35>(P&*EDFB1:8Y^,L59NNURT?OJPNA1/Y?[S=8S==J/Q,3Z42#I2 MJM"\C1Q.*C)>=7``BTQK'.Y,>`#=GD!HT<%$I?;@=9N5J_35>"=5=\RYYV-U MC2D`:T89<@5C>3')$F&XA%C4O(H4%D60TM_]YR^JZ^6:C)WL!;+@)TB?3*6, M_EAB0EMY*;G='"2\:XI[-B%\HQNP:\E.010+9'B4X^O'7G/`:)`8)F^B>A[5_OKUA^'BS5J:$DZBNO4!7$AF8A$0+%0?#7_ MO4EKDIK(+?^U:N-[U3*9#IJ)#BY0S$1IR]K8<&2#@XX0?+BJ*I`;(_+9(%4E)5:MF0Q=W]W>"%%==8P:529W@ M*-/?BSS3_V*L[VU)1#9J);+1Z3RUQC02?\\E@EDR%LZM4&6)"-H8&HKW2,(8 MHK!=W8LMV-80:V(Y;Y4=CZB$I#96)V\WMA2Y.WS8@2I[]>E&?0=Y,6L;3*<(&MC M@V!I(9%?VE5X8<59\X8GSU);5\38IZS8A4VT(D&XQ!9H@YK9-6PNLL5>85IV2687I"RRY\^`1X53^[VNT=D_ MZ#4:T;@\G*N82N8_H"KF:7Z[#9YS$CD5_I2;EN-Q_+/7HRP9Y\&:2Y$$/(ME MXW4EBCU'A@2E"#GEYJ7)_3CTO=SW'+4JFQ$='M==HYC.W7VCQJ"#_5(5N@DR MZ==*I:'0X6B"292L`KG`+)5NX1S`#=MX*E8A4[=0(&F,^Z_-3>#'X[0X/VH' MW1D;D/#K6ON7/&TP./>@ZW+6CZF_QUD"[$702&-VI;ZIM. MCB<3^'\T2^?8]J&EV#^8@_$4M6/X.2M&N"II,9O3_]-QD;RSKC][=*;I,!\F M&?PWAL4!J6"8%[!0:0ZC(K,]!^R[NIHGDW0R'R;/DA.XR_)L1K_A$E)E\Y/1 M*!U3#7>&%3FA3\=8AQM^Q\^QEOJH<+74GV*/TWQDRKNGQ<3\CKU.I#9ZD=/Z M!`?KS,OW>F'RO>1LA@F9-QKED+T(H.Q\$>6)4V3O>R:360+O=3"^2YZ+EQXX M84C03Y/Q9(QNINTUZR6;<+.P#'V>_(+9K9BIJ*LS:7`"6CI8-O6^R'B0]N#_ M`)_`1M']Q%%T&%$670^";[5-GSKIV@<-H$7-VOMN$Y(N7B: M`2;`+^=SW#'K MVZOA>,"'2+8RJ';"]:'%)!;RS,8F(]B08LYG*!.QJ[BYW+&5O-N*O7Q[KTY` M(Y^ED=D4B$+NE;O8NBX)6N?+NK$L13J=#2,9Y!G<>\QN]:=36*0QEH4G"#3+ M0QP8.%Y)C<3$M!'QF<&2SR*1Y_,)<73O&K6SS8;S=#0M+`]&M&]B2]`;W+/P M\19540^WG#F?Y1:,B!,QEZ,>J>-1>-OL` MUUXQFNJ+V4YF/H:K>^+RQL8@0$QFTI=_>EHI\]VO*)>7Z^0C)E&7*[A@7FWW M2_(R+1[QM(Z&Z1SNV%Z'E2#^2*,*`25UQQVG%.[JX7#8.*4%CP$$&OJE^][X M/4]-@C4\KUE54K;Y%B>2-MF;")X8Z&//,

!XOU#Z,*QN]1FSA-6"O&IXD M""E%NPZ#FD29G/;TG1DT/'U3\'Z-9_`#A53Z-<)&)O1M-HDPD]&G*>YL-YE%7DXW0TF@&7FP//S*?PA^(; M(/N/9F.0S.A;$(,+^'O:PD=&YA#Q;L6/$JBUFQ^J]?)?DQ]_?D0F,LV!>?>\ M\1^!B8!<*P4QPI^,`6@5#2X#!X_/!!_#_D,1,XT\`S\`'Y M520)_AJT!FI;M#">:0:,8$;/R*\!V\F+H?0Q["'+3$"S/1GE=.3G76)-`?SE M9(RJ;PZ:>L#/IL)8\?]6?C;)^"'\OYV7@30$.W$RFJ&.F)/"'V-GDSD(146" MC\&O,Y`Q+3.#G89MLCU,1O,61B;,Q%!(RW%&3I&\^UPF/W#9JSI-WIP_"DMK M1GP@1+F"(;/1D)*B^V="=3V%XU]=NIP`,OS90::B&0&#GTW'C\LGRE19!E?U*&\D"K>-,\O2HC#'"\UR MM$Y_%Q8N5ARV\M"2#:R&.8DJ4K-T,B^2#Q);RPB,W@-IGLU58`DT&$TG75QM M/!\>XF>@%DU&$5:6%R3^>/PKLU)*8D$0<)(8'-H$3.;6H8%FU2LE45[5@G?RK7%-LE!O?O'NYK<'EK47\?Z=:/`Q2:_H27I1 M,BLRLD0`MP-9)9]WT-08]!=RI9W,9RENJ"8?_\MB_F!*@0L=331I#H3>@S[& MPW0B[QT#V48<>N=!=9(WMAJX"5CJX67OT4TOWZ#I45<5ZYLC2Q>T MWAX$0)_JY]_,.`ZF7!'V*3Y&]L,THR?Q)VA__XIY3N:[,?`W_&?)^^6Z MVE[?PX)L=VN"FZ>7@6J&IA'\.?39)2#,+(5B&#* M%1F<#=#E"]_AZ8(3.S9"!]P'P&5!=R>#Y&SD]"V0',;SG'P1P+_Q&BI&Z32? M]-K_T=]S_VFL<%,,F0Y@,,W]SV&W"O@Y:M]YV(V,VF;I"/6"8-\+6$DTQW3O M.H8=X+_FCL]`2<)_AW<<]JU``W8V,1K<"'8I3T?#$=ZF5HU#+_QH/F1W2D:A M(!CV,)Y$+H1_I/.:B84:U/WIA"),4%O-@ST;IR.0(D;#&0:!P!EOV[EQ.@71 M940^`5@)5+,;FX>"`ZS5!*61R61\8`=AC8N9_&SN(IZDL?SLWLF,;#QH1\S@ MG,U1U6^/"V*"9W>'(ZE,?_-R34`XAU&WDR`"4T<,4S3 M(D>]Q*D4>!\!+>&.SNQ63M(9A5[E8U*LR=61CX,0$Q5<:`TL+0)*8(`1T#%7 M1\I(+YWQ,";I+V M'2C4#BBW`[3CP-J@N\EP%L(*N74Y=S5M+^YM5@SZ4-^:0O=MH6&MQL_NG5AX M;]P17H$N5Z$KDK<=&[0BZR!++#O7*)#+<76H]9]1_HM+JY$\?-8M&7TG*S@$ MV%$TT6Y'$4^5?-N+S;U?E9QK;W1HU=N43:&IT%H-$&L*2W3#(\JI#3]E$N,!B6E MW^6TAR6[J>0/N?PYFS%MB?2U)2/?VY*19YQY]%9*1IJRE\^\!`>^C=\Y6,/7 M7GG+W'_:J]OH/UD\:PQ+=O(06V``U,FS@"$W_WX95(>6^F//T$,T!6T+U.'9 ME`.S<,4@(][AGM)83EN*S8ZPK?;^TW- M*2.DKF"T[H@*Q4@!%T)ZG,`U`!IO.@&MGC(#*.`[RRF_!.3L.6BYKRJ*,AG. M,-UF;N4BAX.`!Q=V9<;:T706R-*=U5120N/ILX(/K.`2\](K?.?^"_V&$U)! M2`NR'5!7'LXHQBW%Q(\^:0_3M,@R^)G#\VVY#RC>H+):3%0&!%#G,)OAD.:S MHJW2R(0B$R=I`=MV(%<"]BQ'(RQZMS"H?[=5M7V\XAY,.00XBK0`AR4CH^5D MEDY`PYS@,<$1U2"SG/6M=I.<`-L?32CU*,^IAV?=019,,D\3=$\-D9<7,XQ= M;BUO@HT#!/;^=*?`XLX-EN.9A=HU;XG))`H$F?P*(5"OA:T_*OFHF81S(!4I M&\(VC>=^SLMD2M;+5_V`1#'4%4W7A].0L@E1 MWA/9CYS"PE$]S?LM\CQ%/P:M,?]JEG@ZI1XI@S*=CPL:X@1>,PH$$AN[=2Y% MF<5PE7Q"P]4+%+;Z\#MGZZ(FKUT5ZN"%?N37P^27'RD4R<3KH*5U.BWH)IW` M;#]L[C'%YI1QMT6XAK>R_PPO(6.''P$]3^?#,!PMR\@)4<`-]8:`SAKF1G0M MHO%Y,ATW&DOAMF8#'-MTCB<:(PR#"%B]EJ\85?BM4_J#!0ZT<&YRZS59^9-J M7@#">\=`DP0O,H/TCOD0RSBG<99X4&`""6<+%<(YJS[9B`(T1""+. MY@5BR3C(4?BH8#G_8&3P-HHZ-T"EC'NDCBQOU[F'&8/FIN@-ZO6B:WJP8!*" M5C.28\_D\Y]\&QQ#PCM;CK'X8;AL7\#M$TP-H0">$?Z48+4^`W^*;3$IDE*D M1V$P!:=COF-E#V7@#M.,HL&7MW>KS7U5&=;`=S[V0-(%6;W(T<NB;;!T+QEA3`3+.BX+P"KE13JFN((\ M'X`T.QM,1B`@E$0\L'BSG!(81],!J/HNY<74Q"7P89"HQ5*0%<^@`*N$5++"!8!NWN&Y_^JHMBT$PQ&`.%YQAK+>#!%L?CEUSL*_3P9 MCSC*;SJ8JJS]ND50S3"""L@"WE^`?#:%6<&E)T/A4J?1=ICU`;H2,/9L-H"? MDP'6+GF)(>^ER16O)"JX0=`U!C$OC4L#$\T-#DTG'(NY M9('`;O>WK!$[3SB7KOMQLU[@1I#E7D%GT,/!U7,67?34%`FXE3=Q]4WK:^4S MI1#YJ6]$-N(H.T[1VN@J1VMO6*Z:)U>%L+7SK'6_Y>+'I#NZ^$=I-LGDZ@>^ MDO'ECPK(E*__C"QA)`"`\`2L3(D`P)>TBW0,5!$$)D<`P+LD@+V#I7IN89@- MP';8U]&&_87_CEY0S]\:??<-=]0?I=0W+'`X,.*S%=5__ZY']"7"J,S2/&.- MX&0,O"P7V6&<@0P]-Q@L0Q*DGP%3Q8I>:^[_E\-PY3'D;$1QR4=`92!@SD'Y MF<$(A@6!!.#'$R"H^2R=XA4'W/GP).SD8R^#T0\'A>#'#`>B^\!O(X&1R0:@ M7G7*/F?`/RPP^$=G+G[I89$W*/6EP0]^WX\N[S:H0':NB;C6B.A'P,J_W!D)RX&=!]`(WNPZDTYVA'U.[D4U%TV`SD6HSZ'R2\& M,QX_P*"P8EJDV=!H&JAVCT<4'#1#ESW\%D@\[[;7Y=JH^#AL\@&R1=BAMR%0 MJ]3+;D!PG;RH=N5R%3*HL[_LR^=X5]V#).*,!/%\(#V*)EXL#LH;B^?H_.CD MWQ<.9:T+*.9]2?HF9BYNT>I@([2;#TZ*P7#X3P$PS9)F@ER&0ZG>;^[V6*?T M?+_"^RL^P7$6Z^L(M+3C-P`H:F")Z:>/+Y*3I\\8V/;/&YCROZ.'81^>OC_M MUT&SKJY'/9XQ_0B@?H]1@(PZL/*I-_A.`CX#6CFTDEVTT:JE+)3L%,+N2[%M MKO@>9,*96`C)#PQ+4>PWJUFQ3"(<);GU,WW+E'SQ]&F2:&V!HP":E>^@" M^([4URM;4+Y^5$(H%C\`RDYH9Q+9F3KY+>G<*M>#B\_'"FI4>-)Y5'7M!0\< M>'VUHFI0\)[X#OO)M($+^`C/;[/GG\OM4JHJF5HO`JJ;)MME_2L;AT+CB5HT MIFA<)/FUM>0:+C\638O9^;S*DR&%>Z&A,4F0(0,=2P-2P^H-T"Y('QH-\I`1 MP:>C\--F3.IOQBSE[OIFDY:XU^9C&2AVX?L^-,U%5=,3W?-U?48J"LU![TCJ M(-NNPM7D&*#PR'^-]0W*0O3QHZX!E;CC;L$7"%QI;P)X2E@FR'%++'VRV=?` MT<(7:T-6&X9F)\,,81*#LQ*`2W8]H1)!8\I1O(,8^.(WK3&GNW]0V>RGR0=@ M;E+LC63?;C#%!VS&H1[=<"*7I6_0"5A$%U1B\^&#F(F1F[XANG[3XL=1%0_& M*+0+0L9T\5N(I'A4,$6W5"DMXR[U#A8R:F$A=M`]PAU"\>%`G_&0B(!?43?M MO;3&A[A'NJ,C.G;*!EZ\[IBG\-D^.YL/.UGUP]8Y;UMHVVF_A9X>ZJ9UI;.# MTSIR!]R*]MJ!K(U\V]!`C]=C,L_RTTO-(#T^X*_[:ZM2!!SJ[&[;LYM7U<4@ MR6='OM#H,,MU#9KYBM8RVNAMN0T:$9Y$].G8[+N>R5N>Z8"^B5W#DCU]@K)Q MT-=[*WN2<5494[PB=@;/(:3H84Q5/F\#[TB-V4;*-B"B/?Q&8OUO27S94(V* MJE9(KE\VVU]IM.7=DMR+SO\8FA+N;8'?'LU39?*_+.]KJ:Z`1@MHT>Q\-J:' M'K80-'U45+E^?9U4]6*[^=*^(NV]TLS"K@*KG;2QBQ$VT?,7"UKG"H"\'%># M#\`P!4*JAS0,:]##MQB8?2*5W%(/?,6$Q*#3-AA!%ZSIPP:D,0T?UD/'H=<[ M)1Z81+,N>*'Z\\CMZ8DT%APV8#:DEXF?2)51L$ZB'<-`P,!%=92`BL?L*[4A M*Q:)-'H6`IBVA^W2RZ_5[1W:%U57(>0;<2]*("0G(;'6O@O[T>.?A]NW,A%G M%@G`D*2Z-->[)]\2'WD3S71+\@+TC(^W#!"Y!C_FDU9-V\'54K%J+(^^:I3X MV%;+VXO]MJZD-)*@"<%VX_P('Y`XUD:$P+9)^L!6M*<:!NJ]FSG%7O5H?C1) M.#&Y'QZ@$^KZ/3\_6J;S4RI;X=8?HA5KP:Q3%NL4OSK%K(A%S:%]=5LC>QZQ MWDO7%X']^(4,+D&#:AI+Q8LP-!__+^B]"67:KEE'%.2#1KCX#=-`!HL_%($6 M:[BK4S`^=,U\>T.T.&;@C:8=XXP^V=EW*]9DS*+N MXCF/.(L((_6J'>3M`:HWC%8=^T<%BK(JLONU(YE!XMJWQ-IU0(B MUM7JM>]M^A.YB7XV;J+C-?N8KMM\YD_E^N`S[Q8[^TQQA#OR`DM0_WM=E0&- MQ-R/K<;S=QZ(`%7KU2O3N7VO6UV`G1@;(4VCY-7IS1Y'U6HC&I1NZXSB2O<: MQI5P).HMU_P+CG%WP]JU3%5DEG.GMLN0M#L@\=',X"2CTY#./V=^6X?B;TG[ M/K;UAO[:A_78#7WRFU#")I2>#!>-K=*Q+^';UB!OOFGWF2@0EXZO'MBCG:VE M^[.K*V@6J^;7BCO3^\%CWF9@6WX[!.3S6S>432@86@"ZSUA6=8L9:"[GT8J\ M?#M8\8]>K/@[5:CLZ'O-7XDSMQ)\KY)+ MK^T1U@C*!;^[BSOZLSWK@TS8@I34?,R'28J8,#5R5<#SFN!5<6G8&WTKC<8I M\[BG@8Y[.MX/]G,@V.!@^Y[K?["?[@TZV+PWOSF\(.TL]'&9R\'>#E#EP?8' MR?;P6O2@ZX/8:$B]-.['V:'T7O M?3H\0/)]NCA(];W6I0?A][O5CPZC5?:O(&?P;7GO7)IR<>\PU",06V-J5-R^ MI56?XK#7L>CL3`>3=C^I=<$V'4Z;^X*UT$I@WGM0!YY4JY9U/MFU^6<&FKBW ML(/"I<4S5JH9[VUR5;7Z[2,@A=;43;;W>K_`O!>NS7JSK-BOGU*N@"3W/7K? MT.1TM[R-&'2D-:ACF-@F`;)HG_^\68'$BS%#:,<1?YL?8^JM4F#"'D:=IR'L M:.^[I;'#3IQ-3;1E8WB8@-$BS06O3%Z>GR=91`PU_492$QI%PM6*4YBL2::2 M/6OV/1V,YN,P`I,3PA.,!$:_;:DB2ZZS/N4"P0I!T=DM,]@N/6V2J MC/BFF^.2V"^(G271SD_KY4YP+TS\\&-O5^05,)%'?TW^#3T> MN$J/;?]H(^F8TP/MIU*\ZS,"VW*2LA==$K[%,O,P%(73Z+U(Q).E\?4_>_A1 M.'!M'=O^&W:C#2O^]^B1X!%I!QUH_C>:^KYAG(?<)@_MMUG(X.$]M5U8[5T: M7/BCS6J]&_:QD3@_&JN@&-#%,*C0.FYQP+->,=2ATNM07G2>>PG_%+66NXRX MPX[QET2K`SS`P1%TH1T8G6K\8;S]0`[L`[;?MK_O5<$`@T%DBF`%AIL^N/O> M2CX&PGX_M/]O2EX["V'#%1Y!UW;Y$PS<1-'I'GR*ER)X503N/>`@W2"^`;'% ML=Z_?=^CI:Z#A?Y8$B3Q$8CPA#1S_&$,(=J#Q3T(U!Y8$UL`V;UU^-M"KS\D M/C(:']<;Q/S!#?'&.HY6C^GZ8/;N,9V1\3XX$L>`MW]3X^-7ZMCN#Z[6L1T> M7+%.`/L'-_RVE3K4]5&K=*BSZ`JUFX'!ELM`MXZK2"S& MML%FNBY$/[[9P.RK&&XR_@BQH$5*3EJS'X>\#@PU!M7^`&;GVG;-H`.SO?EH M`[(]$,P,:GOHB0HCX7H`L?LK85.&.[.9>R]..X)Z\\D'9+KVRV-M35.-XZB' M^+!/FQ._9>YO7]%!T#0P#'IS*[B8K\&T7ZTW0@>>@"=O$+4Q.KT M#6'/A!UV\=@H=GBXQ7$H\<"Z$%H/^@.-A_IW#%D\\!Q84/&0K40!WL.KZ"#N M>'#9-'%;?SL"3_U@9Q$(_L"),I:25;E)O\WRJ)L\,M)^RSJ1%TQ:$G[3]-K$'IOMITGRH%P?Y4'W>K`B9E`Z1;1T>P6V]2WXLI;OG MY9I`I][=EC=E[WP]_Q6@9"Y0*NP6DDR;!;5)DUL)\KC8;+<,O+@H[Z"C$([+ M9!_:=-!MI,;;&6O]WC.H`(LIL%H'XE,QR,)XA.8HM??Y@L%_'V5%$>]BL[Z$ M37R-([[`1N^NKBBE]`,._>3-Z^?O/@0GBL7I&J[;DB3OSP90++8F^2`2<7$& M9PI5#@[.YN'^EO1+^GW=M0.CF$N_%\'[X/+-&@Y;.XW)AL_S+Z$U>Q$C7'U#'.%YOOI3)R\4&$7(7G@_B;+^[V6PC3,:- MRRY+]PB;@^EW@OJU(G]V%"TNFE/5O],X3%Q;50[8T"Y,5?Q^A]H%K-IYN2XO MR^3='3H4]FO)'4:H[V"E182WA3<%:-O!+%XCQ*PDS?<3='CSZ-Y=EQZVU7O`($G]%<`>!B!/=$9DCC0:#%6,SC`BOVXH4O25= M!`C,=E'MOB!V[U4)?S@;"?=^N2V_B":H4$$H.*H]I[47.^I5\R3*H[LYS[UCME=>,&O2I_-HK6[2=IRJ`>:N%"#1?M]9BG7H" M8(2@#Z*1)2<7<#JOEKL0&PF>K/%0P<#;&19\*4BB'=!(QC=XS.O=9`GL>Z$G M&YJE+BV$!!4&::^)A.]FJ2JTXF"UA=)1+]`&F66OI'A@Y0[(57 M(>5%=,A***VK7!2 MJ$7`EL%W6CDM*(H7S,(H+J']2>*K!:6_V0I#8/;UI7LB($,J]/`%N050XN6R M%E1()"M*YJWKV+Z1#*W!)DWZ*[E)_;3;\!I=$S"1J2V2MH3FN#10G-8GPF46 M(W\(%HT:XFJUX;QZJ>UBRZL\OT_L-".@02WT=7PMIH>X^0YT*[SU!+M_UNWP M/E`MJ9.!18HD_=X'+,L[\?]LS$\P-'AM/AS.Z/?H5D:+-*DH#R!/_9P!>SLC M"-AN4%RI-:#$>Q5D=N04LB(Z!85!S0M:,E_\*U>!812XB!KAB@69=E;R`[$J M*@JU#S",DT-?T^9Z3<.(U+*R=JX-0N=\EIHZT9OC@^N(H<3%S'-JRC6P+:'5 M&F0?(]Y'Q;&8+@_R.F&ME5\H",L;83QA]*THF2KU.L41>[#ET8V.#XV MYEOI._6;46VOSMN(1M]2PJS?_`^5WO*6H8,DX5O'9MI/S*F?. M[3]TI)(T++Y3F?TA?IW&][_[!1WD=/"%#WE?<-5H@!L7^H8*<=LB1L85[R1^ M[S[B^C[#S"$1QM/X%K*XN/Y M>Y3IX]CFRJ4-?YNMQ"@+MGQ-=VTD"VB\DF%<51&5:[W&M35V/8?FE$:)W>%5 M]LRU[>@_;OUU")>]LWF[:B&>)M]>];!_<%?7JXX=]Z/%D'Q`,FB)5OC`^1ZB M*;(UM=Y?<('%UI1LF:?A!#T`.@$!0(?3%M/,?N5,,TY> M/`Q.T(WY'@...]3[CYO/#B3AT,,>]L*AAV-8];V7_`!8@9+Q6\BDVQ0C$)XV M@,A:B"Q0;\"USV^6U14*<@NN`OCNZ@J85&"%/M>6K;O]=G'#CA3T/OCP`7>2 M(-0K!:S#AL;Z8B@P0%_MJLC9[=UJ^?YFB7E%->=5U7">MW>!F&&J_#W>7(Y? MHA8H,ZJY*8EK./9-2]&`S4[G_:1LG;[LCB&8=`$6WD63TVW6N2H0N1$;9!W" M1]@U@RO;52JKJ`I9LJSYMQ5?\6:5`M=HU.,4EL[B/DP)=]&HJ4!)$!1/F:/C+R*IF;;$YFA&04]'FJX0'T4O(:DE0$AIC M!1V=T<>2^Q%M#B;>.43`GA3K)(K#Y=?"H]0!<,D"&<@.KA*3&&]A;.66)$F5 MR`@;"OH)]/AJCZ&!:?+F?3A4BW..PEK;?C`@PG@8'Y#$_/V6/&3Y(W6+3YMU M7SLJ%-M*L(]E,W:E?L/[V97I[36+]ZK\[(O#M6[+U6*_LG..U7-6,VRY%QZG MJFZW$T"_0_%*OX1NH_YS9=[A[L`.FXP8P=M.=R#7["_JZB][).*7G^G0/J8T M2R+6<-Y6G?*D2\":$$;.5.3'(9#I)4BWU!;TUJR-",P3K[(1`G6_MAZ MBD2=+?^YKG?_\O\`4$L!`A0#%`````@`+(QI1^?UGL!#`@``*2\``!,````` M`````````(`!`````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"%`,4````"``L MC&E'2'4%[L4````K`@``"P``````````````@`%T`@``7W)E;',O+G)E;'-0 M2P$"%`,4````"``LC&E'P"'498$"``#M+P``&@``````````````@`%B`P`` M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"%`,4````"``LC&E'TFMI M$@0$```!$P``$```````````````@`$;!@``9&]C4')O<',O87!P+GAM;%!+ M`0(4`Q0````(`"R,:4?^^5-_/@$``&D#```1``````````````"``4T*``!D M;V-097)PC$`8``)PG```3 M``````````````"``;H+``!X;"]T:&5M92]T:&5M93$N>&UL4$L!`A0#%``` M``@`+(QI1Z'-[4X]`@``@@D```T``````````````(`!^Q$``'AL+W-T>6QE M&PO=V]R:V)O;VLN>&UL4$L!`A0#%`````@`+(QI1T([N(I6`@`` M]0<``!@``````````````(`!?1H``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+(QI1W5?7@5B!0``S!D``!@````````````` M`(`!C20``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`+(QI1Q(J`%X@!P``NB@``!@``````````````(`!>#$``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`+(QI1V(#1:^B`0`` ML0,``!D``````````````(`!@3P``'AL+W=O&PO=V]R:W-H965T? MY+VRH@$``+$#```9``````````````"``31```!X;"]W;W)K&UL4$L!`A0#%`````@`+(QI1U#*D;.D`0``L0,``!D````````` M`````(`!#4(``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`+(QI1S?^\&"C`0``L0,``!D``````````````(`!G$<``'AL M+W=O0,R\Z(! M``"Q`P``&0``````````````@`%V20``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+(QI M1Z@';'"C`0``L0,``!D``````````````(`!)TT``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+(QI1P1J:/6D`0``L0,` M`!D``````````````(`!M%(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+(QI1USX0WZC`0``L0,``!D````````````` M`(`!0U@``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`+(QI1\44*0;#`0``>P0``!D``````````````(`!$U\``'AL+W=O M&PO=V]R:W-H965T1C M``!X;"]W;W)K&UL4$L!`A0#%`````@`+(QI1Y]> M>%6Q`0``%@0``!D``````````````(`!S&4``'AL+W=O&PO=V]R:W-H965TA9%I>IP$``+$#```9``````````````"``8]I``!X;"]W;W)K&UL4$L!`A0#%`````@`+(QI1^UQ`"VE`0``L0,``!D` M`````````````(`!;6L``'AL+W=OC;(!```6!```&0``````````````@`%);0``>&PO M=V]R:W-H965TB1(@5M0$` M`!8$```9``````````````"``3)O``!X;"]W;W)K&UL4$L!`A0#%`````@`+(QI1T,$2].E`0``L0,``!D``````````````(`! M'G$``'AL+W=O&PO=V]R:W-H965T=T``!X;"]W;W)K&UL4$L!`A0#%``` M``@`+(QI1RGK1F*P`0``%@0``!D``````````````(`!Q'8``'AL+W=O```>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+(QI1UC_3-F7 M`P``A0\``!D``````````````(`!='\``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+(QI1QI(.Y/?!@``YR<``!D````` M`````````(`!F(@``'AL+W=O$0``&0``````````````@`&NCP``>&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`+(QI1_,N$;"?`P``:@\``!D``````````````(`!=9T` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M+(QI1^K:AW)E#```.5<``!D``````````````(`!^:P``'AL+W=O".?[_G@(``,$*```9``````````````"``4F\``!X;"]W M;W)K&UL4$L!`A0#%`````@`+(QI1Z.;B7;'`0`` MA`0``!D``````````````(`!'K\``'AL+W=O+_[$#``#/$P``&0``````````````@`$< MP0``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+(QI1_)\L,%$`@``]0<``!D````````` M`````(`!T<8``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`+(QI1S-^1$KG`0``ZP0``!D``````````````(`!+LX``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+(QI M1QM%Z:))`@``U@<``!D``````````````(`!M]8``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+(QI1^_[:W3\`0``"`8` M`!D``````````````(`!>]\``'AL+W=O&PO=V]R:W-H965T;@N7# M3@,``)@-```9``````````````"``?'D``!X;"]W;W)K&UL4$L!`A0#%`````@`+(QI1W^4XTCI`0``QP4``!D````````````` M`(`!=N@``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`+(QI1PI!3-UY`P``VPX``!D``````````````(`!SO```'AL+W=O M&PO=V]R:W-H965TR+[_)`@(```X&```9``````````````"``0SW M``!X;"]W;W)K&UL4$L!`A0#%`````@`+(QI1YI? MM:1G`@``'@@``!D``````````````(`!1?D``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`+(QI1TB@O0HF`@``=`8``!D` M`````````````(`!&`0!`'AL+W=O&PO M=V]R:W-H965TX(`0!X;"]S:&%R9613=')I;F=S+GAM;%!+ 4!08`````60!9`&$8``"5SP$````` ` end XML 16 R70.htm IDEA: XBRL DOCUMENT v3.3.0.814
Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Accumulated other comprehensive income (loss) $ (5,195) $ (4)
Unrealized gain on investments    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Accumulated other comprehensive income (loss) 291 42
Foreign currency translation adjustments    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Accumulated other comprehensive income (loss) $ (5,486) $ (46)
XML 17 R55.htm IDEA: XBRL DOCUMENT v3.3.0.814
Short-term and Long-term Investments - Summary of Estimated Fair Value of Available-for-Sale Investments Classified by Contractual Maturities (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Investments, Debt and Equity Securities [Abstract]    
Due within one year $ 90,864  
After one year through three years 136,266  
Aggregate Fair Value $ 227,130 $ 115,608
XML 18 R78.htm IDEA: XBRL DOCUMENT v3.3.0.814
Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Numerator:        
Net loss attributable to Intrexon $ (38,213) $ (52,725) $ (51,779) $ (100,653)
Denominator:        
Weighted average shares outstanding, basic and diluted 112,244,129 99,888,203 109,244,641 98,711,564
Net loss attributable to Intrexon per share, basic and diluted (usd per share) $ (0.34) $ (0.53) $ (0.47) $ (1.02)
XML 19 R46.htm IDEA: XBRL DOCUMENT v3.3.0.814
Mergers and Acquisitions - Additional Information (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2015
USD ($)
shares
Aug. 31, 2015
Apr. 30, 2015
USD ($)
shares
Feb. 28, 2015
USD ($)
shares
Aug. 31, 2014
USD ($)
installment
shares
Mar. 31, 2014
USD ($)
note
shares
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Sep. 30, 2012
USD ($)
Business Acquisition [Line Items]                      
Deferred cash consideration                 $ 11,440,000 $ 20,115,000  
Revenues             $ 53,367,000 $ 21,197,000 132,107,000 40,838,000  
Net income (loss)             $ (39,029,000) (53,862,000) $ (54,719,000) (103,548,000)  
Oxitec Limited                      
Business Acquisition [Line Items]                      
Percentage of outstanding common stock acquired 100.00%           100.00%   100.00%    
Consideration transferred, shares issued or issuable | shares 1,359,343                    
Cash $ 90,199,000                    
Cash and working capital adjustments $ 9,449,000                    
Payment of cash and working capital adjustments, number of days after closing 85 days                    
Consideration transferred, shares issuable withheld as escrow | shares 480,422                    
Consideration transferred, cash withheld as escrow $ 1,991,000                    
Transfer of cash withheld as escrow, number of months after closing 18 months                    
Total consideration transferred $ 146,394,000                    
Oxitec Limited | Selling, general and administrative                      
Business Acquisition [Line Items]                      
Business combination, acquisition related cost             $ 1,644,000   $ 1,644,000    
Okanagan Specialty Fruits Inc                      
Business Acquisition [Line Items]                      
Percentage of outstanding common stock acquired     100.00%                
Consideration transferred, shares issued or issuable | shares     707,853                
Cash     $ 10,000,000                
Total consideration transferred     $ 40,933,000                
Business combination, acquisition related cost                 341,000    
Intangible assets, useful life     14 years                
Okanagan Specialty Fruits Inc | Selling, general and administrative                      
Business Acquisition [Line Items]                      
Business combination, acquisition related cost                 267,000    
ActoGeniX NV                      
Business Acquisition [Line Items]                      
Percentage of outstanding common stock acquired       100.00%              
Consideration transferred, shares issued or issuable | shares       965,377              
Cash       $ 32,739,000              
Total consideration transferred       72,474,000              
Business combination, acquisition related cost                 418,000    
Intangible assets, useful life   18 years                  
ActoGeniX NV | Selling, general and administrative                      
Business Acquisition [Line Items]                      
Business combination, acquisition related cost                 381,000    
Trans Ova Genetics, LC                      
Business Acquisition [Line Items]                      
Percentage of outstanding common stock acquired         100.00%            
Consideration transferred, shares issued or issuable | shares         1,444,388            
Cash         $ 63,625,000            
Total consideration transferred         116,542,000            
Business combination, acquisition related cost                   713,000  
Deferred cash consideration         $ 20,115,000            
Deferred cash consideration, number of payment installments | installment         3            
Revenues             18,283,000 8,502,000 64,743,000 8,502,000  
Net income (loss)             (3,655,000) (481,000) 530,000 (481,000)  
Total consideration transferred, including the noncontrolling interest         $ 127,875,000            
Possible future contingent payments to former equity holders                     $ 6,000,000
Possible future contingent payments to former equity holders, current valuation $ 0           $ 0   $ 0    
Trans Ova Genetics, LC | Selling, general and administrative                      
Business Acquisition [Line Items]                      
Business combination, acquisition related cost               $ 372,000   684,000  
Exemplar Genetics, LLC                      
Business Acquisition [Line Items]                      
Cash paid to acquire noncontrolling interest       $ 1,566,000              
Shares issued to acquire noncontrolling interest | shares       307,074              
Medistem, Inc.                      
Business Acquisition [Line Items]                      
Percentage of outstanding common stock acquired           100.00%          
Consideration transferred, shares issued or issuable | shares           714,144          
Cash           $ 4,920,000          
Total consideration transferred           $ 24,995,000          
Business combination, acquisition related cost                   680,000  
Number of promissory notes settled upon the closing of the merger | note           2          
Shares of merger consideration surrendered by acquiree management to reimburse for required payroll tax withholdings | shares           17,695          
Medistem, Inc. | Settlement of Promissory Notes                      
Business Acquisition [Line Items]                      
Total consideration transferred           $ 707,000          
Medistem, Inc. | Selling, general and administrative                      
Business Acquisition [Line Items]                      
Business combination, acquisition related cost                   $ 310,000  
Minimum | Trans Ova Genetics, LC                      
Business Acquisition [Line Items]                      
Intangible assets, useful life         3 years            
Maximum | Trans Ova Genetics, LC                      
Business Acquisition [Line Items]                      
Intangible assets, useful life         9 years            
XML 20 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814
Inventory (Tables)
 9 Months Ended
Sep. 30, 2015
Inventory Disclosure [Abstract]  
Schedule of Inventory
Inventory consists of the following:
 
September 30,
2015
 
December 31,
2014
Supplies, semen and embryos
$
1,368

 
$
1,184

Work in process
6,135

 
5,637

Livestock
12,753

 
16,996

Feed
2,082

 
1,972

Total inventory
$
22,338

 
$
25,789
XML 21 R79.htm IDEA: XBRL DOCUMENT v3.3.0.814
Net Loss per Share - Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share (Details) - shares
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 10,854,759 8,567,752
Options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 10,660,040 8,194,650
Warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 194,719 373,102
XML 22 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 23 R73.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock Option Plans - Schedule of Stock Option Activity (Details) - Intrexon Stock Option Plans - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2015
Dec. 31, 2014
Number of Shares    
Balances at beginning of period (in shares) 8,323,544  
Granted (in shares) 4,282,000  
Adjustment due to dividend (in shares) 312,795  
Exercised (in shares) (790,265)  
Forfeited (in shares) (1,467,488)  
Expired (in shares) (546)  
Balances at end of period (in shares) 10,660,040 8,323,544
Exercisable at end of period (in shares) 2,502,418  
Vested and Expected to Vest at end of period (in shares) [1] 8,803,769  
Weighted Average Exercise Price    
Balances at beginning of period (in usd per share) $ 22.59  
Granted (in usd per share) 47.89  
Adjustment due to dividend (in usd per share) 25.40  
Exercised (in usd per share) (16.89)  
Forfeited (in usd per share) (25.77)  
Expired (in usd per share) (17.72)  
Balances at period end (in usd per share) 32.07 $ 22.59
Exercisable, weighted average exercise price, at end of period (in usd per share) 18.18  
Vested and Expected to Vest, weighted average exercise price at end of period (in usd per share) [1] $ 30.69  
Weighted average remaining contractual term    
Balances, weighted average remaining contractual period 8 years 6 months 11 days 8 years 7 months 21 days
Exercisable at period end, weighted average remaining contractual period 6 years 8 months 23 days  
Vested and Expected to Vest at period end, weighted average remaining contractual period [1] 8 years 4 months 13 days  
[1] The number of stock options expected to vest takes into account an estimate of expected forfeitures.
XML 24 R57.htm IDEA: XBRL DOCUMENT v3.3.0.814
Fair Value Measurements - Additional Information (Details)
$ in Thousands
Sep. 30, 2015
USD ($)
Equity Securities  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Fair value of assets transferred from Level 2 to Level 1 $ 8,307
XML 25 R76.htm IDEA: XBRL DOCUMENT v3.3.0.814
Commitments and Contingencies - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]        
Rent expense $ 2,167 $ 2,518 $ 6,548 $ 5,249
Rental income under sublease agreement 334 $ 270 1,153 $ 532
Future Rental Income        
2015 182   182  
2016 741   741  
2017 $ 96   $ 96  
XML 26 R77.htm IDEA: XBRL DOCUMENT v3.3.0.814
Related Party Transactions - Additional Information (Details)
 1 Months Ended 3 Months Ended 9 Months Ended 49 Months Ended
Aug. 07, 2015
Jul. 31, 2015
$ / shares
shares
Jun. 30, 2015
Mar. 31, 2015
USD ($)
shares
Dec. 31, 2014
USD ($)
$ / shares
shares
Sep. 30, 2014
USD ($)
Nov. 30, 2013
$ / shares
shares
Sep. 30, 2013
$ / shares
shares
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Feb. 28, 2015
USD ($)
Related Party Transaction [Line Items]                          
Compensation expense                     $ 0 $ 1,485,000  
Purchases of equity securities and warrants                     17,080,000 0  
Fair value of financial assets measured at fair value on a recurring basis         $ 280,497,000       $ 303,898,000   303,898,000    
Third Security                          
Related Party Transaction [Line Items]                          
Total amount of expenses reimbursed                 $ 142,000 $ 85,000 $ 294,000 173,000  
Chief Executive Officer                          
Related Party Transaction [Line Items]                          
Compensation expense                   $ 508,000   $ 1,485,000  
Fibrocell Science, Inc.                          
Related Party Transaction [Line Items]                          
Common stock purchased from collaborative partners (in shares) | shares   375,868                      
Price per share of common shares (in usd per share) | $ / shares   $ 5.80                      
AmpliPhi Biosciences Corp                          
Related Party Transaction [Line Items]                          
Common stock purchased from collaborative partners (in shares) | shares       278,788                  
Warrants purchased from collaborative partners (in shares) | shares       69,696                  
Purchases of equity securities and warrants       $ 2,300,000                  
ZIOPHARM Oncology, Inc.                          
Related Party Transaction [Line Items]                          
Common stock purchased from collaborative partners, value                         $ 43,582,000
Histogenics Corporation                          
Related Party Transaction [Line Items]                          
Common stock purchased from collaborative partners (in shares) | shares         1,772,364                
Price per share of common shares (in usd per share) | $ / shares         $ 11.00                
Note receivable, stated interest rate           6.00%       6.00%   6.00%  
Oragenics, Inc.                          
Related Party Transaction [Line Items]                          
Common stock purchased from collaborative partners (in shares) | shares               1,300,000          
Price per share of common shares (in usd per share) | $ / shares               $ 3.00          
Maximum percentage of shares of future securities offerings of collaborative partners to which the entity is entitled to purchase                 30.00%   30.00%    
Oragenics, Inc. | Share Purchase Rights Plan                          
Related Party Transaction [Line Items]                          
Common stock purchased from collaborative partners (in shares) | shares             1,100,000            
Price per share of common shares (in usd per share) | $ / shares             $ 2.50            
Oragenics ECC 3                          
Related Party Transaction [Line Items]                          
Commitment period for purchase of additional common stock after effective date     16 months                    
Related Parties, Aggregated                          
Related Party Transaction [Line Items]                          
Collaboration revenue                 $ 31,740,000 $ 11,295,000 $ 59,775,000 $ 29,613,000  
Common Stock | AmpliPhi Biosciences Corp                          
Related Party Transaction [Line Items]                          
Purchases of equity securities and warrants       1,979,000                  
Warrants | AmpliPhi Biosciences Corp                          
Related Party Transaction [Line Items]                          
Purchases of equity securities and warrants       $ 321,000                  
Upfront and Milestone Payments | Upfront | Histogenics Corporation                          
Related Party Transaction [Line Items]                          
Collaborative arrangement consideration received, value of convertible promissory note           $ 10,000,000              
Maximum | Oragenics, Inc.                          
Related Party Transaction [Line Items]                          
Common stock purchase commitment                 10,000   10,000    
Other Nonoperating Income | Harvest Intrexon Enterprise Fund I, LP                          
Related Party Transaction [Line Items]                          
Management fees revenue                 697,000   697,000    
AmpliPhi Biosciences Corp                          
Related Party Transaction [Line Items]                          
Reverse stock split ratio 1-for-50                        
Reverse stock split, conversion ratio 0.02                        
Other Assets | Warrants | AmpliPhi Biosciences Corp                          
Related Party Transaction [Line Items]                          
Fair value of financial assets measured at fair value on a recurring basis                 $ 145,000   $ 145,000    
XML 27 R71.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock Option Plans - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2015
Dec. 31, 2014
Intrexon Stock Option Plan - 2008 Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options outstanding (in shares) 1,439,637  
Intrexon Stock Option Plan - 2013 Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options outstanding (in shares) 9,220,403  
Number of shares authorized for issuance 13,000,000  
Remaining shares available to grant 3,219,354  
Intrexon Stock Option Plans    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options outstanding (in shares) 10,660,040 8,323,544
Unrecognized compensation costs related to nonvested awards $ 112,205 $ 62,281
Recognized over weighted-average period 3 years 3 years
Weighted average price of option (in usd per share) $ 32.07 $ 22.59
Shares exercisable at end of period 2,502,418  
Aqua Bounty Stock Option Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options outstanding (in shares) 5,382,000 7,347,000
Weighted average price of option (in usd per share) $ 0.26 $ 0.31
Shares exercisable at end of period 4,320,333 6,171,520
XML 28 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814
Net Loss per Share
 9 Months Ended
Sep. 30, 2015
Earnings Per Share [Abstract]  
Net Loss per Share
Net Loss per Share
The following table presents the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2015 and 2014:
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Historical net loss per share:
 
 
 
 
 
 
 
Numerator:
 
 
 
 
 
 
 
Net loss attributable to Intrexon
$
(38,213
)
 
$
(52,725
)
 
$
(51,779
)
 
$
(100,653
)
Denominator:
 
 
 
 
 
 
 
Weighted average shares outstanding, basic and diluted
112,244,129

 
99,888,203

 
109,244,641

 
98,711,564

Net loss attributable to Intrexon per share, basic and diluted
$
(0.34
)
 
$
(0.53
)
 
$
(0.47
)
 
$
(1.02
)

The following potentially dilutive securities have been excluded from the above computations of diluted weighted average shares outstanding for the three and nine months ended September 30, 2015 and 2014, as they would have been anti-dilutive:
 
September 30,
 
2015
 
2014
Options
10,660,040

 
8,194,650

Warrants
194,719

 
373,102

Total
10,854,759

 
8,567,752
XML 29 R50.htm IDEA: XBRL DOCUMENT v3.3.0.814
Investments in Joint Ventures - Additional Information (Details)
 1 Months Ended
Mar. 31, 2014
USD ($)
Jan. 31, 2014
USD ($)
Oct. 31, 2013
USD ($)
Sep. 30, 2015
USD ($)
board_seat
Dec. 31, 2014
USD ($)
Schedule Of Investments In Joint Venture [Line Items]          
Investment       $ 3,790,000 $ 3,220,000
Intrexon Energy Partners, LLC          
Schedule Of Investments In Joint Venture [Line Items]          
Membership interest 50.00%        
Maximum additional capital contribution committed $ 25,000,000        
Additional capital contributions committed, remaining commitment       $ 20,426,000  
Number of board members designated by the Company | board_seat       2  
Number of board members not designated by the Company | board_seat       3  
Intrexon Energy Partners, LLC | Investors          
Schedule Of Investments In Joint Venture [Line Items]          
Membership interest 50.00%        
Initial capital contribution $ 25,000,000        
Maximum additional capital contribution committed 25,000,000        
Intrexon Energy Partners, LLC | Other Accrued Liabilities          
Schedule Of Investments In Joint Venture [Line Items]          
Investment       $ (1,591,000) (740,000)
OvaXon, LLC          
Schedule Of Investments In Joint Venture [Line Items]          
Membership interest   50.00%      
Initial capital contribution   $ 1,500,000      
Number of board members designated by the Company | board_seat       2  
Number of board members not designated by the Company | board_seat       2  
OvaXon, LLC | Other Accrued Liabilities          
Schedule Of Investments In Joint Venture [Line Items]          
Investment         (83,000)
OvaXon, LLC | Investments In Affiliates          
Schedule Of Investments In Joint Venture [Line Items]          
Investment       $ 242,000  
S & I Ophthalmic, LLC          
Schedule Of Investments In Joint Venture [Line Items]          
Membership interest     50.00%    
Initial capital contribution     $ 5,000,000    
Number of board members designated by the Company | board_seat       2  
Number of board members not designated by the Company | board_seat       2  
S & I Ophthalmic, LLC | Investments In Affiliates          
Schedule Of Investments In Joint Venture [Line Items]          
Investment       $ 1,881,000 $ 3,220,000
Upfront | Upfront and Milestone Payments | Intrexon Energy Partners, LLC          
Schedule Of Investments In Joint Venture [Line Items]          
Collaborative arrangement consideration received, value $ 25,000,000        
XML 30 R42.htm IDEA: XBRL DOCUMENT v3.3.0.814
Summary of Significant Accounting Policies - Additional Information (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2015
USD ($)
entity
joint_venture
Jun. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Sep. 30, 2015
USD ($)
segment
entity
joint_venture
Sep. 30, 2014
USD ($)
Dec. 31, 2014
USD ($)
entity
Organization And Significant Accounting Policies [Line Items]            
Research and development commitments with third parties not incurred $ 6,576,000     $ 6,576,000   $ 2,183,000
Maturity period of liquid investment       3 months    
Cash equivalent investments in highly liquid money market accounts $ 93,158,000     $ 93,158,000   $ 16,598,000
Number of strategic joint ventures | joint_venture 3     3    
Number of collaborators over which the Company has significant influence | entity 1     1   2
Fair value of financial assets measured at fair value on a recurring basis $ 303,898,000     $ 303,898,000   $ 280,497,000
Unrealized and realized appreciation (depreciation) in fair value of equity securities (30,453,000)   $ (37,089,000) 64,392,000 $ (48,944,000)  
Variable interest entities, risk of loss 1,909,000     $ 1,909,000   0
Number of segments | segment       1    
Revenues 53,367,000   21,197,000 $ 132,107,000 40,838,000  
Foreign Countries            
Organization And Significant Accounting Policies [Line Items]            
Long-lived assets 3,623,000     3,623,000   2,200,000
Revenues 1,183,000   809,000 3,446,000 1,178,000  
Equity Securities            
Organization And Significant Accounting Policies [Line Items]            
Fair value of financial assets measured at fair value on a recurring basis $ 76,623,000     $ 76,623,000   $ 164,889,000
Oragenics, Inc.            
Organization And Significant Accounting Policies [Line Items]            
Company's ownership percentage 24.20%     24.20%   24.40%
Oragenics, Inc. | Equity Securities            
Organization And Significant Accounting Policies [Line Items]            
Fair value of financial assets measured at fair value on a recurring basis $ 13,475,000     $ 13,475,000   $ 7,192,000
Unrealized and realized appreciation (depreciation) in fair value of equity securities $ 2,404,000   (5,487,000) $ 6,283,000 (11,890,000)  
ZIOPHARM Oncology, Inc.            
Organization And Significant Accounting Policies [Line Items]            
Company's ownership percentage           15.70%
Realized gain on equity securities   $ 81,401,000        
ZIOPHARM Oncology, Inc. | Equity Securities            
Organization And Significant Accounting Policies [Line Items]            
Fair value of financial assets measured at fair value on a recurring basis           $ 83,099,000
Unrealized and realized appreciation (depreciation) in fair value of equity securities     $ (22,783,000)   $ (27,864,000)  
Minimum            
Organization And Significant Accounting Policies [Line Items]            
Intangible assets, useful life       2 years    
Maximum            
Organization And Significant Accounting Policies [Line Items]            
Intangible assets, useful life       18 years    
XML 31 R75.htm IDEA: XBRL DOCUMENT v3.3.0.814
Commitments and Contingencies - Future Minimum Lease Payments Under Noncancelable Operating Leases (Details)
$ in Thousands
Sep. 30, 2015
USD ($)
Future Minimum Lease Payments  
2015 $ 739
2016 4,161
2017 3,381
2018 2,067
2019 1,889
2020 1,941
Thereafter 1,587
Total $ 15,765
XML 32 R37.htm IDEA: XBRL DOCUMENT v3.3.0.814
Shareholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2015
Equity [Abstract]  
Components of Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive loss were as follows:
 
September 30,
2015
 
December 31,
2014
Unrealized gain on investments
$
291

 
$
42

Foreign currency translation adjustments
(5,486
)
 
(46
)
Total accumulated other comprehensive loss
$
(5,195
)
 
$
(4
)
XML 33 R52.htm IDEA: XBRL DOCUMENT v3.3.0.814
Collaboration and Licensing Revenue - Additional Information (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Apr. 30, 2013
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
May. 31, 2015
USD ($)
target
Dec. 31, 2014
USD ($)
Mar. 31, 2014
USD ($)
Jan. 31, 2014
USD ($)
shares
Dec. 31, 2013
shares
Sep. 30, 2013
USD ($)
shares
Jun. 30, 2013
USD ($)
shares
Mar. 31, 2013
USD ($)
Feb. 28, 2013
Oct. 31, 2012
USD ($)
shares
Jun. 30, 2012
USD ($)
shares
Jan. 31, 2011
USD ($)
shares
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Collaboration and Licensing Agreements [Line Items]                                      
Deferred revenue   $ 176,254,000     $ 113,209,000                     $ 176,254,000   $ 176,254,000  
Trade, net   25,153,000     14,582,000                     25,153,000   25,153,000  
Other assets   5,426,000     $ 1,271,000                     5,426,000   5,426,000  
Collaboration And Licensing Revenue                               34,726,000 $ 12,656,000 66,690,000 $ 32,257,000
Ares Trading S.A.                                      
Collaboration and Licensing Agreements [Line Items]                                      
Trade, net   6,250,000                           6,250,000   6,250,000  
Other assets   $ 3,750,000                           3,750,000   3,750,000  
Collaborative agreement additional target fee       $ 5,000,000                              
Maximum milestone payments required upon successful achievement, per product       413,000                              
Maximum milestone payments required upon successful achievement, one-time       $ 50,000,000                              
Required notice period for voluntary termination of collaborative agreement       90 days                              
Collaboration And Licensing Revenue                               1,857,000   $ 2,596,000  
Ares Trading S.A. | ZIOPHARM Oncology, Inc.                                      
Collaboration and Licensing Agreements [Line Items]                                      
Related party payables                               57,500,000      
Collaboration arrangement, percent of collaboration payments                                   50.00%  
ZIOPHARM Oncology, Inc.                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaboration And Licensing Revenue                               4,651,000 4,014,000 $ 13,702,000 11,035,000
ZIOPHARM Oncology ECC 1                                      
Collaboration and Licensing Agreements [Line Items]                                      
Required notice period for voluntary termination of collaborative agreement                             90 days        
Percent of shares outstanding at the date of achievement of future milestone                             7.495%        
Royalty rate as a percentage of net profit                             50.00%        
ZIOPHARM Oncology ECC 2                                      
Collaboration and Licensing Agreements [Line Items]                                      
Required notice period for voluntary termination of collaborative agreement   90 days                                  
Royalty rate as a percentage of net profit   50.00%                                  
Oragenics ECC 1                                      
Collaboration and Licensing Agreements [Line Items]                                      
Required notice period for voluntary termination of collaborative agreement                           90 days          
Percent of shares outstanding at the date of achievement of future milestone                           1.00%          
Royalty rate as a percentage of net profit                           25.00%          
Percentage of shares outstanding at the date of achievement of future milestone 2                           1.50%          
Percentage of shares outstanding at the date of achievement of future milestone 3                           2.00%          
Percentage of shares outstanding at the date of achievement of future milestone 4                           2.50%          
Percentage of shares outstanding at the date of achievement of future milestone 5                           3.00%          
Oragenics ECC 3                                      
Collaboration and Licensing Agreements [Line Items]                                      
Maximum milestone payments required upon successful achievement, per product     $ 22,000                                
Maximum milestone payments required upon successful achievement, one-time     $ 10,000                                
Required notice period for voluntary termination of collaborative agreement     90 days                                
Fibrocell Science, Inc.                                      
Collaboration and Licensing Agreements [Line Items]                                      
Required notice period for voluntary termination of collaborative agreement                         90 days            
Collaboration And Licensing Revenue                               6,140,000 1,463,000 10,219,000 4,104,000
Reverse stock split ratio 1-for-25                                    
Reverse stock split, conversion ratio 0.04                                    
Royalty rate as a percentage of net sales, tier 1                         7.00%            
Level of net sales at which royalty rate changes to tier 2                         $ 25,000,000            
Royalty rate as a percentage of net sales, tier 2                         14.00%            
Royalty rate of savings from improvement                         33.00%            
Genopaver, LLC                                      
Collaboration and Licensing Agreements [Line Items]                                      
Required notice period for voluntary termination of collaborative agreement                     90 days                
Collaboration And Licensing Revenue                               1,061,000 428,000 2,665,000 1,409,000
AquaBounty Technologies, Inc.                                      
Collaboration and Licensing Agreements [Line Items]                                      
Royalty rate as a percentage of gross profit                       16.66%              
S & I Ophthalmic, LLC                                      
Collaboration and Licensing Agreements [Line Items]                                      
Required notice period for voluntary termination of collaborative agreement                 90 days                    
Collaboration And Licensing Revenue                               1,193,000 667,000 2,838,000 2,153,000
OvaXon, LLC                                      
Collaboration and Licensing Agreements [Line Items]                                      
Required notice period for voluntary termination of collaborative agreement               90 days                      
Collaboration And Licensing Revenue                               549,000 813,000 1,855,000 1,561,000
Intrexon Energy Partners, LLC                                      
Collaboration and Licensing Agreements [Line Items]                                      
Required notice period for voluntary termination of collaborative agreement           90 days                          
Collaboration And Licensing Revenue                               3,810,000 2,160,000 9,976,000 3,995,000
Persea Bio, LLC                                      
Collaboration and Licensing Agreements [Line Items]                                      
Required notice period for voluntary termination of collaborative agreement         90 days                            
Collaboration And Licensing Revenue                               422,000   928,000  
Thrive Agrobiotics, Inc.                                      
Collaboration and Licensing Agreements [Line Items]                                      
Maximum milestone payments required upon successful achievement, per product   $ 5,500,000                                  
Required notice period for voluntary termination of collaborative agreement   90 days                                  
Upfront and Milestone Payments                                      
Collaboration and Licensing Agreements [Line Items]                                      
Deferred revenue   $ 159,069,000     $ 107,228,000                     159,069,000   159,069,000  
Collaboration And Licensing Revenue                               20,592,000 2,490,000 27,326,000 6,889,000
Upfront and Milestone Payments | Ares Trading S.A.                                      
Collaboration and Licensing Agreements [Line Items]                                      
Deferred revenue   55,164,000                           55,164,000   55,164,000  
Collaboration And Licensing Revenue                               1,597,000   2,336,000  
Upfront and Milestone Payments | Ares Trading S.A. | Upfront                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaborative arrangement consideration received, value       $ 115,000,000                              
Upfront and Milestone Payments | ZIOPHARM Oncology, Inc.                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaboration And Licensing Revenue                               645,000 644,000 1,933,000 1,932,000
Upfront and Milestone Payments | ZIOPHARM Oncology ECC 1                                      
Collaboration and Licensing Agreements [Line Items]                                      
Deferred revenue   21,260,000     23,193,000                     21,260,000   21,260,000  
Upfront and Milestone Payments | ZIOPHARM Oncology ECC 1 | Upfront                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaborative arrangement consideration received, value                             $ 17,457,000        
Collaborative arrangement consideration received, shares | shares                             3,636,926        
Upfront and Milestone Payments | ZIOPHARM Oncology ECC 1 | Milestone One                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaborative arrangement consideration received, value                         $ 18,330,000            
Collaborative arrangement consideration received, shares | shares                         3,636,926            
Upfront and Milestone Payments | ZIOPHARM Oncology ECC Separate Unit of Accounting | Upfront                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaboration And Licensing Revenue                             $ 1,115,000        
Upfront and Milestone Payments | ZIOPHARM Oncology ECC Unit of Accounting One | Upfront                                      
Collaboration and Licensing Agreements [Line Items]                                      
Deferred revenue                             $ 16,342,000        
Upfront and Milestone Payments | ZIOPHARM Oncology ECC 2 | Upfront                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaborative arrangement consideration received, value   10,000,000                                  
Upfront and Milestone Payments | Oragenics ECC 1                                      
Collaboration and Licensing Agreements [Line Items]                                      
Deferred revenue   4,758,000     5,171,000                     4,758,000   4,758,000  
Upfront and Milestone Payments | Oragenics ECC 1 | Upfront                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaborative arrangement consideration received, value                           $ 6,588,000          
Collaborative arrangement consideration received, shares | shares                           4,392,425          
Upfront and Milestone Payments | Oragenics ECC 2 | Upfront                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaborative arrangement consideration received, value                 $ 3,503,000                    
Collaborative arrangement consideration received, shares | shares                 1,348,000                    
Collaborative arrangement consideration received, value of convertible promissory note                 $ 1,956,000                    
Conversion of promissory note into common stock (in shares) | shares               698,241                      
Upfront and Milestone Payments | Oragenics ECC 3                                      
Collaboration and Licensing Agreements [Line Items]                                      
Deferred revenue   4,815,000                           4,815,000   4,815,000  
Upfront and Milestone Payments | Oragenics ECC 3 | Upfront                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaborative arrangement consideration received, value of convertible promissory note     $ 5,000,000                                
Upfront and Milestone Payments | Fibrocell Science, Inc.                                      
Collaboration and Licensing Agreements [Line Items]                                      
Deferred revenue   11,772,000     17,491,000                     11,772,000   11,772,000  
Collaboration And Licensing Revenue                               4,823,000 449,000 5,719,000 1,345,000
Upfront and Milestone Payments | Fibrocell Science, Inc. | Upfront                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaborative arrangement consideration received, value                         $ 7,576,000            
Collaborative arrangement consideration received, shares | shares                         1,317,520            
Upfront and Milestone Payments | Fibrocell Science, Inc. | Supplemental Upfront                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaborative arrangement consideration received, value             $ 5,225,000     $ 7,612,000                  
Collaborative arrangement consideration received, shares | shares             1,024,590     1,243,781                  
Upfront and Milestone Payments | Genopaver, LLC                                      
Collaboration and Licensing Agreements [Line Items]                                      
Deferred revenue   2,318,000     2,523,000                     2,318,000   2,318,000  
Collaboration And Licensing Revenue                               68,000 68,000 205,000 205,000
Upfront and Milestone Payments | Genopaver, LLC | Upfront                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaborative arrangement consideration received, value                     $ 3,000,000                
Upfront and Milestone Payments | S & I Ophthalmic, LLC                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaboration And Licensing Revenue                               0 0 0 0
Upfront and Milestone Payments | OvaXon, LLC                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaboration And Licensing Revenue                               0 0 0 0
Upfront and Milestone Payments | Intrexon Energy Partners, LLC                                      
Collaboration and Licensing Agreements [Line Items]                                      
Deferred revenue   21,250,000     23,125,000                     21,250,000   21,250,000  
Collaboration And Licensing Revenue                               625,000 $ 625,000 1,875,000 $ 1,250,000
Upfront and Milestone Payments | Intrexon Energy Partners, LLC | Upfront                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaborative arrangement consideration received, value           $ 25,000,000                          
Upfront and Milestone Payments | Persea Bio, LLC                                      
Collaboration and Licensing Agreements [Line Items]                                      
Deferred revenue   4,625,000     5,000,000                     4,625,000   4,625,000  
Collaboration And Licensing Revenue                               125,000   375,000  
Upfront and Milestone Payments | Persea Bio, LLC | Upfront                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaborative arrangement consideration received, value         5,000,000                            
Upfront and Milestone Payments | Thrive Agrobiotics, Inc. | Upfront                                      
Collaboration and Licensing Agreements [Line Items]                                      
Collaborative arrangement consideration received, value   1,667,000                                  
Prepaid Research and Development Services                                      
Collaboration and Licensing Agreements [Line Items]                                      
Deferred revenue   $ 11,099,000     $ 1,045,000                     $ 11,099,000   $ 11,099,000  
Prepaid Research and Development Services | Ares Trading S.A.                                      
Collaboration and Licensing Agreements [Line Items]                                      
Number of targets selected | target       2                              
Deferred revenue       $ 10,000,000                              
Collection period for the receivable after target selection       2 years                              
XML 34 R67.htm IDEA: XBRL DOCUMENT v3.3.0.814
Lines of Credit and Long Term Debt - Schedule of Future Maturities of Long Term Debt (Details)
$ in Thousands
Sep. 30, 2015
USD ($)
Maturities of Long-term Debt [Abstract]  
2015 $ 506
2016 929
2017 382
2018 525
2019 340
2020 309
Thereafter 4,262
Long-term Debt $ 7,253
XML 35 R61.htm IDEA: XBRL DOCUMENT v3.3.0.814
Goodwill and Intangible Assets, net - Schedule of Changes in Carrying Amount of Goodwill (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2015
USD ($)
Goodwill  
December 31, 2014 $ 101,059
Acquisitions 67,404
Foreign currency translation adjustment (1,597)
September 30, 2015 $ 166,866
XML 36 R47.htm IDEA: XBRL DOCUMENT v3.3.0.814
Mergers and Acquisitions - Fair Value of Consideration Transferred (Details) - USD ($)
$ in Thousands
 1 Months Ended 9 Months Ended
Sep. 30, 2015
Apr. 30, 2015
Feb. 28, 2015
Aug. 31, 2014
Mar. 31, 2014
Sep. 30, 2015
Sep. 30, 2014
Business Acquisition [Line Items]              
Deferred cash consideration           $ 11,440 $ 20,115
Oxitec Limited              
Business Acquisition [Line Items]              
Cash $ 90,199            
Common shares 56,195            
Total consideration transferred $ 146,394            
Okanagan Specialty Fruits Inc              
Business Acquisition [Line Items]              
Cash   $ 10,000          
Common shares   30,933          
Total consideration transferred   $ 40,933          
ActoGeniX NV              
Business Acquisition [Line Items]              
Cash     $ 32,739        
Common shares     39,735        
Total consideration transferred     $ 72,474        
Trans Ova Genetics, LC              
Business Acquisition [Line Items]              
Cash       $ 63,625      
Common shares       32,802      
Deferred cash consideration       20,115      
Total consideration transferred       116,542      
Fair value of noncontrolling interest       11,333      
Total       $ 127,875      
Medistem, Inc.              
Business Acquisition [Line Items]              
Cash         $ 4,920    
Common shares         19,368    
Total consideration transferred         24,995    
Medistem, Inc. | Settlement of Promissory Notes              
Business Acquisition [Line Items]              
Total consideration transferred         $ 707    
XML 37 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2015
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies
Principles of Consolidation
The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.
Unaudited Financial Information
The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with U.S. GAAP. Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of September 30, 2015 and results of operations and cash flows for the interim periods ended September 30, 2015 and 2014. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2015, or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014.
Revenue Recognition
The Company generates revenue through contractual agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement, (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement, (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities, and (iv) royalties on sales of products arising from the collaboration or licensing agreement.
The Company's collaboration and licensing agreements typically contain multiple elements, or deliverables, including technology licenses, research and development services, and in certain cases manufacturing services. The Company identifies the deliverables within the agreements and evaluates which deliverables represent separate units of accounting. Analyzing the agreements to identify deliverables requires the use of judgment. A deliverable is considered a separate unit of accounting when the deliverable has value to the collaborator or licensee on a standalone basis based on the consideration of the relevant facts and circumstances for each agreement.
Consideration received is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. When available, the relative selling price for each deliverable is determined using vendor specific objective evidence ("VSOE") of the selling price or third-party evidence of the selling price, if VSOE does not exist. If neither VSOE nor third-party evidence of the selling price exists, the Company uses its best estimate of the selling price ("BESP") for the deliverable. The amount of allocable consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. The Company recognizes the revenue allocated to each unit of accounting as the Company delivers the related goods or services. If the Company determines that certain deliverables should be treated as a single unit of accounting, then the revenue is recognized using either a proportional performance or straight-line method, depending on whether the Company can reasonably estimate the level of effort required to complete its performance obligations under an arrangement and whether such performance obligations are provided on a best-efforts basis. As the Company cannot reasonably estimate its performance obligations related to its collaborators or licensees, the Company recognizes revenue on a straight-line basis over the period it expects to complete its performance obligations.
The terms of the Company's agreements may provide for milestone payments upon achievement of certain defined events. The Company applies the Milestone Method for recognizing milestone payments. Under the Milestone Method, the Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:
(1)
The consideration is commensurate with either the entity's performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the entity's performance to achieve the milestone;
(2)
The consideration relates solely to past performance; and
(3)
The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.
In the event that a milestone is not considered substantive, the Company recognizes the milestone consideration as revenue using the same method applied to upfront payments.
Research and development services are a deliverable satisfied by the Company in accordance with the terms of the collaboration and licensing agreements and the Company considers these services to be inseparable from the license to the core technology; therefore, reimbursements of services performed are recognized as revenue. Because reimbursement (i) is contingent upon performance of the services by the Company, (ii) does not include a profit component, and (iii) does not relate to any future deliverable, the revenue is recognized during the period in which the related services are performed and collection of such amounts is reasonably assured. Payments received for manufacturing services will be recognized when the earnings process related to the manufactured materials has been completed. Royalties to be received under the agreements will be recognized as earned.
From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. When no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue.
The Company also generates products and services revenue through sales of advanced reproductive technologies, including bovine embryos derived from the Company's embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock used in production. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) services have been rendered or delivery has occurred such that risk of loss has passed to the customer, (iii) the price is fixed or determinable, and (iv) collection from the customer is reasonably assured.
Research and Development
The Company considers that regulatory and other uncertainties inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, and the costs of consultants, certain in-licensed technology rights, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Indirect research and development costs include depreciation, amortization and other indirect overhead expenses.
The Company has research and development arrangements with third parties that include upfront and milestone payments and primarily relate to collaborations. At September 30, 2015 and December 31, 2014, the Company had research and development commitments with third parties that had not yet been incurred totaling $6,576 and $2,183, respectively. The commitments are generally cancellable by the Company at any time upon written notice.
Cash and Cash Equivalents
All highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions with high quality credit ratings. Recoverability of investments is dependent upon the performance of the issuer. At September 30, 2015 and December 31, 2014, the Company had cash equivalent investments in highly liquid money market accounts at major financial institutions of $93,158 and $16,598, respectively.
Short-term and Long-term Investments
At September 30, 2015, investments include short-term and long-term investments in U.S. government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company's written investment policy requires investments to be explicitly rated by two of the three following rating services: Standard & Poor's, Moody's and/or Fitch and to have a minimum rating of A1, P1 and/or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer.
Equity Securities
The Company holds equity securities received and/or purchased from certain collaborators. Other than investments accounted for using the equity method, the Company elected the fair value option to account for its equity securities held in these collaborators. These equity securities are recorded at fair value at each reporting date and are subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments are reported in the consolidated statement of operations. The fair value of these equity securities is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these collaborators. These equity securities are classified as noncurrent in the consolidated balance sheet since the Company does not intend to sell these equity securities within one year.
The Company records the fair value of securities received on the date the collaboration is consummated or the milestone is achieved using the closing, quoted price of the collaborator's security on that date, assuming the transfer of consideration is considered perfunctory. If the transfer of the consideration is not considered perfunctory, the Company considers the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluates whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concludes that a discount should be applied, the fair value of the securities is adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.
Fair Value of Financial Instruments
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:
Level 1:
 
Quoted prices in active markets for identical assets and liabilities;
 
 
Level 2:
 
Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and
 
 
Level 3:
 
Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.

Concentrations of Risk
Due to the Company's mix of fixed and variable rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of September 30, 2015, gross unrealized losses on the Company's short-term and long-term investments were immaterial. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses.
Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of trade receivables. The Company controls credit risk through credit approvals, credit limits and monitoring procedures. The Company performs ongoing credit evaluations of its customers, but generally does not require collateral to support accounts receivable.
Equity Method Investments
The Company is party to three strategic joint ventures (Note 4). The Company accounts for its investments in these joint ventures and for its investment in Thrive Agrobiotics, Inc. ("Thrive Agrobiotics") (Note 5) using the equity method of accounting since the Company has the ability to exercise significant influence, but not control, over the operating activities of these entities.
The Company determined that it has significant influence over one of its collaborators, Oragenics, Inc. ("Oragenics"), as of September 30, 2015, and over two of its collaborators, Oragenics and ZIOPHARM Oncology, Inc. ("ZIOPHARM"), as of December 31, 2014, based on its ownership interests, representation on the board of directors of the collaborators and other qualitative factors. The Company accounts for its investments in Oragenics and ZIOPHARM using the fair value option.
The fair value of the Company's equity securities of Oragenics was $13,475 and $7,192 as of September 30, 2015 and December 31, 2014, respectively, and is included as equity securities in the respective consolidated balance sheets. The Company's ownership percentage of Oragenics was 24.2% and 24.4% at September 30, 2015 and December 31, 2014, respectively. Unrealized appreciation (depreciation) in the fair value of the Company's equity securities held in Oragenics was $2,404 and $(5,487) for the three months ended September 30, 2015 and 2014, respectively, and was $6,283 and $(11,890) for the nine months ended September 30, 2015 and 2014, respectively.
In June 2015, the Company distributed all of its holdings in ZIOPHARM to the Company's shareholders in the form of a special stock dividend (Note 13). Upon disposition, the Company realized a gain of $81,401 for the three months ended June 30, 2015. As of December 31, 2014, the Company's ownership percentage of ZIOPHARM was 15.7% and the fair value of the Company's equity securities of ZIOPHARM was $83,099 and is included as equity securities in the December 31, 2014 consolidated balance sheet. Unrealized depreciation in the fair value of the Company's equity securities held in ZIOPHARM was $22,783 and $27,864 for the three and nine months ended September 30, 2014, respectively.
Summarized unaudited financial data as of September 30, 2015 and December 31, 2014 and for the three and nine months ended September 30, 2015 and 2014, for the Company's equity method investments are as follows:
 
September 30,
2015
 
December 31, 2014
Current assets
$
12,225

 
$
63,627

Non-current assets
462

 
1,259

Total assets
12,687

 
64,886

Current liabilities
10,121

 
15,346

Non-current liabilities
—

 
570

Total liabilities
10,121

 
15,916

Net assets
$
2,566

 
$
48,970


 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Revenues
$
330

 
$
834

 
$
1,389

 
$
1,753

Operating expenses
7,020

 
17,052

 
114,023

 
46,266

Loss from operations
(6,690
)
 
(16,218
)
 
(112,634
)
 
(44,513
)
Other
(34
)
 
5,854

 
(33
)
 
11,543

Net loss
$
(6,724
)
 
$
(10,364
)
 
$
(112,667
)
 
$
(32,970
)

Variable Interest Entities
The Company identifies entities that (i) do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIE" or "VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE.
As of September 30, 2015 and December 31, 2014, the Company determined that certain of its collaborators and joint ventures were VIEs. As of September 30, 2015, the Company also determined that Harvest Intrexon Enterprise Fund I, LP ("Harvest") (Note 17) was a VIE. The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. The Company's aggregate investment balances of these VIEs as of September 30, 2015 was $1,909, which represents the Company's maximum risk of loss related to the identified VIEs. As of December 31, 2014, the Company did not hold any investment balances in the identified VIEs and therefore had no risk of loss as of that date.
Trade Receivables
Trade receivables consist of credit extended to the Company's customers and collaborators in the normal course of business and are reported net of an allowance for doubtful accounts. The Company reviews its customer accounts on a periodic basis and records bad debt expense for specific amounts the Company evaluates as uncollectible. Past due status is determined based upon contractual terms. Amounts are written off at the point when collection attempts have been exhausted. Management estimates uncollectible amounts considering such factors as current economic conditions and historic and anticipated customer performance. This estimate can fluctuate due to changes in economic, industry or specific customer conditions which may require adjustment to the allowance recorded by the Company. Management has included amounts believed to be uncollectible in the allowance for doubtful accounts.
The following table shows the activity in the allowance for doubtful accounts for the nine months ended September 30, 2015:
Balance at December 31, 2014
$
565

Charged to operating expenses
1,562

Write offs of accounts receivable
(112
)
Balance at September 30, 2015
$
2,015


Inventory
The Company's inventory primarily includes adult female cows which are used in certain production processes and are recorded at acquisition cost using the first-in, first-out method or at market, whichever is lower. Work-in-process inventory includes allocations of production costs and facility costs for products currently in production and is recorded at the lower of cost or market. Significant declines in the price of cows could result in unfavorable adjustments to inventory balances.
Property, Plant and Equipment
Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are generally expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets are as follows:
 
  
Years
Land improvements
 
4–20
Buildings and building improvements
  
3–23
Furniture and fixtures
  
1–7
Equipment
  
1–10
Computer hardware and software
  
1–7

Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to fourteen years.
Goodwill
Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized (Note 3). Goodwill is reviewed for impairment at least annually. The Company performs a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the two-step goodwill impairment test. If this is the case, the two-step goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the two-step goodwill impairment test is not required.
If the two-step goodwill impairment test is required, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, an indication of goodwill impairment exists for the reporting unit and the entity must perform step two of the impairment test. Under step two, an impairment loss is recognized for any excess of the carrying amount of the reporting unit's goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation and the residual fair value after this allocation is the implied fair value of the reporting unit goodwill. Fair value of the reporting unit is determined using a discounted cash flow analysis. If the fair value of the reporting unit exceeds its carrying amount, step two does not need to be performed.
The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review.
Intangible Assets
Intangible assets subject to amortization consist of patents, related technologies and know-how; customer relationships; trademarks; and a covenant not to compete acquired as a result of mergers and acquisitions (Note 3). These intangible assets are subject to amortization, were recorded at fair value at the date of acquisition and are stated net of accumulated amortization. Indefinite-lived intangible assets consist of in-process research and development acquired in mergers and acquisitions (Note 3) and were recorded at fair value at the dates of the respective acquisitions.
The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible assets are expected to be realized. The intangible assets are amortized over their remaining estimated useful lives, ranging from two to eighteen years for the patents, related technologies and know-how; customer relationships; trademarks; and the covenant not to compete.
Impairment of Long-Lived Assets
Long-lived assets to be held and used, including property, plant and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.
Indefinite-lived intangible assets, including in-process research and development, are tested for impairment annually, or more frequently if events or circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of their fair value to carrying value, without consideration of any recoverability test. The Company monitors the progression of its in-process research and development, as the likelihood of success is contingent upon commercial development or regulatory approval.
Foreign Currency Translation
The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into United States dollars at the exchange rates in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in the consolidated statement of comprehensive loss. Revenue and expense amounts are translated at average rates during the period.
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.
Net Loss per Share
Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.
Segment Information
The Company has determined that it operates in one segment. The Company applies its technologies to create products and services which may be either sold directly to customers or developed through collaboration with third parties. As of September 30, 2015 and December 31, 2014, the Company had $3,623 and $2,200, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $1,183 and $809 for the three months ended September 30, 2015 and 2014, respectively, and $3,446 and $1,178 for the nine months ended September 30, 2015 and 2014, respectively.
Recently Issued Accounting Pronouncements
In September 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-16, Business Combinations: Simplifying the Accounting for Measurement-Period Adjustments ("ASU 2015-16"). ASU 2015-16 eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Rather, the acquirer must recognize adjustments during the period in which the amounts are determined, including the effect on earnings of any amounts that would have been recorded in previous periods. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, with early adoption permitted. The Company elected to early adopt this guidance and there was no significant impact on the Company's consolidated financial statements.
In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330) - Simplifying the Measurement of Inventory ("ASU 2015-11"). The provisions of ASU 2015-11 provide guidance for simplifying the calculation for subsequent measurement of inventory measured using the first-in-first-out or average cost methods. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2016, and is effective for the Company for the year ending December 31, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.
In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810) - Amendments to the Consolidation Analysis ("ASU 2015-02"). The provisions of ASU 2015-02 provide guidance which changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. This guidance is effective for annual periods and interim periods within those annual periods, beginning after December 15, 2015, with early adoption permitted. The Company elected to early adopt this guidance and there was no significant impact on the Company's consolidated financial statements.
In May 2014, the FASB issued ASU 2014-9, Revenue from Contracts with Customers ("ASU 2014-9"). The FASB issued ASU 2014-9 to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance was originally effective for annual periods and interim periods within those annual periods beginning after December 15, 2016 and early adoption was not permitted. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606) - Deferral of the Effective Date ("ASU 2015-14"), which deferred the effective date of the guidance in ASU 2014-9 by one year to December 15, 2017 for interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016, and is effective for the Company for the year ending December 31, 2018. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.
Reclassifications
Certain insignificant reclassifications have been made to the prior interim period consolidated financial statements to conform to the current interim period presentation.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
XML 38 R62.htm IDEA: XBRL DOCUMENT v3.3.0.814
Goodwill and Intangible Assets, net - Additional Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]          
Goodwill accumulated impairment losses $ 0   $ 0   $ 0
Amortization expense $ 2,857,000 $ 1,290,000 $ 6,434,000 $ 2,664,000  
XML 39 R43.htm IDEA: XBRL DOCUMENT v3.3.0.814
Summary of Significant Accounting Policies - Summarized Financial Data (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Schedule of Equity Method Investments [Line Items]          
Operating expenses $ 61,283 $ 36,244 $ 244,576 $ 91,839  
Equity Method Investments          
Schedule of Equity Method Investments [Line Items]          
Current assets 12,225   12,225   $ 63,627
Non-current assets 462   462   1,259
Total assets 12,687   12,687   64,886
Current liabilities 10,121   10,121   15,346
Non-current liabilities 0   0   570
Total liabilities 10,121   10,121   15,916
Net assets 2,566   2,566   $ 48,970
Revenues 330 834 1,389 1,753  
Operating expenses 7,020 17,052 114,023 46,266  
Loss from operations (6,690) (16,218) (112,634) (44,513)  
Other (34) 5,854 (33) 11,543  
Net loss $ (6,724) $ (10,364) $ (112,667) $ (32,970)  
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814
Mergers and Acquisitions (Tables)
 9 Months Ended
Sep. 30, 2015
Oxitec Limited  
Business Acquisition [Line Items]  
Acquisition Date Fair Value Consideration Transferred
The fair value of the total consideration transferred was $146,394. The acquisition date fair value of the Stock Consideration and Cash Consideration is presented below:
Cash
$
90,199

Common shares
56,195

 
$
146,394
Estimated Fair Value of Assets Acquired and Liabilities Assumed at Acquisition Date
The preliminary estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:
Cash
$
3,780

Trade receivables
125

Other receivables
7,395

Prepaid expenses and other
121

Property, plant, and equipment
1,198

Intangible assets
96,854

Total assets acquired
109,473

Accounts payable
1,187

Accrued compensation and benefits
246

Other accrued liabilities
210

Deferred revenue
120

Deferred tax liabilities
12,584

Total liabilities assumed
14,347

Net assets acquired
95,126

Goodwill
51,268

Total consideration
$
146,394
Okanagan Specialty Fruits Inc  
Business Acquisition [Line Items]  
Acquisition Date Fair Value Consideration Transferred
The fair value of the total consideration transferred was $40,933. The acquisition date fair value of each class of consideration transferred is presented below:
Cash
$
10,000

Common shares
30,933

 
$
40,933
Estimated Fair Value of Assets Acquired and Liabilities Assumed at Acquisition Date
The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below along with subsequent adjustments during the measurement period to the fair value of assets acquired and liabilities assumed. The adjustments resulted from revisions to the valuation of intangible assets.
 
Initial Estimated Fair Value
 
Adjustments
 
Adjusted Fair Value
Cash
$
58

 
$
—

 
$
58

Trade receivables
16

 
—

 
16

Other receivables
49

 
—

 
49

Property, plant, and equipment
32

 
—

 
32

Intangible assets
33,800

 
2,700

 
36,500

Total assets acquired
33,955

 
2,700

 
36,655

Accounts payable
181

 
—

 
181

Deferred revenue
181

 
—

 
181

Deferred tax liabilities
8,145

 
702

 
8,847

Total liabilities assumed
8,507

 
702

 
9,209

Net assets acquired
25,448

 
1,998

 
27,446

Goodwill
15,485

 
(1,998
)
 
13,487

Total consideration
$
40,933

 
$
—

 
$
40,933
ActoGeniX NV  
Business Acquisition [Line Items]  
Acquisition Date Fair Value Consideration Transferred
The fair value of the total consideration transferred was $72,474. The acquisition date fair value of each class of consideration transferred is presented below:
Cash
$
32,739

Common shares
39,735

 
$
72,474
Estimated Fair Value of Assets Acquired and Liabilities Assumed at Acquisition Date
The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below along with subsequent adjustments during the measurement period to the fair value of assets acquired and liabilities assumed. The adjustments resulted from the difference between estimated and actual accrued expenses.
 
Initial Estimated Fair Value
 
Adjustments
 
Adjusted Fair Value
Cash
$
3,180

 
$
—

 
$
3,180

Other receivables
305

 
—

 
305

Prepaid expenses and other
31

 
—

 
31

Property, plant and equipment
209

 
—

 
209

Intangible assets
68,100

 
—

 
68,100

Other assets
23

 
—

 
23

Total assets acquired
71,848

 
—

 
71,848

Accounts payable
230

 
—

 
230

Accrued compensation and benefits
624

 
(428
)
 
196

Other accrued liabilities
307

 
(54
)
 
253

Deferred revenue
732

 
—

 
732

Deferred tax liabilities
612

 
—

 
612

Total liabilities assumed
2,505

 
(482
)
 
2,023

Net assets acquired
69,343

 
482

 
69,825

Goodwill
3,131

 
(482
)
 
2,649

Total consideration
$
72,474

 
$
—

 
$
72,474
Trans Ova Genetics, LC  
Business Acquisition [Line Items]  
Acquisition Date Fair Value Consideration Transferred
The fair value of the total consideration transferred, including the noncontrolling interest in a majority-owned subsidiary of Trans Ova, was $127,875. The acquisition date fair value of each class of consideration transferred and noncontrolling interest is presented below:
Cash
$
63,625

Common shares
32,802

Deferred cash consideration
20,115

Total consideration transferred
116,542

Fair value of noncontrolling interest
11,333

Total
$
127,875
Estimated Fair Value of Assets Acquired and Liabilities Assumed at Acquisition Date
The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown in the table below.
Cash
$
960

Trade receivables
18,693

Related party receivables
1,219

Inventory
18,476

Prepaid expenses and other
590

Property, plant and equipment
21,164

Intangible assets
23,700

Other assets
147

Total assets acquired
84,949

Accounts payable
3,317

Accrued compensation and benefits
913

Other accrued liabilities
271

Deferred revenue
4,458

Lines of credit
4,091

Related party payables
1,246

Long term debt
9,090

Total liabilities assumed
23,386

Net assets acquired
61,563

Goodwill
66,312

Total consideration and fair value of noncontrolling interest
$
127,875
Medistem, Inc.  
Business Acquisition [Line Items]  
Acquisition Date Fair Value Consideration Transferred
The fair value of the total consideration transferred was $24,995. The acquisition date fair value of each class of consideration transferred is presented below:
 
Cash
$
4,920

Common shares
19,368

Settlement of promissory notes
707

 
$
24,995
Estimated Fair Value of Assets Acquired and Liabilities Assumed at Acquisition Date
The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown in the table below.
Cash
$
8

Intangible assets
4,824

Total assets acquired
4,832

Accounts payable
644

Accrued compensation and benefits
67

Other accrued expenses
50

Total liabilities assumed
761

Net assets acquired
4,071

Goodwill
20,924

Total consideration
$
24,995
2015 Business Acquisitions  
Business Acquisition [Line Items]  
Condensed Pro forma Financial Information
The following unaudited condensed pro forma financial information for the three and nine months ended September 30, 2015 and 2014 is presented as if the acquisitions had been consummated on January 1, 2014:
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
 
Pro forma
Revenues
$
53,754

 
$
21,524

 
$
133,060

 
$
41,742

Loss before income taxes
(43,979
)
 
(58,972
)
 
(66,686
)
 
(117,811
)
Net loss
(43,057
)
 
(58,586
)
 
(66,319
)
 
(116,100
)
Net loss attributable to the noncontrolling interests
816

 
1,137

 
2,940

 
2,895

Net loss attributable to Intrexon
(42,241
)
 
(57,449
)
 
(63,379
)
 
(113,205
)
2014 Business Acquisitions  
Business Acquisition [Line Items]  
Condensed Pro forma Financial Information
The following unaudited condensed pro forma financial information for the three and nine months ended September 30, 2014 is presented as if the acquisitions had been consummated on January 1, 2013:
 
Three Months Ended 
 September 30, 2014
 
Nine Months Ended 
 September 30, 2014
 
Pro forma
Revenues
$
31,507

 
$
88,629

Loss before income taxes
(51,864
)
 
(98,816
)
Net loss
(51,864
)
 
(98,839
)
Net loss attributable to the noncontrolling interests
1,200

 
3,260

Net loss attributable to Intrexon
(50,664
)
 
(95,580
)
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2015
Accounting Policies [Abstract]  
Summarized Unaudited Financial Information for the Equity Method Investments
Summarized unaudited financial data as of September 30, 2015 and December 31, 2014 and for the three and nine months ended September 30, 2015 and 2014, for the Company's equity method investments are as follows:
 
September 30,
2015
 
December 31, 2014
Current assets
$
12,225

 
$
63,627

Non-current assets
462

 
1,259

Total assets
12,687

 
64,886

Current liabilities
10,121

 
15,346

Non-current liabilities
—

 
570

Total liabilities
10,121

 
15,916

Net assets
$
2,566

 
$
48,970


 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Revenues
$
330

 
$
834

 
$
1,389

 
$
1,753

Operating expenses
7,020

 
17,052

 
114,023

 
46,266

Loss from operations
(6,690
)
 
(16,218
)
 
(112,634
)
 
(44,513
)
Other
(34
)
 
5,854

 
(33
)
 
11,543

Net loss
$
(6,724
)
 
$
(10,364
)
 
$
(112,667
)
 
$
(32,970
)
Allowance for Doubtful Accounts
The following table shows the activity in the allowance for doubtful accounts for the nine months ended September 30, 2015:
Balance at December 31, 2014
$
565

Charged to operating expenses
1,562

Write offs of accounts receivable
(112
)
Balance at September 30, 2015
$
2,015
Estimated Useful Lives
The estimated useful lives of these assets are as follows:
 
  
Years
Land improvements
 
4–20
Buildings and building improvements
  
3–23
Furniture and fixtures
  
1–7
Equipment
  
1–10
Computer hardware and software
  
1–7
XML 42 R56.htm IDEA: XBRL DOCUMENT v3.3.0.814
Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Assets    
Fair value of financial assets measured at fair value on a recurring basis $ 303,898 $ 280,497
U.S. government debt securities    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 226,858 115,335
Equity Securities    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 76,623 164,889
Other    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 417 273
Quoted Prices in Active Markets (Level 1)    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 61,747 143,927
Quoted Prices in Active Markets (Level 1) | U.S. government debt securities    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 0 0
Quoted Prices in Active Markets (Level 1) | Equity Securities    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 61,747 143,927
Quoted Prices in Active Markets (Level 1) | Other    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 0 0
Significant Other Observable Inputs (Level 2)    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 242,151 136,570
Significant Other Observable Inputs (Level 2) | U.S. government debt securities    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 226,858 115,335
Significant Other Observable Inputs (Level 2) | Equity Securities    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 14,876 20,962
Significant Other Observable Inputs (Level 2) | Other    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 417 273
Significant Unobservable Inputs (Level 3)    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 0 0
Significant Unobservable Inputs (Level 3) | U.S. government debt securities    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 0 0
Significant Unobservable Inputs (Level 3) | Equity Securities    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 0 0
Significant Unobservable Inputs (Level 3) | Other    
Assets    
Fair value of financial assets measured at fair value on a recurring basis $ 0 $ 0
XML 43 R44.htm IDEA: XBRL DOCUMENT v3.3.0.814
Summary of Significant Accounting Policies - Trade Receivables - Rollforward of Allowance for Doubtful Accounts (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Allowance for Doubtful Accounts Receivable    
December 31, 2014 $ 565  
Charged to operating expenses 1,562 $ 74
Write offs of accounts receivable (112)  
September 30, 2015 $ 2,015  
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814
Collaboration and Licensing Revenue (Tables)
 9 Months Ended
Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summarized Collaboration and Licensing Revenue
The following table summarizes the amounts recorded in the consolidated statements of operations for each significant collaboration and licensing agreement for the three and nine months ended September 30, 2015 and 2014.
 
Three Months Ended September 30, 2015
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
645

 
$
4,006

 
$
4,651

Oragenics, Inc.
4,868

 
332

 
5,200

Fibrocell Science, Inc.
4,823

 
1,317

 
6,140

Genopaver, LLC
68

 
993

 
1,061

S & I Ophthalmic, LLC
—

 
1,193

 
1,193

OvaXon, LLC
—

 
549

 
549

Intrexon Energy Partners, LLC
625

 
3,185

 
3,810

Persea Bio, LLC
125

 
297

 
422

Ares Trading S.A.
1,597

 
260

 
1,857

Other
7,841

 
2,002

 
9,843

Total
$
20,592

 
$
14,134

 
$
34,726

 
Three Months Ended September 30, 2014
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
644

 
$
3,370

 
$
4,014

Oragenics, Inc.
261

 
3

 
264

Fibrocell Science, Inc.
449

 
1,014

 
1,463

Genopaver, LLC
68

 
360

 
428

S & I Ophthalmic, LLC
—

 
667

 
667

OvaXon, LLC
—

 
813

 
813

Intrexon Energy Partners, LLC
625

 
1,535

 
2,160

Other
443

 
2,404

 
2,847

Total
$
2,490

 
$
10,166

 
$
12,656

 
Nine Months Ended September 30, 2015
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
1,933

 
$
11,769

 
$
13,702

Oragenics, Inc.
5,437

 
408

 
5,845

Fibrocell Science, Inc.
5,719

 
4,500

 
10,219

Genopaver, LLC
205

 
2,460

 
2,665

S & I Ophthalmic, LLC
—

 
2,838

 
2,838

OvaXon, LLC
—

 
1,855

 
1,855

Intrexon Energy Partners, LLC
1,875

 
8,101

 
9,976

Persea Bio, LLC
375

 
553

 
928

Ares Trading S.A.
2,336

 
260

 
2,596

Other
9,446

 
6,620

 
16,066

Total
$
27,326

 
$
39,364

 
$
66,690


 
Nine Months Ended September 30, 2014
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
1,932

 
$
9,103

 
$
11,035

Oragenics, Inc.
784

 
588

 
1,372

Fibrocell Science, Inc.
1,345

 
2,759

 
4,104

Genopaver, LLC
205

 
1,204

 
1,409

S & I Ophthalmic, LLC
—

 
2,153

 
2,153

OvaXon, LLC
—

 
1,561

 
1,561

Intrexon Energy Partners, LLC
1,250

 
2,745

 
3,995

Other
1,373

 
5,255

 
6,628

Total
$
6,889

 
$
25,368

 
$
32,257
Summary of Deferred Revenue
Deferred revenue consists of the following:
 
September 30,
2015
 
December 31,
2014
Upfront and milestone payments
$
159,069

 
$
107,228

Prepaid research and development services
11,099

 
1,045

Prepaid product and service revenues
5,292

 
4,365

Other
794

 
571

Total
$
176,254

 
$
113,209

Current portion of deferred revenue
$
32,006

 
$
16,522

Long-term portion of deferred revenue
144,248

 
96,687

Total
$
176,254

 
$
113,209
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814
Short-term and Long-term Investments (Tables)
 9 Months Ended
Sep. 30, 2015
Investments, Debt and Equity Securities [Abstract]  
Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments
The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of September 30, 2015:
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate
Fair Value
U.S. government debt securities
$
226,567

 
$
291

 
$
—

 
$
226,858

Certificates of deposit
272

 
—

 
—

 
272

Total
$
226,839

 
$
291

 
$
—

 
$
227,130

The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of December 31, 2014:
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate
Fair Value
U.S. government debt securities
$
115,293

 
$
54

 
$
(12
)
 
$
115,335

Certificates of deposit
273

 
—

 
—

 
273

Total
$
115,566

 
$
54

 
$
(12
)
 
$
115,608
Investments Classified by Contractual Maturity Date
The estimated fair value of available-for-sale investments classified by their contractual maturities as of September 30, 2015 was as follows:
Due within one year
$
90,864

After one year through three years
136,266

Total
$
227,130
XML 46 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814
Organization and Basis of Presentation
 9 Months Ended
Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Basis of Presentation
Organization and Basis of Presentation
Intrexon Corporation ("Intrexon"), a Virginia corporation, forms collaborations to create biologically based products and processes using synthetic biology. Intrexon has domestic operations in California, Florida, Maryland, and Virginia, and foreign operations in Belgium and Hungary. There have been no commercialized products derived from Intrexon's collaborations to date.
Trans Ova Genetics, L.C. and Subsidiaries ("Trans Ova"), a provider of bovine reproductive technologies and other genetic processes to cattle breeders and producers, is a wholly owned subsidiary of Intrexon with primary operations in Iowa, Maryland, Missouri, Oklahoma, and Texas (Note 3). ViaGen, L.C. ("ViaGen"), a provider of genetic preservation and cloning technologies, is a wholly owned subsidiary of Trans Ova. Exemplar Genetics, LLC ("Exemplar"), a provider of genetically engineered swine for medical and genetic research, is a wholly owned subsidiary through the combined investments of Intrexon, Trans Ova, and ViaGen.
Intrexon Produce Holdings, Inc. ("IPHI") is a wholly owned subsidiary of Intrexon. Okanagan Specialty Fruits, Inc. ("Okanagan"), a company which developed and received regulatory approval for the world's first non-browning apple without the use of any flavor-altering chemical or antioxidant additives, is a wholly owned subsidiary of IPHI with primary operations in Canada (Note 3). Fruit Orchard Holdings, Inc. ("FOHI") is a wholly owned subsidiary of IPHI with primary operations in Washington.
Oxitec Limited ("Oxitec"), a pioneering company in biological insect control solutions, is a wholly owned subsidiary of Intrexon with primary operations in England and Brazil (Note 3).
As of September 30, 2015, Intrexon owned approximately 63% of AquaBounty, a biotechnology company focused on improving productivity in commercial aquaculture.
At September 30, 2015, Intrexon owned approximately 51% of Biological & Popular Culture, Inc. ("BioPop").
Intrexon Corporation and its consolidated subsidiaries are hereinafter referred to as the "Company."
These consolidated financial statements are presented in United States dollars and are prepared under accounting principles generally accepted in the United States of America ("U.S. GAAP").
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2015
Fair Value Disclosures [Abstract]  
Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis
The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at September 30, 2015:
 
Quoted Prices in Active Markets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
September 30,
2015
Assets
 
 
 
 
 
 
 
U.S. government debt securities (Note 6)
$
—

 
$
226,858

 
$
—

 
$
226,858

Equity securities (Note 5)
61,747

 
14,876

 
—

 
76,623

Other
—

 
417

 
—

 
417

Total
$
61,747

 
$
242,151

 
$
—

 
$
303,898

The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at December 31, 2014:
 
Quoted Prices in Active Markets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
December 31,
2014
Assets
 
 
 
 
 
 
 
U.S. government debt securities (Note 6)
$
—

 
$
115,335

 
$
—

 
$
115,335

Equity securities (Note 5)
143,927

 
20,962

 
—

 
164,889

Other
—

 
273

 
—

 
273

Total
$
143,927

 
$
136,570

 
$
—

 
$
280,497
XML 48 R40.htm IDEA: XBRL DOCUMENT v3.3.0.814
Net Loss per Share (Tables)
 9 Months Ended
Sep. 30, 2015
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Net Loss per Share
The following table presents the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2015 and 2014:
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Historical net loss per share:
 
 
 
 
 
 
 
Numerator:
 
 
 
 
 
 
 
Net loss attributable to Intrexon
$
(38,213
)
 
$
(52,725
)
 
$
(51,779
)
 
$
(100,653
)
Denominator:
 
 
 
 
 
 
 
Weighted average shares outstanding, basic and diluted
112,244,129

 
99,888,203

 
109,244,641

 
98,711,564

Net loss attributable to Intrexon per share, basic and diluted
$
(0.34
)
 
$
(0.53
)
 
$
(0.47
)
 
$
(1.02
)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following potentially dilutive securities have been excluded from the above computations of diluted weighted average shares outstanding for the three and nine months ended September 30, 2015 and 2014, as they would have been anti-dilutive:
 
September 30,
 
2015
 
2014
Options
10,660,040

 
8,194,650

Warrants
194,719

 
373,102

Total
10,854,759

 
8,567,752
XML 49 R53.htm IDEA: XBRL DOCUMENT v3.3.0.814
Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Deferred Revenue Arrangement [Line Items]    
Current portion of deferred revenue $ 32,006 $ 16,522
Long-term portion of deferred revenue 144,248 96,687
Total 176,254 113,209
Upfront and Milestone Payments    
Deferred Revenue Arrangement [Line Items]    
Total 159,069 107,228
Prepaid Research and Development Services    
Deferred Revenue Arrangement [Line Items]    
Total 11,099 1,045
Prepaid Product and Service Revenues    
Deferred Revenue Arrangement [Line Items]    
Total 5,292 4,365
Other    
Deferred Revenue Arrangement [Line Items]    
Total $ 794 $ 571
XML 50 R72.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock Option Plans - Stock Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Stock based compensation cost $ 8,385 $ 4,250 $ 26,524 $ 14,872
Cost of products        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Stock based compensation cost 21 5 76 5
Cost of services        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Stock based compensation cost 98 50 301 50
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Stock based compensation cost 2,234 1,514 6,141 3,226
Selling, general and administrative        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Stock based compensation cost $ 6,032 $ 2,681 $ 20,006 $ 11,591
XML 51 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Current assets    
Cash and cash equivalents $ 125,433 $ 27,466
Short-term investments 90,864 88,495
Receivables    
Trade, net 25,153 14,582
Related parties 28,801 12,622
Note 0 1,501
Other 1,912 559
Inventory 22,338 25,789
Prepaid expenses and other 7,930 3,759
Total current assets 302,431 174,773
Long-term investments 136,266 27,113
Equity securities 76,623 164,889
Property, plant and equipment, net 42,201 38,000
Intangible assets, net 256,284 65,947
Goodwill 166,866 101,059
Investments in affiliates 3,790 3,220
Other assets 5,426 1,271
Total assets 989,887 576,272
Current liabilities    
Accounts payable 4,546 6,267
Accrued compensation and benefits 14,475 7,736
Other accrued liabilities 7,918 5,731
Deferred revenue 32,006 16,522
Lines of credit 475 2,273
Current portion of long term debt 1,314 1,675
Current portion of deferred consideration 16,212 7,064
Related party payables 147 214
Total current liabilities 77,093 47,482
Long term debt, net of current portion 7,796 8,694
Deferred consideration, net of current portion 8,710 13,421
Deferred revenue, net of current portion 144,248 96,687
Deferred tax liabilities 21,550 0
Other long term liabilities 867 699
Total liabilities $ 260,264 $ 166,983
Commitments and contingencies (Note 16)
Total equity    
Common stock, no par value, 200,000,000 shares authorized as of September 30, 2015 and December 31, 2014; 116,359,041 and 100,557,932 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively $ 0 $ 0
Additional paid-in capital 1,233,497 843,001
Accumulated deficit (510,015) (458,236)
Accumulated other comprehensive loss (5,195) (4)
Total Intrexon shareholders' equity 718,287 384,761
Noncontrolling interests 11,336 24,528
Total equity 729,623 409,289
Total liabilities and total equity $ 989,887 $ 576,272
XML 52 R45.htm IDEA: XBRL DOCUMENT v3.3.0.814
Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)
 9 Months Ended
Sep. 30, 2015
Minimum | Land improvements  
Property, Plant and Equipment [Line Items]  
Property plant and equipment, useful life 4 years
Minimum | Buildings and building improvements  
Property, Plant and Equipment [Line Items]  
Property plant and equipment, useful life 3 years
Minimum | Furniture and fixtures  
Property, Plant and Equipment [Line Items]  
Property plant and equipment, useful life 1 year
Minimum | Equipment  
Property, Plant and Equipment [Line Items]  
Property plant and equipment, useful life 1 year
Minimum | Computer hardware and software  
Property, Plant and Equipment [Line Items]  
Property plant and equipment, useful life 1 year
Minimum | Leasehold Improvements  
Property, Plant and Equipment [Line Items]  
Property plant and equipment, useful life 1 year
Maximum | Land improvements  
Property, Plant and Equipment [Line Items]  
Property plant and equipment, useful life 20 years
Maximum | Buildings and building improvements  
Property, Plant and Equipment [Line Items]  
Property plant and equipment, useful life 23 years
Maximum | Furniture and fixtures  
Property, Plant and Equipment [Line Items]  
Property plant and equipment, useful life 7 years
Maximum | Equipment  
Property, Plant and Equipment [Line Items]  
Property plant and equipment, useful life 10 years
Maximum | Computer hardware and software  
Property, Plant and Equipment [Line Items]  
Property plant and equipment, useful life 7 years
Maximum | Leasehold Improvements  
Property, Plant and Equipment [Line Items]  
Property plant and equipment, useful life 14 years
XML 53 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814
Consolidated Statements of Shareholders' and Total Equity - 9 months ended Sep. 30, 2015 - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Total Intrexon Shareholders' Equity
Noncontrolling Interests
Balances (in shares) at Dec. 31, 2014 100,557,932 100,557,932          
Balances at Dec. 31, 2014 $ 409,289   $ 843,001 $ (4) $ (458,236) $ 384,761 $ 24,528
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation expense 26,549   26,388     26,388 161
Exercises of stock options and warrants (in shares)   909,437          
Exercises of stock options and warrants 12,208   12,208     12,208 0
Shares issued to nonemployee members of the Board of Directors (in shares)   10,106          
Shares issued to nonemployee members of the Board of Directors 480   480     480  
Shares issued in public offerings, net of issuance costs (in shares)   9,922,256          
Shares issued in public offerings, net of issuance costs 328,234   328,234     328,234  
Shares issued as consideration of license agreement (in shares)   2,100,085          
Shares issued as consideration of license agreement 59,579   59,579     59,579  
Shares issued in acquisitions (in shares)   2,552,151          
Shares issued in acquisitions 126,863   126,863     126,863  
Acquisition of noncontrolling interest (in shares)   307,074          
Acquisition of noncontrolling interest (1,566)   9,412     9,412 (10,978)
Adjustments for noncontrolling interests 250   (249)     (249) 499
Noncash dividend (172,419)   (172,419)     (172,419)  
Net loss (54,719)       (51,779) (51,779) (2,940)
Other comprehensive income (loss) $ (5,125)     (5,191)   (5,191) 66
Balances (in shares) at Sep. 30, 2015 116,359,041 116,359,041          
Balances at Sep. 30, 2015 $ 729,623   $ 1,233,497 $ (5,195) $ (510,015) $ 718,287 $ 11,336
ZIP 54 0001356090-15-000066-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001356090-15-000066-xbrl.zip M4$L#!!0````(``&%:4=A5^(_CCH"`$B+(P`0`!P`>&]N+3(P,34P.3,P+GAM M;%54"0`#L1)!5K$2059U>`L``00E#@``!#D!``#L?5ESV\:V[O.Y5?<_^/KY M*L8\N+)]"F.V[^X(*`E(08!!@`5:?_ZTPV.($"*H`B@&UA5J40A MIEYK?6OLU=T___?3-'KSB-(L3.)_O.5_XMZ^0;&?!&%\_X^WWVXNC!OK\O+M M?W_XO__GY_]W7JC9WX\RF*\S=6BKP/[Y87WPD<+UYP_(7(OUT]-D]33.>^YY97R8-2^<$` MA?7/X`LUMZ,G_Z'^?G*%/""7'PCC1Y3E]8\LKM50$V:))/#J^JF___[[I^+) M)+W'MW/BN^4=JP>B,/YQX&YR^=;+T.KVV`O]K'Y,Q24R)+X\I#B)X_FT_AM! MGK[+GV?H';[I`M^%TM!?/_?R0^4'4G2WEQ+E';ZZNC$+_7H2\(4:`K)\ENZY M'U^I>6">7=Q[WFS]S)V7W18#65ZH$3:^DB81RFJ?*:[4/T3X4/]0<:7NH3Q% M]WOYI+_#UU>WD@O!#LC7_%Q<+-V:U]XJ+V[-MV\-#P$TSG(O]M>0>ZI`]&^Q MN)O7=?U=<75]*[%<6S<&L?>3GTP++G#8QJSORX*Z%^+/\^_^^'AUXS^@J;>Y M.7SYYHOUJ+%M^J^?R:#>9\65+^CN33'(]P\%0/$8+U;C^0D/Y.WR*I'7/]YF MX7068=+?%:]9V#@_B7/TE+\)\:!=FSS[6?S75[OXTNH>;(3#_+GX9?53&)`? M[T*4OBE&@DI4K"!L7?[/VP\#]=VKWS:?7/VRY-#+//N^U,#O MYCP+8Y1EAO_7/,S"'/L\XRG,OF/I?)_\\&+OWHMO9L@/O2A_=M-YF&>7L?\1 M36]1VB7CUSQ%]\31+GY;_!C@CS_-HM`/\\6XW@0AOF?AOI=TOM]#Y]L/F-#W M+Q'Z\[O:[RP']JXZLE'!Y&OJQ=GDT?L%Q2C'KN]J:/#81R#`XA`L##]/,,?" M/S[]-C`\5"@#(!P$`LD!:F[(A@:+PW0"2`[&&D]ACORK<(K_$PP,T`1@. M@>$C"L(L1]/A19H5R@`(+[D.>22NXP"=XP+)98$1:>+G(D]M;K\H<^0+%O#< MA;AFV>K*J_2$\$#Z++%`OG3!"VV0C\T$"^3O*,!9R+<+Z;-3VY(:&@VI)<^" M>?:9(9ZI-/!,9HAG=13!W.3XK<3W.MAQY\]6,ITE,?[?K(AC5G<905#X M="^Z]L+@,K:\69A[$7N1S$%RWWY8W7:0WG%%-"M_UA`Q^.=I$M_DB?]CL"BI MT-@N,EIVW,NPK:&2V%#T0!C^BR]A/IFBX<#B6]I$9DY/!]"F)R8O2)(IPE'V)7YFB;+BAQ2%R M1P:9TT)/P$M'>*$U-(4"!!@)2%_Z+$:V.(D*SH!Z9]!6*?J$5!3RD+[S$"JG M*``7-.&"'F\!D>/H+`$4*WLH5M*C\3!/Q9)V,]%"*;5$OLA&`ZW8HFX'*/Q^ MA>Z]R"D&M6FL_VONF60KB&=V-!G3\GZ'EF7W_`XQS.OM( MHDBBX'(Z2Y/' MHC:YJQ\UP87WQ&9P<01K-L`_P)MSH;\NV-GF[ MPDH-K=_&"82]_4R``F9#MXI,QUL_9:M\V3$N^@^!V`76`"*@`2&;REDGB._' M&=_3,N\D?Q9*\?UXC35;MG(W1Y`:Y@A*!W,V8%W!NO96/>F]G%A9!#)B,#.& MI1[W,H**RIA-!*!@B,H]H%X3Z.UXJ7,/='B,'6MGKZ9#L#>@%AD)@KW>3005 MU;:EKUB@(MJU5R6D$[\DK]*T!KSD/,J_@>W[;Z$Q875Z!\%)<`X#0!G,PUD!T[ MYSE*_^FEP=]>BKPXN$GNY`X`FB9`KYL/YVD%`>1097S]0AN2OMSAZ%*CN/8X&@)^\I0D.#P'1U=U,:MD" M$!X&A$<1-7GWP8F MW`IEW6JZT%#3A0M!.[OKVED3`LK>N;+3UNF[1(4QO^]7'L!\`&45*9V+/H9 MM=^8IO'5:NKV[,#5`%4H0=5Z'O9>4=E:U8;2*@K6_?4,D)!W6*! M5/ZC=UR4"Y6+EG`@-L2!>.[Z5S8.7HHSG/D,MB)Y:4'FN3SKW+B-->@]A-I^9CL-SE2D&(U\*(AU* M4G:Y2-FA8://1M1&";%,7T*\O1FQ[V4/D_0:$['\GZTW9.;SMSC\:XYLE/EI M."N]]3I-IF&6)>GSIR0?7+C;+-5N\-436;X852W/QUD$.-8UOA3^0>K7;@0] MHCRP]Y5(#:-&*)0.-$YL:B,KX108Q3.'H&`%N[."I"8BP'I,2KK>A/ZK(_OS M'S!OG><_3)LW"GQ[*\7^ZOE%-SZ*/3RRLBJL?@S^G"]VZAX8ZKO*=&K9O`7_ M/7QF>:J""MSZ^=R+`+.M8G:+QX#7U^&5;/D":&T3K1L.LXS5IATP!KF]YH;= M_<`.H_0Z3=PDG7H#0^@+S.D(H&7FCJN?I7'Y"N`,<*:X(-6P7`%P!CA37(!H MNIH0X`QP/@#GOE<$OGX;'$CJ6IL+HSJ+._?&/9TC<9#EL+ZQV%?]BWTT#G52 MH7=$]CB+<&Y4OG;!`_CJ%M=Q4>VMVVI":)(&29`&[4^##C`'TJ#.LOHF12J` M,\"9YB)5DU4"L":S^*^0P&*851$P'83O[FC\!468ZP%96_=\"E)SPWVRSA/$?[#P<;I_IE\%__!H`T#LLS+1G.R6($"!"H"1"D"YXH0W+>#3*)_D#2@W?3^3S`-O!8J;].)*&F&#RZ/V1L#@--X1H8)OY MS$>[9\V06(4E8*)\1@[_JQ>+9_22@(NNO2`_AIR!55@-(D?H"=EGSPD(L,7/ MTL3/SVGQV"[:,%TQ$2]XKH4SQ19>D>._@V]DSH*\MA6#;^/4T:-S2JC`C<^[ M4E%-:2&_J-FFU\*7P_@>#P[_E6$PI(7(S.>OS[,-.K_-[M)DU:Z]W2P7S/U\ MDMZ@]#'T*[<;>BM`!Z4P_:%^6P0&9)$.=2F#HYECZW7Y"@ ML_1M2%RCY="%`ETHH#N]5&4A%QU2?Y^]KE?@7!2J%DPCI61[BKI%`]NS4^&E'@/-!0;Q!,P(% M_!^1.P(*;`=_!\#0',`VPHQT4 M%/90UR$><$:H-%P'J;2`![IJ\,,/849>7(<([@B]7)[2(S2QTH,UT!W9YO*I M/$H+M;J3ZBD]6%HWO$T3'T4,;GX'QG6?.NT(=5RUDN5V?1^]YZT:^5X=ND[1 MS`N#+RA#7NH_8+'9Z!%%R8PP8WGS\=IDI"C[FGH!AN7-3\9/[.G4?EPW8%0' M"*]E=)?S.W+;ZXT&##*:Y=K&O-U.+#!(9PS>Z.@J#+6QX`"*0!`30@WL16LL M_#J/&=)&4,1A*F(?.B@TU$&A'1WDBU4U9'W%B+H]Z.]TX!NND>'/OT;&7F?O MD+M#[MY6'"(WC$/DMKM]H5V.>;_>GPWO>'>\5K%ZC5)LI,PPN;JR`*'G16B5 MMYWALH45_#61PH"=._C3AGG]4!-KR"R;9I;45GB&$I=!K8>^F)#&O!X'D3;R MZ==+MF-0T$9:XM^=3D.^T0*!G8CYC&M%/I(:$%DB4/S!@J/\!<7)S'M$*9,1 M&RCD/H6LRK5#A10;MOZ*'2SZAU9/%F'<:8-+QYL#MXI(YJLR=.-RD,UT-:H"Y.W8%U MD\PCE(I=.EN:4=NW@0"UM8&UN;A!F!;H6AZ6JNV3;K=U@KZWX--5+>E/YXTO,F6J-O@&7(F3N4Q[)T%PE#K'%BM MLZW4K+-:)Y0,!EDR:&^KW^U6B0.P8O0`&+'A!+W8U@2]8,S2,#IJ M\SZ&W1PM/F8WUY.VM/F87$_J)->CMOQ2DX=]B\,0[H1V^.ZE_;.TJH[E?`X+W$SG\VB@D5>!#O.M>`4]C)X M'`ZBO_"-@C,>ER%\\QU&0"M!*X>IE6+#E6%B.RO#CF\<^_J0AH_(N$^3VS#) M0S^[C'T&9T4.@.$`A2-L&^LLR(?VG-&TY[04^#.^O!4;8`\/#^T6#-A3`:@/ M-:@/'19[AQZ'DH6P(B,+8:&W;LB*2D5O'25S;OL7Q0YU52HLRZ2D56DHS9IT M&SLJ^D5;:&*Z7.\O?UQK,,-U/EJ*6Z7#@TH;QK>TK1FU\2'SC<,0'%+H[/L+;P>(C`VL*73:_:L^FMV5QTJ)VV%+6YTKB])3-Q\5`VIX+`&/;F MHBLRAD+*(`LI'<7#>Z%YS.%9PP#:JX\)&UQ\V0@H(^_&I]N`]=<%/T88WUQ. M9@_Y@Q=-0W#%9T9RE;<`YE*G(<755`2*4-@T26,AUK0H`3, M4-/H'M+,-^A0CVIHT.D%V(.<0Z$$TC"-L@/F`Y%O_H!2*XDB[S99],8P6#`^ M%(#NHP]`,?R)!"CA4^K\AMH$18G_ZW6'A)%">J@E44H@#5711E'=:G40>T@\ M9LT3`*"CLCB[,*+>H`&8C[9F;+M6<&KTS%L/HMI!]_0U%%Q:@#;`$R`"^WNS M80"ALGA:E,=V\P*T#5"5N0ZQRY:2Q!4:;3MTV0-N?Z'!5T/O2S]UQ6&GX908 M:LC$3YDY8;03''JP:7#70^UKH,%70U-#U\7R(<[^T8!DF/H[VATSW"4-_U//K@FNL4S;PP M&,_>E@T([@P!+1P1(Z*DN:0!+Z?/N;E>Y0]!PVG0,-[ MM?'@T0>B[TT\^O(ZYL;RAJ7]&Y3(CZ.5>;DWL?,@]^[EWI9U/TKN$+\Q*=]E M<>9?L-BPGTD:ON^"3",`0'5N=&"`+@I&YY[[GG<8'9@9GL&F&\F]3J+3".-! M8A``0(D=8WMY%MVFK.\58C2"&5J"1BU^.+Z`45O6]YXF-()YJ%X57-J98,!V MQ0/*#>=Q;7`*!`O+*L&RG1G2@,[Q``46WHY6]+!6D<5T#J;!.X[>8&^,$>V- M02/`!PY-``6-5H_Y%B+J+1XT,O4"[.'ON4H)ONG9=G6,,!]D_D4)LB$%ZQC, M0YT>I@3/,$/<).D:2@`!KOOZGH+IM".U>W+IOM!@KJ73:T<71L MEX?B]>FVTA!X]&FSAQA[4&*O(?SHN/S%:/,*]4"&%IKN6FB&,+M+=[P!$\PM M0!O@"1`Y@_4;G`>GPN"!^X83SF&NIT,[-N!&*AH,&G11]9)?,[R!"?4I-FRC M(G5[^N7P:_N4()N2\K[4\(`-J1N8#R\7HB\184_T[/9Q4ME!R1P`V-X\@-9E M^Y3"`+K"V0UNP*:=$\P`30`*S"-06W:#\+U+M\UV#$B]YX9(M'M(0Z_A\'H- M1PKE@?=I48)J&EJU*`7XP*$)H*`NJ1KD]"\->55_<[^LP1C6*;+@M7M=I\@: MI&'].+V&&9*J8V-.MBTJV+(SP8#A$!'B,TJ9AKB M#&AD/KK(Q6ZU'4K='5@QE@#!QDXX@X/(X"=4Z/9U,*?3Q-T-I`!S@:/#L8PUS/,5JA@O)0ZU:-)3@PT\8U+(B,=1KF(8M;;1P2]4MT,B]O^;,(\J90WG+9BGX<4GV9C[#5*+LANST:L2!,[U-GQ,&JR8OR_D@J\.1(L;21WB:(8D MV\@^0T3%H,4N543".,P1P7!P&>/7WX>W$5J4I,SGC]Z?25JN^5D)9A$>Q:W!M0O8#!?K)'BX;5,_A&%$7(S^=>A/4$CR%_'C@B5@_M)YUI M5-@+5&P?8G0^,[%^Y1=RSDX)2;^C\/XA1X'QB,CIB`,'T2O,2H,AK;F\06TM MF]L%;.D8([GA,48[$#_;.5VO@/C+M@]@?AY;"5`_QXE=K_7QUAQG.%.4?D'1 MXMCBAW#&8+A_$G`/T#YF+W\$-,`&G@E*8`1I,()?4R]`4R_],1;+MTLPF+LJ M",#&O08T8-AH,&SK^F;]*=(C`>Y17&#:!%;VH8),@+E,H)/]R:`*S%@5F%94 M0,@\=@1`;$%?;-$"5@A4Q,_\1T(;+W\/4/C]"MU[D5,,;3TM9/PU]\QD'E>J MY%=AC"9W5HJ",'<]G\S';SV51WA\H6]YL1=XD]DL2?-Y7,S8&_=&7Y-F+\N=;+T/!\');)8M]"H7]39Q-'KU?4(RP*+(KOXEB M729_>P[^9#(-_2US9,SSAR0-JTI:IU>KBY^2'&77WK.'S6&QP&GY-T.>?Z]^ M[>-R-WIVG)3:5;/5U1>D/++BRSD4M$8UUR5%])A$C]B6E>]IHN%NF&;YIR); M]2+3BW\D=Y.I]^"!4KZH"'7JN"Y&'I),-U;AL&1'IHBK*F@[;M*8XO'X7GR3 MXX$25I_J%[\FY&GPB*^./.L%TKT++`F4^=KP(0URGM!T%GGI6N!7UAFCPP.S M:!]QOCV=3P>@,WM92'_H]KIYNI((F=:2(P(^*'%`B6-`)0[F0CW0/]"_`>E? MSV$?E"]8S:"@?$&K3KV<2K6K5'NR9Z:UJ?7'9%L056"?LV! MJ@1]253K,\M0,H>2>>\E_\%>@5Z!4M*56[ M?1+03LA")`CMA-24+ZBNKJ_?\9N7AD0H7["3+@T!RS9(8K+\*;W%3T_N[A#^ M$+GMZM*!+M/:S'``2[NSV]V&8*C] M$>/N%-A>##IT*\*63G>Q_'>O3A>$DZM?EU>'(N7U85U5XIB7[(O6&G1Y8/[Y M*%T&_SQDG09KS:CN;DOV,O:3*?KJ/:U+=B5[;>.+&>F9)=VZ*8.;\-33M['3 MM02.7L(+W<:?]G)LT*Z2++.\-'V^2]*_O338[,Q^\^"ER"36K]AO/,Z*\@Z@ MY*B/%R;F((^79_\<8#+32*W911/,4>?FB+JBI%V$E^)G@`4UL)`N.+4)+*3V M^IT`%O3`0FX(BQ;;X!K`PDU2%-['@T5%'7TC!(4$D05-MD)J&%FTX4(:ID9@ M*`:?4("(!Y].["I]L6B!T.;\-:-7Q_/IU'^-;@$\J_Q2GR MHO`_9)M6?P7+XQ)ULX>:`YR8(.=IBQ@VG2\&B5%=]=B*WO;);BW]V%48A_SR9W7Q_"-+A!_GRST( M=-,W_>\PF3UX*4,[>:P]TRM(7X"K3'NW6%(:8DGIK+EM[?&O$G]1%%MAQ4JR M?')W@]+'T&=QH+2Z$R"=)](ES.`9\0>1LO%E M+](,X#D&/#.$1;6]"IP4]4ZJ]][+O;UYX*38.BP:N!JP%N-Q M(@V2;K`6XTF=3[(6``NP%I"OT)BOT&)3(%^A*@*A$1;7D1>7FJ$NXSQ%^(^; M//%_+#I9R3WL`6*;LN7Y*(=(&QD4=I=8`PZ&LHF?]%D"!>]7P9L7(4HK7\_8 M#2+9/(M!E_47>-O^:>2;81>AZ@]KY`W+#U%R3+ ML,Z>9IDY;2CR/8I$EJ5=XX$6QV*FO#]88JS`&8U4V5ML<`6-U]I"Z(;8FJ7>/XM!G M<#*KJ=!W2&59ZLL0^S7;8DTQT=9E:2SX:/@(.'=^J]&6V+) MY]\2JZXULR&,1K;+2.^[J%'1MKFST+8!9%:/6`\ANG.>,"/)DHO)W5WHHW38 M\%D]FP2 M%5"23W9O$!&-L`=Y=QZZ(5[^&69YLLA+21Z2I(P>2-L4.(?H9GGVNF;OO5-+ M,H5N.;X_?##L(;E;2T+C3GO@?.AU/A3D4,OB[Z_?KD3^5,RXX6V:^"B*AH^7 M'5*[K`"K+>R7+'Z6/B6/W\-BS]+OFPU-RX?=7\]3_\'+T)?P_B'/-BTF(YHQ M6'#H?9E#6T?5[V-17]-3?G2W[T4LR=_'4`',[51 M9=0F92]QJB^H:8<0+ M3>X,XGCN42G0'(S+K261.F>G83/5Q$9MWT])I0*<7>_.CH+ZQ1E:;:'DU:WM MZ;OI=IE0NN@6_\'G#^E\\:<\PNY:BKM>2[#!F!$:PD:X$+068'-D'<)*IM/E M"BVH1;Q8BZAP"^H1U-0CH+N*Y1"-&G\K_CJ/8(*)K@FFUU:NU!9.'90^2S;R MH1>&E5Z8G820;Q2FM;4CCPC+F2BN-HKM5!NQT&_0C./S!/]'Y```=`&@9"@* M"#0P%&([80GT/QR),.A_.![9?*.`>Z=CXHP-Q2>[0`BB>FTH;FT[BJ:'\DSR M!Y1^2N($?Q!?C>\7#Y4VESD98UY*3,EJ*R,'CS:=I6&&W'D<7%Y=LX>VH[;K M.8:E?=G,XT1"=T;:>B^%Z6'?YJ.;!X0.*(V196BU^35TK34%[CX>[ZC1-I// MI3/0,-=GOXA49'!;YRJ%N;3L5V M!CT`LQ1K`RBS4S.180)2!DM)'RC[M)2TN/`>@`F6DD9+20$@%W@D\YO\Q5T8 M8=X%^)5G;)+?V,;Y;8;^FF,N.8]UUT6^P9#V=D\11^6(RIN6+UI M=6WKY>15=6^.DQS5OQ<;07+QA'?.LZ#VE6&62`*OOO]V8Y_PUJ4D]PYV>?V$ M-R_PL/?%B\LGO/?/)(SS[P2P^(&]KR_==<)7BIF;*#K(FZU[3I/G*F0K?2$( M'[%]*ND`>>;3?$I*EDG)#AR+@O\JC6;G55L?L5&<3,-X_V=>T(OR=W;?MKJV MH?`E'MTF7AI\SY"W7PB;6T[1TWG%UY0IG9V&'FS)[M'^,2\N'_/>`(7O#0RP M@(#,C;S[-TM[]@7=E5*KMXM<"WN>"\%Q98EW!$F1)5E3>-V2!4UW#8G735.V MW;]"_DI<["UA[Q=<4190U_6K==Z6,WB.,P,3*7GY?QCV\_\-S%Y_*'R:O7WW,*;V'AGU,ONHP# M]/0_Z/D87>`51<&`=$U%5%Q;=7ES3;?N.EPY.MS[I=UQ;%;E%?8[F\QS,M$? MX(BZ-*A%DXPT\7.1?_LF0'XXQ:J'?__D;@/$TC7#,'A5X61-$`Q.%=D08:-;;#Y>?OGYQ_IA\>F--OEQOCZ/\K?5`<.A. M.'7S/+U-HF-&X&JFYO"JQO.NZLBZ*=GB:@2V*V-LX8\OOEMZ=?'!=;'']\F! ME)D1!\77"%[GA3-1<>T]D]M.XKTA"))J\KHD$OVP!%V2W!7O,2&582N"HM8. MNSR(D\9YB+V2X4H*Q_.VZ0JNHUBNQ*W8*SN.:>R.4Y+Q[2>.<\/Y4Q%M"Y9K M&8[*J9HD2JIF&?)ZM+9*3.L.&+!WJ4=#W5A>,>A#+-9T4]0,1W1M"_L:@>#/F;?(>P_5F;K)^.G955FK[JZ@NWP1!R*(\DXI,!H M*8@53540);>*>YD[F=84%8T=TR3-P_\LJ^`V#IA6^GZ=HFDXGV:;GL6:,$U: MFO.]BNP*@B)8$@Z810M'#<8RB,:1I*V:^BY!%SPO\+L4G3#05FB5#].JBRHO MR(9C8',VQ'5F5!1P7%Y1+.+HR;+FB MHP)6XEW2SS+NCIAQR&`9/,\)"HZ/+=%6.4562&Q3,$-P#9P_59BA2$H%!ZTR MHW#D9/(K10^DVOF(%NU;5TE&G/KD[JOWU`P`EF1PFNR*JBAQALAKJF8::S^H MX2AR%_K2/H*/&=O9Z=J:A5^VO1$>%IG`+(F)DI4J[5N?Q*_]%J?(B\+_H&"C ME+]X84R^^H*YMT1.$315X`T5H\0P+4E8Y',X2I-4I6+NI8HW9I1M17D_6C06 M!G_.%TQ[@5F"ZG"VR*G8K*JJ;6#`\<::63@EK6*L$FKUQZU#!@/GS=@V<);# M84-@2XKC:NI*>71>K?H-&4?N5)'6E_X(@FD)CF:+O,(3W\,[LKB"!(X;*P&M MH%=B"T;Y=HH"*3)GZYIB"[HN\K:"/;9FKKCE6E;%2U_(DG9.%<*DI2AP0_P1 M=(4?P/+.<;P$1D>>VW#-W-HZOPKES'6$:=QOR>'.V^ M63@US\(895GQG2Q<=X$7S06$6Y-'[Q<48P?J9U?^;M?WX1ULMY75<2Q)U65# MP/_2%=[EU(45$E25MU3Q[8=K_5_;'#N=:J;9MWV&\K;&&IP@&#@UME5#UQ5L MS15AQ3Y=US3,/I%Z]LF?>6.6'L6ZR0\O]NZ]^&9&HK@H?W93K.`X?/XTLV^4)LGB)`=X0:!W%&\//$PRI\(]/OU68X?"2X`@B M3J,XPQ%,6;1U[/@Y3K`$01=XFS!#:X4905",THNNO1"_P_)F8>Y%S<)ATU%$ MV[1Q&J"*FNGJAN[**X_N2D8EZ]6PW+D=UU0_CM/&>K"$I;L:KPNFA+,V4Y$X M57/-U5AY5=8J12%!%"5=/6&P*S>5?4WV/+!HO/,R%!#/@MU*X>"V&C^S+VB! M([1-X1)%>V)%%S1=/%,8.KF>9*/W2[)OMA1S_(VR^S;(Z]./XW6:QO)=E. M2789B?WJQ?M+<3;V:))H\X)M\;IN&Y8A+#,>TW2EBFT7^1.`NF>L;1)-0JS] M#ETV3%54;5[!"3&.M@75,DW.,&S)5A3'K*1Y(J>T1'04D<6C**B'T'*Q:`UY M;'36[N._Z`H:[PJ\*9@BYR@2]EN.I9N"Y>!_7+$R;TQJ>B7^'\6VUW)ZZX"$ M_91P@H.3,DG!^8>@B2[/&_9"?1S;QJ:F6I[+P/,XR+HB`=( MPI]Z$9EO"*8XLR+='D2-EI]ZJ3RG8F@K.%40#,G`=EBP-&V-'\[2N*J#TG@& MF$1R5V+M)G?+[21>Y(/&RY:L:Z9LDC8&4NEU5WS0):[:2<(4$Y9>_R4FV+:C M<([+<9*AVIA`D5N5[QU;E/B*6^K5E!Q*&!U>EQS5<1S1=`S3MCG>EE>$"*)1 M39@E317ZI:4SL\B+`DX.<*#):9HFF)QC+9-IS!M>JDX$BX*@,,2:\YA%7E55 MGE=-!?.'$T7;-3AAQ223$RIFD>?EW7D+*KG4V"Z:MFS;AFTYHF(XAF")PK*; M%C/"U91*EU>?=K$Y$XZTBR9OJB[.412PYCQF$=M"GM<4R53P'XYFZX*IKICDB%RET0_?UIM; M;<"DQE91LP77D0S7Y#7>M#1+<:QUH*395L4@[/;+4>P; M.`NG$>*:"X)9=9*[K72=!PNK,VBT:5$$&1A3Z5 MO\MP49`$7M0-T^0%7=8T5=%DAJC4U9-Z"ZH;<*FQ8>1DE5,%1^!-F;<1LKTI)MB55DMQ=V+Y-#;\36J\;I+:R?PVOYM'U4;S M9E/DFB/8KF`IDL*+9/41IUH+,@3>UAVATB4K*]5@\>4QG86,0[/GJFL(IBV) MV$O+MJZIJKU<&HG)L"2W4B(EK^N&CM_3,"?U[N9][(*KRZXED#X=SL0TZ98N MK6CBI>HB!'YWR5"S\95I*W6^[[9P-*]@N[R)R1!L@W=L+*;U\B?2F:Y7%X]@ M/[237AT%D`X=:.J?SCJH9"P)EWM5= M:7ON?K5(5I,5596%+1K/,?#N6-'S/GY[!*%HHFPZ@NF2`I"*0SS'D5>"X$S5 MJ1,$3Q:?%W8:$.I^6TE!%$5>8Y%9:A: MOFU.V+PJB"[V-8+("Y9MV9PAKC@AFF8=''E.DR55UIGE!9V&`4?WDBTKMJGR M.+XW<='-EO9"D% MS7"Y.BGH$A99JS*H"6I>2K04',V3KCQ=Q9$-65K,K[HH#5?DA.K\@JH(N_.5 M-;'+GI$GC>-71- M-C17=PQ5UBPR$[<:$"=45VKRJJ2J8LV`:A=8'Q[7(49A9Z0ZJNNJHNSB>%DG M`EF-2[*J02@6HR3RC<;E>F'ZFQ?-$5E<'"5DXZ2&+>XJS@0YU94ES<+Q(4:9 MI2\"9;)"7ZAV.6E,=ZUDJ\?P":!O,&*O*QL!A8-F!O%?*'NHCN\ MA!7?L#2MOZ MGLL8V["LN(%_J:BO2;K!V88F*IHK.8YEKQK*>%[7^$J]E\>IKL``:,[)0^&E M9B+.-`U-E4T=:[W"2XJC<"L>.I9;J8(*'+8?XV*A^-(N&Z+#J8YE:9J+(2AJ MALHY*Q:JKEU1969X=^,_H&`>(1Q,%#=^1/E#LK6LMOHK0F3OIKTGQ^[CH,N; MBB!+-IE[U!3)D"QMN8Q/Y$6ING`=QT4L8?#5?/Q?]JYLN:TCR7Z1)RHKL[;' MVK+#$;;E:7=/1\\;+4$V)B320U*.\=]/%HA[N11(D!`N<"'2#[86DD:=RNUD MY?+?RXL_)(;[O$T04W`EL&,QA$8'!G'X`XPF](6!'E68E4OYYR]_N_AS<7G> M0"F+7Z^?[4TEJI%SYW88X.9`+8Q6C!QU>7,`"<3-*1W]D'[5FP!<2E&MQA1= M`C,\$0*42EU#SNM$<9MG30C:%X*$-4#..F,80UJ1OWY6VJN6R6U.-KNHH$I\ MQXU%@]8XS`1JU6'45<@?'\65`VQC#7AY?G;>VK7O;@!]O,FH#1]QQ;N8N#0C MKO083:2H^N%'&RGDS$Y[2.L%1<(#*]%8U)9,U#G'4>^$1)VFQ(V`WE=YQJ5R2 M,EX"T!A:S*!Y.+I*84YL?"KU*985HK4^2NBMQ`8QWR9U'/9)';2KI^H3@F"; M`LA-:PXJ*8J:."MDI@$"484NV3CET9]*BK9!DEC;^.^`"6.*A8;/F:JPISXI M*N&&G_:JOHG%[8^&PY0*66M#18PU0KA]&S6%^X8MH(ECX;MH[SV]:[)6.5O' MQG`(X@]B'E*3R1C7B9>S5D_L2O=QWD/ZDX*F^!JR%[^"'&/)*@X0MKF&?36O MHXG=R=P@W.:/)(SS666(&6V)*@?/,$"84C\XJ/46VM<%X39_YCUE-HILT2*+ M&$&OMP`T"$U?6'HRV!TLN4O*8BYM*&T&(6:%B\,A*UFX=B$Q(+E9F?Z=LY)) M%P\%V(OG4\KHE&",,=#T8VRUMMX<,,:85P9HFS^P-2;2T0ETHH(F^6+R@*97 MJ-`)9^+N)KPFZ[S[9F4[6BFK.TGYQP!NZGT+CH5&`%-Y62L,F#+R")9]Z4%QV.14VE/ M-=:3,1X@VS88(H64;S-=U&^\(0UF4_G??"'8FI2T8C;:KC_;=LYIE=UMLB]# MW<.#]I]GRT^M#8TO+G\Y^[2X'Y?S]@ MZ++JZ\%/5`R?>DNHWA,HINR4=YP"F/5P"0GTY$]Z"_MP_M()@3"5+F;-J_+Y MY'*N!9'S>G>-8.C*TTSJ&X-O9UVT)L8H=-3:5$C^?^@A#!A*]->/>IFM'+:U M'SOZ106)?*TB1Z64!-G8/!KUBM"G&_5>,+CWB0^$P52Z")%=4L6KMA1),RJW M[DT0"$/I-PA]P_#MK(NQ9*\LN^J,;I/-?<`10^U<7PIPHF+X]#0+B!Z++R5B M(C`1_6C3@?')8I@3.O]4:NBR)G`FQUJ,]SJLLHMK^#SR:X)O9S7,.>5HJZF. M72`TT:`>11!21_^/B>'-J(;2I=*U*13*#EQJ_E)[!0.X+35Q5L+&T\"F=TC1RI@ M+(@(H;=>H;:#FHCL5-O7[H'1#U>N'A>AI_P0MBY+"0+;."6VP1FWSH`U;J%H MXSLLAIF=;BK-4"5@:^EN:^BA$`?6(S@:5!?L==W<)X',SIJ!S$DLA%8EM3W$ M21Q*&N#A33LAM34/E\?O$Z';;VP_YL>SZ^''?+Q>7+X[7_SC]\N++[_]SLL_ M%_]>G%W>9BY?IC*<283"%:>=_#*3TB4DY9)$(MI7U2\D0*NW.).=/_E.>/QK M>?W[\EQ^;/M9.X*0L0TPB7)J%1F$3#M@`2%R:SDFU7G4T)H7=\)@\Z=]P<%O M?_>RH$''MJJSC2$P6$@XW["NK%&]K/NJ3'$3RK_@C+>_V]]IIC*%)E$;6-.B M[5!JB.(&QURF*7VPN"U(F`<2NZ=VFZQ',N(S6:!)6@S@&#/9VGF&30ULAT7D M*64.4>LJ(7)VMF(4)B6^3@XHPB\G-*D?K:@=H#KR:::2])A4U,'7:$,4;A!( MN3)X-0+;@['%Z<\#B=U98F#3GH%4TD(/G"WB]$:F[?%915'[1:0MTMME!HTA M!J(BH;Q5Q)B,4WX#$64L8*V@$R&DH+Q$%G\ MTE<%'X^<(GU9?OK0YB7%\P_??_[C4@1IM;-L1>Y?=@>ANMQ6Q1F)$+FB,5S6 MC5":BTW=LZ+3#X;1/OE9ON93/VD?LQ8#WJ:V:5*Y!"7QP/"ILRI=Q.<>;K=[ MR:?NMOC>5!L/"R.O;G;!O;M<;8.36_SI2]/?=Q]7DZS6?[MA#37\>/:\/A-VQ@@D6!1`3P[/^Q1MO>%<9C\B MLX_S'@;"O6SR?AQ-UI:$5,92)*R.P,&LMQUI#U;5O`%-:,-2O3]%./>ZV?LQ M2"5@14-1+&!S8S8)K'804)_41@%5SAL\441Y\>NS$-VP#_PQ")75-65/+F=? M+][_L/PL__FP#<5LLIC$ M%G?H0JY@=2*6'`LFKRG>6WT]ZC::@'1P2?QY7-/9;XMW'__KXOK.JN*K M8?/[)I?_/*/X`M]"JHJR.JQ"0MKD^I`MC*KK^*["730V20=L+143,P`*=?[E;\C0'-#Y_O1KT[F516*Y6IYRM9U M7U5!%>(H1S;[4X'IQKIKOW?[#@#B\UJ57V"G2*BO&_`IU843PN?&S('ZSZFC M"N=;EB0:"JR"$_W]+IA5]NN$L#R87!H'`=!%G5Q()9D:UOV532Z% M[G98"L):/C$'\4]CL((6&_T%O#P^V5 MAX)OEHY:-)*]JI@EDFF+5(+68Y[*:NRDSWNKGZ_"QX+O8-)7C:I*Q,_[I&U" M,87K8H?F3@2F#7W$I`\/WUR],69DV[9QQ\C"H6.U8`;X'/'4/^.6+S[\NSV]FR-U^Z[N//\C?_>/W MLW,)F=;TO+V."J"7%ZM5LP-#WUP_-4EBZSYD6%FD#%-(FB&;DM?-A3H8KJ&3 M.(FE$3GA>J^O[.F+]&&YW:B(.M3TX.+99"(L6DN.57[GM\34T M]E/\T&TVH-L1VR?0S[4'3Z;N[S.34!4GMDQ4E>;2MA0,GIC0]*NF'^'+)X+# M$20-5"CLT2=@JDF3KG%\U@0=>TF#4T+XY:;0A42^N!Q3.VIA#T*P#6E.L"7Z]2D*7%#8,_+-^'T[`L9( M.6>G-`0J2IAYTICAE3"2)9:I#E;0* M>=!J+_#TC,2?,@Y'$#473"&LRJ.+[&/$,I1O>2@2CW=NQ&_.'\X3X9>\[]U_ M/F$3$D9/B,9%E<7!CGFLDOML(#Z25CU-6(X@AVTS,!F+)I.!BK4M7!O?6&KM M,U]V<]IPIH#/PJUHG9/B"-YFK MZ.;CXO)R\0$FJUI],+68R6N?5%$^YTI MK<-@LY?"VP>KFEI>3V)?#02,WJ:ZUA\36A%IWRE!;JO%/@@8>RNAO1\D2%B0 MC=.)_@12Z0!^#PYW#VQE!.8W7J;6P2J6HDL@T?L"6Q>N@8M;&;'C7M;`[ M69@*S1^69[\N/ZTZ/+^_:?`\2'?;?8\D*NT%G*@PF_9D&=8C>5N.WJ9^E(IJ M.]%V!'+#@:?"[DXV__%0CDFW6<0N1A6SQ/\FWH1RP(:L[F?LG-+9S=-GQZC: M_JXBL9@$8V*T:X+A[(4VK/V#5=[AD&=O]?:+\^M[/W3X27_E)YJT)^I8"0'( M%.!JC8[41G36D09QK4\M<]G]@-MP^OOB_<5OYVT6S_6=$S_.'/G\[.M[TO%`(+I(1R)'0>DJLMYRCFP,3B^UWIH`*Y MK6'="5W)]%5`/J#6KH:J:T9PVK)9UYP04^SC$T_AD4Z/TT7XZSKC7BCV\OU? MSCYM:QJ1^!!\KK5-FB;QDL::X9T\.]OG;L#35OK]=BM/W,J'__ER,_AF&X5/ MR?I(G#75"LZW^0##S437S_1ZNY)=K^09_J&U4.92HHWBLZDZ"S$.E^$0^[$J MWZ::[+=M=0I[YA.7DBGY4EQ,Q@%*5,JU5"M<+O1#0M%:LY7`O%W4-"9.US8Z M!E+EU-;/F;@:T5@]MA7CMM\6L=HS_W97^[RK9]@^]BI;2#J4Z'.A-H%YS'@" MZL[V(8;35:G<7IG/5_FM/\\^M<%7A^"#;&RQCE+ADJHC:\C3P`?!8E>'/)UK MZ<]_5*AG11*]CEF<2LDI(NM@`HN/X=8<;%.K;>ZKYK>7BW\#%S4]=1228H5O M6^THHLZ)12T&Z@BV[[D)CS3N%4!D1V'4JAI] M5PGXNK1J_K2T1IV#C4Y#)OMW>/-AKB4K'6`B\,Z45LV(>V:O2T-67?2.:=_-4 M>O.5/U\N_CA;?EB7W\O7K]:9G\2[G$\U MP65Z3&=VJ]/SLTJAU0=^F2QETJHQM[\(Y^H;05Z.O\E,6$G;)=\X]YN%LT!>3J&#- M-N5$%%9I9OF7=[U:@I[NM>4Q"(][9]-'-"HV>DY5(45K0P()0V^+E7*_N\;; M,%TYV'QOX=@$\'G)%[+:Y]K&N")4UC4[6B5?&"%0[IZ9P;[=Y*P3,3I6I;)& M@H(.E0NK1$Q*V?K^.?KM)N>7E+$^A52S9A62LMH4H1)#4H9\ZLMMOSV-O/L7 M[]]??#F7(.GLKZYC:**"@T(IJE*\"]Y%5T5H/`\%!UHTJ1N/M'W$PG2`S.DJ M9A4I%L4N%+;L4C4JF%9&LJI:%X<'EOM)&>"W3B[XYJ]Q^N"QF,"DC408*AFR MF8#'X-&(?O4%4_!V+?/,?['GE(H1%AU0HY. MM63EDE?>5V'7'BO4(3MB8[\*^>TB9Y?@(IU)48"@,E$M%4,>\;R-6XNA8IZ)SC#'G,;(+:Y#FBV.)-TI$X&EJ>L23>JNKKKGM7,YTMIYV# M(FHP$=NY]"(KY:O)%5P_I\XZ#@2.+QR/H%7F3(`N9PPB"!M5Z_T;VDT5:K+W MHMP?'+6]/;_HG$E2),YEU"N*98( M,K$]5I%9@@IL=RF-E]6%*2<8C\PB6BYMZ:.,2FOM MF`%V>ZN0#['R8DZ;\1A26'OI6:>X]!190,`HG!2&Y47NV8<,*57.CC&B/V_G MA.V3Z][`G<)R]DN5)+0T,96#>\F@\SS'<,\E#Z>M^_+P[I-]CL8:+0&LCVE^ M3[=OKX;R*=3=%H9'[-O1;##Z,NR>/(^.RI6H?QV/+_X]O+Q\CCPT+TD8 M`B*0-Y,U!F="UU66DJKO03,;K@5_%HD<$Q9'%3RB$"9YCIE');T)G(.?MY4! M%R&[:D=997K,UOQ><.P_9\VY`L/C?(ZJ#2@QHVYSUI;).F>-?7W#O>(Q,>)\E,(H3(HIVQ@XDFZJB[&E+'DN4L%\B-2K(R'/6H$3@ MN=R:.@_PAL\ MV1/"3ZJ=0:(U+(*#Q-%ZYJ&[8]L;EN^90FM>*;C?Z/GCR8_GOK[!<`P\::%U M@')+G]3Z]D1TJH_L&:'[.[772:$W.:_\YEE2)SQ@T$$F%J/GC(R/2MV-,*R^ M$4:K_OJ15G[S,N(]JFP(SRE(RY&\>".BYI[6?'\->'\L>/;U@7-,I+!8MD8&+:0"9W,'4/Y+U5ZLZ`G"./VM`.\8(Q.!'@#)#V,U(JZPPY;Y;&]ECI_%SX/6^N:>!^.F#2F,D!&/1 M8@8O(0J4O*O'^[I@*%B/IUR(Y^>5YU%%D29I1.6C#O1-1*LAI7D42=YT=+YJ M/[(2>'^1S7-B\0QU<6.4]5FH8+F2(2&R[BR7L_6I(`52]1>6/+=LCR]*S`(, M@HV*.>:MB)%!=TK+0WW61UG3XPC+UXW'WNV/(`)CY>I*;XJQ339WD;L(OKH7 ML<^H\%4CLL^`5V="R,$)Y4,FU].ZW!T#B)S?LS]0O"I]=?QAGZ.-$@UM&$CT MGP\R"34/^U*2FJ7ZH*D6XO68ZQ>':.]3I<[YD"(D=-Q)BNR<6L1YT2?4H1Z5 M;&U_UWO\T5#:IY,T903FF=(*@U$,@LYMT=8+J(J&7(H>KTWN%:"NQ7OEL7?C MT9=/S>0J-K_5\.'/\--@)/G+VX]86_?_-P)?A)3_6 M`'I'=)]]#D3,<$:"+A^W\JH9`4..NV<$L;&Z'4HC@7&19E86#2J M/JX(T&,HOQ.4WI;#O!_@]N,7KWCFL$@[+W(B#8G:BR0IL@?7AD4A07T&N,>R MY;WR>&'I'U_@I`@P2-DXE6F_V*@=.2%+QS!@?6J[Q^+:";"]ATHZR8*V4BM? M6I.\9J&-=D%![_?N-0GQA MV/KW)`"#110Z)^%5E.34Y]@-M.:F:IWF`*J_`V''C,/Q^12&:0F>PJ\0=%16 M@U#=0:/H=#UJKL?Z]0FY@[MY0IG]4F[%<$EK;2)"US!")JS:>2?@7MS)(&/% M8[0\:Y]Y9#J8VTEGY43M:<,=1_IJ+^W)DDL\."Y9]K054^`JS_/`!#$P7:4S ML+^JR0G+IV@,,=$3%*:;K:TSE5Z@PMKGZ28 MOXOYEQ'PD87'W`%Y]P0+1YO)P[=ZWE2D./U?WW,T1:%]DL#LZ,#I/P@64?!@ MI'>!1$YVQ%OKVR`85:Y*PJ2=C'Z=.^$X(UV'V6OPY'_G5++HR7#L)F6*.GNN MN="O=S,<:3R;-";E8F8B2\&BT[K+P.I<)_1.X#Q+S*K)@,BL@DU!:2:]QMNY MZLA#94A>_=8Y_LBT9,!%]C'@\H8Z*THD$S/G*)VK(E/!+#Y).>,$V6,48$FY M\N0TAX`.K4K)SF]`$N3%!9U["$!/>#VP6.@M^0_"2;166)/IIZ6ITCI)J`*? ME]E@87`]G`TNT_?K9G0QG-V02-\NBHH7_F;V?CS[M9E]&`PO[D8R<>$M__HI M;J[Y0,PB,ID26FFLUL@7[$.60;C*FUKA>U^:GH@1N9T1;KQ5.D(TD5GIP#J3 M6D;HH>I,N5Q#\8'<3+\2?N6?DA'X-K@DM*=N%@:3R8_AZ,O?!YDTY)`]E)9M""8]9U?&A>=W!3&&[7.-F#J*=@@Y;69E<#.:TG+1S/F-'E M')5MV1#*5Y>%D:?!Q$NQL1D-+J)R4G@1G=`<(XBT*,R`D\[+>E*!%DJ]#!MR M"QH)C(F8C2#2G6$\MJWHA0T;*S:`2U'MCZ?AXT-#>OF"MM:D&4R;V"S^/5AO M*31(+I&((40I0`CO3+N^F'#5@5U"TJP=LCZ$OB=D;(<>G,&# MD;<;I]9C5I/:>R*^QE=7P[EW,RVO)\()UV9TOF$VCECMT*8-S@,I*T/KRB7. MO=+M`I-2K)N1/WV?#O][-+S\GS_/)C?-G__TEX?3,5_V*Y/[8V)DS,!:C\__[V?L7_^-I< MW%PV9Y\+`J6O=_9U/)]FM/`>Z]\VS?O!U6U/[C^&XVOZI*O:>7G[/J]6(3." MYBHGS,(X[5)H[!QBF<\II;VN##)E<63`;^=PDCO?C#X/)-G6Z3K1@9*QI%`U[Y8& MK`]E.)R2A<3<#6$Z*9[?3D-S%TD9,*"'B."522D@1M>1)^ZT`+1(,]UOR5\^6-8BTQX0R@DC.&=> M*A&[1:F-,??M&O++I"9^MM"\H.5A]&Z7<7(8,K?)@"%G#U4[CV>^B9*XCUY0 M*"T3\$AZSVYFT]F`/.+1ET,7M`.?'1*IVG`6$CCC6Z*!/)$'"GF%H,=17H>2 M"ZU,;W0]'LV-SVI(N?+^NY0R1Y8\!9*D@@6/0D=L0Y'DZ8>7Y7SK0G-1EJE" MP@;RUA4G"Q)%BYD$G1ZXT)Z,\OXP*]<96&Z,!V`&/#<4MRPQ`T8JK3_.Y\;K MD&VVEM+546>1O??2&I&-[.SSY\&W^\-,7[>XHE;[S/WG*B, M5J>@*=Q86N00(=HJA'TCN69FW:QM(N=19&\+(#)G&=%X+9CS,6K M3M`WI'O4VNFL7NB6V\4=)(4[3*#5/`5'ACCRU-+MA*PC.D&N!CX+V=O$K1D7 M6@F7$WARK!/%TQW9(JFJ=?.-I""N2[:;S2;#WVYF)F_5=Q3,;X,>%=?`06@)T@<3O`Z="E5:5CT@+P8]_71Y4XS@A_%D7D?I10UH M5:HC!@+S7)L<7>L:D1W4O*IEO9&T<.R^XG@("\\NGJUZ@N>*([$P`(Y$\PNM(C@V9.5K4H0;&U8XQ9*'D[QMG`EH-0L M\H`4&JH2TRNI6XIUMI4#`):O>]'[4CPEM$H]>/K+^/+^&N[6'69$)I>$0A5K M*3`I^95E>HAH)Z5=E0PY7U]`=P@XF+BM_K$UK@S6X9Z<>-K9$5@;16&VL6Y@ M05CWCA]!W`[=Q"C8""(5*8&UW$JK5$M<4KR2'$4<()^4NFVB$]%Z+$GR4N"Q M:(/.':XVBDHU("AY*+"_-)-OP_/UPLH>BT[$D,L9PU)_2$D9YD+N<,VB;A@G MZNZAK?W\0TG;V@J0G,@U>DCLMS`T1:,%AU'SXE:3L6G%82G<\Z$*+& M>\=-:D,JI)58+3@IY+HI?`QI6PN/I#XB>J9%1&V=BM*(UA`956L1BA`.$-OB M_/O".)%=FK=93!O?C)K/PXTN:9?(ZUZW+`LLQ^"T#T=Z<%I&X90A.I,?NW)] M`9*@R);V4(GQ@G/`%[N>S&_0];BB51:W\O%8EG]]0I;7G(PV=)4Z)0LJ2T$WV%EFOA39U10C#'R7<> M3YKAE]&>;*L@6&;9D%(V)IVQ@/CEEQ)&Y/F M*+EUL#1(A'9QJRM'0]KC9/L@L*5-'DR6(:CH%9>"H":P4:2T^%%,YEW M3OH?=V:3_>WZ\V3<=MMVKR57^H++8G#I!Z-_C3^? M70V^#M;>8Y7'.R2\(_!*W$5![6_TZK//GRFZO2A/>_?6GWW!74?9+;`V<;DY7GSFF=I3#FG!VB- MWE\AW81F^MY<75\.)AV:[\*SPNFNFLGP?#":\7.)[D7IK<$4 M,>ANJ3.N-RAWW*S<>Y!_^=U\;2V7T^NRWULZ<3R4$580),;LO;)R>4L,88,* MXA.JH741;T%JT3X]/%^ZDP>#NRZ_VU16CC1KE-D$&84( MSK8BM@C,5M'W(^,-D.#H?7@\NGUG8;\?_'B3ZR/'5\#PVWYK+\7PJ39=8 M>,+=L'D2FD8=M=%>$A1>.290M8M<<54E7L#@_A!T@EW#@H*Y28F/#\HG;]ZH MB(YQ)7Q2)D.I&)BVUN=T$KBM-7$'+8^F>WN%2&?42@8.R3J9),?ES5_,>K5^ MNN+YR-Y5!8$4RJ8MMS@HGVQH$R8D;1]996S>R+7FHKZ)WUK0S(HEL(D\E,QX MN?!K23S)7!M13Z72Z[;R<-K)'6M&AYY=]$PQF30#G73V+I-N7.Q+Y$"^;-5X M`8#K0PK7/O]@VG9G[-;>9:YW=MZN*L"JZ!0ZSHP4EHO4\D7\5JM'ZG6SVC=3 M'R;-]6!XL7S)Z\3DM9)1>C<#PMC@N MSZ/?II/KX>TF(1-)^Y/E%K2RF04ILVDG=:!IX&I=+0/NW.OV&'@0CYM\&_P^ MG"Z].%C<26S6%!`H,H\'`9%9WC@R;US4E8,62O29TVM`A"+PZ9`^I/%P^N7[ M+X/I`WW8M'X"1L:45L(+IIA&&Z-ML3&N;L@L)!<7YQUVN6W:/%U`>$)$2Y-" M8-E&X9JT%EI!EAA@M>_QLV]\QT"$`@#:5/QHT@7SJU-ODRU:V8ZAL:4HTLE& MJZ^TYR`R5B'2+SM]'8BTQ>!7Q!AO)U^^TU2Y&@\W8<,U,SD00`8L4564HO.W M0O-J`Z(%Y([H7=8E5HI4+A>L#`&C3?Y>5Q.U_)J[MR#.I"8@I)T^']Q^F@9+]_^`E_VA1T"14S9\D'CJF<`X36*7GCI:P6 MKU+]YB>O`Y5M^7HFAJ$H>E'DT"#*J,4S.8T\+#D],.;#/]'U5P?. M#GS=45PK$7TYA!.91RY#Q\#BDO[H8-1KG"X=(A^_CJ;+T^46'6T`YK`(`;ED M',5YT$@6$2PJJLK1$GL]8F!W-EAV"&-L=,Y)D00(JX5@(ILNL//+ZG?T,4/= MLR&R5QBC1.1.H0,1G!<2C5'=.8#(#);X%7T8J*U2K&4K[^2%ODB-( M%AQ"L,F#;P[/.*IHZCMQKI58^QH;*_8R=-U)0+894&66P6HG#4M4%BD03\LZ M`F?*1=>:)9*NW"/QAKXGW\NL#:DF%*GSQ"GD*$5AD3D;FYZV9);-H+$W!VI.:_O+8;-41AK$!=<^94Y8F*/I(^".C M;]IA2+U,!ENP/B_:=1RMH.Z<@EV1D1^-_S4:[ZZF`-X'KXLB1?(N.'H9W'=R M_2Q4UZ+SIJ^UY""C-TUV`T2>$B(PBN+`@W.LU<,49EEEN8">@-#)C=]161)O M;D9/F>WET6_'3?>`32="+$%&9R4&FUGAN-`!$:.LG='E`_'+H.QN&T_"$JBB M2YD2TG84O+'/$X#BIR./^W&8IY.[?PQO9]G^@VG9B?>*HVAYJ5@.'IB@Z-=9 M+4/+H7,(>DDO.-V/H];8W)+ MNQC]<7($G'DF$[-6W'O/"?2R)[:D,:>Z6X[@T#=XA1U[F[N6+1K+LQ=H*&12 M8+/SMA.[#[$2F:?0RNQC;AI,QZ/QE_M6BKP4D%Z7HX[1[>-#7T-Z.7$4\UZ8 M`B`C34D:B40YF,;4J:)(Z%=X=/KG?WG#?E)SU34;K#IX!)]6CP"0.^6(_C\>7C]/=YD+AO38&(Q)+1)5BJ;DG MWJ2R;?O69'I5U16:H9>X.)!-]AQJ_5H!.6LSN7[:%&@8(C#DV.T3/-9DG>+Z M7B?9_Q8L+@'] MA2OJXZ`OA10H*%K+27'(D)1G'?I8AQREK0U;[IS/"/_29E)7?Y3\G*^C;^NT M&^#OS]>J! M:77;N87\?:X@8KGE"UX;^J(YM"@17UBNT,&5>4&4%GH'G6DRL1!F.O@F0I;& M.PTQM3"AYLOUE`2(EX&IZ4M[=?T@C^BK/KR]^O;UX>O@]FZT448/LG/<2R5- M8`(D^2?5>77E%K;D%_=0C5/_VV!\3+2N?A_\[V0)<^GI1E'P&$/REFN=`CH# M"5J<$G?ZG#A]>+R[&\S:].71>#`N/;O?CC]/IG9@S!8&>VKH3C7=DO/.:?3.ZYRB1>>>H5,C`N^"6"^")3D+L4@R70=,X"`T35%+24F%NS.GU&.7[X%#P; M;*>:=`QSDC(`1UM:+$0L`OPM;-+6GN\HD^Z8L/T\;`3"WU5-=.::-9R$TR%\8'!2'38C2B]$!O MX4O>U"U,I>@WI[QX^-3I9E]&HUE,'**.#$#2C+,-?!*@+CYZHXUX99-/G7#R M\:`,RR:#\0QRAMP4=Q!Z%G#)VJ400Q].EX^,7Y?"?>Y@0T<4KD2RF#4:C"Q" MQY@MZIJLB%Y'BV,,]PSXG6K?+0;H*&$7_)&LAQ)@K_OK&;K,9[HG@VJJ="!0N"QNPB*%+EJ"I52<_9'VN MMFUIW`G?]7RZQ"7XH:W>-8(.\>F\ABA-8,'R[EU[7S-%`=O$>S\(@CMX6W9XGUADDOA?IHG2-$?TWNA0'4UIUL^SV-O4TXU8XN.7U?G" MRF%1?,G"FBP!=.3H&:*'K(5D]?4K5STQD2,-.0]&T_\>W#X.GPZ8WA7=(_%Q M,OO*9]F\GVD^XEU12%F_FKHG^>^S9X7;P?W]D@#AP_#Z<3JWEE9CQ(L2LY&& MT51WGD?5J`3(')6M*2#MM8NGO;N,;1&4$3UX^&[T>VFK\3`8?QG]=OOTD%_O MAY\?;]^-/J\.DCH\5C[DWG]_/_CG9%HC%![O'R9WP^GLK98![>_3"??AM.J2='N>'E#95;O!2R2'AQ]4F\ MYR*^1LR*-MF0@N-_'3ZS1$3GLTL,5:EKSYB3;9%R'`I2]A.\I\W_-0%5]N4P M^7TX'HQ+,<7'R:S"XF%X,%Q@,^UPA0E%Z7A`QC3OX,H8""[QZ:61VMCS;TZY MSE#8@$EA0EHLEL=&&D!(GIUB99W82QS/8K>]9QH"#(6713LG9"2*+QNY0AJ/ M#B:=[O7<$]%\O'N<;>6K)6DV2LHE!=$J@-_?+Q?! MW$35HJ'%(Q++Y?B6"YL06@`U6WL=]4-@MXJ$K`8,F16@@^(F6)-B$"ZW@`4% M2SIY6G`_VISK$Y$U&G4!BU0.:D]\@P?)GM'BHA8@%3U5A0O`:MUA'4M*BE!GJ)!E^@L"O7# MX7:8X_9!EW[QM+QD,LE;'T07&H:8*_7T'PV[G1VWS[+H60M4Z+A+Q!&S:@&S M5M8B'(H#_]'FW-:..X24K:*8D*-!1WX;0N?9T-IJF^MG6[QBK-8'D:LY?#1* M!.Z.,3EHETX6(F)8("9S+H_UU6F5\;@I(1.;E+#\$&07&)'1LDFU*\FM@ M51MD\W0+M=UP9O8<;OSY@PV55.!6Q`3>2"TR/G/E8$SELU#=[(CU[%!G=BCK:+[62+&>E$[8$'UV MLSOECJVJNM^3`2VV#OJ.9/WY.3RC&:PA<'0BV)!IWF*+"GU>TO[BS.[P90DZ M[9\T7XK:/1(S%SHP\WS";K`ZFB(^H/19_>$+D'`6C$#N&2A:1D9;KU(W9YRK M:24OZO!;']E=`BA;.T2($I(47%`8S(6,R;=;@RKM6JM$GQ=PB.>DSS[[:%.T MRG%)2T:Y\+Q<(J@Z[\EM39]W0N/GX:[2E#$HYV6*R@F3C`G,=QM;P%IB4RO7 MDP%>;\VAAI]]7Z`(.U'DR&,YZ[.Y-%M)W66&8=79CK-NZ]CQI?$X;$N(L12\ M^22#CMIXR:%I+5KZ>``[C"&_/#2['\DX"3'K&$2IYU5*Q>Q:/+SU54`E.1-; M7WN]-!Y;;P0,2R\'*Y62EBL#68;N\H]GJ-NY:[9UB'`H".M8,:;`@Q,Q.E%T M68GT>F@]-@-3Y?^+(K%\MI7^$HS81T!+O,9[!GL]J!)[%2-S!8/:(1IX*1#V/3]&5$6J M)TI_2[C],AK>$\^K-\VN>0F.):H9SBR6A( MV1/IR\T5E,BEM6\]AWNB["OMV-?:==L5!5MHN"V9Z]XH-$0U4MMIB_M0AYX4 MCNUA[5\'HW'1&[@:?QB4[/+6'Q0IXEE2^@.B1E"9H38$S>D[\2'<= MJY@WU>W"&]XKP-[.KJ,,94-/@HB221USR)D)G820O.G>03](ONZTH'HM@/89 MRF1R\\?H]G:](J]_O!^-:8O#:WK(_6BAJN#]\&9T_S"\>SO>5#:A0_"Z]"A0 MO#2X(H<6F[()='Q)A@B]P9Y82&OMUD-8DUEF393$L05"`D^+TJBNHP['6ON` ML]*Q[Q!KUJY!ZTLE6^D,:5(.1/^-:MLX4/A?WZ!H;7L.?W=KMGJ]5W^2\[Q^ M-[JC+S?]4I&V`=:':W+JT]%D8:]K?_AO]JZNN8U;R?XB;P%HH`&\;!4^=UWE MQ+Y.[MV]3UN,-':XD4DM)3G1O]\&R1E)@^$,.:(4)[EYB)V(DDX#Z"^@^_01 M7..,H\XV:)%G^]_?_F+6;;AO,34:UCI'1*B7!CB$+2NSS>1'))-;'ZX;J,J[RZO<^;NV5I,;QX M.;T`H82B&%9A,HFY0OZ72C5N9KXP!=34$R![C+)_L$4Y5E?=6)G3YY:F+,%14,<)0[61&AO2S/$EQ-D&Q_M[@(?]/WTB6S1 MZG(\K/8L@TLR9V7:C4@)JS+$T@$\;!N'`3W!_D!_5^9X!H*Z7-W1P7M/^=+N M5M,WG]:;9O>Y'Q>_-3?IM]O-8KVY7)("W[\E'=_.+J?OW*ROKNA;RUT7&93A M#'9L`'>@)#OE'-!3ZBUEEKF=_1HHF8V5$KVA1*5'Q/:"XOS>RW9<.%,^/O"! MJK=]U#A3NIP+G<[D^[0L[],H-?J2MMJ\;WD3AEO!:E^ERNW=O_:KMU_JM?8+ M.,;,43E?[DX3F<(V#D>0,0SLE['ZKZ%?HQ,R@6RP\/11;LBS2QE].XD55/0U MMPYGH'HW\7_B=?OV[!(EE<8ZOZ<4=\GY:%J[Q/4`DX\UIL<^_J_]>D6[1)MC M-776+3&F!Y?!76;9O[Y@'\KQ*"Z/+HPWX+!+#]IA;67?T MDEZ@^1;<[U%$8T?DL8JTF\PQN`CEY54KMQ\=0P^2V'*?52+7KV-;C$3>I'8"B077K!A82J-RF68AO<@!6@FB#[5B@<+*]9U%@H_-1;/\.FL;'%#`P;TD M\%&H'"DJ$ZT0@4%=$T::69F'25AGD&-B,Q1:E(Q<'B_\*#SGK&TKAV:BK@HJ M2W-N.6+SJ=ELFLN)40V'G9]7(#"F,IB1*U$831Y.%&/UD!Z#4-F_<4S/E6!* M)VCQ/18K3GX&)(6WT7422*BT6FVKULXJP5U38I8],VJAU%TV-_NAB:>[>0$A MV^Q==)H2%LA>FE8<@S4U6*FQG9)F!-]919ORM!3LT@%+H?23QQ#(<5[3:-*H"E)H M(U],K)*QK6[7FSF[4P8^(HL^ECJ)A"QPWQD)"BP'RJPG;<0C.,\!/K$!PEE: M4]`DH4IDNGGAVFX-MT_U#1-(53T7S$;^_?JV>10US#5DBDM09*99RJ(TL8N0 M'TX1':KQ1.,H3&<29&(W$I+AS4%RU(JK$`2'+M8GKSK0>#"Q%;.$.<#I?_*V MR!"M5B(FZZ4UP(1Z\"^48==*8<14B',`VKD$FE(6'2@`\#$8A=S:E(!C)Q#3 M==@)]0W!^00Z8K;>$9O$*14PAFL/F",ID/.8.MVA&*Z^S8.I=.`PNC.*-57Y M14E]I/@LHU,Y:?1)=T%`&8M0-S],Q://DVI_W;[Z[`;F<1YS?5R2ST*`(WD2 M(5$6G;IMDED-Z%)UY7H$K+-(,A5/3",IV\(."^WG#S,:$FZSWWN;$&F+*$FFSI&B$>(GBW`Q#YXX3P#CR8+6::N M!>NZ)C=M=!W](]BCS//Q,GS8-->+Y66;M^ZO(MWJ36B M7G@N<9 MHE;=K^FWBZN[2U+$N4UT406MR2%MPU$EE.5M$UV)AZ8I7H[!=`8A1DG,6*$] MY:HZ1#Y+%/81@.0NJ<: MJ,B;@R>__V1LHZ$D9;\\6.,H)]$BE$ZP#ALJ7U%D`NLK]3.P3;P;>8J3 M>&8<`1&T$(%8Y*[;16X/2UE%Z/8P)5GEK/>_>SS6OFRDXX_V\ M=!KAD'VPM(D)16`ZF.2XWC4&^.9Y56UP$-8N)[Z?T?K/F?3DR(!SF;D3+!GL&GE!A`'N%UU%?X]_ M^ZG`'JI6[GZZ6E[\_78?]W;?VA7'Y*;MYQU)<7/B3@926I\Y_4WAGI1.**-= MW8)4UTV_CBR%W.'F=GWQRU1G;@@Y96:@#`H-42*TE&1"E1Z\.M.PMO\6\3H2 M_7!W?7U%7_FAU"613T]??MKWAC)TDMIJ_10D64_EU!C<0.X!$F1 M:6994@1G0DSM8.2<8DU:)@1`/W%]#K"SJKI,2-I`^ANMM%I&'EL2$-(,C]5M MEF#5I>CKR'*LJGL/06E!Z5WDTFCC#>M4@5*-FE).],>\OY9$\U3=6P_.29>1 MXF^G<\R0'TR9K'PRA^K6Y'7$.T752P]K,C%Q""DH4R8-L$XH#950R*&?)8T* MM2ORVM6$?+]>K=MKB)/C;ZX$.ID*Q4%DGE'FD+L:=$^Y>JTNM;8<`O,\U*/5 M-$%0%HI>>#HQ/"-DU46_99YM%?W*.C1Y`=03,3OY8&8"\X461:4@3#:Z10TL MU^].U1OA2Z$>S8(0R`5#U#%JR^EX>!-:U$[JNM5?5*T=1\)^MUA=DMDH?[S] M>0H(:8H>#O70!0ZMDKS=+^Z\@"*>4C'W*Y-8,F6 MA6S14]:+WMN.7$MCKEE4F9F!M%RQT(<^TE<65W.S=$HXO&*4:AJ*O5@0TN\[ M#V76A>&X3@;X4QL]"&,FT-$^?@)&B;&).2:&(;L4L`5J+-;\.Z)G&V):Y0UR!BXQ;$:2AL]D"#0.C MUI$\WQR@/Z^OGISB&2FKU2A,#!DCJ;[.PME]+6TI@O>\A@J]T.\PD-EXQPQ` M*86C6#I&I5,9K$$GH3-5=#HJWXM]JI!C\1YZTIJD_U-"R.Q\B('EPI+ M2@PB5W46AH45[2G$`R]6HYC&%BVA%58%(2C.#R(X8UA[4YN9XA4F@4STFM:/ MP$3G]8<2FY?%;38WNQK[TQ8O"/"68KULN5&%^X0.6WL;"SS6WIY.;^_680K0 M,]&/+;-BVF=;R$2B1,S9VC;"H^256-X&2`8PM*QC)YRY0@FZF]@S)"JCVWE"A4E_-:,WM0 ME88!KIKWG\*FN>Q7]K>9SF6S_)]WS6CU ME>U^*LE1?O_]DZ:RC\W7]=57"N6>?J;W`QZ#>_)CMMUM7YK-\F*QVG:O^<5J M*B/6,:&@G)$''[2+Y.'5_A[%4,9?V_G"1OAT(1_`G&D)#U'KO=(*YN7FYO;[ M;6?=XJJLX/K3^R^+GP;M2I)^C(T8/&H16Z#M M#?5'VF!WNR-%2JO+/^D:R\=O(9&AEH%'0?8]DL/"=CRJ!9'#X^NHU=WV!_T[ M^S=&L<#P2D\LZ.1&[,>%^_5FL_ZU+,?BFKYRP#G\D0W&TW,N-&B'/)GD*3VD MB""*;A=TK)]8^F.,3EG*5]J#/XPV/-T)!-0^6I_+JWIAR1(MHW1Y/5*5&]SV MY)QM*V[:[YP58RB>D;(S8*5Q2T?E4^A??ZQV7R)S4\G+I_E*AAEM26%0^#@,;(B4ZX.#Y`SM@F6M M,'R`I5[W"K1>4I:/Z_M"6?D3I;V7>;E:K"Y(VR?G,!AFDBN\=);BG&"239T' M5E!7(UB!YQ!H3$N9TQ3""DGK"=QD*'SB+29:\RHWM)R?99'''(K[O[N%+QUU MI[GBVT+)OKP(B]7B`;]>_+A+] MOO67Y<6C,3[N[O;G]68@VGN)4ZF10\HNB3(GTW"IC'/MJI;7CFI5U=G,W(O* MQ7CB**)3UCFM6+] MN7Z(SA/4(3#VP_,:P>D(1Z_7;2$CYMHK%LJ\RXBIO??-/M3WJ!SX83LXA?"[ MQ>W=9ALK?&RN%_?;YXLR[&5)VWR]N'J[^F>SV.3EU^;$'(A\G_:.@[4Y9["4 M![56)RJ&`]4!AP_TT1"?*>3Z;G-JL;=/6IL4;")/GTO5NFB%Y!ZKXN0^H^DL MB,\3\L>?-\V)6ZF\%B(GI$P[9:M*+2#OI(PUXTSUHC<+XS/%_'5]XLP<:>+& MS*0SB8O,+9:!BMFTSC,&K*^`%#NU#TASZ[TZQZ9MIC0"U2:9C5NM!Z MME:]//I5M$ACL>,#B%DX1[-.M%'(;$"`)!<4?;+=?M4W]NRK$_3`7SF$1U5WK5 M\4.^6U\L.H;)]C-MLVE7G;7[IGW)1B]?>,1,<;]-5&@1ML2.]X^_T@5R_[G8 ME"JPMZO;34/_G=/DN]7EVWM MD#2_>P[`X`;Z=J#'!W42N+9?C-/Y!+S)9"TI;">+1=L2E+&D5]`-@YA:D);GWD3"MA->F!H.TS(KL<*`':[V?BWM=$"V^L[/6M??LK,\RI.]ELQ#5H&8$< M'!WM]_I2"A#"O_T&PN2E'EY\;?[_`_[\;_L=SB\34[R(")QRPA1$R1J]P1 MWSFI'NE'I'@=23WR_6']?6XU#DD8:,*A>?[?8_-+<%B]^XV[#8K.Y)WW]Q^*J'Y-,/KIZLF7DFT@E=1#2BJQW MEWL"N.1U;L)1]8I,)^`\#_J8?\T.K`N9_#^@=BYRNR>O)NCE@J]*B\N4X=G0 MOV_HBS<_?]BLORXOFTM___>;,F:[NW1T%(=]G<=V4V[ZC(J0&$.,V1/Z=APR M':Z!**;,W'XBR/'@SB;3U,`\!9XSA-(0XECP2>]OP$DFP4-5"P%TW'IL).<5 M:M=E\KR-,@#1N:2TH6R^$!6RAQ''1G$VJ*E(CZGI>:5Z(,V9OU6)14JOL32I6^ZE#99WU$0FR3I8 M(UO'CA)J`-W9A)I2*G(VOK3A65".Z$\AV[`Q_]S=Z7-;1Q)]A=IHJZLXV.=&Y[PF)JE=W;VDP,FFQ)V M*5(+@IK9?[^9`+I!=3700.,0/1$.^:``A6.YLZL@N>!VY81!]Y]YUH^/[.I4`O<<+11$HT.0J0 MMCN72D%]+J70[^];9C.@-TP#,\OOSVC$PL018 M=J(#*9J$`:J?70=,$')=)?7I-M^)@N_/=P0+X!AV681$$*-.[2@*^H[QH:82 M>X^6W5LI:L4BXR5&*VWT.276U?[,\('#X=0[BSOOE8?/>Y\QPF"&Y"!=L!YM MV_J.'<"L/;MINQ?^(:C0_LQ^I_*_-<^?%K.OG^=WL\?^V\-_C([A,FH<@/]#;SQDIS`GB+P7!:@X MI0+3P9<5`'\!T8E<^`!WFG)]6J&SBSQ&]\8B3;'1\KFG<5OIMYVI2J+FU1)H M8W-QD?>^%_,4@Y0*@XX#"2HZWXGLI:O:$FP+!9\D\7(%%/#S\^SI#7O`:@!F MTK`M+QPK8GJ\XNC*D67=5C4>,HM5:N+`^G*/2G2Z!OM>0`+&`HP;#,V.#7=@ M&;8:L)RJ#'"*[*LGK)N'[J;PMOET,+]E;ZD;':!@G=AT6P`W3#B861_ M>RQ?UG\(VOZ-Y+LD^4[>[J<;5SK^UM((]&..KDVCPLE9C!\=2:0+]:0S!F;U M??"H9)@FX6_SU37Z;UN^TAV9![492D?=%@N76"J:YE!;+CI:'-F558R%K+GH3 MEF>2\"+V%_3$8)P,G.M,;'FS(:N"'V3.=L-M^Q+B<, MH`.O,:Q7RIQ%S)&``C);C[]1!8/EEN4$%]B)F>N-E`_&\1T.?:*4>\'IT1TQ MP"5R0PW28P[:]CD.AIAMA=([$L^8G"N`MI?RNGQ=-'^9/Q%(Q8("3U?:1,QO!@F59KP:19%?L*%$O)IE=5P/'BKE/V=ZR MU^TK6@S_^SX^^;W=!X0HG,4Z(0LLZWA1OCN\SM=X6,+LZ%`/D>[,>NWM;`L' MKR3Z(?Y"I%F>=8C1!>HW3Y![7?9Z>HWT-PJL4%:Y@E6U)EI9:4JKE])F(&/N MN"[\`7KMGSIU.5L.`H*6(6`F3)U>A&16M^JPHU$_03&ZEJ;9_(?GQ3]FB_N1 MI[GU'_'K[)\=FLUW5Q8)?_A"H%2TW+(8V&[IZ5^D\S))'D)F:("\(3E7WH"I M8XT0AK-=1[&OQP]3=PT%L_,/W)*V?)XMFD#X*K09U3R]K!98QVXWM=%,__T=)A_*)Y\-):!B<+HR!6$3ME0H`9M M64/U3]%VF)=YTNM7C`D4.`WX.5S6F4O1D3HI,0`(9F2O7MHKS$ER[[T4P%8Y M16]RD=QK$6S*'>\<+7W7\(.]786CY5X374[$?E!1,..*4,FJ;(V/47?8#\*+ M:E*:KX-'7]R>#%.DW+M*)3W6A5%G@P:5WD<(LI4R.%$SCZD>!N(YI>Q.(2$] MW3SXQ6+VM%XBW\[9+)J77Q#-=]F\T>JGC&JW,X>F]OF;H-)XN__^W5] M7?Y+L[QYP'!T=)$8"H;6XJSWKF3ASQ5XF(B83 MLR44Y9R56"YOYST2"_4>76\*\P]FC)%JU!7">\R>83!76B1>-NQ!:`R+]6B] M*S3@\W\H:^SE4*5&`R@$6R<$Y@[3&? M[E?_]KA&$CD]A&"\X$&+*/&\J)``B[4NA!3)JHS:;Z4OHL6/,M0^)S+),PPQ M&%^LXD$2)E=G*"S\!@8N!RJ/?PU+C:VN.>6=XED[+3`&.;\BN-G,#H"NZHD/ M6%N*?V%;[?,JSY(I3CB#+;94:"/7$A9%0JFLEUY`FL.S^!5L-5GS%&7!.EY@ MA>F*(I1KEUJX#)"A/D_`Q>$I^^QZ'`LRG8>N!MH'MZI?29!S0CLL,$D6<`[[7,0]#2\@9I)25:KQ/V9 MJ7=LCX,09IB(W(GBF??)644OJZU+!((7O)1+O&F4IW;"QF!GFYPSD0FZ:U"R M=(QA#.KL26RHE>"#?=(\1= M0Y!0";FM':>:F8L4F8J<&RSD5)`JN8[HS*7` MDDQ2(;[6`ACN,5H M2(G7>Q+5U/`N4:8*/)*%P4I3N$!Q/11T^1R]:P561M5C69(-).&#!3[3.DJ* M7G,`/)9$CAJP,(#2C4?JFLCU@QGP\<,6#R9(OM=!LHV8P5($#=PD9[3JYIJ3 MJ"\P/_2Y/2XH^DA9S]&&AN[SDXX`*6%L[/9`"WZ-ZIIP*+!<3/*]_;_*+!+G MK\*XHC*:M&S7$'U-\@)#MR%'2$[W`"W>)6;5H]V[@`N!289F=9@N34ZJF)!N`ZA!-/EP!#;0#EVNI1C[[(N<&!& M@$)IZ;M+UTU2!U$S%(NAV]^S2+D?ALD&ID1D/GH:W4#).EMR&VOB,S[IBV,O M.'\@WI3E)F*_Z0A7H&'?I\P M)T@]]CU"]IPGE)48`B3&*=%]#SU`_'Z*P+\^KU:_%\T69[9M;W]ZNGW]'3_7 M?+:8@FKFH\5RG3@XBO<6*S4>>%NK1:7V+?P=+=RY51O[0,Z"XBX*&3%8:X5N MU6&;$6_X*.SPF15LM_B;`>;V]9?BV%\,V#7!BSU^]YKG>5M*8&J?J+/WK)_Y!\H/TWL5/M;L5P5"I?-*R MQ+)F&V[Q[8PAB,(J!TK=NQ"\K/[P5^Z_'O;-;_Z'H,]G3[=?456B*"J+U_GR M9=P%,K!HN!)9F&0*D\YXW0+U\%C?\-1I\^(V*,WOAZ%AW"V?\=O/__[+W\:4 M)O1VK!4R+0MDGUSPF[@&3KL:-4R*_D#GI966M\W7Y6%?_I_S97/W\_P+_NU^ M##H(DY+@7LM(&]PE$XBM+W@"0I(NN'K'E7%W&;U75W\$#;GYR?W1N8D%+$E- M],`S1BH\N$IM\9"E'^`\X]PT*#X:_G-!AFO[\/34M^;ZK$O732YDQKX(6N M^%MP-D*'&5K=^[&F>EOX'$%(LAV^)$L]+_J@2*<:>\MRTBP^$7+ZD@#5QXS/ MO$`[FVQ-X"&(6&CM?6/\DF(5@\6E'?5MC>J?[OW#P_QQCI:<@%?M"\:BH&-R M@A#JE,^ZPPL>HD?A;*2<.D#*"Z@Y=H.MBY56`7ZL+(T"SUG'/R`,5)=[JO^T M=`DUNT7XXR].C%$$U^BQP?;>^,QLEW`"E@55(F6J1Z>Q3YP3Y![Y#-FI@%V; M1$\SV6?'E#?=9RCUQ3:W6"^(,PF^NB[9)?VF;GT;MK:_M2)]C<]?OCP_K7K] MT\B7_)>OC_./G^=A_OQR-V^>[IJ7^+P8H)7XOHYB4K%H`W%I!,B*E;!N@H"# MP[ZHOE0U(][\-6Q;9A.7J@(K^4L8EC7)09-0>Q?>T1%*(0BOPV+VM M6EGS+UQ3]-'KK1"#2UD5/-H)(A;&J>/(L:9NZPT;:R*.T^#C@MZNEO_W\1%/ MY%L&P0D/F'09(2-/2;F0`\W4MJHP7H]M`3T;[M5DIVQG4VGDZYC$;2H&HI?) MT?C@Y4'Y1R@_6/Q)H$RL'G0*R5+M3=8 M'2;2>=08`_"U8+PHP8#E4CI:1F:M&D[%^OJCZDU/5*9];[EYV,T7?PA($MJ< M.XZ*!$@NZAA;;'ETJQ(J*`2A[4XUAD4Z68/1%*(C93V#F2-8P;'>WFJ0:OS_ M'A['613XN,"OM6PPJMTU5:3=W@[L`95C,5`?"CH["2DDM^%VQM9;U[10`\WV M07*=3Y7))5K7*=X\_/IYOKC?S*"-;9.*A/%"%Q%H)2-C*-32=!:"&G92]\<5 MKF.@`V^$'0\V.JT2Y][ZM`$WYZOQW8&7XA_SL0^"!<,21RIAN-*^)$RN+4PS M33.H7/43YU/B9[HIOGF(B^9^?OPW,,X&+K450J:@;/`FAVX.(=>+3[I_E;!+ MDJGRCMA927(:AW(:E1(S.J3NG3ZH.D!P@ID^4>(M2?RJ=EA7[)B!20]*.&6OI03[L M/2+;^70:BXF2KTXFYG$1,&^QI+M[5\MM%5M4?UCA'#K1-=W-FA4W_[-9W,U? M)KQ=VHRA/2L\CB*DP+!:YQT#9_&A+G)%;P5K5*13%1C[%)J&N#,QB4B.TR(-RW#:+;_.[YF5H3'>MA?KE^1O_ M0*71TZ=[S']3RZN!DFK[D/3Z^TOSOZ_T9/1MZ%JR]_.QFT0TH@`G7?0VI^2- M%2$ZG\`2!D6J^CA;QZD#3'6J=8>8RTXWZ>[2#CM:Q1(>?,Z+U<'S#7PR724& M5Z5I6V6Q*]KDOZYC$Q5\T0)3NZ3H(-!/-ATF!9/$:LA+(W^44>!JCB*]0;.H MZ%0$&YPRID6EY:"%J!^%E/B!1KF2IVAO94(OP=X(RW',F3''UB@EUP^6PE79 M9HI1YLM)*-BZ@&4RH%NGR&A$G>L.7AH_8KW1!-+J^BNN__0CA7J'1'I&:YI, MQ1,-&/]B%+HCTHLRUNM2P*VN/]]EK7$U#BJ;,R?>,D[5;4PQ9-7QE^'QKCDI M";)17]$:1\^@FB2]#49::Q+UR"*Z&-#MK0&/)4"]6*;J>[8)^NQGV\646I11 M,90$$F@LLB,%TC51S0?.)*BJO)LFU?L[@=@>6AM+<=F6G"5A\MGV!(94MXX? MG.TS@US>&E<[@3'P#";E;`CGUBB(&P`H/($JL"$N8]V')[RL.8X^@D5G*"XX M%TR*0`HJ0TZ] MLE9*34^+#I@T]"0GE&<=$[%/H8[Z2C(P5[3&T2Z7=0X"0V8FNB>I"J.]\S:K MYS#`M:ZA;FF.5VC_X+%+B;"-420C(1!A>;>SZLI`I:$&[D*G"?7^?,Y[Y[/7 M.3,&(J7LF2Z=SZE2$QAK+:]JC:-]+@K!$P@)TB7\QQ)U5.VVBP^US_5WDD]7 MYX)`+5)D+S4!-E@&((F51+5`)=;4S7!-3GHM]0["7<$P)W)V'$.>HHI7Q,WB M':G#W%#5;_IC>5?2Y]^;Y0R=]#[/%D_XO<:(F&3F,F"R-;IX7AAU-KD%&?)B M@"3S&,V&+W/K'9O1N1:9;82,!0$S!(_%>0KK_*NDXT-D9$RYZG;E_\F[MN8V MCAW]7_(>5P-]WX=4]36;K9/$FW.2K>P;(]$QJV312TE.LK_^`!1G1,T,[T-: MB;OXQ>[?[@FGCSXA_]:ZLX\/L MAJ?=TL>:+[_[\'$Q_[2T!UV'^Q,/S'WV][^?_,FK#1I;\'2N5%0^2S+(GO>Q M<5//R@$7E%@-0'"A_XV1)]KL[^Y*^.-S.(V1N/%)#S\M_LK'&NP4:8 M"(2-_>*QV:`W7O"UHA5)!^E=#3)7W>I-4/:5Z%58M:(1,""4)F#4:\*%E[^\ MG]^,HS60@@V4*@0N6OE$(:Q=G28)UMFU+"Q5?BIDZ&9X/V6+!@O(_DJ:Q1RY>IM?7B\3'F.PV>3S,N:M?Y(L\? M?KNG#X6K*][!<\339\?CA(PT-L<0(_@2VQ<]`G-_34RO1+N1EA.(WM7\:I.@ MH%%*PT&TBS_Y^NO:[_=C*[O>,[G.%F3ER_ M>C_YI?[_SN8?WT\6'W;=D)(!3SIK3>&S#Z50>&T:]YL`%?IC?S MI:D]=KPNCZ%$'P6FBKZ4XNAC>7"J3J'K\S4;ZCQBP-1JP^40Q?*0I)1C2#%9-,F/HOU(`. MY\4HWXZY4A079-*4FK-R`=LE5#)"[$^K19))]TCN3_KS^L;:GH4\?3>[ZAK` M75?=14`AXZ<<957)&RBUO>JNY(H'N@VT0]FE?A=-)[.PM<@@3:5$,$HZJ10^ M%+2QF9=>*7(=Z-"CL]J9'WLP"\LALX=W$XJ$AD(R()I-,KR!#5HME[GTM]H" M^*ZS>?RG#Z+G7&T#)F3C^]G5Y.;;NWVYUT5P.IT*H$QIO@IB%Q%/Y&&K;U>1_'IT MHBCN?P@:33OYVNC0B_DH+Y-=*W@$/>?1#RFKY;4V*(J1*$7)V;%^5/(Y%+?T MGN./H!^#!>.3]`-D=2)$AQX-&\E0?7M!*7Q_E`J`/4D@.]QD\EK9C)EW%ICB M+-%HKPK9LIE"J7_N@T! M2QV8V,C#?TY5D;/9$'`IEVHQ62<)6:/,:G4!JPA`3]^-LKV`]A1FQE&1(+5P MVE9*Y$G'=?$4*#8JDISJF76I5#?$&F!B?=[]M_/Y]=TQNQ:,SD%$.GRU@(6@ MDJEM;Z>*0QE#)W0:HN(X,K=I=52B9I[>E*)5U2OI34,F;W+N.T9`=0XR=YAG M*[V%4G@^CA&4@UEAV]%N.[@AZ/S*VS"1P%:\[ZX,BWAN*+=`S9PH-;*1TC9"CB=UJ>VWF MT@(/8O:\*B2W41DN6';\4KL*U:.`7]33'*Z>=.;#_"QN)EFR`D^8CL MLJNB5,@V96P6V9'6Q/Y]GI+.BL_%RRYKK9=Q/0(OT4+ME(:VQQPQ]TX`Y3"= MINK+\K+UGK4JA>!Y@`0ECT+4T"Y2E4KT[22%27BZ7-Y/%M,XN9M><\6-OKU< MPW+X8!`RZ;E`0J2(@[*G*&-;^TH"X3^"SDTNAN)'$MKX'FBOT\?ZYU/'UE-WPM_3!;7/SQP'/KCN^5W M[\+#_?OY@BM`@S=J3V75F\GMX"SIM5$(_!F>K:+TO6,Z&Y)*&H"J4O75B0&0M3(C`+R9]U&Q)8&]FRX;^BZ/+9B2O2)CKD%K M9RP%%'6%K0:?S)"E4,8JY\;#=X#_4?%=GH;V1P^\HC@COM:&XH)W9'0]J:^B M-+_!M_*HD@%\%;I]?.M)_(^*[VH2\-6"F\7N\G3UQ<5UV19CH:*W&:)/E%W' MU&:T?K+&\UJ[(:;WR4!@IYN390\^C#4`PA M1[;#+QO:C9&P,]406D>I M`JJ2L$3"6Y@68&?E`,`>42@A_^8`[P+66^-XA4_F4K^PNN;B&ZM+9AB&-%?P M]D_U&FW#_TQGO[^_GUZ'3]/%Y/=I,U_Q[6)V-3U?`('KEQ,0R,4YHT(01J>@ MZNJRB4TQF$[M@P*G)6M??2/>2#@+X-L@>05BV%OMUX40I2M!I*2T2*86[6HH M3:R<@D^;A(#X1ON_J13&BDS6Y9`#674VW[5X;L<-E*DTAT';[#Y)3G'+JXD"BE'##>_)$$<&9Q66UU14D>7T:D4 M177MW;S[Y0,7QNKY&C0!\S:A62C=R5I5V;-V0(F[P&N#>7 ME<[G=B:?*:\K/@%:$Z+.24HMJ\/VZEWI00OFG)#6C!C?[HO(A<7PN8\.&;-@ MA'7!H:RTAGOZ-SM+#(^_NBV5K"_C$8MJ>"SMBDC MA2Z\CZ)*(;22031BPMQM4%NS<.:-.T1,HV(SMEAZM=\7(!B9*2K3)E#>:).L M"BB!:4R;D]VW>FN"L6\LCBJ8@]`95S0#9>,7(!KKL\BE1%%9#T&>_!?DUNYA;3$ M:Q82D2)H,#[]O(\V`4=9F%[-#K:4*-9,E M#D'+9'G'W<9C#GN3]MON=6F(5N=>5JD*#S\HHFM MP_)@F%_=]RA'E,MXN%Q"7(=KT1G%!<5JEZLN9.HS9K+^JDV%EB_I^!BI[^$" MXCH"EXZXYHM[_N.G<5$'SBGGC>]*&]0N*F.T`RS-)`Y=7>Z]IT?%H3[ M8]BV%.JS51$C#;VG/_ZP4M6=#=?"!`KH`B:3A5-H4X[-*'_`--1M0J$,@E[O M?=B7O?U!^6'ZQ_);SQ$97JG>*10AN!RJ%<0$Z9+A++<)!WE/Y5!?$C\>4GOR MTU(V'C,76*K>:3&JJ@9OO*A&%"@)8'4N"2.`--2[A?R*?E^9CXK18P:P)36A M,QHJ@/?9%>F%UJOY!L1,%75(X$H";U?_?-Q<7.+"1ZC&2B4=-TE+@&H;D*R! MH1=8FG^9%X#1=IO'L/S(;NWF9KXTO8].LW@+6\8%\';HIUZ M/LGHB1GA[><2.G/S.81>+42MBI0!K9+GP&Y"]XSEZL%S?0F.)-\H3M$4,SSZ MN]LT^3B[G]SLFO\7!6FL!U6L4+F0+6RF=Q8(`^G@*P5GKSUO)5&T(#.%TQH* MSSHOS63A0DD6]N>Q70"+0Q*%YT,E/%JGM:*C:2FLTS$U3ZXH!/:V-]P#@))" MV)N9@]S:3DZZD=WS$5U24_86R!0M&X>\<3ISP.)2%#F$_I@2<.#W%\M8G.QC MBG3RO`7'^$B1IT]1NF;:6*$,1?>&;4MT*-7G9.4B1HAWXUGM@.TS"=?+)$0# M"_G7@>E&KPR6_=9,8O:U&CJKE:(N78(MC7)$SO4OCL)!H=:6"7N.TN_@M>+Y M627KNEJ""%P%QH"^YMV&, MZV_?/8L*\=:BZ>+ND9O#RBA0*F:PFI>/)A^UI%'YW>W7SP,6MM_/%LEYV?[^8 M_?9PS^7)?\V'C\^!:W;Y<3.E1!8L*!N#55E+:-F:3J/N#\ZANWK.O\?5`]RJU6RIYXT7.E M,*1BB8CRZ4Z`PI)>PJ4T#CB0+Q73_8)YDW@3!U:1S'((.=^GKA2SEM2;BKZ7 M$_N"0#QP47W1PF4>(DR(FJS(=D*KDB!+;Y?"T)Z65X3GMN"C2J]+L7R5&1SJ MFF2PK9O.LK_<#KW!@>N05X/$Q=TT$J3*\EH4?B5E5!*K3FBV?U'U`M"O-73[ M>+YH@(_RU,(X8W+T4CD.G7D)D6QS-4KC^EF)E,KO"IJ_(%B/<]6@DP;24^VJ M<-RU4FN+*IB>JR9C^:JMXCE<-1:7E$X!)9U[IU`8Y9YN'WT/P[VRN2\(Q`-= M=:T1!)OQSX\WL_LTO_U$WZ(?_1/W MHT*O2B'_&\/'Q>Q&BA897KK[X[NUSM6V]EYGORWF5].;`:O8:4BLY+W1&9T] MF.J+!/U81Y:Y>J'7Z\BWR[?*/'RFU[UW`%_C@O)8NA%V#TC"!_J);]_/XFQ^ M=S6;WEY-[])\\7%G.X+#`#FF+-"%%)1)O"DI20R4E,B"PP#AV0#B%0J+N[6_ M/[*BK*V7H]36UR(#I0M"R=2L)I0)E'%`QOSK=_/%U]AMO-A.[LGLC2?RIW%8 MA@M\`5.%ZM$H2YZ+9*P\Q$01@VU8U5M-Q'96?YDL9FPL&N-0;N_I[SS^?[42 MG!<#ES\_SN\>%M/P@<>V[+Q`ZSX;T]'[9+2!:+0'C48T>XX*V%Z6LL;.4>2= M@\%MJ4>"D&(2HNC`*[_!^E5;)?%'\5H_VO"=;8&G<]EI[7\VA'WM!4")WH[.;A?NCZO;^R1*PK9$XVT=&K,?-H*N^-;[=)2(]#_;N:VB.HI7U8F6)LP)^W0?(<74!*AQ)U*'-4 MY5@IB3XZ^!KH_KK1%S8@J\.>SR=_+NKPE>MDF77U;E3#1?3!931NJA M.SQOI'3D9`$D)CI:;*Z!M?.%2A/D<9O95(<%^UI^OWQ>&WQF/PB\QK0-TZI.WD`GY]U]_>&Q]P-NZ%Q?SZ<6J.*!, MIPVST('W/QG'?-&IVD$%CO_+LGOP_1[:SY53W?+&-F;RSN9[+'`/]D0G&[*C$'7PD+5(QJQOK!!0DVPM MOKC>AD-6?P.K_[W:U)(QTUO<\N?F&[:P?[Z53Z!$RE*R?VF*-?5*J'/M$XGF M&-7:ANOW'_!&AWG_40)P6982`D5%"5QVM<&@[/QR_E'KETOMOP(P'A4V$R8` M6AU3\:P-LD[\5U\&"-!,-=;^:X!B4+2+F5NNX]XD'P!TX*RFTB>NARW![2=L M@Y61Z2+PKA]T87H.]6%Q-SNAJ19*O&<11;/__S)>?V"#_\>`\ M'V&$K`.T12@!C,XR;W8HV8BE4112="/L[EGQP1&9+\9#Q(,M``:QYF0Z[803 MU"&2HPK-7L$#(%(+[1^T#T]<\(W90KK4@O^B+"E0&@ST,GQO_V]^.9N^F?/;S]ZWW2UL#-YCSIAC-!B*,CZK4ES( M46=4M;L%YC4>HZSULQ1`2UA%LBDHIVA:#3734 MZQO,XX`+?@R(;^:3WZK5FM=^?M.K^JTN!K+I4/+=XH)_S=EV2/4J9@Y_43`( MU=4O?OMY4F?1LF&\>#-]2#45+,;F($%D:6P=MFW7K$Y:6^@6MO/K%_WF6[4W MNOLA<1_6W<7>FC:NTXV7Y_7K=5/KY6:\YC_FEQ\_SL[>3R[*Q?1\^>=S;MH[ MXR_K0$`EE*?:7BU(6Y@]:R%42>PV;6T>P99!2[D3V:>LN\&3->]OS#E6$N-] M?TMJ8X)VV]5,PB([5QB]-H181";&#.J-'7^G<:_`>VA.^CXKNQ>6'1N95<2` M._/O^M-[P+-[.U.0=$UR)Y)UA*T0H3:=WQQ=4<26Q!CK+-X+U[XK'@S?7=R/ M8I5U\*YV$,V@E<95>FJURF1*!O#D:TS/?3\,G>$+>@"C2_[(*CIXX^%T51O` M;K3BQ2_+]<'_V_K.PQH),A&44ME&A^Q_>C;(&R/A^/MW6T=^ M\ZVY25\/N^S[T/QY-EU^6-21U=^]YR?,?U]=&8:+B]GE&HCS5?>O&X:(?W;% M'EBJUHC]XM4G;Q)??N)L_KD^Y6+DPQW0>`O1HX>0:J9'5&M"+35IF]K1[A): MSC,6-L\IE)L_F$[/K^XT?UN\CPSI[_/M+=>&">?[V?OYQ>7L#Z8E#]6-L5JU M)J!RQFA=E=.F#%<&GWU;AFOL<\ID,#0O5#XX4&%MT>IM@//==+:8L.Z]Y>5W MW]S>ON1V,I_#@#+4/@^>'59=4*1`T:JLHXEM/$=J\RK;K;)]?N7H?'`:BDU2 MN$A2D<+2*4GEDN4T_^N*->Q59DC6M2M&_!Z%E^*?/MPR4.%.2%A0=!$6)CC$/G- M-'*6L[PV5-:<)D2KS*9VS[9E,2,1B1(&=%M84PZ(V,`%EJ6U*Z7\4S MAF5R21J+WFI/S#N,!19/=WB$V](SZM0/S_K"`,1/PRS0OR>+R8?)XMVG64U7 MN/Q"YU?S.AMI^GSZSM@227DE0!0O$KM[U@0JN8!%_GX3Z=YR_?R:)#:%\0I%BGL[FRF:E8RXI;2+\ M$9-O>JU])2=L,LPEJ%EF%\M-FMGH@7Y'`<@*I@G)%T)4)"MI?0!P@%/P&=9Q%, MGJUO?FMIY.+J@5J#HSNLDFF`);3LJE)M](*J>'983<[>.FFW]-^]]WKR4*B- M+ID1(N\`)*BFM7FRT7OODNW.AH&[8U)96VE\"\E(9R625?I3-J6$!GJCE>M;$21!65U2'V<=$0#QP6>!7.0`N2C&+T MV=ZS')3VT1G=16LB^-`VYCSM@_/R0P+!V4`*M:]MZ5VFX&U8A02"4`E#>T7H MGHR&&@2659M49X! MYYL8]""GY=G9Y+?E.CFSKV.O']O\NA^6O,K9.N6UR=N%U9B16Z4+NQO^=(5% M;Q?3Y=GRPYV:VU4V&I_\^V/7FSJ:O9Z M^P.M6?XD_WZU&+#>OHY^6^\!7YS&"`I",MZ`!+$I\531\C&,QU^E?CN]'+#* MW3VJ`)2,-A7'+F2ME7*15"=(;WTX]A*[FE4!E\O5_PS:Q7SNEY\FGV?GVZ0J M$S&1-+6UDR4^Z]X%U4G5Z*B.O^2:9U\7S%\&M2![]]W;3Q\O/T[._IBWRW62 MC*-"PHH0ZY2WM*F4Y^4J`W3\Y>H\FPXYJI\G_URV`ZQ+B-:B5++D9(*22)L< M-5Z?*-$>>WUW1N;N7E\W[:\L9N6IG'1`8'50=(:NC\/V) M)8?'7^]`>?Y8>[U-XGSYYDUJI6K)RF"TC39;$I+8Q^A6B9[RL5>)5:I?AG30 M8WK)=*36V+[[:_AK*\Y8(B1%.=2*75-SV7MQ6@AP_(7>ZN\SP)+N;.4#06IA M+(!P8#4[^A%M=U*M\D=7O'<+G':O]9>/Y_//M17.\K=Y?6+U`%K11@,"70RK M\+<-/A*;5^9*I(JW2$<_J M`O:-_:2*[<1#9C-FO/=^>!=L[]BR^=2#$Q+J-4YQ3BL5R=:J)KWNU*44RBC: M09X"S%>W^J=U7KZ=*E&`[8;.KK"'5@([9)LVD$J1\;DMN^65G"!TPFT633[QJ-']R@-W/LW>-UG*A.AE9AE"$DLE$#1UT M3KHF.P10C:A11\/NGK:#MQ,!M"Z>!#F+&K.MT]54!U<.6W;:*6*UGEURXRT? M0HUW#*102JJ-*JADY9/L4&.WH+$`3*=/4:/==O1W'DA-"+7!*B@&"K0QKM/^ M?/@:KN#@%/?8MLC/KLU5"E9\'$9EV;%V?3=ZA>Q=-Q?>YD;-].D`MKM3V.W= M5156UH4/8DG2!G[/7MWKD!INH91]4:;R07=D=X\GS613%QE`$5G/G"J(ZW/5 MID&NFTM^12L_(`/-(HL`%)WT(D97.W/;;I=XE]HFI#>R=4\$JCW89_'@L]+L MXBEV;K(/U)\IBBB;U&;C3@VL1S'/*%R22A2O4D0K*-C-+$>&+93<4"DC7Q3Q M/`1N0UDG%&/(1U2%_1L^?T89['57I&:'20,G!]4C2&?RJ91BD5SM52]5K\2( MX6MK>O2+(E('`6T(X804;AB4)(F M'6R2D?I3J-OIY:<%U$""Z45Q(K"?HK$DRT<*L">8M2RUT>KZ&)[>`8)TRI22 M=6V^R$X:"9E[EY:D,^TH>VV.H5X.0W"L0/$3)XJET/%`45Z9,E MHRPZ%*;7Q+DTI_8X@:2#6&9V'&0VO@@#AH@T*MG?,-EBFY$%QPD!/=FV:F,E MLL%QL12AV."=M-E+-B@I)M>-4551-HG.DDGW6.;S8*L_9.Q)`B!6ZYM" M0%(0-W.=&"_4L@GG2HMC!9_&A&L/>L8<)87"5DPF54`H7Q)VB*6B&G,&Q3+`Z=2U"XFG6PN-E@I^]U67&Y/I]5C1:'&Q&XH5W0ND4<9@6D36AFE MZ]+C,\F0F\LI=*>HRO9GG"5F+4'4)C.DG&%;X'K9=SAY60[64QX&C1SC&QVH/^^FR3T#)K@T0!BL/<*S%)VR9VX5A4 M?TS$!K)H`N$]$3C>3@Q49G^A=&@9VQ9(>S:I+PFMQU^!9BN]C![8_:'@"L00 MH*>B.337>C7QX*M:^0%IJ&8BH(M@W]FJ*+3W)O5:*(LVV`OJ91&#D>]`=;#$ M#GB]0?#UYK@>JPXN(FRC9>+DT'H4_Q18D"R3RJR)_5Y7!/:J6VC5EL'>G`-[ M(L`-)9\4E98J4$;AO"M29.A)E%6ZJY!241B*FZ80T&.KL2X!^1VEJ^ZJ?%E!#KT$1A$8=TN"$<)/AV$Y$0;DT6*/M4KAAIL,[[W'$)J_"S0 MXAC\^<`4I6A1HSP2BM56.8LFZ&[5/F)C093WQ^!V3^<7!F0I,L<@V0:6XE(= M0MY1?I;\%E/YLL[L_NP`'/*FEEFPZBY"\CI53]M1Q39;PXQVM3]PR4-,NV1! MLBX&9TP6O(.+-_TJHRI-AM.1(DH'L7@M:9D&PS$V3>9)D/G]"Y MNPPUR;8)^-K*48HA<8Q24,=4R$4*8`)(F9.0,4KXT,U;8F5+MZ1&)MQ!E0)ZN=312"[@%CIZE)%)7^%.WE M'CZ63@#6`K\E%`JI7A+V?"R5TF@Q@),TF$-#H8%9?HXAYZ)J3T(1B^]TEW"J MX6/,]U^4P_/X^_9:E.Z*U,49X=#5B<^F6WDBU_)V@?Y%J>U#!,SWN&#`]3M,Q'9VC3N]/?:H#`40NH9# M38HY92=0]"I?M1VHK-.C1.='16V(8U.458')DP^4@@SL2T-/.\'&AG:>%D1[ M.#2^9!]5J&VZ3'8ZB>#[*#/&MLD-G)[*VB=[V#*%RAZ1MU2*O*.@LXOL+Q,T ML873`FJ@$Y.29YT>LQ*V/*_`J.@5;C#`I25L'H>H^ M0%^B:R2L5G-F7M"J!V>O&+*V.&()(SHEC,,^M/[_[%U;&LF+N/5E\MD'(6[""6N2C(P[3;R-0@G=VG", MQ2J;W?4IB;H#ZW)>&"JC5HJD7)%-F6O#ZKP->R(YY.<3)PTL*J1#`>8T@L34 MRHEZ+G*@0D)?J\Y3/0O`HPD&DU@0RB>0O.%[N6G`K7&FG9ONH6KC`=C0`)GTELD^[SX/4C#*:8E1*0NZ*[)LZ'0B&E:V. MI&1O<8IN%==X"PE\S!&<)L*AQ;$'DL%M>9I&]],3HV>L=@B/>+`$PX;$%!(T MDF\6T^T"8$@JG!CT4]K?,V"[=&SE.GB/#-X+;I2B0=%V.EH5RP(,S=^B']LR M5$-XN)&$^7RGF<%(1_L6K5SF5(:D2O:5:CAR9PR5$PGHMB$UF> M8F2*]W8JH[>CK;M%.Y&"]@)==\"5S2`CUK-`;=UK4Z*C@6I`G#T^/A7 M426:(H3)0H62(5+861LJ20R/$FW/ZV]7JY)X/ M06%\8XD#[Y-YR-5P\A)-,OJ$:(>8QJMH701T6#8W03*\KU M2T!#-'?)X7HH\$](^?K8-J"1Z@6NH.@3J"WC&,9#-,XA'\TE.\+;1%LR;SIV M+ZCA+Q$G'ZQ81UJ,5XQ$-NX39T$;'QMQA4LE6P+S$C[Y`"R:Q%:/1A[MSP-')MN?'$)18#$`AMR(`LN-Q,DB_A&`]]G%8[ MXP2A&(,SQ:+07K;^#61906V,.BU;WOX@;%2`8:'D!$3>\8Y-VR0(N<2P;*3< M6T'AL7K-$&$MTB$:F9#HIK+0+7?4C)7I)4GZN09\>YFW87XD"&V`Z@@,L@0T MVC8O@O*4978OD]8^3$+:X:*C0!@65,BMH91OMXD]#6HN[`O'*7 MI$B]$@%E-<[F%A-MY*/+2^Q?*)7\_"0PT]8'2F42&+/0$%73R!7)D[)%A$ST*[-_AMS]ZQMM-F%<;JVQ:.,B>1%<([?1 MI=R`EK&'G?^H+`[HWE%=7-3Y[8/KKX/Q]VJ:JM4EXQX*^G%P=WAG)X#CLJ%U MLIJ[",08LB`^GG))R@)TTEW0];0XCP"P-/SV,QX56E]4#8#G5?UC\.VZLI.% M"T6F?G9Y-IM.IH/A7$A<"M9MYST"QGYCNS#_SMAN%2I&I#)!1R&CS"UT%6V@ M3SP[I`:!=4AQ.\7V0SL/0W^LM@&,\^[D!?SH;GH^O1]SM$^6Q8E4## M2FXQ*>TCI8*!-6B0NCFTA1;IM.V&60E3+L&O"^F$C^O#CKD0'B`%DB+EFHOD MB&L`IHJE;H#Y<='-PA\?X=%LW`?"22G&-$U`';H&7!Z2$`W",B3H1I@=V8"S M]$>'^.O5N.K%BFVB283$"36$!RLP:N>--R9II?_1,L;'A7@N_?$Q_FO4!\(> M`T<;0C)1:,ZHTD*E-@Z27#ZRWAW9BE'XC0`_\N3\]FI.&?$;ZM'%)I+UZ+;( MK^/J=E!?'/>\PD,2@RKNE0<][_9LB5="!8%>13HE\T51__B5_?XTZ%L"LB^P M'^MA?3.[N:=[D\_5G[-Z7)TXO(]9O4K,"AT#2TQCI&>BU@'1#D:#ED0MIU*F M@[3EN<\.-31&+]0>XN`[B^[[>&<2_;A)NH MXJJVP$:(DGD/R;L$1K3'+)W"^'69DT_F&&& M-L8R9/^2<[`2+-+4H&2CHF0I/?UILX>*7F#:/+%)OJH0:0P%GF_*Y,H3S:AI MFE,ZI=E*$6"CD-P!&UAG)J9_A?!]_-B7V>WM]?RK!M>GK!PD6AB_<6N%```> M'`/:S):X6A;6*H<)KO2&W$]_RN%?JEM"IR/\AY/3GS;M:O.E0EDNMEAS8M*> M`U,`4FI/1)`!6A5![%01%YU[?2^B(C%G:H3^@?_?F:V]EGD4".%2..8$20:< M""!2HR3EJ>A2$LF;3GTKZ5^#ZUF9@G^+;'JU,`"<)KOIZM7-:"\M:B:F9YW^I\;F2B2G\ MKYDH)L7";RGHKC]\`57PG!(;GU]ER*?,*.,8UR0@Q>*;JQ-H-F.RAL@G05'+Z"<-QK'K)Y4218)F>(" MIP0JAPL/;?(LF/*4&+#N3L4OHQY<94YERGPYOZHN9M>HCOCGK)[>?:RF5Z.+ M]\,?^*G\_O+5JOHTN'GXJFU/*ZR5/`6=V\0F0J)*7$*"14,.%I.697,[]D3- MTW^V`I]_CF15,Y3DM*/BBPI@]! MB=>`:)IY+<462'HP1S'O6UJ83 M7S83HO2D=)*9VRL(/+]>C>\+6D??ZM$4F=O[X?E&U41"J52*JQ`YD0F?Y#@D,.*T6DAN'GDPPIRVW MQ7DG2EYLRN3S(4ATQM/ZVW6%2-[4D\EH?/=I-/U/C(,D4SJ9&(%SRBJ:W/&XQ<\U/NQ>P7XTOET<@=A(QJW&<#27#;^R7?WXZ%25O,5V_7M7C;?9@O0?OB07! M9,`_VCG>LD5NRS.TSV0FS]'DIVKZ98#`V.F_K^KSJ\^CN\'U].XS&K6_RN^9 M?!U]K:OQ>J'M^S9YOMWQAZUW1AU1;GZB/&'40QF7N&2U@8]5!7?8+O#97LJ- M@-U_-A^C6JG.;;XA/^9LN'&GX0!("96$P,#0!4AJH M[:0[!$CK%G4N$"`,-J8DY.^NW*;BF>#M+TES:UP]4$_C4>3 M"<[CRWK:M4V2JF^9Z^`_3&\35_TY&[C1;)CS1^M@B>6C&AZ$I+E#"4>.GJ*W MEK6)<+?2/G,)*BDW%,)M(^7^4"'FCP#54:-PZ-I!(3@U)B2NE`$7C1"L+;6Q M2G7/P`VEG9LE/098:S4#!SJ7@E%YHB0@D?&4!DVL".UF)+.A$YY-I:\O@\]Z M6/C\N&S-34DCB,>P#+3"OU$20S$P"SK&%#73IV9)7P8_D*E-$G*-]S>WX]&/ M^=N/XL_9*)ID,@%8%);[203C#!QGX47W$19]OL"LG(O MPJ.CV&^D:.I/M$_41%N2)#`?O99@A&M&FD17']B5"XZV&>EP,KJN+^8<]T,U M0<8]&/[["C5W=_;7L+KX,ON&'+@>C',B'9617QQ/KNK;]RC%&.G]@L[].AN? M7PTFU>BR^<6WQ2?\8'+UZVBWUX/Q3]6PRFFQ+>Z&`F>4#"H%:30GP7-_'Q,P3;4O&W926.D>U",NCVMC M>NAOO2]-?#^9S*J+YK6CJV7=]6JFD#DK%K2BP0>C2*,76`V[VP,`1!$E'M%, M+Q@MJV@ZKK_-\K>CQUJ<"'-W\P_A*#!>/&33E#94OZJK2P3[?):=Z=GE)7[K M>%,WB6"5=#F/E6AB-N'JIIK\!A>\;!FVZ3%B3+3E9H/0T/?@^]:G`VMYL(9H9'DR2B"*M5U13'EA8[^8;+@?+3A0 M"7VQ1QNTSI'`%W=1HT)!V6(_;X]AA^JR&H^KBY6\C9^-"Q^WD2`0#TQ&13QZ M':X@BB:(I389C/J+$B6R=)O94\/8:O_!?AH-S_?!UE$##"P+8"G@.)-@MAFO3*&C7YA@].GQ/@QE_R$_ MR<*LYT1'KI'R4IV"(LPTYN`(+R8>+FMDYQ%WUZ%\F=W<#,;U_U47J1X.AN?U MX/K]\'(TOID_QDXFU73RH1Y\JZ_KG!_!2*-3&W_4\R?^\?#@%6_4_=V;^C-" MT@ZG=+(Q2.&"-TG?P\*XLQP*'RVT40^X'$K>'@!$VS@*@!JC=.TU\'Q%I&0V MBD5"$0'$`*4`D"TSU)/`[^QV;M##[^\Q^KZI/HPFC[>,.P:"@A@6G,:EA3-J M#,9(B_MZ&`V:EK=NOLO>3S\+PPZ1>X'P]R-!Z-$9.YS#QH=\C`UC)MY`R+5, MQ26![P3R#?[Z((3C6:$-6CH6&&.`+,<(R8$T$%I9SN-W*W>_OB8$CV6$N'B` M\=IG&PR9$@KIFWDL-2_V[]Y1RB07IX5A;G","_MH];GQ[]MJ..EHQ'I$M\@< M%8H*0T)RU(;HS.*T(\(9K"].I8"&9V+YI.Q]PWHT*V60;Q_42/G02R(=#*&% M-:825DI!/--3G@ZN1_2?(9J86WA:(R4XIK@AK,$5O"N7H.?._)-"]5C62M!` M3=",)YSSDMA`K&D7=EL&6N]XC[;ZI<+X9TY!_SD<5X/K_-#!\.+SXD=[>SM& MJ>;/#=7#SX]YT<=-"UV;]=80Y0SW4H,VM+F676"47X*0DY%K..PYV..*W%I' M&M3C>56*NYOS>W\]F$PZ[.?A^P]]%F+;.PQ,PL`X:)$`3$B1)Z?C(MZA29+" M?[X#H=5_=;&3+K;LVJ[R2=4$,7(#TII`A>>-*H271=;H'6-*K_N'T]/%4QE( MSKV(B@7EY^VB1<*8L7$%4?JBI/,=QN)B?:$Y29%/R/RV=06"2.Y=H$09'CT2 M_IQ96]B?D>5=SN]R7+\>,_U7&0?Q!2Z`%"HFR+=>:4>HH:[1A:6RI%_H"N2) M3PQXFA9(JKR,(*,"+2/&2E&TO@!2>6#B'<^=%EZ#R"=D?EO3`C#<<2:0$$2J M?=X7@L;^?$CE+0?HO$]>%4^M1)88R@,1TC.5G6"^W:"Q/D)T04IE[E'X&B1^ MA<;GO,Q!DC24$6V5%F[!"M#XE*.E+MC!:=!/HQ_5>#B/^OX:C"\0J_JFHTOP M,LX75?W'A^K[X#H.I_7208CUTM,6SP_U,%>MCZN+>HIRY_3_TJ>FUP-\SKD? M#`<7@[/;V]%XFJ6>7UU1#<^+AXV&WZ?5^"94WZ8K1P46E5W?!I,V1!Q^+YH* M!\O!OL&@J_#@T+7H_U]^OKN\^U*B*)?OX M./@[=[C].)AFU=P]#>=R-EQR]$;6YOH#2!:I"6W-@9@H<6S\X_W8=OCB=K`8 M$J.%3*I0W?];#SNW!W?FM@$7<'!&DWDJ'W+Z5#BCT*LX_(U^;'=]R^$\?_@; M'"(/GEI.5+X\2C*:J(1P/WSKI9/E3M?:22_V5.ESRC_N[64T/HVN!#H8)$)&R=PY5PDEVGW( MF'@HMX!6CX#L@>?Q=/%"")*@C'0<9QWW)AI-P4.#8`#:<:7J"R+XN;H9U$/T MS/>O%(7$[9YW[Z"NEA>`#DE:\/F#:7N+:^'LU&'^I_]ZMSH3DN,H9864D M@A**BZ%8+(PA""CJ3%#>!UJXYPCWD?#]<"_Q?+[2"E<#'M"M`",0'33B65H> MAN;$["-=.[I.T;Z.4/_Q[_]G[VJ;V\:1].>[JOL/K,SMW%V5DA!O!.CL3!7X MMI6]F4DN]M3>?DK1$F1S(HM:DG+L_?7;($6]RY)L4I9E[-3.6#()HQO=C>X& M^NGN8*QQ#]8Z+'M2Y=H^9@'U*424011`((-KJDCHKJ39.9X+)/>$??25`:+%B-.,]:$0=O,NX4"JK)RHL[Z9'%CFU"W53CNCZ^UF3F[JL0]>9K0L:'LV`QZ%- M1(*#+1<"^:$@+A81(6[-#>8M=+NF-[ MJ0D!=3B*0)`]'$2^ZS'NR]D!`9V_WZ;*?-2T+]$^DVJ(DB5?;0GL`+Q.R9&# M<2#*0GX1.#4EC`B^AA+4`"7SP0@8F1(2X>):Z0*]>%C&0XEV78MUS40?I`>' M+I<.M4.A&]T@Q`F9GJC;>*%?]!]Z#E]OJTF`<[U(UNXS7"%N$?\B/U>%5L^' MP_2'2LI^53U0,'4#QGAKP3-G'HTP#D5D1Y[#0S;IUXDY""Q>*'B&N:V(Y?JI MKU!XKN(BAR?.E6Y9IGK>_80O1Q(V+S78B2**&98X\!".6!#`OZ>YB$6F7*9Q MUON:`WDK`K&1YJ/ASJ?;^/^WF]TP]$))`X\[-.2>'<*/$XV/7(H6#I?FN8%? M&C?./WX:71?7\>`FV:HV`>*(VSZEV`4O&7O2#^R:)TX4\%9X\C*4QW$]['`L M0S<"<4$@-F*:"D5^M`]KCI0ONZD-#UV7NS+D+F*NS\-H6CP=1I)0[^7S81^% M\27W(Q&ZGJ1Z6Y$8UQ?70GU>@1KAQO0^NKZ)[L=9=M]/,WWJE8=WHZ1R,G5F MZXN.8\X+$.BMQ[#5#D_NHV_K1<-V27A)&`BQ`&2(I)V>4$1<.63D282[C MLVSE.HJ6R_%TH"1D'`);ATA/SR89-3)AQ24/`J%[> MUX`K>3Z.AUV5]O7I1SH\+]+NM]]4D?;KW_AIOAQO[2"=`L(M#X-(AEQJ_RLD MM/*_(*"T9;1RZ[*>^_Y3:Y:L+5)L>U&D8XR0EOV1[,B77DT6<]><96"!YZH6 MGD*>COH_]2?G`_(J4SH7XJG/<7):]T4VQKS?^NBH]5!??:0'=S]3N)N(-XI`\TA72$8XL) MB#:H.NCZ:LDOFKMNM.?,FJ/HH?,OX3.?^@$/N:[5BT(B0<0G"3M]6]GU M5VZ&34AZQ-2:)6N+Y?*$AO@4H#R(ACI#$#!1DP56>A459L&S>3IU==:VIV&^ M%B#"ZAAM9[CIMA+7#G6I&[B!U$VC'=_'9`:TPN4"^/.LH^?A9%++30.P'SKKN,,YAJWOT-QABZU? M]N2.O!D-DL_7B9>D>3$'T>4-;?-C M8Q,4C9=K(U1<9^/J1]9,F+5YQ^8N8P[/K$H[Y72PPEP&]C M\^"F]CF#+?"SRLJO5QTI5+%R+JN8*P MO-O`B06:'DFXQB`ZJ'%%@<#@MO``14+`VDLR,ZY.$-)-7$"H)39\//[M&G&' ML\AQF41"(^K8'ILV1!#,WR@Y^!UKC67:N/[^"WG4;>N]S&MHAR'XQ50(B$\" ML*N!+\"\>H3Y#D.>OXEX]D[L3_QY"?X%GG-YCR&^_UM27<.PA_+^([^/W& M5NWS^W!#IZ@8!Z%D'A$0Q*$P%)0+ISY%#4*Q;F,!27'9/-6[$33C@LYQ5%%$ M,,[@H:I.HGIJCIP\[6NH-'U=%TQQB2E077W8#$\S/2"H<\/528#.MJ=#'5(N MXC#.4B[;HP+/H8B6Z.P0$U'&)HT2$/AN;.$"QSK3O!OWJN_[J\'8AI3Z M`YL<,.V]"[8#Q1NGV225!Y$+PAP[(N"K M:C0\^(,T9+B6"^;Z[G.R"21)X_.F]TH%2::Z1;H1N;-%Q8GT703L8DI=VR.4 M"'O*(!DMW`&>VA<;U5>?]J5O&V,NTC4O;4$3VIS.8RBD(96A;W/./-NQ^135 MU/:"%7QN*F:YKT?,KUG:MB2*P',,[+!&]96>%@ MI.'[D8-D"*;+P3Z='E[(<.58R:5SB+$'(7MO\[ZY,E(*'T)"#0<9$N9%'J)T M:GRH6#U"6TQW/F:.[5"XIWV>U3SIPXV/PTGETY8(.D0>E0(3'`7SYA-56^[:SL3(T1 MQ5I<*D=PQ#'Q!$8.8Y3XCH]JHD(L5F(KV)^%PQJCJ[W%`F-)L*^;M7D4`H_0 MP;BF2SJKIQ00E)!=R/I;K.^;%2_F?$]WC?=\E_F$@C%RP:/BTPQ]")Q9DQ9P M7/BGXL/NU)8,FI!V)F_C9*`9"*9*]XZ<8?=<`$.\`=BV'5!B/'#KF&#:4PHP M[`HH%)-&>Z&^+BO?_/SCH/C02VZMO+@?J)_>]&'(M_WX)AG<02CVIP^CN*=3JV\O MTZ)(;\[$Z&[Z59&.RL^;AM7?KYM6,KR&?;A8^][%M;+ZP-OTNRZ/+S3_K+P& M@\VM`GX=W^A>5O\L;P_E1<>ZTLTF805K0"3K*DZ&N14/>]8`?J.J'_MQDEFW MY0%BVK?B>G'>@BO\-H?EL9*Y4J\XUP]I&M[K23Z%(%T@6HKGC_'-Z,,/R+$_ M$+MCZ;5N9/RSE5'>PW+NLK([2$.]T@/5+\YL6&HMK6^380^X5'Z>'W2HX7D' M"]*!]#/3@:O5U"@.F57_.1W&W_KR_'']/>L4U_`@T@4:"A_"VJ[5S ME*NS^H=JXB`?5\,S3--GL1/?:]1[_X4MY[,1,U!#XK@9LTZLLDVB]4,%J-(&+]?P;\ZBZ[I]E37%P?+C]VI/ MNTP'O6H@67L=N^ZW!YZ?OKF_QV(;93#*\'AA*_N['ZDBS)!1CW2"?]'AB5%5 MHZI&58]=57\I\P=&5XVN'L;'O+K*U%5_767I>-C3Z9PT._NAVU6JWW\&-5I.'C6I1K^_.W]G74W!QZV>NH0QIKGB MY[0]&U?@6'CWGTUQ9ZNL/<"E1S*CE,1&N8&QTV$.;YTGQ[+Z^KW+S.H.5)QI MU*VA>O-^2N,G3%VQMB95NU,)30"(]R^NAV+!!A[ M8^R-L3?/%T,))HRM:2VM&;TR>F7TRNB5T2OC_SV[/IE3 M]$UE0[JC93O21$":>NE8EZX\1=6./A707")H&_M.)U-$W.=GVK'(3]N^PA%9 MLJ-S(HPY,^;L>`[TC2DSILR8,F/*3C5?8TR:,6G&I!F3=LA@DW<0L9^?:<!N/)UY!B+'J*I1U9>@J@8BQ^BJ M@<@Q$#D&(N^AI;<_*VAJT>7ADS M8\R,,3/&S#3)C?]&S551;>/'3&7:XU#CXO(_Q@H9*V2L4/N!%2&K':V,QV-P M<]:]9W!S'L\[S)M+8+R2NFES[&#TR>![&+TR>F7TRNB5T:L7K5?&_S.X.08W MYVA8:$H9]\X4,<=Y?J8=B_RT[2L8#KUSW]^/\[?7L7QZ$S66#-1 MFIW'`W4^K>ZX`,*]0=K]]O-__/N__;E^WHOS)/_4E]TN\+4`2?N<#I+N??7O MZ2O`TZ%FW!?5_^E-%&`;L?\C?[\(WEA)#[Z(N\5;YB'?#Z,@(A$/*9?4)YYP M(TDQ05Y`HC<_+RW$/%.W@*ZL6\>-X$&EYM!18TA!U4?]^%E2@.!TJV_6%!C& MXUY2J)X5)<-XV$WB@?5QV-=`-462#A^4@5WI$LV1564M-<(1+/T-Z,L]_!$K MT85=R8U>[S*!'6MZ^E-Z\@*^F*`69#W/1BN M'#[KP?O*^IX4UU99@_07*3^_L_3=E1@>269DG>':3Y.`/A MJ!!_!O?P='$8)KEVNK/)`6FP_^8P0)I9Z4U2P/S? M6<")7.U.?J?^Z^DH&>IYIWT+!#>^*G_=L3+5'ZAN8<&,)S.'KT`3,\WDN/?' MN`9_&JJNRO,XNP>JLPHW:OI7]*"+%,ZF4M[R*1G6''K4N1H5R_!1=@D?M7H? M[3'CEXL+:SD>%.6DTY'*RE6O0+.Z<7YM:1^)=# M;",C-0;?M2SE,VFJ%T4K-6C>5"J34M]Z^GI9:R?+E+0*$O=C4#2M9Y, M%NT>=C^]4EK4&YGW1E2S9E:JHPV!GCSHF)4"!?!I7(#1J0T*_&I1$$M&KC>< M,Y.XW83FU^EXT-,\S%1L]&M0/J`-:`EAERE8 MI\U&4U8T?E&C-`.+,[3`<;BQD/WV?U<6M"G5:QFE[MW#[M:*R[2;"[3H-8US MV*;S7';_,4XJ0_PY2S7GXKDM?ZO[]'4RWML#5=EAM6XH&:3[7R4I5;)^SGE MF'GZ=9BG?J.8B6Y=O9RC0?0TZY(4NT0 M\9R8@NO5FWI>);JF?A;6XZ\Q6)[L?F8%)D;@\2B3\_+W(%CHW"`+B0P#.[D' M["0C!\;TF>(S_N>XZ'`->Y*+V77RNG)=1.RR)+ MUR8QIT\L^#=-97_-B8R1T#D)_4U[U0<54&-73P)F;?)72M?\X6O8SR_D:T-# M8S]/1!*/3]@:NV)GA,T(F[%L1MB.1MAVMFS&RWNB!"*V101/(/CX7)\DM"-5 MKZ@L[HNZ5<.Q@98U"$B[%X*0#C>0C_O89G,%^I&;FC$UK]O48-1AV)@:8VJ, MJ3&FIN5:"4(ZMM-6P-11U.VP>S/I;%?ZJI>>T0LKKQ MF'6I^FFF2P.ZZ8VRBOANKYS-SAAB+2<'6RCFIJ3CP,'?5&$- MMK6N?BQJ4SRC?/@$: M08TE`8WR&>4SRK='K.=TD-W^T?GKT+[7?MI5QWI67!19Z:]U''L6"].'U`'D<:R(48CC$:\ M>(W`'9,F]'8ZWD0(QC10.TDA!/+&/@G-P?'O^0@#UCYQ`@R5HT"R?PL'R8YO8 M_.OW)W-.902W#<%M#K)_+[DU5KCE;A,M!^0&T/4EB9H!=#5P1'MR@Z`.L]LO M&SR6Q=^XUYGL<^M[FC$UK]O4"-%QR^$\U-:^]%L0@GSUXH0-UA--X M^N"T#Z^.+^X\NCWZA#7&%9T&BZ1>A\:82-N`TAS/+O7*[UZ8V-/5^<];B8R;P\J&&1?TX'2?=^:\G) M7+D($C8*?LX5U:< MJ;**)>E!&-_3KM8E?*'72LW6ZEVU>I?Q(!YV53E8#`RZ*6N#AN/RMB@,>AD/ MO^7`E'MK!!-*>]JH`2?5'1@NS3]:CRCQ89:T1V,BK:_BK?\"G^9HD>*H8 M5_4ZY<+I=;7^,099A07K`K'P-[)8#P4S^:*Z>@^-+Y/!9#WG%S[)K9X:J;*" MQAJ/TF')2R"RM"+`$OV"_BK)\['*WCULY%8,U4[&9M$\Z0J9RU1/_U;)+(N' M5TI/-4CR+OC/XTSM8Z0\VY.>C[W0^1=[;]KB9C_@-!UA\L1D)K@ M3G>[([3VU#R7JZ:JW#-]O]Q(@DDR;1"@D8!4[%__SLG$RD4BJ00%DF=BW"62 M6#)/GGV]N6YW&@^=^^:M8E*M6Z?Y\-`Z;B:URI)RX,%)(F_Z6;@<2`"0*LFJ MK"5S*E#+]])RB[N0:AM>M@TV`3ZB<7<>!H]`W*HP;Q9[D9@#!8Z`V!2Z>TAP MBN:3KX!0@#(]CR=LROV"^LHB[4Q]4E@GP`8]%2"/2 MMN8,M1PQUU`7?GD#\&D&!!]QCI>6"UE?I1O&;6P.?(E>'\9 M[B5W@A/NTZ?Y]S\4.Z<;78G0[(7KJD?%K))C:=F-H"PFR+ M$Y(R`/Z,J%:-8'6@":3ZZLM[#DZS$J(:V$!$=J"PBG M%,>PQ&"@J2Y\^;LD?X%`%XF1?XW`)1$>L"V42. MX\H0X*-8G7OL)R@?";@;#NUIRF&/X;J7P8&`]@.'%FIVH$Z/*]P,^1`/%V23 MVEZ^6;["+"(MOR.0"E<6JE/Q?!PBLTN5C(3^`14\$$\*$V"AZP[V:MVW32V, M`6XS==X:PJRT]\+))6H/G!.?:U0>KT'E!%KX0QEB($F5"89OW@-T>#`:;'P) M0\I@T]B^'E(O@@D!$@+.3GP0%\!PNU^`E!Q@O M(>8&J5[BUCDUR`*.`G,1P#4CY!+9QG&E,AXB`T'%4:\5\'G(BQBD=@@P\7&A M"-T-3\HE)#+9@A%1>`5HUL&">8J80NZE>)S2C63(V17U;%R#)1%*Q=/#QU@C M("HW@I?GCTML!\4D57G^.,;5E>D1S_QI*@#411B"+02+B80<"[P.UH,F`,KT M7(4X`OQ?@PK;ZHDL7):2`LYB#"<,2T*@C3+;(E=M6,'Z0^86A*"^::&(CX^" M"$RQ4.O4ZGC#T:J"";:HC/$M<))E]$?C=TX=#!$]9L(,Q:7V-(Y M<$6JJQ7?"AM)CAD."D@A+"C%BNT4#WLK%E1EHP\SGH]2MQ`CC\Q*8W.7>%(C MN]IR:*\E(P",/,E8.Y0#\#SJ7/+3A=-\9>N2=NO0G3WZQ]*"A#:XX;[#H,S1 M=P7H[Z>@]I-0CXJW95 MYY!%R_5#YB;\E/CJB"%6PA`)'U<%-]U)J+6G,1 MGSD\GVG;C8:QUBBU/WOB-,1IB-.\%:?I=JH?`EF7LW\MISGWKA,?0S;AOG#E MSI;3Z5;/M^U^MV^*@NIRT%6+9)*\)TP1K5:3Z('H@>@AN:]#'8=,J%(U,N.J M!.R#&(8!9D!:7US!?9=7IVN=3F,'4,*:+3)CR&%2'S%U.L3EV"V'1I(0<1%Q M51%2M)UV]0V)3H6XSMT!]W?N!W,&V[2MGW^^)>L*"8B<;^1L(&=#>M]@8,P. M(GH@>CAZ>G#L1M=8@/-4*(*<;YO*QRU%/OB?]=[Z.)]&4^;-A%N9NG4ZAHSF M._VFTZS>5*X+NI"OX`A$UNF0F&,[YK0[(BXB+B(N(BYRQ.T#OX^/['\#G[QP M%6I_=3EJ/9`S;@-@TX%BUKW/P\G"^L3" M"/Z2Y(Q[.2C:I$)E\A/42%"=#FFU;*=/Q$7$1<15"7'U'B!Z.GA[:32K.)@?<=H"] M#KFTOH8,EV=]N;JF(M07,@@ZYH3-R1LOY!D@S\`N>ER7_`)$6D1:EZ4KKFT[K?;;PZPNZ$/< MC+A9C="1N-ENV;QMN][\<\1@ZVNO+_Q=V)$WV8+4%"UN=)]?\ M=-&X4)_A?-ST\QH8?Q4S+JU?^)/U.9BQ%5;Y)$;1%/Z$328X`T?NL;GD/Z9_ M_&7YF/-%%0WZ'%6::[TT6_@$U&)^NFBW_O0B%I9I(;G1V?>^_J%?2!LT?-]A M4(9FS[_*8^PX]789'V*T]]=IR+GU`7Z;2NL>I,'(^L+G$9\->6BU&K;5;#A; M&S5'@H^U4]>SY?8((3_S1^['W/K,W6#BP\4CZR$,9J8T4<*V?+FMPC;>(GJV M!JYOCW\[A4&.A.'550"WZH%T]6*`O\['(8(Q@RSS1]8'X7$9@=5I?6*+&:Q" M$D.LA"$2/JX*9,E9Z$XMQ,,[D,Y>,$<,!#TQ?!0N)TPTA(E4R[0!E/_W_<=/ M_WG]^8/UT<=M3A8[C]4SCG>U]U?2J/123Z6VN[Z.X6PWC;L1G3I[/ MM.Q6CVK=B-,0IR%.4_74Y!W\\F?/::-%N,/#34 M72C778D:B!J(&C+I8$R[.A5Z(/_T!L`^B&$88.ZC]<45W'=Y=5K6Z70N:;>- M39,X>?.%'"4'$%&G0UH.^0:(N(BXJB*N=I=F39+C;3OX_9W[P9S!-JG+?1:+ M[Y-A18X&CIX>VDV2#^1XVPZP7RQ%//B?]=[Z.)]&4^;- MA$M3)M]BZ/?)&S/D*2!/P2Z&3IZB-LCHXN^@YEP!$]$#T0/9`C;E?`OO>CD'\+?.O>Y^%D87UB801_ M27+$O6S*F!OZ??*F#'D)R$NP4ZI.IT7$1<1%Q%7)/"^'QKJ2$VY;)UQ5DR>/ MCF[:YF9VU>5PR$?^G+=3+HA'$H]\,Z]UPW:Z-9B\ M=A2(1TR2F.2QX"HQ28-,LFEW.\0D#VY[T^Q*FEWY_'TG/]KQY#=(LRNWXLLT MN_(Y8!UB,M$OP/5?&%VY=?K/D:!C[8R`;+DTNI)&5QX.VVAT)8VN?%/Y2Z," M:71ES1@BX2.-KGPC3*3"J!,877D4OLQ:3($Z$A^Y/6A5WZGV*+`&[Z,P80W# MA,3`B(%M9F".W>M6/R7B*-"&.!AQL)J@(G&P[3E8R^XUFL3!3'"PLR^AI!F> M*_=U[':+2F7(647%8UEY<8/:IQ,]$#WD$J+?-M8#YE0H@MSU-,G3)(GU')KE M28Z8&HFITR&NMMUI4)LE(BXBKFI*+9LDNL@#MR7\:)CG:D.'!AE7Y&X@=T.A MP0G-\R2*((HH4$2W2S*"''#;`98F>KZ2[]!$3_(7U$QDG0Z)->U^RUAXE8B+ MB(N(BXB+?''[P(^F>E:N_=7EJ,G]4!]Q=:7JVLJ1WTACZ#5(N.%/`,U$D\G1%SFJAN(M(BTB+2*=.44[7 M;E0U\_UT2:HRCV'_V+7#G2;!U6N4>UU`>!S3VFO3Z;S9LUO-&@QDKPOZD//H M[?0(XF;$S5Z9OC.P6]WVV\.L+NA#W(RX68W0D;C9;OZ:KMT=5.2P.4=N5K`[ M_QPQV/JZZP^VL`+0/.'SRZF>@NLT&W\J8:G3!9S<]-;"0THOR1ZLX&-A2_7DFI\N&A?J,QR^FWY>`Z>O8L:E]0M_LCX' M,[;"AY_$*)K"G[#)!"$!GSPVE_S'](^_+.-0OJBBMR#'P^9:']`6#@>UF)\N MVJT_O8CB94)+;G3VO:]_Z!?2!@W?=QB4VZ&0]A,',E)9+V)8OMU78QEN$YM;`]>WQ;Z<0RY$P MO+K*WU8]D*Y>#/#7^3A$,&:09?[(^B`\+B,P'*U/;#6ABB)4P1,+'58$L M.0O=J85X>`?2V0OFB(&@)X:/PN6$B88PD0JE-H#R_[[_^.D_KS]_L#[ZN,W) M8N?I?<;Q[KA'=M.D]QV:/0U:-.B=@H5U#A82`R,&]DR9A-,PUJ/AN+&&&!@Q ML)J@(C&P[34PQVZTJN^W>11H\UH.=O;5E2&;<%^XLKKY[T=7H]+K&TN(K,LQ M5RWH29Z?,#UT^M3"B>B!Z"'W@+5ZQCQ@IT(1Y*O?`-@',0P#3`.UOKB"^RZO M3M,ZG18Q0&)MFBA`;I@:B:G3(:ZFW>L,B+B(N(BXS!-7VW8:YNHI3YVXSMW] M]G?N!W,&VZ2!`IET:M!``?(VD+(<6HR?U0'W%S='3AV)VNL8'L1!%$$401IT@1 MY)#;`-CW?A3R;X%OW?L\G"RL3RR,X"])#KEM8D$=&DM(WH(:":O3(:ZFW:.< M4R(N(JY*Y@S8@P$1%[GBMG3%537S\^CH!FN-C+FPZW*\Y&RHCX@Y.HKH@`U$ M&:)$$401Z7TXI98JM`_E?J.1F255_*!CF8ZB)JN#<\ MCP+OR*/S=LH%\4CBD6_FM^[8K:XQ_8^8)#%)8I*UP%5BD@;C#TV[V>F]/4"/ M`O$,VMZG,C9T+T-[RJUQX`$+AE=80EK,DO%LQL*%%8RM"'Z->#B3Z8?;8`;' MO?A>6A).58P![>"=+L[X!*QAD0A\J4:.>,+EOL1GLDG(N1I^\WP_J6U!T&R; M`X'^B)?_*")`5%=_LS)-Y0,/W=^MG[,]7:=[,K(C]-94F\QD?5"S8)H-IV,7 MSU&=(A_!H3\%H3=Z$B.>[)*K4[PM'FR^:^O=A89(]LW%#]:3B*;6=)EUC`&2'.I,$^_[/_[ M.[NVU;*RT2+1%/C79&H]305L#Q\T9\`+X7U<(E$+.56[*R$HX'NHK@V+,W)& MA1DY^-D-9C-XK8`S^9>^#1;B`J=EPK?F83"*W4AFCX(OYM.%Q]P(BS8Q,LCF M:BQZX@<2?K%BR=7]0$+P7`L>.XUGS)=7UJ,Y"&<#`9$L+!`;1!9N(Y:C)8 MX9L9$[RR?IT#+N%WDGO<33$+OQB+4$9F=AT]!69V'+%PP@'1AXL2;9=1$,0& M;$U$'E>023#2%-8US"'=G"W4!&PX,OY'#%P&_B>$@_)@#SYP#,]3@LI"LZ1F M![$`5B6-$T=W;;+F7@L$)!"^Z\4XC!;@&P&B\`05$.9:+3"SZI;=,[9JH#YD MUY87@,1"F@7.)!'C$RI%YH0*,(M@7T/F*2('L<(C9&&F>&LVO3?V5]+=#KD_!`P/*U1,NL<1PJB!ABO^:H%X4E9RBO07="Q@D$K/E3PDOQ MA,I\JKQO5&\]&93V'<_Q?\WLM>VTS.T64&L>1+A4V.8\F1^I8(#J4P3J@3HN M("JP,2Z+WVU69:Q9.I%2YM!,E!FM6H7!@GE*@PJ9/T$M#F3T3%$"V`A@%:+^ M"QQT)"8"EI,H*/#39<1!;4Q%F8]GPI#J0:XK[21[#'ZM-I?J4,ERX1HP17FX M3N,I'^.,+?0YICAK\@P[!L4-[#(E)I?)*6ICJ/4`9TD52:6Q*7VW<#*H9(3! MHT!.BJ`R\V`=2!8@M4ZB&AQ%X M#QK6B"U6)UONI^K!+T!]0%R@J_,4T1,47,-.@4)+6J&1570:?S*&BAO"B,)D0#M(U`%:$6)&I MRND"DN4I-=L0-7=LI[O:F6P_B\60;EZYK#]:-TM&/"6_P_.C:G=QLAC:3NI4 M^2_F@_FPR(\1CM`I6T9JTJ_BD\`;F&_=W]YJM$^WBNZ0D'N*'A3_7;7^X1X[ MYRL%<]]+/#5EWO2]+/H!YO!HH/&9>FO"K<>">R,DSB"9S%KDZ+,@!!D]YZYR M[GG>8HWX428L_\;=N&B^JG6N]4P80>N6W6UU[4&S:X::Y92A%(*UIZ`%P*'< MA`T!^P/V]LB\&.%LB.R_XU[?S]>M,%[H3K!J`$*)42A(Y)*]:Q'4.\,\7EMS1.5*4>>G*0/!\?Y]3N&1TO"5OK]"[)8+BC\L();I@:V51^\NLBL_I(KFQ0^*;7UTHZ"D%0'5-#5_6KU'XZ0[%?PQ(462 M/)N91-]NM%3X##KGY"(,S:?@^:C_+@H M6^22<$%<$#+CS"JLF6#]C/D^4+X4L`,6)L^3:Q_S&I,F9:+*%LY6G]E>YJR; MIF,WNZ;.U9AWMMFRG<%J/=A)VUSFP'<'K&MIH8Y:J!DKUD8U;8YQ)V#>2WZ, MA&LB[8C9$*P0[=(I^1XWQDQ!-C^"/5)P76E7D!^/F1O%H1)8Z37XI-R;I[U+ MA3N+JN5(WYH8&,!CXN%OL'R\)G6B\6]S';'6#`1-QH+!E'MG"ENMG7<&%Y<' MH]!]"M`8BV@W!VIVC;+%GO'3717"EU*A!')R9*DJ(AWX^&2$.VA&F8J@?,GI MA^+9YXLI&`CJ_4\X4XSI`]=Q%J:P+]/WED+LX1+&K'WRJO\3S>J2SS,QS97B MG?C`D:W'RHL5":_HG)ROVMO+OE;\:G?/:8J?2_Y3_EKW::YK':7K="D=!6`` MA_-;[.M8>.84?#;IH90%PN#WD58;1`C<0$B%NHI=X.FIWQ5X9\%(C-&5J>C( M!9HI8I!>B<^?7XAZ=\*JI+9\BRL[56?PUK[@NGKK,A5@31I4R4V'3%=RY(&K M[KJB_8(_-M%VJE($=IK&6O6AI_4.YF$ M;!Q=/G)8L;R>,*9^'8R@JIOE)PD-T-$('8KPT M<)%BY_'&R#^&;,)]5/:.)$@>^WR=2__%"'FV40R1S^,A@,1;Z+12I0RKN\5G'F0-461=MN#9IVNVG("YR'=K(S M_+[:T$[7[O17ZZKW8^<;">1F:<,O!725>0G;+@`FF&L%+4\]5EF2:1;8 MD"%EQVFYQ)@)U*?"WT&55E!,L4>_S\ZOS%(/DOC@;$GE"?DD!DH)PD71OU$. MEJZ$0-<[6:UW%SFUXFK+U?6P]VUXF-[ M!*Q?#%(O']DG_8:+'_ZRE%!@YJBN#"8+&#^L%Y()\B^?2RKP5Z@@`:D"J'&( M-D\)GKL#]-$X/&N-H1I<:UD&D/V-0*I&.*6EK5OPE(W@U7+,`Z759SJ(6E@" M_R,6()MPF04ADW`[]2:&CP?M&S0H>+J[T%;4.^,'UJKQ<4U"IE,U2L=7`!B; MHSOP)42O;]9YV^YU3"EEQM(R.K;36QV`LM^BCL093ED9;^7"STEVV8>?_U*= M#[]I4%B5$S.J3]UV:.(%@C\,&"@^(/9 M%FL_*)?8KF82&_!_KIS`F_A!';O5[ILK?#Z\'[1E=QH&PUK,6&72H&.H;`!H M7#5Z0\D+Z#P38-*`K00"X)E MF?*G3,MPU01/Y>+JU:7"LK0ZQ:A>1@F99_8JKH8W3`,/E@97IB:AEH;Z;2JX M-P^1P:/MICNZ)"MW/>UET3\_\];$9^PQ,$&CI"0=Y)`E@">-T&)46E\!)JDE MFZ]!I32N`EMS[AQF"8B2^H:U0#*"*=U!WVZV#9EZ+QZ;VOQR;EV^Z>7*G%D< MQ8HW*J:H;(5,S5CFA9H256LE;#JQ6.&-:>E=M,D/H,YK#U]`?36$5*=\*8$Q MFHIP*Y6@];Q*T'K#B.6Z[$9LFB8*_3-2(:Y05$GM6>P"Z4="XUZ0)@-H\9XH MXCI6];RT+\GYER5W:W?);4K(&&RQ\XR0L9-,2<6)OXF9*@)603DER^T7A)"5 MR)Z.`=DC3>Q?A!L_S,6.=!;^TY3K[I?O&/*M'X@(^15_J"KZ]X%-E2=V&ZO/!K#F0 M-ZP1;DD-U%+[KOU:=ZVC_7-T=BZSOY-/5E[>\%H/:-V2E,E_66&6.-T?X00S#P$7Z_^(*)$8;C'3WJIPQ7->$X6?: M@+R8,[QIX^\NLE]T!_*E?&+X*H[01,/<5[PJ5OTA7N,@(W<5I4XN\@;ZQ;.(<)I6XZ]>ZV].NI.M_ MS$$]QK4-T?>6;#K_"92/&5KEL'"95ZHPD' M!D3JO`;RC9X]H)PNK^>@AZS8.ZT3,%5R7K.2]H']=_(\BB&30A9YTUK#)2\W M-T67/7.)(;F=9-3I8W+$@K'ZK'858%-=XFH(-I0DA;[8^[57>5_@!.BTEMO) M63%#M38M]@=**M)DZ"[)XFIF$5(,9 MJ2K`AZT+,-P?!&!52]!]`:T>@>=(I9*$J7V)UR90U6U$GCVV'$QU:HNSRI-? MDY:T5L$^N12E`O61B5]E/>=SV4E@F^7-=PJ84S;6EKOT\&_PI,15E@4#,?#W M7*(YV`!92YKRZ)TU"ZBR3[%C-]LMN]%FYN<9DN*;W M>/LY2DRS!+>FQY7K4X^W)L\D[>+U]/G,NJHETT:S;7<&QVNA=^RF*5M6D>FA M*7-MYE`NMG?*''H!D5Z?2;15Y#;UV"UG$[TB(%S0VXV%@1W'[O5,,7AC]4G8 M'G]`!4I[/NFP!4KU%(OU#4`]WY0F%[Q'&W'Z._>#.<.IB4<18U+]1W>Q8C(E M*=NH;?W\,[9_R+Y0@26P=\98[IOD"']569A?N*LSV=[5#CM_6!]KRH_S27LI M9DEW4.5TB,-Y(-7^%)B41NTO"=O$#Y(JX$6?AO:?)-&QY9Q/]0'$.AH+Q3A: MZ@7S?F=>()1QJ$?_K@TQ(3%=(E+IL))J.:\Z@H!&,\H32=4(`?V6\O!A6"*< MONZ:B>$[6=@`O$=YFP3N/VETAN=+3Z]?Y.H[@R,,GP_\U#%#KFFW MG-I5;C?M3I/ZZ1^%8E2'$%Z)?>^;#\C#RU$0#_-)GTG"0QXFF(2!E%E!=,'7 MK:,[*OSP[(S/EX,H^3[6>..7TR\V#FW?VU&^1DLX.3=Y#N+S=9._A<)\#81T M@XZ0Q7%HS`]\&*XX'+=5FO/-VFH*SV\!JL.7P9.O6CD6!FRCIB9`I0K7C5@= M\IR3CK;DGAMFZ2[1Y?LE:EO#RMB+\>!H>;UI7SLS"G_WJMNMHC5UF8^OF0K] M'(>^5MM4FEI2&:UGL8OEJ(+_,]Z M;WV<3Z,I\V;"/0[:WKWK0)&X-^T=2?VW`"ZWD*K0(!KRZ(ESOZR+`,Y\B7WL M=58TD;YD?$`9U<)/"O]S_H!(O'IC7MC0@^`7,Z"NFZ M+MUJ6]FJ][FKTEP0#@F@*A(%0'I/0?B[#7)3>*.0^_B08"&3_'^X#4A3)^BI M.5FH_Y4XC2<>539;.&&^D#/M;$4ETC4+;S*BY<\+P6.7#8^@O%:TV,7)DQ*NB[M?&3_"TSZ*)C&IFXR M6W$-O='M]6^X/BN7PM*@,=>524@+:Y1D'!,0@CS&B%:A_T;]5.7UL:TE#IE@ MQ:LXI.XVKK*R2W51)7!?CKAA+)ZT=YEY/\M5@/ MKE=!U-?C2<\F[%9X.B;]KT]CT_)0*@I"P'>JF=/Z`C]H=(6#'%V>RO6 MOA%;7L7L<6K)3&F_JH(7E+1++``KW3IA$I#HTA-_Q&*$BFNQ85WZK"R?HI3A MD![4..:>YKI>/,0BUWIF"QBM5SN^=`'';G;J5JWW7;-E.\8R@REAX'`)`Q5' MN?8(>+?7JE\KU[7:\(N'S*48"\^[N0$6J;:9;Z6L;90$I+X=4GW[A`7S#)U2 MQZ&PK;5(MM79\LVFJ:+Y-Z>4*UHXU(J217%F3J!Z>(-B-WO!V54_%>FL-:2V MW36FBA@SXF>\",RJ6(['Z^'LO&\JN@7OED79/!0SC4-)2Z&DAUNQ'4JF':C"XT1^*J1,V6W. M('6^E<_=\G3J/+;H%G7A)$*H0IA*$TIQ'I3%>GF2# M+#\_Y2XJ+JH?F:6=75DK@"N"2ZM&'K!>V,2/YA3\32=?>$AZ#QH`/S92HT`` MH_;UY^);_`";$I??@]=D#XXP;U&5GR?7_'31N-!-C.?,33^OP;FO8@9@Q1'F MGX,9\Y=7_B1&T13^A$W"B0!B7:K3F4O^8_K'BC63+RK,_D*6C4OQ?[KH7X`D M?-)_.]FU?XY&^9_AVB>HM?QTT>W\J?2$_,EKGY;?Z.Q[W\%?>)H;W'2N"5:J M^4\N\Q)4&@91%,S^4B*3)J!\25H4/NOK2U^I04WJFQ>762!,--3&P!%^G(H1 M$*-1+IZK,L_RFC*PL^6V+IZ'54*A"22<^3=+I<]:_Z>A_J\*6*Z!7X$=N,J* M-BK/5TO@UMMA^/PAR!(/1,]/%SZ(NHL_X^5K[;/-L"?<)-S<'S?7ARR>0A#_^']?E?#Q^`RRNTOWYZ[-:[EM2_L8# MJ`OHOC,%G1=1[1DH[0D,A8A&H>%T!G:C.Z@<)G4Y_4U2[04@59&07OF]);QVX.5AO?DWI' MIN2;R:S3(:ZVW>H:$V8G3USG;CM]Q!2?2@BJ@@C'F])5;[!U..)%JGH!-G5! M#C*J:B2@3HV>.KW5*4-$3V]CDO6/78Q]#2+F58-.+4"G)`WY-;16>TW*7`SB M)?"=1I"BU[6;G8I4@EV`5A?\(3.WIA%38F?$SK:("K7L9L-^M M$H2W<1BJJK,@3,N?EDL0W]*2K`N8C'&J8^(WK:;=:'1-[;PN1TD.D^-+#JL+ M[IPE&W"Z=J=I+!18EZ.LK9_GV#6*GP-<.99)F]$IC'E?3R=\Z+3;=K-M+OER M7\#5!>7(K7$"P9'3(<]!U^[V5[O($'6^3?B?`B>5>QKK`JG#.12/2H$_Z$=+U`QB'_"@"X\0+W][_]Q[__VU_S^V8SH0>37?NCVP#;E$VX M[PHNU]RJ^IC!A\]\_-/%PQWVIOCOUC^_WEU88@1?,#>Z=&X>G%Z_V6\^M&_Z M@YOKV\;#=7_P<-UN/_3N>_>=B[\M'4P1R"\T]UEWKH?MSK72,:$`/U5F4(+@ ML^>_[1X,-N;2'_'R%P8`SE5#+G]B_:PF$M=M'UHO+O0J]/3@Y#%S<=J>2/IN M9;.$_XB%+C/4;06!0%WL^NZI'E1!MEG]%-UR+[\G>39.>PRYSY_432S2/5+G MQ:Z!:6,YZ_I(>IW;UCA6P[!FPA>S>*;WFK=8T^!:!I`U96I,']RC6F:JCFEI M0_TR;/7ST!VH^K7Q;ZK-*XZ\]KFU`&ZIP*KZVF)/,TD=S0[2T:S]RHYF_=ZA M&WX=IL,8>?4W,(JW;D)5>R\7M8),9UAE6W+;O7-U2^1&#IY,;1+1L7IBJ&FW5@S`X7$$(FA M#62SBZI_AF+(L?M]LH9(#&U+3\W5J4;G*(8<>]`F:XC$T-:QH)"S<511HY03 M$D8=@ZF))(PH]?"MBYSU0U4TKK9-16J5+%0%Q*IH9F_W#/9(>['6^1C0R"`[ MVYQE=+"%&0GF[[/:SYC4P;_-<4";G4Q?QVLARTJG;-IY&G1-.3<9ODPEM$T&'/` M7#L19Y\'V6I^*PC9XW%V[LZ9V[(UQL&,WVZM.DK?'01\X$Z$@HJ"9 M::G&F7DQ"1!3T##?3UH2A;O.",3QG$D:8#"V<`9QGB1X9:$L8!X*@6#&DW2W M].;"B%"#(J#5,G,Z)@5`S]`@;6+_]6?_CNUT6C4#VW>=UFJ#@;?'0&+^&?.W M'G2><%CBEVP^#X-O`N>+FV*/3M\@)I@"J:ED:S,@ZJWQB[\YB%93N/8#D3F> M,C"S)*-0,F/['>_@^EH7QZC[WOO6!S6@"DZK:5M?0P;JY,='IC1`G^'$=_B# MJ8XF_HC!"T"Q9,6Y\CCO'1BB^F4]> M6Q!R"+`FL2X/]&H5#B0\^Q%Z&,K"GSQKA=9")7U@T\9X0K M9R,UK64\5#&7)/\$>^M#^`%XBGN8?F@*[;>1+1-(@C:Z;. MW9H&3W!7:%M^`*(TT>!?Y(P+5X>/AO,X3Y/L&%:^X4L6Q;7\#2%$P7Z@],$C66H M'JH.."E_4KZ^D<"_97;0,S;B>G(0/JIT28(I0(DR\.%I"XO+2.E!HROK6A4X M&>'T5==_F1.WZP='&U1'"_5UUBB`,T`D2>A?GR7^4CQU].T"Q8E1#/QN@55J M">ZR"?#+"1R6K<]ZRN`1#&_CBCT!Z^&(TWP\1J0-_.++@=)31+>!@_F`D4(Q M)T0.$?A*<8Z]2%>YZ5?,V6TZSW[T][FK>[526 M''SJ4!%RM=1=[F+-IDO(.A/?<-%C\0U5%R#W1P9(C@P0M@2`H;T MLD0MLS:4SI[X(Q8C=3HHI8%Q``-+O9?%A\,3QC$*SY3-`"/R.1])O$>'LW+% MT=;,D:'TFB/*ET4:W)'R-;@)%B`5.X/3N^/S1`L$$#Q-!3RDM(AB&7:Z\GQM M\#.Z4@O+*-X`VH.'70'=8.(#L($+)UT#[63;=EI;O>%8:JIP/62"0?@R"N,$ M&13PY@'JY$()I4PQ*L`$:6F%Z;B*:5MAPK6ED*@B@/ M2-ZRK"8AIP\#3Y8>%$V5/9)^I]PYC\R#,TJ^\<1,)'T-9H$OH@`-"U2A7%#L MP^5W`!:"YC5#4ID$RE303^'PS#C?"C[1C64$N(U">@AZ.8@RP&`$2";:0RS` M!]I1)N6TQDT4P':NKYI'U2`OD$KB4^`,JZ8>UR=?0F8M12BB-"( M70JEM;V;+IF/"@J?C.`+3=8A'WLI$><:WU)3"&V:1RHV)<5(`.$JT>AY6ERZ MN3VC,1NOC]"^1-Z)SU-JZI"#)<.1+GUE;>R.]!N1>3/6_R-1&=XGV%>T MT+=O00+-[N#6Z;9ZC4&G>]>^;]W>.-3UR%3^%DI`"T%P;KZP(H\ M76`O##%&_9`G:];6UCOQ0ZZ"C0+%LQ6&RG@\%F"88)(-L/!H450@62IY`I06 M(%P4B:@G*\&GZ8LK0BGXO%+_#6XZT7.`C+0/8HDL$P$!VL,[45RB2'67*&GN MDBTL"*7E,6#F8-2#]J-E,ZJS(:P`@`26O8O$S%(AJMQ@XX*$3PX55*M,NC]6D-%G!'I_AA*)*Q2N*BMUQ:WD MSJ3R>Y^F7.FGR^L=@MJ*N*5^F`=/>`G<.2"*-*><1+M`:"G-GG8Q%E?!]>G[ATE8Y;U/J&O+CJU&:#&Q2P%0BR`W&! M2M%TT'XT6)A$R)%I;U*<#PG#TI2Y(X/US4@VT)F M7-\,N@/G%C2FZT&KV7IX&%RW=!>Q0:OO7#>.6V:L2(B?T?!2"E*BB@."8B=U MZRL:E`C&NDF*;67?TL[JM@TM\+*`PE1Q-#,!R*[=:!A*K`GY8^"IGEL(EX(] MJ#C_@XJC_))Z`&Z8_SM>\G'&IBP1"S.66/D8WEI8VC7;U1)HZ9%#SD)9$&I1 M8GYSM,*,^7&:5X/.GPSYL(=!PKN!8D:P0\66A@B%C^,QQ[$#G]&98BJ.V[IJ M-$PM'G,R2C5:X!*L@P#=V">3I17N$U7IHD0OT(VDH0+E)E:L:^Z?:# MY8?JU]?4Q5>,_6[DST(6'%C*;3E<+.>CHHJNR!9[EO.*[TR:.<(0:_CX'"0'6T-3.(,RPS6)R$'Z,=LXZ9[#B2T'X MN_)_Z`NNEG(A<)489!=*H59R*%%8LX6RXZ'-FN+8_3>.>0RA4;VD=QBMY!J3 M+3!0_@4]95HK65%&?@%D*1_K;JJ)D8VTKSJF!/H<0RY`6+/CE$Q,V>P%,0!, MW5,$;FHKW[5[=:+8M_`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`8&LI'X#N>;KGGS$@ MM\R,/;.SSJRJ+T`%5=(M8QU;=&UWB1[6]DE(NMZ6YB"H7@DUK=9_B>*Q=/9] M\,2L^[0GV1U_Y%XP5^W1KN-H&H388VV%"_Q7#.B'5?%OP00ZAKH%'#,+^"-F M(:!F94S`Z9L9R;6.LOQG.I#,6>AR3RY3&?98QHD&<-/5Z@YK06NESAA^L1)) M=Y]XECJP!R)6Z,-OAHBD:6AXY5$1278&F\5DB*UHL%LF=DXT1"MF(`W\V,QZ M#&E("FO+C?,K@)ZI/B>FH&>NEYIB?9(GO$`+3PVX?&@?X'X?EXXM\)J-9D./ MNRDU&5_FD$"-*9J7&2.VKO*X'B^3=ZC!O\K=G6;JU7556:Y!LMU@DZU%HK.$ MZRL@K$F(G4KU."`0,=<1,%+LBWO+?#9BUD?5=3?V=7/6:QQ-LK#>75S??KR^ M^,&&YZKK!*@M$W0F^;H9L+K,5LV`P^!1C+@:&8"O4^UV@1*XFL6%QS0JJ$IP M-7;-U]).L?+G.I6Q)Q8:;+.'0[S;9H84IDI[X134'"9LH_:(G83,K'@L'E?K M<_JKX6/8Q3@,1K$;J5EB8*ICJV?%'+`/M>J#HV:E/8^A@(41V._C&+O^(@RN MK!ONLECJ?I41MG%7R%Y\AVX^K`:L9%.S0CZ)@4-AR[QT2H.]]`@$\D*]7,A\ MP%;:ATH10C[6PQJI\450RUUVP9?3K:$?K/&<4P4]2>7-=+-+ M#Y(SS"UO]5=]+B2(2!!M)J@^"2)4X)K&U/VZG"T)HDKI9A?%Y1P%49O:39`@ MVH&@FKO@R^D*HE:#+"(21-LGG>+D'C:.J+'8"XW%[&:7+*,#"J2CK[G]BN%> M8QA#16E4E+8MR'IVTV#?:BI**S.TLRY*P]S-/#?F^6Q/H3+KTY*B+']/YP;H MJBX/PU_DXQ-LP\QXNYC("^%J).B[?DO)K[T6C%,=2H55G8#<,-N6M^^F_ MUN5P1`&*VDE1XC5GSFL:/;O9W"4SZ;QYS>[:SVDI.9^2$N.-!;F2AX_"Y;OH M.Z>;8N`X=F-`609DW-9J&L4;M^1NK"F%/G.*()OZ!7&3](A0TB:1,&E4I1)) MXVG:K2_,ER';:#G[53:6M(,+QQA,T*VH5?KIY M5V14$3UM5@)[J\T\B9[>QB2C=.WJT[7KKDD=+E7[-((4O:[=[!QP>DC=\8?, MW)I&3(F=$3O;(BK4LIOFBD^)G1U)>F^5(+PMCZC$"H/14OG!6UJ2=0&3,4YU M3/RFU;0;YKKFU>4HR6%R?,EA=<&=LV0#3M?N-(V%`NMRE+7U\QR[1H&3L"]5 M$VXS.H4Q[^OIA`^==MMNMLTE7^X+N+J@'+DU3B`XC:W?XN75").LU* M6@J<'-C36!=(U:J537T4^`.'0>J"#63IGV!0HR[(1:RF#B&*NF"#01UG<_>K MEQHQ[=1DJ=R@*?O]XQA'VW%?JB&'GSE.71W=!C*27Z8LY#?8A^I34IJ^2\.F M^WX?OKYNWM[=-=N=AVLP7YNJ85/[;G`/_QVT85.S/3?6L4E]7&WQ$2%8/LZ5 M_^.3Q_SGJPVV7;CI3E/%489Z+J-,!@061S!*M9E`;49:0LH8)_4%%D[=#1:< MZSF/@/27A6^R9E6Z59D:(0A?JFNP/&DS[Y:Z!F3 M$U_\*YW3JL<*ZAF$/"L$T4,+TQFO<%NTF",/\A;JAD7LL`A*?)4:$9K'8^IZ21`Y$#DD+;V:1AS2A,] M$#T#!B5]3(I5$E;#]O&&)6!2F=3EN,IMULF2M"/W6[_HA([7CEU.D0 MEV-WS*4P$G$1<1%QY?=U;:=-23Q$7$1<5;@B[&:3@LJ5FF6G97U]X9X'*[.M M"?=YR#QEA;'13/A"1MA7X;&2]J)'1UA=N]&BMKWDY2,O7^Z!Z/;)[TT40121 M442#1CP021!)%#UICMT9D)0P87?09,M]3-B#CH)+WJ;ZMM5V)NMQS(FK`I3F MV5O?;O7-9=?N#<^CP#ORA-:T`H!X)/'("GEDVVZ:2P@B'DD\DGAD+7"5>*1! MSQ%.!:S!:/6C0#QBDL0DCP57B4D:]"6V[7[/6`R6F.2V+LK-,U0.MK`"T`X[ MBT1=_J.(X)1<_^=3T/A9?S_V:CT;>M;!]L%,QQ M?@;.W<"?K/L_8A$MX`+LL2<>N=J<]0Y_OU`7X.>+'];/$LF_F,>AC'%\210D M4T+25WXOK6'`PI$:;BM"[D9!**T96R3S3B1.R['TL!#V!!=*.YD0`D"R2A-5 M;'QZ,!X+EX?PX7>^>&9)5]:O\T`/&`'"AM?"YGPNLVDKS8;3LC[.?#&,Y:;M MPQ5Z^S8\VO+Y4[)"M?QA,K$%U@U\))F=DH'LRKI6KUI!DWV.->LVG9]KJV%; M:_MC[O-\&]<.IX`G8>2!CMUN#>QN:W6VYSY/*V.!%<21C."X$3_60=X(9:JI M,(9)\[]B;U&D3*>E`)\-%BH39X)\M:`\]5IUO4)J-YC-@+;4)79IP)%=H$^< MZQ-[<%(1?&"C1R'Q_4L;R%=V97TM[7O(738K$*\5I_2,$[APB0DE)^#['B<+ MB4@P#V`R!)Z.2X'C@`L%L,5X$LO(TD!7>7#'1YY/W!A]MFQ0:/`_0P2J48/% MT30(!4Z30JS%`5@,.&N)2I/C141)\-7($@9VL]FPVXU6%1Q'`;[(=A"!C+RH M93>=@=U:,W/T->>@ULL>F?#43"D\"T7R-66-7PK`MA@2.ZHD&FD*S$SQ*&N. MRI?UQ-3DM''@@04M#0X"V[2OPD-*EFYMQWY5,--K\,J17IU!O><>O>%]1[/0 M%DV2JE/2V%FV:O\E5I-W0(%0HU;?M,7XJ2(>S0A8@WC_H[X`[?8:@,(FW+K_ MQD-72&Y]"L'H(3Q\BUC$07!O>V_OF^#A9SYC8/R"97(+-X2@0\=@!G_EX6C<@AT267?<3:;!.FO!!%G`U%$'S(R;4[**]'O\4RP@Z]UBCFF-D#+Q9P8"/KW2]!Q"VGM;4G M\3Q=6RVG:?<&-)6GEEAR2CSL/'L@-CM7;7,%IT1<1%P$N+?5K$Y+@4H3`LBE M@_>]ZPT:=K-K3!M:/??JH&$<-8PISN?.8T[:W_/.Z1IT^!#!$,$0?,@=M".7:[V[/;?6.39%^$TWDS]!J17[TXV7DZA=XU.U>]U5)C MHCVBO1II600X\AEM\!G-16A0QZJ@.J(^JE:G;6X$TI:`.F]^?^[JU;QJ5.^T(N(BXCH6P%5]"K6<>NJ*U:L__^`2NVUAU]_[;W/NJB;=@85?OZ`.O7/,!=Y?/27D M*'6EOMUOM.Q>UUP'E[WA6`/\)%OZ6-2K$W)4-:X,4A\1%Q'7L0.N8D?5FK$I MKYGD5/Q[IV[S13CFS?$WM)^W-L%@G6ZIF].W&]O`O8PB5?4>ASWN@@$K@P26 M=E_"206[5^9IO%Z-1`7^55NLDNOBZ!<_:^M=GK[!"RKW(ZK<$?N=X[`7^,Q< M%S@":.&^!;^(&8LX/B"[9:PK&.*0R^>'7VQ#5,\!9SVMF().$#'/BOV0N\'$ M%SA?Q0UF<^Y+IF9FN(&,I!5RCR5@`K'UF-@L>F`56"DKV]]G)56/NC$W625M MR5M8Z*;>O'LMU-PPGN\\BM`GZC;F(QZRGI='W)DD[7/.%^KQF,=CW"4H#GVV+%;&_I"[L4?GY\B>/U'S&Y0HUC@0,'N MIO&8%X7KD@&9(&%S=F6E["HE#FN.`R*,G>)WC:OF:A[\7O``AIJ0L]F!;&V[ MU6S8K9:A@6P*GW@>AC8Z7_/E]OU[K=D\+?3L5KOW!K2@L/[0&-XRHWM4AN%= MV^DY=J=IZ#!6,/QY>R7Y^Z]_CN7EA+'YCW="XF!,,'4^CF\+UL%G;1;:`U^YN.?+A[N4'C\=^N?7^\N+#&"+Y@;7?:[M^U6H_G0:S?O;[LMYZ%] M/>@/'J[;3?C[^N'NXF]+`K4(IQ=&VVUEK;ZU3O$+CZR?`RD5^BD@UE*U`&00 MKN7#8KUTL9I6A+1"/RDA6VD0Z3+7">4:R&M>+E6LNWK23:V>K1Y>^G>`$2VM3J^%Y1U[#8NE>&5`C0S MO3;N`,XW,=5P,C"Z5,)@IL?PYN_3(X8WK@Q'^8*%@7>),`7;4Q![(WPU+$I< M9D"%I29R$^#%;9Q/#`B*&WCF!8IWXIHDC@Q&0#//2P`-U\%)XE2FT?%:*#O* M@A?X][.\?AEW&^U6I]=O*2[?<3JWK4'ON+G\L?)T=*;J MR;B*P2CVG-"`U)0+Z@&P[91RMR*QE'L9=+2H4>``&#/Z$["O:"HM[B.3.@I; MV9ROSIC-0I.4#S))V>F^'*WM[Z=?Y+>]*F^J M]P:#A6LV1OBKTGX^:'WE'O65,DC7IA]E5Y0JH7Y(&$<81QA'&$<8=QX8=\:= MLK2C-)YA5AI@016H=HX81<8JX0_A#^$/X4]MX4/X\Q;^K_[1ZTJ;Z@;2>E1C M9LY+'9[VPQ%ACZ&OV+M6WVXZ6S?+JQYHYSTUA5P3Q.R(V54W M-JUI]YH5->#9:-C=[4?; M$+=[';<[]X#G'?>#F?`IY$DA!PHYU`<^A#^$/X0_A#\4\JR5MO0_+[<56]/A M:A^\?'$"Z)1HE&BT36"M#%0@K3;7NW$3$1*1$I$6@,B'?3MGN/8G:ZQWA-$HZ]T M\G>.WLO_8JIN7KG^.OOU#0*@^J%XQ9HGUN4`#A<%?2N051`*;5RU#L<$]PIW M'@?R&4O]()6%&!PQ.),,[H")'L3@B,$1@R,&=U@&U]YZ]C4Q.&)PQ."(P1T5 M@W.N&DUB<&^3KUL>YEZ\_F`^Q@)T#CQ!OC02:AY$.,Z6>=XBGV8GN1O#[8)+ M:\H><6@;]]=,?6-#X-#%"5*R./QMESEZ*Y#:9V/E25+E(5"E1O0G/;;)MIB: M[+5(INKE!U@:KF=PNM/V'6@+CRT)P]K.>YJQ<")\O4@61T'ZA6:CZIL*1D*] M=B)4K[7O])OFLWTY&RY'9J?+ME!535N[V@0*^^ MHF9X2E,$"!-K@XDT8N"U2/M1C_LVYF"H+$GJ+7TP3L/N=AMVH]VH'$YUP8N] M?!64LW@`]_%)4EC?=@9MN]LA`JM.HIV6X/H?%H;,CXQ)KJ,F'R2>GF.L=JTN M9URU$")9<\(TT>JU;,=<;TCX.6DVQOMK^Q&=7O@*#J MU*#(N@J(U8[6R0A[JQR>,Z3NOMWI]H"X#Y>L,]"'W!-?N+A%TRZ^`K;O?$"]_>__<>__]M?LZO^B$6T^,"C:3!Z[S]R&(./";0!-'T'VF8]_NGBXPU#!?[?^^?7NPA(C^(*YT67WMCWHM>Z; MM_WF?>?NKN/<=)O]P<-UNWG_T+^Y?KCXV](1[!"%7W>"SZ8E--OF? M+WZPX4?,;<*,).9;;#P6GF`1QVRFKU,18OJ02HA:V-;//]]:[R[*W^(35%R$ MC^!)46`QZV,Q$[!" MM>[`'\5NA&L8QA(@*U5VU:8S2E>VZ7=<([-^4WCZJ/$4LZ]FL$98<#"/8,'_ MTME3$C@VOXSG15!^+ZT)DW"0EYX`MC&RAB*`%<+2I<`24(]%^+0LH6L>!KAZ M_`T6G9[!..:>WIT7#W'^,9#/E?6U>&*>#)9@"5NYO;6>1#3=N'E\W:-0YZ>R MU"0FL2E)*-7N8E@4=Z<^"!.X*UUC+#G2;FDG*GN*64#$L:=@KP^IB%0A=SD\ M?P27%1[*0$3!"8VYPIH5BMD'P[]K=FP0;$:>A?L`"1MR/`>%YV;6V&G\R#B;3EQC34;#UHR-\#`%9C):+ILCGU-22Y4L8R0,.`/: M@;CW^IT.[%31_P28PP0X#W(D1.4I\R>*3A'#K9!%;!V@Y'.0,KQM4P=^!0NV M4#Q$BNJRU4^!_MQ@!MPSTJQIQG[GV86;#A=I#AE64+^SM16_BXK8FC`95''G MZM?L<.$<@9&`ELM\EVN>!W>*$!G2G+LJ.7=7!+!U"NBI`352,`WY'S&RBFC`&W:[V37$+KXNZ74EBM(HKA`" MI;X-*E-D^8'&D6`(AA[3?&9KW->Y[7`[*`GJO"6(4)5$#7K)6)F>KM+PAHMD M*<_ATM7FWX5,5$#]+&8-4VR=I=BJ=1#DC.,"`[@R;D,B1MLM1#YVSP4CVC<@. MW1DXJ[5A>Y&^,7;TW;M>NV%J4<>C=Y@#X!T8WTL+==1"315/Y8JVM]"JNY") M>TAY)*Q`L4/0TL,8OO`2_P[RCM2(.N MSBW\A!\?V?^^,*+W#;V"JR@"Z-%:=0S"+KZX@L.!H/GI7EGO+O*OM+O,$V,X M+?V-,DO5S>,`1`L<9Z#/&T4-*G"`+B,.:!/,%9O3/KS9C(>N`%C^BZ7.,)\_ M6<#^6.(]1N->^&.,E'C*P[B')U&M'(Y$^0"SK\&`@2:-M2%LW98MP!HO,ZI37HZ+R0+F@ZRG.G?MYBQL&B@8PSM#[#K^! M]O>RW1@B[:`O&#$%Y06&+!6V)`]&&DM\^YEC/V$6!IU0[=7$A;A_ M%C#6C'RCA;#\Y+,Q&+Y8ZJSP/^N]]7$^!5GJS81;5Q-B#2VLVA![Z>E?XE4E M7$+-C\_>RCLV&>)TH"8#!H\;'1>?N(:.\F= MAH$O7+25.&I<=F:9;$*-U%;9]/O%#SHDL`+0C0D5^'E#4L6FEUQM_,7RN.YJ M(RW^;0ZXI%0P]9I"H@$JH,-U!M$JB#=83L^>]8&-*;/Q[H]N%&!7!"2L8S*F M]L"5+4(\FQ']9"RO9U%YDS'VI9#CFX(G_VH53D8-MHU'8M2$>Y[$U\;N50+/ M%N;;Q@UL"FI+@-]8^%K+T1DIF7UWSQ+TJR3,FKUXFV#KKEA14SOHAD^$K\+O MB2M1A\HI9V.@ MDI(ZHW)2GKCGX;_/HJ0-1[M(CA=)%I%Z#!0#9YY%SQ@\)UFBUH;G+(RTL5?@ MI%N?XI7U*^Y(9=[-E?26L8M@TJ^VEU]DS4"EL;C0BCC"1KDNL!5H_(4))KIH`DN.LITZ`&'0U.DWGZ42`- M8C>%C&8-A<<@`)$.A!]S"[X7<)?/D[6K]V-/3,MN-@VIM.2*J9DKQJAW94V-S=;5,]L4W7Q" M%6>Q19V-T^_UG-N']OU-Z\9YN.M?7]\E=38MIW_7;!]WG0]F&A03K1 M-H,FE9DF%.D%&JX#P..PXC=\8XKF:>6[#9G>I:+QO MM>_O^_U.KS7HM^\&MW>-3B_EM-WKF]9!.:WYW,YX-F,A?`?6HL_BD3*OP0(' MB8B>Q!%6(Y!*8UZER7@/M3W'^PRJBBE0Z&?:&MRZKU.C;_6`CM;;JL6C8=KUEMX@QZ"SU_7LX.:8A-N'@PW=]`\ M38X-J%&SJ"K;\MPFY5],2OZVW45KW\+6W#BWEU#K&/I-.DV[V30F!6I_^)M$ MX<%PXHSE([&:\V8UW9;=;9J;>EOWPW\MJSD2$[%*$/X2^)?NOIK-UC-J*A[# M99Z0VEWJ#TWF:64SFXZ.'AR[::XY\ZE01)76@#12'2M+;FVW>^OMKXCNJZ+'#\M,S!U;A>*C4GO MG:C))$YS->O\S!7?^M'&\Z M%<5$:(HLV=+&]!/BD<0CWRQSL6\/#/HUB$ENJ5YN-VK[N5KPP@*;>VZL^:J- M;;FXXZY"KZ#$W.F^LL:\?:(EV"=?8TX;//8-4N[/*UUPO3>HQ*Y9W?57U4#G M0Z#ZYMQCWYPR2-<*XNR*4HL=4WH;&6&$H04,_04;.QT408FO4H<+\WA,[50( MV0Z);%LW3B%D(V0CSD;(=C3(5E%+*(!*G2)#5:IWGW'62KQ3$ICY7)6C]K[7 MHG?+<41U6JWJ4U6/`FJ?LN8)77<.$/LB]A735"1 MV-<.W8]:?6/=CXX;:XB!$0.K"2H2`]N!@?4Z+6)@)AC8[OZPTW)[?E]65,?_MC%Y\Q38LQMK!H56U,ZI+KA2M;)`.L$94Y0#)-4QUJ672(I(BDC* M:8.8,J=>WNH/KP^2K*[`J8-\2J'\A_6R#JTYX#X<_I$?$1\1'R')SZ<#G&` MU`NB/J(^HKYEZFNW[8Y3?=3M/(CO[,-N$?Q&#I=MZ,Z@P-L2-J=->N3>)&K; MW$/;[G<.1F]U(9W7>C>)HHBBGI%?!PO`D?PB:CMS:G,%YPQ!%GMJ M>X$\TH[:=8'B<32$K4UZ][NNW6M6I(7O`[/SUB?(#TR\CGA==4&MAMWJ$K,C M9D?,CIC=R3,[C.!W>_6!&G$[XG;$[8C;5>/Y;M9C=LEY,+N=AY>D?__US[&\ MG#`V__'^CUA$BP\\F@:C]_XCE]&,^Y'\"MN[\0+W][_]Q[__VU_3BQ^8"/_! MO)A?JYES'SB3<#`SAOF!3YS0!#'P'UF8]_NGBXPPZ9_]WZY]>[ M"TN,X`OF1I?MUEWGIM'HMIU6JW7=+ANMQ[N[KJ=P<7?E@!?!.(+ M@T+6G=O*6)0E/%AV7SI=^,+DX7Z=,#WX166GI$R#[E$J%L1_#CWF,OQ M$"SAJR_&`'7K$<%N304/6>A.%U8PML;"9[XKF)>,`(2+662QD%NSY&`L^%RX M._`M9H7I45E#/"L;WN)Z\4@M!EXF(CZ3L,#0>IH*=[J\@&".Y0K6E$EKR+EO M<8^[$1_9^*85K-T'/%FK\ER"M1JVM;:YZC[/__%9VMH&45[$BL)#2C*1!NK0 M0)W3'\="&SSV#1[)X(?:F4_9?BHE,#W M_CP^&J)I$M$0T1R>:'[U@R,EF!81#!',@0AFO;\%G[\NO7"7(3S)#Y`?(#X`.D$Q`N(%Q`O()W`!!^@\-$&P.J4 M_5470V<7%\,9MO/L.G:O;:X0K^ZE2U7+X1I16^T$]!E2E].V^SUS4U*(NHBZ MB+JJM!>)Q(C$B,3R^WI=NVMPYAWVIG?M;RJXSZ=))OE"BJ\US*9V* MN@H1/1$]G2$]D9PBNB*Z(CE5`WJB[NP;VR<%$?.J02?J:6<:?"?1T\YPV'!O MF-4%?<@M6]/$'^)FQ,U>3C9J-VVGX[P]T.J"/\3.B)W5"!V)G=7+9T,LC5@: ML31B:8=C::U&R^X/C*6#$SO;N4MZ85_4+KS>[<+ON+OLFC'TCC-VR7?QN,I8;5A+$'PMCU%O\F1%WK":"&`Z\\`^I778]P0GW0KW:`(XPC MC".,.PK`U098A''G@''G7KA,_:JI'QWUIJ0Z-^I-2;S@Y:Y>3L=NM;8>^45\ M@/@`\8$3Y`.D$Q`O(%Y`O(!T`@H?[0I8ZE>])YVU6_:@20VK*P<`2>AS)*]F MPQYTFT1=1%U$74=A,!*)$8D1B17TPV[;[O<'1%Z5&6BG98=1Q^JW%%YGTKF0 MO*%$5YM-KIZY^0I$3T1/YTY/)*>(KHBN2$[5@)ZH8S5UK*Y_F/T\.HB9#AR> M?0/ M_N>TH_,--G3^"E"X\0+W][_]Q[__VU]7;KX3TO4"O#._$N#J(_`^\_%/%P]W MS8;3^>_6/[_>75AB!%\P-[I\&%S?#EHWW?:@->AV.][FX? M!NV+ORT=1A&P+_0?7G>6S[9?;K;GQGIRJX\K_9`07):"EY7`&2OKGV^0M.WJ M^^86K]V14VZY+`P7\`*+S8"((NP.[C(YM9@_TG_P/V+QR#S'@ MPSSDJ;,.8869CA MW4PU!\<'#+G/QP)OTH]*+_0$&PI/%0W8ZL*0>PP;@\Y9&"W2!\,BYO,P^"9F M\%NQ_?@(_HL"U91<3H,PLN`"K$%0_=#A6\DMX6A_TJQW@".,(XPCCC@)PM0$68=PY8-RYMV:@GOS4#6=>Q>FUKR5PX`$M#G2%U.V^[WND1=1%U$74=A+Q*)$8D1B>7W];IVMVFN M=^2I4]>YAWVI(_];RJXSZB)Z.D-Z(CE%=$5T17*J M!O1$'?FI(W_]@^SGT2#1<-CP[/LCDENVHL0?XF;$S5Y.-FHW;:?CO#W0ZH(_ MQ,Z(G=4('8F=UXM^$J&L]`=1PX)5G M0/VJZQ%.J`_ZU0YPA'&$<81Q1P&XV@"+,.X<,.[<"Y>I7S7UHZ/>E%3G1KTI MB1>\W-7+Z=BMUM8COX@/$!\@/G""?(!T`N(%Q`N(%Y!.0.&C70%+_:KWI+-V MRQXTJ6%UY0`@"7V.Y-5LV(-NDZB+J(NHZR@,1B(Q(C$BL8)^V&W;_?Z`R*LR M`^VT[##J6/V6PNM,.A>2-Y3H:K/)U3,W7X'HB>CIW.F)Y!31%=$5R:D:T!-U MK*:.U?4/LY]'!S'3@<.S[R!&CMF*YF=M;IVI]=X>Z#5!7^(G1$[ MJQ$Z$CNKE].&6!JQ-&)IQ-(.Z"_K-^SV@`S.*KQIFUM6'VQA!:#MW^=X+]?9 ME%LN"\,%O$%WE);8R1J;3-\&,SC:Q??2\@+L1:F+RSFC_X&5]9!UW?8$&\(5*@$^Z[B]KL>V]02OLOP` MP%7HSF:J8_87/H^6&V@U5,OLU8J.?9Z/(#R*WMY7]<7Y&8^FP[JFA14+S[+2=NZ)VW@%=N0%AN"OF$!4@%J:7PK-/E+4'7$(@9WXVT2 M\'ZE7`-[Q,^!`0O76UQ&(1OQT96U[SJ;EIP&872I*!9Q!>E7?Q+^(SQBIEK; MO[0+(+TQEU($/I#6/!38T-R201QBOUCL1R^P:SK*%@L^N,@M0K5GXB!-\0GZB9I)+6I*'7>Q MXI.X62-,P(?56S/X82HM[B/,,OYH&66+MIGU?M>W6XU516LO1@U'[H+^Q0#I M5C%QR@#UU,P&P"5?CGF(XFH*J@&&/N%'QW2MK?!Y%T[__^N=87DX8F__X`(3X#Z3#.UB!%Z``EE]! M";SQ`O?WO_W'O__;7U>N_#C.Y/?[G&]\"H#*%L!4?-0A/_/Q3Q["V`]\`6PB[>M;M.YV9P?]VXZ[;[@X?K=K/E-*Z[-Q=_6R*F MXMF],(9AG4K[+"TVV^9H47_$RW\4$>C0KOYFI5$D`M+Z1\K['N6I&$!HA"WE$KF#`Q*XJ>;5LMDB=8[5G+:ER"X%8_'Y1??:!?U?GP^ MWAI-0\XO@1N$Z^?>J%7"(@)D&?_B^N"$ZFVLI36L440E0Z$`DT2ZYX^;P-GJ M9TP!$=$>2)ZM>%;L9V+V!:UA24-)-#?DAP4CX5W*78LK^D%!4%DQP=/J`@K* M7;++Y"FM\E/TQA3TP!R""S+#:BT840-D,AE$)`U.Q2EYCUJ-9VBV\-C2336? MDS/H7#E.S^GW.N;&Y;1>.2VG?^!))(,J)XJ<7IW&\@R+Y\FMUCF-F\'4WP]* M_>H\W76"SNN1Z+_W$4!%X0P2:!]WY3'-`$HD1,>PIEAMLFT%8#LF4)%P*(^* M(>%`PF&_2E#M]5PV5'"XIS:+4NLCL2.R::$%$V.S[&R+"_42[54% MBQ;EC9]^4E$"DBXD76H&*I(NY;%.)%U(NNS>8'Z-%VJSI,B"9HE_JNB`2N+U ML-;,0;GZ:)8$RQD&X/&'%^("KQ@,_DQ,X;E(03FV$(3`[?S;.`RY[RZ^YHY> M>>V/U$=/1Q_US5F$8HMXPZ#9&S1:SDVC,>@T;NZ;SMW#0QIOZ-[U[TX_WJ"! M:Z70M0KP-.*T-!U5^)K2Q(KQK4:V)]N1\5"*D6`A?&];3U/,#]$N8#3>W72S M25QB'/L*GPH_V8I*H@08:2`/+@92"[F<<^T<6+U3!Z6!#G_U!=[W)5+Y+R/T M7(99^(%_W/+>CP#L`CB7GLB6!S9WX1KWSN#AIM]O-)N=0?O^8="Y[C<5UVBW M6XYSTSMNKK'"(U+X*1S((6AI$-J6SZ/:L@I-9EF>2)8;IU$8D7Z2[BZ5N"M[ MJ76:1'61IA.+*SF-AKF`4ONU`:7.H6?;MVHXV_Z,6CK?)`(=9.0.69H'M(YJ MGR%NKL+@%`H(G(9C-SK4RI#\5-O![]K](Q92*%VY+F[0-^U8T^W9[88QCEN7 M8SX\F9R)_'[8SMJN@K1>:HAT.OUYWSEVIZJBN#W@EF-A=9J!<43=>D3(:R7B MT;>9*JCDNY1XU:HL6#]4F=*U;91VN-+@-X)8%8W*NW:_VST8X(X"CPSJ-N=< M(OQ+8,;OF/E-L3[.=>-9K*,`8C9G(E0A!8P@<)G4!8_02QF,J2;W'&IR"U&" M)%BG"E5DE!5-*'>U\L0?29DV>=8/XEEW7NM:;_7V]70?W"=?;U\^;?#8-WBD M>:!&E<:*^SN9Z=UMS$AV.;9=J38=X'_4%Z#/72?)'K]*/HX]ZV94TK(N*6?L/4&3>5WSU0^,#+^/00;P[I-TSJN55H'81]AWT&P[[I@]P+J M`5S^]7+F)"$@(:`I!/SEA=0["NV]C):?6)3TMN*:DB/N3GW8\$2U\O)'UN]^ M\'0Y#9Z,J9#5`O9(?-R=J^IG21,#I4RQ"M'J*#+%VDV[83"65/?3Q_NH,3;Q M&N(U;Y'`T[&=MG,PF)QVA@YQ(N)$Q(GVU'J:77O0-)>]5??3?ZW6<^[Y\;>Q MA$7R4#L!,$M^*N:[9,K7S(]7;>[\E3'"(E%UPC463L/N-8R-H:L+JZC:P"22 M.&&2>->TFQWCW/.\[2`BF!,FF+[=;ANCE[J@_N&U]1KY"BH='8]C7+!CKS'5 MO9Z`JX#.KHP5P]8(9,?+J$^GJK-C#\P9`2?OB"'B(N+:Q9[HMP['M\_;S"#* M(\HKB37*JJ#XPM;Q!2!9'Z?28N/=*%"M-GG$C]<%4NUX["MC"B,QYQ-V#K4& MY!HB>B!ZR/.OS#6L(:6?R.7$R:79I^#TJ_7T&IG%50+VO7\Y#P.72VRH+SE. M>56U02,<`!/,=VS^1XZ&/9D1`:YR#\W9M)L$9A!Y M$GGN#,=^TVF:PT`B42)1(E&2H#4ES[/OR?PUB)A'OIO#F$L$GUW8D:&6W76A MM%IUY:Y/X+'7MKM-, MB!@1,:)@\-$\D"8P>?-1#Q3,U:-+#828]-%\YZ:%S\#$! M-)>@+@NM]P9I\`(U>WX-!-5'ZG5/V%]X2`;XJ`U.O^]6AY^%[W^\"O M]G%^ZK59O*_MV/U>];W\ZW+XK_4;40Y6C?(9:H]MQ&K*0;.&W6^;B\]3QPOB M1,2)B!/M47KNV(UFBY2>RBRRTS*\7MU?_'2K<*E+-+G+J#"]K.;V&\9:2Y$J M2^1RXN0RL/L#8_E+=4']PVM<-3+W:M3*(\H;VNQUFU0L)+\=MMFMYML^V6LA<3149TSL-O-@S6*J`OVD!.P1A+L MU$CJ#?HC$5T179T\79&HJI6[D7H:55Z?77LKYG"%VR>1F]+K&77=[@VSNJ`/ M^79KFB='W(RXV39#+>Q!QURJW:N!1NYT8G;$[(C95<'LNAU[T.Z]/Z/^,CZPN>1ZFADM1JJD=%J6\"W!::QWDI8>2SG MW(W$(_<6!D^[:[?73$)^8Q1LVMVNH44914$?F`]A(&+@U?.")/G[KW^.Y>6$ ML?F/?P^"T9/PO&M_E#<^NU9]S^Z$=+U`QB'_"@+QQ@O+C#P_COUC^_WEU88@1?,#>Z;+3A6Z?9:MXT^XV; M5JO=:=ST!P_7[6;+:7:N.Q=_6Q(W1>B\T.IKG8A_5EHUV^:DE?Z(E_\H(M`I M7/W-:B^8-L>L`3^2NA->'`%V6!S.-Y@)UQIRGX\%_,A" M(6$QUC@,9E8`EX9I+SWF_A&+$`A4^!:SAC%2\(?OJ^U>65\!QK/U+-;49X:R.$99@/3(OYMCBD.$IHW8%YQ?[^GX/SPAOM/!TW;1C$U,=FZQY M*)"9!^D:\2=\;O04`.KSN37)MI]O-^(RNK+>8TM%>('0".4RR>WM[M6@U,BD MGF-FIY.0`T:%>K-Z2:7-[K`Z?'.VPGJJT>_'NP/;ML8BE`D@R@#%;U9!BJ/! M&9+\DXBF:Q'HG?!=+\9M9BOX(<&-[5[Q+'[:%GX/?,35_`6>LFZ?_)N0<'.J MERR]!/D-?HT,*%I8LQB`DJ"[I4`',$S7MX+EOX)*$F:7Z?7DUWC8!4T!..-A MN`@D>OY-96HESUT&VUIP?"_SW:$_*5V1AUQS&99`%NG%FMNLOW!28%\9BQE9 M0]!W/5`+6)12_,MGA5P?9+2/\!"`GTPQ#F;-X]"=`O4C,W%Y]EPXKA3R('B4 M'"B^A(TUK<*Z"G-A_)]3B<(=DHX)JW^!S['04@=5-,K"V?62O(E**@9%V1&K1X M+&.=G_3=C4-@("#]0C@!VP(:D4&`F"20ET>AF$Q@!0`S_HA/"EPW#F4NG?`9 MF]YG4&TNZ[[;:LS+G[?6G+OW3:=U/[AM-SKW]_?-UEU[T$PUYV[C_O;D->=" MOV8-NEJJT*M=I64\_`VL-L7^BMZL0K?I^=;=S?YBN6L+\O\"9)%6AVGCE<$+ M@#P8;$&I1H&2S\#3*J9WJG&LQ'CWC;I2I"6#; M>*A?)KK>VEO2Q8XR[5$@3YDQ0%P4K3(2,X7;L>3CV+-P-\BA\%&IQ6_&K?P4 MF''9P=Z-/$BA#N>^M0!B7)4RK_*"5L'IE=]IFU]#.^$ MG`>2>1_'/P,M_(RD4+PO\S1NH?E];MNY:SKWW>M>JOGLAXDFA=@D?H30!-@P:X(0:R# MI/==]87R)O#7KQ=G M+SU![SE]`%"@0J\P-=HS:93>CR:Q/C/T690>Q4:P4=#&DD<6=K@5_+(WP(,Q MIC]77VJ`9NZU')CUU`->UOF*R+Z%SJ>1&/U*:US(B>=8G05Z0D$<`ZW`3^@\ M'Q!N#Q,G5S*]UIV9:'&IOQM+^FZ+-'_$I_7 MD`$683$!^O-1NTXA%<^5N3<#6>X*@'M1LP]0O$_0C`A"T"#G\&+8XZYR>Q_)6Q;=/JR/ M?V7?U@0#MW%.7-\V>T[SMM^\N^T.KN][@_ZU$M'MZU[C]J%WW")ZC2L"H64! MN'@]I2^L#!'[44@E&6SZX6@EJ*"4\M0G#TQ=QPD1?I_Y!/EXG-R=/!]>AP_@ M&8VE=(M4%8>A9G.QK]:DC"E/P-^+?.F:B-7#TD6"">,IA?[*>CC.I!B[!(LI M&UF_7GVYR@Y''0F>&;*0;PH.`!)#&4D=N]\UM0NM5FBW4Q(?]HM'GUB\N!]`RBJ!V$G-*#A?7_RIW5EM%[X7VL+:$[:Y#D='6L/23H1P'H3*&O'0):4S#V:@W]$ MS>J-L+1`GX;PT%`R:>'(`,5`:5C'(=]`DIG*9'LS2=9=4UZXWQ:,)0CZAMR? M:T1H658=7K(&6WV-/3,]4!/L="<"=$SP\J4'RHT6,%B2GBL!5\%U2-;*GL&H5UP.&#@ MOK31U#'+OZ6.69>'$0->6[H,W0OH2\00781-,?!*0]S8L3L=8RI)R(N"13E+ MD]PZG&2./N`B8\X!,Q52N1^!7A!&B7=7YVJG^9S*2,]\JAAA],UD4: M"2DPO2QHG;\I>32B@4X7WW`FF$211$%2LUD'M=,5P)/7'N6,^6S"E6LU=0[+ M-4G2VF^[T!ZJ+'58HAA3J7KH#`X1;.D6UKS,4DEK6;BG&'('F:T]4H5,,Y5W/3M:L8WS(8D@D!@^F*'LA=,9B3&\ MFB=A`'T['\5N)%2`ZL,ZL"EGA3N%RSQ8P/N%LE9@;=M^8P9$EQ*Z)DBG/NR=FJKPD"TOG(;\`8W2Q2F?_ M@M[YP"^@9K^9YM^5,4CQPR'0LH]O!2U"A-R8X=)L-%>[W^ZG%7Q4+%VNM[@J M0>^!W3*%W3IQ*$FG2,2L2L8"$:YB=3-4WO11)QP^3SO0!U3(QI-)^#7PD^R2 M.1.C2\R#8'/,25'9$DO"+9?F(SA@-W=1R7@(>"98B,Q\RAYY]LL:=E-5J,+I MKIW*M!\)S0*=HZEEZBA0TEXC]LXAVFW MUXU&[S;-E!KM*$'YJSENGH.!$BA5KQ;6 M#+38`(CP;HT66;Q2\)6DBSP,FLI!)154T@BJA"R*0C&,HU1L#D$[7](9=>J( M>@@8`K[*9%`"4VN-Y;P>1=^JTDI]MV&-.GE1Y9UF(61E/S!E)(!$X<"PX%], M#=,A9,5)4B52"^,R8]D>/#/.D`K3V#?WF4ZA3<+/LI15"[S*4W;/D@J1Y$^I M5-'MM.^U^;K*AL)RFMU<-P*_+6FP_*N5*UC(;$KVTFYZDSX2ZO7 MUH.6$4F^F4RJX``FZGS3O'CET5-ON++^L6I?)MN3B$A"3M%X1`&B,]T0$BI> M#U)IO4655N_HW+!-6FD\*SP)T7J=>0L/&G)E;L42%X+X];F($>N65:21)#7,8^$$ZT23 M$](8LU1-VVG\*7U_]MI<@[C-&FV)=*DM<(6T#34J)\CNV_ MQ:/)+*\'*Z=\:8U'ZBP8CE6M0B6+%1*Q`SBF8F"_Z,=8U9/2!Z7.LBOK$Q"+ MIXW@]-FL6/D`2Y3`S@`:=F+=:Z.#C=`7KLQ@Y'_)\UZH=WA&OW@^S0LS`X-P ML5^:5ZO=;MW<-6Y[SOUMMWO7'ERW[G6:EW/3<^ZZQZU?K-$F$FC55)5(5I<6 M$V7NMG&`[!C>^Z.QA1=:9;D<47^;XROUA6ND3Q'*TZ4^%U_K!^&,>646C==D M#]:ZB0LDE%SSTT7C0GV6<^:FGW='O!FP-.'K1;(X"M(O=&L_]K'56;GA M6G*CL^]]K4._\#0WN%N_<>KKOT(YK3?HZ_\"+-?`;WN&:414;?`@X_/7-?M; MZUFFF1.$FU7@YAT8?TNHZ3R+FEN/Q*51L9L"2O$<>Z*`*2+1GM+%=+-AN`AV MF1UKG.PW0C^A"Z7TU7;2B+F.P*]H^%L%I"H816.WNM6/"3T*K-G$YPZ&3&UG37E M6GN25UT.NFI)3P+]A"FB8W=;QL9GG`I%D'V_J;L.-N/"?*\J:,QGKNJ1 M\7/&%.'8@QY1Q*&,G],83&^)K;+S:COG]"A\O\M M?KO9Z]RU[UK-SJ#9[_4&VERLUXZSEC%J@.&E\)-1AI?8,EP7T:KN+E'2+#_IS::&`N"0P>")AU<6QNTO M"ZW`\YWE^\EFT:G:F\*2<2%ZN6/FZNI=_146XB;7%;L9ES>LIAW(TBY5\1TN M3#5>4V7I8;+\*\OZLCH:0&95ZI*S'S#0^:IXDYXT_.\93-_>*DJ+7GOK<>D5)-?;Q:W\)90MZ#^P*(8 M\&]QQR+^%=>Z"_]H.ZUV\Z%]W7QH]NXZUZU>_]ZY:?3ZK?9#__KAYN:@_*.2 MLM-\6,_2X-.T$\HEH-VE9*IL.8,U"(X4V-@O2E=BNSG0`;T4U(6NQ3;53*WJ M9C>JN1J3216<7*V!.[H*M0K*S]JO+#_K]PY=G768`5/! M5G`@-4#55"T/WM*[7_N`82W2;6MCV0T:=K];?4IM70[_L-[_-PN250G":]TI M.6$UH)_`>4^PZP,V$ET_F^\L@V>MKMWL&LO#J,OIOPD!G8DD5P$T\@@?@>0G MC[!J#=I:;>A'+N$:NX3W]>9L<@N]]^_X,+KV1Q^4QPOON?\CAD=\X6[BHH`? M;[7K\&O($-7UT+O]&AW=MKH/'>?NMM_OW]VT6^UF]UXW.FK=#SJ-_N"X7?5.^.3MU=:N)=[O)"+]&*?TQW M#AL=,3:.+142M4]3#6N*2'\FAD"-5W@W]$\(5(E4B52K3NI_JS\ M!T2K1*N'T3$GDY!/6,1K2@X/3!3<6#A_XOF54B^1E\E(S7R;(*'Z>M(''\(S M,K_Z6_*>VF=Y4(I/.537M3M=8UV,:G_Z>!\5J=6P2(UXS>GSFH%#?(;X#/$9 MXC.5\AF--/VFTZR>W.J"`<1OB-\0OWD[&ZK?J7YV0EU._[6\YMR[ZF'.HZK\ MC?3\UQ%7`SSW\8B^V+FR`H_HVS;B,]=T["78U`5=JA;M),'/F)ZJT)6)KHBN MB*Z(KHBNB*Y(_WMS>J(H^NF5U-8%A,=1-5LO3U&K!KT2ZX(_5>L*->)DM5,B MB)T1.ZM/0)]8&;$R8F7$RD[57T,LC5@:L31B:6?8A:DN^&/0D;9=HZ57M-BI MI.?T2?7(N>/N/]U'4MX917^(U)\]K.C1MC]@,L1EB,]6RF7>.N2JJE^"1DTQU M$#*.+C\0%R(N1%RH>L.JU5J=:$4:#_7-67B) M^GL071%=$5T171%='35=D?Y'?7.H;TYM0$BEC#M[BCK=[ML#K2[X4[6N4"-. M5CLE@M@9L;/:1/F)DQ$G(TY&G.P$$@E>#3#*-"!&1XR.&%U5%FBW86[&S]GK M;5LUTSG8PK;IU%-)6YZ'(+1F08A=[^%Y:,QY- M@Y$%5U@C'O%P)GR!77RPIT^I_8Y0/78DCZ1M2"$ MQ%C`?<,%GB'P>'ID4*9ELE_2%SZ/E?DD-U2]I-0%KKY-]8FJ] MNL>47&V?1.V/?KIHO[+[4;]'K67JJ/!6*6CO@*D\B6@J4"YP:P%BS9060HKM MR>?8#AIVOTM%17MHI77N<54E"*_'H&!FK`;T$SCOR13_Y?JK76JGMTZX.+J$ M"J?5M9OF0I)U.?TW(:`SD>1'G#>1O$TIW[5-^#D.EU85H#SAYM%'@7GD##-3 MX#-E_@1,,B<+/&C(I)"V!0^-O0B=:'!CH<5UTM@Z*#WMRD)WSYJK MQDM^NN(*GF#AUCP4V&';6U@L>27>%/MC]AB$VF^1[WEILS(>2OY'C,UK8#?X M(N&+"/UC\SB$VR1/%B"7>FP#?*;LD.3X47HWKM52Q%+H7T8WH<8E-OYEO M.4UK!F+>&N-@*/Z081.2"F`V5KX9>),7J*I M(>`XGFV5!X(EJH5R,%ZU=/`V^D+DQ: M3NG?GZ8<-PXOAH=IO[\G?N?>0I,B'@+\$>'O3T)Q+]C\'S'"%1\J.7RG&4$* M3KADC(\)N8M1U^S<\FT]3];IWW_]Y7?-MCE^IS_BY3\* M,!6$J[]9Z1?W91J$T27&@116_1S@6O!3X>R,,/.^:5X>'08'D1+^IFH-4HKI&PR74""]8+EX@(N&RHHG48=7L*4JZN'5OY:)10 M2RW)PT?ARX=I98B<,4CR`3;&H?!#-87P&G!28!4 MXJ"*O@>`C;1@LI>%00(,3\Q0!B0S76)?*9TN'`_(%8"&XLNX,B7G_52P[2HH M-O/P,JOGX82'\MJ%`](**`H-$!"I/EH0%C*3%EN(`>>N<=]]Z-PYC8=&O].] M[CP\W&LQT.OU;SK]XQ8#*TP_@:/"JB(PZ\;HMQ5B'[^)B+O%K=1M)^H^(+=, MVB@!8R,+E3'3>AX#]H#H^BEEJ]<38">*&-\A_:7Y#LU&NN'5*[-KG+_\4-9\ MF9LH?T:D&H:RS=@Y18489$@<2>21BFU.&?`6E\WQ[/$ZO6L;`#6'(^;P3+C* M3?8'PG(H`B^8H,<(/H&0C'0N1."AJR=6&*Y@$G)@V\"\DO<4H)2EE/3^@AZ! MN5;(48KA^8Q&(9JZS!J&`0,9A=8VKFOB!2!O+.X_BC#PM=$Q!?L^TGR;34+A M@KD>AV@)3)F'A@9//`$L[2<\RFPF+$ORNL3K">C7Z+$Q7$1LUL MQ,&HY&@=*F!OY`.`YQ@AP$<9`IO=;AN"FC:EF=8;0*E2F)ZD)1AY@V+GB\LQ M`-C,BD=LD>%WSL%1T4``:^UR#1H;/H-VOV&WFX:2YQ*B19Q;Q5;3R./8@S7C MO?=#'G2%(K),N3="BN#2#8,G5/S3\U`\-]0B15D9^,6<+?#O9;78'+YQOJIT M[+5#[4&UF(J=)WNRT8/[&THT(!D0XK&;>5\EG)A$=U9B0Z$L!*-(S+1W##/A M9GYN(,T86)\Z5S!3#6(?/77/\I.K=5@2T+_4^)XRXX3[[;U MV6D[63$ZX'D\#%<$Y!$E-&I1KYWV,M=D2C(RF"<;6^>M9[EFJ]A-R2F?0PHO M12!A8$LGDV8>2-"J(JXC$/7TS7]=24!6%C4RHJ6#CT#QD@E*8*:H(1[5[MJM M@1F?^)6E=;OE4UO=WSJIL8$G"VG-`85PAL1(.YWWGRNZ+9'$4I%_HI`[U31W3FWYF"YR;"E M]-N*6>.Z'2:YY\ MN]'S)\(E36L'+TDL>"^0=?NFQLT49>SKK/0:AP[(:D&57=(V!W3[<8#X*\IZYH+QV7:P&EVEA#R0FR;;;@8K" M6%4VS=!5DM=_#+G/QZ(:]?-TS+MFV]P<1S+N3EYF:;\_2VBND+1#P@N)R3$6 MB:[+@9/HJG"60%J5&_)'[L>5*("G(ZF<)J5YD*3:G;@B]JUJ0?62J7^$M&9W M^A7ENY-/XXR]F6O2O,FC66'=BMUJ&_.FD$.S8I%[]#3^"X\.$:\X.G$ZZ-A. MDX;3D+C<'KA_#X(1-ATGF_#9VG/';G8I.X5DU*YZ:*D=5C4*DJDJ]&-0G@Y7 M;$XUY?O6E!\#'AED<%0Z;K+D6K613G@F7%:L\DY[A9;::S["W7#O$PZ?P0F&.4SH,0OB7\S!PL;H-%\]`*`$&5FJ8U=PT2]0+5*S>0\C*U85\WCE#.=47\&LV1X!$Y94`-F`+)(U0"$.(I5 MPVXYM;#[BFJ:C>\&4(V$5/DB&OS8Q#`Y7CU40"9PVPH2^(XX#.%O!4/5$EE$ M_-(3CR6(9WCCP[:8ZP(/P<4L=(=1')`SY+AS6`(P)7UXJ>9:@`->J.=4Z%:G M0P2NZL"*[\`>J^BDGAGS(\(W6` MAGK1?^?8W;:9QIV*VQ381]KA%D<@8=]:3_6ASU"CV'L5!RH)[-0[X3['3N^* MM8QP5(>,4%5[Y'E!3-*K%9%2046H1O:%QJUYNU9\8:$WK,(W[#9N8KMZ7@DN M%%@`3SL/.]GR_0#^#K) M4%.]I55=$K9E%DJ0(\9D&*>ZBF]&I6107A#"QO61X+0[G$U3.)BD5%=I?OG` M#&/=OWN-GMWOO,DP#-O[N6YFKVFAK)IL:$;=PB]3*G1EC4".N4TP.I M$18UPMI)U5^KO%`LC%(DJ9?YEA!IK=?V*%'CJ(4T]3(_\MP\ZF5N#I8;#%IJ M95XQYZ1X]%:MS+]?ZCO^BF;FRX_:HH4Y+O0P7>$Q?@7FM,YB87WJ6=C[AG''*?QN]E^I;GP_<&78?D>#+L M>'*:K_0\=0[C"#JXY^D-[Z,-OIWOD*R/?+FM-RAK?`&6S^MW+XB$?;(65G(4 MWOM"I1/=9VK``XK8?Z"(?4MO+"'A&2'A=:Z:$A:K:#X<,9B\+#L9FC\//6@@<=1_P@2\1L5D^H1X$[Q,:(C=4$%8F- MU4G/.@J4>2WW.A(G+`T4/#2!.=3OACQT>WOH3HX<*E";B2Z(+HZ>+DA,D#.= MQLY6E>LYJ-S(J0MFD!?F"*33Z5#6(;V@1&)$8F=(8B2\R`E7YQ'/1T=0K2:9 M6N1Y(,\#>>2(+H@N2$R01\X`;-\O%P.24?,L<;7L/C5I(9=!G23408=EO>U\ M5KMGD/CV!1L1)Q'G.8J^KMTAT7=(G]Z)S.HYP$2Y*@K^ZCL6$I3006>U%WU5 M`PZ*=$BT2+1XC,J:I<$X]NKL36R'*N$[;6K!GI):\X6JCD@ MV8_/90KW'3(>R353(]EX,J1%V8Q$8D1B)+UJ0EJ4SOB7.YZ,>0KY(_=WZCQX MNIDI!FFH+N=,OH[Z")NCHP?*8"2Z(+H@.4%N.#.Z%@ZA+TQ+J,2@.9MO82S)GTB32)-(TZ3<[+=[1)SU<26>2!;EFC%@ M;T&HIY4PTK<[C<,1ZSGDBY#CAFBQ_CHM42)1(E'B)E@.[&;#7/,>HL5JW;=' MK]_^PJ.#U`B=C(G9[-CM-LT9(@=/G23DR5"78P\&1%Q$7$1<58BN'H@N8RW# M3YZZR/T9_>7O03!Z$IY7!6$='?TXH/KUC87EZW+$Y.JHCZPY.I)X9U1A6SWV M7??_AG3T`Q$,$".59$@[_YO)YE"QO&M!6#T:N'K/H^\LM+`6^$<_2`"(,VYBQ"- M`M@B8,0H=B.U]W$0JAK<>1S.`\FE;85\'G*IT&X>(/H)YEGC.(I#=?(>L$0$ MI<*YC[\SGTV8_[TLH"V^)%!#@\=A+")XI$9R!5F@.;P;6TS#L[C",1XQ3^KI M<0Q>YXJY.OUAO`!V*6'E8BQ<2RY\'DY4*44H%!Z/PV"FSA>P!C-@ MH(OO->VL6R<\Z:J^S"-9/X(N5H721A#DNU9[M4Q_GPHX+T/N:8H- M)!XX_*KQS\RJF]U5U_=>JQ8R9;C(E2W)/3C9B6U-..`6XB2BX`AXI9`1NDP? MN2(='P@#K]:]>(D1VFBVS=&&_HB7_RB`8PA7?_.D M7ST,O)%^]+4;!7_GOOA?ZSK'4".[Z<-FJAWL9#WP81BS<*$.TBZRLERX&SE? MI]'XDS%6@,N<*2244S%'V0J*!W`"_"T_CE_^8;V[R#Y>_``LW[J/<8@H\T&Q M`ZH#;1O):`*"6`3S*0MG(.)CI85;"=G9**ID#(("Y0RSOD2!^[OU*0[=*9/< MNIZ$7!/A.UQ4_KHUEUS\<)6O#D0#*!01$.NL*,OPK9ZZ&C83A]80-!\5:/1` MH*;RIB!2+/;(A,=2T:J8-RP&&4LB0_%>!K8`BX)07N&RLMW@BI];L,8'7")0 M>P+O,HA#[G+@6BA(+3:!^R:H59E260;=CMWJ&>+%$HXWUUQS>0T0!_X&C\-S M1;@9DGQ-N]=:K9#83XSX6C6%?T']G((>J4\;]=,7R4"KG_!]["W]`ILOB`T9 M#R7_(^8Y:A0$KM:6I^P155;0(8M236M$!<$T!MW(=X6F+2VB3*H^E08Q2W9. MBBS1:FC3`GGMRZ2IS!.3AK"FU[3;O;8AY?SKNC,L[XZC6>5Z8)'@I\T[%&A# M*BT=%66.KKY*#M3%-X0;C[3PV)*/KI$^18"*XNO/Q??ZP,*85WXS7I,]6+D. M+!?TL^2:GRX:%^JSG#,W_;SF!+Z*&3"57_B3]3F8L17/)UC=$^'K1;(X"M(O MM)M5??,D1M'T1Q2/J<=&<>RYY#^F?ZR@?+[N8AI"YL5IK\T=V2*10:WEIXM^ MYT\O^H?*+JSD1F??^UH'>2%UR-K,+FY!P)CR61KUG]<%0.9P21ZME+#=T"/$OS-D$N.SVMWU1QRHZ),7J,#@/!0N?\FSF+UK ME+A(EUQLVE^3!Z/+2UYJ?J$ZTQ<4P5WJ6=D[CG-,(Z$N,Q M#[GOHK\Q>D*78PX9%35SHQ@#:*X;X@FE4;-JW(SDE3+AE7*:KW1+=0[C)3JX M6^H-[Z,-OIUCD4R3?+FM-VBN]@(LGU?^7A`)^Z0:K"06O/>%2H:ZSR3?`\K; M?Z"\?4M7+2'A&2'A=:ZG$KH@.4%NZAU@^RGD%0'U%S=.1`CCBB"Z(+$A-OZX<[D6G;2QVW*K%E7FA`8-36V;Y-WZ') ML^?8_7;?F"&T+U#/HH\A^2@.X:,@NJ[*ATC$3<1-Q%T#XB:A77-M_;1N M"Z>/>HCZ8Z.'LC_271!=$%RXHT=H">@:ZG& M_S@OE_M23ZS$,I`A]_E84&+B"WD=37-#64X]J>.(*.YXY=7ID-:[=M.$&KGKM@5ADJF8*)*%055DCTVP:5./[#'R M3Y!_(E7K.L8L)E+>B%I.G%J:'4IG)&_>UK"]XV,>XLC0D#]R?Z?I9F=HY_1: M3;)SR(50'_%T.J1%)<5$8D1B)+UJ0EKDI=2'5Q0=O"2N-X1A7&5;K,[8ZY.3E4JT0>B[?V M6!!9XWWOVGUS_H[7@G2GB/-1L`+*)22:KQW--^V&N78^),HK]I`>O;;^"X\. MT0GH^*S>@=UJ4QX*.8+($93>9U`9)7H@>CAZ>@`1T6_2=&+RC6X/W+\'P>A) M>%XE]M/)9'FT;(=&.I)#LD["Z72(RZA/D4J,B?*(\K;V['7;Q@;FG;Q8(^=< M&DIW`U^*$0]5GQIC^%/R#+?FWZQ1$.-HOM3)6ZU7_0V!^MW!07A@B%60=MVT MVSUS37]>@MM1H!&YCBK7$8B!$0.K;6XO<3'B8L3%B(N1&G;4#*Q@9OXY4HW7 MUUQ_L(45@.8)GU].N>*!3K/QIQ(:.UU`6J.6YI1G^1^66![4;LU#,6,A/`1^ M<[UXQ.'?RWD8N%Q**^02]NA.50O5$7_D7C"?<3^RU1<1/'G,1&@],B_FT@K& MZJOL9:(AS/8^,B*)>Q573F+O4AN'E6JV&;34;3L=6E]X&,Z"C!<#TDN,# M&;XA*A_.BX!//F>P5+L2D?7$I.4'EA?X$VQ>YL.S1GPL?!'Q2T\\KCGY*^MK M85'P%=`P7@:O@!/BXQ@3_<<A_-`X(/61`01G<"5@:!#^#I>[7"V&^<"-Q5P=[3!>`(N5\`XQ M%JXE%SX/)ZIF(A2*`L9A,%-/`T0="E^O/<'>Y%R^UV1P[4;!W[DO_A<^1]R= M^H$7X*.NZLMQ4L0",HQ5G:Z1$_^N[:PV4=T+=0#.BNZD0+!?AMQ3A^8&,H+C MAE\UJIA9=:N_&O/<:]6`N0F71H*V)/?@9">V->&`7#CX#W%P!*Q!R`B=BH]< M8;D/.(S7:V[CZJ-!%$3_(\I^M7<9P3\SA>.P_V">N"6E)@>XU<@>@+F_R#"- MO,@,<33;YHA#?\3+?Q01*$VN_N9)OWH8>*.$?D(&4/_XR(#P,Q0ULIN^84I_ M7^2T[;*26Y=3T";4&+^'2[Q(D>$U4LN?EB2X/"6_'K?5`XP752L9#"0=1V'A!*]7OF3*@K"%:3D753]L-!>T-C#WFNP*.--?C[.06 MW$G20E$:8XC?.7V[V5^MH]C;DC/$Z=IV;TUUQ]ZK\GF4^A+>>8&4/Y@#X#M@ MRIW.:D[2&T.PLV;DTEY+,FHW:$^+.A%0P\PLL&2&&'ED9LOD\02C1@UZ(M"E M@-JGM]"FA:'T8R"H?PO@[8O+X`G=EBA'Q4@P ML#?*-APZ1@V)NV;/[O<,^2:LK^M$?1ED'-W6KLK,(ZH,=Y M7G+-3Q>-"_59SIF;?EYS.%_%#!CF+V#N?@YF;"64/&/A1/AZD2R.@O0+';=6 MWSR)433]$=T2:33-!>"SN>0_IG_\93DZEJ^[F/:81=C::W-8MTB<5&OYZ:+? M^=.+L;MR%#&YT=GWOM9!7D@MTC=SDELP>[8-B%:1T5'[9&5SR0@O(93Y^H<* M"AO7^X$H4YT:[6YB,(E#4ODK=T"B<_B:O*Q%7_V&EM36%5T5JNBP2K;Y2 M4VN#HXK$X/,D:;=:YCH'DA@\$S%HF(=3*`[5& MS'1N3FG)2SU95?QNS4P%3)5;FQ`D).PX>/+3-"`=!%/!O0.$@X\NED>!.@K4 MU4`"4*".`G4[0&/074W"(WN/HG2;%*.0C7B2AX]RE")URA3IV]T!=7HG*;TU M;#\G=:`JB;]J>CHA!Z7==*C_(Z)*=(3FT+VT\A MGS,QRJO[T8D48*$;":KGX-89D%E%8FH',L-:S6AA8YU\TGV'_Q$+U8N'1!?< MUW1LIVNL<5E=SIU$5Y6JWU(+,I)8SQ)8R^XU2&B1T-H:A!]1#:R0MHZ.A)QV MCP34X034:>1.'6)T*LU%5O?UV_:@;[UY_.Q(+/NA?P.A_+Y26;M:M,E-%?(%B7A MA3Z2GK&9LG4YV68Z[['%EQIR_=UK5\Q$CTV'#GN1W2 MCJA'5I4@I!Y9U"/K659(/;)*#:?R`>-)U:UJ@[5V)#L.0,Z&IJ<#LW%XZ=`3 M<@K&O7YJJ866N@?>DXY&Q6<%(7[T5..F;&1V=&59SRQO_ERUU99+S@;3SUCX M.\^_3]Z\]"U..I>ZYU>AA!)6[O%'7('P<0ZAEBAZQK*:H[-(GU,8"H@S!Q\# M3PU'%=@!"\D4P:#&+8TCD^`SQ\U)#C>I.A\(BHP#?SJ?:/L.,0 M[TJ'L*\0\CYT9W`T9Q28F[5M9D4+.$Y`W-2$28]-37\=(JJHB"#R(D&:"8<1S%H1I;#J25S/C, M)VP.$1,1O3P59%;SSI'4Q%Q39KP`,8<#\L18N)9<`,EJ4@F%S(Y;,XW94/@L MG2):[O97FJ4,GXM45].):^]]5(!_BWT]H329VPR<#8^C,+H4H!^X0@%+75/< M9CY$S;;^(=C?N8\CV0JCZYH-IUD>\CUC"SS_`*3#1#T44'?&?N?9;-7D.%'S MAKVKB=-ZT*M61GR/`L!D M/XA4U;\;)2Q[Z8UJYK=ZC*8.UP7=#T#O`6R9\LV#\F9JW*4?F`%@-C(\F@J9 MQ1(6-:6UXIF`>(I#8U/NO^NM20O>"Z)J8B".K`86`((?KE>,3+&T"Q!@! MP$<`9:!)%W"2AX]*"0J3O(/T+`K=1VU\J.;[9C;;ZAD<,FJ(*?3-S.7$)JW% M<0=!62H>`JS7K.)SSCD13&21_[ M.-/R>-N:DC^(V@<^#&,<-HJ#?33Y8/QF(=VHDG/0&`H M6RF.X$3UP/$7Q\Z#G-XX^]2V[K_Q&1A/\`I$!3,T@6&0U5CD?E21S&DW1K"M M1L]N]`S1;-Y'.CW,8MOGJ]45[X..S;8Y=-0?\?(?!>A&PM7?/.E7#T&5TH_^ MP$?`9OC,NLZYN9'-],V3U@<&>I'B*.OIR@S>8#MH8X(6EUFDX7*S<$!UR4%) MT+D1P,>5#P]-)2#PH'PQ/"P]*]MZ[[M7UKN+](N+'VS%2D"1!CV9^Q,VR77* MQ$.@'"7PD'M_!$9S%*)!]9DGG@N4,;?83AL>>O_Y5N(#D4NP96,H(]'U9+`\ MNACL]N!)E@X+]H5\*`#]"-@7F&'P(UAIUE"@%;5`_TZ$>K_25CE:XAS+6T`A M`>"@3AR&3$URQO;?E]K9A)X9-NQ0]B:N*^L:&!=B+"#LHG#,4S9*IP,4<=B,#O5D MR$*:A\$,%HF^6[``"TKB#&N9S5G%O<9J%?!^FEP^S#TM6TL5&ML:!M$TMR:4 MMU'R*$*G4#R'`TNG,91H]`JXES:R$R6IR"Z56N0#2U0L4*)-!HJJ&J]@V''@ M].SNP,P8^#+=BC!E1DO3ZP)@/6(VC)$S%C%TK)SLJ?.<+3"TJ7QOZ-E!KH7^ M5\VOX2W`%ICY"8(J$&&&V)K`2`VATJI85F=6WAW'D(?K,:G+*@T5^W/L`"XMM[GE>^7V97\S$2;GH>C\299-3-GDU+E*:N$P3E\DU2:[)^AH_Y)HDU^0.T*`&A^26W#9% M[0#CBX[.7]*V^TV:`G8HX7PB%?LT8>6`Y-DRUU.#!JR0?*3I*KL`I;LFT9>$ M(UFN&PB(!JN\@M0H<$>B:COXE8>JI.67)+#@O@[U`"9C;B=C[E`-@,F@P_MZ M76/3),B[W/MTNQZY5R^U4%4,5??T%?XEW*0Z MNF)%N&K.H]K'Y0UGTF:@V"T.4R15NT,1\4M/=4M9?KQ^^R31A])WJ03/C>T[ MASQZPL8#JVTZ"]T,2KUQD_KUI9>)8O]$W>7N^>ZE-6Y<4%$'PF[?4&>7%%-U M(NUEVEA0=24TWTK0,=6/YB!]^ZILVW>P9GUF:.,M^J']ZK-X)/!$;@/,G<;D M]$]A8#U@QK3UD#4P>9^W_S:R5]/MTI8ZNQ0P*LF0Q_:$12H$Z2"D&TO<,!L& MCURUG'VVGHM)1!NM;!D5U1 MTF],N:VHI)\PM("AOZ!6?5`$);[Z2JQMO0'6KL+25-;-(9!\K6E(_/-$,+%^ MR&8L-D[(1LA&G(V0K3;(MC5G(RWOE1CH=-XV%_,0"/4IC214@U5G5([V68\7 MW*4LQCARU3Z1CYJIE(J'6G:O0UF"ZAB+<43YX2UET(G)Z!.FF$X?*,:8^"&* M(8HY=8KI=NUNOTL40Q1#%+,=Q3A.S^X[QCKHG`?)4)3ZF2Y5'EA!5=#6Z;37 M05.HT:F^0>IY$",Y.`\@V$Z(^,"JZIC3$8GXB/B(^'8QT%J.,2<@$1\1'Q'? M#K9>UW8:U8?.SX/ZSCW:E=IZ%HNB4`QCW;$C"E3?$C_P7;@G#%3?)FP^QD,N M:4J;NJ_O&%,_ZX(,>%^562HDL4Z8'AS;:1GSAA!%$$4WV^0C)^(CXGN#`%7+;IG+4B?B(^(CXMLA0-6RFPUS`WS.F_IHK[YW)`WR M:[Y!Z@U(W2E?`T'UL^^OE$\6="'&K0%QS+?AWPEOBPA5/CZC8P*8&K<>$ M:M2@E=H+[0B-EF-W&M67`=;E\/=R&Y$WV8A,(U9SWJRFW[>[S>K#6G4Y_->R MFG.O[:!.9L\F:#AVOVO:Y%&1[4B;3K@*O16F$5&E/E?9O6UG<--?OHB[H4+4?E436"5-$RVZ:&YYR M*A1!IA;5459C@S7L+ME@9(,=CT`[(>(;=.Q.G[J=';"89-W??_US+"\GC,U_ M_,##"0_E=2%S_]H?W0DY#Y*/\+<+XB8&`^8K;/K&"]S?__8?__YO?TT?\0M_ MNG9=.(0(X/DI#'SXT]6%%Y\"3[@+_;_9S5@0@.#[S,<_73S<-1M.Y[];__QZ M=V&)$7S!W.CRIG/_\-"Y:7>[@_Y#_Z9Y>_UPUQ\\7+>;+>>^VWVX^-O2<11! M^T)._;K3?+:DH-DV5_RB/^+E/XH(T,?=D`+VF6.BF;>PWDL9\Y&5`]@J0_A9 M5-EVAWW#U3WO_4+E"9ZOK:SBAZP8IK"=+Q'S1RP<2>LF@'^L=Q57N!1?<>ET[5<7U*P>C]K/32P!?*!QW0:S(6Q"T<6/ MUAMCOB[8">&0!/QM#=-MNODV4:]D>E_JIEEA M4W.]*99O"MX1A4%:/.4MKJS/#%X=VGEY$+YM!M?#I6XP\6$_I0>,XC`%9_)X M6-K35+A3_8@9KD2JXJ\1CW@(&^0C.RD$2^\$"0`KP&(CL#VPT$M5@#%_D=T? M35ED/06Q-[*F[)'K0B5<49A4D\U#_BB"6":K2,J^)K$8`0IS+(#2+\$:,0U, M/P;$3JY6Y5C*ZR-FV7=/(IJJ.K5`\N7K\Y(T78=V!_2OJ`=I1U,0WH[[`:;` M1L%<'+9<.N)2WY:5V5T88DO%Z0^!(_Q4#(`K,"+A,QF,R MHG$JXR'O_4>`3Q`NK'=?@[EPK5:K\8-UN<)$"EP#D3:[S3R_<)!?(-K,P^`1 MA']2?5FX0/\R*N`]HKI<6C%H96[LY96-,AY*8#6X@5EY,R*#0?+#R$*6HQ\S M%J'$"KQ+_4<0PRU`5Z#XL0E6=DI\'!#/F],BR!GUR.77%B@E^[P`^L-:3'Q: M]IR6KGCLE8D6GN?&8:C%/G]D7LRB%#8).2JNE7SV%%0UU%7-+-PO$P$)V_,\ MS=A.B8(?^##$TM&7J+C1K(R*;S/H(=P32NX[BI*O`7PC+<62,$#YZFN?>0LI MS$O^1O,%2FXT5RE9RU1WROQ)HA^P9'T:S1B(PWD0*A2$/8EHH<4V4`G6)N`6 M,P$,#^,H2BP!^Y@JJ5I`,\L%VXTAM2WF7"W,XQ-`.?54H2NJBX+),#W;)%RK M)\T/3%%E>R-5MB\'E1%E4N5AC<-@AC07A0!>C1/6+>!L,`,+US#5P7Y2HEN_ M6\0/UV,A"$JMS8)>ZPI@VU+A=*K](E:&R?H5TB!9@>H\;> M\0&_7GVYLOY^??U)+R+[#>0FGCZ0B86B%D](?O MC"57-D#9@LD6%@HEIA6`W3*`W13`:ODR!JJ1?)2PE!E*[42J94]+MJYH+"68 M91Z`5!.$`NB6>2@.#R'?"QT)$D&O'KW$%30]1T7N`/A_'4^0.;ZD7K;?E@92 M@=5M=%%@W?$Q#T.`3-)SXSZ#\AVR;2,44U0XVQ<_V(G<&:E7\U'!7,/W*G&1 MK":7!WZ1K(8+8)R)8@6(N\S+>PI#4G3`\TM./Y=FF_!`B3VU`KPM.]]E!$B6 MEQ(21TF!>P-@2`%$PQ3`*T-6=(*:!0C)U8\ M)0Q<+B4`ML'U8"J[.M M!P]XS0C^^`"&D0PD7;[^A'P)],^EQ]QP;R)BS23_,_8G\`#%.H"'Y3XQ M4%U1"^$AT@C`L;"C$4#X$:D=14ZZ[N_7@0>Y0DUUUZ\A@S5^?&36W[F/1P'V MPL]7MU<**E_BH10C`>H/'-F[B^Q:C2*)214BT@_A3Q]5FP0ZR,4C[DY]A1!< M'W^@;*2)?D\!&1"!6!2!JC8,.>A.888M\"CX9",39R`Y`\2KX,G'YE;ITA;: M2Y1@C9+WH&K.U`^EXWX?/)70Y`-H)T$<"MOZ^+O'IL!W-+(`TP/4>_=+8$H% M:!EY"BC;@-4,3BDYH'<7^N/J8>00!DX4/N8\"MBZDO?%DWD9N-FQPPKNOW&0 MD2"%"]CR\RVL)?UAXVJT'NL#57*.BH]\0H31+O41_JQ6F"X=5\Y"=_K"ZJ)I M&,23:=+[#)WVRGO]R%-W>@$W['PC*8]`\-64+C.,_J2IP/I/$#WHR;=A0RZ> M_OM/__E>A8FV(XTK0'/F,Y!:UI>@M`;`4-4#DW,";T)$;$D*1G[^\1JZV9$R[T_\;2I!7I@ MR/XEO#IB4CW/]5HQ:2-;S&+N!9M0MR=:[=ZZS_/M'!DTIBB.]TU@:T?`'B/O MZ+;^9,93A_[O/V)V@Q;D`FD$J"&3^XN,3,:!&TO=F!*L7Q3;Z"%(E3CT>@N_ MH`%;#)[IQEX$UF%=$2HB;$K?T7',8=--QDT+R7[X%_YG?0KF,>J%MQHW,O$$ M=\%/%W7E/FMM8>6/BI9\.K)H"V'Z!1J*PM>NLS!SYP78#A;UF8O$-W1U4<^= M@Z$K^D M5'$N]?@LL>>.2S<4VH'ZLB_MH7'7''0;?:?7N;OOW3:=WJ";IO_=W+5[Q^U+ MVR[]KP3(>J;YW29Q75`N"]'-<'GM!6_2C(VR&KDYXLU2X&8+>D1G2>"G(6AE M^";QI:5'S0N(O2O![(K32P2!VG&T^`0Z<004=O]'+.;JAKT.IY_EQ]#P?'+HE>.M8>I?7>X-'TFVWOI5)U#IZC8C: M8!GC\]<5O*ZUF*D,G'"S"MQZQ&FJTWI.2[FYB85. MN%`:SC#YM*^6<[HMG'IVRW%,455=#K]J,4W2^*0IHFE.SIP*19`1O0&P#W'H M"\R2)Z]S-I"Q#@50_ MN*_5M1N.,\<3SU!C MZ]J#`9E#9`[52$R=$G&U^DTB+C*'MJL,"&;S&`N#L&;WB25>/1F,(_Q`"B'< MU[%[36,$59=S)Q.I/K+G""FB05-PR$+:6L3X,@JQ2CNI6-7==9B4/)*Z@W

B M;W>[YJ;Y;KW/(Z8P(B8BI@W$U+#;`V/AJ;,@)K+,-L:NI/P1AV'%,VR-R$?6 MB,]#;+F8V6ILAKVX__5RC^!]5<@72C]/1\5\U^S:[:ZYL-=K`7?:`Q?)_CN$ M_7=&Q-NL0.P2\583E.L?NV!^MD?1RZV5]L;$%F#B*(BQ7=!K>B_4!8SFRDFW MA=(QE)6VFW:S8:P"[D70U`49R"2O7'$@3D.AW;CK M#]H]Y\'IM]).X8/;AG/X:SJK*._R^8*K/_*YCG-F4C:^,\8 M=A+W]1QGN#;OUI^H"R.<<2!\U7=\=&7=/;<:-7^3>6ZR\GS>Y>&JC3"9=)Z6^_>= MWH)&2A;7.;69;KVRS72_6^\NS$>2H%.I$5:+CGM'`9^*73T'Z>>[/20/T=OW MGV!@;YW.3.D)S[7KK:)+;XW@=V0^W/H`KC**UC$2#;M^TW'`B*N.DD^+8,VV MH"1A?/R0JH`T6T72W#HC@X1L5>W\CE!@'!7]UA.$%1"V4R#LK0O=SEWD[M/. MK+[BXJ@(\Y3ISZE0YZTG0ZMO9XTCE`Y'1PY)Z.L;_.F@S4ZB,0+ M02$YA:_@[R0*E,5[QKP4&+*2\#B;SSW`2PR?>/@>"R-@=B&./>]P6VK M-;A_N$N'!=_=M!H'C8?3C-TS"G[2C-W:W41S-V7_2$'*>#JW;RDSC->7,:FK&["Z!"-L,9C06G&+IE71$R&B(EF[))E9BQV13-V:<9NA34Q-&/WI"7K.1$OS=@] M'/'2C%V:L5NO>F/7!N^]U6R^FT[IKI],1>T[DY^>F)7T,VXE8!AL\>]+8[ M,=WW4J\RS%=9['7IAGPD(@L.6D\OC0+5_A*SPYB_^!ZNC250'4^&&ZKVCD"/ M+`I"%<+'BW4?2O@M#J7J)3O$.85JZB(ZDD)\^1Q[SXY0@<4+F&\Q[*^IAB3B M/%8DZ`C;T3(7'N.GTPF39<#]CX(_P0NC?$'9I19ZK"S`>A&,A&L-&>PMF0\`WZMX91-J\9WXB#2\48KF,QE+G-`XXM@;%[8\PK?C+,4YK`D)*`0ZB0$V^#OLZ3IY%\+D"&4`U#]0RX*)@!6.#?=``FPG(* M^!*$""[520NXM)@KQV%V''``8T0$.%(\/`!+NA[+A?,>>S&"`CXA[`#-W"GS M)UPA4?I2&SZ,X'GAPBJ>4/:*PIJ>I@(V,&.(&\#B,'UQ]!M#A]Z#<]=V.K>-FYYN_-MQ.O=P_7&S M\A7&G0#/4M"SBN"K&P??6A1-18BSIX&.!6P)J?1Z/!:>0'Y0MTTE*R[R=S$; MHO20UM)&D*1<4&@8$!L;`8\5./D6)TY;DH>/PN6:/P5Q=!F,+^>`[CQC]/F8 M79019;DVY%/FC;68B0(`;4+S*)Y6;R_S#1IC;VR&N/4$;-?(D[YSVJN)/&\+ MI>_6]`OL&U]<<&#I%JO.]KV69)1&?35E^SQ)M(Q]SZLSVPH3 MXZ,PD(UK94X-N%B2(F@0>#(Q;::"CZW[;_";$B,?04R"A+'>7=S>?[SX01W` M[90)5&73:0`W`8/'P8<[T#2USIS\DFF2G\#\"%%-1%2P]6_W'ZV1`*,GB!+S M"U1AN!YDBXZS(XJBHIQ+,HDWV5K)AH\(^=B+[)+PR919,P376=.@YJUY@-TV MQ#E11R^!O&@"&I;@N/\M^$051&DG=F>BY:2&U\B2S&.AEAA#[O,Q&M!L/@^# M>8B:80:&,/!XV>3.;3PTC1,#%3'Z27B>-6=A^G-J!N6J%<]HB_D^6K^@1H&% MM8+^&.*"94V$[Z-)"L]!VJDI@_F")SS2YB=L:01F5BPE;B-,C`F@_35:>!DT M"$"`Y2]!9`CUG-7TRGT>8P;H;^2#RXPWP,UH:MW?WBK#3A@T?*KT&K_W,\1" M'$)*P;5K_Q&Z&Y3Y448M%!$+?>D""4>[0XI2`CL32!4[ABNDO@V>:B<^#N4# MRKY-Q9.2.O%\'.(V@#7`VH&7!#[/?$>*RYR`U MU=)K*A,`&3XP./7JL:'9Z]N]?N78<#V;>^+35%@W(I"NX#XJI;=!.$]I^=U% M>LG%#W:)TH/0-JJ9RVUCZO2@9T9-4-X:]'>[J<:#:\=@239#<`-RF3,.6LW5%):* M]I*BCM:,_5BI\?!;LD]DQQ%)#_L@Q2J=/ M10(M1T7"QX!?\=CX>*QM#.LZGL0RLGK:UZ$ADK&+#`IYB"H+I8!V4JK[36P4 M5``P]5$!?PAF"@90Y)3S2"L,+#\*4^Y!4QX::6Q1&\94&?,FU51NWO#H"7'D M@0_#&.U3V+"CR*GX3;42];MVR^ZLZ9>S%TH`/OS?]Q\__>?UYP\%K?K*0J/1 MH*UGT#/ZHBE;MEN%_\B3X"K0<[K7FJ)7T8VAYGDI+H26B:^,0\5?_A,#VA/N M"W=9PRG\$H1B(GPUXG?&L,?WJ`2$G%4AC6I7I>N&L08R`!NDA"E; MHGO5^),Y4P*]4;,KZ]=Y*H*\0*(=#-1;.//OK?>?/N*.TSEMZM3M)-,E`JU, MRZ>E/=M*GTA`KTFHB&)%J7IE76?4A[Z["KF<8_=ZH*UV#85Y]5WE#O\6^6_:=9'SK8\@2L+\S)UG,:!L_E%$9,X#0 M0>4I:K`1,]#]S).\)CNW=N*YL?'=+5,,`]7\W#\6@!Z,>5.)+QSSCH9*AQW% M;J0==/G!)$@VCI%YVI:,A[_!EE7.4Y+)L)167*-,J]37@&Z^5=U8?0.LY#:%7#JAGZ01XQQA3E M7GYU.D!`/B^PR'R#R"A;M>>-;!)RK21D3+"@D9<.2<'ACYAY8BPXSEWQP50& M5F2C+C?B8Y5VFJ8BXF-UJ=@H5GF>QF*<4GR+P&8S<\I)A'0<8.IDNLSC'MB57N@`OLZ!38% M)X9*,%%WV?*!>RQ0D5D:2L&XBA($L)!\;2Q+"%C:!;+W=P*65#LSX07!5%/] MJ)PUZ`83'WXWYEH$=;EMB)$9S(9P[.;`D.]*N66+P3GT!_HQ2`FP"6?+0;B4 MK1AY]UFG.2ZG:YC#CLX`3+RZP>V[YL#NFG1742)?31/YWB+EXZ,*)Q1S^$VE M>BAQ57&NQW_%@(&K[NUE1V6FRB7N2A8^*B\3\XO.V'&,3;OG&$M)TM23"ZU; M-D<@6E\P79Y/5.K'SS_?)KF%)4Z_R+/'@B>?AW(JYKD1ZZO'LJR88#6]\BI[ M*;K`X%\V](2<:OU6+Q8?!PHLMY*H,F(B5Z%S7,X(A)`7J#)%*YBCBA;[VNY6 MVMM[/PKY-Z6TC;$0#5UK^H7*:PFZL\I)&_(B9)2N)YF7/`,M"@D*'-;5*(X" M>C=^5GN#4P0P@#()LE#;[*"28^D6G.._\NS__$A@FQ?JGDNXJ;3BJPOK`6N7 M4+=?\)#<@ MQJXZUDLN(+1=X*U`2PK;P(+Q1DG-!5;$96HXW"V3Q\(QICM"T">AHI+Q!%M/ M$2"WS@MI5/;2<27P+=?XJ;1'A*P"">*CKAQ+H8*_YU!8XT">!$F+RO_U-+#V1#X@0:+SO?D"5#*&U"']9NJ:TRA ME:()LI`LV^M:EN,1FD;5N2GC;!,Q6)N)09=Y;D`'(_8%\Q"OF.7E@6/. MTZ+,$J--61#\KNLZ5P/?\$TPR\L%75>_5Y]V(0J.!:5ZBA"^'^NX"S!4"2+& M+)WN8+6C]-LK9SOE41\B0KZN.G/KLLNEYU-KJN\]RB3//V MNM%[:-XX]XV;=JO?N6XW;@9IQ?W]S=W#<9=I;J'Z?2ZJ#05`&M'^JJQP3)E; MHHZ$?(*-%X,D-U_SB=A/W#")[0W?)0%W):LV:DQC);&!66(P`CU67'$@E/K* MJG>U*BC^E15^NX'$K*;/FQY9+(!4CU)U!(*G=?5:=U1/P==O7!JP,(F>6J^4 M=HQNS4NM2AF<#K>(D%5Y>%< MUJL,Q3ZJ3N$RYT=(\QD*"W6,5B25R@_8Z#GDGX%"^?QQXP-0]USP*$LHU+78 M2A-"1F)(%;([/4.IQ@;]9[:S9A2I`:>/TO>+\$>5=<+!ZE<)/RZF82*A@)6\ M5/..1C2:3:!%Z/XF:0,3."5@P[LK4B\J1$L*E')4?]8^?R3BW1L6M>[O6MO;]MUM[_:AV6YTNJGZU&]?-\Y`?5)`M`I0K+WFI)$S4D5*>O5@)@3Q9%IJ ML).9L`E'*3O>['SSY*+5S0Q+[SX!FLB08;.OB_O;V`HN?\`^9%`1K10.9 M3O%%J*`E5%)^7V(4)>H)6,9#I;'D+PFV8R'H$MXJ08!^E.F&\(5?\;%A9PE]*]<-`5(`A-(&N^D_AI\ M`+SZROI[RB8TJ\\\.)$R@`N`2?U9>=WHLJ4MT2!&5Q7H4HFMG06#?\00;BZD M4GF?2?BTN9*,9S-6M-8+T6\,N>:/R-J+Z`>HGB*I_K6QO\=F;47#$'A`C`V4 M=)R=C^$>50:09=#F':90W7036SZ!S4B]8S5L#PLOKGR-@A.GZ8O,G6)OHM0& MR$^ML%A[V=+(T<-"R_4Q49!UF/JQ"+-@P3R=^^2C^J\=OSDBA4*1@S(PR@2@ M3B1<1S+UUU-5_4-Q(QN)/UK,L5.AI\UVI.X96"AB#H*3>_H:&\$PXAY@?*CZ M.16MH(+%DK`):6_&N;1#@#XI#-2G`7N&9EH9%].+RP7=@'1@6(Y%X@8MKDNQ MS&51Y%(`;I MLA;+3U9-O?128]U5[K=X-%%89%T7+\;DCD(U*2NOI;P4W5MM:?O*-M'%)@D_ M+C+S')61C_LZ6."/F(=$J7O-E6KORU[,A#,!5P!`HA>1)5S8E[65I\*)82I4P?:SZGZ_ESZI*&#A_AI*C=7A3@JL(-6O5C9\\ MI?^K(KDKZW_P3-DC$TIMM5.`K[DV!_,2_A0:^,6*T$'1&!5;T`4J4P8?R)%[ M8P3KW<4_OGR\!_T@+7PKO4EI`/.H`6W;7NHN!+8PM?%CN<5?A@"OK/;IV MA++^U>_^+H_5#UGR=B!/>LT@XGOKN*;" M(+^T)2&+V5>:9A)$984T.RQIS=M"JI6#GHFLZM)3'GX>38,1*K%@]BFQB';E ME*L'%?>%'21AK3)`!%GD>*M3_T!.JK9M2@=+9<=(>WUF()&Q20FJI<6E##TQ M252RV!^IZI"B'RKI<*!7HGRFF^Y6O0]2I4X)""2MRU0A3,)LUW)Y/[HKT.J6 MGEMI0;M4K5"7C8Y44*T&N%*\3`\PD63%P]#"#)V+.EF28T-52VAOL*NE]3;P MK*GD*@6=EV*9N4:"F?VI^3(N=<`H*^!+RG=.9SH?%Z&\S!U8XG7&=W_('OM! MD4!B<>AC0CI8?>^5]:O"TW6W;SSN,A--V-CD:)4ICBBO%1B2%^V7Z="00P'4Q7KU"QD-4AI2,77HA*GRE:POJ7O$V MI=P!OLXXUAFO,RTS#O_CLSBJLT30$99@Y$\7C0OU6N[-)K?87`EW9?:ORO8/=46J\P>6U6+A*[H`*8?*Z5$9PZ)3'[J#D'?EWDU*F*:'I?(,$AOFN)U M*2N(EMLB),H$*F,1G^%=^*\L=JS3+"17G^-(I4#H'TM^@YU6^)=MSW=C)WTB M[>,D[>;9D;;6]=!5ZF'35TQ2P\[S!3)1`2>BB#.EB-;9480R.A.#J>#B29Q) M9>&D+5V5#*#UYT3W+WHZ#E%E3TE@7C2HP^\K38C9659;0SURO,&ZV& MLE90/H2"\J_-?N448;/4F"_Z399#-S6U##>F0>5]>=$?5'(:8LJ25)[+I=`1 MQM-<;-"K%)DL([ID>6X98EAJ'UK*(<.(6[8\W4%1^-HWI3+<4_4J\0CDGNV0 M%T(/?\$O0PX"A=O64I1,%<`G+TB$#D^GN62>GQP;KJP;[C)TU9>>4X[EK;$] M2TZ$U,66O+8,VN6H7N8L33.#E.=I+%1^"3Q:A;^2^LNU]^7)02KFI\KUBX>< MNI+7N;P*Y;7KC-_445/"H`(4DU$Z20ESF@6?ND>+C`[-;4PK'>'DF<0#D3E# MQRMQR.R%:4E$8(%C3 MYRQ,F+;Q3)869\Z*4FA^95$8DX?EP+/JR1P>%"5AT@L"!_Y=*N3&D\R*9XON M./0DZ72:)'Z1PP%I#>?*I!B4/DQ-1D),#)4!][R_L@3:)`KB!R_>K`DX\9"6 M/6$%1V@>D-X@(O3'&6P;-S'B8Z[BZ"DSJ.=9EKQQV+JO@1ENMCFG#,9"F\ MEDP)*WCDTW"6*J?/CBCO.!ABH4"8AI,4%]=YIX&;9'FHS>G\:R%5PU,OD)JO MS;$[8<8`TXE323Z&9O,J)@8[6!NSRE,HBHP]SXY(1UBM9^T[Y\Z]D`M7RIS[ MXD[Y*/;XQ_$U`&(6*U:O:B@1[T(^177?O;[NW*J^N?7/3Z3P<=A!@%;EHF4*11A93,&8U3P5`:J1ZXJ'J MMJ9]S_)YA_.^]:FNJL';!F0EZ[.1/D7X&(%7GXOOU0/]RF]N%`W6G7P&.QSV MC(433.O'1;(X"M(O])A<]8WV$S@-@$PR%U2)W;GD/Z9_K)BEZQT/F:W;7SMA M?@N_@5K+3Q?=P9]V=%DD-SK[WM7*O,_]F MJ6K'5TU^?@&6:^"W/P9W9Z7#IG[^P1,*W^$4CP(?_P_KLOY>/P&B%RE*_M7'W1^3]D\$W04 M!,4>'L]W+JF8^#<>0$(=2O5;(8VZP/4[4Z![$0^?`V$%D%(H;!14S<'JU`33 MP#H*G-G$ZPZ&2FQV)Q5LE"!^"$+1BWU(^8=]= M:&>[ESC+1[_%NZMEV6::+]@<^T!R!PO"/-V]Z]CM_FIU_"M9?(X4N^[_#?'F M]>DV9*2?`<&TB5IVHI8J_0;]8Y=57]54P&WB3<;4HY)7K`6*T"B(,=CS&K?8 M<>M>QO7*Q*Q-25Y^)$;"BS$C\4LVP>S^F^Y*C.FL^/18SQO[ M.+Y/^K,VA==QJ=_GWONOO0ZE_?=&X>5-Y7Q^E<#[KM@^9] M59(MFE<.SX,(2Q55QY\4O,4)<7D>(D]`G6?_L6'PJ)/($K"K-#+U%$R#5!O" M5&C,.Y_D([3C2+6:4>621]YFN9;3,'3+C4722ST_0*R.N4S/F!+WZINXUWUE MXEYO[S2SYK$DTAUFH4<25JB='9$MM_,&R4HU2TTJ29Y*O8>$>-L[X`^3);>] M:?#V>$KYFH2)M<'$BM(SL3%`C?Q_51K\'U6+2G/Q$Y-0JXW/R6G8W6[#;JP9 MCFH:3G7!"[R/\@3KZ%X_20KKV\Z@;7?7S+(G`C,ET4Y+'5S>*3WB M*$+W8$;U.R"H.L8$U?Y0/HIH/!EA-16,1-WK3+A.MP?$;:Y4B8A[2T%N(`/' M4-;,AJ2<&^R5R:6\=O^(A50MF^3-HO#IQ;2;_Y<\]/^M>=3U-R'_W[?`_W\? M^$C(B,_>^^X'%4LK).O<7`\>.K?7=[?W-[?=7J_EM/KW>OAAW^DUK^].(%F' MB;#@I#T5L.&8$],FAK8V;8':Q*;]WE6,EHG/UX+Q\,O[4Z-D7$] M)K/YR.MW**25S.C"5J4S"H/=,CE]2Z])[=W5M2C6KXVN"]*N2:&*ZEQ.)\9<@MD,I\BJO.8= ML.9TRX2=@=WJ]LDU2])Y*\!^X5'D90.9YF"-"BEQI+,?1-505'51]D.36J_1 M(T%5"0%2$-&,&Z\N+M$:Z\S;@O#HG<@;_$B5>9"/`8W^?_:NK+EM9#L_)U7Y M#ZC)BU/5=K`O]][<*JZ.J^0EMC-S[],41+8DC$F`@T6R\NO3#6@7*0%D-]@` MOB=;E`@2!V?]^ISO"/1JAP/%]9'QM_X#L9PE5_/TR+*LVW( ML#Z9^Q-C-)\9KCD>3V?SF5_1]YN>%_B.`63X$!]HZR2P+"'7>J>I"@UCUE'V MK",078&CAP,I&P'J`M1MUI[$TCX4R_TJE@'LMFE#UO9L#\!NIX,T`*>.]YJ! M@$S@V:]0%XG7Y^!54XPGGD3UQ[IGAN,K*D^\MU; ML,IU#+=]L$KJ2,:1P2O/)+8GAF]+V;9&8%?`KH!=*5=:`KL"=M6@[C:)9XD; MJU/]X0.[`G8EWH8"9D/">@]4><[`KH!==1I"`'8EL!ET>ST+[`K8E2#LZCM' M*3Y?AN]I3)G*9"?/^ZTLR[-U],`QQZYW"V'IWJ@/M/E-(2NB13$? MM6;?JOQSIFS\(:3):L5?BC@*0[.<_4<+M77X1\(^_?IML3W%!SO+4G\=\E*$D;F`R(#1`:([/CQ&1`9(+(&TG`M MXIKB1@M4?_B`R`"1R8"9?5`J(DC7E^V4WJ3J"Q:M'V?R,BRJ/W.[IDX,<9LV M$*Y>][_](##=72VK$L%$[1B1,`%@N,2Q11,8#@;E1/![\K[Y(U!K!U"%,/BR M21)+8+C4;SL:D[MNLYWGB`)Z@B3SMMEUB!J*[_.L>=_/Z^ MY5QG)H_NCQ]O\E..)R^C^Q]'FSC:['/AB*--'&TVD$:@$R-`]W^+17+G'0R. M-I^\SW&9#:'[OV=!&MW_'6_"1O>_0'AJ1V&+]O_^XU93>II_B+,\+3B->O8J M2O4`;?*"R=1U@NG<=6?NV)IQMM2R7]_V`\JV/X%&( M?QZK)RM72B[,@\)E8' MW1R0;D[IXJEJ&B^J9NULO^N5OLQ2X!-?,Z1MPNLRC3^BK2L/S0*7?S1R1#P/ MO6NMJ<2`HR8\S;`]C4=ZS3Z+> MNZ-`@_B.L*6)JCQPV=$90;C7%A&8+BP"%7-=V7[.V>]DF$Y_)IML'[N&4!HJ M%)7Z8UI>`--JL1;J_,3@XR8`53(^=>?D`V(8XBQL",U`J)Y@2SM**YU8KKC> M_2$8$PJO%T(9S3)M4:0I9>_=)"F(EE['-JSZI^2#3Q<[9&;=C7!],BY7(!]" MWXT+M=C36HQHJ\,"VA'F;;J0@H'<98\C=B\0=@8":A=4Q?!?\%\M^B^?N&W. M_G5!BP3F:X>/^.V:T-LQT#<+TYCI8?:%IM_X%/\XS*+%*%Y.HU61T^5W_G6: M3/FY8W_NC:;3D6'H^G2B>_I(+Z?\',,9NQ.CTU-^WQ^.\FG5]-L-A5)6SODM MDO6FR"MZI>1,.^7"+.F7EI4XM9CFVBIAJ>B&IA5M`KM@6K[WF;;L\PWSBY32 M:I\-$XR02VIK]N)%IM%XR6Y`R"5WC,9L'8'9ZRMS`0BYTM;1AWTN)'#PLX95 M=&/,4\(,I^$>.,1IMTZ3U9EA3-P@;A!CN"]DDOY^^85_4&5W]V6](PPZ*C;6 M^+W,?CY6^<5T-"_?F)Y5[L*VGFO>FRM MQ0#Y%CT&6P&4K4UE$X8X0MF@;/!L4#9EE$T2LPJ3BDI-5#+3N_^.LCQ)^;UO M@==?QEWWU=46!=L%(U=&6/WUCM`X:!PT#AH'C1N&QC7/]OJ5U'TJUGQ/%=," M&:HV1(U"L0K]@?Y`?Z`_RLH'^G,,_*OSLTZ?;E&O,,_3Z+2H^O7R1/L0YRG] MJ?J@D^KC>-W8':3,@,`;RR>F(8Y%]&"AW1NL/#$*5[K_`#1Q;$P'S@[.[E5G MYYC$,\6-IL/9P=G!V<'9*>KL#.)YHDFFX.S@[.#LX.Q4 MZ]>!YY3&R3J*<>2)(P<<.:@C'^@/]`?Z`_W!D:=2V=)OY20%76HA$T)X3JMF M_TQ+BCS+PYA_:_*E('4M0T8*8P41JJBD08^\0R#.&Z+ M;+=]M]$#07ZG\RC_JZVZ]Y/KA]6O1S@`O:=JWG)%51Z`JHS?XD0FX2A4?V>U MYP3W.N[LAO():_U`R@('!PN@[,].#@X.#@X]74, M#FZ?;MUWN@D'=YQ^W<.75C7:0K5KD]5ZLTJN*?U&T\MH06^O0Y>39+VA<59N M91JMV!7*_WT^^TH7R7G,;G_)/C9*V-]E#_9EU=AUY9G.7)]88\>R',<9!6// M"GE(>C%Q6N[MV7BY'JD[<^ MN.RC.*+LJJ1UF)Y'T%HL@L'4$RM:5K2-0-B@;/!N4K3/*)FF? MDGI-Y#)/`3@4SJ';39HLBT6>'=.`E6^*%G=>UP?>'%/<2(OJ#WYGA=F6/@PX M#L+-#-O-B*-<5?VYP\O`R\#+',?+>"[<#-P,W`S<#)(9);Q,1T[?VL!FLJK/ ML0DV4WO,7_+)L(QA?5$FI,ICEAV/$79[;`Z.#G.`.<`<;MYGZ<)`:=@#[*'S M]H#P(*2N4`C2D"G;KS1C4EU<5$Q$])*ND@T?[I%A2OVA#S.)*9`TI^]U?8=, MK;MQJC_&91!'7`LCC`O&!>.Z?Y]+#(&\M#`N&!>,ZQZ*(*:)0V6I95F_JJ]O M=+6*^#:37A`^53)P9USB), MXOK`O6$1L(@[B]")K@O+OF`2,(G.FP3?_%[DH3;'O_G(0(A2P/X-L;LS=FSHF$=QE-.3Z)(N/\1Y&)]'[&N/LHRRMS[:\%%C M]X8U=>=&,'4FON=-1Y9G.(%>[=ZPK7$0&*WNWBBW3XA4CGOQ:&$IGW*_1E0- M_O)U&V<)>QA7[/.U,->>JYOL`]'S4>UZ-`INQ6 M#QDK.^P#5W98WK[K"9RN+&"PNO)%<8-'O<&.=!]VN09IA9>V?I;7!D?M;^4+ M=*F-F(#" M3([6K)QJ,M@)[8/V[:]]H\6B6!>K+BYC=\'G$:E\^K?(C3J[>7B17PE)(N8+M M"-CJO!,'M:JCJ")XHAU9C^F2P`0ON3QTH%\@P*3(V)>D:04"1$F<742; MHZZ-$R8K"505[[`14P+"V;_97)UX.JA:81(PB;L*R22F(]Q[#KL.@L'TV&!\ M8MO"[$45U6\_6U<(*Y!*[9"&2[H.TQ_"4G&WL*0!908L#Y;W+*RAJP+G"[7/%YC)QB%[7YSD6IZP;[+> MT+P)\[5B$(A@T-6`&@(]@![N.^_VC+LCK,%F`O,96N:X>-P M^N`\7:&R6*9@/\1O-VFRH%FFI8?O$P70L*0CQQT) M8IM6Q=+:XXV6)Q0)B*!G$]<,6I.-*MH@.Z^$JX&K@:MY`\ M#XX(C@B.Z#[G<5QB^NWM!E)%&P06Z[L76+3VQ1X(K?>K'J9T\733@U%N>GBN MQ/M<'IL>VMGT8!ZXZ<%I?4T`]A*H\D75OD$L7@#9\R$2+'\$USVT3R'M`]<] M%/"H"@BN^\/5LGVN^WWDI_PY/[@V'[[/-H2N357]X1^*&Z$'2Z%^!N6U#:[F M\:&93GQ;W/D\&"_@B>")X(GV&#TWB&Y:2'JD563]*KP.YA?O[Q0N6*(!EV$P M_7&:Z^O"J*60RL)<>FXN`?$#8?U+JJA^^QF70N6>VQ5"E5)P(SB-I,]G*U_%M#>XW8O>%,\3"MWN+3-5 MU`?8KJ)]PT`"GP]G!V<'9R7!VKD,"VSN^S%11'X%E MZ6Z2GFW__]M_%MG;\S#<_.7;XH(NBQ7]?#:/XBBG)]$E7=ZSWHQ*TIOO_-K? MF2#&JV3QX^__]J__\KV/??\B37^Y>]/GMO#9_`*_1,8Z:A M73,KT<*4,S'=T"YE(#-JAV>1R,FV'<;`>D M9\D?>E7ER0O,^0;9L\)<2Y/ID?[.!=C$<`U19J/*TVW?.H83D9L4W@-LG;2( MY0NS)X2A_H>A)ET4_0U#)M%=89">*D\784B>V31)]0<8A@SB^ZB&$(;JVI/9 MI!6FOV'(((&-:@AAJ&;7(OL5#<]RFB(8O6Q5CB_NO!;!"`M.C]U14EVT/(U3 MMEM=J4U.,B0FP5$YQ'/;6S?7"342Z,X$=)?LWQVRH]_D?9(LKZ+5JDD7B>>- M=<>R]='(MPU#GX^GHUG516);(\^>=+J+A"4UVN(BC,]IV3S!MU,M;M=IA.4Z M#=Y)<7XC-NTL2:8.^WQVS&Y46[-?7&0:C9=TJ=WUHFA"6U#0`-+)!A`' MJY`&56"-PQ7OZN)+\1KLLT.'"#I$=N1WND%T![@H<-&:';6+/XLHBTHN8N"C M['VN1VP=-)*(W_4$RVHREL7&VJ)(4QHOKK4\#>.L(O?6PN4?198?BQVH/^CJ M&X,X@:1QF#WDUN_)O\&#LP]2\B9S(D!O@=Y*S^Y=E_BN,%)XP+?"X=MG8.L. M4/9#?,G2@B2]GI2)0]YXSD^WG?$L\">N&7BSP)JZ<\.O$%ICK`>&U6F$]DXZ M7!!9E.7E;!L'82LXDWVN&$#3O\4F*]U\98%IYQ#.=9B>1W'U)<,B3VY?J()N M^8H$$-0_$`1U@WZ"H%AX#Y:]ETL^;'S>LO%Y1Q*^*^P?>Z02NCD@W=Q^9O." M:M9&%H&X[>)N*#:;540SHF5T3>.2AYL]@_0Z:0)@MW=.UHD:2HE#M([4X,1R MY2_MZ(36'%IY@V1L_[@,!P8'MJ\#,WQA!YS=UAJ!T.$@NP=^2](?O(7R9CG* M/F5%_QH(B&$)*T!5>="R(ST">H\MPB&NAY\G2LT6(E./K,LE02"NSZ+OUC7T.FA.Z1*IWGE)FH*)PDG*=-).L03R%@))UDSPSQ\J./E88T=$QX?P[Q@ M=Q?1[//921*??Z?I>DI/]YCT<.:6:_HS=SK6+=>8>M[97;C;0EDY@\*AN,?JC&?V.W/1G1S@?N-1FA4"*' M'4B]2,+ZP'#CZ#B7D8.S'0V.QAJD%NPF,(75'JH\VZ.8QW"B,O8@O;P'2=Q) M)P+1(`(1%B&5"9R)]F@$(FQ"$A>([":K;1"(!A^(L`JILAL=%1$"$78A"=^W M;+JHC%H,2/UH>A.F,2#4!*%F79%YQ!0X1`4ZS<<.[?#.BWI-%#LZ,+[217(> ML[M;?N!G\]%91)>C+*-Y5K+>I^RG>'D2A:?1JOP(]KMB39?U&C1^O_F\W\=% M%L4TRQXPZ8]^1MGO/Y/X]\\_HYPN3J(U^V?YL62*>M#8,79-=QJ8[)JF&XST ML:L']F@^MEW='\U-I^.-'7S+TB:E*W;S<9A>:S3+HW7(Y*"=A5&J78:K@O)> MC[!\(EIX\TA*/J?5_4/AO^=/A=,Q M$[,:.>%&AVA51BL#T0K1JKXU)1MV_]=$VZS"."<5@_B?1;21MJFO-Z'+($8@ MG_Q:%4U!Z#I8A!_B/(S/(PYC5D`O(A9[7^`2W\&2V1:#EMYU0ZJ(89X],&[/5B%D--.T@ M>'%C,H2=1*ORP!&ZY,EV2L]HRAO@4GI)XT)*`MB?2&4TFF%"I!IXI+HSKCS\ M*3M0R5B$>^Q5(X[`C7&OB$<5E5$YUO4$S=S2Y@U$4YX9V\2RA:$I`#0EA]S. MV_@GFK=Q7M&YK M#WMLI.YUG+(]'.$A3BE*X="?0.4$**L0IO;E=I!/[=`Y@S(-8K@8/4?H4HO" MH3\1R[2(IR-H(6@U':,#/ MW^Z\C2K,G:6N$;H&<5S1&SM@:X,-E&#=JF5U+K$,$U4S)E5?@[8C\'/)%&'W^;E,C_B>N*7-X.=Z[`K!S_4R M/]='NHRRG*X_Q,^)N:R)/O'\B3TR7--PQ[8;Z/8M,9?IS6T0"1>7;WF<3W\2P>%O!N2?`#@;Q M6C1/2QSTBCD\Q$<,X34Z^[`1'%&YUC8@S-\=8&KB-M>AE.MWJ'H\>W?+N(>` MQ=[GH%44Q5RC8@X[6MNT3\\5-G2$D1K MC4?H)!!WCH`"KN_!"6M9E>X,&$S;IVF3($#7)[H^C]/U.5KDR7L:1__X].NS MKL^1;GK^-`@,?VH'ACV;V9YYV_5IZ_,CK&.5&A#:Z`(M&S^U<,6'S*^B_$++ MBM.,_EE0ODA@^4>1Y7R+0*8MBY0/)/"+K6F8%2GEKVL;]NV3I98GY6_V^H[O M-'ZC#S\KI5FQ*N\Y3=;EA9?1V1E-:;S@G:KY%:7Q`\GPZS+M*/@I_!/\4V!' MZX,GO:!\+*,_/:[K,#V/XNI+AD6>W+Y0Y4CE*Q+:8`WSP#Y8IYVVU-;[8(_X M/MS@$3J9C\9:DK`ON_&ZY>.T=ZZ!NL`Y%S";)\ M.>-\)20TE&#YXU45%4Z3U?*V6Y/%31;D9G>1;\[C[:\\WHI*UZ&$4,(7E7!T MGZ=!YZ!S+>K<7OX.['T8*U(`/.S#6)%%#!\KOEI3B0%'0WB:87N:2FE\TS#E MFYLJ&@!_`W\#?X/,1GU/TQ%P4WZS?4H7-+J41GG>N88G2Q?6-:#*@Y8=E1%\ M>VP/$M)8V`7LHO-V@3@!F+J!;+^D=!-&]ST]9;]/PC,P&=;4G_YS2]Q45=]+ MF@Y96G?C5'\L"_@D3`PFAN"EAF4!CV,I8K)AMWE-M,TJY(WK+$.D?Q;1AO8ZY\.(`6HN8!#`((#-P2Y@%X@3P.9$R+85`NG^5#6N3PP=G0;`#!0*4?VQ M+L!R,#&8V/^W]Z;-C2-'PO#GW8C]#Q7:FCR/4.NS>=V:ZW=UC MK_>+`P2*)*9!@,:AP[_^SM]^1`M<5OBML1=`^*V0KOFVOIAN3[M],BU=JV= MQF7]/-;/8_V?EBXL75@Y41,'Z`'H6G;0\./!-["#JJS'HD[RZG!(ZTVO8\[E M\!!42C39%2PO2)!O+>59RML#Y;5/!U:H67?=MB"4F8I2D=0&55E[;(I-FX;6 M'K/^">N?4&I=WYC%9)4W2RT'3BV=ODUGM-Z\K6%[P2<\P9&A";_FT4[3S5ZA MG3/L=JR=8UT(]1%/AT-:MJ38DI@E,2N]:D):UDM7JH:9>VN==,MAW+8Q6JK+ M>5LG77V$3N/HP2;76;JP=&'EQ`N[XPZDNEC3MK#2.)_;"N-]NLR=OKDY.;96 MR7HL7MIC8/:2- MU]9_Y=ES=`)JGM5[ZG1[-@_%.H*L(TC=9U`9M?1@Z:'Q]``B8M2QTXFM;W1[ MX/XYCOV;(`SW8C\=3)9'UVG;D8[6(5DGX70XQ&74IVA+C"WE60ANC4`CZSK:NXY@&9AE8+7-[;5!K!`OT/P'JR8!)P M_XR2*\YD;L59Y/]<9D:?B<3HK_C>KP"D]V'L??O3?_WG?_QQ3\]&6Q)/XS.? M_'1T==%IM?M_[?[CZ\4_Y?O^^3Y/@XBGXIEI@!;GV6V0_O,VCO[Y\9L;N5,W M^K+@7N"&V=U5D@=9^B'R?N'S,4^.6.##4UTO.Q[U>H/6:##JMBY'[>'%9:]S M-1B=7IWU.J/V8-#O'/UI"47TX_X:S'G*?N4W[',\=S=S<.WV$!9]/.,D,-J= MUO<5FF\/@,*-FN4SSGB:!7,WXSZ;N$'"KMTPYRR>+.?24%O9-;GPS,U8!H]Q M2S@S'Q['@I2EL_@F8F,.0HRY81Q-V4V0S5B:CU/^KQS.GKG^[WF:S3G."_#S M!#9*#YMS-\T3CM^S!:P^]ED6TR^/6N,)PXWJ[TIXFH>TYR2>8[\-6'HHM M^`+13!=>$D29&TT#9"CB?2?WDN1.AZDQ%`\6QI-M<*0B25OJ*4&$U$2?]?=& M<3)WP^J;\9KBP<0KF,?#4%[STU'KB#X#(_34Y]VQ>^XFTR`2BW3S+%9?"&6( MOKD)_&P&5P-D)(L&]ANZBY2_4W_\N,QRRW7KOK22;7?6>D:W<,?18GXZZG>_ M?U`B5&63O+']V/N>_85V@XW<8$/*X&MGMA3+[3XQ;WL/L+Q?QWQ`).P(0?IX M(Z3".`Y]\:`/$8A*-V27A1IPA2+V;RABK>ULD?!9D/"L5,TLSEF<>T:<>Q2_ MLTT,-V/JN9O.7I*&:Y].8,Y=^!!"F<]0,N\)[.]_2D1=#OZI#KX&,9C:B<+G M8S.-\#77@@BM/#]@N0L75BZL&+">N2>`ML/ MR\6`UJBYE[BZSJC5LH:-=1G41T(]ZWB.%^[3-S1(?(\%FR5.2YRO4?0-G+X5 M?<_ITSN0+IG/,,1F'P5_]1U$!4KH:?_YADJ^AC18ZS&QQ-@$G=32HJ5%2XOW MJ*@#*QA?7HVMD>6X3]B>>1[L$53;A7M'#0JM_7A?IO#(3@ZRKIDZR<:#(2V; MS6A)S)*8E5XU(2V;SOCC!9_P!#OX)OR:1SMU'CSN&,Z-K9>ZM/BUA+P;-J\FU&CGMWO.YT@_=)&H0J397T+T> MXARVS$T*MZ1I2=.2ID&Y.>H-+7'6QY5X(%F4:\:`O02A'E;"R,CIMYZ/6%]# MOHAUW%A:K+].:RG14J*EQ$VP/'4Z+7/->RPM[M=]VWC]]E>>/4N-T,&8F)V^ MT^O9.4/6P5,G"7DPU-5V3D\M<5GBLL2U#]$U!-%EK&7XP5.7=7]F/_XYCOV; M(`SW05B-HY\VJ'XC8V'YNARQ=7741]8TCB3>&%785H]]U_V_(!V]M01C">9A M&=(%&6(LZE47W+RSGM=E\>H(U`/.L,>CE]PS))RR0/J!#-_$T@@7Z M'X"+9<$DX/X999V[_M?N/KQ='+/#A"]?+CH=7IY?]T=GYH-6]N(`K1N>=[NCTZJS7NSCM#UM7 M1W]:.E#]<+X&H)X@0H>BS_I8H3N9N6'T/7E,\F%":>3P,Y34_';6.Z#/0JZ<^ M[WZL-X&?S>!/V*1D$\`"0G>1\G?JCQ^7R;Y,UK+3T?] MT^\?9$I5OBEO;'<>>V-3[FO,0KL[W=B0'D"U4VY?-"7Y`5C>KSYXP`1Y8@J" M]/%&<-)Q'/HR532?CT$TQ!-&(G>7$G^+>%LB7M]O;3B^#A9SYW@PC6S\[AA@1TZ-P-V5>> MS-F;?X#=E6Z=$[";Q`:`ULE)M2!`=>K MI0>P-OZ3D=/M=)U^;_]@J@'V6$]QG66)44=P7;#-G*_W":[D;ZZ0 ML>YG;SE-33E-C0"W7^%^,MA:KN^N;1Z,4BFJ&A(7K(5="EWWFX3ZHD$UIS/J M."US8[3J#(RIKQ8BG@U%&'A8YUI]F_QAEG[:ZQZJ+#=&UUVQUG>&JN9;(U-VM#>/7B8:^TGSUOBLKZ<>@+NM3MT5$*`=>G@?6^&IRVG,S"F#:V>^_Z@8WBQV[W=^/9WNHCJB/JM4WV#=X M2T"];G[_VKG3@7N;AB=#8P.7+,%8@K'PL=ZFW4%)'^^ML/O"%YDLL6M1B=W+ M3R5OM"+5;CF#0.U3:JT!:+U6NV0*=DX,3IVUQ&6)J^F`VW-96G_K MCGVOV".U7A.3:4W4JDQ7QDIT?&ZMK-'*5\?IMSI.KVTN7O@`M&J`6,\B!2RS M/V!G57MT8HYB+$6\&HJH&7SV2B.#D^$>M9QZZHK[5W_^QE/LMN5&/KN\77`/ M/V0QPZ\?4(?>M,T%WI_<=[N1NM+(&;6ZSG"PIU'TN\"Q!OAI;>FFJ%<'Y*AJ MG1BD/DM1V.97/\#>WGV288K-,M17/Z7FL; MN%=19%^]QV&/NV#`RB"!I=U7<))@]\0\C:>KD:C`/VF+>QTM.>,L*MIZI]I` MB)1Q3>6^1I4[<[\!Z@41?'8]#S@":.$1@U^"N9MQ?$!QRT14,.0)3T^,$=6Z MP2*/'?Y1G27"I]A[XS-?Q'!TT?13'`;>G?C_7<:%7'0&E]W.:6O0N3CKM5J# M\]-.C\:%=+KML^[P[%G'A71Z"V/C0L1'O/Q=D`$J>AL,-@E(]B&:X/R-!R>5 M;KN7D;FM%&B/^.)&=VSFILSG&4_FL`)`]AE8ED$&5("C5@G?V'O-.T&B, M/(>E`L@G3-^%NUB$`:XV2UG&O5D$HGJ*7P"Q>@E'^EPDL9][\#O:TRE/K@/, M\;B9!=Z,S=T[-N8,2!9>C$YLG_E!`K0A.*5Z!H/P"N6C((U MB%S8CAO"8^$+I)*4)7P2`JT"T7')MTB`PW8SG44`V2-[2/-Q&OB!FQ!EGH4A MBG2>>.HRQR))= M%3!M@MRJX`:=7##?`D=`36)YL64\V_(X%PD'3@U?!Q$]/O$Q_T\P\M].OIRP M/Y^=?3IAYZ#8NG!)4$*)'C2)XRS"+F5^D'IAG*+6Q\0`+A`?0'UA[HN':^B( M@\6B",@(%BQ7#E\Y>5)@D!VB^YLL"T.0C-%C@DP8!,W2,JW+!$<[+!;A"A_5U:#(H8ZGV6CT M\QUW$SPI1'4CZU93.;23:AL\*0<9`2X>I55,"NLD1U-3,13XJ8J(0E5>RSA+ MEO@P"TUG<0Z*\1@AZA(_@WM^SR-/5WOA/5L_4-!72!<@`TWQ_H3#.6UFFF=B MCT(U9O#>*V!7K-TZ_O]6#M04Z6T\3T-HWE@5XC-80E&.8X!HNFFMU0:E!4YY M)`W;1*Z^M.+*$4;N-.$220FO2PLO!B/PS;O26D!Y""2"?9JKT(<7]\1RAJ6]`^X.#2PQ290@](A"0PY!7Y+`V^!"7#@'_``>#4H5702<(5#:T`/ MA-+9864:8.!UV`Q6N"9TC1Y4%`[;!\X$QCE""=47R?3%B%8`\3OV)GA;DFZ^ MF"2(0@OW3CP]7\3$R%*T!-4.B8^I%3CP!/T1"0_FXSQ)Y?(0EEZ".<+(2C)YP=7A2$9&P$=), MGF9UX?K*@5)XFL417]H^W>7-`EB64N3*4],6BXKB-`\1*^^6T$,-T`7L*3:3. M9IQ3WB]Q4BC(I6D#.BV<3!47U<55AUN@YEB3T*ZLBUCF,BX*:<^OW3`G[BO\ M;I7;P`K#%=/ZP!Y#GUT>!4+W=@N'#)CLD1O>_9MV77T#*@YB67?+3Z8AVV*I MR/?@B;_GOO0CGND7LR`E;@`/0DIVJVNI+@59=K2\?7*HXC:YXL^6\LCW)SWT\`Z"%V"/>)YD^X#I?K.7/"&?D_`5*^NOPI@+7(!&L%85G MRL,0?U_@+,T3]G<\4_?:#4(\34_< MHP=R:G,.SWIS]+*AZ1.1;+EJ?2YCS%`IH?"5N]_<_3^\LLGV*'2 MTS6H20ME3D$U/#8Z?8H95S`$@(NN-RD2Q?6I4`S0%IP$M\)/HDZ@?+:W#:;- M8\E4[F-`@FD2!@I)C,M4RF12JL+,`ZP'S'=I:2)`0]:PUG,E-*^%AS^PV3I-HG($L9*3%28:VD6 MDAZ(<$R1K\$RPG53:+?51B%]*>1[MTQNE!^KX\%U'`36-$D+L2;TG+1CE)P5S2P93L M(&BC`1T"3`CE*TL9A\%4JF0Y6)YHG,.Q)VXD/&R$,FHE:0YGMNENQ)5"J2,! M@:1UK!1"$A$@LM+E_2"9K]O2?2O5M$N\;,7H4()JB>@UO%0'*"69?AA"F&&N M#]TL/!$8610.F'1;>-94!+RG=)9Q.2(@CE M9>Z@(I[X[E^*Q_Y")"`M#G%,2`>K[SUAOQ&>KKM]XW%7F:@(%=.W2->X]DW6 MA*NM`#WH&?I&,R`KD#INB492:52X$DDM$;_3[D_5TY%`T.,W6;T"@SR@#)&, M77HA*GR5:S5U3[^-E#O`USGG6;K6M"PX_+M[<=0F/]GDI[HF/ZVH5V311VE. M2@GYOJ0@1LQ'$LK(L:3Q:DJ'(GI<(L-8W33#Z_0(D3"/Y`>I3*`REO$Y>:_A MWU1H$<)W+UA(J3[GF8<>'_%CQ6^PTPJWSA'=F)IE2;N9I-UY=:0M=#UTE89< M)#4M7##9-#*A$*"EB%=*$08&K#6,(LCHE`:3YN*1SJ2JG_+Z86?-!;(8,#NE7J2K+:&>N5Y@W6@U5K:!Z")KR+\Q^'R"O5*>@1*SW;"M=##CR)^#P*%8_"A$B7#D))Z@10ZZ"E* MN.[Y*;'AA+WGGHNN^LISJK&\-;9GQ8F@7&SRM570+D?U"F>IS#T0GJ=)D)&7 M`C`7PU\BL+7^/B%AB7]@S$^D9&B'K%S)ZUQ>O@BU;#)^E:.F@D$:%"D2%V(& ME_2/DXM)N4=U1H?F-B:H^2?LD_)`%,[0R4H1&6[""P1K^ER$"042%DO+"V=%)32_LBB, MR<-R3"5F&F<.5T1)H-D0<.#?*M>DDU2QN(H[#CU)'J)U*.,7)1R0UH!'7BL, M4@]#HXDP,2$#[GY_906T,@H2Q0_>+`A8>DB7$FY+1V@9D-X@(L3'.6P;-^'S M":6WQ(SF?/F^2FZ"XD/E)8#S(F$-F2)56SE(L3=@'>"_!3R* MGS'`1$M68(FC$\8^K^6AQ(]`/B"NIKF;5L)K1`L5C[P*9Z$4*(^HS+M-,(,L M4>$DXN*B6";V9)8';8YTI"1(O]&ZXU3P-;"MTI(!JO(1F8\AV#S%Q()T?VQ"+9[6DVB>FL9/BU>0-E7(9H10(]> MD65_++5-7\]NH<)GN`P4"F!>(MVHU"F(.^4R,@+D$'L![844Y\W[2.+?*22E M\:)K`$BP,]@A14DC41RV^8E%/AB!U\?$%EP)@,%!M0P8[[]+=BK0 M(U`/Q9#9#!-LU3$U0/S-2'/?E.%6YD%B,S M,Y6+_]W`Z0]71W>\[%%]UW':H]5^68\[%CB&A4@F"N]4JDL)?]3/IRK15AH0 ME-BT[&A`3P_\0Z8)6=(W"98:H1&085Y48W6*"=<=BL+NI]HJ7I[5B3B]L=:9WRTRPD6I"Q9B,Z$(>92!^,K1S988;Z?CC M.WD>HH9&A#B%,3=W?\>ZG*+.!=Z6!5DN3"$Z.#Q7]J\</&XN>JL*EDUE)V,)5JH7#T0C!X[;5?[D*%=>3)5N//*D7X$AA0HW M@:AY6`8&Z3P29XIL>:E+`#2H^8`*08F(+>D#C>6'J*^#.O2E(+%:,K^**P36 MGI)>`.O66$,1RI)(H:A5.MO71GU.V$>9>^=&%?27&H2,V961<_G:^9HT7A[* M;F:8P8I]&V02GJBIT7J:425AMFX+,RS?%/[*E"^O]"M]N7J3"O$FOJCET=ZM MN$.B^AP)ZX`""7!7FE.9#*Y-*D[":7X=8ZH&JLF8Q`SL*R3__Q3`ETKV3=&& MI?1`_<5:1PNQ/EQ`66Y>*5VO]+T`(!J9#4I6NKL)`)"2KS4S"'&MC11** M>*&*%I=%8^4FBS@V!40$)!RJ-YZ*]ES2OF<`Y"B>!QZU#`FT1A7EI?2N0M?4 MKBL6O\.I*EXOPJY1+#PXI4N[`L6J!$@#RLO4!6(9?@T16[":0R\P9Y M'-;[-\!'*H@@72'`R5HN(4T\7Y6E5),\9-8ZE2R+Z-'F'/F2.V!S&BK`^5<> MXVVRMFPYBP3EGEK3'5.)_K@2AT),<_6\(JXH??A+B<2%38]V*K:)B).[HL1( MOU51@)>%;K7BNHEG!-%YD5M]$]UYD,Z5.Z"L ML=+RH5812:2[E$2:K59-5O"(5`X]WZL"5E*-575=L9W5M3@/KP3QD7BND`'W MKTIJG,<*K/X:02&S9"C?R)UD359QKA!P?U.`TYMQ`:;D9BP^V8)XM-2EV+0> M=%7B0)!J86Y"H9NR>XSD<8K'8V0>)':&]+!P`X'<1%N"/8.2!DA=U&%LB9,%H<'7<14^539!!3 MOX\V4A*`5NA;V%S$(64+6;I\W9($+&0'#H01Y>HI,(@4/KEI6J:K<0C%\(IP MK_;&-=6YKC"#CH$.$WVC(!T2#-_?=M;,+ MMLC>IR7]=#3Z?L>Z`7E?^Y'WG>YVXRL>%4CW$<&6;IOV_>36E,%,2V`:/0Y* MY6V'-;;*.!+]]3$"2!?.((&V!NUN%%N;,6I20O0-:XKUFS'X`-B:!"HK'"K" MH6.%@Q4..R.1YGE?-E3*WJ3*^I!V1-&(2#,Q5+>CPL(M+#M'E=87HP;B,@TT MO'ML/:Z5+E:Z6.GR;-*E:Z6+E2X[(]%O:[Q0FR6%<,-A'%3XIW0'E`P$P%H+ M!^7JHU6C]**OH;FI5(]F/.$C!A[6V8]_'D<>Q\;'143U7"+BQ;U:&CE8@F,Z(V`$3`]#P#VC%FKSM(3*NDJ23:)PR`6L>^4XCWX M+*S5*./1U(8>/;14-DFN[J9,AW#8-,%RO[S,0)!Y!_%RS_JMLLMN`!`LF*M: MIA/V0*DP9CF+Y%(ZG6H'["!;29>:Y%AJI-(7W)!%G/M:"%+OWRS#"JJT3%0B M^6*>'=XQQI@R)75[L``QV0-.[Z+:=Q%CJ)5%:*LO5EZN343Z]654XY$8,2G* M/;$Z7S2%=.2V'>6(D:>'H@NZBI_1(,)U3TM,QV5 M6([IZA0J$O$/63&%,$I<7P7AJ*])-:)-S=M!+E8>5/3(%]]1S!S$#Y;KB6]D M7AHE%\91D,44GJ+*7Y^F(%;>(1/7D52FL6BD)S+81,17;86:4JK1:PY@7:;5 MLFA]%R@_4,20,\J$PPW`T M1M@OA>6,/(EAW]*,3P./_0[(F&&W9L'IWOR*4YV,O,1,$<+;I>033TLP66;Y M19[>TJ;$Q*KEZ_'RKS-L),#.@(&.`ZSZ`IK[$'DG[,W1ZD]';TV"QXQ(?KLI M$W*I.?)J]ME,]DM6^C:F_MSB8`/LBZ/-!0RB">C<$3;91FXD.GOYQ]_H5]C#PJ[2^.0_UB^#3V M7B!6I`!1R_@;4%326;`H;!SJTR,G7,@2"V$HC&,W(18E/+_4?'LU)S/5>@6( M(D+1KPX3'56J[M:28<-1E.QS)4/\@1FV+\JO5E,/M18X*YG#<$FY_1M`,"/' M_UV[Z_2&=2N*_&[HM$\[AA;5',;8H*K2:ED0-6C20DSN.@0N.\;(.^_)M$^7 MZZQ*O@1:"IJ.0`E[(HE.[Z3S?M.J)B1%.$+"8B]ZVGNO\A8O^3PR'A M250#!'Z`A57CG.J%RBB(BE4ALR_LG)785SIS$XZ78AV9$B@X6+@(&BQH0`P&EH4`O?7=7:RZZ^&W6=UNFIN7UM:W4I/&$* M/>XQOBHJK*ZT/DUGW0,T.QUG6#]-H3-T1@-#FO0>5%;+*1:!M7``KL8HJ=GG&1;I[%Z@N1L4G?B!K1=JMEKCAT],3BT.%C MJSP??5_GN5]XF!ML:)F$21G]M-J([@.U$9)")23:BUM&NC'[[Q;][YEJ)[9G MF#M"D#ZN-FUXV2C@\B%KW0.F1P"#$,PJ-=L?I M=(Q)@=H?_B91^&PX\8KEHV4UKYO5#+K.H#.TK&:?ZLYA:36_QM&Q]UC-9J]E M]#LHU^8)J3=8S:1\)!75Y:3W+9>M^#U@>F@[G?YJ!/:54\0^K>56TP7+5YSM MMD>1\I"'QZB9(%]&L9*5-[TL87:DK>=;.=T^82U!Z"[5,RV/8!2O,,L./T!WN*B>P"ST;@G;6E M:YJ&:WFDY9'[S%P<.:<&_1J626ZI7FZ>F+)M+;BVP,XC-]9YTL:V7%RSJ]#W M4&+>'CRQQKQWH"78!U]C;C?8]`W:W)\GNN"&+U")7;.ZZZ_40.>7F/KF7&+? MG"I(UPKBXHI*BQU3>ILUPBR&:ACZ*S9V>E8$M7S5=K@PC\>VG8I%MN=$MJT; MIUADL\AF.9M%ML8@VYY:0N$(^!I%AO:IWGWFUSS*=TH",Y^KTFCO>RUZMS0C MJM/M[C]5M1$XL]%L5"U;(OR[X>!ZI1UY@EU6RS+LJ^:H*)E7SMT M/^J.C'4_:C;66`9F&5A-4-$RL!T8V+"_.O+),K"]5Y2@/^RPW%X?%SQQ,U@; MX[<+'J5[JN-_V9B\>0H<.JW.GK)R#Y?6;*##4M1FF08DU3?6I=>2E"4I2U+M M'H@IJSU+=,?;V>TV_O/^KV.HCOU8?=,OC-.ERVH3N#`F]+V!PVZ5GW MIJ6VS3VTG5'_V>BM+J3S5.^FI2A+4??(KV<+P%GY9:GME5-;N^WT>S;B;<-S MAB"+/;7#.&UH1^VZ0+$9#6%KD][]9N`,.WO2PA\#L]>M3U@_L.5UEM?M+ZC5 MSW,YRN_UXOCOUF%WR.IC=5L-+ MGLV[J$%G9?A(!?H]@+4A>(F/>/F[((/C\,0W*_T2_^8F`8TC^8"]&7F:LW@"[+9;&IG;$=WW=<;9>3P']+MC`4Y?"2:P5,;EFEDV#/Q0GUA<9*R$$B9N1'C:8J+@0=Y,S>!%0"04N`-+)XP%X@R MRI(XA,.8:J\,U*&Z*;M6)UU\64#MS='?/EP>X<+PC_3H[0G3`0W@F,3)/,55 M!%%`:W`CG\71\33&%_)K-\RI7@,74X!-@4?;G7KD;-V"4@2SSS.$?@1?P[[@ M4O'$5'NFFW"&ZSQA'R8$&7%&05JBA(\[=O$JI_)>?2LX'S)-Z>PK[[V9<0*K8%U_ M`*R%0XOG<()R581>"-@J>A#JXEWQ&-BJ`#.\V!VG<3(FCSQ793-BT<3;\1)8 M&0_@YC&/^`3Q5IX.O%ZLTHOST(>]9`*S8)%CKJ\:'R)O(&`3"(H#\8!*`0E= M.I`4%I8BY*L`7SD4`EX2S-WD3JX+,#6YTY9V8H3SM`>&6<\9@6]E;8]Y5#%V MH#SD;LMA:QLE/^;YA$1&GG0!&+2TT#8M=-5+]9C'5W&E($%?8B?H/FY`/`61 MU\,95L!976*+N,7?@?MD[!K0*T^0U_"",33HL*HP<,,T7@'$7]P$I0'*Z(3? M`OE?(L<$*@(BO`(=CWUPV,^?@(W+"X_>LC>_`E&;`4![U49_E/+&;A1/KHH7 M_!I%]";.,!%L39<`:2`D,7!?OQ3OZ_@R?K<;;U[+E4ONE%86#US8>1RM"E4CX`@@>`)WJQ`.' M,7=O@WD^%YH<@!JE(UP=DBHFA9DFCXPSB^?EEPKY09LG56D=`@+_7+-I8I^H MY7!`<0[D8TA>1+$9Y*N#V3+G4D)79;;$13$@$Y7/)"76 M.LZ!H?-4W(+*)-`W6$KP^(C36U%;#\/XAG@QR@-T=V23'.P0#QX#?*`J4A)^ M'?";5*@-"?LDPN0\W/0D#,WRU/4B#7Y#F^'_\\7 ML"8RX4`*Y0`;_!TYDWP7PN0&S@N`#N"8H*TJA!WJ/V"O1$R]$O<&E\T7)&[I03CP!>`=(65UU9*;`>+U@0$RZ.0Q.O>'@`%K4>!D*93<(< M00&?$':`9F#U1E/!T-1+'?C@P_/0?-!.J'B%MB8A-^8NX@98V`!/U_\]E\Q2 M(G&)8@(3\'CN]'.N0`]-0E!#PARO4R`;\S#@UX(NP)2JPE6B_T.87$_S!\EK M$N/2$1W$"-MT%M^DNHIUM^4>E4YG2.B@U3Z/:02GO:826:CM6&)0Z*=!)!;IYEFLOA`N:/IF#Y.+>T\<7#QZ]JFPPQI. MA7U%0V_>"XT99>L.6GP=6AK7!8*UZ%I%[5%Z-O9!5@?4 MY:/=-M>#V.:C[*9T'UCMF*9<[Q*XJ%5*7A-&0#Q?6MX+0=XQ0LP..&%_ MCY-O<.^Q?+NVLW(_81A[H@4Q*H_:DG$A8KD3UPM"='J+K]"G+:\KXB,$(OUN MO"](*[O$[=#"*+Z&VX0'B>6?,/9%R\;RN8?G7P32X!Q$;@(!7"1S)3S%DX`K M\FCB7L<)>77+8`%-CB>A3@A9S=N>P3R&""6%\"9BSP/W6DK#* M%2^*%7.U8I%.EU&TC'+T4D#CD,*CGI?/X!5:Y\Q@DTK_I"PQ4 M_8YTX*OX%WP8\PS#BEP%%#UW06#]-[Z'PI\+-Y!QV[F+29DBX16OG?*()Y0@ M*%T2E,L'U()H[I^PB_M6@P@/DM*3*R^).,T2%P%^'%($1Y+OM5&'?>Z],U;6T$3>54:ST\<&<@XG,["'LTGUJV&7PW&&7[A[# M)P?IJ:S'@,=&P&?/Q69FFA09@Z0,9)N4_BNR_A^@^6_M#K>QSDV3-D@-G8-> M>DW)+.9Z^M0'?@VK(JT/X/9&T71?3\!NU&FW?]Q^;.1K[Y'\/@]"7)K0SL?R MTUY(^+``MT]A?&BDV=5)<^O&@5;(;@#G59Y$`58F"6=1<$M52H>M)T,SGRH7SQ=@:-;( M@R9Q#E#B$;M;ZRY]S".;6W7[YSCV;X(P-+(!TY%@M;CEDO9)3I9C45Y9M'!Q MDX#BIZ+A"S6J4>%-CPH;*=7"+6MJO7@^QEY$U#8&:ZB1LK!L/(A@TX&?$QWH M35I0F/*%F[@9#^\H56$:$14:;"JQZEYXS%/>GK`"@)15@66_V'0)R!];.@2) M:NV$U(]Q]HBVNZF_$?L7_`S(E&'7G(?Z`P49OA-8%#\.@V\`JF,`;W0L6EG( MO(X)+(%A<3`7;9I$83.>7QZ)^RFPCS>*8F4W2>[P9U%0BAD><2);4N$:5>0\ MNXD!]?F"38OME]O->)I1NYX,JVH#@5`><#]GNWL%*`4RT7/,['2:<#ZP.GQSL<)ZBK4/D]V!+9.9G#4`I;Y.*R#U$(.1Y*G-UCH$>B,RFO`; MM8*W$C>V>\6]^.F(EF!^X!7=O];MD]\&J5;TN_02V8I"M?&:YP`4B>Z,0`

0^TC9+J5Y&&X""K9OZ74+_G<9;"M!<BZ<8B:;-KVRJ!($5UO@F@8`D23D M,C](J6P#.P>XZ8QA1`_6[89W:9!NC\AXVMQ/U^-P@61^S`5OB7A1PB\QL;9\ M9JT@(T6!9)U.#4(\5K%.<&+2%V%H; M%^S%`:JF4_9&XMXL`AM]&LA<4DGH"D2\V4&H#)#%58!3QTJCK%:+F^:2T5S:^42ABL M0)NR-==#W!$MZ?1D7YW#"L4)6QJ)^K0RV5DE0\LL4-4%1TO_K&9[?@`I.,'6 MG*B@79,)L+Q,[?"US&-.;UO+[!TKY47`#S?T9Z^IGHJ<:R_^>2ZDM2!W*<\5#X<;#TQF&E M#;BXO_`@6L<]-@HW4:ZSWN6"34$"H@RDFVQ12`8D+YT) M&\PQN2#LXH58-Q9<'M[B4J>U\[+=%SWIA@IB(HZ2#ITZ?,DZU!P\LNX'M!.] M^[&LMU%:4*%X[(\1_-WB';2:!!7GB#VK!Y`7?-D>0_9:04'5O>C%23. M#,W4RJ-<'S:*79?%([4=;@6_X@WP8(S)+.A+`=#"HU("LYZR[V$]1T?V+?0< M@<3H2ECC-93.0CH+='Z!"`):D55=$QVS*^@\YMD-,G-I$&74V7SUC,1I("Z/ ME5^#W&U5[P6G=H7!P_J=JIV3;@[15S"-0W3A4L-#X2L*TJ)).TA?33%"%JZP MAKYQBM;VJ@]@X>,1+18ELH@2..&-T763>0SKQ6Z!HE(MGB9(AG'1SGF[TQ&W MD]UV1A%VA159ZQYM8*(I,E+ M6JS<:K&9K#RY2I5F8;](V8%$B*4>M"VR"Y6J@H2=<)"W*>X-F<8)^XS,*1>) M$:J+J:LU$]5`A!$A).1B6WZ>**>C:)+:7#KY$`%P./OJWM:TUZY<8(8+%$:2 MI]R=*(UR\FZ7TD*GG3M9,(G%EQ..99CXF$U4MB0>E'4@PXQX(R(8B3>486`A M)L$X%X6'J%/BX`<_`&Q/>$7(B5KL8L1)@9=+&@B1.84!Z+L-:Q2F1956<6DH MS*CK[`T/0VH'773($@VB([%WV9R8W@T[O'$3/]T>/'/NIGE2^)[!NA$&+MPE M"$.W>3&Q@,;"P,]RB`F=I*16,N1T`SNFW(/Y(DZPI;T.R;76-,E63K7LL-XL M5):UY#?`*_PM=B4FPY0J:+&3:D@DB)96+\A>J"I%1;P(T0!,Z'R5UXI8$[WA MA/VMF`)3M'^5VTL1D0)@B[[H5BQT*CJ8]-M'E!?YQ07@OCU6<>(=7[RV M]!>=EU:AW+/0,A/UKJ(D7KJP2I$HT;3BQBJQ_?? MJL6FN-BE[@5CY-[7`1F8Q<7+XA+-$$!BNA]3V]![+EN)"_`@!4FEBRX"$LXS M-"#IN2L:V#VVF'I5%GO?R)4#A@VGAO@709BKZ,%#6Q*:)[YTF_4I[<''-Q"2 M%NQITW+6WJ\V5W:$R!(B^KMC\0"EX5QA:Y4\`5Y4>NW]S=M3>R,OE7A2O"AY M*^@%H/ZJ+A@2H(58V;B#<9Y)82V;OBOC0G\?KNZ>E8VYY^8IEVJ.!)OPXHPY M]<&-LIE2=RZ:KX,LEH#&@"VEF)F2F2_!3;YP MP=4_1#0]H-86KSX];GFF$^BI0HL5LJ]>>:BI`')59E(N+1?)!94@`C(\$OAE M^R.10YA5TSTJG4&H/">$Q M!9NKW>)L.(HO?DC3'',/A#L8>?JG)(YB]!P]W.WCY;S9&LHAN@G]X:KP#VO; M^8+&(#IHV?L8_F%OCJ[.OKP_>@NVZ?+.RTM_6Y#?\/1W9=D34TYV4-3?J.?:'TY\F=,EJUI2)!_U+ZK8X_"1?561G8,4.!!`&U M?YS7K7UD/`SF-'T\E>EME,I'5I/(?E?9?3B-KER&AU M.;2OR)HHI^/I+KD%)K3$>:I,9J&13?/`%\/?4_D2"B,2,"G(KPQLF4$#G^;% M=VBLD,<2?;-+UX_Y-(@H_4WDVRM]GB'M"`HB6P?V$Z*71K@QY(#Z3$4%BC&$ M8>$?UVX02?S%%HK)GW+P;B7)1,[!C2-=\?]#6HT^KHGWU#59$CC2_^0`"(T9 M`9$Q!-.V]\9"BPS-[\S5>!![K=EMOV?$*$]&X!B+MYL;03^87[2.1S8S6 M^G60JA;'V@7B%U_#>YJ`N;1BW>M%O^=C$4#,*JY[D M*^E]I'[(P@WXTK0X<%3WYNIK=1-9?<;X'RIA^+3B.=(T'U:)-M";1Z/B\P)Z"'=) MR:,V4?(9@,\O6FL+J.M7G\EJ)>.4W.H\0,FMSBHE"YFJIE+8=$9254.SHM][=K<0;ON03P'EU!1W.?5U7_3L6.&Z?]+\Q26J[&VD MRM[QZ=Z(4B4Y41P&:(ZF)PN<8.?*G6R8ZF`_BNC6[Y9\V:&;@*"4F8^@HP8+ M'*,]H31$H?V*('B9I$5D14YO$5G&$)3ZO6#O^(#?3KZE[8//9Y2$]0]$F]!KPJ@*MSOM-\@N!+U(FZMR!4'/F MX)?GNXP`9)+IJD:RO';-W3%W?:XT55'!7>6B#Y^I2'&)E#Y(QJ!D]DN/D@D' MHDRUL9CP6THD?"DK%.N)",(.$'U[)!6O/;L@4F>'NCT)BD*G4+Y"K+&*P/Q6 MS6_F[K=RRHHL!`89-U]HU5:N<+Z5S1=$E;)*_EV?HNK(5)[4"V-T#(@4HJ*F M8U.V;K5R>D,.'D]==_%.&_94.I4_`2UB@<)7?IN]#V/OVY_^ZS__XX_% M+9BG)'/,L&5I=H=%V1<%1(N["*[PX3.?_'1T=8&B^:_=?WR].&*!#U^`0#AN M]]^W+LZO^IVK=K_?'[V'?SNCTZNS7N_]^]%P<'GTIR4$UW'S@5DSZYKR/2^A MKZ82:>EY?V`">,9(>T\]&[=E61@_$@G8@.KGPIX@5*G[!I5EN:)9*\4&\1HI MF2WR,>P?Y_N*UB2FLG_ZSJ!UZ@S[A@+/*G]25+WIV84R?$'FF:G%#T$;'+96 M>U`^<>F5I$C*W9+IK$7KF3Q!A,N4/C#)067DMUB+EZH*6:H7#,-85!!(M7J* MJ9C"K8+W4<7+#0YN3I2HBKBG)WWQXL0=JEU:P8-B*IZ9<'^O?6(H+:A,TQ2J MNCN=)GPJ\^9$?R(IS8J]4#JGH?2F]LAIGYK)YW%42Y+BN"AM6?9J,I>(]UV[ M[?1-01_E?`'80N`OW&`%F1%=L4;TEJ2XJ2ZAWW5;9EB*0SF]L$AA4Q..:,/\ MZNLM_!\W6O+C/QM3[SG==L<<+CTO4^\/]K+T6C)U<\E%H,(Z??-2O`(UU5M/ M%%%,)F"AJ,Y"7RD]^0L'RQ@-+8.]DMIFQ/O;YY&?G>$^Y.<+"-!VN^6T>NUG M$:!(!(AH05I$]DOV#2C=`2CIUQB3J3\<05_ M+:IE1'9)EO!;^/LRXLGTCGURDPS^2JM"F?KDBV8C,4L%(T/W2]%0U`7RDUXE M&4@%\$D*Q`26E/I_`,/?]+ZR$BP)KHF.0]Y`8D+K$#F(FU`]V+6,C!!.9@17V/U^5CFCG73PE1`FJV4 M3!O"%F?4;3G=EJ'BAU(&_-^'CY_^@CT)(_%9?V^$=D98?3->4SQ8-,GP M>!C*:WXZ:AW1YW3A>NKS[@'&N9M,@T@LTLVS6'TAYH71-S>!G\W@:H#,&"L^ MDF,J*U^D_)WZ8R6L5:Y;G\%7#!L;58:0%>?S\!0_6LM/1X/3[Q\<8U:=N"9O M;#_VONYSO_`P-[C;=,87&VR)[EFEMS-!5BYN-PLWU MF:?WH.:JT\W(I-M:#Q;=F]_S$V1^2&_P:CILNHK-@/=*MYD3#VJ>,6ZH`CY<8[! MGJ>XQ9JM'K\:!/M$^-N;N?#M"=>&LCL-68FF(=&9:%6A9:0Q:Z M=4C&LL_GT5M_H'28M=??WRE@V[+_:K.`HD7C)0TOW:4YP%EK<-YI]4;O6Z/+ M_L79Y=G%\(J:`_0[IX.ST\ZA-09HBU<>BBA-3;C4X;GTI"6T.&&_ M%4<4`7?=M*[RI71T:]]HKO;'/.F8H9<-1;P*FV7;OHU)Y"[[S#$CVQ,3@O%6 M'!>LD=4:>MFY!=`F$5T1Y+^E_..DZ$>UA?1^?W$UO#R[/._U>OW30:=_<3DX M)>G=Z;9'W?-NLZ7W%AGEMH>7[>'U+#V\JJ1)5'L;1^_.U$A<.+4+,)4RX&&R MQU?Z%6V`@M"KG[:A[5:G__ZBTS_OC+J#3J?=.VV=*]KN=\Z'STK;>YFC*PHA MZ%"I>B"=@<$G9TN`HBB*><1G!682H+X$M&IPFS9TXLY>*T"6JSFVP`!;$;(2 M+QW0]$[/MO8W\ZH_[@N$*Q% M,EQMG+S]@;D@6=U/'N^S.6U/`N$Y&,5348DL!A+K[7QV0*3#S-THWK,'LC(*VY?-@VNW]Y^R;3/DUBO= M!Y8%IRG7NTQUKU7Z1A-BW\^7I7$PR1@=YSDQKQ%89%`IV36QXBD^VL+)>XX^ M(X`T>>_=R/\Y\##/-IK*,4T[NW;/NZU.MW5^U1ZU.J?#=N>\=W5)KMWN^^%I M9]`[0-=N/I^["5R75@;_ZC-Z99NF/HAR;B$ M/*:RHZ591W$V@\?2J]!E;.215;^SD4?N(B`?M>3ZS8U_AMZNC7.;[\$GWNX\ MT2G>>_:N1:.FM#NR&[1]H)ZBM8T>)\7+VYY4Q-=NOT"KG9HUUOE*VL$O0IY? M;AM';K9'NW9E&<5RAQ8AU5#9SW)8,2#D51+/3=FJ%MLJG<:*;3SHX7V>KF,O MCW]4NGI@#*^N`MBVNEN7++J8)`C&`K)HN?X2A#B`(.+LD\R[MPQQ+PS1XN.J M0$XYSGHA#\H%2.S_2/'&]=@?F@[K8&Q`.>A4(1UOFTJ M'V=$/O@?^\`^+F;9S`WG@;MP#!G!=T:==F?_IG)=T,7Z"AH@L@Z'Q-I. MVYQV9XG+$IJ:4' M2P^6'BP]6&?Q=<05;FQSFE]=CMDZ M'.HC:AI'#YU38Z4+EAXL/32>'GH=6YQM'7#;`?8LX2G[FKBX//;EY,P6H3XT M8]./7D>_&.HK?;VB;G^Y`^![R`:F'=:3O]T3SK!+C"K"_I8 MW]'+J1&6FUEN]D177,]I=WLO#[.ZH(_E9I:;U0@=+3?;+9NWYPP[YN98O7IN MIMF=/V0N;'WM]=K?VK["(.+',S&4M=UI?5]!I/8`T&;3BK6'5(BZ!?<0M((( M^)7XK+\EBI.Y&U;?@]<4#Z8M,&QU+J_YZ:AU1)_A?#SU>0V,OP9SGK)?^0W[ M',_=%59Y$_C9#/Z$34J<@2,/W47*WZD_?EP^YG)1ND%?HDIGK9=F"Y\`+>:G MHU[W^P>QL$H+\L;V8^\;/?<+[08-W_<\*&-GSS_)8]QNU]ME_!RCO;_.$L[9 M+_#;+&67(`U\]H4O,CX?\X1U6P[KM-I;&S4-PO%N+!-V^6^B,6/K&%E'0W6T:#<;N::HUIZ ML/30>'KH=:Q\L(ZW[0#[A1'QX'_L`_NXF&4S-YP'GITR^1)#OP_>F+&>`NLI MV,70&=C.W):T+&E9TFJ8]GA82N+':_=_X\CZW_:H^=7EJ*WCH3["IG%T,6K; M##A+#Y8>+#U81]RN@/T090F_C2-V&?%D>L<^N4D&?Z76$?>P*6-NZ/?!FS+6 M2V"]!#NEZO2[EK@L<5GBVLL\K[8=ZVJ=<-LZX?8U>;)Q=-,S-[.K+H=KW0SU M$3"-HX>.TVO94CM+$98B2HH8]8R%-P^%(NS?]]!S_:\>`W:&=7;L67[>S*^X#U').)?@6N M_\#HRJW3?QJ"CK4S`HKEVM&5=G3E\V&;'5UI1U>^J/RUHP+MZ,J:,42+CW9T MY0MAHBV,.H#1E8WP9=9B"E1#?.3.:7?_G6H;@35XGPT3UC!,:!F896";&5C; M&0[V/R6B$6AC.9CE8#5!17'+MD^W]&#IH900HYZQ'C"'0A'676\G>9HDL6';SO*TCI@:B:G# M(:Z>TV_9-DN6N"QQ[:?4LF-%E_7`;0D_.\QSM:%#RQI7UMU@W0U:@Q,[S]-2 MA*4(C2(&`RLCK`-N.\#:B9Y/Y#MVHJ?U%]1,9!T.B76<4==8>-42ER4N2UR6 MN*PO[C'PLU,]]Z[]U>6HK?NA/N*F<731=D9]ZWZP%&$IPE*$=@MJ)*P.A[A&3KO5ML1EBYR]X' ML77'J?NZYC2_NARS=3K41]0TCA[Z?3OUUM*#I8="P^K8,FWK@ML.L&<)3]G7 MQ,7EL2\G9[8<]8$\@F[7&B_6,U`C\71`Q&6NNL&2EB4M2UJZW.J?6KEEG6Y; MYK]E\-M>".IEY_3LPYG=Z^UI4N3A-ENTS@E+41O!-7`&'7-JH*4H2U&OG:+: M`Z>UKYGOATM2>_,8CIJN'>XT":Y>H]SK`L)F3&NO3:?SSM#I=FHPD+TNZ&.= M1R^G1UAN9KG9$]-W3IWNH/?R,*L+^EAN9KE9C=#1_":XL$$'X8MU>4U/QVUCN@S'+ZG/J^!T]=@SE/V*[]A MG^.YN\*';P(_F\&?L$F)D(!/H;M(^3OUQX_+.%0N2O<6E'C86>L#VL+A0(OY MZ:C7_?Y!%*\2FKRQ_=C[1L_]0KM!P_<]#\KLYBE[,8_T9J8_>AS/'SU)\RH7 MVZZW0_HY9JG_"ER?_0(_S5)V"<+`9U_X(N/S,4]8M^6P3JN]M<'4$'2LG2E0 M+'=H\?$SO^91SMEG[L73""[VV542STUIN1;;RN5VM6V\1&AN#5Q?'O]V"K$T MA.'55?YVZX%T]6*`ORTF"8*Q@*P;^>R7(.1I!H8C^^3>S6$5J66(>V&(%A]7 M!7+*W<2;,<3#"Y#.8;Q`#`0],;D./&XQT1`FVD*I#:#\OP\?/_WE[/,O[&.$ MVYS>[3R]SSC>-7MDMYWTOD.SI].N'?1N@X5U#A9:!F89V#UE$NV6L1X-S<8: MR\`L`ZL)*EH&MKT&UG9:W?WWVVP$VCR5@[WZZLK$G?(H\-+]S7]O7(W*<&0L M(;(NQ[QO06_E^0'30W]D6SA9>K#T4'K`ND-C'K!#H0CKJ]\`V*M@G,28!LJ^ M>`&//+X_3>MP6L0`B?7L1`'KAJF1F#HRYC] MHK'N`NLNV,D7US8W M,,H2ER4N2UR6N*PO[C'P^WCM_F\<64?<'K6_NARU=3_41]PTCB[:3G]@;""[ MI0A+$98B#I$BK$-N`V`_1%G";^.(748\F=ZQ3VZ2P5^I=F__O,__HBW7?XK#[*[+]S+85\!3S\!;+T[\?_% MU0#5"$'WF4]^.KJZZ+3:_;]V__'UXH@%/GSA>MGQY57GZO2BTQYUAMW^H'?Z MOM<=CDZOSGJ=;OOTXOS]T9^6CD('ZP/#/->=Y+VS3#N]Q>99ICN>K?B(E[\+ M,D`=3WRS,M]$`)*5D+SWW+?=R3P'"KEC,UA[RKA8=UJLFR7< MX\$U]W%2RP]QPA9YXLW<%+Z8)/&<>4#<;A`AI4F$BY/TA%'TB64S-V)!=,W3 MC,8+,=?S@*`SO!D>E2-"PD5J9],0@6[>%&0]]6`8^(N7+*_U*7Z[>Y"8<]XZ\!O:>Z>^&3]SU9O#S M(@;6!GOPW8S3*!N\*\W'O\.:<6US-_G&,[9(@/S8=1P".8;PGA/V6Y1P0!\< M1#<%\*5TUZ`DM:'"^!JHEXXR;,#0+J5W!<#(O`!NT*XK%K_# MJ7JAFZ;!),!S31FP9O@U03BM@^+8#>&ML(L9AX,$A(6_=?3T8X[/P)LS#HL& M,*38J&X32&^";`;OP:%;=R`:[N]AMRU?N'=:\U,9@R""=(4`)VNY1"Q@2`0A M@*D)(D0HA&X^GQ-PXX2NF1=SR`)D$;.`XY-*[N`!8<#?#OM7'N-M@IPD>ND' M_X=4K>E.+`0H%5?BP$'#2]7SLL2-T@GP)W@$+B?P>75]^`6^!Y3_//+@P4"Q M'R8K]RIDJ=R/N+#^&56^IJX1@$T7W`.4]`#"7B;1/TB\?`Y4#"B7(E[Y/./) M'">KXAWN8I'$``D$-$$;7G\S"X`MP:4=4>GIZ2_]:Z&P_[%6;/UMQ5M38**%;`R MIJWM-PF<_8\;Y6YRA_.4^U7V@KA8C#C[/0;I%((NA8/]2%U`O8F%MN_N6" MG47([N#J"%\$S)O@K=!`\#I7Z01(=0L` M'[+%@K60L,_Q(!W4G-X$\M;L!JX+0/&"PQ(<$UFYI#RATDW6KPXVM7H,CS8< M]BRC`+DB3HIC*5Y6=E017D[!9!S"8YT.ED381GS79!K1R11=^8#%!1]5B`WV M)&@\P;50^,8<3H6+,U^XB5!'X=$ZEQ0/+'CM38"'GL370)M@$$@SK=9J MG=:C6"G"W_QI#EB(F$@&B.1.'M*#,HA+5J7K$SM8)AMMC<(:^>+-N)^'_./D M4X*TE]U]"H&>8`MHU1`]7*990'Z!WU(^R<.?@26F53_U%I;+H/M^<-X[N^B> M#RXNN^W33FMPH3S/K='5Z%DMEWWX:[F"$LL)3'!XUUQSA+EIRJ5[T,7C#\/X M)GWW:&FQ!0@J4<66$B@!(&)D[H95(837%`^F8`=#G5E>\]-1ZX@^ MIPO74Y]W/[R;P,]F\"?L20:0R'A?I/R=^F-%$I:+TM,?BZ!2=VW*ZA8)E+26 MGXY&@^\?#%=5(VKRQO9C[^ON=.-N^9\OEB:]US!>+<92-@(^>TYG6`WUOB@D M/5)$]^N6^L=:5N?H^#T)C+ MDRB@7!"DV4EPBW\?HJ1M*OW6$X1[(.RV1MA;)ZN^=I%;^.`.0EPTBC`/F?[: M>]1YZ\G0C*,>A@5R3).8N8E_XTH!F\:3##\3>(XB^*,_PP?V"U]E<0(@UF6+=[]\,/-SK^ M@#__@!<>R>NSNP5<#X^F[(4C?+9\.+Q*7C-+,$[UWQ27:E\.^Z.+J_[EU<7E M1>=B.+SH]41&W?G5Q<5E2STW=,<\E+&LA^[Y9S@.J^N!=V,>[!'[X<$%C2XZ M9X/6<'0VZK0NNJW.^T%'IOB=]_N]P<6Z!3UTSY,6='EZWNX,!V?O^Q?GW6Z_ M>S7J7*G=]@`.ZQ;TT#U;+DCAPUGB,7(Z$Y&)V]S$>P`WY!4_8.KNL7J4NAU3 M^!]SG#'<)!]UW.D,^KW>Y47_?:\%V^M?G%Y=JAO;G5Y_=9>PI)?8X4[XT<@= M[H1P>]KA$AT\Y@W;<+ME*(A5@54?YXF'W\Y#6`/&8WET_-N7HS]A=#K**84+ MBP,HPTZ4Z:24C^#)'`8L!V*9^XV2T;0"'LSME$P<'U#<,HF3"2?G0GKRQQ\J MH""67OT*>3I\#7(#MA2\P_^'C_\_4$L#!!0````(``&%:4=DH?`2+S$```D< M`@`4`!P`>&]N+3(P,34P.3,P7V-A;"YX;6Q55`D``[$205:Q$D%6=7@+``$$ M)0X```0Y`0``Y%U9<]M(DG[?B/T/6L]S674#Z&COA-I'KS;LEL+'S.P3HDX) MT2"@!D#)FE^_620E4;9(@KC$=C_8ILG*1&;65UF960=^_OO767YT[:HZ*XM7 M+\A+_.+(%::T67'QZL673^CDT^O3TQ=__^___(^?_PNA?_WR\?W1F]+,9ZYH MCEY73C7.'MUDS>71/ZVK?S_R53D[^F=9_9Y=*X165$?+3WE6_*Y5[8Z^UME/ MM;ET,_6^-*I9//FR::Y^.CZ^N;EY^557^ZJ-+<+_T%TS%+Y" MA")&7GZM[8LCT*^H6_!?M?SI:_CB4?L;MFA-DB0Y7OQZW[3.GFH(;,GQOSZ\ M_[10$65%W:C"N!=@@Z.CGZLR=Q^=/PK_?OEX^HB!+=1+4\Z.PV_'K\L\5[JL M%@8Z*>S[S+BBAG[YZ*Y=,0\"!V%^NJRW5^[5 MBSJ;7>7PW?'`0IY8FX6?5'Y:^+*:+=J]<8W*\KJG`FU8CZO MS,IYT9SY710?G2DKZ^QI\;HLZC+/;!A`GQKX.XRH^LR?7;DE=3V,E2:5<0IS MWY[Y-\Z[JG)V]?V0AMK)?5P5/RN=N[Z:/&;25^#9+&L6_0Y/`D`T\!R8(+(6 M4NZD'$VT7EZG%]?15'HW;^:5^Y`5V6P^>^]@PCI7MXN67PKKJM_*PH1))@]] MOQJ?Q<6B76M',L&S1S-/RX'3DKZOF`]N\Q>5!]-\NG2NV2W>#KJ1Q#I7%9CD MTC6947E7&9]D,IS`Z]//:U5?OLO+FWWLN95^)#'+V57E+H-KOG;OR[JSN)OX MC"/VP^3>4=[O&8PCZ*=+@-QEF8,'"L/Y<]FH_.T?\ZRY[2CX;H;]%+G+FX#W M6W`]S>W:-+)#Y#:D_81[I[+J'RJ?NP_@M\';+VRR0ZJM-".(TV-:[\QO!#7N M(\WS7)G%5Z?%?!?,Y6?U#5XV,^7JCFI[CC9D^:>YJR` MF'U>53";_:+JK.6$?Q"RC6#>5J%`"\I^HOU:EO8FRW,8L:<%Y/\7&?!>&NLW MU^R0KAWQF`+V&&K]&8^I6"C*V#G$J?[U)?SF:DAS557=`C[O$N0[!D.HV_UQ MTQCAVQ^'U7D']S%5;.4%]F'13]C3`CY"9OYUITQ/M!SLT3U&]9Y<^HI\#?ZX MK'9%?=762JTY#"1J*YQO:-U?A'J939\6_UMF1?,/^`QS:1MI MMA..)5@O_/=AVD^A98'/G5Q4;A&H[!!U4_-AA>AARRZL^@I?N)!*0VR:A23J M?5E_]8'30,^8T1UUSZ/ MI>V>CQA/V8?I;U4[5O`WR.,&AW'')XVG>JL)N3V#?H)^<-7%LIIU8OZ89W76 MIK"WG6@,@7J,A^X,QU#DH>SAEVG$XL=0$0G+=$IG^0*:\-M\YFP?#7L]:635 M0X$ULZLJ\.=*%?5R174@?5NR'T/)\ZI\%^!T7_X:"*][\!U#K58^JPUI/^$@ MYP[K&^>N6I3B=\BSH?6@(H0@:=XLNN',A_JE`?7?9/F\K^0=P@!C/'E0T[0: M&EMI^HES5EVH(OOWW5Z/10W]S)]#W@EV:[-TU)[!V(+VF.6'8=Y/0?#15ZYJ M;L]SM5R(`R=X%=+7W?7\-J3C"=?#[GW9CJ?40]R_L55_%?=_R'@*MW)$[1GT M$_2CR\/J^;F"9RTB,&7:9!:[R,81J@?^^[#LI\SZ9H16NQHV$PPM2`][=F,V MM`+KI:\38^:S^:*7SYI+5WVWVZ:K8GT>,K3"K7S'+K*^0I55$TH<:]6.M9KZ M3ME:48\JXOW6B),9M`L[JE^7=?-K!=WWI:BF>_LU?&Q9>NC(;5@5VHVXK40] M!9KKVOTQAY'[]KK-S+NA^;!"]!EB'5CU%7[E^3]E%P5X/04QAD4OL\!XX<# MC_>+*6]4HX;LQ7:/F$+9=K-)!U:3"%\I&TZ;NNQZ\>R/99Z#7[A1E84(.L_+ MFW"\""+H-^5<-S!<5BS:QN^3"O&DP0!B?+2/!H/*RD6EQUX5>O%U03SÐ=74< M!LJQRYOZ[IO%T$&8K*Y-^-OJZ_0;4>YD`#U<_NH%/#/=T#+E+&'4DAB92%*D M8V:1]\XC+C$GGCG!K'FL4AXN@RBK.QM/I=/K>56M[9+_@ M]?@FBU6+XSK@*'!$&>#[CC[?^6]R&, M_;3)9_/)[A68:$[\1I1'6MPI\&;K7-F20RII3!TW&&FL+4I,S)'VG*%81,I@ MJI/8/],JGE9YDF$PMX!?X9@A3@E!4<0) M`@?CI?1QK"4_Y)EX%#R4SV?=*2;QEC;;'=WMQRB-%98)U1P9+3`BSFE$PG]# MYHF3).9$1X<\W1\*UGJ9](``=EI\OBG#.*G[8^R!%\1+,4D@.D8>3(-BXBEB M0AM$8NHA>B*4\XXNC?W58-;+JH>%-'BJ&PYK]]Q2K<"94Z60UHXBIRQ#Q$N&-O'70UL?LQX6V++KX7S;/;/4\-A+IAQR'"=(),8A$240:YA( M.4E88BCI!C;Y%P1;#[,>$-@^7[K**=^XONGH(UZIA&&FA4Z0UU*@)'(.Q4IH M1%T48T.B.*)Q-ZA%?S6H];+J6)7#O6Z/'*AXUNI*R(D*7\N#IEN&S+)!ZKP/ M)0./O(7IQSD3(V==@B1W&$=$)T0_4]FJS4&<)_3:1I9&Q@$(%4>4"U!907C' MI")(""IQHF0DQ$$7G[IT6CFJ?::8*9ZX[VEYW!`&]=VU4%L0T88\C1.N"(T] MR"!C9*F,$'',@4E-PBQV5AAUR*6B`9`QDIVF0$@+%-QKH`F.K<0<$<9CQ!U, M5"PF$:()YSIBW$C1L:>GJ=8,T-,];#%%;RY/M'QPS65IGS@Y\D3G;J!($^H] M(\)"%`(QC^`N0E)!>.*8HLQ;\'5QQ[Z>IE8R0%\/9YI)DH)PY&KE?MHL]3_9 M/DT@K'4R!F6DU8@YB$"=,`PQ1KGW7G-G.R[S3U.T&*#;AS+,%)V^%'/WZL^C M=BE+G'):4A2%O0E"A/6NV`/_V%#K/19.X$,N%@S0R7T-,D7GAAO<0PX&_P17 M=*WR15;6W%VMNCB%M:736]&GQC)NG=%(,"V1PRI!-+8@CTHB3@S7V'=,YZ<, M[#OU9#F-O:;`ROWIM7:S_E/-TRB*&$ZL0DK8!%FA-+*243"@B54B9928CLLC M4P;R0R!A(/-,,@.L-FH_;.Z&Y*/%A+"%+.66D!TT!YSC2"F&!8^2%)X(Q MY>#GPX_SAP#"P&::9-OGW(6;A-;N=,AR<TV!E?/*7:G,K@Z2WVG0 M-A=M09UZ$DO!(H,4UAPE1D4PJR8*)2)6)/:$$"8UQ.)R,8ZUIUAY6U_$O MO-_658;UAFFDB#&12!"SUB(J;8R(%QA)[")B%(%XNV/T&?_)^KZW82:9.+ZY M!.;A8LM69<@VY&!$JKAT'N)K;Y&,?8P,LV3PW<9_:O6 M@YMI"GBLW^-=V,6E,$]>\/<$-G:1IEPQPCVVR$BOD#">(JP=0,46NUP>*0"[7#=E8YI*$FAOGN M&/G[QBFQ$"F`[,!:@4N0`H*\F'EDB8O"XI.%*/!/TOW[]=#FGNYNFBDSZG-U M&SQR^Q3Z,4%*J8$1X"'LBSE#DE%0T;$$6<-%S"C3(NI8EI^\XSMUV(;$N;>5 M)MF/,;O*RUOG5O7"O7S`3MK46<,XUA'X2K`@9C9"$9@0'*;T3L>4LJXG#*99 ML!D8&6,8;+J=&\94\ST1LITPQ3Q6/EQ+$1'(.HV6,:*,$"1I8J0E,3[PPW4# MPV-P:SW#)1X'>(O+-"LX`V/A3W61R_OUUVBUB1V_;YX:8PV)A$4*DDE$-0-T MNT0BDT0L=C:17MM#7J(9N/\'LM$DO;_^-L/=G?]]Z]1HEA`7CJ]0##&V!6@K M&N8_ZY3PFB28=PP3IEET&;KO!S'1]J[_[IH^^.+>Z3QZL]?F+MU%DC*M').0 M+U/L/6()4TAYR)RU3)C&/F*&'O0BR4#].H*=)MJG\;GLL$MC`U&J621CICA2 MBE$44>61D)\0A+DG#/(*K`+ MMU&R\&/*.T9ETG&58_)\KE//CF.C9\CB#O8JQLESN5XC?*1K&$='P6?U=X%A$VEJ68*QCC"22CD4FX0CH5B"N,+2Q\0(*SL6B2?/[P;!Q("&FJP$N"\H M-A.ED158R MI+BG2$1$@0F)T,)2J5C'>N+D4>;PB]'/9N/G0>A>:$LM]HPG2B$2N\5"'4.Q M5#:D=SZ.(!G'AWV+Z7-T[DY\=;#J)"<8R]FL+!;B+E\9-V_J1A7!5EM`LX4J M94[SV&N'O(?IFZ@8PCN#*:(DHBS4;6W4L9;Y7.C9K^N^/;(XJ*DFV15Q?R_W MN./M6506`M5Y[=RR$\)G)ML4PNXE38H44QF)D(^V1=:`Z MMS`6%(\YQI$FWG7<+35-K61@<(QBL8DV46U^IS!,O.5L\6;AWUQSYB'GV[Z[ M:A].J;521Q1+9$CBP116(,82C0B3B1&0.3A\T%66H=W+Z.:;`DX?LJ*L%B'; MSD3IVZ:I=H)J"L&:M4K`+.HPH@(;I"-B8N>5B).#WFUU`('K`#:=*FS=\1*3 M#6'K!JI4,,L)$1X99@F2+A0;/`P_;PGGFD98DH,^43]JNCRLX=8`,NBUF!NN MJ#Q7H9ITZ9K,/$2Q(]V-N?XJMW!+R;N\O'F>.S*?OBKEW%59N"K+5.'6TS=N M^>^V(;,'F]1[837,7"C2"82O2ECD$L(1%C32F*H8DYTE[G&L$0[L@@KG57F= MV?#&\R]U>`O?\O(0P/+JK=';W4=[)JD(-\."IPT541Y"-8\D1/?(1X1%#`9B MK`_Z*,!XW?[MO57<&?RQ,#EJIL7OWVY/6P1ISF8'X91*G#%24?5+,Z`;@X M0GY[/[^J/(?Y8_-YTFVX&H)_RK$B0G`<3D,+Y+$4R(8DP7)I(-,T$"IT!.`T M@?14^'LF8S^+7UODE!V=V[>T:23!Z*'>236#B4*""`HRT/!F$BNQQLXF'5<_ MV8_MX0:PY+.@YY=Y'39TUVY9?UC$%\M?[#Y`VL(FY;&@ECD'B0BX>:)QA*(D M-N$4M12$29@,.F;__,?&U+!&?19XK;]+=%FX."T^S76=V4Q5.V;,?7FED2`8 M>T:1"*\4(*V]0UQ;C:@@%.%(8,IC!G\Z1F3RQ\;<.,9]%MAM?+O%/F#; MR"1EL:3AXG0$T:A!F,$(Y$(H""P2HEDB-+,=[Y./?FR(#6G2J7/0D(N<^4[( M:L\EI5A3'SN!M"$,1322*!$R1I$D%A/*6*PZ0FN:DR_/D$\.;]*IH17><.], ML.Z97]RZ^7"!8DM8;>&0:HYUPIA"GG&#K.0\W.KK$8]CHZ5R1(F.QV63'Q52 MPYIS"CAM,-*[K%"%Z5FV?X))JF04&XIMV%)!D/-2H1AC%4("(26$`S8^Z)-9 MSUVV'\:F4SNJT[J>A^7"X&[!9HT#;VO<'M/?9@8I&)@D2EJ$.5&01.OP2BD8 M83Q*C$^P)*;K1>W3+`2-U=%;W-2@UNQP-/!.%K\F2^G7]G&"34I_]\OKLGZR M%MJ14ZJI,:&X`BX^T2BQ_\_>E?6VL2OI7U0`]^71CNTS&9PS"9+,`/>IP371 MP)8RDIU[?'_]%"79EA-K,=W-EIT+!(%D-=EDU4?6PF*5-6!PH=Y=CW.KN M-B$L(^PU+R5@FT#0#*E2A;+%(PREJHL4E"5 M>O.X7O*^4=(G!<=3:#:OV#];F=ELW$6?I"B9BK/@&0RC#)3U$IB7BF6'HE?J M%SN]7S]L!J%D\UWF,-1L:])YKU1DS`,AT909 M=(]Y&0%K]-S[=S^9LF&;3KN[57=Q?G*BB3[EY!UY=RZX/K]@)Q>*GEWHDW/& M*@\IQO4@]ZJ\]DJ_YN[BHEY_^%Y&NCC_.\W#9+'[`']?VRY3;V1V%*P.$:0. M`20OSBUO8K1:)5_K,J4I5Q+Z);68@(K:`RWG.*5Q_R.=_AV]N^C5]7+]Y^XZ6@\/=3(;:WC)@):=`$HB@2QYA$"45ARW>*HJ+Z^.>C#P8H;] MJO?44ZP%W\_2]WD*DR7)\/-E6G)C&D^NRHW-?VTSI9[3O-.&>RN"!*5$$?VA M9-E$FQ`U`VE"L%SX2H5GU#.!OK$R$"U;H.@/-YD6D'^8/A'W<4@TSF$==$(5 M)R5J?:C?&6#*>*"Y5*E+*)6I3DR[2GDT;MQ]WU`:C)P5?IK5_=V'"R/_/45Q M>SGY5XIN&C^M/YY\?X3]^\];O#@OZK-[IZUEY.3\3)AWI]0PKL[LQ<6%TNR= M.J.RTEX?]_R@+P2UIFZC%!_SU6:ZL9-^R&>3Q7V%W(_S=#6YN5H<=D&HKL.. MI\Q521.>K62@D'N@"#7`==;2"TN3JSS@'#?PON_=JQEY6X#O(7-)\7VMEM9? MZ?I;,4`.P=I![3NOJ3/2GE%BD$[BS.';F@M!=1O+L>TRHNR13,ZH&67#&=.\0!. MA02"6[1).7Y=!1/Y(*.M3)`YZIE%GRK0,&2L0,*]ZSO%,U3'IE]7SJME\J2T M+D=W-D'M"]FS+N&^!1D5/74F*TX2;D7%'@!O=`:E:5X7-F'&D=J2H*-&J?>) ME#9DK4%.@>IB-;*3Q:-3VHO9_$_$,P[EY.L\+6-3E\D]MR'G^3UU0B2K2BR: M<#%#"BH#R]JO%T>TU,;:FJ+DS4"G"5T;>8]_3!:K<9_-;OQUOKF\*Z.ZVY^\ MM5E'.,DR"*1EUB7M"2'`!-6PQ'DRQ.M4Z>NA;\W%W"<1VSB=5Z$C*VW\B_M[ MO3&>IFG*.P-#][3LC!=<1X:6G_<9:-84'!<4K4'N`O-<:5*;O?F-^9K[IF,+ MW"RSAY2LD4BAURSU<`#%:B_R3(]Y9=YBRE7SL9[8<'7>$\I'E7W.;$RY+DMMQ:%4HA/6G)T85;+IH!,[GXXCC:#0+*'H`+83'G&A:8 MU'J>J7GCN'D9&<>!S#*5Z"3>&9MKJ^%DNBKP<+)8I'U'GQ4==II82Y;A==H3 M\%822"XA=9(W.7!5K-=*D(T;8#\\R`:B[X@B[X%FST?;4QUT2C.T:]'D]48+ M<"HKB!HUR42<\#$)I$WEZ2DC;QQ=/=%S7!?"1W=;[3]8M^T<53HQ&2`93TMI M>`.92]S)-=,)U4:5>:7ZQ-Z4:WL(2HZ#GO/U2>#:,-VH=O(L(&WOIF->A)B9 M*_EM$T0:/"B7>"%'5$3ZI'GMOO2F/-\#$W5$45?"YF[JL;6ECXY*%2U+"@R5 M%(DM!0B:&3A/!+5,ED;SKA:(C>3O7:N"GA*;'D]$!![?M0LC* M,B%`.Y>!VI#!%B\<4S93Q35GH=+R8VVNDHWGTGPQ)2N"1WX>QF3ZG"0+![;N MSJ4^%>+"G/,+0CFUZITX.[7:&$+)A=*GE8`8-2-+GP$BP]!QM*.3+[->#DZV M=-.%Z$P2&H=C63E)LA*LB@R$%($[CO3@E>'U3+T%1#4BZH@:4#FC7HW[14K0 MD]UTR5K#!$N0HRY2.Z#)2JP'J:SP1C$I0ZT>]*;BI@`>L0[6G5*$"EUL&`-4:!\*DJ$*86[@[;,"I/U7A]I\[G6 M5).MHT]5W5K"31:*,+#.!Z!9$2#2L7)_!%4KY;1V1YTKMS>\_%I]=60Z_SN! M0E.T#,_5UY9E85=!\^VE]4[B_]ZLKJ0=L-OW]8K."&&SX@82L0*2R0&*CQXL M?GB60;\JB%@M@!^&'4TX/8J%4 M).;@*9#L%(MKRKC;1A;4ZI1]!&!R)L6XMU;<[CKZ.8JDC+ MA_6^`]^/GNN28B$9;T`([)(IQL!(:X`G)806,EFYUW3ZMUK?DY.HEB^O32E_ MG`NBW/B>3&]PJ3^LH-.49_-T?T`@$TY)!)4`OY648-JYV@0R;:!S-#S_61WNA=8M,+0^7]X%G+M' M.N^D98HX2%P8B#H;D%Q+R#%1ZEW6-M1>G6R"EA=SY9=*"-6$J4AMOWXOXWC-E6O/\+BW1X6S?:-$)$8.UG(/-E@"UU("S^$X3N(\N M>6E)Y7EV&Z=7[YQ_&7&:^5LWA[R;\T\]WE$BG"8F%3`SR"E8,!Q5;.*S3UK$ M9&K#&-K$X?7"]IXHTU2U7U_&.4BQOWNV,]&0;#,K93(22$<8,(Z(]C(Y*ZVC MQM?&1+5Q`_:MJ?5!HC:>Y<7UA[P41I]GE[MJ%/WT9">TSU05OSU%>]EPXT"J MR"%1*3)*+:1=[1W+MKIY'8=^^E#KMN'TG@/8R^^[!3A%ILO"(?V\D=DJ* M?X[AE`A.S#&9+3WJ@M]#\/H%Q&EC9B\2OJ>4)3E#V7,Y6Z9BWY_':&>[3CD> M/)$.L@T$."NWZ!C)J+0(4_QFJ+)6WOYIH\SU"X2^:=5$L4]+I],?:8J4N"QE M'^+59#I97!>Z_#@@T=5A'70EK1>GK$02^%+JQGB(*BC(/%(7J`CNN/6_?I$R M&-%:0.:_9M/98_5H/TJVMNG0O%&&90W>A@`LH5!4N%\"U28N3SP)K3RY:B-+ MCM4#W"?%*YR%OTOYC4;'H_TP\PT7V[A;,_NWHI^>Q'V<.R=\.]XSY4)GQM9*OV"X[^R-2&[7?E$]8Q-1NTV(F![`DUV"E2F""LT&9DF/FR)7>W@)&6Q"O;2SV1K6@4K3NR^S:7:XV MQ\>CNH_-OAM:S2#.9N&FO!=?=(YRX?KV_11%P=4C.[['UUVXR7Q9DN2OY!8W M\_1(0`_]GI,8)Z47=[DQR;-T[2:7S<;PN2R0^>V'_/'2A;32Q^\?_(\)"N1Y M^(8_7Z#DG:*]?KE*>/?EF[L^F=_U%$^N[]M\F'XJ7H!20^C4+2:+QO/Y\B@O M<(]O*X=O_YQ<%N\JKEPW_3K!%ZV(L1&_T.R%C;&S>S"?P[<4;TJ)WG??\+>T M>#]]Y^;SVY*.X:IDNEN=798.QA_BSS_N'M&P4AM7%$*"CI2&6N\RU5VH;Z;7C0*H_<@ZCZ>X6%8.I$!O^ MC&%[;ZPN.][4X"O_]1@1@-BX=ZC]'[ZG[/)]/I_\#-JL6U?UA@I M/U>#;/"*YC.9[?;7E3OBL^G*AM_\^Y@* M[U/D>$)4;S[6648)-1IE18P.2@0+"*$R$$(8U]%30?<6DAI^-OO30#[Q=(+5)<>S>? M#/*HZ*7CT5D:.2X"YM"N,A%1;)Q=U[=V`O>RO4?ZP^]>#^3_E+Z[V[6[_^-\ M@I/X[BX_I2LW08K/B_=W@5CX1W+S`_>YFJZ[$O?CG15H&1H"U$BT$7F2$$1B MI;2AU*3RFL^PPG!PA.S8,!L1NK5@W3.M]],RCR__G/4#Q_ON.BZY=!K'9D4T M$#CC()26R!;JHK"6"E:9>V18H7S$$'P)<8\3=OCV7>%>=1UV1B@F`EMBHGN.'7B5YCQ)\%[.;GF3P0W]=LBHHAO*`&A]! M6%UNH:#F[6CRUEB12:W@'38"\>BA5TG=XT3>Y$>ONU[I#[F!7#`T`Z[`DI@? M_XM&BI*1,#@E)4J$RMC78?)4?MP7]-9) M:7VV@:$.:S24[)8@N%-+XGK"7%)L[XGWTT`:MFI**R"UI>VP,%HAO!<,W7?5 M46LC+PI!\H:#D[AC$HYJZHJHFS_>8,=\?Z7YUU78 MY$GXOYO)8NF):_>BQKZ_IP?Q$!J8[\(#\,<2-3C=+"B(O]UYMP)\_R]#!9`X&W!JJ22BT58&T(Y; MD#:RP*)VK+8J\U$COQ^4#8CX:O:\-M"7BG_E1@@^\L-=[KE$.>R+.ZF56=YG M)2D*"#9K<,E&D%2$[(HSY[ASS(X-P`'70R__O4G;22*M`,Z5!JT3` MQ1`AJ10TT2ZR7&ETM$F+\H874)],>VT+YN<+0\OMXLLW-[WSDS1:.'O'T?G@ MN0I4@?>EZ'TV$BS%KX%8(I*.P<7*5(C#GJW^!@MH".:]MH5TE^`I;$KC1HOG MR7=WC/F8C#*0I!)`N!"0K4'JVTRS)B'PV@BL8<^0?X,%TQ?#7MLB>:2J[O8* MM'Q]9W1.(F8--E@)D6L+.B(N$C/)&$VYY96R9=C3\M]@J?3(LY%=83_-9'F? M_*-#O;.M>^R0870I,6J8\L`<%Z"EH&!YN(MR\%E:7YF3S_Q."^*5\.ZUB9%? M;N@/;IRLWX<&8;*66`O6$06$*0YH+^,2:]M$:R%X>8/ M(93T;(N/[K;TT=:JV#Z.+B9+A3`)+$%SCED3`1$3\%,(E"3$<&TAH-=WQEZ- MT>%MC%XY>!S&QN,IS6_PA]E5.1I:`6D:UVF`&QH>!P^I"YH[PB*JKRXS,!QW M5&=I6"NRP6CCV.]R;O_29?,*F?GZY='2S3>:%%J^O5,\"!J3@4P#`>7_O[PK MVVTCQZ)?=#'<%V!>TIU.3X!N.)BD,8\%KG9A%,FCQ>G\_9!ER2H[LB27BE6E M;B-PK*6X7!Z2=R'O(2@O6@J"\U)*3;4/'5/R7%_@_CKVGJ[C-MR.8P[?=(@A M=<4?Y[LO6&,5C`PJA`A*1@-)]1;`I*<[QP=V1G5,071](?81]XM"8W5MV\&N MQU_,GZT/STJQ-60S*HL8UB@30%"2$Y@J!CD?%3A#E?(<4ZD[GNRZOKCZ%#>( M`@,X\D[QXY;W6RY[L;W,.,#.<:(%E18B;;""`A9)FH9K#YHHN;LBC%3"Q=\E M=#ZUG:3_L9O<=&A'=K8>B)X-]`L:4IE`%,%,0EI=#(1(&"C"S5;`6(CTXN\2 M+)_^Y.AI"$>>(R<2[9:LKDK2L5IB`50E2\QZC$#9M*ILKR6D-[LF=;F^6/C4 M\'[A0`UA4YQQD'9_3!(CY05B@"E3P(+@J2]8)LN?,2LI6Z:V>Q[ MTY+Z(>S)SQ^S[P3?L)ONZ[J)8[6V&!9NEK=FOF5WR;&+3/B6DP"%59).\^XH ME0Z<]N;5ZS!EB.&.53>AGN^3?;_ZK3%S_9PS:`1#9,@*>>Y42"6;UL-_?4NG'T MN4HHZ;G+I_YB1)!,%`:2,`W$(\9EE$SZCO`8QFPK"(^^!3<$2#YLEO,Z$WJD M-G^H_VR8Q4ZR>;[V3.4%C3[]`Y9^P.1`C=?<@`A6R,B(=NPDW].8!S`*@J-/ MH0T!C-^-NZOG8?G]+2K'ZP]5/-A`A*1)6-:#4IB"36($Y[R)WKNH:4?/XC`' M%@I"HU>I#:)L!+-J:.7?LJV\_E`5D)7!(`6(TPB<40)>:@+4,H*9H5Z:CM0= MPX3E2ZHQ1PA(XJX3#3JF*2*.=K;AQ*:`)=I)O*050WL6FX"%UEG"MAOJH?0@[P#-FP8MC^?)>F?SZ3\&Y/RM!B+!^^ MQL]YS5Q^3_)_7)CR'9W5XQ;\QSPI5K/\UJ^FGJ^:YU>KD/]HQ:-/E#]FV./= M0ZHZC^2'Q?*SF86&EO4I0UHGPQ1QBH^FU_(K0R*Q0'E#2SL!*F79@XG,^ M%Q&M2OMC])<3$)14,LHBYJ7B,9+,!U&-._8M+U8E\?JL_$KBX`PA$73$#F+^ MB_ED5EB,C6:>6$$ZXG48+_]5P/52D8\!UWV_GO?R#8A\K8C*.T&XURJ3T`O@ MBG)@3*4F$61U,A^XMQW=@,-$#T8%78]2+6-\G:NY_;):UU_S;&F33[WH;.NY MGV=FM:IC'?Q/20&?KY?)YMF8V9[C;$HJV]1GSQA2V(_4?^KU73V_F8>&!7,W M^IUE+>`,:90;8@"UHX9->RP*E MFF)J6$>9<,LY]19+]Q_;^X;E^[,%'%4OJQB:-?=B^KWYUU; MG[QSZ_JA7G\?L!GY=3NGS);98K@6E,/4QJ["_S8)M[\\E/(,OJAB:$SM]-?/ M]>T\Z:,NAQ@>,VO5\]M/BUGMZD*B/:?B24KC2=7_8Q7B9O9;6HM7G<^%HH>[[>U\S4>626L=Q.C3 M+!=:`0Y(@D0B>*JHY%V)D@J?=KMJ?>"R$9@J8G],P%-&,VA+CW))*,,4!,(" MC'84@J,\IPH-,GJ5C)F.*5ZGJQYT1D]_.L)E0S!5`.]WDW(8/EA'A632K6RD MP)HTT4)14$G]`A,943%2;.5?3F48$\9]C<)DD1S6'^=N\;4Y6MHW@MME5\13 M3*UQX*(+:=?4%@07&(*EV@1LK+8GTT469A.:W1X718^F5],(SAP,@ MC1!@$Q..,`N[5.]H:@C27J? M"L`-(OE2#P++@]%;3BK^J7QH<5< M^N_%;)8$_&]N+3(P,34P.3,P7V1E M9BYX;6Q55`D``[$205:Q$D%6=7@+``$$)0X```0Y`0``Y%U;<]NXDG[?JOT/ M7I]GQP1(@$1JLJ=`$)SCK21R651FGPY!9^,TQ.1C-)QE-Q].?TQ/*-# M=G%Q^L___L__^.V_SL[^=*^^GGCI:#8527'",A$68GSR&!63DS_&(O]YG2UZG12A5?B020S)9MBYO,D$[=?3I_21*($D$%,0V'TC[K=B^=[\>4TCZ;W ML7QVWC*3=#R.U%=A?)')(HSBO*$`=4AW*]QP-IV&6?2W&--I.DN* MP>V^'E=BE&9C,;Y(6)KD:1R-U5P;%O*OFGSYX'9P+^:]\W90ZI7'/N!^'MQZ MXE9DF1@OGK<)U%[JW8IX'=[$HJDD+XDT97@ZC8I2[W(D:1"%'$>N)5$-+O?V M[(RU1EZG$=7.1/)GQ2P3WZ(DFLZF7X5G7T=L78:9A&0BBF@4 MQKH\;B32'L/KRP\+\XD?IX^'X+FS?T=LIM/[3$R4:WX07]-[6X M:_+[ED`WC`XGTN0F:2P]D)K.UVD1QORO650\:S*^GV`S0:HMEJ3-I>LIGM>6 MD3TLU^G:C#D_C+)_A_%,?)-^6WK[$I,]7.WLTP$[#99U;7H=B+&,-"_C<%0^ MNDB6#?\5R=F3C2;R:S]*I'^-PICFN?2PUY.PH%E%:4R+99]!(F/V69;)UZ2 MP093K3GA+@5329GQ3,:IMVPBOQ.YW.:&6?8L[;/:(%<$VA!7?[A^0'C]9;LR M[Z'>I8BUO,`A))HQ>Y'(CW)G_K27IPTM6QNZP:P^D$I3EA^D/TZS?9'[.W;%6"/[ M;T*TF4#S!)^@=YDH`Y4]K&YKWBX3#;#4(=64^42HK;2,32.UB?J:)G?7(IMZ MXF8_FON[=L>1W1L-%('8NN$JS1>)$% MOL["))^?J+8D;TWR70AYF:6^,J=E^JLE>SV`;A=BU?)9=;HV8T[NN=7YQJ7( MRE3\'GZVM&Z5!14DS8I2#8-;E;\<2?&]*)X58ORJ:3WUMT:_53$OTT(&@M+L MXN=R\.A!#%76MG0A_&D4S\9B[&?IE(7Q:!8O^&T#@"Y&;A6:6E-C9Y]F[`RR MNS")_JYJ/B5B=7I^ M&SKU@U3#>R_"H6U&&N"I1ZQM`=937W0T MFDUGI98'Q41D;ZIM=`5K,DC;`M?R'?NZ-64JS0J5XEC+=JSEU/?R5JMWIRPN M2R/H5+93%=4LS8O?,ZF^'TDFPE@]^CV,DKSL+S?EZL/:OG4/_;J&=DQ,]@,X MSXMHJB;/>M+C0?*A[%/NFX=A+-;ZL3C,\^@V$F/W615Y9M)IS\)XE1EL%^F. MN>L4XIJ.X0`:#=DMTM'/P;U:`U0(LY>S+J=!JEWF5R'LVC=41C$/ MTL'K"7$(R9:%4?]7BZ=<.4OH^)/Z6#/UH$FM71'JS;B=G1HR-+O)Q5\S.7/Y M0YV5=TOS=IEH,L4T2#5E?N'YA]%=(CWY2.VU1B-5S14E=Y=I'-5X/>8P(GTP MW$@';0W0AZ#+!?M'+FYG\5<9@^>-TPA]#-T'.*V:[Z\PX]4+C\O#%"\LPC:U M6&^(/H2MMYIHD.J%^2P^GL MII#394&B;OS>*Q,;`0NS4879XN,Z;,NWT*.D.!]'T_-%F_,P?O4:UI;WW*M7 MU]7K\:B4>:UGFPS)SRI7(1$>B]MP%A>:[&VETQ&SZ53N=)OS^H),JZR6E,^F M8GHC,ET^-]%HD\F)I)6-9C?B;`F))JL[*&UD6!I)E)0APU?99M%2\=3\TH3Y M>.*I$,E8C+LCW2Y./@A>C!^NC;\LK\Q5M=%%(:;+\60' M$7\YE?2#0TD$EHDLC"`!'F(<$L(-ACP&?60Y#B"6]U*F6-T%DF85P"T*5:Y7 M^@*5W0/'H[9KF)#8R`$8(A>[="&,!0RX5YB5O=!L=**N33P MU5TK76LF[1PI*9A\4$[_SZ,XS<7XRVF1E=-O\3!-"FGO/"['D#-?W,U+E;?: MR3J&MV%^4P(YR\_NPO#^7!G0N8B+O'I2FM29`18WQOQC\3B0H?9X-BH&V5!D M#U)6^A1MFA6[F@>�%%W&.^P0CR.&0(+Z!``/ND)Z/9X4T/-J(#=9RVCE)I M,/WH7B6\%XSFWHNE?;L!O.T3>(P[@$/;<3F3^)BNYUM+^0R3!1M#G,ZL86MH MM;*%=M2U6?>M`?3Q#*%_`W@AR]'J_Q"];PP2?MQ+V2_+M M133\*CK8VR^`%@8^]Z'-.2;0="D`2S`@MV!?*MT4VF_59Q,5I-VAHZ'8RTS< MA]'X2N1"O6ZN2B)E+!VG94ZL$G&GB@^@$$!J(8.YIFE:D'D2)^(;E3B0R M$31[TO_QA'-MP-2'^M?Z*>=8<;&M@$Q MF.E;W#00`!!CA@CR*Q8]^]BBQ\X4D+:+DX8J_S=*[R=A-MVIPY>-`M.'R/:X M;V!FV28P99!315&21;^O:."(E-<(H`9:&R2C-$[OGOEH-$A$+1UNZA(X5+), MY7[6\1P3&R9@GE,Q3(FF@S4_@D9;@*L=_0[E+D3&L^*'Q+FLEEX%SL^[TXFOF@6V(YD`P''D&FZ9%G,MYBT8LS%"FKGA=YV-:HB1AO*&%X/[ M23$)XVFT>_Z];1@0N1ACW[&I-"^7,LY,LUJG;>!9MIX"WW7RJ3%*.M',0_AG MFNP.8=::!)Y%($,^-J!-+0=2ZIC588;M>40O;@'O.E/4`!\-A5TD12;D!YZ( M[.Y97;\A/^PN^=C5);`!`2ZW;`@\;%L6,&R.5@Q[>AM%\*ZS/"WBI5/B(\<2 MH1NE7[^RW94\;QH&V+$\%P#IZ2U/U39C9-H5)^3O=9U0OL*SW=(AW/$5: M;4/V"TU$<;RW_GIOWX#;C&.'8X/YC,G9Y1)E;2&+6/ M;RU'5W9US$;2.)98%)W7*=M?+("N!1BP?6`8#N`F`M3US8HE8GB:\4)7X4*+ M$+\MU=="1"<1,KN_G[^O%\9U%+:U?6!8E!.*#6K*S MM%8WRFL+'0U%+E_LV%=(\;9A8"#B,AEL,L>5,:=A.RYVQ*=);2Z M45UC6/I8/K==7>H^KW^S)S"O3R3PB6-RZF#;I!8U?,^EH*H;F?8]6T]>Z.MMXWEM'*)G%G(AH[A$H@0-.G2AQ'D'F\PWH7:=EA&([P^ M@B4<7:!]G`;06AW=(<7P1*Y@SS?M"P98W)F4<=8A2V$ ML][>7=^MX+YO0ND&/9U3DL6+U]?IFFVOW:?W^JQD2_.`N1:Q#$(=@I")*9%\ M5T7;#@)`[\:2UO=;O:BY)8RZG>*_$K,?]VK^=3?3CO` MED/E9@4!2^X_$:,6H%41F@/IJF[DU^[MCLT;M`9H']&<)^:_E?;J.K0-H=RK ME@&RH&NZA,I0AT%IU]!?EIP2"%P]XVB])*)SXV@'GN[=AVHNRL#U4F11VI+C M>$TU8!3;")N$(],%$)H$X.I2"((YT`L@6J^K.$:7T1#*/IQ%==7IBNGOHF`S M:?:K'Y7>]`;\CFZ!`QT+,`0(=P`DF&'#9)64'F5Z6XK6:S=Z%BZ-8\B@R('.X[#*+66=@QMO;.ZUE_L^06+1'N@ MZ9P"A4\J9GUSRU<5O?ZX3Y/A;#02>5Y>>SV)9*BC6LCU:G$+U;9CH^:4`V:Y M7*Y[S""&`6R;N@Q6IYF$8*RW96W]U:%>;*9_./NTID$BKJ/I-B?3E&S`3-L# MD%/LNS;PY3K*EV60Q#,L2\N.VG^#Z;@-20_,9FN2!+P26_W@5)24S[ZK0DA1 M=TNSGT9`'4J!;S@8&2VWF0'51+C!=H\KQ49/9FDR_2<)D)/>XSB[H2K*5=6XAKNH;WEQ'M`*P6GT9R:(,N!9_G+CBHEFQ/X1\M&_%NDC,DX_G6TK MD>QRR(!AZ-G`89Z\C`OJ8+%.2Z]LR);G`4+!KE>9H] M?T^+]DJ1=XP1N)2:0(8Y+C'5]6H<6]A?)0\TW_6$[SY'WSNR_10HWA1S?M7+ M&@O.Q?@BR8MLI@2=3Y6+/)^),=A@?GJ$`NB9KB47!63X$+K`!"ZW5]..ZIT# MP?>7Z.\%OCX,:5BDHY^3-):*R/E?LTCN[H621I1?#._CC;F6`WH')@`<(IMZ M+C2E_"9SE^_INM#2O%0*OK_,?W>8_1H[49YQQ?)J$EPI]':YG$-)!1;V,.&( M2+2Y3P%U7:N:-:Y!J-X]<_#]'2'T!&#KB=Q(Y&_2A<,PEMO?2&2#Y-#HJ![1 MP#`M&1;:$"/B2Z5#,4_UA'!)U`V:+]5(S0XH])-)JLY9_91+7) MKU/%X^&YV_J$`]\VL6=[/O4!-Y2XD%45AJ[/#*YG1Q_K8*`S./OU18?;43VB M`<7J>@1H(.9!Y/G<0+@ZUW4Q=S1_//5CI?D[@;*/0\EA^"#AR7T)X\7T/DOG MQ8!MG5!NIA[XP#-][IN^`>1D3_Y_SARV>+ MOB^@?'Q\_#1.PD^C='I>0KBOM&@XFT[#+/I;C.E4O4KUJ@QQ0X\K,5(:'5^H MM$:>QM%8O0<^+.3?$N[![>!^D4C+/5&$49R_%%,\%2*1!$Z[O@!QL^(6%\Z. MMGR]?F?)TG)V[%K;'";@&*H[4`BAAHFI2UT$3+GA=WVDPFQG[]W,'>WQ1Q,Q MGL7BA6WH"EO>"K4K"]#Z8`%F5%U3!GWINYEI8T-N4`$X+CZ/XC07XR^G1586F2X>IDDA_0>?7_WWY307=_.@ MJN,IL'@1:)`-1?8@'>*>B]\V-0\(4)?AV*;C8]-"ANE`[E=0,`S[NG.SUA5O MQV`1:>N8]I$07;"I8%DPFN^]]VMKGX`2:KK4AZ9ER<@3<8.X5B4?0(@=[T5P MS=2U6?>M`?3Q#*%_`]AS#]R1Z+_QWFQQN:P<^+S"X8T/F&HYI M4FZ[%N8FJ5@GOG\DMX>UJ(*W=R^WAHZ&8J]$+F2WB>3!DSN;.+TOSV47LNW4 M;9VN$A;"'(M@8F/F,D8];*]L'9B:F^CWH=X.`.K#9:N+C0>WZR5)N\.\C>T# M@J#)`>T'C9'Q.C4;C@2:&>"2QY, MDZ"Z6L(5QKI9EG8V3<.;35O:%,:=AU`"X\YIZQW$B=N88HL1%,!:X1AL%A>] M$DGLFTU[VA3VG0U2`@?/:0Q-K`!(6^&M$!A9CIUIG0,4F+1JNK/I1YO"P;-! M2CGU3NP+#0VG-NSG"FA@C.>("=4J:2KQNYM-X]FD\RX=G@1^#=T66B%KN-1& M0X6<@-;'[GG[!8MP:"?Q.963CX.@5/*X1C+$O^02]5A'!YZON``:NDU1RC>KA8&.M?Z-B!' MB>;]X'>'LYZ;`X%U7J[FH/70!-/<0.J#NJ:"O@:PX6V8A6N;UM1SQ(ZL$Z8K MC8#G=*F7W]_=/&N&,672Y+.E/&'=VQZYD#U&%PZ"H-=*SRTUXXTO'()2*2,HX<(I32S"OJ$=0I*F,`^M[=5D\."9V*)?>W>WW#:Q M#1/,E?#.&Q>JJO(W\V%>"6'VIG^LH!S'.3B\?B%WIQ&TG^^+4LMSE?]7X1M^"O MY79YM;@=][U/ZWN8Q>:KOUW_-3*I/[QR?7=?E5_C%_^M?+O>9'SU8S63?.^L MJ\/N*SD&@?ZTWBYN=Q4=)XD*MDOK$P1\^7#!-4-&2*B%DLTW,C<0O];CH?3S M2,'LPG)S8GY^ID=K8;VJZV)WWJ=]\6P!<,S[Y5*"V&(5,V\$W-.#K?)IM_9& M\PJ>R9/UL&ADN4O=&LKO%\M8I7!QOPSJ<_?-Z6/C"H608"(H2E9!)CR43HF& M3NQXFB]X-%?@L%P?$IDL$G!U]7#WJAD\2!1J^V3*9)QFA.PX$E8R246>QDM+#@L_P>!)$L:5NTIZV3QT\<*"A17Q#%B MPCF&B/3*DH8*8&A:3Z/1+ID.R]@S@,C!SOJ*P6H;\`E3?WFSVI95N>EF[[%A MA?!,1[D5%L>*5Q91CAHJ,==IP9_1;J<.R^X!@>F`[G74!(+950W=#E]VLG#4(Y)E!06P$OM@+"@JG`/64H6;D`,UF,^L MG%(NP9XG^MDVY%UK5/M0Q0^Y7O3N+'E*G/N[K*Z6F_*8AG?Z9`5'#@A(J69< M60050++1HJGP),V=/YI%GW6C'1/("46K[O0\D&0=GJM@0B*G$.*.8`B)!I:; M!@],8-I&-YI'86+!&@S'A&L#1V4]:!#EW?WM^GM9VF557M4\>B$E*=,42'(5 MD(K5#CVGDFE-6^682IWF2Q[-!S&V@&2`<#C9J,7U;-$X-$M!A'+*"HLX@8A# M3(EJ3VGM$GL=CU9K:T+)&`C!R?6]OUM7NBD39=L),T5(.3E9`[`AWW#B!.!,>:Z5)^V$0 MG>@*'ZTLV>3*RE!(#JRR#"0MQ^K*<\ M%Y"3:S'J:N=^>GI]XE1%YND@JEQ0(;*QA%[;=B`,(D39!^#B_X"`!. MK<^<)S\OIB@00%I0S(12R%(E@H789*;H8!(DMH*]>%_S2/@-K=D\726"^*$4-`Z+#G6H,EA,QHGVE'P8AW#DZ":8T/Z?;E:5W4@<;?& M!D`?(/Y07I=W]UW[4<\9"L*`M48@#)R!+'K%39-I;XS7:?6`X,5[A,>!+V$W M>A*#"\K8Z@<)7G9L.+W&A@U5&@Z5\EXYR"E%0K7',1,D<4^Y:)?O&,!EJ3NQ M_+:\+E?7FR?Y+S%:&]ZS7!T+)!T?6"@`$;>(2JPL5I@!Z!\U-H<26[1=K.]W M%-2RY"!7ZYOE]NGE]==K/^X?*C`WEA+LI83>8PN],RT%'J;F&EZ\WS89H1P\ M/G0+(B[WCW+[[N;3XN\CW.\SO/#AU),>(V^#Q:^==`HV'FFC`GAI+S\O;L,I8D;!>^?6[U8WBJO[5FU7[X+^69156\C7\V2]7B_!5+FYWM'[ZNMBJJIGI6FW;,<^_[U\N MEE/%$3@`A(CMTKF42A.A?4S95`1R:Y3YY6+I8=LQIHQ%6FCBO,(@?'$:[3'$ MSH!W]_RY$)"B(H=9!)`5%0-)#2BC0, MPS`<%C^W\Z6WL!QVO@P';E:E[NGI^Y*$_C9IGWD*#RBCE!M&F05.J-C4NL'! M:'\9/I-!&'U(CD:$\9\K5G/V7\Q?FB:4HMH"WUDRL---<614(:RV#@''K93$ MA43^!IT!<'F(LRK5(G)%=!+`_F7*`^+\IQ-NDN7X/R2^^?'W];?RFH5%1A; M?MZ>$)SN&EH0XHDU`GK!.`1&<@=4XXEF=FZ-BJ=G^GI4?"\IP0%@;ISDDGL@ M%0!<^!@AW5$FA$C+1QS?0)R+Y`R":L*]Q/JNP[,`\=&V]H<'%,1`@1#7-"J\ M'E@&54.[!8*G'4/CVX-3B\"@J.;8,G;+:_&SRTT,`@;PU.?-MEI<'4MLZ1Q; M<&*CP)-P\E/$#6'8DH9>;&&N#/M)LEE2`\%#HSJI%*5(3R&]1=@!#`BDQ"@G M(9(M?9[DZI?94VH&Y%=?23@1H6Q)3&-UU?YMO;[^:WE[&SZX-ZOM8O5E&=ZS M0^>/KK^7UPVWY[L9\#7\K-[$(>%5]C[M3G>_V[J:98/(5 M/O_CI!EID@POI`K?(M;,.QV,8$0DQ1.6@P4$10+&`Y!K[30#0H>B5PAZN,98(.R\WD5I;&PFFWF MUH>X$W5$'MIG"A-.0V1>UI?21Q9 M#X]#EC#7X;-&?_]]\9]UU2OFWW^6`G+'*0-*6*ZE`!92(1L,!*"Y',%S.YO' M@W!B,7I<^Q^+N[(["'K:3`7Q3CA*"?-:2R*A5*C%PF,HYJL%C,+Q_E(U()K_ M;`F;G4YRB8*57Z!BR<_;V_)J^["X?5^MPVFP_=ZIWAP>%&QY2;@PT3]/!496 M[;HQ[,YVI=R\=)S1^/>BF^]`@.40"?.PV:[ORNI#>5L[8#=?E_?=`>\CHPHB M4.RK8"'BE(:OBQO;PJ9X=TFMS%'O3$(Q'&(YI.)3M;@N[Q;5?[M%X?FC!;;8 MQ/J@U-E`E^(!%OEH/MBYI4!GXO^9,"6D,9CUMW*U6&W_6&\_K>L.IMO#MNSQ M`6&QC''H")+.`66Y5X@UBXV-ZY-X.EIM]K%Y.BA8><[]<`Y=E9O-AW)3QI1^ MM;JV,0U_?1\]V3U4@![C"^,Q@P8BB+2A&'M*2.L-\MRG.;)&*[>>3QL8'KMI MC8\_-^7-P^W;Y M[AZ"'EQ>J[MUM5W^WP\%FD^3E0.3%511H$GLD6VC;U(S@&F#")>SNXDWD?0, M@][$\O0D>>DTV0D#"XG(S5&MMSQ M%*FQTN9VE>X_+?X>>?+9E71_=U]681&K+['*?YT/=[-K(]`KN:O'Z()Y:`TE M0:B\,"PZ7X-VC>.-8`X-4ITF0VZZNQ*Z.D86(&CV5!/-N%),>,LEH`V]S,A< ML?ZC65R#\NUY&XE!\9EMYE;[4:N'[=>ZV59',/GU`05RW'L*@(=$.(X(0\BW M<""1*PQS4MQX,!:_L*,'@"B/L^7Y0CO#&%-H:0#G4ED)`$$<08M10!SER M\XWTGLNN3NZ?A=#/)@>SB\?.A?WYV1X65FZVRRL3KPU4W>'55Y\OL+3&.,UQ ML.FM\U`XUQZP3*-L28&]NU"=R9[G[><&`"6+4;JNRN6755]>O_9X@3D5$),8 M)R#6$4H1@JTN!6@:J\?LN3TLJP?`).6.[T$MY8"FUCVHH(1!'"QCAPR!R#.I M&'D43S/+6C]#:VN#PS0H;P\>P'V&%8)+3"C!C%-#@*0`,M_W0_1W%K-3E*K#@6'SF^,`B:/R& M*!2H=5P9J3C!K2KHM$CKX3Z:>CRF\W10H+*8PN5-&99\?;I,=(PL`*#",D=$ M.,*PM\@ZUHH_@2PM:#=:<'=,H1@6J9Q2$=;ZI"Y,#V'X<4!!C*1&8>,`XP(R M@1UJ31.,1%IYD]$"MSEDX"R`?E]H>5-PF3_;:&/C,5ABHI8$#`$^08L4(A MT^Z&PJ99`>P2!69^5_PUKJF\H?MXOJ-?TA;:(BG(E46ZB) M#*:RL1@ZT!I`'"06B^67)!99@!LC)>C-ZEO0B=?5]S%2<_93/ZV]M/_5E&DY M[2+>]LC">?EPH37TCG!`B'7"F:`/:E/G<0&E$>U.0AF9JKV9TY5J\^KSA9#: M$.JE$0`ZK[337C2TN1[-!G,DV)S#DA=QT?-!F&T6S?N'S[?+JS^W>WVVI;4C ME^;8L$(JB+5T+.R!0E`1_@_S!AI+4*XR6B?%:,YD\GHT>'+HBH>6^RFLH#.? MHGMPP8@!U"/HC.10,X[<_EI/H-@8/^.*2L,PLJ=TG(W8/T%69A,5FKN(G!\= M>KB_OPTO_QB/)+6Z=G>?J^_KXU6ZCXXI.#80!;ICV592F!V_IQLAJWP/H%-X^VAS\27\-`Z<&5K^OY49J>&H0T;(2T))HZ3Z0U4G0N)K.\ ML%O_(S'4&X]I8HP?A3QUV?9YP^`UU=@Z"J.J">T-V`'"8]GO_&S$\-+\"^8^ M.(RZ?S7>[;4TPVSRRG]8_D\3*?@K?KYOI_VNC'?;]CN$S[;H]H[AV&[96Q\1 M1)P_O!9<4L$)5(P"Q1R6FKMTYD9/GCSE$NK0+ME;N@<.&2<2&.F1L-00Q+E_ M$$8XJB8+-M^[:38>,\WH2!6[LV;B]RZ6-_&KXJ?58EZWCX5[DJT\L;UVLF_@ M$@`4EY*,(LI=Y((R_<@`H-%^EK3'-@[[+P-W,D,V23C7_C&?M95RLF_@A!,: M?5N#G=(0.R,P?9070JM`N;MN&;D\3TL&H_;^M:6X?;>2E63P"O(?WZ+`1Y*& MO6H3H(ZVE_KH94M)I*+(4KD=DC.@L/)E&2%N\B`RR=YYV\SO9^NK]DO=?E_, M3GD!^YH')Y6'*"ZO&>"(,V,8$8]2(157W!/MP)5C^#.@-"'WJ5+?XT!/%VX^ MV"<(QN(2//K:.BHXT!00!+;R66U5N;9]&%W[N<\&T/M3A.+,=B'\Y[+0\9M_ M7]RF[>5E_:GZN9G=SK':A_L%QIC`3&IO=12`80\%WPZ=ZM*NXV2@X+4%SX;. M%"_TDX5[**;\>[W^VLR?K-WKG]9URGEZPOH/>6S@7GM&/4/<8T&D\5#9+4J0 MHW[3PMO/?,<@O)?1.Z88*F(D\910\R@I%M07G`MG M&H+W5D_/C.9[UI_BW)%?46T&^RX?ENNVCA_$ M1)AJ`3@7(L+@_';`%-)^42&C>2RYT&]&0:?/K8[OU3]/7-O?;1(D-]X8(2P2 MD%$5K7:\_)@X2WL>]^T-= M`L?$4F;C*HSQ0.9Y[)J0NI0<-+.T()!*+U'?2C.NRY)#8:[6>NO=:MFL_:^GN^D`#CN M=QWK$X2D"`@;OT0I:XT@BCVY'AH5%B&8`_MF'&AZK8%VK)6ZOHY?7ZU/L'FT M3]`<",F%HHAIRX35WL4A^^A"$BX]Z/=VCN969V8S)S133,V;$H'U/"W5?O[9 M5LM5-=M4#-0_=W]SPHD[_R$!,$%@7.\Y0`SB7C$LU193&<'NI1QOSZ)1CELW M&G93:\])@_ZZ<@-L9(KZI2QJEMS4A`7H.4Z=F/0=D0S!N'U'C2A.)>N M3`68GOB':;%ISZCKN-LP:$FML!`D:^@L`UCP[28(Y:V\A&DP++OM>J;5-"E;N7`6>?ZUF=2C']5=W>'PKQ?_N#@A$,1-F8 M4AQZ*B2B$'8805A(,-XD8?^CHW>9X[(DPM6/M,O_=?'M4_2IXK^KFV.Y5,Y^ M1C"20@D1A(1K@Y`%<46\E5]'-[J,A<3HVC,V<),$>ST&K_S9J%D4HZU3W?HV MBO`G_UV\22&:'SXIM&.SW7"?C)PUVV7`JSY^&!$L>(%$I9 MK#B3&"G;@>"][&>.LB<`+56'AB/:0ZW^N$\@75U_J:OUZDM]6\_B2/3/E):^ M6OX\H"['.P7A=,I$`BC!G`BCK(3;"QD<6=4O>4OVM)Z3J$%6I(;2^T>S[L7P MOGX!88"]P-AY9I@1EKC.]>84D7X+E^Q).J]YPII MQ)F77F@*MV'6G+'3=^_W*H+XY10A+TQCY+;XN)BE5/3JIJWK75\@7\*)E]]0 M7@GE=)+X9%[/*YQ\J$\@'F@L4I4'%->0!`$!R$,%;B8!5B?S%$\CX\DBR?O: M!T`=Q-):X!",4Y;3A-&M;,RH?HO$W*61AS/S,F][!BR*33.Q211]ZIQRVR8X M19'$#C&@'1`D"@UL)[2F4T42?A,?J/^?QN-LN4*$-@Q!#X)36 MA#.AS%8.PEAAMR6R\#A`_O<8NR73M1`B%(_>AL?IXH)R6P24I/WJ'8Q=@R:4YYD5J0"# M][__=]%\^UJUARWYZT;!*D>%L,`BCSUP+.63V@X*HU)J$^=`MK&\59\?)4XA*N MVT.-3+6*C#?'I[[73OX*(9-4AJ3[P"1!BD$.YDIJ4ET,S$ MWRMG+C=./;R[+ZE4QX?5ZKZ>V_MVL;SY5+>+9OXE.C+UZN'GUTU[Z-SS94Z% M7@\+ACJ%N#-<&(B\]PQ3M!72<3C9M8PSBY5F.S*;#+(>>O$8TGEU_?C5OMY; MT?Q0TY#.YVU\#SA&"CI&87Q'N@$ZA'MQ.MI&7EY.,P#2@S&U7-Y7M_Y^.7\6 M__9GW=X=(.Y(CR@WMD!;$Z45E!IBHNGK)A[+"\N%DI>_?+CDH_%M%`9"N!-< M*4GC)X,11TQOAVEASREUM$)'D]#W1DS&"1]:UJNKZX>JY-'L?VR6-TFK;/WW M**%$A[\M1=4URX1UG*5V?G[)R*+T_1^6JW5[OW&RSH@K.M`C*(D=H4Q#KCRR MBFN=2OL]UH?#\F12URGD.Q53M*=U4(A@IS7&DF,*O:=4/Q5W,FJJ@)*C$46# M.6ERXU!L-%%Z\=:/+]X9=6KV-0]QX:FI=Y8@(1!30%*'MU!0`8HJ39.%TB8[ M*%.LJ%\.\^2NROX.@5*LH_D27BODXI(3;F,^$DP4BW*WVH81=8+U0>B\)_Z+ MVTXK@?;IZ?ZC6=>KN`Q,4]O&N7W\?#CCT9D]@_)6"@>4)$A2R55T8CM9%?&% MG:P-):P9$YP>B[//S<_J=OWS[RHZ$7ZQK):SN,0X>C!ZI$>`V$%EHLF35%B` M!%`6=,5;66FI83-QF1>4'AQN%&=WS7,ZI]SKUH%QB^(?;P$73CF9RN]NAPDT M[Y>%>;3]D8S:^;?=OBQUI';PAFE#G,++`:J,\=YU,VM)^UG.T&7=,>OLA,C7+ M?S3+V9N(?NH0G,),Q^G-2:THXAS%Z6DK6;0P_5SET6;H,;GN#Z#/?U?: MS<;1?D(A'^XBL--YH!*&WPCA$H_U%7L?_+K-7N6_, MIW8L#_8)B`.E'.*(`@(H0=X@MI4103/5HN7HOF4FEEZ^AIDP*78/\[EHIRIM MOVH<"*'1TS1>Q*F-DCC;884[&*B;2C7>M'^9@=2717"'`C.%87X^R--5D/%S%$N4EE$H2KY382HNU+_A.WW`"S]"(#%B]=PTISCTH3S$&GXOX1;M: M_U$];+GH:OFOYOKJKOI:'3T>.=XI,,T-85@;#:&5B'&/NXG31J-:EO7/QT$S M$D)]XDGOZG8QJY:;VPOI^X_R>:!UP,Y!X2VQ5C,C&.8&P.TP$PQE;9R/0F0> M:,Z?J5?U[+]NFN__/:\7:9(FZ4.BE^S,S?%'X6-]4]VZY?JPM[:G58#4@I1= M0@'B'17,\*=Y"EC0+SY_Y)N;^1RTX8CDY_%A*`=MZ+V:KC\>K`1]J M'BQ'%J<"BEII2(1FE)%NF0YA(?%6_?%MLF/0@RSWG_KNVVW5=M_\T1QEZV#[ MH)Q,]8ZBN$0AY5RZI].Y4P[VVV[*[J=DH2L7"%.L'?^JVD4RU)^CZW1B2^EE MTR`5A4Q28YE&*!46059OI5$.]EL;CE2C>;RMI(&P3$WRR2V!UXV#YM(*JI"F M'A!".=&\@X8:K75_7 M<3Y+0_[X05]]/GDN=%;_H`P`4&FA@30*>&,QZPY74J'J,ORK',2]#M#*#L^E MMH$?5QFCSV."-D!1(`CT#F(KC57LR6@J_BML(XX2 M290)L"G4YGE\HZY6B]67;VU=S:^6NR\5/*(RYSXBQ!3@?4B&?+;RO.6A07&E-X?_ M&$,!D>58=5;>0=HOA=5X5STF4*<1X;N4"=L52:T?DO"XY;[J@#V>$J1,:;@E M9Q!"1054F'9F//ZCW\7]T=)Q3&?`\N`UM1L.Q=Y$R9%-!W*J%2%QM>R)HX(P M(-D6"J\G"U,?G$WG;$K/R:;S-E"FNB*:(YN*M=)#BHP'4*:;E4P(NY7,2@7* M/7$81M1Y:57ZH?.>^"_N!*($VJ>G>S?MRY]-"KU[6QZ=9WV"32M+RR0D!!&E MH^7DG7P$P\DJO@W*W'$V24-BD:-T^=)8#N][.!:7#V=%5!J/TTQ!N>3( M,H/U=KS:Z0(34PY"_5!<:S\8RJ>O&$_X(JP--GFYHI$!TT8[XPW#0#`'K)3= MS$*CX&7XKOWQ/2<:^6T87#8:F2/IK>$41`_:,L>%X9WGD_K-Z[AA3C]I:K&,/-=Y8+ZI`2X-(8#:`862-3 M.,+C,"7OF>WSJ9MZ.3OAAI_7.\25`@-:6B,05YI"9RWJMD09+BW!^B@O]"A0 M36&S-P'`)[SWKDW0U'@E65K1E\D)F/R=`[` MIU9!*F4(<9@3((VPUOIMHD8)[S:!\X]RD2FPG435#`34?C>3:U%P--/ODGX?'A!M]I'G?;A91@ MBC@!HMDW,/X1&'4NGCHC(G=:9S@+CP/DGRHB[:VU9B124'N8$LL"803W`-%. M"F5<66]C[DCD`5!,?S'DX6;28O98V?L(PT?[!:H0M0@IX9GRPA'$G.\\Q.@X MEO7BCAM\/@R;]W@Y"%#(/59.8(8EA$C%UZ*;'*'LIQV35ZS)HQT9@;KX=/&I M72QGBV_5;=]YHWM`H#XZL)Q80#SE"B#G27>82EU/FS':1=)))Y"^(/7:LDYG MJ>I[M;A-"_]_I'V>QQ"\ZO:WMEJN?=-^KE=U?/97M9SO[-8=W-;N_<3``6$< M`"-1T`'#G<(SC-FE364&YTL(Y6VF_"XM?U"%4:[-IJ3XFR@]`E4CF;GZOHQSE;= MM'4]_[/1]:=J<8C"(ST"(P1Q1K74FL,H.*6LVZ4%1O=;?/-?@<-\J/2>JS=Z M4\_WS!!')^3#W8)EV"(8%RO$@,S,T4[AG^GZ5[G&O M3'/W=QQK0OUS/6MNEHO_J^KU2LW^?;]HZWFZ[QU_G$YS MTIG+:A71FS]54]SYW9GK_TG'$033CG.%C55(&ANMG>ZV25@DI9>*RM)5]%?` MNL\\-INU=5P&V<4F4]QR5NMZ_:.NE[Z:U7]5M_=QBGUX,VU;_5A&,382K3;\ MV3@#^VK1;MH=FO&R?4%`.(*!]W>U.WJ M.6N3?4]Q.4:V4^S.(+NWYPPKN*];P$)10B2UR!LMD#'>48>[4\T?F^_/_CME!1)UUM5R%HB#$4>"PMSB]$* M^2,B\#_-V^$XL$[),";=%D5J-5)9]MK2F&TSS+,,0%D=,(:C206JJ!',4-7WPF)$EE-:<;8<7ZC'R<%BF M36=<6E/"E(LIK>$1(84U(Y@+';713C3]<(+G*7P6*:TYVP(OE]9TZO]\2VL( M038J1I@UV@03H5-2E#H<:)Z>TC"@346(N^3=:2&PD]^MK*?POFCG;-I/18(WN)W4 M%+=VOCY6;PN>P8@AL'K]')F=SS8_:O3.A[_[>WVH/[U=?X%_+E[<"Z M.AF=\4HG;#USHM&!Z^Q]W- M^K!_LWE9$>74URH2):6!F0@T%M!4>ZL:?==P3'G>3M[1_+:1##HL2%F+5(?M M+_5F_3^__NOE38`_7I>.TC+,0VN$DD1A%7#KO>)`0MX>L-%J'\>Q7U]4,@PV ME#`1Y]*8%#>DD[0E3"0PG30I7NDS7>O1ZA+',=]`X&18<3C%(J=30IXS#]V$ M$2(=0=\V-0J7]QJ.5DLXCAV'0B?#D/]=7ZSWA_K+J>GP']=5UG%A@D",4()$ M8#3@=HU%.).WY#Y:A>`XANN+2HG`!-JV_7)7T7Y;;)`,<3JC\<*W*HM29X)T M/.W^#A;&&=STT02;5Q(^LMA1L:S&<,!-2(Z3$>N+WZMB<%$I02+CQ"@BJ#"R MZ:=VG,TWHS&(](89)@X-W-&]WVF@IDX%L^F-% MRHB(E6!.JF-=[:_>[=ZO=H?C+X]GWM\WZ__?]JMOY[AF63>L3(\0 M$%0&;0+3!)RS)B82*.]0S9$U7XIY+65`G0'A?EU].9V//_L>%?$06"L&HSWA M"#.`WK'VM<8JS-?3&=WBW1C6&].?CUNS\Y262ZG>:93W`,9ZO]_NOM\>=O)B M*N7):RL-K?)*!ZT=3.!(\>!=FS@(KEA5UGG.S@C0;X=%:*(UWWO-@'>7_]H> MP'5K=`7:_3[=%H+/N&&EE*0,68ZDTQHAERJ?6XREG)D4Z2B5VT60FXA3`7ZZ M/[EZ_V:_OZDOWNW2O\GI^_4FX?WN\L/5"CZ_^[0;QS(>4`$^B,.[K=))Z]X" M6+9!CL9`\V:GDLN?HW!N?"1+CLU%8L-FIK(Z"F\&QBC#77FB6PX9NTN%U8O*QW,$0Z MF-E7FXL_MKM_PPCJ5E_7A]6UN?C?F_WAMA//.#D#/J%"@5FFI7#!&<61HYHT M$S^E.L@LRI18*,2^;=4*:_-+9+U@796,1D(?AZ>.Y^VYRWOXP=6^/4_S!L@>* M$.FE>/3"=*12EUM5C-@@(>IF3E.)5536MQU$CN3EO$=3`!J-+R-B-A`I7FI1 M]CS8_P&5C$R"CT"40\X$Q2C$R0T8SON\S4FC:0X5(5`1)$MF&I[KW(.9'#_! MM)S;5)(*3*/G6'FN8?`-0C:I7F;A_Z M[?[)R+#[32HC$!/4AJ"I0!$1CVB+`,&YN!<-RDU1/M:Y+ZQ[1NTG5;75\/E!SM]KP*:T") M2Z2B-RZX*#"2[7MI5.8J\C+2ZW-"ML2(]UO]K=[D\PBBRX[;:7Z\/;$TMK[465YU*;U&[FJ-,6P(A- M>I0IDBO0MHPD=&\X1DC9/!A65IM;[=;MY@`(73\H.LA,UIQSZRJ8(+P63(ET MNCH5P:#6'>.69_JSRTL,%P1Q,!:EPA2881ZU]T[@]'Z=^"[+_5_;:[A@?Y3/ MZ<2GW(=4FE'%+<&!(2N,4PRQIGR+27#%\IBU[!1R,3BGBYN>ZF#C,'UW=\+4 MG6.F9/:-YZM?O^?I5:E/ZXVU^MOS;CK+M*$F+[]S>[ M3U>K?;V];#[X\_B-M$3S?KM+]W]FC"O:ALIBS@P"2R)/";7*4A\"C4HYBQ0R MF4)[RTA:SQWM(0A\&+H[#ZO[FK^=R^0BC:D,1TI&SRU6U`@-_]%F&N)4Z3S1 M!;*,I/IB8,_@=IO`>%Q`_Z$^'*Z?3'*>_E*%HD':$4\YD<@[ET[):1I-S(]G MO9_+E67DR@>')\.F=TSZ<#N_`W;I)"-P,F]7GL&W!)_@X^IO^/SVJF&:P'UA_LQ(RG#VYHS_1X=WG&83.O M[D0'K0+E2&CLN&9!*"^55\(I&AQ$8#_AB0X!&1.IQXIY&*2P)I[1!I%(::D= M0CU.=#C7I'U/=.B&U&JN)SH,IV%LP%\)1`O&M4X^^;/ MMOJ9&L;=0)MH7]F`^K31!688 M;R!P,JR8+WWK(5"PV`6N5(3!@"/&9=,T!&-_EMTFU"S.L5M?5$KXLZT8WX=/ M]6:U6V]/A,!/7E^E#N#`O&"6<4\LBJY-/6!K\F0(YW:(3VX`/`1D1:AP;-[O MFWV:YR_7]<7)D.;9[U3&&O#T!'6>J-NB4*M".\.@*.8;[O:TUS^R:\,B]/J8 M,+N@=BX$F,[P[Z]7F]-*M?^XN((P`*$8B0F>6<-Y(*J=);GQ,SMP<0#+/&/K M;$A*&OE>9N)L4__XE4HBAQ7FX-5$92&D8!BW8;VGNM3$/[G!>P)3U.R?#C>K MZ_--_N#R"HE@>0"?U0@&>'$CL;[W7S/-/5HP/:*Y\T&9J&#UM_K3]O-F_7_U MQ9L+8"F`L6KW,+ZX\'U4J$FENM]6U\_LV"KSX,JC2)$W-D8,+C@#S%F+-(XX MKR9KHC*;S,7:62&\."[?50#?70EWJ:'?\,UBC'[F\97U$DM!>-0Y*[2#+1EMJ.!%X`WA,3^=WAJMZ5)>V/CZRD<@$9QRGC)'*CA4:B`8R)S)-( M)]K;.S%!>V*[-)_AS>8;7+_=?2_D)+3/JUQ4ABJDE>;(6XHA3&$-KES'^1_[ M."^O(!?8I1'VT03R?E=_7:TOCF<@P?6W;^_=9U-XO2^UIQ+&&1HD(OSVN&M" MHF[MPG)UK";:H3T#PH\%_-)>B/>[[=<:'*B4E#T0?>3[1Q?`:$'PKHI1'\1TVRVU<[[4#]9;N]^&M]OZ%@ M=-?E1#LJXL%!Q)IK)R*5UGG+FL40"&4R]PE/M'%]!H0?&O"E$?^VOTFJY.%, M5XCL3SZ[(L@12DE@6E)&D77@:39XQYAY=,=$^^!G0/`A0%X:J8NR^(@H(LXB M&`\(M501%JW5MD$4N9!YC.Q$F]UGP-LL6)=&U&-\\?"#3Y^V-QL(-E;?3^S. M+-J.*L80!"%&IKT'0CL:"&_M0'S>Z3A3:=G.@-Y#(SZ/E9;'W=G=)+WH+RE< MOE.3WES8>@-$."E9.D63*F"!C)AI!+2(@+Q5LET1H"%F;D%=QAKBPL!?_CA_ MZY9--KK?/KU2S.J`()+'4<#`()F.;61C;*X^^3+6'.>+<[F1?/6T2L>=@N51 MQW;8@?J<)U8!4RP#B<@RJBD7W(LVE4I%IC3,5"K"Y<;A$;!=VC#;]/;CZN\' M']X'OX7&VU/-J((0U`'\QFEG2;24X7:Y%Z-<(=V?=UUR8,`G'H'_.8TDM/?; M2P??6'=0>!ZK!16UUFL<)(.8G%(!CIIK)[0H>:;&PC*6&>>-]>RH^[#\ZAC9 M#AS\]6A(A:B7P2%FJ$0T&O@AMC%V.JT]C\C+6#Y@8\[8YI"7Z>4;S3EGDHJY%-,LL<8Y@.@K.MG$^@N2?H M325`GAK2MBM*N#UYI--8._@G5,?& M7B3)(ZTHL%,S82T^(H(]SSU.K_-[GZ^.?;9)>ZMC=T)J]?K5L1&W`(6_W5-N M)--($M$`$HG)S%-UIL[(XF#G6OU,=>QNH)5T8L91/F8\.FVQ<`@'QJ2A`&'; M7Q'X?.7">ENPLP1R'E:OGR/EN9&ICCT=-7HGJ'NJ8TOIJ`D<`C'BN6`"4],T MS\A03`IN*%70L^$^I8[="9<8;R!P,JR8KXY-;PMX.$4(X2@MC;CM)_$N M\P3?"=6Q<^S6%Y42_FRJPEKMK][M4AG`\9?'@>#OF_5_;FI?[S_MUE_/")(S M[UC%`/.&EU@(@3P#E&$Z:;#1DF=F^%])$%T&U!D0[M?5E].!U-GWJ)!$2$N* MO67!I^UI,-,U_3=,TOD&W:-;O!O#>F/Z\W%K=L'Z%YV9)Z^M MC(F*&H+`R8(V82?P?1.M4,52,^3&GOEI)RJ,T$A,EX!]!(T6L66UQQN4IFDY3CY"[<#0P1A/5*3RW MXINT=0[?FR/=CZ>XF\U%^J'[WN_DM%-YF>QI=I\6 M(%Y_!&?&-3P,LW#EK`D,JR1*K60DE@31N`74!Y%7*#_-=M$"/.J*UT2L>0#/ MN\NW\%G2Y,((O:]WG\`E2![G=G,`X*$QGYOAN"VSZD:M?L^JF*9$2"*9])[H M2#@/M,%3!+$DD=D!^5<4U&&V"3WWRJPV%T\W]YGX;HA;5X9Z%`1RUCHD#:(< MVV;%BUIJ\ZK%IMEBV955$V%8KAP4PMNXW7U91>C9)BUXOME0-:LD1F&OUZ9C\.%T:-"[(/T'AJJ;,?;TR(6K)7EP9BEK-QB77Z:(`U?6\4"0UT[38"1O3N4F M44H[WU6UWA;L7*^8A]7KY\CL5L?F1XW^57/I+T]5)KQ<0_?RMRJ8KJVPD1&I MC5;P0&::75Q$.)8I+S-=:<_99MB.A5&F:5F6:5_X5J4@!H00C(9(J!>8!\Z: M/<+$.INWR#EAL6NN:8?#J,1`_N1IWB\,WD^?_DV\Q,@%0,N`6T09EABW_:*T MU$+34GS!(4`L0HY!3[H/""'AHDLGHDD$[">X14LZQ>;K^?6TU]E'WN>*^J\IC$J04G@NI$/H"'H4MM:>Y^%?K9% M?JQOZ0/'1!%'MR?-(85_'[>=AZ[.]ZH((S9Z(H($!X(H9K1K'0?+:-ZIKR4KH`K2:&QT MIW;+'O4OTSE[=(\*1>.C<$)2BP7XI(RYUJ6P5N8%8B7KFV;BHO5!M5QMRL=' M$MU3EY]D5I7<&S*=V$DH9P21R!G&,%4@$[7#@DDE3F\3'BM3,IT,F5(D6`$H M2$22P\$%CSB(BKG5;Y`)V4PY@O[ZH9!AL*!DR&].>860Y=Q@1<#LAN&D:ZIR> M?PIO`/,-!$Z&%?-ER`(*UDN)&>'&*Q@$I&K[&6EF!G]"&;(W>C=@_%6RQ)-4.Q=*0E&S-TR]09%&2)1:+ M=8!E383;39,XOTP@$XE$ID16U5:UV-!<:J6];&\T3BZXT(VQO7MI[QRAKG, M5U]N9ZO\=8?[&]NZU_X=F/+N_F%3P1#DP&Q=7(5E9HO%PZ;*O?6R:',,@^&& M=%ENX@8P6RR>JH$4C_F7>*M?+7OW_6KQ$/JK_,YFBZN'Q6[L)PUVW"6OPNCG MS2-_B;J;K9;%\F8_]#:WXT-UD1%!8J2]F%X!$QS8/ZPR2R6,83T@.^X&,K9, M[SG1]O?L0W2422T$LA90%+8H&S0CQ=T.3>VA3'65VG@+GYYU#LK\,V`^V?O\ MGE@$=?W=!H[X!(S8:^:L-33(:FF#%`U$@@38FC"!65(]]>GH5Y"6-\NIDB6% MBOS^8%N%W3Y6-2-A6MX3YRD5""L:GU;7L]5^RB\/)\$#K?BR-]P?G3F.B^M]3-=].(BU+=;1@/#0;+`;HYO,2R>( M!"8L#.U=6!?8,PN4HHSS\/=1]Y24X!RRP`W=108YDLHR%`6+"*)$>:1VH"## MSAL*];Q<4$X"\9$M;^O\ZI>;\C'LNT44_21^B$Q-7DC\\%7V6WXS6[@@'39/ M!VQC[Y3*.':,4>H4@)Z!`+3PQD9W*..X@[!;-/B1;%GGHW,Y%(#MU;ZV9-\. MY>!1_\L^9V(W7@YCY:GIVHUZHEX/",'WR3<8B^'8ID@.,Q!$*X))4II@90,`S-04:RL%$!8YZ$.?RS>#\CR;L[I@YLG!B%&CWFGL$#\7BS+ MU8L$9!??EOEJ?5O<[]*JS&YR_709CG^-=H836LFT$4RXZ-("I0'<:DG]3J0+ MXUFR_;&9]I-0F\>'=PR[P>6J#*KBYNER,5MN`E0QP]U]Q.13_H.P'N(HW]1; MAT/\2"-YOMP]6.HLXQK+J/,Y7X2%,(^Y7)^J5SBSJ\JU-UU/`QIPAMEI#PRT MR8+3MFIFF362:.X=HM90H0E"#FL`)=2[RK_Q68XHK7@@EXH?41^F(P) M:(ILD)[\%YO;?+5]\'/4S>)-V4Q@!X#P6@,"&>/$*`[C?!@"1&#?[8WO>,_Y M!B!,.2PD*4C\-?1T<:VB-\A-I84+9\9*YP*LB6)/,L:>MZ-Q9!RG'P2K$[;",T[^\% M6MHA&FIEC#+'$/,::\D%QH@!5L_1$]S-M_?TQ]43UD*&0^^,''+T`-I8+U.4 M8^R8@0IXS8RRDN]7@B%<3%?/&(1Z[3BB%U8?ES\HEL19[]QNU@9P.K$@K`-1\#USQK!` MI6"/SU'/.J)5[,MDQ@@LX@2DP=!BRB#6]?A-4+L[$?KTZ)`3UB&Z8I6,UD=7 M_(M2&?'>8TL-T=XH#54X5M4H&*O=!'U*>]#A/4KVPN'GI.GDI'A:4I[!EV[V MO;A[N#M*Q%?E,J88XQA1@J*K%J12Z/T\L*.I;I9;RMQ.%/C1G:W'_%/0\7)5 MSA^N-A>K+_GJL;@Z)E7?*YZYF&8]QC4EAOC(XYJJW:RL-QTUJ=/#^$Y8P`X` M6T)FB/:LW4#71T]?!^MD`B%OB%(80.@M=\IC7,^/4^VF*X?[D>M]V@\&T,=C MA,D)[XG0O[>-_H_[,+?*#_;W8I&O-^4ROYP]52;K1CO]T7H9U&'PFGG%P\R% MP`C;^DQHB<3=SE2C"?(!2%".ATZ*!;W-'7P3QAB=^XOY+G^P?HJW5$=D_M&Z M&0D:#03&`R$A<@1[](PBAAU]!4X/_3YA!6!H#,_(,W'$1X7!T;H9=UHP"K2# M1(;UY[$0Y'F^0$]7.QB0ENVXI#=J'Y];)J="3)E)AM(KVN@0.XEH*&$($62U MU%AP9L/4ZR%I`Y*I@.WTA0$A?JLW=$(DS?W;8[Y-Y=Q"*7A;.',L3B),`W"L M)"8H^KILWVW@H"%W"[1V>I:0"6L!O4%+SP8F3/VF7.U>AAXU]QVOG&%&J/`L M;'B`5;'F=`T>Q-QJ/UW!WX=\C9PP($[_#APR.6$_+<8XA^YW=U%LX08\8+S"`VR`EE'#-N+T6E5]/5%<<@6P-G M],+K(W#"Y'3":3)`;]//U]MB-=]%^FV.2O9.R4Q*8R41BAK(.9%$:5T+/()Y MNL?"+?T_>N!;#@E$$AW^MLBOW?+ZNKC*5\>U^<.U,JLH],XIZL+_ M%(8QMF4]1XU=-V*/IO0-0.SA0>FP0'WQYZJ\RA>+QL7Y0ZE,>>*LM!Y)1QCB MVBDBZV$!"[I%#!PMB>%`"[,?")-X,\<,UCYP$L;4<>&\<@CNV4ETM+F>[MN< MEFY#0M*!BO];E/>WL]5AW\>WA3*D@##<:V8)0$R1&$5Q-ZAP^%,@D8M<6CKU MPJ`#8?ZK6&_*FWQ97%7\4*Z:+9+'JF30*0O"KHPE8B:H9#*,O!XP%;";SCE: M1ON!B#8@(AU(>+&:;?MNI-H/I3)NH(&(,DFA1-AB3G$]SR!G73>WXM'RTP]$ MJ'X@]*%-I="ZJZMV-'I=.F,8>.>]H8%S@)%6:E@;QJDB))7%YTRTZ@5&!YJ] M&'],''9SL\IOXA>-I&NNE&',G*:,0N4@I(P#&D#8#1I8T4VOEQ.GX*"8=)%M MLU4T2O^ZW*SR\&\7H^/>KXIU[A^6\U]_NVR6;?8Y,@%^@#'`3=+7H28M#%.V%Q\])V\D8Q,]+TMZ"M\H'=_FPNKJ=K?//Q"]P:\'`>/1,^?KO-UY.K9 M0BWGT1UT%01._79D%QZAP2S>KH',"2JH@3!>``5AQ8V&]<6/)EY,+)SF:(&[ M1T&KPU*O.B[^?(BSNKBNN]=/%?O>EHOYP07?HF9F`3(BG,ZM%XA[KB1T>S:W M1$[X.F008H\#4]<-?5WO1KL4(TU[>XOJF=;.`AO_PS*F MYA9&Z'HB!H%N`CK)ET,A'E9#4"09UC1F%=@_PS``$"ZQ;1-P:$Z#WM\*C$D*3^*5YJ8"&C%N'[,<$_'-^E8>?Y]68+JZW>]6F^'.17X;A%^MUN:JVLX-&I0'[R+P*$E500`V' MWEL'X/ZMD;6DHS,3_'F,C>=&M`.3Q5ZVHXGWFG5"W"#H#G',X0J9,%H`X0'G M6CA.D7:B?K!FO>[ZIO;G,C\.!D\'6N[B0#XG,;ZXWFYI5=+M13[_6M:;VP'B MGM!"!HG@6D,/:)"#+NR$!.V%H-2HX\7"SV5\'`^O+I[?^PR]+Q[YUMVKFU6^ MVX?N[HKJM!Q&791S=1U8U%U?YU=QP[*'%_Y0S6>2>XX=H1)*I!0SC*+]GA8T MJ8YQ6GXNP^:9P.S%55O.KD16-<+CVTFKNEF5M,88:Y@51CKD`HCU%(#4'1]L M_5RVSS&0ZJ=R1B7E,5\^Y(>,V^^6S5!@2"61)H(10E#8[]CNZAYA3CJ^PH<_ MCZER*&126`U^GRUG6^74Y_EZ-]`&B\&[Y3-`@*:.*""!1T13J,Q^7HC;CMOY MSV=_'`*=%U3_S[\^`Q,&]X_MEZ^_V]5]A<^W;]]^F2]GOUR5=W^M<'EQ\;TS M;[WN,_^^R9?S?+[O>)`^GC>T7Y?7Y>INFTDDW\R*Q?I`_R,;6O=^GF9V7VQF MBUVPC>UP]^1OLJ^V:R+*XP`$&X?"&71#-U%%+B%7,6774K'J.^5=>K9WG MOO6)I8HC'_0/HR#!U%)EA=_-FSB9+*32;+$XO/H'I^&/MN3!<:JVA#C9^>8_ MHOTQG__M+YM5M4_OOBS#(?/[QBVJO>=O?UGG-_%#@IN+79Z@[=R"KGI?+JM, MA7$\.AE4*G^&&8 M1\-PO%L^PU![*0FS5BL:M"9J(:CG%7Z@TW,J'YA>Y7@H?1PN2$_](_%8ID3\ MWF?!B\=\%61I6=D?+NZK#>U[V!2+=:Z?_@@:V^K;JM@$A:_YB>9IK62"0:6@ MM58RR845*FR4];2")CVQ!+T]25.FPBG%FD\=UHU0J2@3&B.*D%262K%'P$+3 M;7VDNWW?'-;SI\===]^F^>?9G?'$@+T:3:#DG+O M-9?08"(P,(C7BX:AB1I&N/,FUX3ST M3#5VJ)ZI4':"[]O3$OC=P^K`:'YD_IF(,DE=8I" MX.U^4$"*29HJ^B-\./;>:7@D>USQZWK]D,]M4)B6-ULWFJV+Q:?\6_53\UU% MFP8R[Q60#AHKE6)!CDJF]L1_]#FP,T)*P2Q5"(KXQ;6*)?:%,!H0X M"1H\T-YII#R#K)X!=QU]YD=S=QV=[%V!.>-.4+E9]=@(7M?/``?$&&HHZ607`TC]@S[0.],$NB"6YC@>P.[U]+6ZR?(TKLTC6'V:CE?&^7 M#_^,3C]-6F+G1N.C1<2<-@+'&+9<26GVJPE9U2WRZ&CNLF-S53(@D[S;F__? MP^[I\M?RV67J+:]R4ZX;'Y3W:3;#4EN`C?4J+$D<,XQ.+1#`VNR6$,DF8@AB,/I^OX]NV>JP7UT%J/X;5=+F87>5;WZ&#K-6N M@4Q;PHBER&H&,<-2:&9W,^=>FVY[UFA>P&,ST2B@I6"7%X\3;/%8S//E?+W5 MXQM8Y'"E3$"D2-ALD?4:VS!?[VH7"$X![*8@C>8J/#9;#`94FGNY./_\A2'H M[P'#]6_E>MW(#8WU,H.9L-)0)95SCB(8!'0]SQBMJ1-#C!:"8&R&&!*K-*[D MSRY.%]?JZNKA[J%2RZJX+/&W4#R:'1_S.(=SNG\W#N[799AB-<3?6OB!G]I4 M(!SG@4[6.&,9\`QSCQVBVE/`K55'$]^<%9%CGN&G-)-1YST',6H"],YSA"WP M-1)2JDFXB(]'WA]5R_&0^S=S&G<(>^Z81I"PH'`++9"IP=$$IDKY=M+5[CC4 M/\E[_#38?AZ_8<8E4$YRCRS0'`)JV3-:EHH)7]D.0Z]6#L3=4/HX7#"]B]<) M$?\,IK#G_?!3OOECN7I7%XY;XM&$D:,VX992%'3V/;;(=7S" M.NY-;F>*'M9"Q@`K,>M4#I2+ZE#V;+D[A6$:&LB,E`)+)C3'#&LKF"2\GCG0 MU$SKOF\T-AD.HL3,T:1G!=Z_N/XZ^][_I%.WE&$I%/=08`4TX-PYP>G^7.#L MQ!(13^W8TQ'&-&:/2BL_9,CH]8Z^7&V^YJL[M9S_5BYOXL=W8@@GZ_#+P]W= M;/5T<:WN0KDH%N+%QM]7@3[/DJ*R457UHYDJ?-B'3(S1D!K;GT9``/48!A$I MZLO5E]DBW[E7%WDK<]!)[61AI7#C%(%&2>LH\EKN-D@95I(^&M3]?%BT#Q%P MI(T,$QN3>U)-@DP(.H3TSQAPYE.Y2[4,%#`H50_Z8`^+V63M/\]K_VL8Z!&C MS]O"&=3:&`<)<901X1UGR-82&I1CE%>*/WWZ9?ZL6L\W5<-77U-\.6WW M\C2T"CJ.(AFM-JKB`@P8C$-I-ZPP%WF)*;VY=GK4ANY`*N+<>6-0_:B_/VQ: M]639:&R>^JH0K7TO/=1*1#PHB%L`C6LT-!S:4>0R^YF>01R`2KTXK_9X071U M,U]4+5[$+MX?()'"2461<`H0AAR5IL9-69NW>A4X>G)!Y>L%V2%K9/+']:F1 M/[P_.$>0D$!"JYG&$2ZLR(XU*/+*\10X^S)$C3P'V4MHY(M,/TIX@M(=>D70 M'%(AL)#:$&NAQ)3OQB-$(,\R*W#ZI:1>=01>/[&3XP(,;KF:/J2A\"IX\%;, M5^W,_62YC'9J=:V?ZKNK'1!-D87^(B:]1892EOAS7;ATK7F!+PRO M@G,*P^ET,U,*&5:SY7,(^N6*G>TESYM'ME=%JG]/%M='17'.?GEP2%,&C&>$ M8:^-IEIY"Y2B&`D;?WWIT$ZKB,M#,AX?^CGS&T$*04"TLZA3FC@(K:!FBR$G MA)>JJ=`<&BJH*@?C166!'FP\*OU8(((S:WDTJZQV%D9A/:Y%]\B4 MRO;*C"$5(_[M&;9\"(L<;-QVKS59],<'`Y*2$!^M:&R=P='LPGX'1Y1MP(4C M\P@YP.I9:(R9W\'%?"Y!ZRET[BV?]"%:X-7W[5G&%QL2`2#2GXU5E8YJ&^+& MA3H`I''6(TBY!DK7(@!6['*)([>!N?C/^X6E2V8ASF?V==N@/"`6`6XY$\8J M0."+"-[SO)2.WER9?3)[!BS=,9O#Z+;+1#EHD#=&0Q'[3)6PHK9J*Z/EZMGHZA<.65@&F'8B$RD`.$01(*@%VW88JK_Y';PZW M#ECL%I!BAKUJN[E`*17*#=J_*A;P7(@-2<:<>PHA0X MSVD]Q4L5?STLVV6,JMP1]&-2Y5=1CU]BVZ9J3'U],DA+'`,8$4:,@TI:H>IU M5`+CAA;-';]BG\E`D6/9#X_W\Z>J>JZQ5^V7_-/\N;;P]4;(Y>_SU>:*Z]V_ MI]2?3_/5OZK5E^IJ?CM+8_F5V=580K'$]X.)"^2FAK%5$>@XL4A:+Y&249$W MI?<7;[Z$<5Z>Z_!T$22A"G MT!'KO9!6.\A?%FG<6MFK<)G+$9I)O1(RAL'PY_,L,;M.A8^O-B6/TZ^V8B>3 ML7<7SK%=")9Y`*%W.!U-$HAQR%2-ON9T:.4]QSL<>F*DEP3`-VEEKS(97OY% M7:VFWZ:KI[_3RP[K&@/.<:@\52@N\HY*4(<3(-8(MU:?^3N]K`H4HE2MA%,5 M5PDLO.PWH=Y5>!KG!Q#B!/&$42^H]]SO1<>8E M(*-)+SN:^*;TLM,@''+Z$3,<$@6@=91++9D29#<2#?$#+D691TAS'E(>&F/F M=]CI985H'6"J2IRB7#H[1;S!@%C)N(%UEQ4C`ZOXF(OWT:DJI\$QAFWS*X?! ME_G]O9\OTC^6<1F]^F"P<4PY:0'PB&(7]X3>UNLA=@"T'@H97;)#MNTY!/Q' MIMD72-XQR@D@D6108":`@TR_FBE,L7SJGO6Y(Z7J/:'G-#K&H-Z;Z/?RP^PY MV+$Y&-VC@N_Y6G`^+J_4-DZ/:EK MWWB/82J.(-Y4T]5Z463ZW?.U:,-IY(V.VWC.E.&*0LAJ3'VN23V\Q)IA3KGG M$S(&)7??'Z>+39L22K[G:X$IJJVP%!J%$`5"`+2SX:S.=)0.+U-FF$I^/B%C M4/(Q9H^?ZO1OT4UV&=[+'O+Q;L"=&1CP>2OH/C^U"X,AZ MQ7!<;)F7G#G(%*K1AX8/[.CP^QL/YS(RAO%P9`YI6K!O2H:+CNQ,(%@@Q"T3 M1--(A+1*TIH1IS*3C8>WU[W\&.F=FWLG!=*VC^-P$$,GH-9<'O#&'T-H.YZ$>)^5`B+**-,.P.L1K!>[BGC M9F!W6[ZG070Q$DG"=U[,`$1%8:D:]-P`+X%5=OP!2 MP6A>F9WA[7A&.."*$CN*05@+>/$%[:2.!(DE)FD2A#C.ALR;=-UQS03W>8&5 MX6V81CC$^N1Q%"-J3]CI4F/JQ*X$9`EQ1`!I@&8:.89-'1VCFO@\2W$,X6?"62H\I=$+MC'?J\C+%QQ`A'?RXZI?) M08RKLZ-H%_(1GM>Q8!F*%&FHN?/`>26PKF=`!AW-"SL-;RV[O$N]*$\C'E&7 M][J?U[$@'#%"2:RMD"+=5T9-G2#(.'J'%7$&-J+ZX6D,(^KEOBH[7:8J`LD. M5E^7F[O!>APPC=^->UO[?)^ M/=F`_E(EKN/O7UV,EVZI0VV#H&QO`M=23P<3]J01QCRH0YX`8"*&K&;0\$">/EM=8$!F=#(:3990AVVZ@4]82S?_;1F4',"L`3G88/"H!F3_ M=!:INIC^_AJ7).0L1;8O5W#QJ#K)ZGZC[?&GSS=O*R&G&LDOMVDWC/2.OQ2$ MYHI:`B2`2F!DL6=02*\(I%0CUFJY]C3I[HJX=2/O\649._Q>X''7R"D&1!GC M(IB*&UECRZ4J53ZOL43CQ?3I8+W&RS$PV-J-'V9Q-JQ^6TU6FP]_W(K>4LJQ MH55P-*U'`$##%23.\=IQ%E8O5_=**\3+>4DAZ<2IZC"WF*3 M:9K[?/./Q?QZ?;5:-M:8W/=H((9I@+#W!$L2^V0)874'L00#*RW9$=CS3D') M9FV[MAW#VH^/!B:\P192'O^,^S2/,=\IJ_&9M]OTYA+KB[6S0"DQ[7ZIEE7\ MSEWS!UD_H75`WC*K!!(:(V`4ID#M-!5(FU* MT!].19R.U7U\Y^TOU:Q:3.YCW]7U0Z0BN956TV_5MON'YX:L]P1-`'8*:$V0 MPE`:)X2N<5!QJAM6DGD_^M(G8B4T9[OKJ:[W;XJV_6]0F>->$`BR47`F,4$H MKE\(.KW;-IFX*`[+-!B*EZ,7<$LX73=[Y4.^U?KC.=]9?UU6?ZW3E/PMI:_V M_X47C_V'V662FB0!D"K MUB30(A*V.F/W/!Z4Q`H9*;!RSAH7E^DX#C:2*1^M\;RP4M?7W9Q-R]O%Z'PD M!NO3_%+=IXGP'Y/%ZNGW19QB)E>;V)5^>OTO+2[.XU\24J%'AKE+57;C'UP9 M0&H.*#%YNZ*^/9YG\?^3)=P35F4V2R]=;'5,_?QP``8`;Z#1R#E(%"3(XUHB M38D?KJ>R#]H:-.,LO-Z#)@S.+SE,!3C;R_7[W71Q_5MUM5Y,5T^-3JX]3P9J MC"42(\:,A%YHQH7Y.7F][;].`??>9=`E!B@YFY:W;COL9MIP_SYYB9N MN!:MGHJ&5A$K:Y31ACG`O=&0<@5J&9G@>7Z)WAR:'9#=/2A%G%9OK)7XX1;S M[4"+J-1.6P$LL$HY9ISU9(<7HS(O=G0ZX9>SU;H!YD*DMZ[*!]L$0Z,\!D.! MK==8.XR9V@T4H?APS;2S&6O7@+,P>G^Z,#A#;3@J<''JVP,3^YX/6##BC%6. M"TPX8]2\("4=+^7D.39W^'Q^FAG/0J4$V_]8S&^JY7+C156SZSIIN`ZYM@<9 MCGM!<```9KPC$;,((4RUW;>20RLS#;]2^G"^^Z\7E-Y3$`K@E(?#'<31$I8( MT+CKK2574.45GNOO\$_7^M$+2KU$D]8/#Y/%T^>;WZ:WLVG*.6D(\!G%E:ATG1XEY'-B'@C\GOB$H0:SPE#BH&9,$0I_C7`^K!]:2?SAN<`U!D)9AK2W)EJ<,LI4RX$U*4;C MD;[['`;FWCL/]M=X$!%=W\^L/LV_5F>J>`C>E3*V"@)90NT/=;?7T-S<,U`&CI2%4(>8QMH@( M7DM*.,##M>'*$#PO@.9[UI_!V8MC5)NSLWX^IVHCL^E5\[&V-T\%S#&F+(K+ MX\PKJ<:(UD:4QWYHUV)UA?&\*T`R>/J?Z?SQ;K(X;"7^_%!07G$5)0/`Q"4R M&4R6[CH%>*G%_W(LG85'B;G73Z:+/R?WZTH_J>6R6IG[R7+98@\>;!.`0E!@ MC25E-AK%J92>J>5C44.S^#[]>.&@C+VNT"JJ#9N>QJEEDJI777^>?4DIAHN( MB9XLI\L_9O.ORVKQ+>'R8?:X7J6S4;.KZ?UTX]Q^+6CK&M[7)P/Q4B!A,9"0 M.L4-I5+OQIHA>KC68P<:J>'G&D>W^# MH+A$<6TR5&$)331:`*P7+`^=&UBICLL3O'=?=":J1;Q^]7GW7ZKY[6+R>!?- MF/LVE]ZA-@%2SJ2R$@A`$/9$2PUJ^1`S>0DTIY_X'Y0)UQ5:9>I$W+[M:7O& M[:$VPQ0!$5R*Q5E`(@9)UL1`$Y>?YJM_5:L/LV3_I*S'O1ZW$]\2H-#`8`(P<)98("`WIA;+<%GLL&LS MQ67SY?K%,$,U_FMZ>W?_]'$:3=!7[O\Z_#Q9;8Y[/I>A.:`6)[PA4$:D@IQ2 M#*"&'D`G?"V.MC#OGKC.O;1E5:(__(HD=,QGU=.OD\7_5BN_GETOUL_HRZ^GQ1[C_CLGCW^UV53@%,9D_I"'*4^#&:18?RR4]_41`8,\3B M-*B8UEC&/990.]`(SDNG[;Q*7-D)I'<8S]`1,[^/I,\7B8;E_E!SFW8<\XK` M-`>;^HD,"$$H$53H6B"A?-YAK0^%>L=P8L-;$$.J*@H]!9S3FH M1?8*Y24+B?$J36E$BQPGV7;Y1?E_B6`O/\[C5-I<+["A71`,&4"%2O`"I#%+ M%\!NY60,YVV-Y7@UIP_42FC'GY/%]#EDN*H6Z2+"B,?JZ?G_VTU]ZKO[_KA9 M9M5#0JQ!:[+>%Y"UUL3_P0WJQL?Q(VI<'!29[E4P?G4J`6>1I)-$3_5Q^BV- MC-5D=CN-0FV,N3^6UW1_2*1&FV&\+/CU4J*#^[W88UFA:M@VT"!EPP$*=#;J\R,!&&;3\<7871KEH)20VC4$K4"9IVA'['0]$Z%7 M_!8N[MC?NU35CRDA<3'.S4QR.N M*&AO'%(^%A2`*`*]AXI3A<3F:F$J852`UI3%GI)H=L>R#HIP_&VRS:\(AD&! M/9!0>:BIE$Y8_(R`4$S:4N>:&B\UZ)+(@R=C.\5I\C[*U@@$?/+112@Y8'%V M<]K60GLK2N5N9%[1VA6C!^O6G`9/D07]Y!HG$!K,D!82D+CH>:NL%#L4L);# M3;C,X*&AV$D>#N/D='!IDV6IO$!Z3%;=&NL]QHQJ02!54E+L/*CEH)`5H_'T M>B=',]!8M^8T^8OPF%6W!G(MF*::(<.A1H13)[=R:.=QWD7G1>K69/-XAOPE M>#QH&>BG(ZX,.*)U`"Y50:`I*D&C\C(EX4YF:6A>V+COZP/ZMIRZ!^ZBRG)4 M\!H!+4Z_7T_GHZNXWRUS^>I`E'M=^<1?:2(QIM-\.I@MQL891`09QW)+LW MT[-/Q>@#KR(1_O4B$I!R$&;7?OI]D]7=JAR'&P5"$0?&2*6`L19)X2BO':7, MTKQ5H_-H70F-Z`RD4DFO&\&/*L[PZLD@#(L[+T@8^?_RKJVW:1@*_R/P_2+Q M8CNV0$)#&KQ;V9:Q2F5!;20=K`2A1A$8WY<2`UP%884(C:D&A=0T3.+\94-IUAWB6:E[9]SM&;=66B>` MCKT:D4.8[A2<,ZZPGI4C1GGS@S5?]L;<1Q4]715SL=WBOKZ_7M3+JM[42+:=4SH7!^SLBI`3Q2`C** ME7(D=J#B3KE^]1@8E-:P*7/&R!C"?&5/]22T1LX;63?7[[ZWOP*6<9:16KC[ M'$F%]TCU]%__O)PC,9&#U_FPBU;4`1M4-'`FF%V)4(^I@I-1)#'ZD4>>;3Z` MSO=&!@CXZ#OI(U?&!P=*RX,Y9@!9::@5JE^#1ER5%[48*(MC$AV$Q]N4;3&Q MA7E%.L][H`.ZZ4NF8((XA(130L;N=[O"2P:F:3&6`KBHMR#.^E%IP*P"#!E,#.6]Z46-4G.(*,<<8U"X68UC18Z2Q2XNV9.\V5[A.2P-S M"L+M&LC8WS^;^]/-Y?ZYUB-,,>"`&H9A\%2!Q43VZR$"I^6`9&\H-R$YAD(T MD0G;3?/3_77[HXG=R#):L`.C>Q"8;X.V!=9"PBW'!#S#H!)+UO(WBRO8@@U' M=2IR;>Z:5=A,M']/N'LB+[5$HQ[5@MK&]BR=96\PA%C%SF##`^]V,T\HEEMS_=\&#`9C.EUBY MS>^9+:WRVZJ^:2Z;ZV:Q/6IR?=DNEP'0QWIU\^56+9?M8X"Y<>VJ:A^N-KG$R^V\/[R/7UW5ZR;\\0=02P,$%`````@``85I1\KM,"$=-`$`YO8/ M`!0`'`!X;VXM,C`Q-3`Y,S!?;&%B+GAM;%54"0`#L1)!5K$2059U>`L``00E M#@``!#D!``#4G6MOX[AZQ]\7Z'=@Y[QI@61#W<7%V7-`4=1VBLP%D]E+L2@" MQ682=6TI*\F9I)^^E"S9SL4*29&VYLW,../H^?-/\:>'%Y%__^?#<@'N65EE M1?[3.^L'^`ZP?%;,L_SFIW>_7)SB"_+^_;M__N-?_^7O_W9Z^GOTY1S$Q6RU M9'D-2,G2FLW!MZR^!;_-6?4GN"Z+)?BM*/_,[M/3T^ZWP/I?BRS_\\?FCZNT M8N"ARGZL9K=LF9X7L[1NP]_6]=V/9V??OGW[X>&J7/Q0E#=G-H3.V>:W]GZC M^73:?^VT^=&I99\ZU@\/U?P=X(7,JS:V0)#^ZP\OOO_-:;]M(83.VO_=?+7* M7OLBOZQU]ON'\XNVG*=97M5I/F/ON!L`K/THBP7[PJY!\_RFL?PS*[-B?E&G97V>7K$%U]%>[;9DUZ]?8E&63Z[06(0:BRR_L>AO;URX M?KQC/[VKLN7=@OMS-J8`"HKKEVJ-R6MM^*BBGVST7QNXAY^?EG=XO5J-GMS%'6ZT'QSO+CD?M&+YFOG_%_=-YO+#V"XC=[! M=>?*[*%F^9S-U_!\.R!/0R`1I/@=KH6"K M%/S1:_V?OY]M"_S4]V+VVJW42KQ.JZM69V<.UVMY9VQ15_U/3IN?G$*K>S[_ M3=[%YU51S$Q6Q=K919.G%&5_-L5O"L MX*X^?5*=32IEOF2%\?MX;1XOZJO&O6B[^#[-^.<%2XKR(EVP;>1&T(>T[C[] MQI/.+/^4L_]F:9FD6?EKNEBQRP"&D4TP05%$0NSAP/*L7I6%_?"RWCS6WFS4 MAJ7(-/1ZS\-XH+7'*]9FYED.BIR!1ZYM?W,^2E6(H75"M2"'VXWPT^NB/*VX M]!W(=@#>RC\!'_DC#GS]QA;W#'PH\OJ6_ZPI!V@+<@@A/+M@+: MQ\:F;`=HA/A@V%\=3#=DK7YD;W\P*1YO M/RGC5J$*O@N:JI1+"I;*QHFS<#8K5GF=Y3>?BT4VVQV=22+/)4[LVH%G6Y%O M(>*C&&+L>2BQJ1^(MD[U"`;;XT84Z%4=;\QROT-#+6Z\K5-I8QI*\KQ5Z3)' MO!TM%L6W9F:6M^.X6%W5UZM%IZ+ZPF8LNV\:^9=BL>`/@&]I.;],7`MZQ$60 M$H=B!_HA^NM!$'-'K0)) M^@F[#_YH%(-D+?G@8)3U=(B7QNIG*A@U5\#G=#5LI6;H7GH>#$F,X@0'L8.\ MD-B>U4I97K`2.=0)X0W.-$/5MDW5B M5*NSIM@Y25B.)J2P]=\5%L5+I<1"2=.$`?BY+.ZS9MWE*]%YIIL0U_>#T'&0 M!5W'<3V[CVE!:EW>L_*J$$TQ1X62:8Z[JH1;);E-RQLV!W4!"D[*M.W9L8<[ MEE=#PRD&3!7#W,'I:/`^2Z5D+#N(ONN39"78^X7P"OJ]?V5ECY_O#K2_0' M6O<%OV>Z[C!LN\/>)%ON^&Z:J-??53L5+Y5:-TW.-.%6N5X`O9F"L#T:$=_S MD.O'2>0BBX:0VEZ4>#!P;>H)/E(EKVKNB=DM_S_:_-E3(P::CJ)C$VDBJNH+ M+;>-_+SR:KE:-$GOI_J6E:18WI7LEO?'LWOV/I\52W9>5-77]>@(39(`^E;H M\Q:7!+83PZ37@!!.I*;"=`8V/0NVU0I:L>")6K"6"_Z]$?P?X(]6\T#C.D!% M"$_Y'Z<.I!OGFQ:HWP M1D*1-^]9X8>LXKF+DP34CVR+DQPZ813:I`\:N;RC+@'1<9$,4[-+-[:B>.;! M9[&]Q&'M2+U2J13@PD<`?:UVR2%*T3Z:[:-*Y<0@2,,U@ M[_&9+V]V(E5]G`AS1A;BU2[E.$M4>I8?6?U+7K)TD?T?FV_?._^91V^2L0_M M0-]E%/B.:WO8CZD;Q)YG$X=N6&=3JMB[U!/<,)FV"L%-VK[&#;+M^_GJ74E- MSDMW)P]ONGJ7DFL%6XF@T=CW)7%=E]G5JFZ76-8%^)R6+0'7^H_8QQ3R5ZR? MJ;>J)L)-<^7;W]\T8:0*;;^6:5XMVGW6\/Q_5VL5772"4.@@/XP"QW>B./21 M&_318>011<:."6F8K$E1LNPF![-5R=ON[!'46ZT@W8@=P=A1?DN3]5!6J_.T M=YSTCF]U3A>H`[:*851'O4P/GEI*M1^9^DS3/>%QGN7L/>^85Y?$"0(O=F-" M2>S#Q'>"Q.EUQ#&6VX!"=_!I37PTND$KW-#LAT2M:)T!,5,A1F=!A.KBF%,A M&T_'3X?(5\_T2*NY?&K3(JI&ZJ8O3Z4_77]-'RX=%.(@L4('PP@&`:5AX&UD MT%AR;;SNZ#*-76FY_&Z;+]HV/WO2YK.NS2^:-F\&N>)5H96X1NK`('!/VF&$ MXAIPS=/D;>_H>-Q*U\WW15OYXJG!5M%&8=9N]N>)LVK&";$J=UZOAQ12+T[L MT$;$]B!-(DI"ELN/83D0WC1@5PUS3W6Z)`W:$'6_EVY!-`^U1B[L3:7QZ MRE(8N/U4FQ6N*E97'UC:A)U_RK\TF\"467X3I556?64/=<0-^/.2=U<3*TG< MV(EH[(2^ET"ZUN$$*/)I)7S&;^N`U\,S_;AD>:)2#5OK1F"MHK0B'==?2U-BLO7S[ M>&W&2/$5>JNKBOVU:E;=W+=K;?IGAD-=Y"[^3[LJUG$"SW<""IND M(*`!)M!=*XB@YQ);AC<:PQJF4*<'M(+4UM+K]%B,2T>R5XY6N-2X?*')9K: M8GP5U^399<"P48PZSAK\EXX(TDC2O@E21[8$`W11,N--BCP4^>77VZR<=YN1 M/W;KJ#Q"8AUZHD31MA-P?DZ$*VX-Q3S%>H M.=:0(R-SM/Q"SWTAF7*1VXQ=TP<>J\[NFQV?LADKNY"0Q`23B/@4!@F)+"_` ML`_IAX$GDWN-B6,8HJTTL-$&.G&26=@H(\72L4-Y*$?9/?8=:TG[@$D#J9H. M:R>2LVDI2J'_SALYSLY_N^UZ>H1&<0AC&&-,?4+CQ-TDC;Z'_#%#[:(Q#CW: MW@A3W#M"U46U07<3!HX<=Q?R[B!C[YTY$L/OLG9.A$"CB_'&(+R:+6/(TW58 MB<<#$,<*G3B)G(@ZCH\W'=80!R/9(QCE./11&YL:X:4R@0S8J(5!QQFQVFN0 M'(VZ$,T&+/@0##"@2DT MCCNBKBDQQX!A(WESI*[7J[Z(8T;2QVDB1K80PWA1LD05+>>;=]]LU[%PY`4D M0,@A+@_J!9NQI@BC$701#W+P)4WGRB_OJANI!!PS'HYECI!]A^#.N;MZ\X*5]]F,571],M(EA1#Z)*$N M3Z1X7F5Y,.R67$56C`)/^H@H'4%E6I?2VZ\?N+#;Q2.HUL+`-9,]1$67O6*< M.H*O--=JI?G2^DW3>H(E%FS M)N+B-BU9E%9LWKPHRT.V\[5]=.@$!(8!M1Q,(F1#+W9Z\%K8PE!R!P`]00^& MOMF.N)/^Q;GKHEPV+\JQ=CM'A7.E=-@NAL0C^"V'Q(U`T"H\O6HD@EV-1T*B MF',#2-1L_420J+M4KYP_H]TT<23>I]FB66.?%.5%NF#=&HB,[;P1YV!*F@U; M$8)Q@FD8(>A',/`B/\*^Z\N=P:$AGO%^ZN8%8KPLRKK=(I4457T"?BZ+J@([ M.ZF>?3^D-_W34C2`T#UPMDL3LU9WRY]!IQ?6! MK<#CO_8K8-X0-#5:/Q5BZBS29VP>/?9)["I=?$CK M=@59S'G>WI5;33&T;=>-/9Q$%D(DP9%/N";>JZ#W#Y(%4X$6`?IJS%$=J( MTBDE'UA]6^SLIUWA?/Y?19;7O_(/3S;\(8F-,;'CB-`@P+&?V%'0;A8!H451 M(+JF0G=8KG'/O91V,\!"IBJF8DT?&/%>_48$%,V MCFW>VZV\MH"QJ9-$O@=;0,2]Q7>9*.J9QI0W14R<3X.=X\\:4KV4W.,[19FM?= MZ=A9?O.Y6&2S)UUO%WL.P8YMXS!P73\(D]!;[Y[E>2A`4MC4%/)PPX4[@L%6 M,>@ERZYQT>2XX(J7PYLMN?YEV-QC\E',NZ'%,7K-GP@7=9?J^<(9$Z8)\S!: M55G.JHH4RZLL;Z=JMNEKX,2VVYSR2T/+B_V8.JY+G0A:!,,HB$3W]!L5PUQ+ M[&6!75W'Z^P-N330YK28.Y&6IJ8Q9(\7W`N,W M]/HU3]OR73^D,/:=`)$`NCB.^@`.#RVU!9CP50W3LA6BN(>AN#-B9#-CBARR MQ/PPLZ=77_P!O,A;-!%N*`A_OG&78M'E6GKWII,?68GE)(&':(":UYZ(`_L0 ML>7*;6PJ<=W#M';%_?UD_)%H\0:L46KS1]K);VO!6^U>TJ@IM7Q9Z:^U?:7B M"[?^#UF>+5?++@CRFO%A"[FVY?DH01@1OP]"?$]JP%;NRH8)T(F1;/J2YH@U M?G.^R#7_3L>QWE9^8L,``M3LF@@$%,47.NX861"D#SM!;!M&2>C:;H01ICCA M(3>TL?Q`*NF7N[)I$*S%R()`SAQ!$!CS11($:QU'`\&N#4,@4+)K*B!0$_\< M!",LD)[+V!EI:+L?5NR&U+:#(`S"*$)N!!W<+:.XT_RS9/T63U'L M\+X.(B1*XLBV:8RMS0!(Z$6C"207[0@L.@&]1M7!#`TFJQ/*G+_C625E[<&X M]<0Q28*IN3UAEBD62(!J8ZP2.A?ATT-6L]EYMN1_S?OTS2)!0G`>I.RKG(BC9)'XN@FF[ MU,Y%D+9-Y&R$5XKZ"F;'FC*!LQ%&R2_TW!LRP/PSS=.;-+^X8\U)W/5C4JZR MNGJ?S_J82>`XU,4)ST!]'B4BL%]R9%F.)WRJS.A`IE':Z0,;@6"M$'"),L@8 M;:@`9@_II21SAVQ40O!H/R5X?$A?%>$\TE\A5K]APSYPZW)O"A375I;"P.TE MP7<\JXN?69[]_O'7?EH#>]B-^77],+!#*Z369G[3HC85VA)![)K19<^20O.N+"H$5#!)'KEFCU!@K:9@(4E\4V8`#1'B"]T MW!$RYRJ^R9QSN(A_%,\;/$5'XDF MN.XK]A[&CG9I`J@=7X9"XVTC`5[ZP)9WB[37M@N>:70.\*[M]E[&-ODX/NZ8RKT'6&=.'X/8Z$:?Y6M M%`'PWH+O(?!XHR:`8`V%*'3>.Q(0_L#F656SY7;D(2*>CZD/7=NQH4]=AUI> M'\0GV!6%K_R5#4.W%W32C(_]($$,!8_>AJQ9>^3@VFM1'9A5,$@(+';>"]$:SLV+)+OA=P9J;X[RQKE^*%<'FVC0@ MGAW@B$8\)[;ZD)A&5&X?6?4XAFFYE@8VVD`O3FUQYBA'AVEZ:#/EV*KNHZ&] M6O>:-+#628>U$UGEI*4H+S92U67/6$)URZD22I(P].W$]6P?++,^:+8WJ[)YU1ZU477)GA80D=L3[N@'V:1Q"U[)[$3%Q MY,[DU!K9,-4ZL2?@9BVWW9@T?2)8=@YXGLMA;V/WSSMV/]7:'PA5 M'>V@81DO!\AHIDXF0DI#A7N^79!!"X5)^I$[DE:WG\K/:5EW'Y[N6O1+GOVU M8C&K9F5VMTE'L9=XA$#?=P**,'61S?O,_3R.#WT9IIK28)BNG5)^.X)&..@_ M[TIO-@M;BP<[ZM6ZOL:J2HS"4Z@E.1X;K"`C;%9T>(#2INML(KPV7LSBL$U! M+\,_ILO^]2@[CB(:NMC&M@\>\O#6O:N^_.5C=\?2Z.>ND.?.!WXG- MH>1+5MZP`#5=A4IZ^L-@ M82BVDFC:L;*27%697[^D7K93L4-2I,1:[`"#[DX<\]QSR7,O7Y=GML"GD6;` M-OA$`TI5_6=ZF9"/]`?73?Y4KUR$/0A#+W%('"$GCDDZ;L&SXTH3*X3P-Z19 MB-^NML/@@1:?@K(@`J3R)9RS\2FFT!.HG*L,R$C3A2Q2";N&)(YJ;'F_[HJ*#M&[*]5\@ MZP%/5SPEKI'6PKE],ETEK\"IBSK48(0]5%2ZX)JY%)2#7#%M5>DM93Q?[)'M[X?<^RW$_W-X\9_7WWVQ7%8'E)%"$8 MT'0WHH"B`9U+4C>=K-PZ0&E7\KCW[EZTIRVN_!/-BL4"G M:\V-#5JM?C]6Z">=.W9\SE[:]W=ORSY*#7#S^K>JK.L5AH[O.C`E01"2Q'+" MR!GJ8[DVAIY85)CSB&?,L]*GN!2<0\--.60.8,#NBO0XIM9 M3M^CZX)0*F/:$`E49T^IJ4L*[%V](:@G2=KM(4=C@YG.N_\LJ[]H0AYGST63 M;?'FW_O^U?&5E<((AH$?IS%&GA6[H3.L\[INF`:\.UYS8M*\/,OPM0FZF.4I'BGDY5;H^G*J-3>VM`;P[`YCN5?R_05.=* MELQZ8B^!L]G(^MP<%!0[D(&[H3>L#^\;@RK?9JS4+`W(:XX1/?'NK4+FSVQ9 M+N%;`S8Z%S&[7'9(ZK*CHP^;?<4^]^VQ6#]RJ0_(JIS^5<[2I#O:>E9L MV(4(U@#]==&\S)L7R?E.3<:DN=_\?+F4;D+DLZQ97"6;?YTN;G>KU^6KM>VR M7]O^LV@>'_/M)JO3FKKQV\JSHS0A<9)&V(Z(%1(_#<95;L_Q)F1:6G'I7I/A MVH1D=H!O/720U2!OP4^+C7K=*94M&>/)I?8EP9]'3DZ-=_*D5,<89\LE-0?7 M]0.5_EO>N;P8SQK]>(*`Y2/]X;`^$>F3FF_T3]X8X^K3E"F\\RPRJKE?EB- M/-U*.;]]HBW$BO#W3AS5X@J#@J4>^]Z(B!J)E`Y[ES!,]B*=RUSQ.WX68PY5RD=0`+RJ) MK^^$5O4;!G.X=%H\-L"UDE&:9]7_3*3.FGYJW+#]@]/X_N-0IS/L.=;[IWM% M(/9K=KNA&8%NJ]_)$V8A7?@*T#F$1QL(]BIP?=LEB6>CQ`OI'#[U@Z$*$XQH M$B-ST5Q)P[HS@9+M_IT]3"5Y:T<-Y9=C^>)LJX_8MSS$:[UFPT,BQV4:I;XP MY+RX'MO.7(S10.`4W3Q:'OW2G:&,R[JI5]BWH.]&:1JZOD4L)['<$8%C!VBB M:LHVJUDSHS=2KJN3,Q?#0=,UA3M=0J79EQ;0.8A7(9_')3YZH*!%NKQ\GJ%0 M3#RG^L%=-_6=> M/#Q2'/@KE?.'_(\ZO]]O/Q;W^0KY,`VP[]AVZJ"00"N-AF/`[)EVHL+4FY1 MON*@VQ]:UR"NP!%\,.!?/K46(%O-6L44+QJB['-9*[^>,9UDU;?CWD`TE"'I M+W1=[^HFVVZ[JWQV2'%Z@85(@N,T)KYM!6,HPHB[4O1R"#4G]Q?BP/%N\W-_ M6:XX@J[G+I-J!_-O/IOM6\FHPGNW[:VH,A[H_G0/AMN2US]=!]!R@6W!CC#U M?/?Q$&;CNCW&?5]68#-*P4DWH7/^;TB=NCZ)(B]P(]\ST<>2QTT*'6#!]GPDMLZRAV0OS)6%R#)GYB.,N)_8*T7*#57E? M-!]99;#$"T+,OA?&;AQ&,/3([3+US'.Z*:5@_.MG<9'[B"=5`OL3[OV%\NH*;(]6I8I^GO?CIUC'.7=7_=6'^^-APUK& M&:W0?+B>Q^62Q^J5]B:#%BCFL5?@*+T&HB=D&&S(T2%]@I#LFWV5'PH?=W?H M_ZO1%CIU"*_)QC*`%AR<[81`0X8J!,\'2O/3QF::' M[8F:^Q8LT[7>E&$CI"T@?E]63U12>NEY[$R8'*KT^5(VXS#"C8IRC\&/\>E. M5V<.&,O#WY9#P9O>I"O0&V6P?ZPOEL+/R$K-L>]>LW-2#`4P#$F/D8&0YR'<&1(D+W>FW\)3` M,#@EH!.CSHAV\J/NC)T:]TTY7S>[Y_1F`2-T^J$.O!$'ZWA8%CY4I]1UAJP/ MSV$IUV$Z#>1RS0Y9@^6VV'0-4EBWC]GN3RI#VY=/WW;YYF9_1P$56?7R.6,8 MV`^K^K%X'J:L,?W\0UY_I@/J,:OS\G[XQ5W_%ZSN3+\'LHIL#V(+>]!*7,>- M4.0F:>H2A.+(0A9.>">/9J'6'$C:>EMM/8>CTHG3UZS-XI!CJFD68'TQZ,1. M&F)8.&*F@LY6T!H+#M9>@0X]&`T>5\%I5.ILII_IK68+J6-)UKN7_F_[JFZ] M\3]O+^*?T)H%7/]\]TO^3'_;99VL!$TK*H<2=R#; M;-J%^6S[>N6\JS57CWP-M>K;KVCKA%RQ?Z]R^K7Y_7V^;I?[,[!N"61_W;3[ M=;^L1Y?DF[\/K62OMLT/P'ZEH^((=&_$!9S50,&PRE_4(-_F_3'E=973KZF/ M&OA;#=[2V!8Q_=#!XHFK_[-VQ3,K`F8.!P,6#`PEIC1=R:;DH(UJ`X[?FQU^ MML*>A0*2>)&-7.R']'_NL'#BN2BTI9-1,^!KSDIO3IX(UYN9FD&H3(IJ!O)Y M<]5&>Z[:][WK<<.^^\7_@2XV(7\UPX+9$]GZ1(=.,U=V1^7_DUI#DMI9^B=O M=FO68#$QS36,H4OYKF%0^1/?\0(2=045L+)Z^;UL\OHF;YIMOEE9!%MA["2N MYP16$L?0'@\#>0YVN9^,FMB,YD3R<,_P><1'DT@*$-0=0K!_+G\$@C[4PE_/P.P1@W;,O#I27A^,8#EPOQ)! M!UBVRQZZ5)@FV55>/-WM:=OMO*#*^]IHS]D+2X9!DWWOJJIWUHL# MS&*N$PLYO=>.<+)3?\V* M+5LJ(65UDVWSFWR]K]HK/K?LIRL7)F[H^%X$`XO^/PE)&*2.%Q$O3`*?A"+G M#=6UJCLD]D#9>!VA?J`#\T--P8(#6O"O%N]_"QX@5$@_WWG!99@7C&CJ2-=R M&I";PPN'_]3[P9"S?AH,*W5W84'-O-Y]S;O7TF_I'^+O1;VRHRB.4QO"U/,A M(FG@.V1HR<)>("*.$E^O604/B`"#!/[%0(E*G0QK?)JFF3`Q\1+E2HM"_P%) MTE&_$@SE546JN=E4A@;VI'S*BMTTC9'C5$9SM-,IJT$\3,Z@0&_QPZU(D\@U M4J&F6711L120Q:U@?]S\5G[-JQUK.\GOFD/ZU;<;N7%BHO-K^!AA`@V%".H1Y""0C:=6CX9FY55,1'[XP8X^N"J"FCVA!)4V=/J:E/"LI9G%=-<5]06O/ZTWV2/Y=UT0Q- MTI0O)%'H83JAM'R;YGUC#N@&*!)1LBGMZ+X$=02-K;YL.G""XC6)2#[=FHM# M,6&SU?B1S MX@J^N%,,44Y-QDFLY,M2R/\6Y:NF3U-._,1N9/VG>P\SRNJB7E$$)"1VA!'5 M><^BL")WP!'9'EFU9]+Y!%9YXT(:.^+D'N$CHO;I6-$W)I4SS2>?BY(LIJ!O MJ.:KF>\5./4!:"'/_7RD(*,79%2;F$\@,-)(K1T.`\B MS=EMBPTJ.#!L\L$QV8(3]A=#CA7T-TD//O3QX= M)(U6%!VF4"X='0[`3F&NHL#V$')1&,4P2>S0]8(Q.MF.);05IZQ1S`<50)#?C+;AH[JZ7:],W`5$<<]-G\KR\VW8KO%N\WU MKJ$=DU5MFY26!8SD$1HGG0$1@BA(;A01#"['T MD?>!2;6-Z@OT`\[VN9L#4M!!!0>LX%\#VKFW/(2HO#"`];C$D%&LR;ARCEXM MO:$\P+G-OS<19>.OE9NZ-DEBQX5N%-NN`ZT4#4T&OMB3N5/:F7&SN*]4PHKS MQ%E5O;#[LH=WM0;HTAO%$ASS*>1<](KIX3&SHS9V%[4`PP=:@,OM^O[`%=<> MKSS#ALB;$E/.[M].I4="NDBQ*YK\8_$U_T%)V\YV@!*3*`XQ"J$7>K'C(Q1X MZ0"%P923-'7MSRAU/^0GTJJFD'Y1M5N&>7D5[/!^:`&_D2$:I(WE&DP\J[&ZZ.36WD."^ND^+I^>\UW=WC+YDK>K1FQGN:M6<)?5^69X4&E, M9JTP36"*(RMU"<80^T%LM:ALSW/MB'=A6#,*?9)P-!-D2><1=-!C;P]TU'WE MU0\M_L-3:(O-'J<1?D$I9O*D(:(QE[7E(L-%.HU+GYZWY4N>W^35UV*=MU`B M!N48+-ZV[J/_]NG^2[XN'W9L7?IS6R&VM:"[[Q\0%`>>:T$%E$,Z8"@YF@=ZN$]4Y-NT*'(QC?W@P#W3V=;(UN0+*K#U!-.TM44E]':`#%>797T6FL04N66H M*Q?<`N*X*ZB(*I%'$#13)E=T48(ZOI+Z/UK[1CR83(P!%0ZGX2\5]1!A`>W5 M?6C'1R1V$]L+Z#^QYQ+7#<8I2DQ\1TQ`!;]\)@&M>U3"JB#*%:^`:J1)3D`' M0/("*DJ5J(!JI&R:@`I0QR^@I]9>%%!)8HP14%G\/PCH)"*XUUZ^Y'5./_R( M=YLD_YIORV?6==+O+$'.^Z8=DO@)1@Z*7,>*V?4@/&JW%29$9"5%17N:97:` MV)[AV1Q`"JYE*&&6;V5B;E+%1/F$SR-\H`>X5$4,#M8N3/U5WMK3`OA;5FVN3O^L34HF%.B8W?5\>FVRUP77D)=SN):8H-@S%^+' M4GW`D%BSF/FE&4-1]$),AR#?O`VPCZ,KZ"0IMOS0A8Y#)V*.G4;C,G7L(;&+ M\FJ:U!UQFG+]%^B$97VL).N+)4GTW(KA8NR")BBFW)"AKMJJU_=A=)`F?!OF M2[G=DK)B(6UEIQ"E*`I]QT&QC1(K1$D"?9A`:$<.PB*C4.;[-0\YR3/P4DSQ MY5.Z21++B0[GW!D>T`-:ZIK/$2<7E&<*@X;(S"03SES,D:=#6$!6)'1\.TBP M%Q(?!IA`9/O#]Z+C(77*/A//.;K=IH/7/L*T$X+ M)?7C?:+$1$,I.W)*L9`T<.@!-SF&B0`_[C,C7]!P\=NSW7M_FZ1]X[Z;2JQL M@MP0A@%*<(12/W9B"(B9ZYV0:?V+*H)TZ.;5@ MI4+Z=R`[9/W)NZ7N$;_!$H>R3"+7,+699LNY2\'3"1)6I=LJV]7;;LUC\^]] M_VS,RB6NCZP@36.$;3\(@\`9M3"V;:$JTA.;TJQ,--G+BX<=6+?O<*Y?0'.` M";(1IZ1HR=(K)ELS,"LK7$?0P!&VA93K;:(XM&LBPX:IUU1KSNB7$I+$IU&. MG_JN'5DH<5SL$90@[`[?[SBIW4^CTAUG43CN+Q:?1`T8^!<[J5?[.935SJ$\ M@V<.O'P9-AKX<9^;.8@9+O1$X(Y2]/)&:1`"4Y@B#SE^2*`;>Y,0QQ!*_38 M)IX%$Y^.X#`>VB2A*W3B;5)#FM/=$9O$TYKRY$F+D1[>5*C1T'%-Z58T!_+?\Z:M$0V>AV$D>E)2GC\Y[=%# MW73Q62Z2GV5(0'_$6354@"0,>4>!9*GA+V/29$U[X/73?7LJ[;'<4M+J]'_V M1?-R5,4SMA"V`R^%-B9!`ET4Q"2.8@Z..A%<>S M0J&Z0&)?K3D).(PYR>H[@D0)*I5ZCF0E::'B-"=$\`B,&&.F*8D@^G.2(4," M_S/OY=-3N6LUJ;^$9KDX(3`(0PLB[+H^B9'=-^0FF`C=[A+_=LT*T0'JXK'H M.^[B3/'I@UZ2Q"3BF)_%'FI_S<<%I9#GSA"QF&#`ZZ?8)U+!?Q5GLVE/KF7; MSUFQN=[%V7/19-N^4>PXR$?0B1)L^XC888K1T*B;!D([!]-:TBPE!W"`H?O0 MULMO\8D^-#:-3SZ1F8]*,<$YS^)2\G.1J0M2I(9A0V1)D3&O;RHII(A?K@XO M>7UJ'O.*W8VJ\L=\5Q=?\^O=NGP:K]^'OA^%MA?[CDVG6VD(4ZL'`/^7O:OK MC1M7LG]%3XL[@&=6$B6*Q#Z1HH0U-AD'&6.`O7EHR&W9%K;=RNV/)-Y?OZ34 MDKMM=YM%D6H96.!B[HSCB*=.D8XJO?389K.J;K:;IL3]II:2MVK"L3,IG2YMIU3/.O5344#[ MAKU40T?4`4H?;8IJ6=YV&\6[UO*0(X*1B/W(]Z4HBS3J=#@B.0+M#QDV,:+F MB?*NFE?PVD9FU.GIV0BLP<2K`^3U":.SE2QZBYD3^C20RHF(T5`K7M4BLD"* MMLRTD]RNC=AG"8LR'*4R``TCFC,1=6WX:0RZ&@[ZL&-)N:Y5R'*YW*S*7VH# M127<7B1\@!(#HTU/6)PQ!I.3\RY[]DDXH1Q&7$U$+\RPUQ8Z"U`;_I3VU'+0 MU`OY2_=R^)2RVW1MDAQS)4E$(,H0%V&!@X9= MP[C4$Y#1:(0)RA$&SZ4PIU@ZH3A6R)V(`MFQI7;0^TR3YY_Z$E<)QV%*:,"R M'*&`)C&C79H^"CD%W5(W^/QX2?1/QG4'35@#9M/=$&:<4=?BRFU:_9-&U;T! M]$U$6898<"S%;DH&X++-?%46ZU*4[?]?+E\?`]JOM9-D.(YP&LM@#/EYEJ6A MWR^W<`)+PMMNV['^='"]?W2`?U-O4;]]A$ZSP-0X/M$3L'.Z`Z9N+CSAZ`H0 MB-(3\NC*.1/13F?FO;H[Y))&D\--S8;,^FJ[66^*Y:U-U@_,W\&)0!IWH2.1J1 M,#WY9V?>'M83O?0:E7-.F=F3)G=R*"9L>6XR>IAA($"#-?ZJ/4T,56 M-?FE7C4U1/9RQ]?UVZ'P+`QHQ"EF&"&,:82S``=]$)R&'"YJ(P$;5?[`P>PX MOM$-@"?G$&C0_'K]>.'U1G@[*UX=ECBRR3=ZM&V#_I,1^JC^G8B0CVWUJYV` M,Y`..'';EX^ZKH\OMOF"HES$ M/HM)EOE"Q`QU=PSB%"6@DQ]3P>Q\MU2"_?V-\OME6W8=?!9X&JQIGRJ>!ER7 MYY-["]4<].*XLO=\7/GBQ(OA[76*G;477F]O_]CX[N7P/9-'/_0\BB-/'I^> M5E>:R+PX.5I>'>F>&#Z#L.MRO=X>EIEMP[Y]A-FO4=$I)'H%JP#IIW/-]U0-;-.[R-KM4MQ.9UPY^%>O9J,V2#R85+`)'5 M^;P!C**&/SS63TC/3I5>.TLM;3CU[T50;OPXD5G!I85O148NR1RJU7\7BVWY M-A!,:)BQ,$RR"`5!Q'V1I!T0%`7`2@>V6Y^&4MM1YR%.&"3.(_%OL,/EM6`/ MGRBX\!K`+T*"7H`G(KO'286KK@4'35MT;1BHI[G6J'Q7%_\]Z6>X> MCA35JIQ+Q\Q"FK`D)PD.DSR)*>8\[C,C,>5:UR>=-.QZ"Z@!YE7M<-_4WO(9 MH_?8'$YL-'CS4'J\EBLO]1\=>).5LAOOG);ALSO&E@+O\K;>'M[>&6?E_[:> M;]7JO%G%3]; MJM_5GAMTA/VA/:E*OWP.;&9F-^" M$!&6,4%$F$1!F`0HCEB_:\4SIG6#Q46[DYX1AZNPN3^,)\%17&%M#FS0.IH" MSX3Q)$19"&`6%:@53;AK?7H3 MI:6-[P$.&99[&,<7UH,-MS/C4)?8R4B,XQJS>?'O+@5QD'Z8YJQXFDR#;,-P MQTQW3K1EH&;FP1:5=O(/;-[>)U&'Y&9!$,1Y'%"!"$H%P7'83\FI'Z+(6@H" MU.K8>VO%'CA7J088[1:R#R";LVR'97JJKA:W@T2$)4\-3$J,[R2WJU/EQ($E MZM'>+XIUCHVKGIGCAW",CU.E%"2V*3?(:=GTWW?T<)];JYCM< MD*P=OGRNEO6JJ22X%# M2>@G?AEBT30)&,MSE@5)'(>$]1M/F$3:P8R=UES'*WLEW=3RZ-AR"+#6M<3R M^X'(^`3#Q'&ZW.J'"N-S;!8-],\SR,#Z6-!]TU8\]F[*>;%M9Y_Y=M6\OM?= M*YMOJA]-!=ZJK\![LUU7RW+=W#B[J9;%<]68]?9F7=U6Q>K)*W(*R?BQ5F[);7-U=%[]FN8Q.:8[" M7'"2\XQF+.@N1Z8LC$#GJ*PTZ'@\-!B;H@L]2+5&EBB]?ZAQ`CTZ98=DO=EZ M='YA4LJ6MWJ:-Z@QR%@\Q*4]*&&/PWV8%\UT MF9W(6+-C"^1%,QA!8[]HEOAAS/*4R?&?A`$5L>C?6Q-1@"ET%(X$:\3Q^O\/ M8`WRT$3&_=A6NWD`"T:Z?GRRNB^6U?\V&]&I.H.PJ&Z;_V#+VR^RX6[O_.HN MKY9R4%3%HG_;>\UNUIM5,=_,_;H);@O17>LQG>M\Z0L=]ZML+^J?7[J-Z=B/B,;/3+ M".`,E&LESP\\"M[Z=>KC^]7_<,%D_6OV1F$ ML?VLMQLX7HM'A@(2D:XV&Y%T>MIT MS0]LY@-1W71?U85,L9YB$+HY@F"0JY('F"R>[[N>_[--$=]J"/.A[S79=NT4#& M.XR:]P>[,U9@(UV;$`NC?-_D(T/(0_X_&NR_G#LE[4]U53 MOG(Y/W&ZUP)A[\?%3KF"C7L%Q=OQ]*U%`XE,X>P`CJZ[9,DL0MQG"]*KM,Z, MOS#W2+1FS,H$(BYS[+6%;@%025[57^KON^_G+$9,4.(3D>4!E_\3J/^^2+3+ M-(,^ZE@=)1;5<^=R=?]OQ>/W__`DLNVB6'GI=K&1,258)F&,O2^1SLB"R:.$ MH:@QD488(_JRZ(P9,TD^9SPEF&1(KG<"FOJ)X#3.=Q!(FF.M;6D7 M[3I>)K0HO+I#:*L4SB"J3T_AYV89-D,?+8G3P_6>\:I*\2WB,Y>_.<'EB?.! M+CPRD5.`3DQ[IQ2./?KTJQ"4-YMG@>[/#Z8B183@@"8H#9.,^"'U"99AXOM^$G?-849!=X%-VW!]QD65P%&[!NFJO*TVS8;"IUI. M;]?EZM%3H*%U.DRY-!$>-S0.5!X%RFM0G5=[>G*TQ0=.YR35Q\",D_)C2HO6 M-JK8;1S(@*M-\5\N[^K58QN$=;K'N!\G,0T"G^$@80F60MBVB^,H9#HUU:RT MXW`4[>`U^QZ[,R=["+7F%0X#[!K^A#L:<3.`0H!GN>F!G`(QJ)C]^JQK(%\7] M+/6CF&".*44J31R)+*9=`XSF6@E9^%=='__KP'@*#6!@`[EY?V2[HP4VM'49 ML3"V#TP^,KC-:)G`Z#8$7@_M$0:S]I>N%H[(\QPDM?FRN)\?T#".Q._&6$3 MT(B!!KRQ%!A"!4@S\FH]+Q;_71:K7/YD/0`F:F))`61M:2W?0Z3$U`#$+U MQ!5YPQ1%CS?KFK)'AI:JF)`W.5TQ,N*HLIA3HJ4MUZM"U7#[Z^GQIE[,4BH% MRV>,",'S6)`@YOTBB(=4ZYT?^%<=:\@.C->B`:@&D)OWE<(=+3!UT&7$@AX< MF'Q$`\QHF<"X-P1>#^T1X+(#7\O[2F4TEIL_B\=RYF<^%0D/HYR1/$K")*?] M&H5SKE5JS/CCCD?[+BOW#,I3J,#5"*",O3_XG9,%TP`H3]:*%!PR<$02!I$U M`648AO]5\8)!1`!T(I7+CE6QN%S>EK_^JWR:!20*@SS)HPC%A$8LH9SUB9(8 M8YA00+\^CE+L4'D-+$_B`FL%F#5=L7!)F)%:`+BRIAJTFI"PD5`@A%4D@QC#& M_1Y*0!E0+`8U-5+\\])LV@QT*K3?OHT%*BD//,\KY;/\\XFYO2!T@G47X`Q.0)$7#CD8D,>4?& MO?$Y2+K!?W].DOBO3C8F(69`9PT9MZ>X[LEVI+T77@^]+2[9R*D'+4E#[[D65.!-5`,NV9=4-PN+3VS%H15[B? M/IR\&IAH++"F=-J7V%R.BIW81SX/HAP%-"18L`QS'W5(\CP&E?QVT+Q[@:6N M!!;`L65]=4.O:WE5J*>MKCVO-L05[J2/IJT&%II*JRF9#I2U^M%I?.S'><9Q M0+.,,>(3S&F/Q,?J)*VO'JQ5E!3OI MPRDKW$)C934DT[:R7C^4J[*XVS3/G$<\Q3CT&4D$C1ACH=@!$2'7*]/LKG7' MNOJ,Q(VZ0GBV*JZ.*':JK3K..*>P/N,;KJL&_OE8LFIBH)FJ&E-I6U1GH8\2 M/XAPFB4LBWCDQVF7.Q,I5D^0UYMB855*WVT3)*`]/'T!57_%C7:^3Z=5Q;3* MI,,$_S2U<;@B:O/_L710WRPS]0/2IO6HV%_;Q\=B]71U]U=UOZSNJGFQW+#Y MO-XV=Q"^U(M*W4*X+FX6Y8R12)`\CK*`8TRC(*$(9[&(HCS,&`JTEH^VVW2\ M:-Q!54^J[X'UGM%Z'5SO6P,8\NB85>Y/"^0Y:8<)Y,=A7/^UMW,Q;_;HFTT/ MZ#S^!F#GC:G'%;\3>`K.B5FUVVX)7&[_-7\H;[>+\NHN^]>VVCQ]+CWE M\D>Y;N[#O?YI6:J2D.Q7M9[AE!!&TCSR69QD:82%(#M,.1>"0;8SG`)Q/$D] MH[QHBIIZWQ0J75T`$V9X$=X&3Y/H2\$VOZ47PRD87^.+;69^CT M0%T^UJ:HU3V,69SY*:=I%+,0YPB),"))UVJ4Z#WC::FIT;6UQ055UZ&$ZNGG MB%P.5?R\:9Q"O5P+KS+Y?P/0,0+)NC]?027W``W M4SLDWK<6"V0O`,R,?KSODB&SF%Z[`^D$["_,.Q*4FY(P@<#;&'H]O`\`Q.^? M5?W]H5@][EI@.4N8U%??3V60'B5Q(.*^!3_1"H<-/NM8^OYY>?7E/]G7S][5 MN?P5/^6:JY!0WD&#R M!&Y?G-+8JI$]26H>NJANJL69%JF0E,::7Q^`2S=;5G=C)>F\V)(L-\X]%S@7 M%\M%L0W2.J^_%N5=G54O=`_E8_'TW)!_)ASEN[R-8&.T?9+L)#ZR4&0;O@EC M[(40^L%>)4.'Z_#[;""GU#RQ];CY_,RY%+T_S9 M>#@5,N9U#.>6S"T%ES=Y-JPK8,^W$BL.(;9],\26:YC#QGQBQC%7D7S!)C2K M?8<*'&`);;WP$\>SY:*5,SZ9_8XNAL4!C7LM;YFYN,LC7Z:Z=1YO0Z2Y7(KVR!OR5GL44<.L/9_*XNLPK3)BVT86D3?3C2(,H6$@ MOVO"-J!A(AZUX?ES8,CS3L+P!B(LCIFQ(7^O:3Z,=0`."^O(U(0H=M-CY3FAI<&`X00L]G M>GM(1[N:8]X`MWW,<7,`#-:CAQ[_RIL'T#SDU08\I56[]EZ4#].1W"%^[VOJ!*.L(*QH]N$K2`P`4?%T`^>X";TPEBH>VFK-JH5MX?#86J M?Q.Y*T&T6OQ)EW65;LAY/D^4U.JD^$1%T. M6T`PU&9:J;^_N1-5N7E9@5=Q\>F M!Z%MF(&9&&:,DJ'Y(#)]UN"GLDW-@6__?N93"X>.\UV+FXS#`3B'MBIE^W)0 MFXMHOH#6H00=3'#`"7J@AT=,.ZAS\Q^;B730]R[=YD>[`XYO.?E]6X*%S MSG>=OJ:Q[2XC4:^H]7UL3-8+E!Q<'DB2.GPQ@(" ME!:S2KV=F'-OXI>RR%Y_2:L_LR9Y+C8U;D(R:WHER6%[=&V%D]@(X]B-H(&B M`$+3Z>;.Y_O_+/.B^8T,Z&?2*3\6_T73OR\/&O\B:25]0K9 MMFNY9/J/W2"P_0@E".\7PAS;8IV(:VA:LPQVB.DTG+Y.WF3;?`W^H.C!2P^? M8W:H@_G+D_*92>?<(>[X_GP/6KA@P$NFZ:!%3&M9@QXS&(.>V0_LD_69_2$V M9]?A%Y;9.#]9)R;E&EE?P-QURU"8C@_,Q+])A2R;KO/K8>764,DMNGO`P?B'^*77: M@B*?6KO>B7D:B&->E^KN3.ZO4$9YO=Z5]/[D*K$BVXQB)[1M/XEBU[+PD!^: M@1_B%>GD=R7KFI1X.SS#>`R)_4PM`05>*"HZT.[)H"O6>;HC@Y)")D.NNT]* M5TSN1[]:@)2,V/Z&*;BC5TPYUZ4DN&=;D9J&=+ZXU6&Z`BWK+2QPP#7Q&M1) M?LZL/LESNI!U)P6&E*J[FW1Q6ZJ5G_\JR,3V(7^ZR4@7)#%]FZU<)S`]Y`70 M-(V0J*<=1'L`H15R73Y2UZKNA?9N%OX/,B$9P-']L!Z==-U;8:[9Q&L>FOG$ M[-1<^PKL<8(;!L8G*I%[@L`S:J?>"0M1/PV&7:RAJX8ZIH6,MY?-OQ95EN[R MO[--6FQ^[;_$3T]D`M.5OXBRP]'\TF^[2MYBUY,8$/+Z^$+,=]0JH\*ISQ MQI<#=C`&#\;HE^,F]L63Y;A+;#6%+O.GC^T&/QTZVS0OZM9=9!)9$R=2$1\/ MK_4#/73:_YYD]&E$Y"E54%R-MFE$RF^3ZRE3./# M!2RN3&1H.?7PX,Q@AG8/$X1_TFY_W?;X%7*MT(`(TZLBAA78KFOL)P:N:S.= M4E73DN98NQ=D.NCITHIHW%3$*UN&,AVE?/%OS^;H`&J+#/S48?MYXDSD+%%G ML@\U!"\DXU!D3*FC#W*JUF]IE7=E],A8)\W&[09']V=_JI("B+\]M!9I4;0),Y2(>ZVQG*Z>/!55[_V1[) M)Z@YM4Z3-]@T<'Y'\&GCW@<#8-!AO2))P1.]`55L^Y]0]2QW+UFWGC,_\':#UFWU7 MX+F%!W8$'V\A:B4LLZGNY/3RB6P'[T.+#XQ(;A%>@0XCN#[+L9ZRT0R\G1%* MI;0O1!?5VO2V-+-ZPMBK@?6G*SX_955*XWI?CZQ>V8:'7(/,AA,WMH+0CTQ_ MWR`R/9>K-IAP*],=+^\1\98*$^>/3<2FH8Y/N0ZL[5&!VXO\Z:DI=HJ>,P(E M3^E"5$F!(6^KCRFBAJ<:87O7O6BZZ M6/C#-:O-=5EL/^S:>-_-I/CK$G*2Q:@Q.GGBDY:6HFY*A"]0I*M&X1$5YV1$ ME+6EJ(CF MDZ8?@FGVC?!9&!?;\U;'/,N.-2LQ)S:GE?.Z@'UH]3:5&CLBYQ0T+-OR@QDM MQ-35-NF?.OI"/J=]!<#S#R&38H4&E;HZIAI] MH\WV+PUXCN=`#YNA'>/`M.,0V;!OV#0CS/78D7QK<^E;-P+%7B-1P+&4O&FB M5Y&\,3([I;H=".-7-P&REZUN(@:QJ9LP54R+`E^?B(E%T[^68`:Q#V$"3=/W M'1]#*X+^T$`<&I@U\^?[5,UJU8/AR"4Y2;F>AP,KY?(1.OC M1BQ3'CA:'^DOK>MXN'M_]N`^2X)\9/2)+%B,F`6DNH+`2]D^P3FINZG*S?.Z M^5S=9M5+ONXFD+&/$].RS-@U/,MSP]!U4-^6A7V/Z_ZF4`.:Q;#'U%UFZ''5 M8OFH&']L1"IEQR-I0*>Y:8PM3TN8Z^T_0S M.>2Z@05AB`.B:T8`#<-(\TM8O^2ZKF[+(;M+7=IN@GV2YKHMLUP\26J(U M=.W$1-[0*`P-$=(IED_A=)B623!E* MN1//B:B52T9I9WW<4_PT4%QEZZP_"W6_+-D1=.+S)W/:!4P MOIPL5X4QWV>^RBABB@X?BZ;*R!=QD57;MO8IK1W2MQ?&"/F6#0-D>!Y"B8GC M?LO8MZ$)F:N/2C6B.28,V$`'#@SHKL#U=<[41(R/ZS)]:&:E;C#PJN[?+15C MA.,]95W,"+[#Q=)=F!X]'MEU0@2%3%^`Z(GA+B5]SG,P_>/GIX?F(=T]YNN^ ME[O;#VAD!*D+$`G9="72GH& MY_92D!+OK[/;ARQKKBES]&7X]A2D[430C5P7N;&+;=^PPF'#W,$)FWI*-Z)9 M1WM;9 MZ#Y-$:-90I*CD6&5;3(&.9?=3I$G MM!`GQR+'RMQD;`HNU4FPRK2"=\[^4TMZ2CA;0.ZJR)!2=7?BVH0>W5S&]_>D M0?I(W9!">P;R/82AY0:1BZ(@B4F#21(FCNU"2['(LPT]%9NB^]#BK+)M1I^Q_^1NM`K.%J#:B@PI M57/B3B3HPLRMI"\7!1]J:3;J"TT=IT7V<ZQ7R#.# M)$">#Y'GF-B%!G:']D,,V7=Z53:J>P^8N1@3A0Q:S(IK87$X@&'G>"[N.?>4 M?RC:E98ATT._[E)D3&Y05(]LS]"IO6T=)"]@#JK'+K[:9*+$,46CPZ/G^4N& MJXJ^Y?;XMLC&K_U%BO8]X56(7(.$1!=CSTP@\BUHF@,*PS29RV!H:%IS9#I" M#-(#Y#?E$(:+)U?=$WD<(JG#'9X(M3QTX8H7U3$VC`V[UN/K,/V,/5 MS+X0"UJ_#0^MOC\.:/FYPW4KU=5"^!D[$<0T4K^`4*;3NG*2_JOM6?K0AZ9O M6J;I>$%H69&!DZ$N'@Q\#_$]NJ.N79Z!*_3R3I?EMN^C#X^A_;]^'9V5\(6L M:6@P3/AU=#[JV(N`]-ZCN?`*\M+3`,;OH<-:"4>-%QOJ$'B MHLAFNLVCNDWMZZEYDZ<[L$Z?\H;^719-E=\]@Q'IXBS-^DVE-7$F%C[XP@JN9_(7*HW*RW-4>TT,:4AH\_'V\V[0OJZ2[L M1GXX&OAU6#X^YDV3;59ADD2(8/!C,G/R"0YL#&O3;A!$,6L>KJ-MS=(X/`.: M[N&^JY+DFQXP1_JGQ167<_"YO<"GG\=+D0>\H`<,CA"#<"E^8,_#Y_:'6"+> MO6!*,_$+0Z.-?#0G_Z/UY$OO29J:__60KQ_&^7I>'P;2%7CLQMZ_RB7M`O2> MR-IU.FH!:;M6\\II^KO>0/AK1H]*Y\6V^PD=-"OHQ*[C(XPC&WNN;ULXVB-+ M$I_IE,6$<#2'2WQ)"T;#NQK@]S^D^/6JMI#_M`14W:Z;)L;2-]0''X9+]J'6 M8*S;EV+Q^>"95'>DGCY`OT.YNI@MX\\?,XQ+62P7V>7)9@KVPV.PMUG:U+?9 M+EN3MH-7TNA36KRN4!Q$R$\,Z-B>@T(<^>;PH(-G1=AB#>*2S6@.SH>WCN_* MM-J`QVY-'FRR.M\6:7/8/NL!@A08&;"!XG8%( M]E`W(:%B(6S\HCDEMBS:SKDM7[*JC6Q=-ZX'OH\[KV14.L_.B6BCB-(%1!%5 MEI3*^YNHZG\JF^\;M6S#3I!MQXD;NB&*G'B_(>Q!RV$^823?TDS:7Y2->OT7 MHYHS!&AG62X*$'@J(X$8I8+!0#NU6N,![=(3Q(3W2&()"U+D+BTRR!ES*C@H MH$CR[$Z]PC%,$@];@>6YB9^@`)I#>6?/==GN0\BVH7W;?X#"NX<(=)#&A^47<8;I7($F62X7LB$O;0;3:21>6IA%YI>LVI+QV6[VU^VR M"'UN),KKI[+_EGR]WI7U,^F$7[)O34",_W,5F-#V`C=R_#@.$\/%0>R0*3)V M3">PH!7R:)`F"+JWWSO4[;L+8^B<@J6+?S8]6P#U?'+7`[XZHKSUP1@T&*$& MOU/8+L^3@P/A30^!)?6+W4UJT\" M]DAING4$$708P>\#RJG'.R>)9P:Z+G#G*T!L MH,)-K)A/I^4Y/B/=$SIP(6H^I<7E;*-%H>;CES0GO[O+DK*Z37?9;;9^KMKB M>7CSQW.7\0_H5U[@F)8?NP8R`P?9H>7ZWH#/@P%7D>3)0&G6_Z\%\>$N_SO; M@&V:%W2]/6=9^IK94_(18#8G*8\#>TL^W)?5AYK8`@[&@(,UXXBQH##!XPC! M8*'%US]`R-!C-T?@T$B\DO!!8&7YM@B?JRHKUJ]?JK2H222C=?R+3?O=KJOJ M_SU:!!W#@89CA\B$"?D*F28'2:H%O\`+%J"A8X(M=D3F&. M8^\`'9HDW^V>-WFQO2FK%E33G<*FD?=+^8DXAY[++G?DT[?#+>25&9BVY3B! M@P,2=3T8HW`?;AW'3%9-V:0[M@`V-3:NR+4W@UGSCM6.+H-QQJC)?<46G);L M)KZHQ+@P=@7V=H'>,#"VC%Z&.;9M7[=AXHBDV#5G0M%4H&$2++\3K#%PB<@" MTC=Z1(^R%L>:-%334AB&U#A/.NQ,YS6]8>:'"RKZ@HA2ERX_:*@UESU(:*!9 M15!8!;Z%'3^QC2#T$XQC%,?[)B&*7$5IQ<5V)D\1OA-RXH4J^\9=74V*7&E! M5LKK1&)[DU9GS[=/K:UBNLG,_/(UD=T4=KWCI(=]>Z#:ID7^=[N80ZO*EKM\ MD_;K/#>DMPXWF#[?)WF1%NL\W>W/0HV.,QY.,T*4.(X78=MP+3/&*`F]N#O- M")/$C_@V!J8&I_NTT=F4X2.N\I@-[;`WOAL#D'F3<"EBR\S@W`4:F7($C M8UHWCLVAWMP;!`X6C8Z2SWF27+57SBWZS]4!%A(AYK/_[4+_O(Y@CD51=M=\ M+.JF:B_.?J'SFQ6V'#L.`MOV/1N:20)AX+=-&3A(0LSTA++,YVN."/L':HAJ M7)?%]@/YC$=`@8(#4GKUA(+E?>%=B$\V<==-)9\^JV)1B^*^0]49T90A=B&Z M)V5"J:Z?<:H/[3BTW]`FOY#_BK_E]18"%DN-GP8VT-;$!E<5Z2% M&M"L/\>CY0I07.!WBHQ7;,3H8U,;["0VTXV5RHWO!:<4%QA$AAUIQ/99/5-^DKG3>UQ[WZKX=7 MNG$2^2@VL.]8/O0][%GNOEGL)%S5%V3;TJQ"+3SPU&'B5!UI&MGD9TH&^72H M(Z^'XKY`UQEE4D7T0B1*F3FEGO[(4<[PU_(UW36O=VF=;?K% MJ&+;-V?:L8E#DO;Y$$6&A0P<&4-SH1LRO5HEVX9FD>JA?6BQ@?L!'$=%/2D" MS\O4E-SQR=/_47=F2V[C6!I^%=[-3$1&#_?E$@LYX0B[TE'.ZKGP108M,6UV M*44U*;F<\_0#<)&84HJ)`P(4ZJ+;6Y;.CQ_41RP'.*]M.^H2`)-:_\3O(ES* M1\F+U:7]%+EB<*+M;S!;E5L&7"NHI!F5VH<(P.;V%<#'KP_]^+4/%4;49?_+ MJ!W%*4J3)'+P$,K&42#*9=G/U[UIRV4!"")MT_OT7<(AX,YH.Q)LIZD/QS5W M">Q*FR:.W"7,D\.MI(DBK+W2Z"N;=597[DRJY4V;],3X*+,QJ<> M`V$(EO-N@:W.HSG"VYUP.PV9@<]NQN2VIZPMH*V)@7&/7L:W.9`7V9BDMI>Z M_FGD2$EB0S*801\,8@P\9?FTEKYF:B3V'<0=$M]MT&+.G#V&&VPJ#!Z\LY4` MMLH0-LAI?V/;0-(`*0IT![_WCQGQL1^DJ>=2FV*"LB@]AL(T`&T0R'R^YG%' M+\/:]8=CJR=KPU1:*C`A;"&<%CK0,TT$"O@ M)DS01A9O2;0#-Y`W(0C1Y.1\ZB3_AIN-S"*/R>O!!$D8:Z!%))IQ02(I$T19A$^ M-&QFU8PO;/]<5UE5/^031*/!H')*8C:[.>HL3HO>S*/'R_=W2)6V$0?:Z M@S)[I[.M%-]#7=)2N;W46=:*[*B^8\&5G555QAFPPZJL*97ZYPH(EZ-'2"-.`IV5U(3+!P5LO<./IA[BN!^2POQ6"^E(U@F%]Q4!;FLZR$ MP7PI2Z5A+F^M*,PG+)B`N0KC#(&YDJ94ZI\KV7IW7U;%-J_+JCW,Y]+(L4E* M@A2QB8#G.Y'C'(-YGE#2^+P(F@$^:)$[M2MIFMA"B'Z_8*06MDIO3;^Q&Q,+ M#O/<,V0-868CKE7AFV&).$_Z&']LFUVQ*I_*8MT?UDMMVPY)1J*8I)'-".8Z MQZ6%B,0^B"G241;BRITUDB9[;'>&EX*H6<1&.=Q`'=1#GVL&31%HMJFF4&A^ M0\Y)I,@:81H-RY_]&"K`-(@]0A,OR^+0<],@B?LH7IHFH+P\X1AH6Z5?]NMIX>77Y#^Y9G*I3XKVE? M&]Z_AE!^X48KW-V6M7S..Z49U/U>_"RVA^(QCI(8T2CV,H]Z"25LUFT?0_MX M;M83.)[F]T$O`UI^1(F3TI#6:J):!/<*;P_6<\]@V)1VW%PHRC?I?>3-M$L8 M:*.BAJS)I-KNR^V!,?5^5]0M:!M<,.CV]^T_Y+^*)OVUKW/F=\GF^"\M;:\4 M&/'#*+61FU'BX!`Y<1!%>)`ZP<"]:8] M*0;BOTLGP@#^JAB)Q);^J('=(/K.D`I1&KMKXMUA MPD-BR#O'""LJ\[[#T'L>B_VHZKQ(:2S7=W%&W3"-:!"[L8\2=@)TR#Q?7*<\F`<@3()U$75 M/!NXREO)BH$*[9Z_VJ+/:;5K+A>L-6CUY96'DFLPK M7M>5`U=-G6.G&/86R&.):8=;7_M?;5=J;LFL":DI<-H1C M:MIR4215F4'B(SI>I_/^":U6U8$O!WSOXIY'#]PL00Y-J(\II9F+DLBCCFTC M/T)>YL`R*=2$U$RP/[;Y85WN3[=$YYOQCCIT)*?(9L%AW/(.`\=P0W78DT2# M^"9FW]3P3:W_AC!/=:O.!VXZ3!/F8+]5]WNQJKYOR[<`C!-,PAAA.TH"2G$8 M!AD>`)P$.((@<'ZT91(#K)%"(/$4&"H&NV6]A''N#1L-XMR[SDT@3IWKAM!- M88,J70\HF&E-P7[X!]JN*=.PJ78\SRK]M2NV3=%I>+3#T,[\"'L4,0D>CI`3 M#:'#D(+2[57$T\ZU3F);W'PD$@PW!]M/JQ=H%.W>-7*2=^JZ MP1CB*6S2!?-4VR6^_I8W/"S_)?WWH?R9;_C52>?(S4CLQG$6.I$;13:;6KMV M,@3W;5CY8S41-9./JVN_I>UO1CJAZW%J[!5`*W353#>*>D(=3RW9* M^\`0]BENU/E"G@;+A/GW*:__+-J=QR\\R;Z],K8G;ABX)/#XP"I&NH7LA.'M M),HZJ3((;==-F^"9`J<-@9B*EE3*'T/`364>#A`D1OJ],333-\.I$CKYN@!NV%-DY#:S;.`GCUH6)4LC2Y:_X/6;+ M^RQWFQDMF]6F:@YUP?=T\N,*OK7K['ZJ:JOH^J0Y]4E=K(KR9['F;^G_9C^Q M8Y_^HRL/S//P5T6]S\NMM:HVS(^JYJQM_C'O5C0A0]]X=ZCO#`-N2%/R81#:-`^(Y<9RZ0T@2 M8@I,292.HWO]T*F;L8(YTTXQ=BWGI-1ZP*6)!G%KTKL).QG',,Y)]Y7?)%U>%\7KK=,T6]@#CUB(^0D]A!2DG"*\$=QWP1S836-]5' MU&OE.2%)L.T-$GP:@"KHSPF@&XD.= MK]M$X4$?."51WD`Q\"WD'8QT(U$&T>RZ59,IAK/]-817*EIRD5"HR!S`[6H_ MV2BQJB_V+9PXR0+?Q9BR8%'D^&X\Q*.(TA1V-9ID$,TT.NH"7V0F:YH8@Q;Q M"T:@HR2#^'/-I@GZS';6$/;,;\?%I5E*C('40]@5-1MOL:=LC[9K/GMMLZ?/ MXZ>)X[F>D^'$2X+8"9"/AI$8Q5$&.I.K+*AF+@TZV7>-*VT3_(Y:X745%!DM MQJZ;>`QCV:2]!O%-U,H)WBGO#4/XI[Y=EP4@=!@GS,?_J:KU7^5FPT*S"2I[ M>DLV*$1-4^R;X9_ZJ2JVPR!#J1]1$A!>28NXPP$3FF8!Z,2NNJB:"3FH`<)0 MH:MB-+R-H3`<#D):#IY46IW,.VOX=X/(*&SK!!K5=XTA;-30L$KW4ZV.CN=_ M[H4@QT@DG/KHVN>Y9U]J==B4M7LV/A=P6BU& MW_BKOP-/W_99CJLS^\Q\OLYMH#AGE5@IODKXO,O+F@]_[VM:-KNJR3?W3_S, MV4>>VSZ6!:Y# M()LXH'&P/A6:R=P+MP;EUD@K]'B(OIX08[,9G0`#]-O^]ZK;\?-8MSF(EO9Z M@M/Z^\\06"_0T//#*`M9"RQE]I#_NGA-N#1R21`BXMFA;V>9$]G'>'$".JP#+K?/KAETA#UBD^3&^XSK36$7O/;\6:5JMG& MB)\TR>MMN?W>?"[J+S_RNC@/FS',):Z/W9B%"=*$\-(J?=@HBD'YV7-C:281 MKYW1EC3<%;75"H0>,YGKI1B6EK011J=!F?5Y<-`@2KUCVP2L5!EN"+.4->?\ MI(E2FX0)]J7XSF??OQ>[JIZX.9OXQ/4)(HY/6"R/A.%PT(4Z=@HZZ*LFHF:: M]2)G7-NOR%@QJ"WO*0QM@YU'@0:13VD4)$F"8N11&RV[J/JI MU4A`0GI9U6Q$6U9K1I)-WC3E4[EJAU-H_:]#=YJ:%LVJ+G?ME78NCEV'IBD* ML.^%2>"'\7&>GOD1:'M;>7#]K'TE$LI4]6:+,?6F/L.8>J[/((Q"79S`J+8. M,02C^MIWD:^NU4AAC/[1%/=/:;,OV4RT:!YIX+G8CC.?!('OAZEC)^AX>LB' MK2H"/UHS`ID:GE%RU`,D(-0G,;YIM`A&KW-W#*+7:X\FV"1IIB'DD55?*7FB M9&\S/=VQVYQ&?"$);#:/3KS8\^TP2&V4\%.)B):G M(N?:9MU8*F>F8-K)8CX"4TM.%HZ465\-N(7T+:>F$D.4.&P(C10UYMIMHPHL M$M^&6/THUH<-PR+)=^4^WY3_UPZSNONW'OCE#8\!BMR,EQ)`CN\%-$`TSM*` M^AR2:8)!!=!5Q-.]!=%+;*N@OQ)Y9_6WTGUMA8K>0Z_4:\%]B85M!NY**'!8 MSY;$^[9-;4@H--T0TBEMTOEFA'*[A`J8W/\LZGRSJ=HYY'T[?4Q_%?6J;`K\ M\L>6&?I777)L?"J>OQ7U8QPZ"#F4TB1,HIC&B&GH)00V#ES14B:JXVJFX"NY M5J?7&@1;^,4:2P84Y%!N_S00;^T\#(P@TZVOG5Y(.13E[HL71KEE+\B52'G= M&U77&]_K?+LOUM:^:E.[B[X):^O;B[7_45B'<0^UI5"V_SILVSQ=ZZ]R_Z/] MH57UO-L4[=^Q5R#_FZ*]K^\_^']2[GD1@MWAVZ9DA']Z*NIR^WUF$16@^6^\ MY'1VH0&%5;0UK=+_#0"\_-#34[DI^>+'_=/#C[)>]P5?7OJ0GILZF)`H0XZ' M4R_+"/;[D&'J!T)#?15Q-+_<3O+X]Z\5.%2>$KT]38F;[[^[EC02]JX:>7A_ M[J',JVFVF>*OHB5-E7OU3#V@=];'CV3>Z^`=`Z[@7Y5M!N!>65,J]4^5TA6< MC^6V^+`OGIM')TI"WW>Q[=FA1[PT<9+@&)XBT+JSJI@&K.1PL5:K5NUR#L!X M%4LZ>CQ7OZPC9/<-UG:._DFO[\![X&^QQB/1+-`ZCZQMXGS<5ZL_NRQ*>N!3 MJ2ZOH,WU;WXK_FK_J7G,,F0GJ4-H@E`8A,2CZ3#8#A,_3A[9X/U;)0Q(-4$A MW]6Q/O&O;"N(?V'9E/2934<;+MPJ6^5+?T&%/)OZ?JHUW92OI^)6G7\[=9@F M_N5L3]S4Y:IX3-CW/_)CFMDX2[&+LM`)APA12D#9WH"/U3P$:46T1_,:KNGB MF_:?Y=8Z-.O33_P7=!0"<%!PH*''/.!8HG6K5;$TAH[-GT(-W"-3<"*A_!P9 MLHT7/][[:U=LF^+W8L.F4^N'BI;-OBZ_'?BPX;[^4M0_RQ5#%=JNC\MF[(]9 MP4!E9]0-4TQBSPFB*$))0HZ*7(I`)^8TRM"=SS?28ZW+IDU)[RXCX?AA[W>) M/&>=O2*&)D,Z!(:R7K35J^8[!V/=_%:OH_*VAUYU'A>_])%C:9GZ&>2ESA0E^2M-N'BJT7I=<2K[YG)?K#]M^'C@:>O+_SYF[I&KVS:.7 M8&I[A&8H<%,O98!K9$(9K%:)[#[[?_+.*KG\;:S7,H$\;CJ1ZWN5; M:-$7O?TC1G-CN@:X\7&2S5E^$FYQY7S/M]=^9[7J^R.<=];0`*MMP<)0GV/V M!-87Z4-#P+Y,6ZL;?$G@Y6Y61;%N,F;1$/#^B/,DQ`0W%%(;7/]CN5%G]XVE6T]OO.)OU-M]#&X)!;NTZU MM1MDPXO@*+%?C-(WF?QB9WHNT/K]OM*Z2-P+63=!5L?>&<%1UJRZ+ MW:@W#5!#FJ_NM42FY<]R76S73;>8^A@[+O+9J-JE&?8HBY^E9(@8V+#;:F>$ MT3]O31XX7!:DM>01(IR+-E.ND M6[UVJY5H#>*[%3RK)2%[TC9M'?=C<[H?AO)PH7Z$YJ*8TH7RF2IG/=FUX=25 M3U5]T77]Z:1;WIVFH@.$4EV6Z&!#>+]PHZ^FR2QGN5#.^,=RQ1Z:$?. MZ%NSK_/5_M$),,V\),)!0`.2A&7I)UU&1]'51! MTIGE71//8U[$/;D$9CD717*7KS7Z2M+R;(\,R%:>WX9*X4,S`QTG3I$HBDA` M:>9$J1O3)*%V-`1S?)2*'C21CZ!Y@'CQ!9C!#H!M<.3J<6PVN M'@?EN/O0GR5D(]KU\1J)=A#;E-^W[2U:O$9X7;/_J+N/93B5R(^8[/)Z7[+Q M;7N(T=KTO9(/#6W^88TNW6JLY_S%*K>KS6%=6'PNNS_>TC4<:VQVQ8K_Y?!9 M=SS1K:S6[;^7S_PDY,^BYIMCS_WX^]^'G!^%Y"IX+D3^W&:NW'6I*^ULJJMR M8M7E]Q],D=J7R=386$W7&_@ZD6C$Q/M$UA)XW9G3/2G'=UB`$/$B'Y$T"Q#% MU'/#;OAK.UGF"N],SPFACY*G*BJCVX!DQE6*ZZ=>"]G!G!=(\7%-1STG*/VD@Z;%. M"9$,J.GTAD\P*,'M-9=*$FUY'TNR!@ES::@7W94J+=9HQ0;$AS;#\52]E%<^ M>F3QHI@%BF@0(!<%*1EFKEZ4V2B$0$I=5,W$.E5H/RFTRE.Q8-9+\%T&A9Z+ M@>TV=L,H-VB\LP:5=]9(IS6JT,R5WJC:_;L.3O!/?2\8`D,-#;M2U5ZU=>*9 MUL^\EDMWI/;^Z<-VSQ[=\MNFZ$HX/Z8A(7&BG&O`5MA('NE8/5DW62UA>87SIG>=*HJ:QD-0X;`C%5 MK3G/+%9IDD0^"MKNRW6Y.>S+GT5_54I9-.FO=CUQS;/W^-&&P[X7>%ZGK[L@ M,L%Q[%)J!Z[#YL2I@U"4TB!QB(MQYB1"^P@WDJ89A^,KL MJ$WM=?<793%GWWN[3)=#+#ZWG:\,O;'X!^E>P52RD)'"=(:$I3)M_Q;3I(1H[G@\;F-]2I>V!_ M!6I?N3CHR^BF_2DX/_B;="5P"5L]YN7WT>;GRS$^S((A=#P6^&R5#7)S%"EXQ@&"W>4_<65RB];43 MJ>9]`7%X#O0UF:N$W,*^+DCPDU]@#$M8;31+9=HC!$1IHV!7-G87I/=WYSH! MM<,PQ';DVID;A!X-@SX0\3"%G3\"?[IF;G5:P`>"X"8)+HQH]0>&GO[:V+X2 MQONWBNN[F')LR-3*@K1YAL!D1@/>NEERAA7"N/C?-IUUWP=!B1VDGAV2)`U( MX">>'9$^"!MQ^:`BK;!/UHR)7@R4$T!WQ!BASQ@8'WH=MR+#*QLFJ"!GER%$ MD!1?J7ABEEVL^WB\B]J/?10Y;NJYU/.]_V?O6ILCQ;'L7^';]D2X>P$A!!\1 M0A454=M=454[&QOS(8/*Q#8S:?`"Z6K/KQ^)1R9VV6D))(%S-J*CRX\T.O=< M<>[5Z\IE(S3H#?@<'YFUZJ9EM/CU35. MYGT2*/UOW-$KT7[S=JN=DYM*O*F($[7'FS81CE'H,6P1IL!QJ!,ZS@`N(!@8 M##>"B$S&FOJD2MD35=H^5:5L4*53N75>7KTK/R1;5]V08XW$&0T^723(7%F= M)>\KOG28]0472>]>1F21-5IM6)E$N50)N;PK^1D5N[@L>+6/K-@RA"\=OW"= M@((($APD09P0E,1NOZ\80L]#4D>T%#>M.4J,T+;G@Y_@G5!O3B7I8L*^(-]R M"GZ6ZI4<_I(C\XP@:_+*2I17EW4OE+K31N*$[<;X4+/!0%U'V_\[Y'5;1KG& MCZ/O3EB(G_@1\FPOQE$(`"8P<2(:QHX/G3#PI-)Q+0!T9]\G3!;A!71IFE?6 M7]/]@=(/O`-@:([[B M=P&,G;:B^G3B#`OMU]7@L)7(LEX;7]U[JXW0"1+])=N6-P6_W.)C7TTFVW6G M45H\_'1=L?N4I]_S?;>SJJX/=]GN60D\A#!-$,78\Y+0Q;9C!_8`T_:@U-R] M:6R:A3VIF_RN/;,Z4G1^;*`UQ!HL:3.\D2U6;XR5-M;SV#!9]@TY6S8BK,_/ MTX/%R1;K9(RPLU<41)0X12B^F'7_ZD*/8?-?C4I+N$$X8+T0,C]7)2VKN_1C M<1HW?3=R7"\,?8PBCR(61DDRP`!`[DI"U6UKGZ$I=OP<]LYB**T6GT7S M(F7#P'1OC1!+AA'E+A`+$TNR+Q<&7AHG7+5.:-&.J5]>Z"5I/2/DNART$J'6 M9EYIII]/O[L@+_(F^Y0_L(#P[*!Z=_HO"0FP(R^`('"P%]`(!_AX6MT-W(D7 M%,QM5K.\/JECWV+]M07[<^6&V4>WYWM`-A,W2O[T)'LN[[KO!WB#1:&L6)DK M5J*C.BQ[O9R_6O+$MT5GO$(NRY0?LBJ]R?J=ETR3/3_P'022A#B>%Q)TO"#` M!4AJ;GM:"[JW2?>@K!Z5[';I::R)B9M^PN1T[#E7B^VC?HF7<_NI9_&X$A&: M:<3S_=4**!&6EC.2AA__*_U[6<7[M.Y.OCHH0="WHX`@'`8V<6`0#A`"&TH) MCLIV-KQ6NU@*>5,E#J!3$!6\H!`(Q/W-(D2"#T?(IQZ(5.&+GAJ2J;$RA2TTEM+ZJH5T_>Z3DG M_I6[9+:T:O>&2GF=Y`C3&OL2H]-T=I9OUJ^U\\P3UUL%-$I<>-!D^WVV;0[I M_G-5WF=5\]CGRV$4>BB([2`@D-?JC8B?'//E2.Q:*@7-:%;2SVF3M9?J5%E7 MP;K)MK=%N2]OAFMW_E&4/WZ]+7](7X4PG5DQE31$JIP@CD%9`ZJEQM*O,W1& MX!30NA(M4V')3YBY]YU7$('.2J`L"AE3_SZ7T,L M3KO_=SJ;(M?EOF[Z"_JKB*L57)BKPHI2:0>2GO%BX]9M5M=?LCIC?W4;%3N2 M/63[\IYWL6&QF`+?B1W7<7$,`:#0\]SC=!NB4@=GU+2H6:\_%K_>=RC9*+.# MVXH-H:)O])W55GI(&E]VB,J-.GQJZ M9Z^;ZF%:Y6+IDF7S1(B;MB8JS_M*%%"M3>*KGU,)4Z!__UUGUX?]I_PZVR!^ M@L.-$61M`]_S'3^TCVW#6)'^232H6?]^VOW:0;,X-NN7_V5!ZES5.,/OY(FV M2>_D!-97_TY.L4GXG9Q,F(J+;4[/KL MQC2_BRT(*TZKZC$O;MZL\Z>)T-D9AWHN568;5U:+;S6:UM$U+<>08WKU6B9K MCWAN,84H%1HVN@A]?-/P!D;0QIZ;V`'AAYZP;P,X($$A@ILBN^%_-%O7I@(0 M>CO#[NT<8Q5^24?`K#$R=7(WF?O9`JB5="V2*.\-TRKY"J?3='.N@]:OI+,M M%-=6-62J4-O?LV:3N*%';6J[.`GL(((HMH^;T5``R*8IFW0_6U=%FI+*%H^H MA-]I!D&=6`I1-UL85;.F5@3/$FI:[QB8:=HFP_'Z=4S*&G'-DB=)<./'GGU9 M=G5!4UZ<:9L5-1O+?LN*0/2O-A`$;5<UV#KH5L]=JF=#VK9%]E+LACQVO5.?O)=;[E MVUNV/WEU?_1J>E-E6;NZS'^>WK!OVU&:5?#:Q:\\HW[M(?5O<_?,R#CIU7TT M6CR]BKTU>BPKM;\FDLD[R;HZV7VC^#'B%^+=M'WLI8+H,0G<*"34`2&V"69] M"OE'&,`)969_5;=M)$P^_7T;H>% M"P5*\GIF%*'+0RL95F@SKS33T2<7"FROY\%IG>W:C95%W8K^"%6-'T^?^9P^ M\I]%/]*JJQV[@8Z;Q,1',*(TP$$0^R`F=A1!X+@4>7(7C1M#I5N/1^7N6IB_ M?N*5ZWHZP3%P(N3P*6>#T$(*47TV`8`6":`2#U8 MEBG5)/MJ<&DPKLB7+E)PB:"!ILB8L4_OJ M*1,"NB!)VAG*2\ M3M^4H](S:11?HS)'Y[0EJ8[-LF/SGG?&=L'IR'9<5O?]TL&\=:"S1+RR[*.& MO!6L\B@RI%3=KV3G&=\:@+XV_OQT/.#CVTF"G(C"R*5!G,#0)L?8@ET@= MU=OW;N++62_IB#EJNL5[CT.*6%`5FU0Z98EXU2GP)HZ2P`[=T'<"X`=VXOAX M-!R+H\U]5N7E[FN35HWQ@"6(44;XGILCK($X9=]N>1%V)G7935X47,%8`.N> M:/V2%U;=QK(SE0G6XE3C<4R#)U<1PJZLSK+W&[LZ_&;"EF0ON+R()4N`OF`U MR17&XM0']L&F_EA\;K6U.R>?4.1XD"`0LA$@!%&($.FA>C9.I.YJ7P*?YA%5 M"RE;,@Y-' MN?%3CJ'4%L.EL6J. M5]'N[X>Z:35M=\AX3?9=_I#OLF+1H=1<_QH:6!ET[8+#+&ZE=333^N5HZ%]. M\>Z=!;HW/*=S&*:HSUQ(`%1&A^HAFE(WB0=&OE?C8UT?LATY5&Q\V#77+&`""($^R[CN,A,"")_220JQ:F`8"0RLVI%G:$(A:Q M]`B2-&_G-$:?$]8B&QHM?*X$NLDTEO72LKK.\N90C74HPBZ-L1\%R(]B%$'' M\0>HE$\QR[W]"R#4+@\]J$7G9":YSDP2J\UGBR>N(\O>;:+Z@G[PUAL2OZ\S_LR04>H?@0Q"0ATXLAUH1T$MGN,$I<#_AVXB2\K,ZPV.[YH1?W>ZV2PE!DDD[)B\9EOVY;>2_ZB?F.(%6GK\ M-G9]A-P0!7$41A2Y%(8#_@A[R>8AJ[Z7IE8XE<&6D;6QA;(SQ6V-OFFZMG*_ MFTG,%W'XS$3?N8Y;8FINN&FXOVAXV(OQN=T?Z/1`X+J(^(&'(3,@)%$(!TN2"("%CO2K@J\Y(O]TG_,`U&J1+G=@ M4IG[#6W\7=;S"^X%'L?;-WJ3];?H>]U4Z;9YQR4%!-UK9B)9=5^[D#BMDR%] M4]%ZG+FVV+V)*(CBB+A!%-BNZSO(#HX#?^3&9-'"!K.0RR_":2IW<*AW_-MN M^+Q@U8-Y_6!5D5NI\]]'N+[,&+U\8!;N2O]>T5B/&8 M[ED3($B"@+C0ASY.8IM@UQF&_=!'L=I*J@9Q:QXECTLXZ(VM)GVM*+ZNU,WJ M8^SYBYS.EGYX9Y%6G4OG1-L%.M9[B;A+4",;=1=SG[G(VYX);C\Q'`P>S@4+ MF>6X7@!"[$-*8QL$-HW@4#L7!CZTC49CS;9HCM!O%*U8-FCK[B:&`OF*>LB" MP;TK?M%^\E@"XU0!XR\7'/7G^5]G)F"H9UY*=F"*+M49@U$WF\LB!I1BN5`( M0N#Q#,@!+!7R:>S8\&@%HJK/]YL%;^!XY;@RR+)I@6*_&\H"%G#X\D'_:/0% MAW][86'H!ER\?JE\L=G1QH5K2N7I'U'KZV:6$:FW\J!]5ZW3DZK:* M$R])8M<+J$TQQ+9#3I<@^;$#Z8)UF6;AEM\H/JM:4[\S7'8Q_/]W^1KI!.]% M1$W3LM`N7SFW+5V78E17X[Q5OLLB`'8P2JB=T"@`>!BS^4X"UU"M0I4IFG<: M/2GO\V-(6=,^98[UZN:K%HL=S='+YSG??+JANE=>=KJAG"WC M);T4.ME8NA'M=CG_(MV3O-[NRYJO/@_5@38AH$Z,0XQ(!#PG<)"#T'$.)G&, MWM8[#ZGF9.%_GN<#57:7YFU%$/96M1`/Z=YB3[XS'/=G.MA,6#?GV^6B]LE& M:V3D^RW%==9G&H.MFKYR(;%4$1F*0Z5*%\E%PN]O@_XNO2[Q9=#R^"3EWYB2 MNQN$PQ"%$-MA&-,D`C9PHV-0]V@@'1]7AE]SU!S61E\83[\'P8?K;=&YEO?SF9G^H*P60>_%9I7VMW6%+#72M%+87RM6,T& M=^FU@M) M!Q-`D.>A@!#8_M=;&"+;64$*H\.LY38,7$!*HZ6?+9K2+-W%5IK2_)O,G*CK M%.93&IT]][)3&JW,F4EI]#M?.*7Y6&S+N^QKDS:M/<<5'N1$`&,7D9"X(420 M1CXBL9LD48S<2+A$UM3'ZQ/A#I%UA+3N2$9("RG(`\)^.,SX/\IW[+4 M@07UOO$-L3T?AB%U`DR1;0>AZT==F\1V<(@V+!GX7KXE&4J:DGD_QJB$7Y,G M"-OQRG[`R(;,4N*BAMOS0F.<5#G1>KN_:;\WK!LWLK^ MW.X/=?Z06>EVF]4U'ZCS#[,'YLWC?]36?57>5WG6I!5[2K:]+9.ST')= M5M:ASGAE%_X'#'O&%.CVRMHQJ/ORODU@^3O%$J`[/DV:[O-_=GV#GUNIRMUA MRT"S3_PG>U)396G3F<$>F(Y-W#]:-1NAY-=YMK/8__;MP1?>=,H,S/9[_F__ MNEH,0\$^MCM4O-MQ8/W$6)7M6>/\9R5_>)VSJ-"AJ;)MQ@C8==RF1=E6?K]/ MJ^:Q-;*UCH^$^)^R9J^L[X?&8A^SRA_%E;7-JI9)AND)<3ES<7&3MRN.=9TU M]6^\COS^L,M.:%G3Y4V1_W-H_'#/_F&TW7?#M?J$[7#/D'+ZAX":>^)W08VP\,;FL]-?9<=LU^W=17[2_N M\CT;&I9%]AJR='N;LS]N_Y(!._EK]$@.\.:PY]WO\5G'8'_?Y`]YP_L5<^8N MN\ZY%_NNM3TCTZ?N_YMPAL->^39ML4-@MTF+B`:\D,`HE8Z%DQFUMI0:M%5V M/21E7;9OXT-9[NK?LV;CAD%D8V+'($PPH<`F@/1MN1A[OM3*Q)0&-(^(/G>J M*IN\S.-,<)9=-UV2\]T=F?.>PN)+QTCP;GL^" MSB=DDJ1\S:H'IF1M/IJ"_F5>4E M/LY(RBSZ5J(G\VPH%?:GB8M"FR1PL>.'E.+8#N/`M4/H]L\'$0V9>I1-NI=; M#'KSH5**<6Q?^$WXQO]$0#&TKG((K&X(\[22WBZ/^Y75#$G#Q>/C?3N!5]SP M_0M%/5HVXB.U(.P*P!F6RTG,Z?8,@T M0IUDW/R)M>662%_EYUPT',>856`#P*''AT$SL8D]&=F2?K5EL.)SQJHVDU$@S)28P.DF27?KL^&FQ M6!R,82UY1L49!9E*VDIT8S+\4DW?F:01PVS!!H`8)]!-'!JY802(1X-AK0.% M3*;D)4+XT884HN[Q3%((<9YD!$(+1=/TX>N;[&A4AZ'Q-\5!FK!5:8,\^A>E M82()$H/R;N$]*G;DM$;>YRX;]F0$/(`B0#$);(`P](^->E!JH7)>2YIUX\LK M^P^D]W3.8E-,3LP1*:BCB+Q M9<]LSWY[\R$KV`!KSYJ.=G=YD?/!59,_9$/KCN=09,<443O@S2,2#XNNR".Q M7.$*-4UJ7Q1M45Y9-QW.]OU+GR"572=51+7@LJEYEB5740>"/XP(?@IR(8T3 MH^[<&JM:[E>B>JJM>KX"JX.TZ1/.&^@EQ$\0C),$DX@I+_#LOJ$@"AU?9CU% M_NE&%E;*XX1IIFB:^6W6)DXO*R5L[K3RTG/),G/(PL2M1&5F&/#6G+$D%?+: MT9T'_%3^B[IKZVT<5])_18_=0`:K^V7?2(I<-#"G$W32NP_[8"BQ/-&.8^5( M=L_D_/HE*5%6;K9XDW6``2:=3J>^^LK\6+Q5M>T*X]CU/!\F'DQ#0`(2D\$4 MHNJEI!X2O]^R?AS'Q):B454-&;XD=<,25:K*T3_^_<(`S=VM\0-.I@B(`H-+ MDQ`5%SX3$64Z)LO(]WI7O[;6"]=PUH4PB)(4`1P&KN?2+ZE%83@B@=0J3-^: M[3-P?@M*#)P>W-;E5$Z+QMC>L7JY<_*SE)V0*G-T+T2X##I4 MV_ID2I?YH$.?%U/KEF^9E^9I!F&`V*$<("C$>-#.A,#5KORCV)<3>T'+_O9) MPROKAM<8R.11)@")!96D4DFS-4V7K-"D6`2EY^7(Q=XK'/IU2=VBDRP_%"-,N4-Q\]!3)%DOY6THIM M6$4PQR1+_11F488C)`SBR)=Z):1N99[3+6.:I4&GYL:1428-;A@M99=(97=H M,J<+428#CDS=#9*D1K+8*]L\)]0]_,]#M7_Y1[E_K-?'K*Y=90&"``6>FZ0I M)BLZFV5;&7/HTWQ/+4 MM>#T2K*O=@E>02C`";0)T$>BU?EP/=<))//71*GY8R0.>7<<_0B(]PS_!<= M^489GJP7EXGK(E7F0E2U7Y"3EGE52=SD6IH(8;'RJ8+BV3U>>FJ>EOYU>Q,NR["/M^$,=N2F*4P2P4 M%D(WE$I_)'ZMY6SE>[\:G'D\'`DX,0046%K(IUX%>:W]$9'=N2WWQWP`[/=- M=7_8LQ:$=_4G4WSF94$:X2`%@,`(I!22N+@#H@P$?O69V,Q6IQB!%>4 M.M^]`LWJ=G/4U-V?"6@+!HJP?V MAKS:'NAU>9HD/O?#FTZ^-/R*[DM>,P39WF#(&<7@ED#H76M9*]E>^OWP=%\VUQL.8=3D]"T:A(`7QRE*0!S[88J3 MB(A"8#!(`JEB_I8@6);(_WG;/9QK7>O4X\[-[Z114@IM16>:0BX@,'+"^:Y1 M=@>9UQ3KHO.JK_:E-56-WQ-2:SE@"U%@VU[6LXX"V23UXQ/WN_+O/:0D_;F* M(N*FB(`T#,+LS8(GU?M`VYAE#;YE;=X:WACNYZXXK"LV]DFU M*W:\7=JWW:9N^CYPHD6=PM452W&8F*7.&0+)-/4S*IW_O>/K!0;2X2CG?@Q[ MCK53Z:HIPA>BEN;\>9NPFB5J4E]>L-W6?]'1S8[Q\_IPO]\.>M4DIIYXS!F=XF>!%!4FL?_)Y['K7;A\=R?:!_L2[W1<6/ MOQX>Z;\KAS[`Q:LHKT64"Q'E=XUVK]CEN>V!)8ZL7/ROJF77DZZ;_>W#3L>?X=$#H=1(=CE%#VF6)R?@Y>7CCD)N1!S*\WCO#`X2XXU`=G M<,+Y.&1Z\_-,49P^62\OFFHS-P5TV!9TZJW:AVW='IJ2;?J50P@/70BW/(1= MBY8N\L\\\FRJ+8?(TQ\>NJKOV`["EO64YRVCZ3^]/[35KFQU)V0CS'\R.\\; MU05,U3,[7%]J`,G6)*>CJ&00KC>H:!\)33&._9YH>N"EL9=$7@@02H!+(I(C MGT11C./$G5P>6\>&19D7L-B09<`-:A$,_2A,W"$B8 M!S`)8Z]'1Z)$KNK)3)`LI\E\H&[X0.4/38_OYHL!O_S-MEEB-4TM%Q@F.5UE M-X-XE(0+SOV+\^5GES%]=8Z%>H^>7#E'7YRC,Q MO[\C.#_IDZ<,L/Z_@S@AJ7^4C-)J6[ZZUWA73\1_+#4:X2S&7A:Y21HAX/LT M5Q18?3\G,A/(10#:/O4X^L1V:AOAU;%*!/TN^_J!*=KS6-$.0M$^FH+^4W(. MNDSPI\U(BX^[Y'G+ZY`/#CGO+X'3OY:=5^O6V9%^P-D1/=;.O_M5M2M)U&0D\D@0^3$.W$ M)0@&,E.7$8.6IZ(QQJX#V@BE3,`[%J@36+8BEQ/ M8>V$_!HE?2%R:M:GVN*G5%+N_JNH=DQ_KW>WQ;M]X&$3>.6Z4>!&GD=(X&9^ M&)`@]H7U)')=N=?%AHQ.&I@Z3XIYN2`Z'M=5^URWK);D\>SEZJ/#%TDI-$7^ M-#&LDW471V_+AT/#\\^>N*8LMN[5-1_Z/_DOP_$K!AZ]7$28HCXD;H02#/(Q9 MJIJCP/-!GL,89T(W[Z;=)K$+1D%/[^1SR2/F_HY8_X?^X,ONBCX\-%VN-DK4KC=TWNINOM$4 M[J8IGZK#4SLN+TD0"1,_R]S4A\1+`_:X1HA4D*:97"YE"83UW&H,ETWOZQ[P M?SQW:-F8KY0?N-@*S<1=R0O&1&W?40!VOHPA?V6!&5!SN1:XKRY8.%>-WE,; MAG;CM9`4S;:7;S?]YB#5<.GQ,,0Q(A%"`8S3$/AA"H`P[N7$4REP7(>1K@4FT:J\C@MI9F!0KF4A0/J MV1M#FOMBY(>\G+H2J4?D0O1(UXNWUR!-D#)I.X?=GN$UH7@RP0J\5#$",FG=>D2[,H)U"M:KS>.P.?`%^?V*:1_T*1N+$UC[9/O0)-\+ MV"0TZDYMYV,I\ZR496O?VO90KG/^'OJ&/X7F%6++I^=M_5*6>44_>)1PT48K M]R&$*((PSA`$((`I&>8O#-&D'-:6;=O);5>QJN*@^47%(U3GJ615B/@RD[U2 M@W71K+NMILX'J:>E-N)R?NZY=$@DDV6&UNG@.AU>IP/LW-7."/(0@O.=V>>) MA,1CT`M'1&WZ`D]L,XP_]^SGKOUCL:<3V)9MO;"!T_+8]0/I72D&IVA?+QZ? MBTI^O.F^!I6G_I,YT&80%S`G6G6OGF[*=1%.*,@!RY28*]_@5#XL$T!Y/G3`NV9YTS^<`> MH>:9[+;#[10"N(P^VXC&A)GRPH%0V%9JQ50)6N<58(:DZ?MLVG.8@"6,,W9=*^>YW,LWXRJ*X-%WE=` MHE,KR%".,A>0U,,I->IGPB8A62)SEJ%ER/($-F#CP^^^H/EJ>3_[]8!3#)W8 MF#="[$*VY\WX\K[KE2F")%[C;,JF84^!/FXMY\,H3O(\(MB/P\A#?A"*6_%> ME,J](=6U97EP"7@3&]?:H7/:8>&<3,JE=P.)"^H_>8:M$Y)EBN>%J)8Q=]Z] MKS%)TV3MNMX_E@WK'U:TCYUIL=1VLRS,`@C=-,9)$*=)G$?"8."[J=PU(W4[ MUJ\6<6B\^1Y[JERQ#L62BJ5!XC2MLLR>DDIUM/6@AG??^&QK82OR]"E!)X1) MG]2%2)(!1VK3GS?YFX]-6;1E7G;_'[VJ1L5SM2^VQR?57DQ"&+AT<13E*8%Q MA-UA;10EKDPV9="LY<0*]=60J]VX7$;;EOV5YVU5W%=;I=(9)KF?)F<7HEU. MWP1(YXN`^96Q?RQ:T4.]7,6*Z32>OHEJ.A8+D44;GKV_DVJ'/`WA_%$^E-4O M5OSR6(8BQ@!FN1\&U'H,`YI$)N)6K.^'2*JOHAF+EN5R!$E?#I48555"VV0: M$<$1R"7)WP?<22F?#O>+%3TMI\[JG3YE&E(G-O:.(%:8!(E+4FHXB3%!0>!& M@VV*B4@_CM$W:7T!>]<4:]F+^&;(5!4Y6RR:U+BA?\P1Y,4%[CUO4OJF0?MB MY4W'I[/JIDV8AKCEAY(]=/K!+UFM;XJ&U]4\-*R-^LI/0!;$$8$9B0.'=6.@V2J"&BW^M].5)O83\(/=_/O,S')`\@)A[,1`D> M/\JD*MX8MZV@G@H%;A@X;=U495=5,6TR:E(K.AS"3X%'$"\N<6\YDSO[4"5\L;*F[M'YLPX]LC2DC%7\V%&B M:4JY2F"6XQ3%A$"2NQ#&Z?",TD\AT58Q&5O6!4R`>=$6,2D*5?7+.'Q`JF? MAM#-8I#B,(+016DJT-`\4+)>M240UB6M1RF>EG;766HCB9J9**B*WWSTFU1% M$0YQX9A%HTOR.L07E\HIM$IIJ-$X+59FL1W$"_ M-%9E?[&RJ.?5M"6R'FD&[L?<%"_\[#J+7!1&:9X0!'.08]]WA>$@\#*D=PU0 MUIKE*X##_8WG#H^Q"S*3V=2]'6.#2+-78V[.43OSO9@>C]*E&%FV%RMIR@Y- MO@ZC1I6&D.&^'$Q_FOS[\;'#*LK#T/<]XL9!B%P_AVXHWO0&&,6:ST$T#-N7 MM^;PMB@O6ZS==P\&]9,['=)5I6\FOHVHH,`ZW(@9H;VX(GY.I)0X&HC'8G72 MA&]G)=,8@;JKWUXOQ@`"'P=1Z.:`\IF"#"4X%<)Y4@U"S5FUK)O]^K=7 MS^V4(6N;9JWUL&6Z)Q8RU))G\A$+YA;%&&!8KD-J.35L>:U.G<\FZWY_\ M4?XJ=ZSP$D&!!T&`XBC+,^#F.!<[DD&,\UQ/$F6M69;"HC7S,F=Q]:D>W%"INR0^=O/6M1-:E>Z5NCU6#T56VY ME8=3XJ;(ST,,(H3W.)V:L2BQ+E+HWQ>EK4+D6I65E# MER9Y>AW12Y"M5COT[K%D==-ZXM<#\:-ZVDWYS/K4T3_UE;5I4-CWQ3KFA?[$ M9EL^\!]9?S@DZ$^TARW_`?Z>IW#N#VVU*UM>H_N^VO&?TJQ".I'T#Z8A&R%; M0+51XR[5]C[A)IXNWM4?O_P)TBP`)/'=$.0`$9(2+QJVC`F.-!-L=<.6IZ?Q MD\47<21EY.6B,M/*R?<\))N9L`XEZS.PY#>+GW`IEZ'KAV2YR;H!WZ:\5C1# MH.XV+2NZUAD>[X>0,/&@1^(XQ;'O$^*Y7BXP1!F&!G9JU0S/LEF[K5GV4S9/ MYK=K%>G6VK&US[3!3=LCV.7MVWY(I/S6K5X\%JN;)GR;MH%K@L#)NOF]W*.B M?>1UOM?E&K[\;%G1W.,=*[KV^=4AX+VX$T#5FH0$NR@,B=A%#B/L>ZM]O2^V MTU33H%DIS1P03A[.%*G#2[(^]UA9[\`OAY87Y?XZKAXY0);44I,AF*:D%V)? M3D<9\0REY8XPTBWTO=+$Y"XGI!"E$^//4,/>RF,AGI3)`LYZI\Z&^V M]5]MMZ]6"?C&A=9XK+1$^))A,BK0@R,C@;YRCKXX1VMNHXH4=9K1W-7CXYZ%JR@X7_][*<]W8]1$`K-M]%B.7("1L M)C!.%4HI:=F;)!_:Y9-NZ/ MF/-M"I%VVG&=(.F$6!KA=B$2:,:7M^VXS!$DT^7NH2S7+2L_]X]B?VBXE@_]CZ\BSXLH*D0%-4J2T'5A+,HR MA7Z22[TKF`>1Y?SV"%Q3\^8)ST1Q7%QD)%6TQ]\M.8X>7#DC'_BS$.X%B]S@ MQV^;NOFMI9XX1U?F[X*H3_\I?9XUO$L1\GF=?M^`<7;*U3-9OG\]GI,0B0@, M$L_W`N(E(`3I\"@CA"C.Y8H"Z-M32&BEJ:Y03Z,'"')!R%D@TSC)JVKGT<25MU6WI4_NX'L%?. MKMRS;_&3M(;7."S7N@*H%0=%+;0>`&.R"$?L?^_8Y[NU`NZE5?($DS*":2(@ M2]5.([Z=DU%S!*HK*EBON6P4VV\[NI:FBOYM=WNX;ZMU5?!*@V$4XQQ1VWE` M-=[WV5TQ`000:&1;5!O$/'NE(Y5E8YHUVJUW>_I+M^Q0I>JAZVJK?D04!7:> M*!A3V2-<1^!EM[W&B"\MM.<8E5%;8]%9JN2:<_"<[AJF4N?XZ2/S8+<&FTVU MK:A,M:LXR'(2N3B".?%A&&"*1V!Q211KIK4F(%A/;T=+#3;$BP&:_BF5@0`H MGU[-Q+S!4ZV/99;OK8`)09GKQ.LLL7(G8>;BM%3M->KC^9,STX2J*_!-PZZ1 M[E]NZ(=_3R%@^MUG]B.K),U#[,513-(`@A01XHL$/,(AUMU.4#<\[T;J^F6)Z'0B)]X#,!6.I< M/"J\J5KLBZD30FDA%@O12AN>*;]NDB1/5S%)M2MV#]/?5^4906D4$-^-00A# M"A/B0<]19N+1JVE(EG//MX]>-P*^<:$U'BLM$;YDF(P*].#(O^&C5\D@R,N[ MK2@O6_JM>3UM6K!+^J02NR*_9Y1]:]L#Q5/6&U0_/=6[VWW]\">%7F_$WZ"Z MW;.C-Q_2=!^[?H0`CM,@!9Z`X>(\GEINUX;M63<@JAX:6R"WCP7]=RP#?S[< M;ROZF=YL2E;,]'C!=OCQA_^G[MIZV\:U]5_1V^``F0W=*3V*%YU3H#,IVF"` MP7XP%)MIA.U8V9*=:?[](2E+OM162(J45=O^`V@.P9"O\7OKH.C7^Q73U'+#4Z@V1KR: M;W$XH[D;?=UU6Z[3\FJNNU6O*SP M3I0"7I4U76[7[\X_Y?99_)/C_EILSJX`O8^L`ZP1F`O#M.T0SZ`^L%7WJFEZ MRH@E_<_\1/?]$V)-M-PND`NR."*1%^4P9!/"D-G>&XRQ[VO?O5:S8GG4S%9O MG.*]-*\Y-''A1(`;L6JO2*7Z.KT]%L>,;9\[`M$'!%I?BC_A1W+Q78_3FB3@8: M,=/5YOL#K5\P?=PNW,!GEM(0A"S])B&"7M!5*8\)R926I@V8FW3%X5`??,6P MC4B==+E5SZ$FH-740@$'^+M@%P^R:SVONLR99((UDO"9:)E)CP92+B-DZ>5> MQ_8`\3%_>`&'K@]2B-V0=.41XM@E[HC42\6,]S((!1EN=1DB)$,I3AP.\> M,HA]E/H*5_E-F-.0(YT"IT>]ZO([4[I_&OY\XFDF% M/94)&=7;/T$GFQTU?66?Y7LB_'7$CG2^!7+E'41[KQ]^0-VU'0Y#A,]A-\.4 M*Y7Y]CCF!A??(+E_%>CF&60:##.5^V!O&$?2U[VUI M69MTYMUPB$XE,#ITCW%,05A-AM4GX/;)'3/_%NB7^)*<>X_C M>B8IKD&'AFY7&:!*^5K__9,P>[KIBW!(@.ME?@S9?S@-LZR[QQ5'0:`X^1YE M:JH)N#BQ)'J>UJ$D,[1*2IEU/L?ENHS)5L-D3Q19O8%_B:4A[3)![EQDRX@O M5^[5&R#(PA'^!8D]["=Y$H$\R4%`?"_NWKF.D9='!BX]Z9A5RLP,O?LWZ7G\ MCXF7$[<;<:XF=1KGZF=[:GY`"RW$8B;*:,,S[1/NBN1)JR9Y>J++[?T3^;%\ M9JV7?F7)T?U&E$SE9?B;9WYQ_ZU8BW+4GA^%+@SYPK"K'A63!(8J M$UFCABW/:5NLHO[]'JU3,[A.^S-+9C:ML/(Z&.('>L"N**9FXR$GIS<+A9J@ M'J+0`74X4LX^ZM@7/Q`9]JTHJ@J3`YIJ)2`S454[OE43M&A%9;UL[0NMRVIU M_D[V@DW389B0-,ZSA(`\AW'>54:-00P#E8S4J.$)CM*PQ3MJG2_&E/\2UFI$R5Y%&* M9I%98XE=P5J,H,RQ^$2$HQ5%$@H0_ M>$=@&G2G-H'G`[P7/[*1W$XV8U5=^CJ`\HM:K)-*2-XOW!5E2?ZENJ*T4UI= M48TRZ:[X;??ZNJ;B&.6:(\C7U3^?-D]5_2(.R/5I4$["W$LQA!B%(71#-T>P M,Y\$7JHRCS)ET_*$ZABFLRJ;Y;IJ=C7M'W@4Y3?*`V[%Y,08\W+IR2U(5TM0 M3O@620K'Z!R!O-T43)*]`6$TS?],I-&X6Y7=9JLHC]W[.5^*F+IU@Y>F5`G-6.U]D2%7[:[$,V6@J2C+P[)ZH0_%#]H(,S!$!"@-Q.$4O7\=+_[YB+!X3I;CE=9*!19E-4*>P2JRH7@1D"YC62< M,#&H&GJPJ0T)`KES/(!W(\,1^+MV:[(M0WT# MD70/#`93!7(F8\%D[E:WZ2\*567$S;C.0M:<&,ZK&O4:Q9<^O]=4+(PVBRB( M$9"COKOHF$<%8]AD!2^9M)_[BSFB]AWU9[I?'T)VBQZY01<56 M;(;%?29A4=S)$1'I$#M9KMA75.M=XVLB*/'[H6!=8)0S:!^CFT/J\G:O>H9ANX^.5UA ML3;=GD`7H[=XP[T1#V,T"\1&:S^`)`N3F%E.W(#TEP*J/P:37&$3KP$,O5NNB1S0]OIILF?23)LWJ_S#74[Q,FGMQ_; MYF_B;L3;-4Q'V*>ZG;QF`;P,N[$78`RB-`I`$.;=><0$I)@H);HV@4R2\NX[ M]+9J.W1-Q;KW`:[JQOTT(9+,=^<2'9W,M\7NM.#WU^;VRQ=WSI$'O+KCJ0]. M[\2L8J:8$<\E=GJY\5^G:;%T+VM^WADWD0"/(',H%9XB1G-)BB?Q]3P]GHY@ MZ409E[RDR&;5'#W=Q?>WV;\H-ZM%!(,X0QA[?DR")`,Y)ET1I@2#3&H9R9`I MZUL$[?+R:H^2]V[Q[.1SM6:-<>H2$<-D#63!AEB>2>YKRIO*2E-4[&MP7R$8 M'0H$GTR3Q3)S6Y+VYW=4'DW"W_;/:_DWW9ULAS`G((Y)Z'@B8X<3MSK8F!+A0 M[1"8(:.61>$+^_OGHFF?1^.U#EY%+=9RLUSO5MTBU[+:\7O[G5+PLT65V&EF MOZIY3K\^1%/Y')BIX,CM[=\D+FI3WSU$YQBCTX%T'G=\4W_KO-.;')J7Y6_P MB);A$,Q$=,W[]=.1*RO$20OI'\66OTI=TK-G80YWAU`,/,0W)4#N>I!D+`], MTCP+W=R#J:MTMW&T,<#W\]-'4B"_WWKAL/]F%A:Q](^(+V3170FTCR=O]6-NHX]:?^T MX4`>_JD67AR@/(LB+THP)-B%,$P[+!&`2FFL%0#V)3RV)^$*/!N7;3L46Y=J MO@K#@3L,^7S%N2?7C""KQ^K7$V$-'_6%5Y=0BV++6BI=A-#+XCQSXRQ!&28` MH=#ML_HD3NS*K10$^X(+K`NN'->V)-]GE((T*KU+$?EGI5?-R MM/AJD&I/?G/66Q8LRPZRP.<[;2D.29($B/1@"%9Z/]4.`OOBF]@67SFF+6FO M<9*GDUX.?>[*RS&:%%ZE*:5NJ:YKD"56709^]ZC*,1E57)5R_K.HJ.3E: M==4IE;K\I`SD6_ECD88`D=!+>+)BW+K6^J["+1@[ M_`[+["RH55=8Y^%#A;T_5MA/>X5ER&\>$/FK2#=U`"STL]%V>9'R2N&P=1"L(.2H*!U%4&F_8M M#V,/S[2F!0=D1SO5N#8ZGEFCV?Z0)J!;'M74(F-E8+,6H>G&-ME(&1[>CID; M/\)IQ>'7&N3T7-0;YT;0J3S4/53B\#J_6%)NOG^MWHOU]OVQ:.BA8.@BQ[D? M$C^-\C`-LQ"D/NIWII,4NC)/-=NPJS2TJ;_4?+I:HRFB1OA5&]:FIG;<<";0 MWCD]7F!^%`N^9;\ZPU>4\?!S*`U/AZJ0Y4$3Q)#E$FV9S8T&77MRI!D MGC[Y`F?+9[K:K44ITJ.J?%E=LW;:UE;+-BM13.+RKX]JFC8/_#+D(D89FP7& M?IXG`0I`[,(0$#^">00A25VE6@\W@&=YSM9YU!8;/BZ$>.R4N%'*W/I]>>TC MQ_6+&^??PC?5NU6W"+[U0U;P4PVM&[)P'EU MOUL'0VIZ]94V;.ZVY*^>8OI&UY6XO?^-UF_EDC9_T)='6B^R-$5)F,8IB!%$ M*,,QR#N[R`NDRAH8,V9YO.DP"GDY0NET,!5R>S/D?CRAFIQ7-3WO*[^(?8`GH<H4S\GU\7E?'HOEZD+"2)I"OT\A*D;`2_P^X3: M2Y0.T9JV;5G;+DZEK_<^7/$[UZJR9CP>=XEG[B8@!4D0L,P3AR`+`MB9@`1+Y8(ZWVM9 M)7LXSK=E25DCN.-U]`9JB8\GZN/IODV.U.3K0(_&#%Z9&?G)NDV&-%]Y4FU( M,M/N,S>OS+!UR9C!9%H;>C6^+2B(X?_23?5:O-&:+)=[*]`%`'N0@,#W$A?C MA,1>9R6,W$!6#S6^VK(D]HCNG,^?D4)_UV'I8S&T3)":'O9@'(9&1Q-U.)*7 M1RO8"_TDB1(/81QBDN$\3#HK((RD;U9I?+5EK6P1.0R2JECJT/2Q6%IF M2$TLS\C1D4L=EN3ETC);>G(IW:1D!/)G#Z\(Y`@J9B"08]!71MJ#@D!F+/AL M#L]/MGW[5_:O;@H?DS0+0!0CGP0)F\#GH=L9RB.Y!X'TO]WZ6B1MG#TJA\-2 MD`!-NC[62OM,J2X5GI&D(YB:;,EKIGW6]&3S)_;NG,)I=H]-N2J+^IUO1_U! MZ^5_^)F$:E/)$BPCLA>/T1R\DYRMVX*7`^F M.02^'R892)!'2+]+Y0%?>A*O;\&R\`I@I^^_JYQO&L'LKJI^)FEUX+]/UV_.ZNR6:ZKALJ_ M5G-1BZ]R MS/E266A8VM=G25%OF+WF"ZV_\>>^8=&42WZVO5SOMG0E+CP]T!];R'CXSP)' M*,21F\1!C-BDGV'";0TE+X0XQTIO,-O"8+VOO;SNVFD6GS0)K.TEI1:M\R?= M.I^KIG%>V6Q*^*-]O=5P<.0RK3G$12VI.KZHVF%VOG3LWUV(47L)U>'@'8'^ M=O=1E4@>R)9LAVTFB9%U-Z]>'[5)JX9P9YMMN>*F6?+UC2[WM8'::@QTE3/B MCI3J9_0'I(AX2>RG/DA@G+'Q)?;SL$?JHUQ/TR>#9UGNC[7EV"?GX)33>>7P MYNJ<#1`_"Y+V<#!=R%5'BEE&6W\0,13H.0TSIB(D-0)-WAQF-SA-S\#5<>M& MP9`?TK;LRY^K-8M-0_Z[*[?O?U9;BMN-AMTQ`.)C/W<#D`&81B`%OIO%'0`` M8J5K8N:LVAZ`>!#V0']S6JBJ(X@YAB4'AIN0JZCW1Q@[7AT.TSG@9`)^.^F6 MY7!(D8W'82Y":]ZQ<_VT1)VT+.[W]UY>RJU8E2:-<(TZ9/3-_O,J6F9!FE6-.LB+P/Z-(['F6C1 M2"W98^(+1^L6E?-$E:K:Z5$VK#63L*4F M,1U1]T_[36WJY%,0I7`_R39AFD6Z#\W*>2W*E;-[K38._4&7NV[)LOA>4W%D M8^3UI0L$7#D1,(JK&9P"&(>_,M1H5*XQ;3:[8IWO-OP`_T'->0EOIN,!=B%& M3+V3*$(A0KG?F4LQD*XG.L:&99EMH3E/+39GV8.[<_@K#2I7=L80^;'J3L6A MFOCNZ=O#.DKT1/7_J=A3N/8T$8MZBBQ>3'BJ:E'OL[C6,OGKK;]]V?R]^6.# M'S;_Q_[X]AO_5R\%:[3\7],?QDK,RPR"J6(L>H6%+^3HN:?0/?TWJI-MOGYDZ&XRR9VA(T+UZ)YB5R\&MMT(X4J\FP-%/SE6!Y M%SZ67T4ZY+?`=X\-_>^.62!O8M&WWUS*(H014WD/1)BX;NI',Y?GY-VT\WJ:P0-;4Z/)G4F2Z\& M'#G??#9$C<(9G&)+V_6(_=-=Q?I+U93B6L)CLZW9-&(1A&Q\(7X4`,3?4`9N M%L19[L8H",*(89(^'&+`ELUS(7MX?'#N`3H=0N??'<;I#X1\S-O@61"#M,^E MYQGUZ:<3(,8)DR^@WC1TV_162`!!GKI>2%*?P-1+711T5A#+.Y3JHZM]M>T9 MF$"C6LY6*!,?B;^7-5BF^?3YHTV[8DURQLDZ:X1G'@ZY,, M7W;6(RYP,K3^,(;"F>C..!_.UQ?&$R*M*E_IDC(A>US3YD^Z/<\LW)`@A+P$ M1I$7Q:F7(1=T1EV<1BKR,LZ299TY`J\O,D,9AF# M5`VHD!F*9R)'AIRI;+1"U?6-Y9)OB#<'XP?;B]Q/8A<&01)[GIO$84(RK[,) M?21U3M&((N!)\4^3,6TR\7,_`!\F4`F$EH$&8^9:J6L3:.5 M(#.I0!F[H>\%T'>WTFRD:V4*L`'?(,\Q1349"< MM*#(QU%C`RA&5;5V=U:M7'WHW18\U.UC#V%5K>VMZ(L#P0LLIA/_B9"95I-* M<]-5>TC;C]@-.0=X.`X#.^N$IQA*;0G5)!JFMUHSR6VA M(I1B^\/Q4)3<*#)^:_H6G#W7NM&>\2)T')M'/=!/A-XT&W5F.ZD3,FZ*8P?^ M:PKN>\VG,P\C&#AV8$>1ZWDNQFYXJ"'T/*$:?\%/&R:M7AM!XA(%B(^A#&(C M1D6](FU(-3+='.-P@5*=#M%5O$`E]J!X.R?6'-MI+65G]R%>#%N7LB;%6MF\[";1#Z*9) MX"*,0.R#PT9,L`)`AT##L<_OY?I9M1Y2#["QN8@#MDL4I1/UJ3"75IL^$II^P,1Z[7[+JW^3'=/@I.C`]Q(/(!LY MKN-[&#@>P#W%`L3U7J%.>899KFVZO^U5DVFYJPHI'\&-C:88OS6;N(-ZTV`W M#LPND)M.Q"?";5I-.M6M5RM<`F=7Y894N_<'.B=W=$/)EO6&12Q_$)8E3#&- M&3,7>!BZGFL#MS]"]_S`G[V1ZJGD/[92$"6R_H9:"9RO--K=61NF7WV^0CH- M9>HZU9#E/;(:"5+1LZH.RX<>R_2`Y1^7L#1T2'4>IXNG4QK@G0A_Z;'ETWF4 M-H`$$G`[.M<*RI/-%I>*:M[#*M;/_RC+Q<]BM9JYT':#(+*]!,1>E#D@@GT< M&`J^BZA%H/%D7:=C>V8EPUAZD.7-YXT,JFB6K\>S._%B3P/_UNMH=4K^]^@) MP.O`74P+:L1](M2FUZ9/*43M@'%37?_]#"81_584H8BRJ.\#[/[5)P:@O.Y.3/X1G8OY6)X<=:-<1(Y*8RS M"$=T>^-D07\O+8YM++;/D)5B?(LQ4(;U"<^7RV)5Y+M+1R=&EL`9@"ZL"%5( M)[)`E,TH]50*.&XC@EG@E4_'((IU"L8&*S5N%JD MP0W+1%:ZJ-8GRS($C>9>R[\7^1.-*5GJ`*T7GY]![CM!0)==9PRAYWA^%(,4 MQTE__R<+74I1]GUX!6(QC/J+;YH=OUF2& M%[(+!*4=]8E0F'Z[2L/359X&/[;`\;`+L>W$:>#;?I!2#DY[B2GPA3H_*(@Q M3'5=BZ?504-YAA.&4)C33*(GS6(3:)1U'B(^UI+%=7H\)6W)>692`T?X2O1# M_LYJ._HJ_3BPHS1THRQ.@!L&`,5)SWQ9+'1O4%*$80[J[^QN&K4D[S^+XL:Y M)3,/F>`6K4.KU>C6UYF/@;FTBU-#-ZORG9"VB\UG MCINEP$GB.`,PB.GN$MI)XO3MQWT:?8FPC;HT\\13[RWO>A M'[*C)&-O3H0`1@Y.W#3J*L32*+53L1(722'&*UPZO:RJ44RTX:@D=GR\-`)H M8GS4H]5J=+/FHB>!N4`_BDA.A'94K?C82E0'*`)'W&NRO5]B*K#H6UXY49*Z MV`,NA"B)'"=U8+>_3/TX3<0.MR4$&,_@49W8TZ[S6BOA(VT9R'@/LPVC)7J, MO28,IT:?6_'**5`N'EPK8#@13E&SX=-AM3(@5_GD5[GNF0N7ZVU!`:I/3#IY M,81)EGJ9YV,:%/E>!KVNZBA-$L3U>)RRD)'299NRJ@^+Z,I9=+YY/M27DW'4 M0;W,.J/B*1G3'.G%P4":`5R4\STKQJW_U32`/%*)?VZV#]=9;^SE.BNO_1_= MV5A/.?V].;&V+X3LK$6^(]W?7)W&-#S?[E<[]M6ZR7UN/>VWC&RV[-#TJ5@W MO[5[R7=6L:V;N,W9F=^NM)Z(U38B^UGL7@HJA'J:=Y)7E%MKX>NR>LU7%KL7 MF-<2YN]SELXHEM:J7#^3ZG^XO1`=G=JUV-"U:\=R;;A..!=M(WQC!Z//CE+S MU!=_E^.Q/-UOWTF\,$@3Q\4!`CX5'X9>'RICE`J^RB$KQK"S&;[)\=XE1R6> MYI!&D7.W/`Z`@MZ%,B`EH>D\RG$&HDM[9W5<)Q+KZK#D\W,<>L!1*!6;I8X# M88R"-(S<(,5V&L6])`AQ*E()+_%Y(?I1;7"HLT#L.G"\>VFCF(GNI&^>)1#* M#"B`-Q%:4;'@:K67(!CRV^?!O9TD2WP;Q%YJVSC%/G92V&5'4R?SN2YOZY!C M.*Y)3FXUZCX4]9'=\1Y;=2,H@J_D9MH0M'KVTSS7^_0CJ;BK-H3HWVUC?4=W MU%T;D0_+PL3F^.(M3)UC-=4MLHPIUW;)TO#()I*'`KTP1)&=`>1A&(4XP"GJ M=^9Q)O9ZI;24L=Q)U25'E1R)!E2ELLR&`%5---_L=OA9>/C3S1*03B2TU6#( MY:2S-#3"K/28_QI$UP.Y&,,X`90,$\^SDS3.@-OUJ4QCE`@]=*(L;"R.VN6_ M%+;2ZIB*4=,H<$HR%-7MN#*O?MKMYG1U#C(.UE)&>V+DI6[/&0[3!)18>?%I MB1$.88!MWXMLU\4XBKRT3[('7BC>4T=.C&'Z:NIA65;.JI\K4"PLEH22C[M& M0E&,M1H`C^GJIFUW1#E*`ZH382<=EIRJ']8!CDPR8H93^CD?@RSS`6O\$Z=9 MW,=OMB/TPI+(=T=)/VA).UR'2#C?H!4=Z43#[?(+?(D%;I0FP@U2JI]/)0B: MS[WZ6CT/&PE2,4S[">:37R"QS`:$+K*,# MUXFPD!932OW33I"E/G?S^;INDQD/S8DLVNVJXFE?/V7R6+*HB>I%D:(???ZZ MIJQ`MH>N&PC;*'412FS?16GF.=CMKT<@&PO=3!]9-<-1 M$QX>,5H=&O)?;:.S.ZLWQFJML8;FL+*U8X.LSJ+;]1?2.R(7:/Q&0S\1YK^5 M]>4DUI]$%%RN:UW_8HGY^_UNNZ/!"U5AEH1>F&0A"&"\8MT6][N7LBK^0Q9M$<,/ M.B?)ZQ.I+-=F_P+X=?27D'G[4U#_U/M?"X#@SO7AG>V!^E<`_;+OAW?0=;JO M%]LMNRU?O]]^@$A0TATKC&"7"(HWLA+U9DHS@C]\'V,RB(?O=![\:.;!7\T$ M&*AV@PC^#$A7(GA5:"?"XUI,.1'!ZX&'OR/=8E$PML]7#WFQ^+K&^::@H>8L M@#!(4!RZ(?W#<]A3@X?22"\62GK(RC#,K`>U+':'Z4NQMN:-9J+=Z60QY..C M,>`3XZ(!SR8DT6 M:5ZM*;EMT7R^?]W7-ST2LBSF!8TH(66XQ'<<)P8P18$'DJ"3;*>V4$,G#>), M<]%!(U9-RE02)"$=D/+QT`Z M29K`.'8<-TXC##LUO-@5>I54M^P1V:ZLRR;F0X6M%=5U_%:W(@A>BC`,C<5$ MUJXQ\SYWS34(HT*&8Q;2[]N4/"([@PG`$02>V\=$,/)%BC$D/C]*3<;7]:XB MO]BY$SOXZ8^W-24@KD,HFT30BIYZ(N#3J?]#?H-JL,\P"9W.#J M*;D@&-P\\ZU8EU5]"M^",/(ZU]JFFDWJ=.84:V2 MR$_\C/Z19:$7QG;W$G1*_TJH&<9(*HT2+5T+BR:>I^<>H8FL[;&M-I*7 M%P1=VY.2LR1Q[I7%?HX5AE8:.L_4'U>IWNWLE7:JFC MRQ??C`JL6+QS^N'(B;T6>8$SM4$[$3;49X_@JY""0''UYL&4)/.GLNG90&?7 M[\6<'2>MG]%S14A=./O(6'46)8@2INO`T(]`X/AQ$*,$.YGO11ZP':[6V5H% M&J\Q&NA9K[M>4^N@JO6O6MD+=8D&$;_,;#<#6XS=_@8X\S?UN0G>DMU]-.'. MTW6'%Y833L0(JA/HPZ/?IM+@-!1P*`]-]^/O9$OH[[]01Y:0-[(J-TSL#U*] M45VVW^KJQYF#/-_&,?5H*,)U6R*\[E5NA+>97/@&-S@!M_:O15<2W:$6K^>EZOR^3V=S^_7I)47 M(3=SD(/]*(GXC1T!-S"9U:`^#F<_H?1,8%J&'(S_FC82E'\EE1;7?U!&3/75B?YF9] M[4^Q:>NPH-4\G-;;^0=T'W9J0/]?%[G[9O@1.-R>M$EGL M)5F"`/)1&&:9Z]@XZ)3P_`0K4+BBY)OP>J>SQ91F5\H.:JNQE>HP2+F!$4=` MAV\X!O]^"+XFGZ$Z"DJ.9,31D/,N/?[[=O+G!_R7936^W[F,&+\STH3\-#V4 M+N,NNRVM$,KZLH_"#[[4PV$4!52<[0$('+H-LN-.?@!\KA[4VH7>Q(-]=EPL MYE:C307II.B4-=EWV1[J`DW5%CS_+SO4Y($QLNG6#81Q!.PJAZW?R4AMQI^J5A-S$ MU3AJ]"8`H907,8.>#J]!-=/D(@0P5'()9K"4W:903EJ,3_<]!OST+@[;-.E< MPH[+]"T+#!==WU?Y,UD7\RT5U$K!T`^\%$91Z'H)2)PL\4`G)88PYB5IB4\; MIN9>(^&\A`Q,UXG8,$)B]#L`A]*N!.7*8,1/M(:QTI)CZ'74P:J?#3[#I0K( M3(!!5;0OM4P/&;9L_.I!5NA`+PE!$&19`!%T<1HZG2P0N=RI`6D!HS*G2#`K M#YD`?YI$2Y9%N]!+D4R%89.@5)/PZ8E;S3#K![NO\:LL3%-B66D;3G&M&B!B MC/OX4E0#44&<.5Z690!X`(6QX\&.$0!$Z!;@UC) MLFVMDC+9BF(FP;4&L9.CVA8YLTQ[;/4UHI7$:$H\*VO"*9I5@H.+91]?JN*- MH.>J?"K*'17)AKX5Y]LI\OW`#V#J`#=)7-_MSHA#&`&NUGZJ,@RS;:.:-=#M MVN37B^!UZAT+/#'Z/8>;#`*6:UF`JRB@-QU4AX'-#%*/H67#!TK`,=/QN,`*'D",01RWP))J69; M4)YJKJ969$XH#2SJB@KR:Y/3OZ0_9@_=#Z\YJG'V68S.,+8ZIA/@:PU&E#JG MF0!7?RM69+LKU^1096'[,,;4"^`HIL[`#B,:LW=2HM#EODPJ\6G#[-QK)%@W M)P/2=3XVC(\8$1]!(\/`,ACQ4Z]AK%32:4?D:;UVBJK1Z&=[S_"G`C`3($X5 M[4LMLT-OAY??BS7YNB.OVYGG^AYE9P@2'Z<.A*F->_D`>CJ[O/`+-4ROO)TP MF,)6K;'F-B0"\%^GYYLA+T;-K$I._-UUHRN^D;F?_D%?-R^&Q!ST;H@CZOAL@F$1^=VLG M\@&`W!UA9`48]C6M-NS!PMT[_?.=+22A7B_2R%UW':.`)N8F.I6LQ]+JL&NU M&@4T@=XL8X`GV>HKW[ZPMRF7J_+GMN;Y30?K:[ZHVV57@WE)E59,2)[#X@R- M*T,W`A#<5$AD1ZI\&2?@<#[JPC$ZR##7=6:X75FF%U=DQO`*4V M)Q,92-GT+;'69Y>8]?1NY8/3+>KM]FMJW=$/Z]U-%^I:/U^*^0M[@'F_VK%W M.X_S#^5/PCI86SLJEOYVL7M7](Y:QN'ZCFB$,9Z`WQW9X--[J-&@YFY*GY`E MJ>CWOY,WLMZ3F>\YL1M#Y"(/.W0R.EE?,PH=$`L]#"_Z;ME.'+N!:'\$& M\\)(7?:88X`DYO]Z?+Y?P\=(X_@/0)S@+57()M(67EK]4L_,,1?SLU^GOI7^ M[(%41;F8812$?N#"U'=CX#@N!$'7U1$&*>"^AV-:CQ$2!XT^UJ96J-Y;LSBA MZG6V\B7]-SIJ\I%^N[+* M-[J*FD"=+;#C$+W8GHC2KX7]XT;Q']'5$[]+C]G?+W*7-U4^9E>$5\(7=Y,3 M+19%G9M9-1N&C)!9$E#)"?)MY$=!%$48(:\3GC@A]Q4!?1+'2\Q3\C[LU_-> MUO0 MGU$_]D0&A:^4-VO'MJK3M(18Q?+XOYNXDCT/]GEQ:/5S%^#D\F@ZAF-RODN+ M46>]E#[(^"IK\U_LG*JO3>MR4=V)U9^;PWJ(M\ MJ,K%?KZ;82].J4/$-K1M$(8HQH[;J06#@#N+/X8NIFMW&Q,.!9:'W&O56F'M M-^Q1^=X.*S\86>]-O@H%DZK@WRNTGK$X9N`9Q[5W/(VJV0,;WZ_)H_%*YEA-TR` MDZ(@BT.01?3_TA]T$8;M><9=.:\B4_?C])]\V5%#QG`$W(-GT(.;&+>1W3M: MJ6'&]:U<49;(JW=K=]#]PP7QX0&R[$4B]8$1.BX>>4RDCXPIUHQ@YTT\]/402D$,.MN,:!0H%.#(?'C9359 M.<*P)&73*/YIF?8AKC2)ZAL;41=VDV%1\F7#$6EU9@\J'?_6PW1&1-:_W61D MY!S=P[6%<=CU;?;5=I_3WZ6[P?,E_\Q%=NV&EH1L[P[[R6U][[DJW_,5NW/5 M%AW]+%8KMKNLWY1GGZ9AZ`L[!F87.;6Z4=YAX?*GVL=X<+J:9#S-DQRC$D>.#(`-N;'=W"Y"+0Q-ENMRRQRT=.NA\IKG8G;6M M]393Z]2:#(>U:C^MO3Y;?4OK^,8EA,%)D:V0X)#>._?6Y9MHWCO7U ME>4O=N7\W_5[AL>7Z'H'^_0^+++-M\[U`3=::"%VU;5YT_D_OE_7ZWW='HKE@_M[J&_\_=M?8VCBO9O\)O.Q?P M+O1^?"1%:1"@IQ-T9^]^&"P,M:TDVFM+&I4L4060X=`BF+HA+:-$M_R+#QBC=.`^9;>V0`JCJ,GB?>H%$>((-]U M4K"F-W1W-Z`>:N7TCZ]?U$@0=?7^%@_`1KE:5I0^V0%\[KP,@"TX&D97RB>F MR8OGZET_/>@;-04FK;2I)]]_YE\LP>EQM_KD6,Z0%)1M_W^;<5/$!\J@Z"C. M5'=PIA;:O&]P_J&/`X8D1;-#)F4RW[IZT_,W$DI?HOI:[&Z:^J[<+=/$\7VZ MT3N+41KXD1^YX_8P"*V`>2N60@BJWP'W"$%#$PZR\LC'BOD@5U6QH_LR"5() M`4>&1\2S"6`U$<1MB/,70/-0XOCIA/.,V)44_IX/Q* M@J]ZP'4=[JRNGZ^$(-OKAE41`+'OLTR"^8L)LB?#)ZHG`,?0B@+QB>:B`L\L M,#AAT4J#AM("OUOF37G(LU(L46PA+XEB!\5!ZL/$QEYVV$$8Q)/W$^A!^\V42.#BTHP23["V#R(9V<$C<0I2AN?,@)I"?+`WR#(A] M;,Z?+PN2[G?3DB!JX*>9!_.G0-+GPV?*@#Q#,R#J%,T)$-<\^(7S'SX>-*0_ M`HZ9-_LA7[>TL)4%$0J0FUE.&B(4I]&(UW?=V:M`3"`_6?;CFQ#UF)P_8_8C MV^_&93_DBS_-/#`@^Y$]'SY3]N.;FOV0K].=_?#,@U\Y^^'B04?VP^\8^4=E MNP[<]!QO]50TNY*@OB'>*-NV;IZ_UKMBB2!T[SB!&5IX`6'XI3G8\&N M^ZI1&7>\]NFDT_EH$]V%.!A%NSK)"&Z*?"R>UN#50W@\Z/OZ:._;[ANOK]!.=C1\@X/2S-V08G'XH-%SUQ+)EZCNLU?^SZ05N"9AB^6%]5 M[:[IGL4^P[EJVWVQMI<.=I$7.-BW,L=!MFNC-#PF.9"I8:.BH94G"B/2]Z2F MK.AY@M.^`[\1S>C72/_@OL=3KDLNAWP#O,$7URE0<$2Z``>LX`AV,98:>KS: M;PKEX?(=Y5;L%&/N&55CW9MK2!62R"RTWZDJ/-0;PFF;_K4O=\_T6E0B0]TO MOC]NRMW2M>W4\4.(D>,2&&Z"_+&Q(7(\S/0Z7N9XJ@]!]H`&P6PI)-!%14[! ME$(MFTKJ9I5/&D_1_0?H\2W`2'/W6]!AU*R'#*Q=$$&9G!NB?%)-JM5-TANX;+<6[`,26!MC2FCQ,=Y!X`7\&W\BJV!^@O]^)H\,/J`'TIB.#G"6K M*X=6I\GJS#$\0=H:2$J=--AKP+-:21?]<"I1G1*(*//ADR/B8?NF9PE*WP?8S3<@;,V`K<*/! M05N%M0R!6QG)JI?8%!$,(@Q#Q_(3[/@X2RT_&*_,0$$:B=P)I0*&84ML&;%: MEH.4+K%E^T;_$EM.=);E+"U+;-E.^^1+;%51F\T3\I?8/.XU.%K+ME3.$IN? M7#7MI[_G3V5UWV:$RJOM8U/W9TZ6F8W=+,W' M1V?I2`SD!0'G&J;'LLZJFI<7L>)\D-X.<:5@^&`&H)N#+;CPI[66OP MIXS8OJK;[C38[F6,G3(OQZ:.H?I]-@-&'OX<& M1FS@SP[=_W)N^9U`YN70J)='OM@G3*&2O;IG&;JP*7EC3M(25.Q$U44#;1#WYD#$-BM)C8-843A*-5!5> M&R[JBA`AS,KRK7BJ-[1*^G+0/XKMCZ)9!DD0>4D:8"^*+3)4@M/D,&AD<1T: MGS:2ZO+C"`Z\3/\YM68BFVRBHX](/O4Y';J!63$83PRY%.'&FV\%0NA$@9I+:]!-JR,@2+PK= MU/-@%MLQC+T,PF@@.$1$UR;3>=87)N4T2NEW,S!K#;E M.F6,4\&$R#98R<3L85"T"40Q;53)RJ;=?#XV4BNWBF$@MRR:+RQRF-M?2G_O+%2OL MB*??XBM4:N3GBVT9KY0J/G'E8TG)$OTU&Q>6Y,+$&;($%\=?2YI!$Q1C6,RC M,,:1#QWD9Y;G^:&'PD,.Z">(ZWH#@:_7JQIBY4`1UOB50P%AD[1CG@+?6T88 M]8.3/@,5A->""QHB1`;[*XBZ6M?5546>QQ\DR;F^NRN:8DW'_7*%KK\-20], M+,N&B+9]3:"5)9BL+P]+?G:U*[8D?W-" M9"$'QTF6(,>V,QP=MIH@\N_DE[#,(\WS!A;\V?VB@RCE[2L[LQ->O2HA5'*3;$I2B;'&)97K8(435*N/_*_R^U^B^JFJ7_2_7/Y(_G- M[GF)$@OZ5N3966J[!`F&P?'\$0R9WKPJ&5B3KJTZM`NP[7&"'R-0L!J02E`W M;I@RG6"B(3.QO]$ M41UQ=R*ZZ/=:K$];2W5UQPX]R5%[_+-J+0_1S.JKQ'M&ZK$:2R\JM$)R)]4# M3G'!'<%4UNNT6B_C.(B1$X>!;=O0CVSH^H=B*OD#GEH.$!U7]?:^U6Z?;UZ* M,KWRX[$#"(KJPG7KZCD7+P+HH%M2#>"%&%/N>[0@O<2]MB+`&2(Y:P!3W6&( MJBHQC:$"((<^(=U<>BA-'"]U/0\[T'4M%'B'?!IEB.M:9ZXOUEP'K?>[=I=7 M:UJ$^Y&3CZYXLU,^VOBU32ICW"^H[_^3D+QE;M>@7*`8%8B9-`,EAAW[!0WA M)$#!@GB)?`N&B44P0&1EOAMYUC&],$3;5%@FO`CE)(]9%[^O'HKU?D/T%ZY6^VW7T'E]O7LHFJ3> M/C;%0U&UY5-Q5:WJ;?&E;MNN'>9M\?<.$:[^M829A2P7VJ%CVVZ6H21T411G MT+/L+`WY7JJHQJ)802G(NNH:8).,X\0$T-D`7A@!*'Y.F57N*S;M-[-/Q-)OR#@NMQIB*IK,[>>YZD1UO^KZHEH M5]T\)_NF(?_W:GPG1(&3V$Z`@A"3T`,SU^K&MQW:QXLK*Y8VJ&)%/]6+`U)A MT9Y*,*\Z:^167(8/(!=@@&F2UEZFD$E4)7G!./649==9F91*'+,>WC3U8]'L MGF_(C-W!:IW^M2\?:7(.?Y`T/5_MEKZ50.P%46);T+5A[(5>:/EV&N(HB%#X MT1V^\@92]X".V!:@0P?R:@T.^,"?(T+=S^6'E%UX(.71;;\<0VS35&<8@HT7+IZ+Y4;/7X3B^FN?!.D7!41@Z MH@'%WX\D]>,ON?%PQ5I44T02;]GL"$-[1>PX],6:EP!1ANB&&/8W=2MA`IC5 MX&N]*]J;_+D+^S7MXM$.)\DP?8N(@]CV/,>#*`HM,E07^LD_KLU5C1.MZ*T00.V21##WU\^M$S=W-DKH,UUWG4LPQ=T)?IK!HB M-A(,J65/.(XF:E?USSPEIM;;@'.W#9%%\6:YF8I=/MQB(%6G0)HMA M]GYM,S`MUKY-#N,L[=S8*'DG)"C@TX!F;[(MJI5-/IZ6FSNZ8"Y725[EZ_SZ M\;%N=ONJW)5%"^^+:C4.C8,TL%",D\@)(2*),L;..#1)I)FVJ,D<3W&\&&&" M'B=X`13T2'GZ3.(,0?!?"&#A5NAIIZR2.9H\CD#V8)-/^60SM0%E(V4 M,W%#-J4&!`[I)M7J9B!_-Z_[VZ+9TCU!R]B!-LIL>I^;%251F%F./XX!89)R M-NUB_V+%P>#Z9-OR8U-6J_(QWWR\@5E5IZ@#+Q<6XT+T&;+^%L/^MKV3*`&" MVW/[(P/EBJSSZ1^7/G1\[#@PR@*81:GG!&EV6-K#+!;?DXKD[%.(B6 M(&=J.):L:^0G(TR3).X`2E3K^,G_#*(G8!6/^HF2QGBW#'V;NAKF/^F M5Y)E9452^#+?_-Z01516-]^*MB#?]@"K]4D9;AE:7A!:5A([(5DX)1ZT;.N0 M/\8AQ_TSZC"H+HAUT$$^8@?[[B:_NQ$]N*?PP5W=@&8PH-N!M3Z:P'4_BT)G M,=30#/$39UVM=]$!-NAP@P-PT"$'!#H8L0,"_O05@BDNXKEFQPQ7B5[%\^Y3 M=>X)ZA^RJ7?T"!-VKF*GP04F5/%TF%GKG=D<\?/W^JEHJNZMU,^\62>;O-SV M\7N99D&`(4[\,$%TR>+'&(ZCA1@S]:N>.(2690+=EK.BH,#=OJ\&TAD"[@^P M04YQ:?'MZ_OOM7/^6;W#.^;HEC?UJBXR'=D)8CY M`N4I8R@6^`%4WYN+[ELMP".!Q2%'DPC\6,MU<<L[,-+7`P.W-4`% MN-%((+N@ZR)23-%/^D,256\&6NL*/#;U>K^B:EYOM^1#)`!BQXZ2R,M"WTO2U$.'*&)Y,;.L3QY( M3^GJ9?[SJG#%7?B8PBMK`4H3I4)5I@';^S4FK6SRUHHTL3JI(,23J]-T9@\-Q=K/Q(H-4#OY=GRIHHCC2#F-[YHWY95T;9)O?U!!J23\%NQJN\K MFC5^ZCNZP;8M="U=_[7%L%G+%L8EB`5W3QS5!P_FRV2RF M&-]9FP5:79P<[00GAB[`T51P:BOHC06CM9W2G]@$!H,7X&CRZ>\7X-@]%%^< M2$K>I6OUZ857\F;.+4/>[!M*3OT9Y(%GV;5:-<6N6..RNU&4N`85NY]%467Y MJOAGOMG39EI=4H";_&=%@'GOL>\0-,'2?52;K`$K`^F@!^]+>".&`.>*$I:.NF+WV!-#>K4-#^:U*7+ MY/-ETW^>9[FBT;L,RT0S'K0"#&;0#OX%Z`#2*N.P..ILZ78NG%@# MJ#F`VM-_WE"?=7F*SIV>VA4!7T[06Z(X\2)L)]%.'2COFDFR4YLYZ/`(&T< MA:^->FB@PP9.PF1PV6[VM3MOCEM61O$ M5IK$T(TRWXFL*';"8(00I1'7G=4RQU7]`OSL(\E9E)+*]32E4TVS--$[`@5_ MSM=!EH-&`3&L5B>$4;CN0;4+2[(`$VQX$W'_XED<(L)7/_?OMU1)1O&"ZW$CFS?CE`6D35SY-DV',?#;LS5 M7T1X$-7O>PYX^*^=$J6-3TV4,B:J*4=0GN+1_&LH(4^:D?8AAX#E$W&-KQ.)85"*H-SP!:E$9&YL)'&Z?:J&),6&GZ MN^WG5ID36E@41H1%T]1%R(9SRB).R"P;4I.\?1C6=N1)I=G!$EN9:V&(LLS& M%O8(?N^`VLYL>ZX=J`)0%2L=133C1E,1W[&)Y"=R&Y_<*MI*2FT\U-(&*S_Q MQM&W+M.T4W3"7#$DJ)C"AL*]H).=-$^@Z[>O]I\DWU(0\.1OMDN$0SL,'#^+ M?=N-?&1[479(_:$UVX$+8<"*@]YMDZ\+T!P!S1D!A9TZ0QS4X4\SHN%PJJ+_ M"]T7?CQ7S`^*9_RG*S1.G3Z_8H"0KC@&O:&_;8[5SB#Z)&5$_W MP#&%V$\PD]@/=1B'75"4EDQTS"RO8Z[(VJ0BT^%YF601=",KCF+?^G_RKJVY;1Q+ M_Q6^]4R5=P:\D_L&\-+MJJ3C2E*S#ZDM%2U!-G=DT4M*3MR_?@'P(BK1!2`! MD/8^=,>V+CCG.\#W'1SB$B/;]$'@M,:Z83K9<@-^"Y4O"6\,F?!!BT"X]#]9 M41.I63Q*X8C][!^<=#YH>E(BWAW>X:.1`2`H?!8R-"33KQ2X*S$]O3SY\8RW M%2;O9V);O[;P8`3MQ`>6ZZ<1)+/[-.R<<4P_F,72@5$>*):VQC96N23&58P( M65X^ET4%X^(_\2H#;:&?A5;^_(2D[5R-^^R#]02^?L<;EE3N*$^Q.$%*KWN' MDJP`)%W+%R2&=!))/[N5>9%$5FJZCA,EL>WZ28`LR^[R$0>D4TGX<(N52W9[ M@L!S=X(`;HV;4+5'A%B_2NN)[BQ4^:<3)VZ.CYQXPQI\-H::-'=\'WJ'&BL! M%(6:*BMD$U5L=X0N\N[-+`7X^IAM?R^*U?=\LUE8<>I",W3#R$MM'T4Q0JBGJ`+KC/$LM+779]I) M;SW!W1&WC=;O-ZRQ5V.JK:0LJV^]0\V5"([2$K3<$$ZBPR2AS1UW*GFL,.LU;*4:W*)'1A)_;*J/HBSD-*Z6_2N!'KS M->*3@=.DE^,ZS3O4R)&`*-1%&:&:1`L;2X$5(4#DV;*1'5A.BE"(6DM!E(2+ M7;'+-OK%C],\(;7K/.'?K$T_TJA=M[QQ0MGC#9I^G5,0KUD(VYO7,:W")=@+ MWJ%2B2*@4)H&!6/*)4/]%Y9+NLZ\NLM>Z7*C3"5 M^8&?FDX(S,A-B6,H\+OMN7:2.GP/*6?OAO+GE8U]QK)G(*/D^\;$:<^AD-@A M+FOV[.U_8UML3XBWT?:U/@3L"]![ZVN3GG\R39\;NXTWNT9$M/S%NM;\=_6* M!D+#KE]E?>.=[0I6AY/:PTQ4!78F=1CV>&,1."A,0(`L,_7(V/6=,.T>[4.$ MO/E47_CLU?.,O"'6S<&Z615?.$,[AY*+_*C.M]#RZ?+VO3=876$>3593$>L[ M_R\J*8*0:*V?#`F7RJI)=LKL&*\Q,7SU&;_@[1XO$M,V_<1*`7+LT'8]-_:Z M+5RVYR2*SP"38J-B36S-,UPT^OZUNH+RPH+T[ MC*T;K'X:T/,L$_#`*K<*(#60;W>2+Q>&\7-X!6&99(K>FOPU^]%[\;``<9%X MGAT1XV$41LA*D>V8W>%E)G`GFZN/-EQ7@K++?LQDSCX^UOHG[UK#/*^4AKA\ M](Z#TV]X.G\MGIKF]=*ZU3N=->9IJJ@LPL-JS*@C/RZQ$:QWU4[X@.]084$>W-,&.PFEQ,7 ML#1_XKV'Y6=E#6FP*"ISR`W;#%*O_MTQS4+;:@'LV$\B MX$#;!W8*R0]IM]+6!7XTCPQLD.F*$['C6_6:C2(:%@4JC?;4:9GR0,\W.SN^ M6^_N??2GN>1JROO5V`=#O=HIR]!VQ2\W[;WEG.L4_I.D7J,ZPKO/P,:AHRT1 MDQ!$[?G8!S)S^HK+IQC?[Q;("6PO"2+?=&""3(2"L+V-.3$]>GZ$_JQ+R$#5 M12YBBT$^]V2LB#43::!8Q/1F3LJ"-8O\B(6?NF?$;R7\TR0ZRKK!Z'2&&/8? MW0"^EKK<&/EVN=FSBM5]L7LTVO.P:`_9'H['>LIV^Y+Y/Z-DIQ\##2G-H)"_ ML\1E&`:*TI,1`9ED+4SO+XL8!/0&)"=T$F!')@JAW9ZXE3BV'T]UCI6(C4*I MR-##K/K3LX;,)ESB(A1"_:M95$5O'KD)SR*GV2]0Z?U%TUJ4(9WB'2X[&02# MPA4FP\,RB7C]B7<+%P0@B4,(O`3&J6][K@U:,X,H2:<2+1[;%(L5,6%&YRYR M!4N_/,F.TRQDB3CUAN6(6*])AD2"_P[E1\A]A;(C'@;5R'_6W-B)DM`/ M+2NP(@!C8GH4MN9:GF]JD)W1-FJ9*Y%N7>4KMG:HV.J1G_'!4RI#6N.F48YN MNNM>;MZ!,EV+DGR%DM8OWK92R8-!CF))#@NWYZ6V%YDP2'S@(!"$<9B&KI\*'>,[M`W5#_PH?=#_-O1_><\R00$9 MC"&?`.B`3XS`.^38#[=*GC< MWN]E454+A&(+ID[L`RM)O,@!,`K;1H&="EY5/*8EQ0S4&5,)(W4-NTYX06<+F9V,O"="5-)1-RLE>[+;;[; ME_1>^#3_07]J&O1<.TY"$%AI$)A^2%*ST.QH,@Y,$<8:WHIBMNH,8\-KW9@F M2%`C,.0C)SWPB1'3,7*M5=.0TEE\+A#2>$QG0D82'"ED=S=!$OJ8+1_)!+-\ MA;UKM>L6`0R!"^(P%)([W.B%2.<5?BQV)S(NQPK@`4K!QUV$T_/3L/T*7Z MT7A49T)&,CSYN8HD"QRNG3+T^/8]&;]_9.7J>U9BHF]?BO6._KB(D0]2Z$(/ M1#;P4T@:3CON@S;W9IRK*7?Y7_0=Z M0LC);OQ,&GHD9'+HT"-W7US`[P3;RT)\!GL@I+A1R.V(@AEG5&RK7;E?TBYS MN[TKBP?2%1M=,:,$(>"[OFO&MF<#"%/8-NG[$==9$C+:44[V!]/8`"GJFROJ MM1'YUGANK!5,0T=!RY>'ZD)5E/][@!+\6KNF244O8'0A%Y6![$R242FN%/([ MGB!3D4:>,=T@3OK:[M<9>6Q'+K33"``GA"B,_3#IDN#`=Z#(E==: M=V,\4_L89>%#[>GA\AA3@BT?6VF$58RP#HC>=8A.7,V[C-4%XI($\DRX2Y8W MA9*>*,A@\)"[Q[W4G?R\P:B5I6%"Y0NO9`SX3\]?M=3#S"9*7$=%%S",S0 MC"!=J!,[GF\FZ"!B<>!&4A)BGH:F38>WVK@5NOM@8=NIZR1!@ES323S;=+PP M3FQ$3`2N&WJ.2.%,C06*2VJMT;0(?7P.9M_P&^/^]:>7OS'S_ULP,U,4);XT M;/H`B>5HV@D` M08H0<$S/\YT($GFP(^19P`GLE.MY]?!O5\RT]2W;M46"K#D`*3Y&5`N2&-OU M\3&^U>;HIK!?\+A`3\.QFPGUC'"@D-6-!!:ZP*?G37[WF*.\J)8Y)BY645$^ M-PVFIFE[T(X3D(9.%%JV"=*&HU#L!!;O4I=QK2BFD-8XHV>=0%OA5C'BP/(BS[$3Z-NAD\1IDC1M1\!W7>'< M;VR#6M+!OI%&;>60W'`TN`+IHDY,#;?,EXM:B/8FK:,Q,8`P?9=DB:]=TD]&*G;L]T MW<#DOG-S5".*::UGF]$S3B"U&@?A]?Q4&WIBY'4&N"')Z3@$^7-3;4@.2TV' M(\J3F%YR_DQ>*@6O&:2E:\+$ M-%W/!RZ,VA8!YSD&$II1S-3]1P;L&K2#@0)<,Q;*ZWRM$44QQKX`X!#6'HLD M/V]K1'08]+T-PAK\EX38#!I?E22&]4XGDVEGY@JO=[7978O)[LB4D M^%SF%4[WV]7MA[LVRP]#TPM#WTXM+[5LWT^]KN78\_FS;CG-J7DH:"--EBE>/D!B;"X!SH214_'HJ7?];> MT8*PW?Q,V<7NE8)/^G^"2L;A-#%KC#2^D-%5AG)!7#QE^79!\U,?)HX/4]N# ML6,F8=L,C$#"=>[JT._6R`>U18,9@1J)OE809!M.;& M#:+FGV.'03!P33&_/&8EOFM.X?BF>6X5A1S!C/.:*TS:O/8=BZ!^?ZN,DMIF[(KNJ!RCHJ97-T:UO_\?O&2O+7&Y(P1!K\=9 ML:N/ZZ.Q-_E37K?+OV7\Y*SQ(EIG)HMR$)[!'%&2(X7LSB>X1NG,>O@/^1;? M[O!3M8B].`H=Y*>)Y<:1&R#'LMIV?=^Q1=8GC6Y,XZ.AH\TFQC=JH\&,%-WZ M,Q[ARS(P";C#GQ@-P57)TJ1K>%U8EB0-ZIDL29+G3Z&H3XIO.U[CJB)-9?1. MI:C8[DK2]!=Y$Y<+LP&"4#/Y,A*=NK7W- M\]Q6TE1^OZ<\\&G=-HA>6?9#3X^EN0ZPHL`+W3@-+#_U86@F7:X3.R'W0A09 M;2D>D/1`10)UO4*K&8UCS[J\ZO29W%PF7#/(T*6Z4ZCI5:(UF:J='ZQ2XFM4 M;,BK;-G8"Z8BNR4=<(%0$H.8_F>'(([=(`I0VW9D`:Y"KM0&U0^A)S)XJEVQ M_'?OZ%C:&P\=Q8;/R-S(KK"?/?15@/[TA!,VFO2@)`-=%'Z,; M42PJS!CCF8PT-LSZHZP>=E1"]M7J\)812B((K[!ZJ$-VI&+4*!/+#/:2-@0' M*X,Z)(>IPB#\WZHSVB!5"8Y`X6/_83C.C_$'^G&>Y<<`P\7L_Y659;;= M\>A*X%BAZ<>N3>8Q9H!\']KM)"9R'<3]G%=BDXI9O[54Z31"9@2N2\%$X(L) M0X>[[,F$3*SY16,BS,=.*+Y?[?UCIQ#\P)R1$07(SD!45'A5*.V.HL]CLE=V M&]C7`B[_=Y^7F.U3/ZQDJA:I;28!LI$%+`#)#"9%$6@;AFDL=.O[^-943RZ: M0+#).ST)=O=J5'BY+W.ZAX@MTFC'HNZG,=>@N_0@1AKLNZP1N$B>)9X5A`LW0=\/&@-AWHT!V%9FOU=F5DF^,%VJX@OHF M9QCDE9+E1T!=/=GXU[2HRR\MRT=_6#K([)A?49F9-;*R+`;Q#/)"18X-J#$/ M@8Y+E/XL=O@S7N+\A1ZY>TNWPQ$-_)SM\"*(4`""%/@^"A+?M5`2Q&UK*4+< MSS%'-*%8;JAE1MF9=D,&&ULGESK#):LXS/ M^J#C%P--$`YC_MM^KV,UY6R[W3]1+2#9J;$][JPC;V0]C\09DI<`W0P87887 MA=3^),#5'[,?^=/^Z0Z3_D,ZUP/^M*[U@VU+V.#5UZ)5DH7I!#Y"9@I<&'H) M$0W':D\OBD-D<5_!+;--Q6S>F$I'3F/K\5/Z]7ZW+W%_HE^LU[C,MP_5\7.; MHQKSKC"^/^;+1S8&,=O_8>15_1-QO[\'1(#NI(;RNG1,%44Q+6D#>##3^+0V MFFE):ZGQM>BF*%,!SB\X4P$_\&GFJ9&S>\QV')V?7N-[JRT1W$<4,SM"#T(L^U0"?5II=P MG^&ORR`-5;C:0JJEQ$1C792'@4ZH(>L\/2Y39-07`[?.&"NQ28"^B%Z7S%D& M4TQ/#RX836&5.7'8%MRY<6/T8EY[8C!7C,X7(YYK+`4N-9AC3(=)]56, MMFN/^0R$7[_/Q82#;%#*4"*XLB+@RA,K"2.VEU7,0@1 M]_8G.:U-\^<3L M7%9*L]=?5(X8W_3R8YFCDOC+,[8;PM?Y0TZ^69;678#TJI#)",>L5$J*0R*G_#5(S;T6'9F2DO+]5;Y/3U' MH)>5Y%OP\G%;;(H'6MVDBK*O:Y[T`\1V3/CA\<98$5,W!;MSG"TC MI`J#RV6>;?*_ZL`3G2)?2RNB;*'A/\DW[4J&S6*WYN$A>7G_ M7+!3J:K]TU-G%74D.Q0$N@,IZL]2CY=%Q4Q<[LNR+N?V])2^H<6!N=Z'@LQ$ MBW)7W;`7GO(-)L*\Q>ZO_4$ZC?AQXT4@UX11UYCEQUS5WW$M*'\NVAIEK/&!+P2/T1H( MWF6=UH>;Z)/(#C)J4*O6FA>#GT3EP@+P<2C.9-'W2"<*F1U+D%_2+"_KJ0:[ MDAIN5Q_R[#[?,"GZB+-J3V3S$Z$Y*J!DGDG>\&>Q+=M?$9E\5O7-]U8*$83` MB4&0Q#!(P]"S$`C"&(+8M!VND^'U6Z68QZ@C32&E,9L)]XW1FB1@1H#R<>/\XRA&*%D>4#,S&#UL@DB'W=6L)OF38]N3%J?Q@!]3QJB8I,NK>7:(KY->:, M6LT1UR(HLX&&+A<.UJ5-*Q#9UZZAY0U`^T: M&\NV6LM,-RQ:@ZY_-,=IR,A8#)((?6$8JP`W)_`V.H/)NYC)T[+[133YR5M. M4.;)S9)\NTR],@'D9M;?BV+U/=_0PZ%OMSO2F7,RX:CMB?-JN2DH_W_%/W:( MP//OA>>1&4@:!$D2H-!VD66B(`A3Z``_-)W(%>%6R4TK9M?66I:M'>SMQOD6 M\RYA4@4]'Y5.B+H8F5X&W#@8:WRCYAK,7MV)LAB:%\A445AF0J>JO"NT]&U! M2OVR?,2K_09_6B?LR)^/>/=8K'J'OC1%'1B8GFM#F#I6:B9^"M,D!A"Z;F2# MR.(Z=4]RDXHIM+62IJ>UG49MJ-&S=&`I71;H?"0Z`=YBY"D):B6!:Z4 MC/Y,.%*V5X72+BO(B6?:;.X\BV(_,*'C(<=/S3ARD0?;1@//-;D6+LII23$# M_A]U5]<;-XYE_XH>TX#3H"B)HO9-)$6L`4\2))D9+/JA4+:5I-"VY)7*F61_ M_9+ZJG+B*O-3DC%HC+L[;9Y[+GGNY27%>W(I:JJ=)9UJ(C`HH_-#OI>L;KES(W46;=([?5>L1"-]6*:;YIF29YGJ?9)7 MP!MY:9SOJFTE[T]?5E_JIK\73N5-[VK?;]4W69)QA&..(,8Y(`04"1F`90*E MUJTT_V@\:^T`9CC/<9(G.O6%32ZYE!ORU_PWHQY MJ0;IVKFK#X>N1+MG-%@I!_9'M5>E?U?WG_4B_PO+V96_/UO>)/]KTZ9#[E/YCQ>L3_5^H=Z[^Q9U]Q"#"WV4$4 ML"3<:R`8$"4@!TE1D*3(XAP`&AZ%)@2B>+.7GZ!]/FE_-7KN1<4U7?>*M5O74@>*;43N'*69HTO!FY2G1<**F(0( M<%"$B!9H1"?^!9VI/J,#::8BS=T!TGR5&BW7>"_7^/+*_#6;*Q5GKD;K?Z?? M3_7&Q+^O.`;86.VNCF-.^DS%G&.`%.*HX#`#<0ABR#G.Q&YC`)@`I-028'Y4 M,Y9UYHT2ADZ:H\#CRS^+5'E>5[AXU@G>ZCTFCG[%05'W/JO8:.)Q$M M$E"2%&8%Q4D>4XJR:;<#.`U]UX!TL,Q2")HW0&BYPE]8\.6%^8+!ZXH`_G3? MQ).O6.V-S'6@\>8T*[TQ:UZ^.@+VKMQO(`("$\I3CK(8Q$F<8#IB@P0KR?NL M@#QKO("@5^J?UQOG%7ZUCG`C\R^J_/CYX?&K'N^4/_V^RM$UUL,,R MHU=9K-\_E/)!\NIK\>.AK%KY('F41"`%"4512+,"%%&U6V[`6*I%B*U M`D41QFF11C$X0,L3K\4&$SR>:PT20__N6]V#JRO?50P5XXACA[4'&P^^TM*#E9X)0#F037J02#7@],4:#95;HRX`S7<6+='YUGY+YWB*YO/Y M9;;`+DT*CFT:(_Q@US^=P%Z&_.G;C&/V'K>XK2@#.DNXR%W#CW=>: M%CBRWC9#<.D$OW>-R_U1%L.S+"%%E(81!HBE,0+I>-^!DYQGOJ^,Z:&9X4+! MG?J.<$8O^#NW\.>`^4XOI-^&,*[Z_O"1CY=2;UU1H-=W`^V MH-KD';W[A[OZ9UE^*IOONYNRZY9.MFUY2^M[&6GZ<_*[SHDR*GWY./48_E`V MNUK\N7;?'EYN+HHLXS&/2!''G#`20@RZEYO#-"(PTGHA:CF4GG>*3UZ+&TP+ M!MN"SKBWU]*ZX-B\X&"?^9M]!XZ6.YU?6\>.Q.XEI\E*PEH*R#B]-N&B[K&(``^C_#37@S^_J$[EM_:SP!GQI#6H0UZN,$(USAF^7.0;G!: MA6_,H]#IH'/L,-GZ:K!B36'&E'NE>.+=L:L+'/XM/ADA9B);.13(C5DEW/)S M^**_[[:`,T+CA&<4@[#@.2D('SK0B)]SJM4SUVP$SX(]@3H\JV'6W\60/S7Q M]4^=GIZ:L.9%&9\EYHS8V1&Y$OVR-*)V.;;#X_7=[N:?^^%#@VGL_,>N MW61Y&)&L0!3F&"=8_!2EXY@LAE!';*P&FDMS@K\D'%VEL>-037!FH\]0=UYD MSHO:G&/EC.@X(7,EVN/&EMK#;'.D1)_%KV'U_797;5!,0<)A6-`L#0E*80&S M<61*N5;7)P?#S:=*/2!7NJ3#J)TZ>2+36*->Y'%6E3JP8Z!5!M2N7+%,+%+4 M+6.RE&XS?GI\>+@3PWTJ[\LJKVZ+^^OF9SVVG!*;P!`*88QX3"(<\Q!G;))+ MH)9$V8_BN\PV@+L(6@FOZ\!;]@`U+J19$GE>J^;E4+,<-M'7(0L$M&#`IM"B MSC6/ZG?TYN/3[+J=':\J%^;.,G#B[IL;UE9PCR"@8\)MIKQ).ZXOKFRTQG]7E3T=9G;#VAJ#:LK$!'K>#7;B:' MAF9>[>25L?KF[W$(E(I!(L)R%#$6@S0/X3@$!&H-F4Q^KV>MG.!HK'YM:EY6 M2)^LZ*GCA,1$%[694==$GPR9Z:$.4RI*^(N%)U30E(<5**`Q]-I^&F@H'R_+ MV_&W$THA)%E,DH+'&:,9GLYC$$N5+I1J_DK/>B>1:"QH'2Y>5CE/-.@)G`1A MHFTZ5*C+FB=*S!1-D1H5,3O8=4+'#`Q?@829H*ZMO&UZH>1J:NA,2,B+.`5Q MS`I<4`0(H9-$)IG6@8K!KY_O`.7*N+&\"6MJAR:>"3,^)%'BRN_ED2N%IN\6 M]*WD(,3&@E-W1DS)4%815GXIFZ:\'5XZRYM&3"-9K=N3[IBEOZU2P##+V'IKY]O-GGU>WP M94J6V(U3DYLEQT3NH*M MM&N+:F^S3R-@_!*ING=4AM%$NXS.1:*;=/7>W(Z6-YJOOSXKT:8-/"+,# MAE8@QBZLJ)U.&V<5BT.QI`@!PGG&4Y900`I&,<7CT!!1K6?478RW8+7"IECJ MA&K;.H4?EMU5*9:LL"JP9E2?T.=\]=4)`Y.4:Q.F=)EJWO`EX884809RSL,T M*@J(29)'4UJ;ACFWD#G5(3PKV_CUJWPZ3)F*"WICM&'.V965,=>N*,'B_A[Y5H M^2*FU\LO-_L8DM\(+.VN?Z[R2OR[S]^V50C`AU(LQVHOT[FZV@M?W'6O]/>( M^7;7_&M[)X)=G$40I3"-4\9@QF&2%-$(%!5(J6'.U"XVBS(N^YB#E'YDA_2H."O;`H$"8%@TT7P5.KIC!T$72SH;-L M^>ACYQF]!+%AO))J+@)?CT:RN4+K/H!$T1?[V/,!-'C%0($`)H2#-092$ MA(RX2$24K\?-`L9SS-$K&3Q[1.V"AA.'V;,RO()C[WGMK1>:RII9Z%6Y;4N1 M[7Z4%S+NQIY/21SB/,P9SM,(0Q#!"`Q?&L1ID4"E[[_M1O"\,B68L06Y9M)G MR)A:XN:?++WDZ]!UN$/67@0=0PED;4+N>7IK9, MDZ>?.WVSH4_[[;[LFQ.)S;7XYV.I-A1.QUE!8%Y@$C$,Z/AQ=YS&0OIT-,?M MR#-HT?9N[!;Y6(D)%;0#Q&#[M2D[T)HJY9A[-?5:CG9;51M:L$U89>NVP0,? M%SD8U:+RC`;Z</]Q^V/R62]F-Y4^Z^ MRYIE?MWNF^W-?A.*Z17G"0LYRGF1Y3$$V8@F2W.MDJ`G"+[K?AW,8!#9WGEV M6NJ,>R-178)V6W4=?#"`#D;4P0%V\-<(?.[[DV;TJBNN:W^M4WJ=6WE>@_V0 MZDF,/Y;RF6+AC_=?^*Z]V=[]3[EM-C%A&6<4Q10"G..E5E@V]X$.C_3O`OV#+0L!@A3Q_Z>T(I"&KUN]GJ7.[*A#8.^D^<\]N!=I]X-B98!NX[56JM(F=5M)L3*P_/183M^P1 M10(,RA$$*>#B?Q#DC(V(<(:U.BYZA.%?DU/?FJS!N2=5]D/W7+HLT;\.99YX M=JG-^LY[K>IL8*FM/IN2:Z#0==O2;=/\_%(W_]DVMVW_A!>(>)*0F*`TSQ'F M+,U`0B("4)&&B.H]56H[EF>M/5*`6MYD/`9H^(2@-;NZ@NN?6&-5->#4LVH^ M2Y:2--K1O#K]LS3GI,BYH$GCG65Y:O1Y^R-_W'^KF]V^;YL)BY3S!``>QKA( M88Q$-CN-!K'6+2G#(3SKUG`L+F`%$RZSCKJF%*JIU`SLZ8F3$7&>7F!^CIHS M4F3)Y4H4R-:*WUYC=D"*A=X,K2X)HR!)0\*2$,0PA6$8P7&\,(5*S\I9#[*( MYICURS4GTE1W/'#H0GF6:9-[BAXM]=%D=+7ZHVO'BPID1(SZRPYBM':_NZ'U M8[5O?@X/ND49H[0@:02+A!4\Q$5!)L$C4&O/9C:"9_4903U=0+J/IIEQIZ8Y M_FG3$YSG&=-_1M?1BQG/L7-&;^S87(G86!KQZQL:#BA1EAE>-^7N:_7+6&F" MPRAF*<]C5L1)`F$XCB7$3DMEC`;P?2>QQV2E,6;$J4F,=\[T%.99NI82F.>X M.:,O5E2N1%[L;*@=SBV-CUE/EXJZG5L2HS#"`!>0QB'D*,M1?)`SJMSLSW*8 M1>O..G4<%Y2>%Y^9V719;)Z;2/4GO6"FV/K_K3[ZOH\;<_(O4.N5_"E MM"M+:N<3T4D`&#;..,VB.(DCE"8T!ED"0E2,8V(,J7T(4!QHT2"@5UAS0ZQ- M(/#`J8+SC-'I>";CF;+"6PWB6=T_=4WICW$% MK)2=D,1/.IW9[(A\6=%GXU!/S3M808?K*8D&77KL*%17\=FH-%-P"TI5U/N< M]2>4VPEA*U!M-W;4CF>2LVN!5U,/#<1#1I-87D?$%&&01'PJ-E.8.[H:J#[> MHAGZE7'S'B=4JY6,YV;99ISOI)2LU.3E"\/FM*EE*%^ MWO[H;US+\WLY]`931BA,8Y1!R'"8YQ$&XR`IBY4>Y3#[S9YU;``T/F7T1M;E M_M!(H`RH>CGQ],N2G@Z-!`V7="0:O_2H)Y5^:3++)#7GDTKV^)N9)U)&I2-E57[9[3>4%C3.H1BY2'.:Y6D<38>#!<&9 M3C)H.91G_1Q;G0WS?;_],;Y1&;RY[B&JRJDK;M6ROQEIU1/XY(7DFFY\J:VLM,-&R#=6I8`!+,4!'C-)0](R`KT"2<<8B8 M68\YT]%TEIM1I[FI5ZJ9D'EMI:6_[ES1O9*%Y\R<$ZVWW-"DO?3$@%>[[?7N M;K??E>TFIEE"\X@6`*4X1#@JX/0E6`0Q,>F+JCF$YV1A6F1R==T=-;E M3RTQF($ZO81@8DVF`D>0+H)WY9DW=KU*TE-R%)3(D,V5"9"I%2=TQXH4!]7K M#>=B6T3%YBC!A,<1"`%'XX@\`EJ28S',;+7JWV]=.2M/O\RE;57:*8WNBM&K MJ3\;E9V525V)$KFP1+G(K$F.20*4MVVY;\4/5/S];O]D^(]E6XK?^6U#DSS# MH1BAIG2I0A?8WO6+E[*EBMW7??)5C[@'30#LNX?W9;?R[OZ M0=8INZ3JIK/$(J%RXP_M3&MV5UBD8#W6B^[G'NY3093OC/:(ETO.5/A4R]J< M>F8E(NK-O--YG@<:+:\4B[WNKF_F))]4^BBFN^P0T.PW8I.;$!:2.$-A1%D4 M%F"Z1)&"R,$E8^.A/8OM`5=P*Z6V_A+\\\]/?P9?!A$^J@T99Y*^G/+RJ>+" M_G!X_>'(3Q)PT"$..L@+>\'%O>99O&%VNOGK`FDZX@7P@*LLD0N9PISSD=U5 MZ%/$G3@O]>B!%1RH^K1.Z0*U(Q*5-Q7%MJD$CO9#V8QW!'77+=G>/^_)V M:K#`81)RQ#.,*<]H3L*01OW3@6F6IFFDLYEP-:;GN/;?NU;,PYU\[KXJ]_W" M?)`MNR3F_]+<+#CC66V3L`3%>J%J1"A[.`<=QHN@0]GMT`:V`C MG"3."8(A0R$"(2@8R@D9X40<:S4U](7!LUZ^$ZE1(R>GKC9ZXUQ-*]=`MYYV M"L3C19&I)\1E]]NVTE>NO=S'K>U6"CQQL" M6!YADH0QB%B""I`R-`Z"4JSUN8C>;_:MG6."N=WOF]WUXWYY$UB[1I6HZ9&)6F*2,B%4)94@@,>,3!0PYT5HKSP;U?F*GJ^UUEDHJXYUDM M!UF48KWD8X0:#%B#'JPL^_9P@R.\%\OOY'2I/:-VWKRT$D'T9U\]TW37?G_Y M>]GNNY89EQ4KK_=BH_F/;?-WV<7?XG\?=_N?G\J;QZ:[:B3^)2V;_797?6ZV M';SN>(KMVAL1NQ^;\G/Y8T\$H7^+W2DO.,@H8B`BD,4LCO,.;QB3%$&F]W[S M0B`]R_2G;W6S?RO^P_NNY'-55U_[OSLR6/L9Z*7\J2;SK\*5>N'@R"39R4@: MU;GS8%;0VQ4<#`O>R#\QV!8,Q@TW!/X(#O8%?TD+@\[$^9^T]N.J,^%E\=FQ MDC"T/`^_/_5W]8=M\Z_MW6.YR0`3OYV"J&`\#`M(8$88A3Q) MLHP7::+U>9W1")X#RE#W:B6JBZ"J@X=M$WR7R((W0F<>V]O#^8WVYW5FE*J% M!?]LZFGZ<0'Q(GA7!P)3T(&:^Q.ZYX@YHZ!V1*Y$_BR-^/4[.0>4F`A/G\L/ MKSC_7WF["6%1Y)"#)&28)0!E..3CD$D<0D/YT1YG5A%J^QWQ=H)G+COZA&J+ MCULSUZ;)M'\5P*$T0I7G* M"X(8@3R%,1B'RZG:Y4W;,9;0I5T'S5:35$DTU",/_-EKT45P^0)W\PA1CT)' MA#3I7*L`Z9KQDO@8T6(N/$=%SDW&,\;EU?49Y$,`6(<-7O,]R,YGFEC2#[F!7T,`.)+W@; M2*C=SQJW_AUQ?#X#6(9>W7+W268G7DV>%'9$L/J7%/,3;=HWY*6I/!PO7`K% MJ_:[[^4+Z)7<$W$8X-JGW-01TE9`C* MW]]7N^O'=IZ8<2;9C+-56SFH%)F.6:N(7DKRQ/OK%^"')-L2#8``B_U\*=!KM)QO!X8IE50+"8,BZL2"T6K*1X$I5=6\EZ11M&H5?1"* MBK/61[^]FV)UOZG6U;>F'AP/`B-O$7Q#D@O0-R6D`[@WUI3*_#A37*D]?U,* MJ9M#^V(LID_'7_FX?!)?$7%TNW7P=+&K36M=^#3.(DR('X*$Q#C)^(\'1S&0 M6GF:SSO+X:3SZW09N$G6:5>'IZX=:US>@77D^;K2D<7G&06H7'FJIH+3\PS[ MTXWVV,6X70\V?(JCZ>94HCM\R4?ZXH; MZ#/THMS6N]L=J#;%;ESY]>OKR^E.FB,NHC[]O:Y)7M.FJ]<'FV;+/S+>,3;B MTNA!\/\>E\8+8"HN&>J*R>-2?]P\K^K?^?^[6V`:L=@/@RB.,@8(I@G)>G_] MC"GEK,_FI.4H]:D0=^Z*B7,?I4Z+07P3+LX4H-2[<]HX9;4G'0A7AW$@)BN_ M#P\$I^/6RXZ:('QICXV?+(KIZV`IF(WL&/G*>-\?UM534?Q5U(_EJCCO_I]5 M>=(7/U8U&5URZ<%W5?B]\`"IA1ADN0$ ML910<=ES"@^M"&.E8X>.N6[]O?(09ZM'_F+Q=U>TY==E5_CGH?':E:BJV?TS MAU?[/3]7G!6M/1MLVR8W[Z0GC?Y9HN[9#ITC_(X;63]['!ZISE0!V40GSI'Z M\*+`%_M1U*MR6WRLN3H+',$H0!"PB.9Y@FG*`#J^L(=*M>1=\=ER+#X4W3O$ M7N&56.OKTIQ4"IRXM=2GUA'3)%08&0J.(-0Y6>PE7QCLMLF@^<\V)&QNQ2W* M*_[QIA)?=;Z+A]_BJ#2K:/..&T9F]U&2''T MRUONO&)S*\CYUNN+DYB45=XB)XUW_D\"2O.Z&":EI8Z31N7'NN+/W.Y))/&* M$GKBX&9S">>Q(!Y",68`QT$<@#A)TX1AVM9YC1#.$Z`".0/F;.-I=5_<[M?- M/*[W]JHY`]#6T#QXK+C&8D)HN761B3566\L8E-3[<'W]LB#LU>S?6` M(^`SV:*7,T;38FF`[X_EKBN,_.%.C,H;/BB%-\TH//H!*`@ABGW&L@`%*?,# MG_9^,!PG>A@T9'Q"*.;[G:A\?G3\]=.L34=37:'*RAEZ09^<0\J[Q$XY4:5( M:KA_G..JZ?9=I*P5(:69FR_+MKQS^G3X^*XL:OX'[I^NBT>N^X]RNX@2"!D0 M)56YV3`@*8E86W0>A0!!I7=L0R8M\U6XUM8OO_(.WGE?A&NRA^Q-:RR'T!GD M50.GGK)6R"BGU0`/#8OM"`5-MZJR.D)UB?='L10W:S1SV]=^T$J'2D+;Y:&, M9C)8-*J]:W0TV[A+D+0@H3HKWV\>]KMMPV;0U5)):$I9X#-$,8XH`I2PI#<9 M$*ST\CW&CF4._F-?B1R:)A^@N:V,K)KB;^U=3EOOE\99#ZA>#C1*6D4"6E95 M?_K7.G;E=1I*5+&RB[W70LE`;H2\KB%M3%,N`6RT/*-P%70F0Y"%442!G[,X M2&$HB-F;S$.URXW'V+&]+%A^VY1WY4KL77[8W1>U]^'KMJ@?FR6HUMT>68$) M9$G+JX\L&\J:0E;@$K("+62IRNLPLI2;(H$L/7E&(2OL3$8!2_V8I22)4A#$ M:4:3L#=)$[7+%\?8F1!9GS?5)5R%)G`E+:T^KFRH:@I7H4NX"K5PI2JOP[A2 M;HH$KO3DD2IFW$PG\G*SW*S*Y;J]H+:WEH$D"%`*46C MC#1A&5*-9PK%=<>(-"752PTX[W3QXU=W-K5.9>(QX\D6))Q)1KQZQMI@R MM8#DZW97+U>[!8HH1AA%D"4P M0%D4AS3J#8<4$)4IXWAKEIG<.J@X*S2@H=S<<%KYU%#=^G;EG>P]'/WSOO0> M3CU+?%.R@;FB.;D=F3$:;%!E:V1J)_A=SJX6;WZ++`8)?Z?&@.0@A1BSA)L5 MATF@J(Q,J5YBWTBCEFDF<_)`=>/5G.!RS)M%:S7TC939L&Q2B7F&E'>$ M@N;;=3$1SZAPXP^XI4\W_"\UF3`^RX,\A9D/$P@)C@D&N#.=XDPM^\Z$O3E) M>.4)-_42\8QH+4?"J64V"$%)A:<]WW:4;0"")D5WA']&FR1[Q$U;+@/'>OG? MZ7):$IAE24S2#(5I0`,_C1CL3=,LD[I*TZ0]%ZBGEW]G1.V1W+,DM`7NS9-Z M)R&<#ODT9'>=?#I-DC[3WU@*?*%5JT31AF6_"*Z\\<4L18KK"R7%K`LW44-7(=>K17%NWYY498-%( M*1W!S]A65$;'ER)DTGVY%L6M.-KZC^>,YSC),0I@3DF&(`$HZPB'?0)"I3KR M9BQ:1E#OV;8)_%^[G\9`R9#0H>?G"!85+*#2#-K/*.$,YP MHRJ;@U4UJVY?;TIQ)IY;S\L?XM/!(@R0GV7BGL6,T@`G#*+.(H@I5'JK'&'& M,ND.GC7/XEWGFVH"W0@5Y8@VD8!J&'NN7>_6;)ES%R4:2IP;KZLCD#+1DI=I M0H>W^RP+MHV202JD5-3GW_"E[MZQO_U[6 M!0\X?U5W._&Q,TK\F"*&`Y!RVWY*8)2QWB@C5.HB>#.6+(.C=]"[[SQLHN^V M\U$A>=2`IL-LF5Y.-=(BQM0R@W_HO!6O"GM)2AB>7E7B+S1MFOVNW)= M_K>]`:6ZX[]_5]7?VQ^W3]M=\;U=KWC@SMPW=ZKT3X6W?'A8EZOF5[>_C8\?VKD/OVK-U*-6MAS$Z2NX_3"2AXB;$6?5FVXFXK-'0=H0! M91V9V1IIRLN-"6/RC$_^N"XWQ7L1[Q8XC!E(_(@;SG-`$"1!T@,1`5]I:\*` MN3E3/[POPD^O<=18XH>"TG+\FEAD-8R9T'?:I(^#:CHY'^J2.\(WDRV2S?C0 M%6L\[3YOB[O]^KJ\*Q8Q8@RS//%3%(8PR(,0'I86\BQ7.N]@PMY$O/,>#H]C M<K.]G7?J-2C^2=)94-`N_*:WWTK@<5GA9X1]ETB*-3M6-HX#&.`H]+&/`^I3DC!,VLK&($IVO0+N"B@-TM-$7CE#22M,J^T/Y%35/!Q:?>?Z;?]E_Q?\C;LSFW_P/ M4$L#!!0````(``&%:4<:H1B;\,```(J`"0`4`!P`>&]N+3(P,34P.3,P7W!R M92YX;6Q55`D``[$205:Q$D%6=7@+``$$)0X```0Y`0``[%U;4^.ZEGZ?JOD/ M#.>9QI(MV]JU>TY)MK2'*;I#$?KL4_/B,HX@KG9LMNW0L'_]2$D<`N3BR!=" M-R_=P9:6UN73TM+2Q;__\V&2'-V+O(BS]/,Q^&0<'XDTRD9Q>OOY^-OPA`R] ML[/C?_[W?_['[_]UGE^Y&?1="+2\LC+15B*T=&/N!P?_3D2Q?>CFSR; M'/V9Y=_C^_#D9%'K:/XKB=/OUV$ACAZ*^+)Y%83EK>5R6=[^=GO[X M\>/3PW6>?,KRVU-H&.;ILM;&$NJODZK8B7IT`N")"3X]%*/C(RE?6M2@ORCY MVX-Z\*S\#W-6&F",3V=OET6+>%U!21:<_OO+^7`FXDF<%F681N)8ZN#HZ/<\ M2\2EN#E2_W^[/'M&8)2&GZ)LG7I9DH3763Y3$$E'YW$DTD+:Y5+<3B9A'O\M1F223=-R<+.KQJ6(LGPD1F>I MEZ5%EL0CU8&&I?Q7]:AB<#.X$_/:13M:ZI7'/M3].+CQQ8W(VL7&U'TD/;G:FG M9L>I6;\IFT]NDX:)4LUP+$2YF[T=]3IBZR+,I4K&HHRC,-'E<2V1]AA>'7Z\ ML!CS)/NQCSZWUN^(S6QREXNQ\G%E&-G!9%$D:S1V?ILN#_Q++WY-%8 MON9Q*OUK'":D**2'O1J')FN% M`C5J-F/MCRP;_8B31/;8LU3._V]C27NNK*^BW,%=OBD-/<,,\?)3ZK"7)%H`UQ]9OK1PDO7[8K\P[J78I8RPOL0Z(9 MLV>I_"EGY@\[>5I3LK6F&_3J/:DT9?E>^N,LWQ7)O2K74K.K"%X\JJNEVA1: M8K46SC>4;LY",9]-GZ7_F\5I^2_Y6XZE=;C97K$KQAKAOPG19@+-$WR"W.9B M%JCL8'53\7:9:*!+'5)-F4^%FDK+V#16DZCS++V]$OG$%]>[M;F[:G?,J7N1'O^K@F:6FRC0W%7?GT\FT6BOZ9Q$==)[&VOU`5##?J#/L$N!'E*>]S, MIQ&SERHCHI;IPNLXF4%3OIM.Q*B)A(U:ZEATE6"-1XLL\%4>IL5\1;4E>6N2 M[T+(BSSC"D[+]%=+>-V#;A=BU?)9=:HV8T[.N=7ZQH7(9ZGX'?QL*-TJ"RI( MFI8S,PQN5/XRDN+[<3(MQ>A%T7KF;XU^JV)>9*4,!"7LDL=9X_&]&*JL[#,!I8^^$WGY>)&$\X4XZ03OU/1U=SZ_3M7N MF&N@]Z9DNQ/J*>[?6*JYB/LWTIW`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`S;M&*])OH0MMYHHD&J M%^;S<*1.FXKX?M;V998DTB_\"/.1C*"3)/NACA?)"-K/IM>E["X+$G7C]UZ9 MV%MAJZ?0\5QMJ;A5ON$\O!8OSF&MJY?D^;-JZN0[5B??@3V3?QVU%KE4:QZM M,OJ28(N\7H@\SD8L;5FUZ\FVSO>P#/.6=;V)<(N\RUEB(=KE^C7)-OE5Q[U: MYO<5R7;XU0!#^9K%&I:_6UE@.Y>E%F45S>;W5LQ;%`^E2$=B-+\=0[:99-$Z MP69"W83%]4RR:7%R&X9WI\KAGXJD+*HGLR'@Q`"+ZS_^L7@JZZ1%V>DN65M3K3W8I![P7)LP\+A\_'R^;#_/H55=X3F51XO1N=CKZ)!K'R:BJK:[*>5,0 M97T92&IAZ5).7_J4#CU-_0GGAQ=:`1"T;-N#ELL0YQ#YF/HN\CW(D>5:E*&] MO="KR%P^")[9+ERQW?)4P'Q&LD;:?:H'KD\<:I@0.\@%$K;4IJ02!AC0?PM7 MH[;QL\Z-L>(V.NN1%WDVFD;E(!^*_%ZR31[B8DL'6U<\,!P("&*^QPT/ M(Y]!#]D+J1"P.?[)1JMN+)ZUKN@>X:/64!>,%GXV">-T-X9>UPE\C[F`0<>E MS)/Z,>5(;BWE,TSO)P-2.[9>#YS&VMV.GK5#VK<[*=LL@?LE3D119NGRGJ0O M8G(M\@UCV'0I MK:'NT5![O66DFF2S9'\EXE:L[$$A@,1"AD=-T[2@YTL]86Y4XC#B`$W4P,,+ M?=H%2G]55JX^G)ZB[8C9Y*DU+@40X-1_97VS*)30T(237YL(&% MC9]TG&L(C*Q/I6N,>B2?+[/)KC3\1#YM'=_6E@VPX9G<8J:!`(!R?HHPXA6+ MOO,V\4\W4.C,>%F[.M:`P?_%V=TXS"=;[?^\4&!RB!R?<7@KTC@J9+-;$?&Z8.#)":#%L.LZIN4#'W+?`A5S%&.JB0/GPX$T MUW83*`Q%E*6CVH!X43QP(+9\!]@VYS8FV/28`Y?RNMH+1>X'+-K2>1-P7(WC MO#XVGI<.;"FSQ3D'P`+$H1!1CRV'.F@C36C@7W/D:$?+&F#@\76>12))MH+@ M1:D`8\LV+$8&NI:`P)_B#2["^]%OLL5O"X8 MF`BXG@UD_.(1*&,;@]O+D6;@\15XH$ MOH6AA[AM0(=8+B3$-:O51,?WL6Y<"#XRG8T4K6'YL[3,A?S!4I'?/JJKJ>2/ M[;N&ME4)'(`!998#@6\[E@4,AZ$GAGW='`/XR%*VJGB=[69*H2&-L_-S;_NN MLE<%`]NU?`J`',0L7S(D8UK3J9C#3#L#"7[1%&1C#6N8_VJE MG,2>I='VW1=;:@3(8`0A&]F806#ZOHE,NF37!=H!1*-6SR[?IH]JZM&.#XR^5LLY;_WS89M:_T- M4:8XWGFJ8F?=@#D>LUUF&Q[W/-E!*;:KP$S.V!GY23<7M@B$>A#35KG^D8LZ MQRL6OI5:P`,.!X;A`F8B0"@W*Y:PX6L/8^\3!3JV>GVD0DNU.OF/Z=U=,G.. M85+'\AO+!X9%&":VP3P?.S9P'!M5TW.7&5PW/WKH:;%N4-"6FC40L3S)LVO; MSNN"@8$P]61DY;E4!EB&XU)816UJ!5CW>,RA1AW=8J"Q?ON(+S;=YDT?5]_L M"&?K$PDX=DU&7-LQB44,[E,"JGV3KN'ZNLMQC5)N[S"4[4SC?6-N9Q#[NK#L MC!3+_H@IV7\'?\,Q`#==R M'J?BK!23=2Y[7Q*!92)+AB@8^,AC$&-F>,LA"V!+-^G9*!/^CAQVQ_IN!J!G M=QH]"WWFMS^*T>SN]MTPJDDH8.KF%&Y:EHQZF6<1UWB*?S#S?K;;'+HS_GIT M=6,&G566Q24"5]F*EUVY]/;E6LN&XH%'+6P9ZAXMA$R;8,EW=?K!10#H7B-S M0,?U>X%(2_KMUMDH]_HE3N/)='(5YK>B+"[%_/.=S?W/9MJ!;;E$3KT0L.2T M''G$`J3:MNA"`G3/T1[0F;E#\T*M&:./N8J_L.&+BSK73%1>E`R0!:E),9'Q MN`=EGX!\N3D:0T!U@76HFTLZ1UD[>N[>AZGB8C9-F]\HW([W>DDU\(CM(-O$ M#)D40&AB8%>WK&";`=U0ZOW%Y;WZK89FZ.6JDL5E[$],?Q6E-\V5JK>XKVW5 M`A?*V8V'`&8N@-CV;,/T*BE]XNEF7`YHXTMO[JM%/?>!IMFW^>9?4_^:I=%. M&*TM'TA_"@#Q,&3(Y;9#7`M5F\$QLEW=/=<'M$^F-_RTH>#&@V`ES]-MPO-( MCHMZR8(M]0/?EN[4)\@@R+5=U_4(L99]`#JZJ]&-#O*],ZQTJ7"=%KJ#MUW$TC("XA M@!NN;3/3A<2S;;>:'Q/#0-I[_#Z2[AV9H#&JGF:QLOU(H?OF68&J5]2"5UUB M@6\X%'J0<<08)`P#S*M<,G'T]PXU.U?Y[J'5D?J[7C>^7P4+>F'5KR2],0C7W9YF]E;?5:KZL%W+5]0#T3 M^HQ[%J%26!LONXF$`'2(4APS*JD_($,UOW7KR#/7+ZI@ZN9VNU".O+[#%, MRL?+L'S!XU=1RFGT3;PI5:)/,&`>1$@EASBFS$8N$;]GFOKLE6VDSH-B@EN=B2+'-$/&`;_%EAL'&VM.C0[W^\'UC7,-D!X1R MGDTW'2GKLLG`LZ'O`-?SI6_@A`("[*5;<"C7/O;1:*7F`^.M6>R0("[)]0UQ M22XPU#5Y+K6IR0W('$HQJP[Q$&1J7V(+#_6RRO<-\?TMULMQ#94A3N]%7L92 M!CEEF,1%D>6/7[.RO9,<6]H(*"$FD!$G1Y%02%EO8M@_"77=/J3OEO`SCEJY]8?NI- METI[VYS@OJ0"R_9MS!"6VF:<`$*I574_:F"B>Q4J?'_W,G2!OE:5W_IB0BR* M5YGF89B(XBH6^2#=-VBL1S0P3$M&RPZT$::,2GU2ONQ_E!+MJ<['>E=?-FD1 MB!4CI/QS'$?CE340;ZS*%%>9XG'_]8/ZA`/NF+;O^)QPP`PE+O2J;="4>P;3 M!>3'*E>?=NG7.^X/R'I$`V*KBR:@@3P?(I\S`]G5M@EJ,U?[._4?:U9]V:2/ M-?]A>"_54W"IQK/)79[-]S*WM0%@/?6``]_DC)O<`+)7NJ:,6]BR/W*D/7!_ M+#7U;IP^,/I'GA5%NSM35D@&!C9,R1]Q.4*(01&G*)O,S;%K8^)P.IF$>?RW&)&).H_[8EOU MFAJ7(E+@&)VI9%:1)?%(W:0RE'S-53ZX&=PM\K"%+\HP3HKGHHJ'4J22P''' M)W;SVS"-_YXQ\L3I7*:+%54.;G@LT1/%8?(D!+DNRCQ<>]ZN5?J!B1AQ/9=@ MVT?TC>[,&Q; MDJ;UQ@+;(^JB4LBEZ_=,QS:HY51:9=C0_D+%@3K#-X+DRWS/6]NQC^3DXHCF M(!^*_%YZQATWPJXK'F"`'1,X4K&V:2'#="'CE52>#7_6>\;?$A]9ZV;I$6Q* M+0M&BYWWQ&ZL$Q!,3$HX-"U+AL2(&9A:E7P`:4]8#AUVS6R]'CB-M:LQXUA< MGRY;?G6LM\XW#C;7"PSF.M"CAFN:A#G4LIF)*]8QYS\Y,)K8\O7W#EI3\_^S M=ZW-;=O:]A^=P?OQ$<^.9](FDZ1WSOF$46TFUJTLY>KAUN?77T`VZ:3,:&.49?SQHX$XV\;\J7@R`-(ECJ+4`^#CMZ=98^V*SYO/!TD1=M`Y+E/[ M4RRA$ZQ>%Y+X)'5,?R[-IP^Y%*G>=EB?M18F'MJQ30+MC)-2(T^T!)1#C!ID MH3C7T_!(8KRL[C8HZ!EGX_/R]#M.P1[6\!A2&>(_^-R\KV:3R_;M:`73P5M@(7Q4`<\F@1<.(UYXPGQF.8V M:1G[<56"`,=!G<$`/_UCN;BL9K-6!KQX*B@/!)<\JNQ1$[.$*XQU/2WM;*[" M,M;,Q)(,.`[J#`;\4LT7/R:WU=)=7K:2X/6#(?*2VY2+BQ$4P%KA&*PGE_P' MF3P8:\V,DCPX&NT,*GRY^/CC>GT]F=U,VZGP^L%`K`!(6^&M$!A9CIUIS'@* M3&X]\['FZY6DPM%HYV@&MY-_+^;M:L&31P(TG-IX5"F@@3&>(R94HQ&K[)U@ MK-EQ176"?)PS!'\Q7R^K^(.;5\OO=ZD32/RA73]L&Q(4LH9+;314R`EH?6J; M6X?-HF*328RQ9JJ5)$:/N&<0Y5,"=**GBP\?3"L]7C\8+"1(""I@-)^)=62'.@#XQPU(96;?Y8:M<>5L.OYP`'4TFN.4+K]+PQT MKG&I08ZRO4ICO=M>5(/H"?42'NX>0@$?6AI<#O%K@F,HM5.5,BI@3&FE*<3- M;HM$[E8V=G?(B.(W)Q3G<5G2O=8P%4QS`ZF/9J&*=B'`AC>!5ZXMR]U#QW>D MGD;>AU0V/4P6I\USOOOX[47;M'\RE/>E@SJ*N:'&F_B/0@(XQJ$5S`BLO?9^ MKPM\&.Q>B/$)]?5="F7N2SKN-#XX!*521E#"A5.:6(1]O78(2:Y-/_8(8&'B MM#%>(NNT;GR`G7L\B[9/L>AO3[R_;E M%MIDVCAEJ";8:(91O3ZFQ+DF+QPGZ\[9OH>A.ZIL7VL8],8K9*,RJ"3@CHMZ MZD"AI#E0=F^A\&5C\FTZLCDGX/>$,``#@E+4C^F-0-R@+6@$1` M_D7\GXHUPP&>SY^'%3XN\.$,[D2=/8,#TY*G%&GDH-+Q[$8"-HN`%IU!4_E! MB=(OO!D<>:&7;=VKK;S8/2`8!A01*9D#<@\,139E=CQLB)KGAL+&GD+3+S%Z MP[>$0KM;J^_BN.XP.C@(F%#2^ZDTK+G4/_`G(-O^ M1N]O#PC:00F4]Y!CYY#05#U^E1PJ?Z;J<:]";R=4'M(GX%"G1N\[QP1GA>0^ MU7U7V%%#&*#-^I3.ODAR\.9T6RW_6)PIE[+A/@&=NI,H"(D(ME8RA!15!!G( M9+T6HWEN&=+#]>;%>C([2^(<"/&IPE;;D_R?Z-3N((.DCE*A(:'Q\T]MP!B3 M0GI%(+?.Z(/KY^P/8T]V2.EKE(N.K_NS2U![[TN"QIQ(0T6TXYR#E'),8;TP M8&GN%C!V/:0P*W8%NON6SPF.&WWW9/^TT]7E;+':+%MIFOFF8*Q`2EH/L=3` MZOCM<-9@@>&Y7NL^#5?+"&FX`^_F9KJN,U@B:NOXA541FQ.=02QPVEV MT'L"-)A@";WGQ%@,N6+&W,N"4D3AW@I0)\2BR_YQV(L"@L)C1:T63AAGN3/( MUV@0PL^U6MM`E'F5,#B@+$ZP2SQVJ[J8?ULL;[8O/F46UXEV$`M3NXYT"8Y` M18V.A\=63H!P)_'>7L3#8/&AFJRJ./O/2>(S]_>/J$&UV;UO/A\H@4)!987B M6""`$0:F61M%N=?NSVP_Z$J`1?^0E]!F'XK(SK]O)[RZF,?-H6K4IR^;J(S' M/]_O6CGH/0'&R:1*O4@YH;$5P$!4XT"`RTTL'KLF6X9Z0XKB!)3TFW5$Y=?I M?'JSN:FS/YYT3>S@`LEZ88!Q?B2>T=`SY9U4!($&?\E5;B[&"*/J)^'E,&(8 M'T$_5RD,'46?[-/5Y63VGVK25DBKA[<'HJWTUC!B$!!**,\=J#%#F)UK=&UH MAAU%Z#XD-3YV7\R__K5(*VG+,1J-,06@M-L\8R2O/&75[W3MWEIP!$&KFUB`?H0XQ=L[FRN0$ MOI=GB]FNKU[1[^G\2,'XR?RRFJ65O<#AY_/0,$T(0E!HQ+`2S)HH7$LE-,@; MQ_!>+?UT^Y#=]&6\/'E3P)((H0#"*J*BG66>^1H/`URQNJK/TV'&8+=T9DK& M5I,O@?&,&,AKNV2 MA7K8BX*343G0P%`,O-`ZM6#4-1((T-S+6^=@=Y2B:+8T1L3+WHSC9^\*4C+' M8?PVI736"V\\:F`7)+O2U=C+PXR,G=D"&1=!^S*`7[PM0&R0(Q(R*:FG#F'V MB#YV('<+'?L]I/&1-%5F0!&A(/(8218-`.:8!KA'QGNX- M[[_3(L.C(VFN1,;%T>EM?SMI\[(`*:#>:0:E$1-/;NQW=A+,H^, MH=D"&1%!CZ=E0`!S``DSCBM'-`$I0>%A[89EM]\\O!1TV3M=(R/C@6(X09#E MA%>^3A0HH3R9H]9JB8V+VP`V]\%:F'H`\9.W0']&I?NTR9I0?K%\P;N]5\%Z M?7_`\9"/'XRQ$BDHB228V!H[ZL"YNJP'(MC.AN;E1#3,)$XU8#'W'C("`<*,Q6U8(,QH6+_ M!C7&PMRZ;Y+D.$Q+ M<,5,5JF@7/J?^[_-]'8RVYZ.:S-9+N_BV?0_DUFK&=-I?%`LZLS>*>4)X-!1 MX85J/C6570;P?7`IFP0OK^0-`'4)BGVY7BS77ZOES<7\MEK=JU]MI_0;CP=F MF256(\ZUUM09#X"H5R4-/]>KXOT2J`=D2_#E,P:.Y60W)MD1Y'G/:C@1\%8@A`/1>@?2H34 M='X&0@M+.HR.'P&52A$.O),$8(HI;\YQQM"Y9KGURZ/^@2[NVN[JT@X*2F^% M18!2K(@T0@I=KP.*[$*#AZ>"W%V&!PJ0E8!+["S#RBBH*7P\?K-M_[';:GW%1/J'N$BNU[9;QF3Y M9[5.DS^05QU&!T;C=P<54`@C2@Q$!)KF8X(JMWS4^_!-'DVK_A$NHR8M?E3+ M]=VGV63;$"R%=+8-G:*VWZH?[1X6#5%GXI;L<30-)"880-Q8!X2R7!_WP3IU M\=8!/3&I1W#+F%[KR?S[-)6?V*X_SM+]?3G;7$WGWW]9+*[^FLYF+53J,CQ@ M"3!C`A`+-1$>02&;[9@CD^L_>A^Z]M&$&@#B$L3J0)YF]EY:$6"9,)8@@1I\UO?_5JMKQ=7W2+W.T8$K%,1<2>U%T;$ M\Q=YUKC$M`;%[E.\UV.I'UR+J?*V>O#"51"YI44J5LE8-IPJ!N60VERXZ/R73AO>LI# M/!#$$N+_,)W\,9UM[;34XW*]N/SS>C&+HEG=;W<=$GZZOB)(G(*]7!)$4LL, M9[1MP/,_,-2MTD.;N M4&//".J?`;LI=ASD)4/NGR9WR0O5/<;^?$`@F@'A.!9>6X@Y@TK;!BRO<^.B M[XA,V;+>$5$_"N`BEM;-C]GBKJH>LI9>0]%F<^T;&QQ$5FL/)=/QI)?`6M3$ M>VC\)L_T\!N`4'UC7<&>(H(W3BM.3%`)^ MGZSJ%>@B2;`]M+ M^?=T5NG@V=4.>JH3!X3ZIB1M%D3)"C7BWA48.+]L.1H0-M)\F:_ MY'H32T4'IE?5?4O=W<+?-R1H*:UWQ!-JXD%)B9>D]GDZ:[,;'AU5QVGT#.@9 MU4*W M(D>8B8;>XWZ*96XV^SORSPSD/>X#[KZTF%:"=!@5K+<40$T<`,89:E!4PNII M(T]STVQ&>(]O,&+T#_,)O"V==IJ=8T(\=+D2P$-%C!3<,.-4PW[MLBP4;#N74[D%!&"Z9`90(@+$Q0A#7>!P8X2=QX9S#;M4;Y(7-LF[V6#`N MSI<:Z#V%*>U-.Z^;+1>@W.M^A_M]3F:(#9Z/<2#&)7C24MRUA33O_8 M;&^??5VDS30N*0(>I_+]8AZE5ZVZ9)CU^XN",D`YK)0%%"OG"3*XB?TI8'+S M/@YW1YT9>T\JIE(;Z6*^7>:VI.3'S7JUGLS3`O=LI#M&!>TW8JIKRQW?8CF2)YE%=7VP3E5"I]>G4Q-Y,?TZA&M252OCTB M,"F959IC'O]#4+K\^^@R)CK7>AB[8W4DK.M'*B48]SGU&)]75VZRG$<$5NKR M]"ZA0 M,GD]R:VM'K?P*.OK:KZ:WE81QL5-]6&Q2M>)/W[[.OF[/,K+$@&N?>]QZ[@W@D9!U66J>QE@ZR>`*/ZP#Q0Q3`2PN-D+"II>BD M%+F']N$.Y+*^FY'P[VB!E*#8K]/Y5ASUJEL(]O+1`*7F#%G*O6'&$XNA?/29 M[O8W=HSP2>ATICO?C[1GQN$9@WAP9K,?"(I0)*`*8B;[XIH.0XQMG79,'(.5LR+M,'\D]X M5J:7W*GKYZ.@YN\9RSGME6=QO!!;>$F,T0=8@GV1NC=Q[:V5P9^]O MBRB(O?V>WGH^2&")$@9@9SV$#FDD=;TV[[(#]>-W\/8I]]UNVVRD"X<+OEQ' MV%9JL[Z.R/^WNNK&HY>C`D3.*>2C<6N%I8!)`7V]1DK@N=Y8+L6F(_$^":ZN1YXB`>FW*X-S:8^-WOI;D4A;6)^'1P;',5\." M]-)ZY!A1B"!'J,3:-CNP%L6N+9\UH_(!+Z&]-EBDB[23U;6?+?XZ>4?D9B*' M*:ROA@4$#10,<@J),H8KX.G#<<`TTXJKO?E]55Q?S MIHFVNEQ/;^^O#&T3BC;QSQ[^,DJN`R;]_(*@J2.("@XP3@XMS0F##^AYRM&Y MMH?KAU$OFR^=0B0ESJ6XHF_3]8?VACF/#P6*-8S3]R`:\I)*02A3]0J@9N>: M0%-:_J_+@><)H$R>S/]N'@K!IBNVEXMX(F^[)SZ&";\N.J+7I4?X`+\N&.HD M8Q3+Y9+8B3CAC^L.I4K$F?I/+C,)P]+6E>78WJ738E M&/G+9#I/0'VN6<`C#X MMBKO63FOOF_KY)6KF3PFD@XBK(S[Z/N.+_/E]5DEAQ_T;[^_/"C^O'L MBVI^?H.,1[\ST!3<9!Y0PYVRA"5;_9.?_^,U.5TTSU4_+ZF:ZN5EU:V&1]\+@C2<<20D$TAX*['AMX$;M M3(A<1G?W"?ZSXY827@E:/X*7FID?WHBET_A`B&/&4V.P9B(Y5X52];JA];GE MT;JG6OY#VH%D5211+OGI]625:JGT^_:5:WDXOJY6^V\[G/H5IAP+:862PE!A) MD4O?"Y-<&"O^G[TKZW%CQ\[_*.&^`'GA.C#@.[ZP'03S1,C=U6T%LN1(:L?. MKP]9$M7=[M9&5;'*LC$/8_L6J3KG?$6>_?#\^L"+TC:QO\#8J3%@JQ\I%8"L MC2IN(M0VJKWS^[^;*(+;-BFSV79TM].HY4;I;Z=A[P%=P4[!(JVUH5HS:;12 M6`N_^X:<-J7'V]A["(P&@OW+K`223[(FU.I9+S*_6+Z-'TD:R7Z_;-J(VKZ4 MO,*=`H8,"4J)DS[J$(!S![=^8PZUL*H0DA:=[>+A MT_KN89:'K!R.8^Y=%K\U)8TU$B@OH!.13"0SE=[+XG$WYR>%_QYH[$$H-7O6 M;5CUU;K9M[<'2S0/K(R($T9MY9ZAQBAT"!,KBT34!2$DDUAH(YCAF@C-+,WT8@=+F4O!/E.8L&'8E MH$INP643K73;;/[_"4>VW35.2.0X?9-@(/-$8Q!5$&J%UXPZL--`HBY<"M&Q M)T^/"J"]R6L8Q$9V-M-OJ2KRE*RCD]8'YI26%A$<"6<:QRN#9^)]ME+@)01I,_%^OFR3=4@L37MPB80(0DE,AYB[7S4,NIC;U. M^#Z0A9+LJR?<.<\R^6EQ0(H;89%"5AJ*J'9*X4PQ-KBTN&;\>3:U$7!'^[X?7!=X)&!3ACFO?86:,W$+AR)A/:E"+OP/KTB`Z*^_%1@[$,&P M+I:_)S^*_2O;M4%28`@5EGNCK;(.(9#IQ:E)8.^YJ;^12^\RW@^#-;=-W=F: MXZ?-"#IGFT`M(0A!#Q@F!B"K`;7"L-N9#"0M_GY`,KS',S/UP;L M#89:8<.HM%(!ZVS6=#%SMC1Q>NPYJX-@[C+>%^2>_OP*T_FK,W'WY)N>N#I` M)SP0!EGB%#4&8&1S"BV.&D4IA$:88]HC:OIC^&`1L91/T4$\;,\V`0N)E><( M$&65\5YX2'>JJW?%?4@ORB:]VJ.K*SD,J+4]3CZ]2'%[=9O@260I](P)QQ#R M'@)H,Q>H=,6MP/XDIO0IAQIH/+T#T`$LGKY):`N9N8K?H"?>1?.>^*S!$NI0 M:172^8E\=3NO#]QHJ32:%2?PCS;KI38Z?JY8ZDX8E8KE;IKFMNWJ\-=DO6VXTT8:?^Q&7T]FL]6[ M._5M,ITEU[M?+%.OJ,?^/(>PV<7^(0UOCPR+QP6@G!,`]*[[%$'<]M\J;%0= M&*M!>0#9#7+,MDIYX5G[\]I@XBVF,8<(8@^Y(DKL0@%$&U;J4[HP)^(Z`=JQ M,`8!GWY83>?-:M5LYF4F?F[_RZ%!$N=L$Q1@++6V9XI8:KU&T93=73N&]#\M M=:C,B+'ALSLA#0+5QV'9>3;UTR]`HE6@#61!1;';QBA MY)++_%!>ERJNI7V_?C_%M6,)#61`O?;FJ0?OW=UT-HV"/=.P.KI=8%A:3X&C MVGJD"7:1,YDKT<)EO6=D_#EL^Q+6(!!^UI`WOOTI'9A/WR1P88F#C#(OL%;" M>(_RM4,=*1XU?'KFQA^X=BNBVEZ#5]I&GXK2TW<)!'F(-"7$*PH1)%0;I68QFS4WFPY_/]6IG8C0`SL$Z)V!%$)C@(*":BD( MR;1'.[,TH#_"/)(1`;([@8PK4-5),"K$NR*2+X2'C&O$/-,D%]E1XXI+1I:Z!L3?\J1E, M[5$H0:(ED>E=P1PE2 MI?;^V+.G:N/F@"+0F7`*\I3S>]P]>8_%W=.AZ,UZ<9?_BUFL7HTN%>X4&$8Z M:CH.(&J48P(+E1MZ4.!L*?8NBHM>%=SJ"*;V[`IZ=XUP0"N M&'444J])5&.(V25$,HM0_X7?UPZ\KD50`V+O=XD![^Y.A=C>-4%Y[KRE*JK& MV'KBL.;YZ&820S),T/(J0=:5$(93Z]XNYO]6=Y,5XD1V] MENI2[/VB,;HAKLXNY%(SR>'=W6[PT2'WR"G+@K'$<0`58CK^STJB5(X_,HIQ MZ0UZ>@SN-[U!.Q3*N&(\,P-]Q5KO4<3A:J&R M-PG5P*B[NVMNUN_NW/>;SY/Y??,^'BCOYFVV<*JX6'U.61??)K,CM0KG;!,@ MH@1HDBJ3M'+82TW0SKP2NG]WRQ7%U'ID?`WXO?ZBFXF$/U>T'X#?.=N$J(G$ MK]M)YI5PW'O-?,XE9ISIT@92Y[M=ZIZ2O<"O1\8/![\3L@L.+PQ4.(T%M$Q" MAZW&%O.<$\0E@=I3\G9&0`;Q+EY1;MW4+R=Q_<:>/OP\/7KK#WH)[-\T+^9WRV67S;" M/7Y_GKA#\(YX**W6UA"B`0&I`^^6=H%AZ2"5L3?[[.4B[8?G=5J5;ZY5FMIM9N?9DT,2DQJ)8&8T8')%^6W]0^02SM;2EQ+5NRFW.6-^?ON* MU\Y.5S>SQ>IAV9QH&%ZR=8#$,(F,X!1A[`0V=-=K7C!+2IVX8X]L]68Z5A1& M#>BV;4<^3._GT[OIS62^WI+V<3F9KR9MA5*K-$8N/HT/;\J5FEMX`+D7[APT MH$(0!YBD5G,?]52>G8O"13D-<>'V9PW4@=5KH[FKB:@@T:0-R^7?4ZMGK^$7 MRU1&-_FTV/Q=W2^;9E\/I/+-`L7,6"4$L,PZY86*9GHFDI;W:A][`Z_JH*PF MHBH6;8XG-[?V81E9M7%AMY]36S2_:ON3'`J!G;I%,/$+1%@[102+=`N`W8[1 M$!=;)FD`>?Y-491RUZ/DZ9^MKH-'Y07;!@Z5 M!0QB:SF5%'-,?/9@"2YM_P/-KO?R'D`^-4Y,.TW9#O/;U9/JI&3NQ=^9S@\9 MWH<7!JHQ4\;:U-UCE_LWF\[WA[!XV<;!0V>Y],GSY:1J:Z2R9T-(!P:9B'9E6*TJ MH3J^IW;>0SM1]7:ZCCS:O:U^B!;=^E_-,3_WJ5L$I;5WW%,G(>0XDBT`V-E[ M3_TF%:,G5X;/GF3Q!(G_\>]/Q?`V/K/YYY__=;O^!5MOYY-_NUE\V4@B?3N+ MV?0VI0WO7&ZI!F_Q)>[WN8E?UK?F[6*U>OXZS?=U)"\>I7U;83LGX,:)G(*C M3]]L^Z\GQ!?/VRE8;;5B6@H(B%6&QRM0*@^X,)`[?+R>H+<:BKOI^JDX7B^6 MV#X4$"-*0NV1,%9#+U,N=*9"*':U,:^^A/VR_*&,T]4B.QS?B)P32"2C@$!-8GZ`V*29^YQJHN;H(TQ3=T,"/ M%#73^_EFL.#-CR?!GWBTM'^;;4#4U6=0_H-!4`((!00;`:F/?Q*09,YZ`0=) MJOA]/XIJ@JQB1[^D,;]M_-OLX39Y61?+EI[U>CG]]+!.Y\''Q>LNUD/F=K>_ M%*"&&!&BB=+QU.'4";,[;@B!I6VPQSYZL)8F-*RX!H9^?U`_B5HB8 M`(*GOJ9X)S,F86E1POBGOXP`W#T(:&`PEP$UZ-2(47H,M)%>*2>:[T&\FQM>[5[H!+?+GA4I&HRU1MQ*BR3EU"N6HAK. M13$BY8].*.B'OO?-MV;^T)Q2/OGSH_&29=!09P6TA@AFO<>9(N.%KE;-5G\N M^&4"?M%BZB*^%B2T/$_QFM^^G=ZDDV%^OWV5/0DKQY8%"T@:4>:AT)X#("1B M:O/B%D`M>2U`5$^2*A?AHC?V5LG`F\S26(7V]?ZQ6-PF0_E0@.>5QP.20@%M M@<'2:1NO(8OMEBJD]375<%R,D@[Y6!L='YKEMXCG,P#R9$70CA%K/9/8,`*3 MWZ^M:FEI@\:6UE>,L)UP+Q@I9V6]ZH@GKWL8(Z\]'C@7%F&$E1;86<@L\C)3 M10@J#:*.O3M-9VCI@*DUH)+I/4%+#4X@#9GT7AL@C4!`4K1]>ZR\+(7$V"W* MSB!1R,@J)\;&)IS?MQD\JY.LE[UK0E+9+892$4VY\8!XMJ//J^)!LF./=W1M MQG3%X#K^J]7ZW5VK.GU8S`ZF[3U_,G@*,&#":"&%QIAXBVBFQ:#B-F@C+)CK M0)XOG%"7\+(>+K*Z=!06^<&`L=&.(@>]0E)A2[S(EAF7D5W78\/TA8I"5M91 M.E9-_)W4],7&.W&V:.=9;ND_J(D<6!TSUPN)!-.-S-.)`B;/,I>F23EM%4L4:V-(CE"S. M_!F[R=0]?BYE;56H/.8:G0*6QZ>#B"V&+JB;C^\9BZ^Y_S93.93?^ON9W,;]]O_ZB^1K'<3%MQV>;QSWL"CQ?M M&9R@AF-E(8OWM*/Q.">N)=E+RW7QZ*2QAZD[Q,)B&%'4.-9RDM5QM?NG)X.$ MP@JI-3;)CZ&\(<[MCFCN2X^LTVW^P>:)=`ZL;EA\.(B= M_F`B5 MTDHBA+$%!GKDL^M#0H.NR`'0'Y0Z9?&@:GJ)>AZ2[4&UC=>S0$)+*ATUF3Y' MB\/J8W<(](>GKEA=YZ[;U2!%#FT4O[^:]>=4`)4/V$,N@Y/6!XF-5@9#P(4P MP$;^P:VI8Y74O#2)=.SS=+NV_/I@=GV0O3;J2S=WBV7SI#^Q^QY9%<4\G4^6 M/]Y$_JW.+IGI\5<#C=8-\)9JBC77R&/+FBT1XY*1BV0CNBLDD1NN_[;!PUEEO8#P$L97`,\ MYW:UBOUI-YZB%Q.KK*-@S&*,A8ZC;!&"+"19[G MG%:-.2X>YSW"5-"N05>%X[7+U]NW_[R812FN4L.>=)ELO#//WZM^L\ZV@_3V MS39O=%Z+SOWKHWUM@%"04T>@\MP2++CQ1AM$$/7PJ`W:,^T?DP)U"I'M@T$" MJA74BGBA&;(XVGTJ4X,H*+Y'1NZA[%C4+Z8[7,#C*FFZ^04W!*<&&HMY^J;5 M]^GAB2('U@5G.7+>*XVL3%*$#L'GQ;`!864^XE(`(A3'ST>+;TH.M\L7&\\@AI7_V:^[6Q_%#('UP6%D&""(&VC:BT\E$Z)3"=VO+39X=@K8KN% M3Y=JLIU)+VYS:ZFH]AZ?4'P2&/!L*6``!"_JM3D(%,F?+&7;^R5`]T" MJ1/>5@EUMLPYBI6GCP4*%%?$,6+B%8V(],J23`4P]&CCO5\TPZA;A%S`T4II MCZ\$PX[BY-"R(#S3Z0,0%DN%M464HTQEJB.NELCS*^.F0PY7]?J\C<=AFT)T MBJMG]W#@FB$C)%3.8PPEITIF=UC4]8H[((Y=<^[:OU/*T$JI6L^Z_[^9OW2/ MOH]P]XOE_TZ6AT),9^X4N&.4,$/CA8R!=\X@L#MV&1_&JN\93P5`>)G&U2.3 M*[N"VFC2ZDDP[#2OT(ME@1K.K)7`$BN4`H1!Z[944D=,M9K(K^U`C2CNY;IJ MBD4_D-CO0+I4`G7NOI^9T/%,CFY^("`HB8XW"L.8,4F8@PSNM(;RNJ:S[]BK MQNX@LJKC,HZN]3(B-B]']GBX>B(X@>GBLP M(9%3"'%',(1$`\M-Q0],8*[JG?J5X\@([4P@&65OCFZ:Z!P5=_>+\EM1V/FJ MN-X*^P>XY4P3D.0JGK.XA!A]>.[>;F,']NU.P-Q+\<'#`3' MTL+4;E%IRYR0OJ*;N^SRN>U3&'\6P)W%]ZX]M=W/;\O5KOE6H3ZMBNU#1(Z_ M=G"R`+$CW''C!.),>*R5)O6F(MDM)S*2&U\]N@:30L?^6D=(.SY74-@I(QW@ MB"!#+&;(5"_L6OCLN_*)YD".ZJ]U)831O39UO;N2?-YS]53'[?D<`4)(/872 M8H&-%8RB>I\9@'!VSY2I1T5,PI,[0Q)C.W/G`?&'*0("2`N*F5`*6:I$/*-7 MX8PZGJ5L+@Y_O8CT*HBN?;SG2REO]S]<[L-;-Q,'R2T7Q`FAH'58`,9.FYQE1Y=,9XG5OA$[9_JGA9JN?JU8.R7PED*,-G#]71.UV^V`3S!GW7 M:FS4Y])PJ)3WRD%.*1*J=BN8(-DJ[:Q7B->)GKZ8/H36LO,O\YMB>;-^%OB6 MPB'B[YDOCSVP'A\8%("(6T0E3AU',0/0/WFM#N76JX.Y-0TO1T=UROA!\G]. M+'6(N;&48"\E]!Y;Z)VI*?`P/V3ZK'>#"W+YLUD]!%@.Y42FY?Y1;-[=7LV^ M'H%1F^'!1^LM/4;>:N&UDT[!ZGG$J,B\7("=]4YP00#K00BO-6;?,JT9-M`* MC0%SW,7#RB.5J9ZQRXU[/OG18!?X[);#UM4$%!FOLE%0G<44?553L^6UP_;HH++**S-EI9X%+I[T22N M9>&\O6?B8_,?*8/7=FA0&E!.)81`,<@59_%,+Z17!$3A(M4(^&/J8EU<_]>G M\LM_WQ3SI"E(^D.BD#Q3$/%']4*OXN_80\OWGX3HKV%/&<-062^%A4Z1:LV8 M@-RBS5,M&M2]+,M.&-O>;K0%@HHKN4FK\8O9/N_CAV^"`80*IIF46'"NB754 M5BM6TN>>N*?Z8--E!V*VV/EV?=!,`J!]%+&]7.CK>*HUHLPXC\3 M+5/-F!D0+?E<[AXO5ZM9.H]\^';WL5P:W](J+U6SQ)I[QO_ZC^'84(=]]&Z`@"'KN"<%4 M2**XU*H^>,4#629$IOKX,P!$SN-P]Q@Q#ZO5"[_H^(GFT.=!2JX.GGQ9<#QQ&X?>\W(V7BM&SF=P;_;FM)>[=@,#D@H)::V-P+=8*<98[6Q! MJ;+!\U->KG;.[[Y>,?QLOMI&/_]>S-8/J^)%Q^Q!^_[4*[%1*R_*M)AUBW8_ MQX8%C],;*,;"*ZY!*F/FT(['0%O4[%T-1^E5Y+*.O^[O$TFMQP5FHH6RJ;4B M3A!R0$E8T0H4S*WK.=7MVZW\R_XX/>C.?2KR]$R3V50Z>W$YNQH28PCCT&'B MJ>54:6PUB+I4`4L(:`P([YE2M5X7F]1)[>U\]G&^B/(HUH\RNGFW?%]<1^U_>KL=P3DE4XU'2T0SL;#LY0,53R$F.16')]@TF4W M4#JD(`86Q!`1.S5M^MN6.K.8K9M:BAT)0Z@\4PJ#HFS'K3W\V3+DKV7Y<5VLOB2^O%G>/VQ2W<'E=>3J%A'/"6WL M7=;7KPP"*Z@PBWX[]S:%2W`)*NX*`W+O>:>,\7R$'=>D8PEE",CO0MX^)+H> M=4)#[X?]`P)3VA/@E:"&"('_S(M57,WG^,]^OIQ%NS9;[.B]^CS; MJ%4UTXW:U&.^MY"7=@4DB/-"I&Z!G!NE$)"0;Z_@(,?IEO[7%5"SX6!,&8NT MT)&7"H.X)S2J>.@,N-0.O-W@JK?[H-.D,O!]T(\Z::MJVU\.'9D@$$&I@TP* MB*+7C*)70UQ%.8RZ^]+Q.!QT#E\;=2>?09'YW);^2$+[BZ$V\P0/:`IR-XPR M"YQ0GFA9\<%H/\IMSY`X[0@EAT#8@PP&Q>+V`F+GBL+&&YXCHX*PVCH$'+=2 M$LNA54Y4-"(E+]X^=PN$0W`[F_%C@0ME@>MQ5,#08$(L!-XQI"E.?*QH]/%O M8]RT7#2X\A@_%KAP%K@>1P6"G`;,:26(AHAI8P6N:+2"YUY0GY5_=VEXRN/U MZWL_IAQ!0R-!6F+KH:+NB3[C;6Z@PJM15%,X%9PEDE^/R:<]36&A%4/&`"., M@UZE2D$5=P7!V:7D7@O@\^$VU,OR:1(:`O]_??BM_%*LELG\V.+CYH0WYJ:A M@1!/K!'0"\8A,)([H!ZIM_LZB*7C`P(Q4"#$-4W>CP>6 M0571;H'@N>9URF>3L>'3J41^!<\<>D0'#@`AK`"(2ZDT$=I7-Z_6*),;/#/5 MJC<3/"F-(,8AML..K#WOIBU>\1O'!DYLLATDNO44<4,8MJ2B%ULX2B;"*X%M M!FB^[Q#?L7A&A6,.#(/T%F$',""0$J.B20-(@"Y[7;)2U#9"WRTPB0.N22GI0,VW*J M`#CPT,=SS.Q+^*#:C[/TC2SK)SSIIGBAW80GR$$=I:P*C3-1C'8OH/FC9 M6,IN1%ZTT0VG313]?N&L%\(YH26F&D$M*FY`8D;)IQE`,_0$F7)`68RC*":7 M9#^.$B$,"0%I]!$5]AQ;Y1BN=+IPJG';],N+-W?WT4@5-^KZ^N'N89&:(NU^ ME+R]ANX\K><(A@DN,++<4JJ0HLXX7_'``Y5;ONVR5$=KH!Q0'5V+89!#ZEUJ M:/!_6\&^N_V>2<=.JD<'!L>,$<(SS6PJD0H`I::F%(-+*WL^+.`ZY?TXMNG# M]>?BYF%1O+LUG^._%>LW2S-;K;ZE&Z1M&M2[VVJ"G\]B<:Z!X11PA#!AGC-E MO"6,I%(?6+G&B-I^>?&LPTH+BI_W8X&.B.0O,82$@<("*>PC75`C<4'%7'J2 M]P'#D\_C(4Q,M(@:Y551Z1KCR1$!6K=YY.=@19]?+P;"W)/2!.,N^@!/ M)TR=FE%"+/KEJ4Z*15A1+ZQ0N%H]0BXWX?/D]BLC=-SKQ22=QL^QSR<_^&\_ MW7'$AX-$;1]6AOK;[[-_EZM6F:CM9PF0.TX94,+R M:)J!A53(^IT!T$O-2QG`_O0GA9&1^+3VU,"L.$LB?.#X$M\[#>E'?%ZGVQNZ5PA$I5:PQ=UL]74@&:@;!S)HLSDGY-^:58ID:OY>:J-.7=?;$Y?-X[ M/B`NEJ4F+P1)YX"RW"O$JL5:+',#),YJ]/XZ\=`IHX=Q>J+MO"[6Z_=1A*D8 MDUK>V%1`J;Q/;V@M_)\6XX/QF$$#$43:4(P]):2^;4F]9S,!-M7>\,.[0MT+ M8>2#X-LV^>$MAD=?T&*/-?-.4^D1<0RKBNKXWR@%#2[^$B*7_>."[J]U#N_/5I@O,7PP$EJ,V$XC51C1AAD$M144S-*D:K!55P&"%HC+)O7(ZNUWU;' M4RN:A@9C,74H&0D:#R-6&@M@12TF(-=UG_J=ZD@PRV+ZR!![E@;R/&`_#W0' M)@M44:`)WR@=B-($:&YK,LXM-@&`<& MAR3QP`.DG0!"46Z>-$S(U8F&*)QH^)) MXM>%NMU#@[$O@?1EFMXLXQ^+J]G7D2Q0_?M/LC='1D5_4AG,B3+.4V6UQ8CM MXI8`]![QD:S+GA6WV>G'A@4#`.7,I&J&4=UA;0T3%:4*HUQ_FA(B#8LVC08_5P(".((QE-211WD:)3(OI[53:9X&]&2Q=$A\!(75JPW\VN3 MJL*LF@-!]WX?L+3&.,TQ%SI%O/UL7--CYTN=Y*Y&CX[K$AP4/JA`:84>,5 M%2H:R=H?D[ZY5,)%X>)4(9:],'D(U^,P#]ZV")]L,3HP#ZVA!'C@A6$I_\O7 M[I9!*M$L=H@3IA$R`JH5%2V MU=*X);D/7U/5++U(K>R.P>[KLARWW!.]DXO>Q-]/H@U2V?A\147.NSMF`MH/1R0"!&4J.P<8!Q`9G` M#M5&'2.1V]UJ@HEO0^#G+.:.ZR]GN MUM8GECKC]L!JJ`I2^FKBW^>;%RNOLO+:Z:C,YVX8V'AP6B=+KUE``J0"R+ZDF:.I9/8G])+\\=R/N' M0(7.6-O[UGQ>,[I:]:C1C%UOVE3YWS..'!;68Z2U1[L$=:`T`[:Q!'+/=#[> MR#3%,.[]/@BI#:$^`@A`YY5VVHN*-I??E?Z5;=/6$CZT3<_@Z1`'A3\?/B[F MUW]M'H_&];(;HA:/#0M20:QE:HJA1-1P\4^85U1:@D8I#-XS"^*AD+;F!K@DW=*E_,I^ MV)N!B'^6J[_KHE!'<;#GRZ`P@AQ;Z2SW@!DJ!&'5\KAAH]08>572/Y^I&3)/ M69/K33R?')7W=U\%Q7A<&-96,6PM`5Q!5"T+`9:;`3'!`(^>9'T>0S/D[(OB MYJB(GSX(:=D(:4DT=9Y(:Z2H?21F_Y^\:VMN&U?2_V@7]\LCKE/9\HE3R9RI M4_N"XLA,HEI;])'ES/C?+V"+]$T2)?`BFJ=J4M$H`(7^NMG=:#2Z^8P*.P[$ MW6PLQ[G2LB7RXHALK_>#@];0.\(!(=8)9QC0VC2B2K-OS4U0S_>[@^@,Y:C" MT59R[/7`X#75V#H*HPX3VAOPXBWQ6)[E6O3`0I'!QGT2D8/AX`'",Y;(Z3\8 M:+@U)-I5PHFA\6\+Y;:**;+$ZE;Y'(;.'3'8EZKFM+(DAQ\1$-<,Q0T$BS;, M@JBI/`8-`D+.Z-)J+W*PM]A(KS`/^1)OVYE^6OU/M5QM_HB?(Q#G>9_=O^^7 MJ6>:2W`9IHO"5O#92/BL=I MYWC'/R0@A[UF%$!@`":0&P]`C0(%?*Y%2P83EFHD3HRO'B97Y>1\JD-%#IFT MXZ/6I0XP49E+AZ7F3@AK?*O!/"X(^\JN[.3)OA/"4Z8'#ADG$ACID;#4$,2Y MWQ+CJ#K/C?():H"C>5X-SH-1[FQ4JY1>%!<9/]TMK\JGG"+]&/]H.65LG1NX M!"#E33"**'=>"\KT$[T24-2>-3-]CW,8]K^]NM$ST&<4K*-.'UOG!AZ]=\H5 M--@I#;$S`M,MO1!:=98:G\/HKQYY?YQ49:.<$9+^YVTD^$"SF'=C`HSJF%)/ M(9222$61I;)>DC,@-S#]<1B?PYZJ'S1'R5I85U?WB\WE^ENY_K5/A2 MK#?QPV';>6A*,*GK`\)4"\"Y$!$&Y^L%4TASLP`G:#;[XEPU"+(Y-T=_%?]J M*2?VI-[5VSJE0<'X'L'6',2OS]=WO[<_"RN M;Y:+P]G>[P8A0(G5Z\50@8!2&KEX<(#HWICM5KV1`GG<&=PP/0Q?7Q6I1 M?OM9EIN+Q,S$ML-.[[XI@6-B*;/1^6>.*2P!,G6XB2B?+3H3RBH=Q8?M"=]S M24^K;[I_4M!0>TP8,P0(@+!1C#<4,MG>P^SC^!;=F7R$U&2AFN-7;'Z6:[58 MK.\COL^5?@X[&H?F!"$I`L+&'U'*6B.(8L\F4I^G"<]X@G`JWZIA8,W:;+Q0 MB>K[]_CSQ:9%$@[."9H#(;E0%#%MF;#:N[AD']TDPJ4'N2IA0M'^@22A3UC' ML"5?R\/DO+;[)\0\)@`D"X\;*`6+BGEXQ+%6- MJ8Q@9PK65(MTC>*Z#`;_V`+8ZL2\'QRP4@9Z0ZSDBCIEK&JV=13$/=Y,@VI# M\/R`6&6!/=;%FKO(T=9.'Z\'!BVI%1:"I(R=90`+7F\M*7?F+&G[(XO-J3S= M<Z&L\L@3O688S3I M&P;_#+/Z\M>>[SR9XG:YB7]5J\UZ^>?]XT;%5#.]%9$V MZ:*&EY$^!6H?E&EMR8O6P1]0.3PK"Z52)#%"".1%&60GKNP@<695;^*W3%O0#BE"O*'<5 MC<_5)DLZ=LT+"`/L!<;.,\.,L,0U^QE.$L\5TH@S+[W0%-9YXYRQ[$"7^$_UFOK%>ZA:!1?+1>HJI7ZLR_*E,W1D M%8(]10]?/_-`]8!#PP.DVGHLN:;44N.9@L[7Q5XT%2>7&#]JL8=J@QP<'PSG MW%!K?>0C$E9*"WB]7$C46?*Z^W]GNG.KZA_,L=Z.'NMW#/KF(,21MH@;`+17 MW`O.X1-Z3&J%3BZNT5.GKY0>\^R,W[45Y]\Y/@#J();6`H=@-,).$T9KVIA1 M,^BAT0]KW_;PZ@',41(!4OR^+=&D'A.T)IP)96HZ"&-GN2XU81GH@-T<\U%EN@I&A.+1E,9-#/%4N1H! M)6ENQZ<)2D_/?L10$'^$G%//!')&.$8H5=!*A5U#D2=N1FW"AF!S>YKI:?AF M1.3_=UG=_BS6^TW-^T'!*D>%L,`BCSUP+!6&JA>%DPLQ44^@C7I M#],SRDVK)3DX+SALC0-:I=;54`G(.1$UG=++W)LQ$]0OO7#[.`G*PG8<%^2I M<;E:7=GR5WE=W3Z60OG[-@7_VF,@[;.#BYK9(*D]\0H089!"N*&9SJFH8T^\ M?^>7](WQ&'+U5B]?'-&,:.^<0#S06!BB$#(($00$:-Y&@%6NSS.AV@+#V+.^ M$,VY)I.ZGWVZN[LOK^S]>KGZ\:5<+ZNK;]$3*^^>OO]>K?>=_KZ],)/UL&"H M4X@[PX6!R'O/,$4UD8[#L]S)&T=L,AA=C0QWADQMTXLOOV]_VI?EOBM6NX:& ME.5@H];E&"GH&(51(S<+=`C/-\C231YZ`#.#VVJUNB^N_?WJZE4*Y>_E^F8/ MTP_,B'1C"[0UD5I!J2$F.GB-B;3\+)6-/@+O^\.T/Q$XC?V!$.X$5TK2^,E@ MQ!'3]3(MS#8#'\![&(3U)^(Y7&K,JKR[_&XB^LM4CO:B6OU(4FG+/T]-(NO' MY4T_?%)#N]T3@K$&"\&@Y-A$0EX[*L[4T^KU8H]I8+5G1I!46HV$ M!EH[QP0`@-.:/J:R&XQ.T"OKRN!J"$#/\3ZF].5JE312]"%>?'_.SE-]O:Y2 MT&YA@!FO0:;K:OX1'MH'8-#TP:3;VS!`F!F`*2 M.EQ3106800>H7GA:]0[E.02D]5AA]X1`*=;1411>*^2TLK#.$TLP43RCQK3= M&-LB)5EHCB$GGZM->?>E>$COQ./^8_MY?]F_(V<&Y:T4#D0/!D47AZNXSVAH M55$OSU=R3F5V-22P&?OVK]5#<;UY^+.X*Z_\3#)X<",`+&#RD0] M*ZFP``F@+*B7:]AY"I%/6@[Z!32#_X]"]]+1;R\&^WYT8-RB^,>GFS=.N>B/ MP<8!`YKG]AJ88,BN1[[W`^88AN.U3W7,`>&>&4%)''UTIB%7'EG%M?:PIHUC M.8.><$/XH?V@.98K^C:TM\?05((!"&P,VXA]#;TO%JEW MP4-;X'KOG(`X4,HACBB(E!+D#6(UC0B:&04/NC+Y[;O;$Z1C:/K7JVP)8;\? M'`BA<1]EO(BJC9*H[;#"#474S4A(>N#JVP[S7>$<7T!:0]B[A@>D4XJ+(9PZ MYJB%#BM74\4(F]%Y=1>6'I2.+"3'27__55W_2NDMK]9[1.+[@7F!&2:(<*$L_?Y!6=@S.F#GH/"6 M6*N9$0QS`V"]S`3#O`U+9R'H!];C31G<<^^?^ MTU+VN@QOAP0,591*#33!!D;CR#VD]7H%-KDGZ1.R!)VX5/4"6X:*?RQE%^OFER_,04[O'1^4DZE?8B27*!3WU>GR5>-V.)@;6YB0/>^%U7T!.,:F M\(]BO4RFZ6MT,5KB!V^'!JDH9)(:RS1"J6T3LKJF1CF8N^F;X-VV_N,&'<$< M6S1:(P3O!P?-I154(4T]((1RHGD##35Z1L4W\IEY0"JR4!PIQ>&J6CUVU_HS M;DHNOT=>E%=IR1>?].77UOCU4?.#,@!`I84&TBC@C8T[W)IN"=`,W(H^F/X^ M]Z%W:,\6FCPB*?/@O"`1CX8;66F\T0A";T43M=?QOTP1FE#WJ7'CVKG(GDN" MMG5>=;5>5W^EHYWB-O[+9E>KH9S'!&V`HD`0Z!W$$0NKV#.VBL\]QGFZ-!PA M8SV!/7X.N2[NEG??(N.*J\O52Y4.#XC;L8\(4>U#H06D7$,GK!&`JL8@0#>G M:RB#B-I`0(\O9G53T[3:Q[CPU7-;W?3=4WWLIR+G1PO>*0\-BBO]>+R.,100 M68Y5X]LZ2'-K-'Z0.&[?HC@@].X! MQ`?9!O0K,2>".2W[V(L]#)H"Q0V(&"@-TDU(`IZ5,!:YV5(3:D@[%?MW(M1G MN;/QXO-LKVPX;7SDU?&'E%EZ#0P/TJ5(= M>'I,E:'3H/Q(58:LE1Y29#R`,EU39$+8FC(KU9SB@)T8>UR5H=/0'+O*T.]5 M2L0[K;[0JSG!IBV591(2@HC2@@/>T$YQB)'@X\>D.;$8>5K^%J8PP&EJ-*.7:QZV8$-O* M*W&YE-E<.9AB&+8?.>@7T*ED50LC35RP<="H:(@9?;RC]K1JS'1N??$)JH,^ M'-3N")X_GQI1:3Q.NHERR9%E!NMZO=KI&=2T[,2E??G4I\%VQGQJP+31SGC# M,!#,`2ME(],T$CX/_N;QYIA\ZM/P.V\^-4?26\,IB%ZJ98X+PQNZ/9U![;A> M6-T7@#GWX/Y]7^CJ?G7@6OZN82'Z(YY8@'VJ6604`M@T0NB,F4''EUXXVQ&W MCW;1WA$2=Q@(8PL44=@:"TQ-'>0X=^L_(:D8))K8#YP?_8J]TT0)P%-%1`J! MXXS*YOWBB,SHM*([PT^]8G\:MF>[3PTI`2ZMT0"*D34R';INEREY=E'`#R(" M>1P[XC[U:;!F;G]7Z4,F?XR<'&+V?Q^`G]E&Y M:BNL:L[R#,C>%D[(EQQ4-@9!.4=1;*Z+Z%4M3+$JKHK+V]MJO;E?+3?+\D[] M*%>+%C_TN-DANLH,:&F-0%QI"IVUJ(F=,3RGZN:#*))!8![#07E,)VUQ7YLQ M05/CE61I*\VE8IP0)9^#+CQW?SK!7,L^_=5<_$;C?WN%N>=102IE"'&8$R"- ML-;ZNM5J-([*SNAP.X-ONSB?A=L8O-]FD;=R_]6X(`7SG$?5Q;E/J9],H.8M M`&YV_#^5>U5_V(TB`T_7J]IEX.6XD,H+$2=`M&8&QC\"H\;K40+/J&A]+S+0 M`;OQ$Z8O.O0^$:FRLY9&"82DPTIPT.A)E"\7$\RL[],_Z`?-L1+D3NU](I&" MVL-4@14(([@'B#;RKHR;C[WHS,=#O4].@W%\M?%T26BY^%(\[.F*?M2\0!6B M%B$E/%->.(*8\\U+%-^M^9B6OL6E3USG>$\'4,@]5DY@AB6$2,57JC'?4.9* MU@1C',-*5H\@GUU-?5DO5XOE;7&=JZ^:!P3JX[:0$PN(IUP!Y#QICIZIR[9S MDX^-#*RX<@'..I-))\_J5[&\3O[E\Z7IW$1SQ"PWZI?Y7KU M>(SP5[&^,M?%\N9)W/?(S_X)P7G&K+*&T=3>?E]FW&L?JS+\NKW2I=?BN4^]A^8$1@AB+/4.TES&`FGE#5'"<#H M_V?OVKK;MI7U7\+]\HAK3]9*DZPF;<]^XE(M.M:I(KFBE,3[UY^A+-)R:NL" M7J6V#TUBDR#PS0?,`#.823V&D]?$\<72]K!Y7`$+E"/M[V5-'D\1UY?U\&?$3QGGLU2PZ M(;%#7G@9$;;!E`EJ=B.V&J4>-X[4[]%$Y']SE[:*;-]^L:?N_Y+?/YYAP4#J M8ZQ?\C+*#$0)LQXPF\S_DT^.),=NU'1FJ,1>Q("0M)%[2AVC%5K")!>8'R$/ MVR/.`4=<#S(8&6/?+,HQ?/JV;(>E=7,9%M1%PSGFRMO@D;5,UPN$O*:KRF-@ M9BKNXV0C?/U@*?:D!C-FL1'1(&%4J;BDA7'P\@$X,=)R-G75M?(LKW, M:>-%\-YA);23)L)>NL*%A7A%(7XC(N3YP"<+7?6D8QUAAY8PA5"`G* MM635,)5/+LPR0F?IT-1J`'M#=GU:KB?S\/UFOIG.%I]?3.QU`JM.:"6+/A(6 MB.:1:6:8U,35^R>EDUWOY_M;R[Y>-IO:AWN(@_QM^/]EG\]S1HFUW"G.E1+4 M6%6=4"$<'#E:NK.;T3UY2)X[F8I/`*^%;_YY8*3'7\XMTYK*L,>4RX%"B6JQ`9$D*^! MULDG2R,\Z^R,:9T@W96Z^#E??0:HGSNHAU$1+T2!%"KV3:!T=9X&&!5.)DEKQH"G8`_OF0[!`LF5(#--97:2<2,MU7_*8SL>K1( M=Z)]-1//>>".,Q./L#AB&B77L,VB2C!'434&C]D@JTLW!$F0VX%,/.?A-N), M/#R"084U(Y@+';713E3C<(*G5CX=J_S/E=[A3#QG83?>3#R$(!L5(\P:;8*) M,*H:#2R2;XF.\%RA%0XTP*[/"SY["N^(N?#*&QGV3`5"I%126:N91=148^-2 MI%Z::<2+'BS/WBR)=G`?BE./%WV.U[<[^FYF/84IIYVS92)F$KS!M3Y6W*;R M[%)V.,GB/X%.38!.\*6^_SY;YS=O9U_@C^G!I+(O/`EVF9/1&:]T614\!!IJ M?8J)D%=4Q*Y%42W;Q#1%Y'].%I//D\7'^[R\]KI^B*O-;%V\61RN5'/LM8Q$ M26E@)L(4$-!5NRW9_-AQ3'EJ9OH1&B4=D:%=@).N6JZ7/^6+V?^^^^UP?ND? MG\NTX89YZ(U0DBBL`JY-,QQ(2$T1/,(0ZFYDWQ31!&&W5:B*UD,+BHE2&2<&$4$%496X]0N/2?'R#G6 MBNA/HU,2T+V$_N5S:/-SJ557DWD9G#'],EO,2I?T>O8U#]_O\T5Q0C'VL]K) ML'(N$@OZ6AH1O$(,DPH'[^@5I8!HB0\_NOP[1+L/UI4YDR;%W?O5A\EJO?O' M\_7]U\7LKTWN\^)F-;L_084FMI@9'KES2`@J@S:!:0)61+6#$.AH^I4NMF;7 MI%[[DK&"@;PA%F`+UC]=T.8^> MR0))V&5^`#!F1;%?S33TRBL=M':PVL,^*GA7;X>"N]:@N@YD MN&P7ZH&\F6]/*%ASZ+6,*L,9T]R3Z*PB8$6$>G]=GKD,<69U3AI+V5MQWZ_YZH_E MP.=J"7PY3L+VA3`0/0/\;?U0=_Y-46SRZ?M5^6W'.X!_]]OS MZ)KP@0SP01PTD6(2U(8%L&R%'(V!IIIV9SN!KY:^W0NE#SKORGP4GY:[.5>- M-"]^6BV+0TK]V*N98410PD*44D>/B`;]58T6&]9;5>/KH&#+<"?L'5X8E@-3 M9092VOIU%9I%FDBC*/>8*,2\K-R8M]X57[=3OE7SZ:0(!8CCV^EL;O*5C)>9^J+SP9:U,Y&.(LC:VN$D5?^/,*-8 M'[SM410-&+IWY[2<4,\FVYDT/*>IC!$;),*,.4TE5E%97P\0.9+J81EABK'. MN-8AWBT1ZE"/DG5W\P]D,C()=@U1#CD3%*/2Z0H,YWWJ+;`15H#JA7R]2*'/ MLZ+7!K=G?>`76)K23":IP#1ZCI7G&A;](&3EHV(6YF8B%QN5:[K4+7>'P`]$ MOSUX?LGG9?%@MRQ>W(Z?WTAF!&*"VA`T%2@BXA&M$2`X_<2\4=&E*^)>.[CW MP;SJ_#[.%K-U_G;V-9^"X3I9?)[5U?[V`(YBM,IL_YKT5^NYF_G=T> M2@#3I-E,"1:D$03C4-:59"C8ZB"BO,F3:B'B$8:#=4+('L$?F6[>J[CWYK$* MWRG^F[2&,X,X966*/B%X5#*B,I?>#JD(-G8J31LZ;BZ(J+T*H-L#RQ?Z5_F5 M=NZ`,O?G9#YOZ5#]O.]E6`-*7"(5O7'!18&1K&>U4R2(&*R9*5U[7%UPH'D.L>D]92-V_X&OWVS0$LA=?\VIY M.UN_/>)5KA_*/)?:E/UFCCIM`8Q8':LS1=+3]YWM^+A859@,9@<'=GL+VF2Q MK6>\7*P!H/E>X$_B4=TI36?!!.&U8$J4>>NI"`;5)BBW/-G^/]L=<7%L&D@$ MK7&P#"T#S)[U]['D[U-,Q:-WY7^69G*B__J:Z+WD0QW"[UI0%61N*#>RP3?_8.]91&,QHXD["5CV59<:,0 M4:*ZY,4\9:FI9?"UNSIZASYA\2P_OYS/IH^?ATY^NILL?K^#-?SA_;=%/OVX M^0.Z-YNL'CYL`2Q_N"KN9O?5^N[NRAR!Q8?-ZN9N4N3+V^H7?^S>*-V*'Y:K MLOU7UM9>^U"F+&<&@221IX1:9:D/@4:EG$4*F>0,GHV<)1?`YK%+J@WRK]L> MSGX@*< M0(Y'2G[<&B@@@GSZ:0D6]C9D`PQK,&H^3;[#[[=/O4*5/+LC*2UF6"'PZ M-H??;;[DTVNK^!*(%)I+)0(77IK@D5%>":=HL*`2!J\:V'_%EX",B=1CQ3RL M>%@3S^@.$1W2YI@JOIS,DJ857\X#?Z#+FHD)W0W86(%HP;CV"%2ICMQ7 M8V-*7FORJNXX<&)"]_-P'XI3[25TCRXPXYBUPGN':*`20N;&SJIFP M_W:,U@Z\?=+GPWRR.)Z,^V\/9V!&(Q0C,<$S:S@/1-6+-#=^D)*HO2Q#C47\ M"FF2L>V3+4])4D[FS(^O9!(YK#`'[1R5!?N<85SOS3W5@RBP2R-+0U![IC.9GTZ7O<PV(QC@Q8W$^LF&2Z;*"'?$'5(E'="!SMAKA_=YQ^M[ M?G*M8-,`X\&.:Q:$\K+6WYK1U#3#5U?BID4/3BKX`T56_Y+?+#\O9O_-IV^F M@"S,MTE]M?E@7,$N=5@94_YU,G_E*F8_'\X\BA1Y8V/$(#\&TYK5DQE'G!K$ M-W83K!WV'8_6'DY4%SSZ:X.)#R_G?F/OQO"RC_4GTP89VB0B/#R M!BTHT*AKN;#TY(07EXQZ!).E*Z%=VF3ZL%K>YV#TE4Z>]>YLX/[+V7?WV_]^ M%AR)F#/F@J=,2:7!+NXA!LCF!QM".C2 M)D2O,V"'*"+.(EA+"+54$1:MU;9"%+F0&JZ0D!5]N9[,_]4.S>1S:8S?[;7V M?W%SL]PL8.,U>3AR^[K7?F0QAB`(,;*\G"6THX'P6@[$I];K:Y:?_=]YTK[H MQN&N>SZ:MD[1JB M(2;?1K_TZK[C<.MU)J:8U0$I2W`4L,9(IF.]Y3,VO0[( MV`,!+U#/I`BL/^TR>3G%T",#=FG8VU4>IWPQ"YAB&4A$EE%-N>!>U&?F5"0G MR;J\!/K]*8,.Y')I:WTUVD^3[WN_?#I>Z&G1/]:-+`A!'TU(0HXI#Q,/=<=7>ZS.N77*OF_&N\_]S%L&4A[4V`?BM'O%;(\MK*16BE MZ3::3[B(G>0V6[2@DT8+D([$69X40K"@S53%B+*T0\3Z\P M?"%JKQE+&I>+.`O\@=(.)9:+0-S"J/PVM8>13"-)1#6V2$SR*>/(B=4=!TXL M%W$>[D-QJKUR$8Q'IRT6#N'`F#04(*S'*T)J//W8>=98_&>7BS@/Z(1SZ(;E M(J1TU`0.&POBN6`"4U,OVC(,DJFU/]$GBNI8N8BS,$T1>4?E(B1AR'H3R^@H M8UC`6-JZXY0E'Q3]8\C0+L`)S$@O%\$Q+JN!PM+''0\X0/]TU34I;>I)SF4D M^&E!]DT131!V6^4B`F&@\I@1T#7BB10FQ*JCCN#4H/#+B/MK0?0M`9O`@/1R M$70;#\4I0@A':6G$]3B)=S\6A>\G! M;UOX=R3)TYP%R(-CE@?@O48[(;*9*2$6S3$-NR:E&.+X/=!L0^3AS)E4_%I MN3-3J_[GQ4^K97&(9L=>S23E41J)B1+PAZ"1(E:-UAF7FL_Z[+5K7%>!3^;` MLE.X!PKJ>,VC728/6S^\6<"RD!?KXDU1;+8Q3>5?SD\&D?J5#&')RXHE5!#L M(Z4>-E,5AM'S00XH+Y6PP\EE9-S>"T%Y\WB#;-H.G5]H.(M(1>%IF3O,6^0\ M*2LX[)#23J7Z6\[6[\\7W>ND;7/\1\94W`XO<>:L"0RKLE""DI%8$L3_LW>M MO6WDR/8?W>7[\9'/NP-DQ\8FBP7V"Z&1V[:PMMHKR9EX?_TE9;4B/Z26V$\I M%QA,'*?9S3IU2!:+Q:K*EL;6L=P['XT\OK_`/'HJ\`/1;P>>J]LO\=]2YD,( MP'6QF$:4TWZOG*\B[K$S=]6JL`V+.XVCS;X5B,2(<<0)MQ9)CRAUN,*3.?:K M9#)OD;N]*J2=:W?[AMMD?O-Y=_>X>-IX=5#8`L>`T=H`K@"F4%='O%ACG1L9 M>&Y7I4]EY$#X]QLZ?+TH?;EXG/@HW3Q%"/PVOTU_3_]X:3'#B'($B;/*`JV, M@AJBZBXZ,J*^QD1O+KM**3NZB-1:%,E@C,3Z61MU61=%W/SE@0AA@3$&0D,X M-LIR6EU[2R;#+QE7?#23ZEU]W:KCO"*-)2:68@$\0,@KA94&58U?9./$>>%4 MZX,51\8>GZ:)\X\]AHX*;:A#P$HCL5.SWEOCN?AF7>:^D^./3X-Z)QP MP_2;STYL#@&;20N2 M18L#K8*(>XEHRF/G$;8,4D=)=5,:::-SS]K/,CHYEQ;MX=O',O0U*JM("^^V M^OQA4^?3YP.R'`+C(EHJ+MB80`[A5BZ,?Z%#H[X,G3;TT`N_-MW[QWR9(O9O M9\5-K7FSMTUP``!FO$E5*SF(`PC!+5K\>SL6K?QUPTP76@?=31FE5EI%I0+!D=_F6L)8J%Q[>^PQ9^/R!'2NMX'XOG5Z[T]L?D+K(+@4 M$6:!/;986A/7%K"5F60?KXQ][NR9,/5T;:B8/LCXVWQ:/A9?RN721SQ-.5_- MYL\1F:NGS7G24A<1NN+UN6^3'\72_5@M)I$2L[A0O:PQ._H`L8>O!L*X`PIY M:Z!F"@H:=WH5QES8W+"-2][)-"?_>!3:DTU[.UM]J0DMWCX4D.362$Z%]3I: M<)(JZK8V%P&YMNPEVP[-*9F-?R^7MHK5SR&C5JO%[(_G5;*6OI4G3Z8GORL@ M@K2WB#D>]P)($"7-=@^@".\N$LYJ;_]2K3L6EM#6[!OY,NT M8]^\(P"OK&>&<:PAB]M50LS6:-*:Y[J,SO`6]DBLV2;JZ3>6Z-N;\@AG'RY$ MF$RE("56SBI/C$WY3[TTD!'.#*D="5TYB(=+,2@$7=AOY.M,=!XZ, M[#D-]_./[#&(80`(4A1@##5WBLFMO.IB4R@T5O_)D3VG`=U[5D%A*/=0".61 M(]%LLI80Y35BG&HZ4';)H4(UCE9535;!TS`=459!:KD6QJ<$6$@(ZA7PH@*` MR.S+9F<9MY-%AG8![C6K(,1&"PL89-9)2(D'R&P75-[?===SU7U31`?,*JA] MNA`.-*4&`A2-*8"VMI0QLGM/W)FKOB5@>\TJZ(#3EG-($%56Q,F'BZV<'F>? M!IRA/ZL%`C2%=SSQW-8B9ZV$&$CM`*)8TZK;BNM<`^`\KD2VL0BTBN]HXKD] M$=;;:+=$.GN`O4165=WF2N=N%L^CGFI+M&@/WW--F(:Y-@A3@N(J2`F$-$)8 M22E8=B+;$>XNAO1FY>+=3Q3W\;@4/U8Z]N+?+3GJJ]<%RQQ3G`!BM)(8:TL= M?$6%0BFR67B&CJ\,IC3PW&^VG3@B$F)? MDR"\`-YB;P#QT73CRCHOHM%&(/`I!F68*(CWW3UF+.]M$X`3Q!G#%28**^D, MU60KHV27FC*[N<[+;A#N:6R:\O'I^?45T;";+&?3N-S9V_<>"?X^C^C4<.$X&C^7\ZRK.5O?E0]3J\E6F M>NYEOC%0HG1*3LP@BS:SLTQI76&#??9!Y+EQL3%U#H9\=Z6.WJEZ+`&#!E9A MH2DD`%O*'(B6<"4'XQ=[Y[]SM1^BV8F@]T&>?Q:SN_LTGKX7B\E=\?MS;5<3>8W*8R]?H([]55!1MD-YU;'8AB:E3L2O$,NDYO[7Q@4Y=Y`AS2#0!(7T:"T0@91,$B^MVY(V1UI3F!G M:YKH@Z,UPSA_%Q*P<9YZXS0'P"G$J?6FDM5YPB_G8+`WUK4+>4^.A^MRE=SM MDX>'EW4_9]^+K^E:V=K)[GY,'YYOBIOUU>[)P_3Y8>.AN%27!*?>.*.?H.FAW*0:S5]^S2.)=3><[$!--''PM90+/WR^0MJ+H!U^-7@K#440BJM MLR[B';=?ML)803S(7K?K2)M^R5F.59G##9BC:OS6-0TDBN4]B=8)%0@KFE+? M5M)J/XR;IAOJCH(S1_$X6SV]!.\D%];5NMAQ;7;'#\\&2./2QY@&'`&/*,.6 MT8T\!FN;FW'V;.B6H]H/*62;@=J+?V6R6$SFJUJ"O'DN*`FHPX`9Z:BA1&+` MS4:..)JR[_6/<%_:&3F:`'H&MM^7(V*BV_I$((*DHK0.(XL)1G$>IZ1"#[+L M%#0CI.-E6'6YFCL#WJO'\GE^R*W1RON#TH9+$F%3VF,(HZX@K'`3-OO>R=FL MSEU2K5VN9RFL)[?B@/F7VG0(`I.*XD%O-!<.8V>5`J^Q8D0+J0>*./PY5=>X MG#-BY$]Z8[#41*8#P3`S'&*KA/45/M;;W-/5L1_P-^?+7G]?E_CW>Z^CJ1EQ M$FW;^E@P+M4?EH@+S10VG"%/MH@B,T@YE+,C\4#:Z&IMNUK<3>:S_[[J='Z3 MAN3RZO9ZYU6#+'2[W4J58,N'V4W5Q]W.7=UN*ZINJY$6UIT`CQ,[.EM.'\]Q4X^@4\(;[BI$ MO;27&JS9,QW+46EQN*E-W=RL[SN-IASS>4Q['L2-'[$2`RH)AIQJ"2U0BC(> MN5]_Y?D]=I_G)&N)E'OB`MK^1(`<26492KY(82U5'JD*%,,NMGYSSXPJ1Z&] MXS<;RV+Z/W?E][_<%+,T"Y#T0^(ZV1G\\5?A2W$W>7#1M%R][#GG_^2IP+%C MC%*G`/0,8,_B3&M3IB#CN(.PMM+Z^/U9PRFZ;`OV]LGRVI6]9^/O'PE,(X4( ME9SCY#?SG(E-?ST`0.;&0XZ()HVT5+8"6TYRI?\\3W3R<[X4:RL%$!8 MYZ&._UF\[9#EN5D3QWJ;HQ6M-@`P)TUN.PO1H4/>+CX3O'2"2&`X1-H[3'"< M##=K'H__S\W-.%9F#6XSC$")?;C#_S:;KU58U?2Y^G,>%7P_>[HN%M,DWUVA M7Z[7JCJP)3WA+4$;P9+;5EDH#>!62^HW&`CCV048,L-2I^Q+-5VY?*X7Y5.Q M6+UMN#GAPZ>SMTA+.FMFU`W`#KI7`RX@Z\%4S" MUULWS&-F!CK"W=OOTWS+I[PF4,T<8H)XYJ/XAGD`=86$8.Q2"VNW2)&/A0:[ M0G^(P3\Z3V^W$P,%1ED2#6@(%(9*$DXXH-#QJ'^A>:UCJ!N9;1'U&I>KW5/% M3\3;?2PH%2TO#(6PA,)HA<'$JHTD4:;<7=')`_M[L?BC'-?0/EK)96OX#C%T M?QZ][Y^3+G8@$VP@(AXEXXHK!!#77`,AK?12&5@;LM&-S%\F\W7*ROC';X]/ MB_+[J^UY0-(]+0(A%$3AV'HQ@BH*"4@E'^5^$(M^%(/[:,6770#=3_;0"%$* MC5%ON_J_B[H:JP?:!:TM4IY8#I!SS!"@C*SD!-@/$N-TUH1J$^X^:.6?%_/9 M*IJGL;]^]B/]5$NIO6T"H]@Z"03R0D`NK9$2;H>-%;DG;&-/--L=G=J"NA<' MUR3"-"\6+[L(U'%I?Z,`TGTE8*4AR"*A-;-P*Z%%+G>Q:U07Z:S)U!K6?;#I M2S%9%BDWVBF+W?Y&@2!#F21>6`\`LC1NYETEH>0N-U1N[!67.C2=VL(ZXVCI M-6:X6/QULKCY,^(0S;>OY>WJSYW4UN].B0ZT"%9SX!55#!@,>-S1>>&WY%?X M@LHNM<^&=K'M8V))9P2KQ?,T:>NWE+O]+JJO=F8YT"I`X[0&G'(*+688*.55 M)2/G)M>;VJ@^TUE/+>V!W0>A]N)0QZG##8/%AJJ4[AP0J;2T7+KM+"HX49FT M$B?3JEQ-'BZ!5JWBWGT^3%E6BMN=KV0\>>'8G/"J1[+Q6IS^KE7O@,< M;.L3`5(!D,)8(TP`X$+%=7ZK%*=SV2J/9JM\9>N\N$O"7`)?!]+-H'/FSLGS M*3-F;!8D@!(:E9PKEC`.G?XY?JW(CMN!X/\GS.9P#W$4,N#-\VZ/.92/NROJ M&%744T*PDW"3USN5ME9C"V1H%+ZP6]&+20K!?!ZTGL[+K:]V2]-1AF:._KS!$CNZYI4!0:C;F5!@E+ MO;`<;_(-`XWC%#[,P-[7[=,"E$YX2U!,`F>DPL)3).*B@CBK%S".:YT3+E4W<0Q#PN06&RK9I1:4:8\S!^JO=J6%7N(D)M&: MF19?[XN4AFKZJM_#N:#W-0F"8N^B^1.-'H:- MM/\^2*(=P(>B4VV:Y?V-@H:(<\45E4A2K@F`3KY**""R^`+N(+>GY"-8DX5J M'[RY6MT7B]>JU;5I;S\\&P1V``BO-2"0,4Z,XC#)PQ`@`OO<$\DS88S(D[%2U,N#M_#/]@F>`@Q M4]@ZX"4Q$F$(?-5E2X;)[-,--3I39MD-UGU,2:_51[<7;(_<@1UH%1AECB'F M-=:2"XP1`ZR2T1.<6P:@44SQ)2QR[6$^(*]JMV('VZ4RCQB[=,,#>,V,LI)O MQX\AV4E$1CA7M:+MXQB4A6UO>[(X2Z=3K]C3^=VK`.['4S%?%L=MTVJ:!V$% M8M$DP$YQ+(FS<:N[D=H`3G-GJ_-AU*G:_VSSUB[(?5#K[VG9KUGDML\$8P06 M20!I,+28,HAUU7\3+<@A;C9"L1[CU-:=^U3.6X5]Q45 M"L;J[/LO(YQ*,O3VF>:S<.OG9M2/V>/S8ZWVWSP7F&*,8T0)2MEA()5";^7` MCE[0Z4.6]CY<;LK'KJ>(QYOGZ>IJ\;58?)]-ZQ:+SQX/#E)'D;.6&.+3^-!4 M;:2RWF0;%XWN,%W"NM$"V#U2*/D:-AU=UNY_]K8)`B%OB%(80.@M=\I'@VTC M'Z?Z@FHR-U/OYUQI#&B&K^X?3U&V=:3>WV8/Q7)5SHOKR"T%^R@OTYK^.%9EHYR_J!VS@&VF5$,)0X@@JZ7& M@C,;1:^ZI`VX(,.E1?5\7+2RT.S'U?\]+J7K,[3Z%>GCP\&Q)$04`W"L)"8H M'=:N)8(XFG:Y.8T:7<>^A"6H,=3]D\=$T>_*Q>:"9*W_I;YQP(Q0X5F<8@%; M5U37%7@0-),N1_,DV:P]D&3?ZYC/O;;+Y\^%X#B'AK&*>>",$X< M9:"20U)]0<7D.Z1'$TA[.?(Y:E&N.S4\^B5!(NVE848!*0BF$4].MPBH;,/X M](0A_5Z)Z?F,L2M]],W(VBWXQX<#8LQX@1G$!CFAC&/&;0T`Z7.3?)SKI:LF M.C]`JRRP,[;>W^YGBYM-4>;#-;4^>3)(::PD0E$#.2>2**VK^99@/LQ-EIZY M<*JBRC81[<4&OI\5M^Y'[&:JWWUU>SN;%HMZ:WA_JV`5A=XY15W\(^5AMPQ5 M,FKLQ MKDF`3ED0YV?WV08V_>RIP M`PU$E$D*XZ1C,:>XDC.NUBXWFF_L26);TG@S-)LH>6VHN^GT.&6_?3HP'!<7 M[PV-%`1&6JEAY3"GBI!!/#+GH>=&0&;H>Z?_LV*I[NX6KWE$#ZK]<*.`,7.: M,@J5@Y`R#F@$8=-ID%\-X_B4J.>F_5;QS%G8)XO_8^]*F]O&D?8_>A?W\1'G ME*LR<2K)[-9^8BD6[6C7EK(Z/,F_?P%*I.38DBB(EY1433*.)8)`]].-1J./ MZ*R^F2[G>?BWBXT\@XYT\6^=W_/_S$I+C*B[P1O?HX`PCM>D_5O=VX\]KCV MW_Q>AJAVG%FMH,+*"VL`]N7\-3#M%U"^9N]]$R3O!#)[O?)[OIE%5Q M^NK!C>7@,YG%!#$G.$9$`DW"J=>6:D\K?G6E,L_FW*P=PO9XG_RN[%Q^^BUR M]6AFF362:.X=HM90H0DJ/<>:0 MU%AGLDR>V"1F'X!>O0$R)ZB@!L)X@1JHRHV&Y<6I)E[T4E&HOZOE!$2\SE-J MGNP).U[QXLF755S5[7WY>OVC4+ZQ?=C>?:_&DYD%R`@FJ?4"<<^5A*Y2TI;( M7^$ZL1'4M$/O5`-I46[*8Q^6;F:/`1F%D_!F(?LI5J/)YI[2RP\0^6 MP%HJC-#E0@P"J6;ST#N5M@*8"9#B>,S82-$_T4ZK@2E)Q#Z`1D;&)%TS5+_0$R09"$W%(<]"04@2`*ETK2 M4*)[N>S3R&3FBL$4!` M!?7I8X;69KW*V]1=:^`WQSD!8E]4`A`T9*QKK9/;$?8FK1S@'FS+4&K.;)W`^TWL^6.U,. MAX*XB$"ACY&Y\"2<'1XJ4"-6@F.6(V)X4->.L#*JS7(@4PM<#?QVO&70-4KS M+A"XKM3N1Y/Y/T>/JWS;DN@`U/8^DQFJJ`)$208%PX)[R,KH'QL,R=8TA*IZ#D="L1U"37@!VZY[M75T`* MZ9.9R\N4Q_Q"F/UDL9O-"J^YU4S;X MCLRK8!0("JCAT'OK`*RR&*TER;&@<(")PRTY,?OC1@)`XUO6LXGW2CO0]M^Q_(A-$""`\XU\)QBK0391JM]3J]-,$`DXI;@4YCI$W`P:9ZY8=\ M?A=9\!!0N5:E;KJ<+!_S\>=9J53W`..$$3)(!-<:>D##1NZ"!B:HVL6E1LEW M;;^D][L]PB?@:-L>#O"K">SL;H/C'#W]_E=U)IV MO_9I:OA,:@%8S9'\/,,]FFO/^725[[N9 M>?.[&0K(5A)I(A@A!`6ERS8!80ASDEQA!?X*OO*FJ-J%^^C/T72T-O%]GB\V M$SW@.GKS^QD@0%-'%)#`(Z(I5*9:%^(V>3_ZE1S@35!V!S&-MA/?B6'9^$E? MOK>C9N'K5]=H#?[RBYD@4F`BXT4G\09AJ_"Z)SLDVIGC"?1=WAV\T5/^Y$N# MM_K2.V21!Y@KKB7EDB.@*AIPSLR5!@BF(J'61<'Y=.Y.8+>6RCR>/BHH39VK!1!B6K-*!8$&K#H="%OXE51$!]]/3=DC!7@=!F]&VR'#UN M:K2M)U^$/1\2X^-/9U1QY,/YPBA(,+546>'+=3MY3:4S4QG^L\PV3M1N;I0W M'<'6TPQGT&^S:0RL.%+H[N!S&:?.QBZ9A#F+L?/6*;-9)Q7AO^L!3Z-,>4^M:*]5*J%24"8T114@J2Z6H*&"A255) M0\];:7-O:XWZ7>,OI3"K`%!A"RAC&BIFD;!>ERMB1O\NS%J?Y\<+LYY&[)0[ MD_O[R>,DO'9Q>U^_2.N1IS*,'-3&<*^*IIK>&TTVTV:.T&NK%-`$`V=M4;>3 M@UBE;-?J]<]\^74VWD:ZO_YMGK\?/1WKN'+.L!F4E'NON80&$X&!0;R40L:\ M34V-&6`ET%:/<=VQH+M3WNOIUCSN[7LPHT@7"1S:3#5VJ%RI4,G9,@,T MY;L!Q)O'PH:HG[!+IA1:5989XP&27%*G*`3>5I,"\N?JKY<,B::XL[_.ZFFT M[';'>TOGOJM1)Z7F"!GDDL7[;X`!PP8[&82HVNVM2DU=&6#X4C?[6)/4[BQM MZF:Q6.5C&ZS`Z<,ZP&H=,_,^_[OXZ+"WN\X`F?<*2`>-E4JQ8)MBZRK=+$EW M55%>IK/T[BE(@,9;]Z%-T[\3Y!5%JV+R_"%T55_*9*`0)^&$`[1W&BG/("M7 MP%UR>LME>YH:P$\JA7O43D4LWQG*Z>7S&>"`&$,-18YIQ5GXMZYDP^/4!KQ# M#R+O23.=1?Q.3G'KBE(;=\OGF9TLMN6$YNMR0F$U:CJN;@3"/V.HV*$37O*@ M,=<:,:>-P+'L/U=2FDHLD56I!=BW(X+Q[]'T+C>SQ<':'><,FV&I+<#&>A7$&<Z_N[E9/ MJ\(N+>IXQ<_"UX.Y.GG.XSHN,4`PHX0>YH<%!+ MAO,A4M],`\,*@A^+%#]EF(PZ[SF(M6:@=YXC;($O*2&ENJ(;O%0(_&S_MD?= MRXT==PA[[IA&,%`38*$%,N4Z-8&]="IN!T7ML/^D(/+3B'TY0>2,2Z"Q5)2`TP]]:0>2G4;43_]!6A-[GR[^F\S=MI"A%1_M@GSI4ICG# M!%$5CG^$6TI1L.4JVB*7G(4\/(R=B8;]NUX;A.X8=D4@Z^.:B94[ZQ2P'1@@ M,U(*+)G0'#.LK6"2\'+E0-/4+-H!UHAJ#6+-D;=C8!TR">H$QYPZ5#A!:\.QKNC%^^F3V8DK MJ390]@9G=D'P]F1]-E]^SN=/:CI^-YL^Q!_?Z,;1J@ZLB*#V ML_FGT6.^74+]XDM'QL@PL5@B1C7A(/RQTDM>TH`S?ZU-5MM`R7YKJ5$>='$H MWY+G&4\!`HOPY4.>JU/OYPYA4T'C`?CA):$D:YMZXBGE7)A7P'CJYS>'\01@T0 MN0M8_?7IC]ES/I_&:4>EO96IHZ`Z]FBFL;%`:(1%H&4XF`H4BUBO5RN5NWYS M_7P2AI]JU"*OFJ-UM^OE^@Z#./=M)XV0,>&Y<.+<:):VC*)"D,BZ,TZD] MJH>.NO:MKS;9T,E=VT^S?JF77W@4]&AQT.@_=:@LT,%+#[4203PI",31U3%* MPPYK3E*>FFK$VU$P<8OS`(X+;"E2&C.7ILVT3SB_$SYP@2$DAH-=,XD`LK M4G$-BM2:H_7S]>4:S=/\(<[U%\;S.7SI`\_;-;UCQS]'RXH8O\XUF)5&(@LY0`XB30U2SEJ#@M8QS"!SM`)>'QIG MRZE_399?)]/;:?[O?#2ON)^LAXX-G/'HLS+*2*V-4%0%,8$EM:!B5Y3UT0:$ M3M)&#?.B_WURNZ"B[V98S^>O\]GJX:N?/!=+6S0)X*/OR"A!F!(53GQ,&,\M M5]Y7;#/PBJ*Q!X3EIMG2/ZR;-?]X*0N\XBJX4 ME,E4[\G:68"E00FC@#D4Q.'+MML2H5EAYQH;=>*M9?63:X^/(ZF_6Q0 MVXCFV_N8CI%/%YM&W86_L:AG5Z0Y?1DM8N^3'P7):VQ:YPV<01G886(_.02$ MCQW!*5E'5<S0?U\\0./,=F12"`*LL=4H3!Z$5U)0T)(3W MTD!E^`JK-O+VAB!UR[=.:ML&W56CW=CNUS(B.+.6.T>L=A:&>?N*CAZ9:]TN M>X#!SY5LT[G0)9:.UO9Z^<4,24F(AR)(HS-86H-]18ZPMFMMFYG&S3V02"+E M85"\V>[K)AP1\^^;VK=;\R^34($XG2([#X;BQH0BP"WG(EP``$$;I?@/4]-=1N@,ZA-5)Q! MTN90D8*&S92)?LP3.'-&7`>$88]MIHJI4O*19H>?TY/WV=@SKGW:#1OI;DQ>UJN5B. MIK'>ROO5D?S)QM^5`'A) M,K$3FO)'>/;0C4];K\RD)8X!C`@CQD$EK5"E`2"!.=YCY5*;EUZ^A)S)RBX$ MQ3U]>YS]R/-U:\S\[96_GQ6Q,/FX6.3BSAVE4 M"COGIX-=4[MX?V;"EAT.:US:&#(:-)2DY:8M&16IF\S@,[?Z$Z$A\O6BY6G= M6CEHDLVOXO=@'X+UYD0RJBV72GC%G5;6![-8TXH3F*5>MI_5%_:WA/7&X$'; M>*_/=O_*)P]?(Y6>\_GH(7??\_G=9)%_F`?"=N,A.#2#3!)*$(_U:*WW0EKM M(-^:#3@U'6KP/6\OT`)LE;.7(%7_7*N;Z3BV8K\KFK#'7VV6':WAUAUO=:>0 M6>8!A-[A6*-0(,8A4R7U-:?7U.OW]%[^^A-!7"E%LC\.I"KN*%L%8PQ4-/2?7 M>M'0%?):"WT]C6]##7V%W&!BG$">,(HE]9[[:A48IVZK`ZQ$T0/G#T6[GD;X M(4>[,L,A40!:1[G4DBE!-C<*$!OBKZB821H##P>XGD:]0<2I!>R[6$&,>(,! ML9)Q`\LI*T:NJ)]L*J]JQZF=1LI!GRD[BE%BP#D.E:<*>6$#D4LMQS+H M0XJ5Y-QN:$J`3NYB,W@#Z[IDY7S.7H*T%'V#;Z9W\SQ\86'SS0_ELMO<:0Z_ M.3,:Z&8)77V0?EXN3!,BPP01)C3K73#$%(."XI8IA+]?_5#]A[LP'`+[AE MM,VZ2]@1`A'O\\ER->]D%WCC;<$FU<@;S93@3!FN*(2LI*E//W'4CZ[[+0X# MX>TER(O[_FTR+Y[I0E[>>%O&%-566`J-0H@"(0"JK%*KDZ^/Z@?,_9:7@?#V M$N2E7V\69K'7FD,$,^"@LP##TM]!F"2IEQ\G!\&MO5EN^EM:^N+M)RAK]%JP>6'L)@E4S&22:$/==7O;7G$Q&L$"( M6R:(IH$1TBI)2XXXE9Q^]`MDSPX@$*`=)E^1V/4O:YGR6!EED5#A,(L8Y$!4 MM@1')O5Z])<+*&@V?PGOQT<\9W,K.Y[*/&[M_8+2V+3-'9OR2G)FO+_^ M@K0H.XXE4A`)2O)4I6(Y(2CTZ=-``]UHF+/-"3TC:YR,#2=AD4U0NGFBC4RW M@>FIK?2PG@6(B,!2,^J]`5@`K]IJ5)`*1O/=TWA*:1)';ZQ927$2!MP*./FL MNE='@L02DWH`A3B.I,P;".A&$]RGQK(_5&K'T5OKF)0X">-\)](_E7GNV96` M+"&.""`-T$PCQ[!I$Q*H)C[5\_U0R29';Z#CDN(D3/2=Y(+I9M"]NA(,A9CS MJ`5OJ?280B?49CE"7>K1K`^5WW+T)CHN*8["1,]F!]<2YTQ<8GC@-=4`VI=# M0\Q`FEIPY8,ET4QNDI.PX10LL3LM8B(#/:QCP3(4!TL--7<>.*\$UJU;PZ"C MJ7D$'Z!LZ9'E$8RC\!,VS>GGSL,Z%H0C1BB)M152Q#4'IJ8]1\(X^KOHZ_=\O[^]Y^]I>B+IH5_]W,JT;ZQ]G=+\7B'G594][>!*ZEY#+Z_E(:'YCO*$+7O_86\"RT[H9'3C+*$.V_KZ5&$M;?ZL M-2@Y@(F6?;:'1T[1LL?G1;8+!.K?7V-3"UK5Z4]_WQWP705WZ2QQ2@.'O5)$ M,6Z`D%X12*,2=>=5B2.-SYLZJ[WN;%)W3U%!TW M#.QH%1RM9QP`H.$*$F?Y*\0AMN1\J#DQ1^9CZ61"WG5>3;"S73#$&1\7])9J MZAF,'A`VK9S"^TFJ)(_#O4&TW8]!2=@FW&-0V\#%]4^+^=7CY6JY\_J"]QX- MQ#`-$/:>8$EBGRPA;#/42W!&MQ8,I*CYH(`F:WP]:/;1^+>/!B:\P192'G_& MA8''F&^(;GSR/:<'[0J=EL8/`C3'//$E:BA^SVU<4]KB:W$W?ZCE7Z^ZMC)F MC]8!>[^]C$IZ3U!$X"=`EH3I#"4Q@FA6QQ4'&*G*-YP2EP; M$^TZF>P.B^<0,Q19!%_5B]GD\Y9@9UYF>?R(9^U+*.S_R1*UU1`)T&*L$C-N+>?#:2^/%C-M/!(4R"Q MWF7X6B,SR23]MA-],LFW-`D.62J@L=0;BCR6Q#?'1J&)2!,[6:3\37=[#0K; MV@1%C36"4LBI=0!(1!E?R\B$IOQ\)K;#U?S6<`<"-9<]ON0F?:JNYXO[YYV? M"3-DAK15[(ADGDODH"4.GU%[$N"[B,I(".?F6&TBEA9HXPVS`'NC8:4*]#*R`1/#:4>84!J`*(,#VB6 M[:LWDVK\X@[?9$N+:!!.6P$LL$HY9ISU9(,7HS(U+_`(R3*H(S(,G!-1I=/Y MV-HF&!KE,1@*;+W&VF',U,:\A#K?O8K]-=S-F"1,)^!,=ZK/>\\'+!AQQBK' M!2:<,6I>D)*.G^^J.46WN]F2A.@$3.F3?[.M24`$0Z4I-UQ*;$@4D?*-;Z;5 M))=EG=Y4E(IG#K;\M)A?%\MELP&JJJOV9&.;:MN=T-+O!<$!`)CQCD0+BP8' MZ^M7UY)#*Y,]X+U'GF]O-,S"I03USS-@?$[I4@#7IT:X@S@N"B0"U.(66*B@ M2KVXX<#[,D^$7:-@/%[XYOY^MGBZN/ZYO*G*N"2<52MU>3E_K%9E=?/3_*Z\ M+"?*A/J^&SU"-]L;!11UJ312CO#H71!NL'1MJAFCNO/8[$CNQ2[<>T5=>[T@ M$$6Q41@A)3@AC`LO:"N]Y'*2#,@,Z19#\.&M-S(&X-/:]]$%;8>V?2X)8QY2 M8AC!&CL)+'74$N*18YIU[@'UVOSNA_6V\.R>;PA*$"L\)0[&_DL"N<2L%4EA MF)H_=<(&W5O)\QR(9XFWU:59ND*V[3,!2$^!-M8IPPT"T8U!&WSJ.]7.C#&C MJ?=MG"T1X&P$Z3XI^?)4,)Q&]S/ZNIY3P1FQ+*[6US)$RSK7825!B>_1(`G$ M'$3X9UF5]X_WG53XYKG`-09"68:TMR8N3&24J94#:W+69-A7E?/A@,Q"B-E? M_0CQ^KE`(AI>:VNDDW'-&D=,Z5HYI+:3G`0\%4(<`&3>\P+N/X]-.L'J=G[U MJ?I:+%?-H>[O_K4H?IS==T9E#WAM8$8()8PG0%'N#&'6BC5*7EN;>B#F6.F6 MRV/)J),L!ZNW=+'G4> M4A4)B6L7=4'*JKS<78CFS5,!#W\V#!E*6?.A MD$U0^/^5\X?;V6*[`_3]0T%YQ564#``31]QZ"M]L,'@,^+E-1R.J^R!@<\PI M?E8N?IO=/1;Z22V7Q'E?U MN>/JLKPK&^6_%K33O1GK*P/Q4B!A,9"0.L4-I5)OS-6020K09A@'!Z#;-@)/ MJZ%\3OHZ5[WL45SK_09!<8GBL&"HPA*:..4`V(X5'CHW2:''G-R;C"GO.NP' MJB?+OD9;ANR'8GZSF#WZ*E!JU\B)G4S)B# MBKB=P4P^%.!YJ@?>O.UI=[KYMC;!1\=9"D:8-DXZPRTU&]<7<#U)"G&.38;# M%?Y=>IP/A6/21M+-K"K_^PQT=;5SS/R\(Y<\^5W!""NT(L(Q@!T"'`+$6Q&9LJE3 MU+'>I#SV%)5+$0E<>[_ZKIG?WY?-3NWRQ_GJ7\7J4U6[B,75%I;M^98`A08& M$X"!L\0"`;DQK5B&RTD.:8_,KY'U/\^EC`2._:.\N;U[^EQ&=_]5#*`-9LY6 MS='CYY)H6_BUQQL"940JR"G%`&KH`73"M^)H"U,/R!SK#FM>;HVGB"P)"_.J M>/KG;/%'L?*/U=52K(37UAWJ?J?Z-W>?O+;5$?SYA5 M3_4A^RCQ0UR9;//(]G]1$!@SQ.+`K)C66$;?0Z@-:`2G9ET>4=GWO*/8Z"HX M@%]F?A<),U_4*ER^'SWO8E:?5P2F.6@N4V!`"$*)H$*W`@GE4T__';.+GY]@ M(V@BRQG!9H-XLU_\4F]TU\F);6V"1Q9#ZXC!6'KK&$*J'9JAEB8UY,T..PEX M%EP;&OQI4JUJ,[CXLXH#P6WY$)W'RUK;-[O(UOL=@1$-N>":0@A,-"ZL[49^ M@TSJWBC_\,/7SECGU MH'<&+#6Q!#JBH*/06?R^M=/F"?YH$[""B& MT#%CF?,4&='N;4.J?'*:V8%%;L[*`QQ!$5D"Z.LU^L5#4=_^5]VLH\:[YMVM M;0(&7#`01W[/'-)&VOJ^P+5\`O+DFZ/_#CL,C7VFY(PFN!:1:%;FNS,TOGDT M*.^)99Q#22T&0"K!-P.U1"JY+-<157B;@#R'H9QG+?"UJ!X[W/[G1P(PS-9G M1V-W:92#4D+:+4-H!4H^5/TA(P('HCMMV1VW7)7W=:6P=JZ-RY/F(O8X2JZ> MZIL(5Q&Y>MW<9`&<4T$>C2E5$G"CD#=$844-M4`I&A=B4'?[=F.?@=ZJA,[; M57J^(A@&!?9`0N6AIE(Z87&+`)/V7,\.#L&)K<>9!X7\^`KX"`1\O=LJ+."` MQ7'.:=OVWUMQ;IE7X^EW:P6?_1`^S@H^$!K,D!82D#B#>JNL%!L4L$[=03QV MEB0H<4<%G_U`/-X*/M9[C!G5@L25NI04.P]:.2AD9TV&?56YLX+/?D`>;P4? MR+5@FFJ&#(<:$4Z=7,NAG<>=5]B=6(;EH(0X`,@G]&@=@*O+ M>-`Z7%*[:DQ)N)%9&IH:D#]V\HSN@`R/_:1\ZW4#2X_605!C!%/:U)=H6P1T M70-D+;,U9I*[6#+P;5`Z]*5:,NPYJ/9Y5EU]NG]8S+\VAP:[S\Z]WR`0I&4< MG:F&1DLBN(2DG<4U`FJ2R@69.92BY_D(X.:@C7Z,&)75392__;@7BWJU;X[0 M>\D1C:Z$X51!WNY;2*`@3BU)<(07C(U)JC&PSA()?UQ499V$'CONR[^:=/1. M8FUO%`A%'!@CE0+&6B2%HWPM(60V^:[T8SV-DH-:@Z&=*\6V$;Q7A9173P9A M6%R-0,(()TX90RPDK2R`JM0P]K'6ILC!G,,@3DB#K8^O/$8`_S%;7/T9Q8\S M[<_SZU7]<6>ENLYV00%FN9,(ZB@!T(H2X]JN.V53-X^/]GMK0*2'EI!J%$$UONLQ`!O(;2(T#HZG^UXR&F[/L,A/.FR_W./ MJQ&[&X>Z'@,4@$2!O8K66",F3@':XP$XQ8I3#QN)<61 M96=JV$/H?CX:S%EV_>I*F!?7;X!XZD^K?B\(<=B2"EIIB;;6>J0DQQ8"H`A7 M.`Z89QH-&X%@HP">,>^WKK(:)Y#]!J_.MD%+;9A0&G!)K=6,4:];."75Y[H5 M.`+!AL8Z#[?>*P6VOC[XN?L[V=79.@#&@"=<8ZNB[%AS!?D&399<^.C8-PQ' MX=?0:.=@F)DMZQ[7/VH?_>OLKMYXV,/]ZM,^>".0$)Y!CC@'T5E`0+9R$P!2 M8Z['OO$XAA\V`MYY,M7JTE_UYL7+Z?_.`6Q[H\`H,A1#BJ!TE&L$B+6MA,KZ MU$#'0;N.I\FHP4`>H.)'7R^]=]M@N;<:"FF,<9!`021IER:&29-Z&N]8Z\>, MP).QL,X2F&\K*EU<^[*:59=E?;UY!.+Q_F78W!6C[],^(,0X\SP.N8`#YR'P MS+5R:Z)3K_8YJ$K,:7%L3+RS>%'SJJZ2M&A4^*5<_F&BSLI5_6GWUM6V5@$@ M@S@0A@,KJ,%0"(=:&0W3J5O2!]6`.4U.#8=RKM2/=XH,=HY4.]L%CZERW`.( M!%:(*4H4;>6TRB*)#H/1)M!<:.$\B, MTP"V$A)+D^M0'6%^[2@[4P,!FX,Z]9A:1>WM$:O9UB3$M8BG!&EMHVB<0X)$ M*YU5UB9?%'=$I5A&I,U`L$Z:(M*?1'U?$9R$&&'HM<22"D@54>UH:S7WJ2&_ MPVJWG.84-Q+F.1CWPWQ^]6=Y=Q=[_:9HVK+]KTZWJO<[@@:,>N4(MX8:#H&) MRY96?N>3#P3`#[B!/A;H$Y/N[>^'D._]=P4%XV+&:,NY\XA30+1H=X.CI\"2 M#\Y]P#WWL<'/XJC=/\S*15,L?&'+Y<-\.;N[N/X\KVZ:4I*O>]_+B4MX740% M$U7O_M45&1PT5+&-B3(FD\?%#[2]GQ'_+#O^\T51WE2F*188N[J85H.+OJ(H8)!H%J\B:?TYM^^KHM.JL>-42JF$PA9HB5JLK5`Z-9B`/F#2_LC8Y]DZCL`_ MWWC[I;B\FRV7S2&P1KE7_WY\#N_:8GFY*!^VW#.5^JJ`M$#1,W6*:H*9I(2) MC5_A"4]=OJ(/F-T_,O8YF/CKLKBX;NN![SI`_>V#P5*,-!">F+K2.7,02+4) MQY!TC^T#!B0.0G;:$ZK/3]577&TRY^S_EW=MNXW;0/2/NL,["?2%I$B@0-`% MV@)]%)Q&20.XT<+V9G^_I"TY#M87B;K:?@GB1*;(,X?#H<0YL]@L;DDP'D!S M'[?OQ&OG#0^!3*6F83'G<:R+&6*`Q9:T^Q1TYX M[>O1$[`8$J?Y#'7K^J#`27WX'C%NOBBLBW]^>2G?O[QN;QBY1:K?(ZO(`:MV M?\T_>G9"LO7H=;E74C,/#FD!WF:2*HRK_DN-;HDC?1NT[`_646AQ4EOUQ)6Y M1`XI)R10#M@IRYS4]1@,%LG'%N9#C8ZV.\6`)/PF/"K<2#/NY/=RFPF)-.6& M"H\RRPS7]8R1G*%4@0!L\O.6^3!JX$5I<,RG\U9'=BV_O3V7J_^VUK8-:_!U;CM73'DN MJ>=82@W&@&.FPDL%\&Y@=1R21(T#L+="B($&YIQA3E$-8-'!3.>07(NF_1/PZ*TWV8 M9:ZT'H[,GUP`"?@P@96SDNF8SJ_V"QIXFUJGK'VRPKT&%NG&2!822HE\#KKY M>W'LQ62?S>>80P"`:^&YHD`99=+60&`C4UG9/E_AFEDYH47FZE,K<_6G5 M:E0!9R3#W'..C(]B\T[6&!GB4U\K=LIBN#K6CF^(,7BJARW-+ M^D_7YI@P`@*8Y02%R!P#Y5D$I6CJR565WA'6G;WW=RE6SR4ZV.ADU"^/,-5P,@>]9[]M;V[E7BAE' M!"(RUD*C'$2]\_.F@_)<^Y=2U^Q[I[+'M$>:MZH*L41KIA:_FC'F0UFM)2:SJY)S@E1@P1C9+7\6N-RFA,0>: MG2]+A3HAFM++9?DC.)8B.)6L_/ZX>?Z^K`:ZFZ3[OGS^=")F2FTNEUYBGSFN MXU-$X9S/D-L/E.D;.N#0(XU&1#R!6@U*'M;Y.$]U[;CW8MV(9[VTG0O"%<7$ M$FL0T8X:0TT-@=-)!:V-,`X:@?E^^LZV/-( MQ\\0[MS7PE3V-J952T(4`DH(9;@>)0*7NM-K'96_%ZO'H1\/C[M M[Q"TAA#P^1S76K:4"XL1LD)[Q'#X24%A76.A>/*#AN;QN=K1[ZUXB<'K7\.O MJC-S&]N+3(P,34P.3,P+GAS9%54"0`#L1)!5K$2059U>`L``00E#@``!#D!``#L M/=MRV[B2[UNU_\#UR\Y6C>-K,I/4Y)SR->-3CJ6RG^\XAY0!C]N'/P9G_'P=1E M'J'3CSM?[G9/[LZNKG;^^8___(_?_FMW]\_3VVOGG+GA'%/AG'&,!/:<)R)F MSE`^`=@$*<^*F>,U(>00)X(D41^?J[5[T4@/"H253 M35#PH%##8'>*T$*UM+M_L'MTL.-$CG+-7"2(QIB2UHBXAWT1)$]V,U)O@(<= M9Z\E/YSY.%@30XI69XZDXZR+(T5K)8[J/*Z"GS**_&LWP=N5CW8/#CNRD77> M=FPD>&MAX_T>XJXT-UC.%;OX>>$CB@3CRTOXVXXUG_,3QX%T7 M'A5IBJ=R[+;G2<=:+R,M%)-@=&?`/(#;\*%CWD2(ZV1G-58Z\&&>;BQ[48(@ M6W[;LLT`NV^F[''/92$5?"F'J".;L3H$?J(`]':232T^'=W%Z&( MN&HJ/FC#2885_=S-"*S(1T#A01)_:IC`E'*A**DGB5/ M%PM")RQ^!`_E'/XAFV'>!:MCW[W%IPM,!<$@BMM`:`(S#B>?-R! MN'@WB8'_[2+_#83!"42)?C["4-,5H+BAKZ2XSGA,*,CA^^-.`.KV<2+[]Q;* MPY.V0@$*H:3',OGHH:U,@(+]GHJSX+BM.(`2P`)Z-<>3%.X!PB&PV#MC/NB& M<47JA'K7Q,4T('1ZBQ\Q#0%=@G^YO3*N'Q4SC232]A,.,@_[Q^'!P>'!_KZS MZYR3P/59$'(,?^1H.HAZ3DK5BD56PF#+`WHO]0OXL:B[%CD#K,0A^W M1\SW(S->_#0Q21=+G7B>:@SY5S""\KF".\<"$3]8@Q5KR==:^/C@\'C_:`4+ M`U36JJ,UZ_P4-_P_@Q/DK707SN>(D[^Q=S*74?-HTH1QBUW&/>Q=T3-&`^83 M3ZX"[T!)*D<7C"8C&,L4=K`^;_H^?#:[Y>%J;IFQ[T3\.VQBA9I(X1#JZ'(X MF2"25";*X.KU+K0<3<[Q!,."S(N?K]M)JUMH=J_C+NZUE)Z0-)V^'?RAPEKW MZ,''ZS![3*C6ND<'AT?[!ZM8]Z>(_!::;SXG0HUPH',8^P1H!5.76-JL&KL^ MO#Q\:PPO4W+*3#F"@V52572.*5>C7#^P'KXUAI,U%AT"R39&OPP%Z/0SM#8/ MY]<8EI9CM%207ZB'^0VCKMS<\>4X%@DS#F*,Z<'&M.REL$O-6A7*6Q6\S:333J)^S#M\8)N\[HVSM59PN34^1+ MC[Z;82SLS%2%6V<>F*+AGYRFTW60LHZV0(J).1&UP22Q6L>(@V0S+`BPVL4^ M>4)-QGJK^I*EL9R?F#$?8FL9]-TS@?R+OT(BEAW,5T.TP9S'K,U[/::TG&2D*,H.3JIP0YRL=LM!=>>9L.NABGY5F&_ M(>UF9^)TGVGL(U<]NJ(IX.\$H@+NSN#U):&PJB+(/PD"6%;=SY`XX0DE[T2D M."-ZBV61(J'34Q20%FFYS?+7['JEM%VUZVF;:"G?\QSK#5X?=L!EGRNU5><:V9O4^,>8] M$=^'$.H*!*%3`FJ(W/Q&UNDWVJ>!0,.\_]XP[R<451R6T8P[W\\.Q6*PDJ[D MCL%`!^(-0_-[0U1@8=TA0FCI`/($GA?Z>#0YF\$['%S1,\3Y$B:?I)`J(;`N MMUBAR69G*+NBH'Y\CYZM+*1#-U1''1C"L@C= M4?A;K.B.P98MI89:E8/CN7=\:.$B-OK8;U M23Y^U*:'-%-IB!'>&4+)E$8I$DB>#SW#>K(O8C3,Z^\,\[JF]ZV=O>7A9)5^ MNJ+_8H2*/^`W:,?6`A7(#4.6>6Y/J.W:P5N0:(NQC0[I@NN3KVA1^X;=A.:S1O5\\?M2LC"ZZ&C&BR5 M?]=U4%Y'.\V^45KQ6?E&$6@8T%OYB?;[)=W$MIEF+RGM'=AY2?'!X"3V3I+E M<>(S?`C^2^0]."\QR;1MK=EEWJ[D,GJ.*3DEF+(RS$-VKF.=D+(@4I^C.MPW MY*@L#+VMR:O/F$^C4OD3]Z^0!(JRC:4J$.M#^_TC0V@?4U)6T6D-II!:Z#@= MKT"T?B3=/S*$:%4F'&982RMGQ;.3:$-3Q'1<\_ISXH`=1^;.S>1D.NXA=# MA%TV;9P0CYN6V(6;#%F`F0!^83?ZFT11[QG3SII>+- MBV?7#SWL77(V/\OX'TW6Y31K;;W9G4IQE]&=-*:V"*KQ-Z/SN*8G3!2$)S*P^TUFFX8S==F71] M!STPA4/-AATZ9RO;9[NWE5#K\806#37[16G59>47^@YQ@F""'SS%9$#KX-B" M2'VD?&"*E"TLO*V1\RWVY<5G8P3J40EWY*J&>(@JL-.4RN)5OK]PM:7XIH0&KH<*:O<^6O-MS."PW+ MFNS8R5H2;.A>IF\;FN&\Y#-4Z-Q`SSTEV^72R^4D/-GE!: MS51X0KY\7F/`41P8+A8>O"0SGG6<6HG:D,=-%X$@9^&RTD/9GE MM#)4$:4AD6`ZV*%H.!$1E5[=ODBHH,6N280VY!H6CJ9C'&6##0F$1IMF.U#: MFQ-7D$=8K*UN6RNRS38N'N\:IK0AUS"Z_6K82"S9RQG"%(--X\7\'9E2 M6->ZLFK"=>4-ZH1.Q\PGEA]GMR14W^_VC1N-V:)=H^UDQ)V$^F`\D\X[=]/. MC=1WWGWCYI2UT8=.O:)?I!FP+P&>A/XU><3!6@KQ7K3Y9E]ZU\F7LKQ@Q)>C M&-.+]HPU8(.SU5M[[3.)W8QRN`__#)&!M4/\E/P:[&HT0P0E=X;2D]?G2*!U M#Q8-S30/"N4$1YM!(6M>.V`N&1BZ?;W=[!?*;11J>F6^3Z$7$^(>Z/)B>^S)^@>`K7O^G%'\!#O*/=]9O3?)S#9'Y^&@;S(+=`OF/B,YP^8 M[S@4S?''G68PXJL]X(1^$$*#1(02Z!-GX0*:>^`^^4`$GN\X`J3YN$,9I>'\ M@\?FB-`K>"&%W'$B0(@<"?/N%:`7\OA$Z5X[T=[:B58/MCG14E%()8WJ)7)S4$:B/N)US]$3SMX_`K(O3>H-4ZG527$5!T9,YH]!? M^;*HH0?DRTX.ZL$/1)CT1F@@D+R(OHU'N()]PI3\>?-'P0<,+WI@]721?L;F MH"F5T!Z'W)TA[0YW^8ZH??BQ:N!D(C"_`*O*'28L395*N3YZJUL\D7R-VE'% MG(%R1B6%=\\2J[ZHK,MJZ<2?M_85QM`1,?^)DK"VE@;H0IE%"P M$`YD6C^1U@YX(]*N-I9/)L0GX'O!:'(_(]R+;\]8%OIQ(U@/>G42P4S*@9:* MH^_QLSCUH6OF_TIE7!V_@_`B(;/^:7H.%"`HO(/0!9\B^JU@TLK7/3"EFB#3 M^KU^XM"G(9B^AP:9\M+7PO5-Q&HW7OAD/".GA`6PG($&@C/&%T5GK@?J@4L#,>1?AM2#N2(+ M!5(!*E_W=^8TLRP+)!NDBD$V&.M4.MM?(3J57:B\2C+`FYT]^;D34&@BI<]%$/([1KBGB&*/#1:+!@7(565VB=3&+6*7F<- MWC]1820>L\(H77BV^4'9D)VHNC+X#`4R3/C*^#XS+_TM>(X'8)$I??"5B M-L.^AX*+P.7LJ49I'X"U@?(#Z#@Y7VA21TO<_OUGQK50[-'TEY=';LJI-+`F6?1]IG@P M#>Y9-*C\'IV?_XR>R3RKCP`)1,B6;?X%LB9G+:H MB"#UBX.TW=`:#;]TNWW+PKR@"?07K@OB>OK)#GFO*:9X0LJ1RH9XV(KNH2Y2 M>>&N8&CC!W-[9.=RUY(VB[\5UU'3*S;YHSFUI1KT`1CFQ76X>K>6M\(.YS@* M]D_*U9M!.0D0)I+ICU/!2F2';/4S3@=#_C50/= M^AOY477XQ%Y<@ZJ)GNJO0B0)CM4=^Y5KMA7)]&L59R/$9T+E3DT4*02W.%JO MKZB12F*;W[-O(0GV[.*'>M2-[[VW8CMWO&@ES-<77U:+HS[J_HBY("#1F+,Y M"0+&ES=,=-!1/='7IS[YF2GDX^!$?)T1=W;+EL@7RULD\-E,P@3W[)Y@;C$' MM:+T&M*$.>DB<53:4Y])$Z&E9"/:Z%?65'J4:6HK@(6K6%/IMQJ4<^=%4#>/ MP[`PR7;M.M)X=2H`*W94@$[AU8E_AQXAK`[D]ZVOY@O.'K%^>&-]Y#:O&/E] M=LQ_1]Q[@E`'EA-W;"+DSTS8.I"^;>Q79V@KI>@KS& M`:R>$?TZ`[],Y`:U?,B#&5DD!8?Q;)Z(-"59@/;.PZJ'KT"H&^J\T!5!<<0RONO?$:&(T<06)B%*[_HH MQ".F,/O`6O&>J6)"49I!:B`V/W4D%32YU7%(FO5;U),9)1;.#W5BY0")3 M5(__&8L9\[*OO1@N%M3Y5T5;6J46K*<2N==(KV_Q>Q>5C1:J*\M3-2Z;JV]4 M=M&8F5Q_DX,KR2A'`QCY6%[6^*L+G;371+GOBHQOO$GN>UU&_RV5M]@"]Z*J MIQC]/%@N.P9J2VCG.?E=)W)9(_PQ?-1==/./YPD?\$X9VB1M< M7Y_EY]8Z@/Y-K9<8>WG^;7.Y]@.<:I"A/EW:?JCJ1\K4$M1`\O MK?D=<3D'7U'!,?Q](;,W"TX"+"_>N;H>Y\UB#;UY4_U.IC-_>4U@@M'BC/@` M:_R1RV7>=NU0^FA,$@@VQ11F#WF#55PG6S!A/Q'<0`\H-@T?\)-2ZQ M$WGLP5]-@B[K7IA/9[O_UJ^9LH6^!6)>7#4 M0LP"\*L1TTJ\7HN5?C[WBF;WEA;%J@?JH5CL"5VXL'Z>$U>[J_(DA$5X^;Y6 M:^C-SQ7_8H2*/^!)R+%6\1K=VJ1OVP31!8(B*X%<#;5WN=P.FKC%T@;&&R77 M1JUW^JKJ(M%)(NVP32$]7/-^XRGA(F^EO%(=0"^O'U8?JY*S1GYD*C_>_!"D MGW:.UPCJY/XB/B0J=U,)=JRH?_%B-^1YU2DE=%[U[56T,@575T=.NZK MT,4]@\'SXMGU0WG,(J[O>H`E2Y+SSBZU:H_66PTDRV?BRZY+TYNEDE,$7Q80 M((:NBX-`W9D^(SBJ:!M1?$_FZ;[!&NCT+UG<64ECS.-BCJJ?`S:"L`FE>TD"(UO>C?TB/U0^B&!?Y-;S8_G\MS M&]G)IZ2:[5;[8DLMQ(9/S"57K&95Q8P'YBW7=#^[)Y/:::]W.ETF894[C- MS\753%X\+TA$0"X";V4-^AU$G:)9O!K,U?OB5-):ORTYBC;J2MOCQC<][&X) MFQ7&%`:0#JX;`B.<[=+F<2J0*@I^*DKA:5ZQODJ8+HJ4"YS8&R M-,;7/13E$?U9+,HJ/.LCTQ!/^SY36:"HE./B&88>$N#3I?I&Y!,';HI52NW1 M>BCZ,[3E7I,Y_*]0\FQ^M?EU4YSS'TWBC=]+G.7`*M[U-^$_3K?^:NL`F\'Z M+^(]TVY\)R6;F=[W3ZBJ?C2&;H[1*6&EDP_&-_T;"""06R#BQ9MDWK+Q$1\A`IT/.[NFS MF)23\&&2K;+G^/2@6_J[HY#W2*P3R"(5`LTX;<(U2A"^\/R@PU0D\HHLE0U= M"(Q?M?&&%;U%]8)T!2H9V((D^"#MGK*N&BK2M+7A076V(`105/1P;H05U&+8 MYY_#+9=@(@\Z=U^$_)HK+X$>@9O.1BFV:,$]C/#20B:S^'VNIUJ>&QE+ZZZR\%F=H0PMEI%?]V!RYM7[C.4WVLAMY^CK-$ MM/U189XK[*[7RY(R;D:Q:[F-U[&B.Y7K(S$IZP#)'K5$D=.#/QU^%/WFF==B M977H-YX)GU_$`_^9JW)A\F\/6I/F`W<5V<5'8Y^4>#N9X4JL,AE`2T99:9DU M$*6>DS?1KF5;3^39?I;"55[9DXENPSW%?EG](1[/-3_ MI6UHH\8@Q(T;M]`7)&UA(Z4/-:?%P'@48C]T@H:Z2W<3?@F6%YQ5?V3 MO=904QJ>5GPQH81($$+BY-1G?\B_%(>&&SW0C@_,Q42)56V]M=51Q1"BA>>$ M@D#L2&/_U=)(Q"+TQS]Q-^&;6SYIU8G!:77KK M7[R"9V)/;-AQ?"P*ZU7S`LU-@-K1CHB>Z/Y4#UEY/6PN(EUDO`GX^5^VB'1. MTK8.Z+BK9$_'P'4$L!`AX#%`````@``85I1V%7XC^. M.@(`2(LC`!``&````````0```*2!`````'AO;BTR,#$U,#DS,"YX;6Q55`4` M`[$2059U>`L``00E#@``!#D!``!02P$"'@,4````"``!A6E'9*'P$B\Q```) M'`(`%``8```````!````I('8.@(`>&]N+3(P,34P.3,P7V-A;"YX;6Q55`4` M`[$2059U>`L``00E#@``!#D!``!02P$"'@,4````"``!A6E'QJ06AF^#``#H M/`8`%``8```````!````I(%5;`(`>&]N+3(P,34P.3,P7V1E9BYX;6Q55`4` M`[$2059U>`L``00E#@``!#D!``!02P$"'@,4````"``!A6E'RNTP(1TT`0#F M]@\`%``8```````!````I($2\`(`>&]N+3(P,34P.3,P7VQA8BYX;6Q55`4` M`[$2059U>`L``00E#@``!#D!``!02P$"'@,4````"``!A6E'&J$8F_#```"* M@`D`%``8```````!````I(%])`0`>&]N+3(P,34P.3,P7W!R92YX;6Q55`4` M`[$2059U>`L``00E#@``!#D!``!02P$"'@,4````"``!A6E'Q^DWZ&8<```+ M4`$`$``8```````!````I(&[Y00`>&]N+3(P,34P.3,P+GAS9%54!0`#L1)! F5G5X"P`!!"4.```$.0$``%!+!08`````!@`&`!0"``!K`@4````` ` end XML 55 R59.htm IDEA: XBRL DOCUMENT v3.3.0.814
Property, Plant and Equipment, net - Schedule of Property Plant and Equipment (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Property, Plant and Equipment [Abstract]    
Land and land improvements $ 9,085 $ 7,565
Buildings and building improvements 7,311 7,265
Furniture and fixtures 1,608 1,236
Equipment 36,018 31,983
Leasehold improvements 6,998 6,382
Computer hardware and software 5,722 5,060
Construction and other assets in progress 1,927 1,002
Property, plant and equipment, gross 68,669 60,493
Less: Accumulated depreciation and amortization (26,468) (22,493)
Property, plant and equipment, net $ 42,201 $ 38,000

XML 56 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814
Goodwill and Intangible Assets, net (Tables)
 9 Months Ended
Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes in Carrying Amount of Goodwill
The changes in the carrying amount of goodwill for the nine months ended September 30, 2015 are as follows:
Balance at December 31, 2014
$
101,059

Acquisitions
67,404

Foreign currency translation adjustment
(1,597
)
Balance at September 30, 2015
$
166,866
Schedule of Intangible Assets
Intangible assets consist of the following at September 30, 2015:
 
Weighted Average Useful Life (Years)
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net
Patents, related technologies and know-how
15.2
 
$
142,066

 
$
(15,141
)
 
$
126,925

Customer relationships
6.5
 
10,700

 
(2,255
)
 
8,445

Trademarks
8.4
 
5,900

 
(834
)
 
5,066

Covenant not to compete
2.0
 
395

 
(115
)
 
280

In-process research and development
 
 
115,568

 
—

 
115,568

Total
 
 
$
274,629

 
$
(18,345
)
 
$
256,284


Intangible assets consist of the following at December 31, 2014:
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net
Patents, related technologies and know-how
$
41,872

 
$
(10,849
)
 
$
31,023

Customer relationships
10,700

 
(806
)
 
9,894

Trademarks
5,900

 
(298
)
 
5,602

In-process research and development
19,428

 
—

 
19,428

Total
$
77,900

 
$
(11,953
)
 
$
65,947
XML 57 R65.htm IDEA: XBRL DOCUMENT v3.3.0.814
Lines of Credit and Long Term Debt - Components of Long Term Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Debt Instrument [Line Items]    
Long-term debt $ 9,110 $ 10,369
Current portion of long term debt 1,314 1,675
Long term debt, net of current portion 7,796 8,694
Notes payable    
Debt Instrument [Line Items]    
Long-term debt 6,773 7,653
Royalty-based financing    
Debt Instrument [Line Items]    
Long-term debt 1,857 1,926
Other    
Debt Instrument [Line Items]    
Long-term debt $ 480 $ 790
XML 58 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814
License Agreement
 9 Months Ended
Sep. 30, 2015
License Agreement [Abstract]  
License Agreement
License Agreement
In January 2015, the Company and ZIOPHARM jointly entered into a license agreement with the University of Texas System Board of Regents on behalf of the University of Texas MD Anderson Cancer Center ("MD Anderson") whereby the Company received an exclusive license to certain research and development technologies owned and licensed by MD Anderson, including technologies relating to novel chimeric antigen receptor (CAR) T-cell therapies, as well as co-licenses and non-exclusive licenses to certain other related technologies. ZIOPHARM shall receive access to these technologies pursuant to the terms of the Company's ECC with ZIOPHARM. The Company issued 2,100,085 shares of its common stock valued at $59,579 to MD Anderson as consideration, which is included in research and development expenses in the accompanying consolidated statement of operations for the nine months ended September 30, 2015. Subject to certain exceptions, the license agreement expires on the last to occur of (i) the expiration of all patents licensed thereunder, or (ii) the twentieth anniversary of the date of the license agreement.
In connection with the license agreement, the Company, ZIOPHARM, and MD Anderson entered into a research and development agreement which governs certain operational activities between the parties and pursuant to which ZIOPHARM will provide funding for certain research and development activities of MD Anderson for a period of three years, in an amount between $15,000 and $20,000 per year. The Company and ZIOPHARM are obligated to reimburse MD Anderson for out of pocket expenses for maintaining patents covering the licensed technologies.
XML 59 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814
Lines of Credit and Long Term Debt (Tables)
 9 Months Ended
Sep. 30, 2015
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments
Long term debt consists of the following:
 
September 30,
2015
 
December 31,
2014
Notes payable
$
6,773

 
$
7,653

Royalty-based financing
1,857

 
1,926

Other
480

 
790

Long term debt
9,110

 
10,369

Less current portion
1,314

 
1,675

Long term debt, less current portion
$
7,796

 
$
8,694
Schedule of Future Maturities of Long-term Debt
Future maturities of long term debt are as follows:
2015
$
506

2016
929

2017
382

2018
525

2019
340

2020
309

Thereafter
4,262

Total
$
7,253
XML 60 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814
Related Party Transactions
 9 Months Ended
Sep. 30, 2015
Related Party Transactions [Abstract]  
Related Party Transactions
Related Party Transactions
Third Security and Affiliates
The Company reimburses Third Security for certain administrative services and out-of-pocket expenses incurred on the Company's behalf. The total amount of expenses incurred by the Company for the three months ended September 30, 2015 and 2014 was $142 and $85, respectively and $294 and $173 for the nine months ended September 30, 2015 and 2014, respectively.
The Manager of Third Security is also the Chief Executive Officer ("CEO") and Chairman of the Board of Directors of the Company. Prior to 2015, the CEO did not receive compensation for his services as CEO, and as a result, the Company recorded $508 and $1,485 in compensation expense for the three and nine months ended September 30, 2014, respectively, based on the estimated salary and benefits appropriate for the role. The Company anticipates that the CEO will participate in the Company's executive annual incentive compensation plan beginning in 2015.
See additional discussion related to Third Security and the Company's CEO at Note 19.
Transactions with ECC Parties
In addition to entities controlled by Third Security, any entity in which the Company holds equity securities, including securities received as upfront or milestone consideration, and which also are party to a collaboration with the Company are considered to be related parties.
In July 2015, the Company purchased 375,868 shares of common stock of Fibrocell at $5.80 per share.
In March 2015, the Company purchased 278,788 shares of common stock of AmpliPhi Biosciences Corporation ("AmpliPhi"), a collaborator, and 69,696 warrants for $2,300. Of the total purchase price, $1,979 was allocated to the value of the shares of common stock and $321 was allocated to the value of the warrants. The number of shares and warrants received reflects a 1-for-50 reverse stock split of AmpliPhi's common stock effective August 7, 2015. The AmpliPhi warrants have been included in other assets on the consolidated balance sheet with a value of $145 as of September 30, 2015.
Between February 2011 and February 2015, the Company purchased $43,582 of ZIOPHARM securities. See Note 13 for additional discussion related to the Company's investment in ZIOPHARM.
The Company entered into an ECC with Histogenics Corporation ("Histogenics") in September 2014 and received a $10,000 convertible promissory note as upfront consideration. The note originally matured in September 2015 and accrued interest at 6.0% per annum. Upon the closing of Histogenics' IPO in December 2014, the note, with accrued interest, was converted to Histogenics common stock. Additionally, the Company purchased 1,772,364 shares of Histogenics common stock at $11.00 per share in the IPO.
In conjunction with the ECC with Oragenics (Note 5), the Company is entitled to, at its election, purchase up to 30% of securities offerings that may be conducted by Oragenics in the future, subject to certain conditions and limitations. In November 2013, the Company purchased 1,100,000 shares of Oragenics common stock at $2.50 per share. In September 2013, the Company purchased 1,300,000 shares of Oragenics common stock at $3.00 per share in a private transaction. In connection with Oragenics ECC 3 (Note 5), the Company agreed to purchase additional common stock in a qualified financing, as defined in the agreement, during the sixteen months following the effective date of the Oragenics ECC 3 in an amount up to the lesser of (i) the amount that is the proportion of such financing equal to the Company's pro rata equity holdings in Oragenics as of the effective date and (ii) $10,000, subject to certain conditions.
The Company recognized $31,740 and $11,295 of collaboration revenues from related parties in the three months ended September 30, 2015 and 2014, respectively, and $59,775 and $29,613 for the nine months ended September 30, 2015 and 2014, respectively.
Other Related Parties
In June 2015, the Company entered into an agreement with Harvest, an investment fund sponsored by Harvest Capital Strategies, LLC, and a related party based on ownership in the fund by affiliates of Third Security. Harvest was established to invest in life science research and development opportunities that Intrexon offers to Harvest. These will be investment proposals that are suitable for pursuit by a startup venture, characterized by the agreement as "start-up opportunities." For such start-up opportunities, the Company will provide Harvest with exclusive rights of first-look and first negotiation. For any opportunities it decides to pursue, Harvest would establish new collaboration entities which would enter into an ECC with the Company in a designated field. The terms of such ECCs would be negotiated between the Company and Harvest. In addition, the agreement provides the Company the right to present to Harvest the opportunity to invest in other ventures, including investment opportunities with respect to the Company's existing collaborations. Any such opportunities would be presented at the Company's discretion on a non-exclusive basis. The agreement with Harvest does not limit the Company's ability to execute other collaborations and joint ventures with third parties. As consideration for providing exclusive rights of first look and first negotiation for start-up opportunities, the Company receives a portion of the management fee collected by Harvest. These fees are included in other income in the accompanying consolidated statements of operations and totaled $697 for the three and nine months ended September 30, 2015.
XML 61 R68.htm IDEA: XBRL DOCUMENT v3.3.0.814
Income Taxes - Additional Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Operating Loss Carryforwards [Line Items]        
Deferred income tax expense (benefit) $ (578,000) $ 0 $ 374,000 $ 0
Deferred tax liabilities 21,550,000   21,550,000  
Domestic Tax Authority        
Operating Loss Carryforwards [Line Items]        
Taxable income (loss) (15,865,000) (600,000) 22,935,000 600,000
Current income tax expense (benefit) (318,000) $ 0 459,000 $ 23,000
Operating loss carryforwards 227,100,000   227,100,000  
Federal and state research and development tax credits 6,800,000   $ 6,800,000  
Expiration date of U.S. federal income tax loss carryforwards     2022  
Domestic Tax Authority | Stock Compensation Deductions        
Operating Loss Carryforwards [Line Items]        
Operating loss carryforwards 29,300,000   $ 29,300,000  
Foreign Tax Authority        
Operating Loss Carryforwards [Line Items]        
Current income tax expense (benefit) (27,000)   (27,000)  
Operating loss carryforwards $ 116,700,000   $ 116,700,000  
XML 62 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 63 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814
Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Cash flows from operating activities    
Net loss $ (54,719,000) $ (103,548,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 12,202,000 6,870,000
Loss on disposal of property, plant and equipment 519,000 170,000
Unrealized and realized (appreciation) depreciation on equity securities (64,392,000) 48,944,000
Amortization of discount/premium on investments 298,000 1,121,000
Equity in net loss of affiliates 6,565,000 3,510,000
Stock-based compensation expense 26,524,000 14,872,000
Contribution of services by shareholder 0 1,485,000
Shares issued to nonemployee members of the Board of Directors 480,000 486,000
Shares issued as consideration for license agreement 59,579,000 0
Provision for bad debts 1,562,000 74,000
Deferred income taxes 374,000 0
Other noncash items 305,000 244,000
Receivables:    
Trade (12,014,000) 3,443,000
Related parties (11,182,000) (5,168,000)
Note 1,000 0
Other 6,390,000 (41,000)
Inventory 3,451,000 582,000
Prepaid expenses and other (4,005,000) (679,000)
Other assets (3,817,000) 89,000
Accounts payable (3,560,000) (1,197,000)
Accrued compensation and benefits 5,895,000 545,000
Other accrued liabilities 1,323,000 (820,000)
Deferred revenue 52,400,000 18,636,000
Deferred consideration (943,000) 0
Related party payables (67,000) (192,000)
Other long term liabilities 168,000 (234,000)
Net cash provided by (used in) operating activities 23,337,000 (10,808,000)
Cash flows from investing activities    
Purchases of investments (181,572,000) (60,478,000)
Maturities of investments 70,000,000 98,245,000
Purchases of equity securities and warrants (17,080,000) 0
Acquisitions of businesses, net of cash received (114,480,000) (67,117,000)
Acquisition of noncontrolling interest (1,566,000) 0
Investments in affiliates (4,699,000) (2,105,000)
Purchases of property, plant and equipment (9,841,000) (5,190,000)
Proceeds from sale of property, plant and equipment 420,000 151,000
Proceeds from notes receivable 1,500,000 0
Net cash used in investing activities (257,318,000) (36,494,000)
Cash flows from financing activities    
Proceeds from issuance of shares in a private placement 0 25,000,000
Proceeds from issuance of shares in public offerings, net of issuance costs 328,234,000 0
Advances from lines of credit 13,719,000 678,000
Repayments of advances from lines of credit (15,517,000) (4,213,000)
Proceeds from long term debt 81,000 268,000
Payments of long term debt (1,032,000) (156,000)
Payments of deferred consideration (6,252,000) 0
Proceeds from stock option exercises 12,208,000 1,274,000
Payment of stock issuance costs 0 (256,000)
Net cash provided by financing activities 331,441,000 22,595,000
Effect of exchange rate changes on cash and cash equivalents 507,000 (98,000)
Net increase (decrease) in cash and cash equivalents 97,967,000 (24,805,000)
Cash and cash equivalents    
Beginning of period 27,466,000 49,509,000
End of period 125,433,000 24,704,000
Supplemental disclosure of cash flow information    
Cash paid during the period for interest 1,119,000 47,000
Cash paid during the period for income taxes 1,165,000 0
Significant noncash financing and investing activities    
Note receivable as consideration for upfront fee from collaborator 5,000,000 10,000,000
Stock received as consideration for collaboration agreements 4,667,000 5,225,000
Stock issued in acquisitions, net 126,863,000 51,682,000
Stock issued to acquire noncontrolling interest 9,412,000 0
Noncash dividend to shareholders 172,419,000 0
Deferred consideration payable related to acquisition 11,440,000 20,115,000
Purchases of equipment included in accounts payable and other accrued liabilities $ 533,000 $ 0
XML 64 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814
Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2015
Dec. 31, 2014
Statement of Financial Position [Abstract]    
Common stock, no par value (in usd per share)
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares issued 116,359,041 100,557,932
Common stock, shares outstanding 116,359,041 100,557,932
XML 65 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814
Goodwill and Intangible Assets, net
 9 Months Ended
Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, net
Goodwill and Intangible Assets, net
The changes in the carrying amount of goodwill for the nine months ended September 30, 2015 are as follows:
Balance at December 31, 2014
$
101,059

Acquisitions
67,404

Foreign currency translation adjustment
(1,597
)
Balance at September 30, 2015
$
166,866


No goodwill or accumulated impairment losses existed as of September 30, 2015 and December 31, 2014.
Intangible assets consist of the following at September 30, 2015:
 
Weighted Average Useful Life (Years)
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net
Patents, related technologies and know-how
15.2
 
$
142,066

 
$
(15,141
)
 
$
126,925

Customer relationships
6.5
 
10,700

 
(2,255
)
 
8,445

Trademarks
8.4
 
5,900

 
(834
)
 
5,066

Covenant not to compete
2.0
 
395

 
(115
)
 
280

In-process research and development
 
 
115,568

 
—

 
115,568

Total
 
 
$
274,629

 
$
(18,345
)
 
$
256,284


Intangible assets consist of the following at December 31, 2014:
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net
Patents, related technologies and know-how
$
41,872

 
$
(10,849
)
 
$
31,023

Customer relationships
10,700

 
(806
)
 
9,894

Trademarks
5,900

 
(298
)
 
5,602

In-process research and development
19,428

 
—

 
19,428

Total
$
77,900

 
$
(11,953
)
 
$
65,947


Amortization expense was $2,857 and $1,290 for the three months ended September 30, 2015 and 2014, respectively and $6,434 and $2,664 for the nine months ended September 30, 2015 and 2014, respectively.
XML 66 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2015
Oct. 31, 2015
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2015  
Document Fiscal Year Focus 2015  
Document Fiscal Period Focus Q3  
Trading Symbol XON  
Entity Registrant Name INTREXON CORP  
Entity Central Index Key 0001356090  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   116,397,980
XML 67 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814
Lines of Credit and Long Term Debt
 9 Months Ended
Sep. 30, 2015
Debt Disclosure [Abstract]  
Lines of Credit and Long Term Debt
Lines of Credit and Long Term Debt
Lines of Credit
Trans Ova has a $6,000 revolving line of credit with First National Bank of Omaha which matures on May 1, 2016. The line of credit bears interest at the greater of 2.95% above the London Interbank Offered Rate or 3.00% and was 3.15% at September 30, 2015. As of September 30, 2015, there were no amounts outstanding. The amount available under the line of credit is based on eligible accounts receivable and inventory or the maximum line of credit amount.
Trans Ova's revolving line of credit is collateralized by certain of its assets and contain certain restricted covenants that include maintaining minimum tangible net worth, maximum allowable annual capital expenditures and working capital. Trans Ova was in compliance with these covenants as of September 30, 2015.
Exemplar has a $700 revolving line of credit with American State Bank which matures on November 1, 2016. The line of credit bears interest at 4.50% per annum. As of September 30, 2015, there was an outstanding balance of $475.
Long Term Debt
Long term debt consists of the following:
 
September 30,
2015
 
December 31,
2014
Notes payable
$
6,773

 
$
7,653

Royalty-based financing
1,857

 
1,926

Other
480

 
790

Long term debt
9,110

 
10,369

Less current portion
1,314

 
1,675

Long term debt, less current portion
$
7,796

 
$
8,694


Trans Ova has a note payable to American State Bank which matures in April 2033 and has an outstanding principal balance of $5,694 as of September 30, 2015. Trans Ova pays monthly installments of $39, which includes interest at 3.95%. The note payable is collateralized by all of Trans Ova's assets.
Trans Ova has a note payable to the Iowa Economic Development Authority which matures in July 2016 and has an outstanding principal balance of $550 as of September 30, 2015. Trans Ova pays quarterly installments of $183. The note payable in collateralized by certain parcels of Trans Ova's real estate.
Exemplar has notes payable with outstanding principal balances totaling $529 as of September 30, 2015. Exemplar pays monthly installments ranging from $1 to $4 with interest rates ranging from 0% to 3.00%. These notes mature from September 2018 to May 2020 and are collateralized by certain of Exemplar's real estate or letters of credit of certain of its members.
AquaBounty has a royalty-based financing grant from the Atlantic Canada Opportunities Agency ("ACOA"), a Canadian government agency, to provide funding of a research and development project. The total amount available under the award was $2,142, which AquaBounty claimed over a five year period. All amounts claimed by AquaBounty must be repaid in the form of a 10% royalty on any products commercialized out of this research and development project until fully paid. Because the timing of commercialization is subject to regulatory approval, the timing of repayment is uncertain. As of the acquisition date, AquaBounty had claimed $1,952 of the available funds and this amount was recorded at its acquisition date fair value of $1,107. The Company accretes the difference of $845 between the face value of amounts drawn and the acquisition date fair value over the expected period of repayment. Since the acquisition date, AquaBounty has claimed the remaining balance available under the grant, resulting in total long term debt of $1,857 as of September 30, 2015.
Future maturities of long term debt are as follows:
2015
$
506

2016
929

2017
382

2018
525

2019
340

2020
309

Thereafter
4,262

Total
$
7,253


The AquaBounty royalty-based financing grant is not included in the table above due to the uncertainty of the timing of repayment.
XML 68 R80.htm IDEA: XBRL DOCUMENT v3.3.0.814
Subsequent Events - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Nov. 09, 2015
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Subsequent Event [Line Items]          
Monthly compensation, in the form of equity   $ 8,385 $ 4,250 $ 26,524 $ 14,872
Third Security          
Subsequent Event [Line Items]          
Monthly service fee   $ 142 $ 85 $ 294 $ 173
Third Security | Subsequent Event          
Subsequent Event [Line Items]          
Monthly service fee $ 800        
Chief Executive Officer | Subsequent Event          
Subsequent Event [Line Items]          
Monthly compensation, in the form of equity $ 200        
XML 69 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814
Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Revenues        
Collaboration and licensing revenues $ 34,726 $ 12,656 $ 66,690 $ 32,257
Product revenues 9,446 4,115 32,645 4,124
Service revenues 8,945 4,261 32,157 4,261
Other revenues 250 165 615 196
Total revenues 53,367 21,197 132,107 40,838
Operating Expenses        
Cost of products 11,215 4,224 31,654 4,310
Cost of services 5,451 2,316 17,316 2,316
Research and development 21,598 14,851 121,286 41,343
Selling, general and administrative 23,019 14,853 74,320 43,870
Total operating expenses 61,283 36,244 244,576 91,839
Operating loss (7,916) (15,047) (112,469) (51,001)
Other Income (Expense), Net        
Unrealized and realized appreciation (depreciation) in fair value of equity securities (30,453) (37,089) 64,392 (48,944)
Interest expense (310) (230) (1,012) (309)
Interest income 567 202 1,211 349
Other income (expense), net 589 (79) 530 (110)
Total other income (expense), net (29,607) (37,196) 65,121 (49,014)
Equity in net loss of affiliates (2,429) (1,619) (6,565) (3,510)
Loss before income taxes (39,952) (53,862) (53,913) (103,525)
Income tax benefit (expense) 923 0 (806) (23)
Net loss (39,029) (53,862) (54,719) (103,548)
Net loss attributable to the noncontrolling interests 816 1,137 2,940 2,895
Net loss attributable to Intrexon $ (38,213) $ (52,725) $ (51,779) $ (100,653)
Net loss attributable to Intrexon per share, basic and diluted (usd per share) $ (0.34) $ (0.53) $ (0.47) $ (1.02)
Weighted average shares outstanding, basic and diluted 112,244,129 99,888,203 109,244,641 98,711,564
XML 70 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814
Collaboration and Licensing Revenue
 9 Months Ended
Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaboration and Licensing Revenue
Collaboration and Licensing Revenue
The Company's collaborations and licensing agreements provide for multiple deliverables to be delivered by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, performance of certain research and development services and may include obligations for certain manufacturing services. The Company typically groups these deliverables into two units of accounting based on the nature of the deliverables and the separation criteria. The first deliverable ("Unit of Accounting 1") includes the license to the Company's technology platform, the Company's participation on the collaboration committees and any research and development services associated with its technology platforms. The deliverables for Unit of Accounting 1 are combined because they cannot be individually separated. If applicable, the second deliverable ("Unit of Accounting 2") includes manufacturing services to be provided for any Company materials in an approved product. These services have standalone value and are contingent due to uncertainties on whether an approved product will ever be developed thereby requiring manufacture by the Company at that time. All upfront consideration is allocated to Unit of Accounting 1. Unit of Accounting 2 is determined to be a contingent deliverable at the inception of the collaboration due to the uncertainties surrounding whether an approved product will ever be developed and require manufacturing by the Company. The upfront consideration allocated to Unit of Accounting 1 is recognized over the expected life of the Company's technology platform using a straight-line approach.
The Company recognizes the reimbursement payments received for research and development services in the period when the services are performed and collection is reasonably assured. At the inception of each collaboration and licensing agreement, the Company determines whether any milestone payments are substantive and can be recognized when earned. The milestone payments are typically not considered substantive. Royalties related to product sales will be recognized when earned since payments relate directly to products that have been fully developed and for which the Company has satisfied all of its obligations.
The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration or licensing agreements, collaborators or licensees either consolidated or accounted for using the equity method, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation. The following table summarizes the amounts recorded in the consolidated statements of operations for each significant collaboration and licensing agreement for the three and nine months ended September 30, 2015 and 2014.
 
Three Months Ended September 30, 2015
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
645

 
$
4,006

 
$
4,651

Oragenics, Inc.
4,868

 
332

 
5,200

Fibrocell Science, Inc.
4,823

 
1,317

 
6,140

Genopaver, LLC
68

 
993

 
1,061

S & I Ophthalmic, LLC
—

 
1,193

 
1,193

OvaXon, LLC
—

 
549

 
549

Intrexon Energy Partners, LLC
625

 
3,185

 
3,810

Persea Bio, LLC
125

 
297

 
422

Ares Trading S.A.
1,597

 
260

 
1,857

Other
7,841

 
2,002

 
9,843

Total
$
20,592

 
$
14,134

 
$
34,726

 
Three Months Ended September 30, 2014
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
644

 
$
3,370

 
$
4,014

Oragenics, Inc.
261

 
3

 
264

Fibrocell Science, Inc.
449

 
1,014

 
1,463

Genopaver, LLC
68

 
360

 
428

S & I Ophthalmic, LLC
—

 
667

 
667

OvaXon, LLC
—

 
813

 
813

Intrexon Energy Partners, LLC
625

 
1,535

 
2,160

Other
443

 
2,404

 
2,847

Total
$
2,490

 
$
10,166

 
$
12,656

 
Nine Months Ended September 30, 2015
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
1,933

 
$
11,769

 
$
13,702

Oragenics, Inc.
5,437

 
408

 
5,845

Fibrocell Science, Inc.
5,719

 
4,500

 
10,219

Genopaver, LLC
205

 
2,460

 
2,665

S & I Ophthalmic, LLC
—

 
2,838

 
2,838

OvaXon, LLC
—

 
1,855

 
1,855

Intrexon Energy Partners, LLC
1,875

 
8,101

 
9,976

Persea Bio, LLC
375

 
553

 
928

Ares Trading S.A.
2,336

 
260

 
2,596

Other
9,446

 
6,620

 
16,066

Total
$
27,326

 
$
39,364

 
$
66,690


 
Nine Months Ended September 30, 2014
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
1,932

 
$
9,103

 
$
11,035

Oragenics, Inc.
784

 
588

 
1,372

Fibrocell Science, Inc.
1,345

 
2,759

 
4,104

Genopaver, LLC
205

 
1,204

 
1,409

S & I Ophthalmic, LLC
—

 
2,153

 
2,153

OvaXon, LLC
—

 
1,561

 
1,561

Intrexon Energy Partners, LLC
1,250

 
2,745

 
3,995

Other
1,373

 
5,255

 
6,628

Total
$
6,889

 
$
25,368

 
$
32,257


The following is a summary of the terms of the Company's significant collaborations and licensing agreements.
Merck Licensing Agreement
In March 2015, the Company signed a worldwide License and Collaboration Agreement ("Merck Agreement") with Ares Trading S.A. ("Ares Trading"), a subsidiary of the biopharmaceutical business of Merck KGaA, and ZIOPHARM through which the parties established a collaboration for the research and development and commercialization of certain products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. Pursuant to the Merck Agreement, the Company received a technology access fee of $115,000 as upfront consideration, of which $57,500 was paid to ZIOPHARM in accordance with the terms of the agreement. Upon the selection of the first two targets by Ares Trading, the Company is entitled to receive $10,000 payable in equal quarterly installments over two years, of which $6,250 is included in trade receivables and $3,750 in other long term assets on the consolidated balance sheet as of September 30, 2015. The Company will be entitled to receive a further $5,000 for each additional target selected by Ares Trading. The Company is also entitled to up to $413,000 of potential payments for substantive and non-substantive development and commercial milestones for each product, and royalties ranging from the lower-single digits to the low-teens of the net sales derived from the sale of products developed under the Merck Agreement. The Company may also receive up to $50,000 of further cash fees upon certain technical milestones as provided for in the agreement. The term of the Merck Agreement commenced in May 2015 and may be terminated by either party in the event of a material breach as defined in the agreement and may be terminated voluntarily by Ares Trading upon 90 days written notice to the Company. The Company will pay to ZIOPHARM 50% of all payments received for upfront fees, milestones, and royalties under the Merck Agreement. The remaining balance of deferred revenue associated with the upfront payment was $55,164 at September 30, 2015.
ZIOPHARM Collaborations
In January 2011, the Company entered into an ECC with ZIOPHARM, a related party. Pursuant to the ECC, ZIOPHARM received a license to the Company's technology platform within the field of oncology as defined more specifically in the agreement. Upon execution of the ECC, the Company received 3,636,926 shares of ZIOPHARM's common stock valued at $17,457 as upfront consideration. In addition to the deliverables discussed above, the Company transferred two clinical product candidates to ZIOPHARM that resulted in a separate unit of accounting for which $1,115 of the upfront consideration was allocated and recognized as collaboration revenue in 2011. The remaining $16,342 of upfront consideration was allocated to Unit of Accounting 1 discussed above. The Company is entitled to additional shares of common stock representing the lesser of (i) the original shares received or (ii) the number of shares representing 7.495% of ZIOPHARM's outstanding shares at the date of the dosing of the first patient in a Phase II clinical trial of a product candidate created, produced or developed by ZIOPHARM using the Company's technology ("ZIOPHARM Milestone"). In October 2012, the ZIOPHARM Milestone was achieved and the Company received 3,636,926 shares of ZIOPHARM's common stock valued at $18,330 as milestone consideration. Since the ZIOPHARM Milestone was not substantive, the Company allocated the ZIOPHARM Milestone to the applicable units of accounting and is recognizing it in a manner similar to these units of accounting. The remaining balance of deferred revenue associated with upfront and milestone payments was $21,260 and $23,193 at September 30, 2015 and December 31, 2014, respectively. The Company receives reimbursement payments for research and development services provided and manufacturing services for Company materials provided to ZIOPHARM during the ECC. Subject to certain expense allocations, ZIOPHARM will pay the Company 50% of the quarterly net profits derived from the sale of products developed from the ECC, as defined in the agreement. ZIOPHARM is responsible for conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of product candidates. The term of the ECC commenced in January 2011 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by ZIOPHARM upon 90 days written notice to the Company. In March 2015, in conjunction with the Merck Agreement, the Company and ZIOPHARM amended their existing ECC. The amendment modifies the scope of the ECC in connection with the Merck Agreement and provides that the Company will pay to ZIOPHARM 50% of all payments received for upfront fees, milestones and royalties under the Merck Agreement.
In September 2015, the Company entered into its second ECC with ZIOPHARM ("ZIOPHARM ECC 2"). Pursuant to the ECC, ZIOPHARM received a license to the Company's technology platform to develop and commercialize novel biotherapeutics for the treatment of patients with graft-versus-host disease, or GvHD. Upon execution of ZIOPHARM ECC 2, the Company received a technology access fee of $10,000, all of which is included in deferred revenue at September 30, 2015. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to ZIOPHARM during the ECC. ZIOPHARM will pay the Company 50% of quarterly net profits derived from the sale of products developed from ZIOPHARM ECC 2, as defined in the agreement.
ZIOPHARM is responsible for funding the further development of ZIOPHARM ECC 2 products towards the goal of commercialization, conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of the ZIOPHARM ECC 2 commenced in September 2015 and may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by ZIOPHARM upon 90 days written notice to the Company.
See Notes 13 and 17 for further discussion related to ZIOPHARM.
Oragenics Collaborations
In June 2012, the Company entered into an ECC with Oragenics, a publicly traded company focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health for humans and pets and a related party. Pursuant to the ECC, at the transaction effective date, Oragenics received a license to the Company's technology platform within the field of lantibiotics for the treatment of infectious diseases in humans and companion animals as defined more specifically in the agreement. Upon execution of the ECC, the Company received a technology access fee of 4,392,425 shares of Oragenics' common stock valued at $6,588 as upfront consideration. The Company is entitled to receive additional shares of common stock, or at Oragenics' option, receive a cash payment based upon the fair market value of the shares, upon the separate achievement of certain regulatory milestones of the first product candidate developed from the ECC ("Oragenics ECC 1 Milestones"). The Oragenics ECC 1 Milestones include: (i) 1% of Oragenics' outstanding shares as defined in the ECC agreement at the date of the filing of the first Investigative New Drug Application with the U.S. FDA for a product candidate created, produced or developed using the Company's technology ("Oragenics ECC 1 Product"); (ii) 1.5% of Oragenics' outstanding shares as defined in the ECC agreement at the date of the dosing of the first patient in the first Phase II clinical trial of an Oragenics ECC 1 Product; (iii) 2% of Oragenics' outstanding shares as defined in the ECC agreement at the date of the dosing of the first patient in the first Phase III clinical trial of an Oragenics ECC 1 Product; (iv) 2.5% of Oragenics' outstanding shares as defined in the ECC agreement at the date of the first New Drug Application or Biologics License Application with the U.S. FDA for an Oragenics ECC 1 Product, or alternatively the first equivalent regulatory filing with a foreign agency; and (v) 3% of Oragenics' outstanding shares as defined in the ECC agreement at the date of the granting of the first regulatory approval of an Oragenics ECC 1 Product. The remaining balance of deferred revenue associated with the upfront payment was $4,758 and $5,171 at September 30, 2015 and December 31, 2014, respectively. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during the ECC. Oragenics will pay the Company 25% of the quarterly profits derived from the sale of products developed from the ECC, as defined in the agreement.
Oragenics is responsible for funding the further development of lantibiotics toward the goal of commercialization, conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of the ECC commenced in June 2012 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Oragenics upon 90 days written notice to the Company.
In September 2013, the Company entered into its second ECC with Oragenics ("Oragenics ECC 2"). Pursuant to Oragenics ECC 2, at the transaction effective date, Oragenics received a license to the Company's technology platform to develop and commercialize probiotics, specifically the direct administration to humans of genetically modified probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus as defined more specifically in the agreement. Upon execution of Oragenics ECC 2, the Company received a technology access fee of 1,348,000 shares of Oragenics' common stock valued at $3,503 and a $1,956 convertible promissory note maturing on or before December 31, 2013 as upfront consideration. Prior to the maturity date, Oragenics had the right to convert the promissory note into shares of Oragenics' common stock subject to its shareholders' approval. The conversion price was equal to the closing price of Oragenics' common stock on the last trading day immediately prior to the date of conversion. In December 2013, Oragenics converted the promissory note into 698,241 shares of Oragenics' common stock. In September 2015, Oragenics and the Company mutually agreed to terminate Oragenics ECC 2 and accordingly, the Company recognized the remaining balance of the deferred revenue associated with the upfront payment.
In June 2015, the Company entered into its third ECC with Oragenics ("Oragenics ECC 3"). Pursuant to Oragenics ECC 3, at the transaction effective date, Oragenics received a license to the Company's technology platform within the field of biotherapeutics for use in certain treatments of oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus. Upon execution of Oragenics ECC 3, the Company received a technology access fee of a $5,000 convertible promissory note, which approximates fair value, maturing on or before December 31, 2015 as upfront consideration. Prior to the maturity date, Oragenics has the right to convert the promissory note into shares of Oragenics' common stock, subject to its shareholders' approval. The Company is also entitled to up to $22,000 of potential payments for development and commercial milestones for each Oragenics product developed from Oragenics ECC 3 and up to $10,000 of potential one-time payments for certain regulatory milestones under Oragenics ECC 3. The remaining balance of deferred revenue associated with the upfront payment was $4,815 at September 30, 2015. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during Oragenics ECC 3. Oragenics will pay the Company a royalty as a percentage in the low-teens of net sales derived from the sale of products developed from Oragenics ECC 3, as defined in the agreement.
Oragenics is responsible for funding the further development of Oragenics ECC 3 products towards the goal of commercialization, conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of Oragenics ECC 3 commenced in June 2015 and may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Oragenics upon 90 days written notice to the Company.
See Note 17 for a discussion of additional arrangements with Oragenics.
Fibrocell Science, Inc. Collaboration
In October 2012, the Company entered into an ECC with Fibrocell Science, Inc. ("Fibrocell"), a publicly traded, autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications and a related party. Pursuant to the ECC, at the transaction effective date, Fibrocell received a license to the Company's technology platform to develop and commercialize genetically modified and non-genetically modified autologous fibroblasts and autologous dermal cells in the United States of America. Upon execution of the ECC, the Company received a technology access fee of 1,317,520 shares of Fibrocell's common stock valued at $7,576 as upfront consideration. The number of shares received reflects a 1-for-25 reverse stock split of Fibrocell's common stock effective April 30, 2013. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Fibrocell during the ECC. On a quarterly basis, Fibrocell will pay the Company royalties of 7% of net sales up to $25,000 and 14% of net sales above $25,000 on each product developed from the ECC, as defined in the agreement. If Fibrocell uses the Company's technology platform to improve the production of a current or new Fibrocell product not developed from the ECC, Fibrocell will pay the Company a quarterly royalty equal to 33% of the cost of goods sold savings generated by the improvement, as defined in the agreement. Fibrocell is responsible for conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization and manufacturing of the product candidates. The term of the ECC commenced in October 2012 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Fibrocell upon 90 days written notice to the Company.
In June 2013, the Company entered into an amendment to the ECC with Fibrocell. The amendment expands the field of use defined in the ECC agreement. Under the terms of the amendment to the ECC, the Company received 1,243,781 shares of Fibrocell's common stock valued at $7,612 as a supplemental technology access fee. The Company allocated this additional consideration to the appropriate unit of accounting and is recognizing it consistent with the unit of accounting.
In January 2014, the Company entered into a second amendment to the ECC with Fibrocell. The second amendment further expanded the field of use defined in the ECC agreement. Under the terms of the second amendment to the ECC, the Company received 1,024,590 shares of Fibrocell's common stock valued at $5,225 as a technology access fee. The Company allocated this additional consideration to the appropriate unit of accounting. In September 2015, Fibrocell and the Company mutually agreed to terminate the second amendment to the ECC and accordingly, the Company recognized the remaining balance of deferred revenue associated with the related upfront payment. The remaining balance of deferred revenue associated with Fibrocell was $11,772 and $17,491 at September 30, 2015 and December 31, 2014, respectively.
See Note 17 for further discussion related to Fibrocell.
Genopaver Collaboration
In March 2013, the Company entered into an ECC with Genopaver, LLC ("Genopaver"), an affiliate of Third Security (Note 17) and a related party. Genopaver was formed for the purpose of entering into the ECC and developing and commercializing products in the field of the fermentative production of alkaloids through genetically modified cell-lines and substrate feeds for use as active pharmaceutical ingredients or as commercially sold intermediates in the manufacture of active pharmaceutical ingredients. Upon execution of the ECC, the Company received a technology access fee of $3,000 as upfront consideration. The remaining balance of deferred revenue associated with the upfront payment was $2,318 and $2,523 at September 30, 2015 and December 31, 2014, respectively. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC. Genopaver will pay the Company a royalty as a percentage in the lower-double digits on the quarterly gross profits of product sales from products developed under the ECC, as defined in the agreement. Genopaver is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in March 2013 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Genopaver upon 90 days written notice to the Company.
AquaBounty Collaboration
In February 2013, the Company entered into an ECC with AquaBounty, a majority-owned consolidated subsidiary. The Company will be reimbursed for research and development services as provided for in the ECC agreement. In the event of product sales from a product developed from the ECC, the Company will receive 16.66% of quarterly gross profits for each product, as defined in the agreement. All revenues and expenses related to this ECC are eliminated in consolidation.
S & I Ophthalmic Collaboration
In September 2013, the Company entered into an ECC with S & I Ophthalmic, a joint venture between the Company and Sun Pharmaceutical Subsidiary, an indirect subsidiary of Sun Pharmaceutical, an international specialty pharmaceutical company focused on chronic diseases (Note 4). The ECC grants S & I Ophthalmic an exclusive license to the Company's technology platform to develop and commercialize therapies in humans for the treatment of ocular diseases defined more specifically in the agreement. The Company will be reimbursed for research and development services pursuant to the agreement and manufacturing services for Company materials provided to S & I Ophthalmic during the ECC. Subject to certain expense allocations, S & I Ophthalmic will pay the Company royalties with percentages ranging from mid-single digits and above of the net sales derived from the sale of products developed under the ECC, as defined in the agreement. The term of the ECC commenced in September 2013 and continues until terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by S & I Ophthalmic upon 90 days written notice to the Company.
BioPop Collaboration
In October 2013, the Company entered into an ECC with BioPop, a majority-owned consolidated subsidiary. The ECC grants BioPop an exclusive license to the Company's technology platform to develop and commercialize artwork, children's toys and novelty goods that are derived from living organisms or are enabled by synthetic biology. The Company will be reimbursed for research and development services and manufacturing services as provided for in the ECC agreement. The Company is entitled to royalties in the mid-single digits as a percentage of the net product sales of a product developed under the ECC, as defined in the agreement. All revenues and expenses related to this ECC are eliminated in consolidation.
OvaXon Collaboration
In December 2013, the Company entered into an ECC with OvaXon, a joint venture between the Company and OvaScience, a life sciences company focused on infertility treatments (Note 4) and a related party. The ECC grants OvaXon an exclusive license to the Company's technology platform to create new applications for improving human and animal health. OvaScience also licensed certain technology to OvaXon pursuant to a separate license agreement. The Company will be reimbursed for research and development services and manufacturing services as provided for in the ECC agreement. The term of the ECC commenced in December 2013 and continues until terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by OvaXon upon 90 days written notice to the Company.
Intrexon Energy Partners Collaboration
In March 2014, the Company entered into an ECC with Intrexon Energy Partners, a joint venture between the Company and certain investors, including an affiliate of Third Security (Note 4), and a related party. The ECC grants Intrexon Energy Partners an exclusive license to the Company's technology platform to optimize and scale-up the Company's gas-to-liquid bioconversion platform for the production of certain fuels and lubricants. Upon execution of the ECC, the Company received a technology access fee of $25,000 as upfront consideration. The remaining balance of deferred revenue associated with the upfront payment was $21,250 and $23,125 at September 30, 2015 and December 31, 2014, respectively. The Company will be reimbursed for research and development services as provided for in the ECC agreement. The term of the ECC commenced in March 2014 and continues until March 2034 unless terminated prior to that date by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Intrexon Energy Partners upon 90 days written notice to the Company.
Persea Bio Collaboration
In December 2014, the Company entered into an ECC with Persea Bio, LLC ("Persea Bio"), an affiliate of Third Security (Note 17) and a related party. Persea Bio was formed for the purpose of entering into the ECC and developing and commercializing a food program, as defined in the agreement. Upon execution of the ECC, the Company received a technology access fee of $5,000 as upfront consideration. The remaining balance of deferred revenue associated with the upfront payment was $4,625 and $5,000 at September 30, 2015 and December 31, 2014, respectively. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC. Persea Bio will pay the Company royalties as a percentage in the lower-double digits on the quarterly gross profits of product sales from products derived from the ECC, as defined in the agreement. Persea Bio is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in December 2014 and continues until terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Persea Bio upon 90 days written notice to the Company.
Thrive Agrobiotics Collaboration
In September 2015, the Company entered into an ECC with Thrive Agrobiotics, an affiliate of Harvest (Note 17) and a related party. Thrive Agrobiotics was formed for the purpose of entering into the ECC and developing and commercializing products to improve the overall growth and feed efficiency in piglets. Upon execution of the ECC, the Company received a technology access fee in the form of equity in Thrive Agrobiotics valued at $1,667 as upfront consideration, all of which is included in deferred revenue as of September 30, 2015. The Company is also entitled to up to $5,500 of potential payments for development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC. Thrive Agrobiotics will pay the Company a royalty as a percentage in the lower-double digits on the quarterly gross profits of product sales from products developed under the ECC, as defined in the agreement. Thrive Agrobiotics is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in September 2015 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Thrive Agrobiotics upon 90 days written notice to the Company.
Deferred Revenue
Deferred revenue primarily consists of consideration received for upfront and milestone payments in connection with the Company's collaborations and licensing agreements, prepayments for research and development services performed for collaborators and licensees and prepayments for product and service revenues. Deferred revenue consists of the following:
 
September 30,
2015
 
December 31,
2014
Upfront and milestone payments
$
159,069

 
$
107,228

Prepaid research and development services
11,099

 
1,045

Prepaid product and service revenues
5,292

 
4,365

Other
794

 
571

Total
$
176,254

 
$
113,209

Current portion of deferred revenue
$
32,006

 
$
16,522

Long-term portion of deferred revenue
144,248

 
96,687

Total
$
176,254

 
$
113,209
XML 71 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814
Investments in Joint Ventures
 9 Months Ended
Sep. 30, 2015
Equity Method Investments and Joint Ventures [Abstract]  
Investments in Joint Ventures
Investments in Joint Ventures
Intrexon Energy Partners
In March 2014, the Company and certain investors (the "Investors"), including an affiliate of Third Security, LLC ("Third Security"), entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a joint venture formed to optimize and scale-up the Company's gas-to-liquid bioconversion platform for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to our technology for the use in bioconversion, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50%. In addition, Intrexon has committed to make additional capital contributions of up to $25,000, and the Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to $25,000, at the request of Intrexon Energy Partners' Board of Managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of September 30, 2015, the Company's remaining commitment was $20,426. The Company and the Investors have the right, but not the obligation, to make additional capital contributions above these limits when and if solicited by the Intrexon Energy Partners Board. Intrexon Energy Partners is governed by a board of managers which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members of the Intrexon Energy Partners Board are designated by a majority of the Investors.
See further discussion of the ECC at Note 5. See discussion of a concurrent private placement securities purchase made by the Investors at Note 13.
The Company's investment in Intrexon Energy Partners was $(1,591) and $(740) as of September 30, 2015 and December 31, 2014, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets.
OvaXon
In December 2013, the Company and OvaScience, Inc. ("OvaScience"), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, entered into a Limited Liability Company Agreement ("OvaXon LLC Agreement") to form OvaXon, LLC ("OvaXon"), a joint venture to create new applications for improving human and animal health. Both the Company and OvaScience made an initial capital contribution of $1,500 in January 2014 for a 50% membership interest in OvaXon. OvaXon is governed by the OvaXon board of managers ("OvaXon Board") which has four members, two each from the Company and OvaScience. In cases in which the OvaXon Board determines that additional capital contributions are necessary in order for OvaXon to conduct business and comply with its obligations, each of the Company and OvaScience have the right, but not the obligation, to make additional capital contributions to OvaXon subject to the OvaXon LLC Agreement.
Contemporaneously with the formation of the joint venture, the Company entered into an ECC with OvaXon (see Note 5).
The Company's investment in OvaXon was $242 and $(83) as of September 30, 2015 and December 31, 2014, respectively, and is included in investments in affiliates and other accrued liabilities, respectively, in the accompanying consolidated balance sheets.
S & I Ophthalmic
In September 2013, the Company entered into a Limited Liability Company Agreement ("Sun LLC Agreement") with Caraco Pharmaceutical Laboratories, Ltd. ("Sun Pharmaceutical Subsidiary"), an indirect subsidiary of Sun Pharmaceutical Industries Ltd. ("Sun Pharmaceutical"), an international specialty pharmaceutical company focused on chronic diseases, to form S & I Ophthalmic, LLC ("S & I Ophthalmic"). The Sun LLC Agreement governs the affairs and the conduct of business of S & I Ophthalmic. S & I Ophthalmic leverages experience and technology from both the Company and Sun Pharmaceutical. Both the Company and Sun Pharmaceutical Subsidiary made an initial capital contribution of $5,000 in October 2013 for a 50% membership interest in S & I Ophthalmic. S & I Ophthalmic is governed by a board of managers ("S & I Ophthalmic Board") which has four members, two each from the Company and Sun Pharmaceutical Subsidiary. In cases in which the S & I Ophthalmic Board determines that additional capital contributions are necessary in order for S & I Ophthalmic to conduct business and comply with its obligations, each of the Company and Sun Pharmaceutical Subsidiary have committed to making additional capital contributions to S & I Ophthalmic subject to certain limits defined in the agreement. Each has the right, but not the obligation, to make additional capital contributions above the defined limits when and if solicited by the S & I Ophthalmic Board.
Beginning on the seventh anniversary of the effective date of the Sun LLC Agreement, and upon the second anniversary thereafter, the Company, as well as Sun Pharmaceutical Subsidiary, may make a cash offer to purchase all of the other party's interest in S & I Ophthalmic. Upon receipt of such an offer, the other party must either agree to tender its interests at the offered price or submit a counteroffer at a price higher than the original offer. Such offer and counteroffer may continue until one party agrees to the other's price.
Contemporaneously with the formation of the joint venture, the Company entered into an ECC with S & I Ophthalmic (see Note 5).
The Company's investment in S & I Ophthalmic was $1,881 and $3,220 as of September 30, 2015 and December 31, 2014, respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets.
XML 72 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
Operating Leases
The Company leases facilities and certain equipment under noncancelable operating leases. The equipment leases are renewable at the option of the Company. At September 30, 2015, future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:
2015
$
739

2016
4,161

2017
3,381

2018
2,067

2019
1,889

2020
1,941

Thereafter
1,587

Total
$
15,765


Rent expense, including other facility expenses, was $2,167 and $2,518 for the three months ended September 30, 2015 and 2014, respectively, and $6,548 and $5,249 for the nine months ended September 30, 2015 and 2014, respectively.
The Company maintains subleases for certain of its facilities. Rental income under sublease agreements was $334 and $270 for the three months ended September 30, 2015 and 2014, respectively, and $1,153 and $532 for the nine months ended September 30, 2015 and 2014, respectively. Future rental income approximates $182 for 2015, $741 for 2016, and $96 for 2017.
Contingencies
In March 2012, Trans Ova was named as a defendant in a licensing and patent infringement suit brought by XY, Inc. alleging that certain of Trans Ova's activities breach a licensing agreement and infringe on patents that XY, Inc. allegedly owns. Trans Ova is reviewing, defending and filing counter claims in the case. The matter is scheduled to go to trial in the first half of 2016. Based on advice from legal counsel, Trans Ova believes that XY, Inc.'s complaints are without merit; however, no assurances can be given that this matter will be resolved in Trans Ova's favor.
The Company may become subject to claims and assessments from time to time in the ordinary course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of September 30, 2015 and December 31, 2014, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.
XML 73 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814
Income Taxes
 9 Months Ended
Sep. 30, 2015
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
Tax provisions for interim periods are calculated using an estimate of actual taxable income or loss for the respective period, rather than estimating the Company's annual effective income tax rate, as the Company is currently unable to reliably estimate its income for the full year. For the three months ended September 30, 2015, the Company had U.S. taxable loss of approximately $15,865, which resulted in an income tax benefit of $318 that was recognized to offset income tax expense recognized during the six months ended June 30, 2015. For the nine months ended September 30, 2015, the Company had U.S. taxable income of approximately $22,935, which, after offset of available loss carryforwards, resulted in $459 of current income tax expense due to the corporate alternative minimum tax. For the three and nine months ended September 30, 2015, the Company recognized $27 of current foreign income tax benefit. For the three months ended September 30, 2014, the Company had U.S. taxable loss of approximately $600, and no income tax benefit was recognized. For the nine months ended September 30, 2014, the Company had U.S. taxable income of approximately $600, which, after offset by available loss carryforwards, resulted in $23 of current income tax expense due to the corporate alternative minimum tax. For the three months ended September 30, 2015, the Company recorded deferred tax benefit of $578. For the nine months ended September 30, 2015, the Company recorded deferred tax expense of $374. There was no deferred tax expense for the three and nine months ended September 30, 2014. The Company's net deferred tax assets, excluding certain deferred tax liabilities totaling $21,550, are offset by a valuation allowance due to the Company's history of net losses combined with an inability to confirm recovery of the tax benefits of the Company's losses and other net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.
At September 30, 2015, the Company has loss carryforwards for U.S. federal income tax purposes of approximately $227,100 available to offset future taxable income and federal and state research and development tax credits of approximately $6,800, prior to consideration of annual limitations that may be imposed under Section 382. These carryforwards will begin to expire in 2022. Of these loss carryforwards, approximately $29,300 relates to benefits from stock compensation deductions that will be recorded as a component of paid-in capital when realized. The Company's direct foreign subsidiaries have foreign loss carryforwards of approximately $116,700, most of which do not expire.
XML 74 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814
Inventory
 9 Months Ended
Sep. 30, 2015
Inventory Disclosure [Abstract]  
Inventory
Inventory
Inventory consists of the following:
 
September 30,
2015
 
December 31,
2014
Supplies, semen and embryos
$
1,368

 
$
1,184

Work in process
6,135

 
5,637

Livestock
12,753

 
16,996

Feed
2,082

 
1,972

Total inventory
$
22,338

 
$
25,789
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.3.0.814
Property, Plant and Equipment, net - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Property, Plant and Equipment [Abstract]        
Depreciation expense $ 1,987 $ 1,807 $ 5,768 $ 4,206
XML 76 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814
Short-term and Long-term Investments
 9 Months Ended
Sep. 30, 2015
Investments, Debt and Equity Securities [Abstract]  
Short-term and Long-term Investments
Short-term and Long-term Investments
The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of September 30, 2015:
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate
Fair Value
U.S. government debt securities
$
226,567

 
$
291

 
$
—

 
$
226,858

Certificates of deposit
272

 
—

 
—

 
272

Total
$
226,839

 
$
291

 
$
—

 
$
227,130

The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of December 31, 2014:
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate
Fair Value
U.S. government debt securities
$
115,293

 
$
54

 
$
(12
)
 
$
115,335

Certificates of deposit
273

 
—

 
—

 
273

Total
$
115,566

 
$
54

 
$
(12
)
 
$
115,608


For more information on the Company's method for determining the fair value of its assets, see Note 2 – "Fair Value of Financial Instruments".
The estimated fair value of available-for-sale investments classified by their contractual maturities as of September 30, 2015 was as follows:
Due within one year
$
90,864

After one year through three years
136,266

Total
$
227,130


Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's investments were primarily a result of unfavorable changes in interest rates subsequent to the initial purchase of these investments and have been in a loss position for less than 12 months.
As of September 30, 2015 and December 31, 2014, the Company did not consider any of its investments to be other-than-temporarily impaired. When evaluating its investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer, the Company's ability and intent to hold the security and whether it is more likely than not that it will be required to sell the investment before recovery of its cost basis.
XML 77 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814
Fair Value Measurements
 9 Months Ended
Sep. 30, 2015
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements
The carrying amount of cash and cash equivalents, receivables, prepaid expenses and other current assets, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments.
The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at September 30, 2015:
 
Quoted Prices in Active Markets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
September 30,
2015
Assets
 
 
 
 
 
 
 
U.S. government debt securities (Note 6)
$
—

 
$
226,858

 
$
—

 
$
226,858

Equity securities (Note 5)
61,747

 
14,876

 
—

 
76,623

Other
—

 
417

 
—

 
417

Total
$
61,747

 
$
242,151

 
$
—

 
$
303,898

The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at December 31, 2014:
 
Quoted Prices in Active Markets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
December 31,
2014
Assets
 
 
 
 
 
 
 
U.S. government debt securities (Note 6)
$
—

 
$
115,335

 
$
—

 
$
115,335

Equity securities (Note 5)
143,927

 
20,962

 
—

 
164,889

Other
—

 
273

 
—

 
273

Total
$
143,927

 
$
136,570

 
$
—

 
$
280,497


The carrying values of the Company's long term debt approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates. Financial liabilities measured on a recurring basis were not significant at September 30, 2015 and December 31, 2014.
The method used to estimate the fair value of the Level 1 assets in the tables above is based on observable market data as these equity securities are publicly-traded. The method used to estimate the fair value of the Level 2 short-term and long-term investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. The method used to estimate the fair value of the Level 2 equity securities in the tables above is based on the quoted market price of the publicly-traded security, adjusted for a discount for lack of marketability.
During the nine months ended September 30, 2015, $8,307 of certain equity securities have been transferred from Level 2 to Level 1 as a result of no longer needing to apply a discount for lack of marketability to these transferred equity securities.
XML 78 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814
Property, Plant and Equipment, net
 9 Months Ended
Sep. 30, 2015
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment, net
Property, Plant and Equipment, net
Property, plant and equipment consist of the following:
 
September 30,
2015
 
December 31,
2014
Land and land improvements
$
9,085

 
$
7,565

Buildings and building improvements
7,311

 
7,265

Furniture and fixtures
1,608

 
1,236

Equipment
36,018

 
31,983

Leasehold improvements
6,998

 
6,382

Computer hardware and software
5,722

 
5,060

Construction and other assets in progress
1,927

 
1,002

 
68,669

 
60,493

Less: Accumulated depreciation and amortization
(26,468
)
 
(22,493
)
Property, plant and equipment, net
$
42,201

 
$
38,000


Depreciation expense was $1,987 and $1,807 for the three months ended September 30, 2015 and 2014, respectively, and $5,768 and $4,206 for the nine months ended September 30, 2015 and 2014, respectively.
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.3.0.814
Lines of Credit and Long Term Debt - Lines of Credit - Additional Information (Details) - Revolving Line of Credit
 9 Months Ended
Sep. 30, 2015
USD ($)
First National Bank of Omaha | Trans Ova Genetics, LC  
Line of Credit Facility [Line Items]  
Line of credit, maximum borrowing capacity $ 6,000,000
Minimum interest rate 3.00%
Actual interest rate at period end 3.15%
Line of credit, outstanding balance $ 0
First National Bank of Omaha | Trans Ova Genetics, LC | London Interbank Offered Rate (LIBOR)  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 2.95%
American State Bank | Exemplar Genetics, LLC  
Line of Credit Facility [Line Items]  
Line of credit, maximum borrowing capacity $ 700,000
Line of credit, outstanding balance $ 475,000
Interest rate 4.50%
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.3.0.814
Lines of Credit and Long Term Debt - Long Term Debt - Additional Information (Details) - USD ($)
 9 Months Ended
Sep. 30, 2015
Dec. 31, 2014
Mar. 15, 2013
Debt Instrument [Line Items]      
Outstanding principal balance $ 9,110,000 $ 10,369,000  
Notes payable to banks | Trans Ova Genetics, LC | American State Bank      
Debt Instrument [Line Items]      
Outstanding principal balance 5,694,000    
Periodic payment amount $ 39,000    
Interest rate 3.95%    
Notes payable      
Debt Instrument [Line Items]      
Outstanding principal balance $ 6,773,000 7,653,000  
Notes payable | Trans Ova Genetics, LC | Iowa Economic Development Authority      
Debt Instrument [Line Items]      
Outstanding principal balance 550,000    
Periodic principal payment amount 183,000    
Notes payable | Exemplar Genetics, LLC      
Debt Instrument [Line Items]      
Outstanding principal balance 529,000    
Notes payable | Exemplar Genetics, LLC | Minimum      
Debt Instrument [Line Items]      
Periodic payment amount $ 1,000    
Interest rate 0.00%    
Notes payable | Exemplar Genetics, LLC | Maximum      
Debt Instrument [Line Items]      
Periodic payment amount $ 4,000    
Interest rate 3.00%    
Royalty-based financing      
Debt Instrument [Line Items]      
Outstanding principal balance $ 1,857,000 $ 1,926,000  
Royalty-based financing | AquaBounty Technologies, Inc. | Atlantic Canada Opportunities Agency      
Debt Instrument [Line Items]      
Outstanding principal balance 1,857,000    
Amount available under financial grant for research and development $ 2,142,000    
Period to claim funding from government award 5 years    
Royalty rate to be paid 10.00%    
Amount claimed under financial grant     $ 1,952,000
Long term debt     1,107,000
Accreted difference between face value of amount drawn and acquisition date fair value     $ 845,000
XML 81 R63.htm IDEA: XBRL DOCUMENT v3.3.0.814
Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2015
Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 274,629 $ 77,900
Accumulated Amortization (18,345) (11,953)
Net 256,284 65,947
Patents, related technologies and know-how    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 142,066 41,872
Accumulated Amortization (15,141) (10,849)
Net 126,925 31,023
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 10,700 10,700
Accumulated Amortization (2,255) (806)
Net 8,445 9,894
Trademarks    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 5,900 5,900
Accumulated Amortization (834) (298)
Net 5,066 5,602
Covenant not to compete    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 395  
Accumulated Amortization (115)  
Net 280  
In-process research and development    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 115,568 19,428
Accumulated Amortization 0 0
Net $ 115,568 $ 19,428
Weighted Average | Patents, related technologies and know-how    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Useful Life (Years) 15 years 2 months 12 days  
Weighted Average | Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Useful Life (Years) 6 years 6 months  
Weighted Average | Trademarks    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Useful Life (Years) 8 years 4 months 24 days  
Weighted Average | Covenant not to compete    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Useful Life (Years) 2 years  
XML 82 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814
Property, Plant and Equipment, net (Tables)
 9 Months Ended
Sep. 30, 2015
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment
Property, plant and equipment consist of the following:
 
September 30,
2015
 
December 31,
2014
Land and land improvements
$
9,085

 
$
7,565

Buildings and building improvements
7,311

 
7,265

Furniture and fixtures
1,608

 
1,236

Equipment
36,018

 
31,983

Leasehold improvements
6,998

 
6,382

Computer hardware and software
5,722

 
5,060

Construction and other assets in progress
1,927

 
1,002

 
68,669

 
60,493

Less: Accumulated depreciation and amortization
(26,468
)
 
(22,493
)
Property, plant and equipment, net
$
42,201

 
$
38,000
XML 83 R51.htm IDEA: XBRL DOCUMENT v3.3.0.814
Collaboration and Licensing Revenue - Summarized Amount of Collaboration and Licensing Revenue Recorded in Consolidated Statements of Operations (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue $ 34,726 $ 12,656 $ 66,690 $ 32,257
ZIOPHARM Oncology, Inc.        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 4,651 4,014 13,702 11,035
Oragenics, Inc.        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 5,200 264 5,845 1,372
Fibrocell Science, Inc.        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 6,140 1,463 10,219 4,104
Genopaver, LLC        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 1,061 428 2,665 1,409
S & I Ophthalmic, LLC        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 1,193 667 2,838 2,153
OvaXon, LLC        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 549 813 1,855 1,561
Intrexon Energy Partners, LLC        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 3,810 2,160 9,976 3,995
Persea Bio, LLC        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 422   928  
Ares Trading S.A.        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 1,857   2,596  
Other Collaborations        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 9,843 2,847 16,066 6,628
Upfront and Milestone Payments        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 20,592 2,490 27,326 6,889
Upfront and Milestone Payments | ZIOPHARM Oncology, Inc.        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 645 644 1,933 1,932
Upfront and Milestone Payments | Oragenics, Inc.        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 4,868 261 5,437 784
Upfront and Milestone Payments | Fibrocell Science, Inc.        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 4,823 449 5,719 1,345
Upfront and Milestone Payments | Genopaver, LLC        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 68 68 205 205
Upfront and Milestone Payments | S & I Ophthalmic, LLC        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 0 0 0 0
Upfront and Milestone Payments | OvaXon, LLC        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 0 0 0 0
Upfront and Milestone Payments | Intrexon Energy Partners, LLC        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 625 625 1,875 1,250
Upfront and Milestone Payments | Persea Bio, LLC        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 125   375  
Upfront and Milestone Payments | Ares Trading S.A.        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 1,597   2,336  
Upfront and Milestone Payments | Other Collaborations        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 7,841 443 9,446 1,373
Research and Development Services        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 14,134 10,166 39,364 25,368
Research and Development Services | ZIOPHARM Oncology, Inc.        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 4,006 3,370 11,769 9,103
Research and Development Services | Oragenics, Inc.        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 332 3 408 588
Research and Development Services | Fibrocell Science, Inc.        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 1,317 1,014 4,500 2,759
Research and Development Services | Genopaver, LLC        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 993 360 2,460 1,204
Research and Development Services | S & I Ophthalmic, LLC        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 1,193 667 2,838 2,153
Research and Development Services | OvaXon, LLC        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 549 813 1,855 1,561
Research and Development Services | Intrexon Energy Partners, LLC        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 3,185 1,535 8,101 2,745
Research and Development Services | Persea Bio, LLC        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 297   553  
Research and Development Services | Ares Trading S.A.        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue 260   260  
Research and Development Services | Other Collaborations        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration And Licensing Revenue $ 2,002 $ 2,404 $ 6,620 $ 5,255
XML 84 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock Option Plans
 9 Months Ended
Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock Option Plans
Stock Option Plans
The Company records the fair value of stock options issued to employees and non-employees as of the grant date as stock-based compensation expense. Stock-based compensation expense for employees and non-employees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the consolidated statements of operations are presented below:
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Cost of products
$
21

 
$
5

 
$
76

 
$
5

Cost of services
98

 
50

 
301

 
50

Research and development
2,234

 
1,514

 
6,141

 
3,226

Selling, general and administrative
6,032

 
2,681

 
20,006

 
11,591

Total
$
8,385

 
$
4,250

 
$
26,524

 
$
14,872


Intrexon Stock Option Plans
In April 2008, Intrexon adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Intrexon's board of directors may grant share based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of September 30, 2015, there are 1,439,637 stock options outstanding under the 2008 Plan.
In July 2013, the Company adopted the 2013 Plan for employees and nonemployees pursuant to which Intrexon's board of directors may grant share based awards, including stock options and shares of common stock, to employees, officers, consultants, advisors and nonemployee directors. The 2013 Plan became effective upon the closing of the Company's initial public offering in August 2013, and as of September 30, 2015, there were 13,000,000 shares authorized for issuance under the 2013 Plan, of which 9,220,403 stock options were outstanding and 3,219,354 shares were available for grant.
Stock option activity under Intrexon's award plans was as follows:
 
Number of Shares
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2014
8,323,544

 
$
22.59

 
8.64
Granted
4,282,000

 
47.89

 
 
Adjustment due to dividend (Note 13)
312,795

 
25.40

 
 
Exercised
(790,265
)
 
(16.89
)
 
 
Forfeited
(1,467,488
)
 
(25.77
)
 
 
Expired
(546
)
 
(17.72
)
 
 
Balances at September 30, 2015
10,660,040

 
32.07

 
8.53
Exercisable at September 30, 2015
2,502,418

 
18.18

 
6.73
Vested and Expected to Vest at September 30, 2015(1)
8,803,769

 
30.69

 
8.37
(1)
The number of stock options expected to vest takes into account an estimate of expected forfeitures.
Total unrecognized compensation costs related to nonvested awards at September 30, 2015 and December 31, 2014 were $112,205 and $62,281, respectively, and are expected to be recognized over a weighted-average period of approximately three years.
Intrexon currently uses authorized and unissued shares to satisfy share award exercises.
Other Plans
As of September 30, 2015, there were 5,382,000 options outstanding under the AquaBounty 2006 Equity Incentive Plan ("AquaBounty Plan") at a weighted average exercise price of $0.26 per share of which 4,320,333 were exercisable. As of December 31, 2014 , there were 7,347,000 options outstanding under the AquaBounty Plan at a weighted average exercise price of $0.31 per share of which 6,171,520 were exercisable.
XML 85 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814
Subsequent Events
 9 Months Ended
Sep. 30, 2015
Subsequent Events [Abstract]  
Subsequent Events
Subsequent Events
In November 2015, the Company entered into a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security will provide the Company with certain professional, administrative, and other support services in exchange for a fee of $800 per month to be paid in the form of fully-vested shares of the Company's common stock. The payments made by the Company under the Services Agreement constitute, in the aggregate, an award under the 2013 Plan and will be subject to the terms of the 2013 Plan.
In November 2015, the Company entered into a compensation arrangement with the Company's CEO. Previously, the CEO did not receive compensation for his services as CEO of the Company. Under the new compensation arrangement, the CEO will receive compensation of $200 per month in the form of fully-vested shares of the Company's common stock. The shares of common stock will be issued pursuant to the terms of a Restricted Stock Unit Agreement under the 2013 Plan.
XML 86 R49.htm IDEA: XBRL DOCUMENT v3.3.0.814
Mergers and Acquisitions - Pro Forma Financial Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]        
Loss before income taxes $ (39,952) $ (53,862) $ (53,913) $ (103,525)
Net loss (39,029) (53,862) (54,719) (103,548)
Net loss attributable to the noncontrolling interests 816 1,137 2,940 2,895
2015 Business Acquisitions | Pro Forma        
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]        
Revenues 53,754 21,524 133,060 41,742
Loss before income taxes (43,979) (58,972) (66,686) (117,811)
Net loss (43,057) (58,586) (66,319) (116,100)
Net loss attributable to the noncontrolling interests 816 1,137 2,940 2,895
Net loss attributable to Intrexon $ (42,241) (57,449) $ (63,379) (113,205)
2014 Business Acquisitions | Pro Forma        
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]        
Revenues   31,507   88,629
Loss before income taxes   (51,864)   (98,816)
Net loss   (51,864)   (98,839)
Net loss attributable to the noncontrolling interests   1,200   3,260
Net loss attributable to Intrexon   $ (50,664)   $ (95,580)
XML 87 R41.htm IDEA: XBRL DOCUMENT v3.3.0.814
Organization and Basis of Presentation - Additional Information (Details)
Sep. 30, 2015
AquaBounty Technologies, Inc.  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]  
Parent ownership interest 63.00%
Biological & Popular Culture, Inc.  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]  
Parent ownership interest 51.00%
XML 88 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Statement of Comprehensive Income [Abstract]        
Net loss $ (39,029) $ (53,862) $ (54,719) $ (103,548)
Other comprehensive income (loss):        
Unrealized gain on investments 230 4 249 95
Foreign currency translation adjustments (3,102) 39 (5,374) (28)
Comprehensive loss (41,901) (53,819) (59,844) (103,481)
Comprehensive loss attributable to the noncontrolling interests 778 1,111 2,874 2,874
Comprehensive loss attributable to Intrexon $ (41,123) $ (52,708) $ (56,970) $ (100,607)
XML 89 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814
Mergers and Acquisitions
 9 Months Ended
Sep. 30, 2015
Business Combinations [Abstract]  
Mergers and Acquisitions
Mergers and Acquisitions
Oxitec Acquisition
In September 2015, pursuant to a Stock Purchase Agreement (the “Oxitec Purchase Agreement”), the Company acquired 100% of the issued outstanding share capital of Oxitec, a pioneering company in biological insect control solutions, thereby expanding the Company’s capabilities to address a broad range of global environment, health and agricultural challenges. The aggregated consideration paid consisted of (i) 1,359,343 shares of the Company’s common stock (the “Stock Consideration”) and (ii) $90,199 in cash (the “Cash Consideration”), inclusive of net cash and working capital adjustments, as defined in the Oxitec Purchase Agreement, totaling $9,449 which are to be paid within eighty-five days of the September closing date. Stock Consideration totaling 480,422 shares and Cash Consideration totaling $1,991 were withheld as escrow at closing and are issuable and payable, respectively, eighteen months after closing, subject to reduction for satisfaction of any claims for indemnification made by the Company under the Oxitec Purchase Agreement. Cash Consideration related to the net cash and working capital adjustments, as well as the withheld cash, are included in deferred consideration as of September 30, 2015. The results of Oxitec’s operations subsequent to the acquisition date have been included in the consolidated financial statements.
The fair value of the total consideration transferred was $146,394. The acquisition date fair value of the Stock Consideration and Cash Consideration is presented below:
Cash
$
90,199

Common shares
56,195

 
$
146,394


The fair value of the shares of the Company common stock issued was based on the quoted closing price of the Company’s common stock as of the date of the acquisition. The preliminary estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:
Cash
$
3,780

Trade receivables
125

Other receivables
7,395

Prepaid expenses and other
121

Property, plant, and equipment
1,198

Intangible assets
96,854

Total assets acquired
109,473

Accounts payable
1,187

Accrued compensation and benefits
246

Other accrued liabilities
210

Deferred revenue
120

Deferred tax liabilities
12,584

Total liabilities assumed
14,347

Net assets acquired
95,126

Goodwill
51,268

Total consideration
$
146,394


The fair value of assets acquired and liabilities assumed at the acquisition date are considered preliminary and are subject to revision when the valuation of intangible assets is finalized. The acquired intangibles assets primarily include in-process research and development and the fair values of the acquired assets were determined using the multi-period excess earning method, which is a variation of the income approach that converts future cash flows to single discounted present value amounts. The in-process research and development are currently indefinite-lived intangible assets and, accordingly, are not being amortized. Goodwill, which is not expected to be deductible for tax purposes, represents the assembled workforce and the potential for future Oxitec products and technologies.
As of September 30, 2015, the Company had incurred $1,644 of acquisition related costs, all of which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations for the three and nine months ended September 30, 2015.
Okanagan Acquisition
In April 2015, pursuant to a Stock Purchase Agreement (the “Okanagan Purchase Agreement”), the Company acquired 100% of the outstanding shares of Okanagan, the pioneering agricultural company behind the world's first non-browning apple. In addition to supporting Okanagan's further commercialization and exploitation of its apple products, the Company expects to utilize its proprietary technologies to assist Okanagan in the development of further novel beneficial plant traits. Pursuant to the Okanagan Purchase Agreement, the former shareholders of Okanagan received an aggregate of 707,853 shares of the Company’s common stock, and $10,000 cash in exchange for all shares in Okanagan. The results of Okanagan's operations subsequent to the acquisition date have been included in the consolidated financial statements.
The fair value of the total consideration transferred was $40,933. The acquisition date fair value of each class of consideration transferred is presented below:
Cash
$
10,000

Common shares
30,933

 
$
40,933


The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock as of the date of the acquisition. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below along with subsequent adjustments during the measurement period to the fair value of assets acquired and liabilities assumed. The adjustments resulted from revisions to the valuation of intangible assets.
 
Initial Estimated Fair Value
 
Adjustments
 
Adjusted Fair Value
Cash
$
58

 
$
—

 
$
58

Trade receivables
16

 
—

 
16

Other receivables
49

 
—

 
49

Property, plant, and equipment
32

 
—

 
32

Intangible assets
33,800

 
2,700

 
36,500

Total assets acquired
33,955

 
2,700

 
36,655

Accounts payable
181

 
—

 
181

Deferred revenue
181

 
—

 
181

Deferred tax liabilities
8,145

 
702

 
8,847

Total liabilities assumed
8,507

 
702

 
9,209

Net assets acquired
25,448

 
1,998

 
27,446

Goodwill
15,485

 
(1,998
)
 
13,487

Total consideration
$
40,933

 
$
—

 
$
40,933


The acquired intangible assets primarily include developed technology, patents and know-how and the fair values of the acquired assets were determined using the with and without method, which is a variation of the income approach that utilizes estimated cash flows with all assets in place at the valuation date and estimated cash flows with all assets in place except the intangible assets at the valuation date. The intangible assets are being amortized over a useful life of fourteen years. Goodwill, which is not expected to be deductible for tax purposes, represents potential future applications of Okanagan's technology to other fruits, including additional apple varietals, and anticipated buyer-specific synergies arising from the combination of the Company's and Okanagan's technologies.
The Company incurred $341 of acquisition-related costs, of which $267 is included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the nine months ended September 30, 2015.
ActoGeniX Acquisition
In February 2015, the Company acquired 100% of the membership interests of ActoGeniX NV ("ActoGeniX"), a European clinical stage biopharmaceutical company, pursuant to a Stock Purchase Agreement (the "ActoGeniX Purchase Agreement"). ActoGeniX's platform technology complements our broad collection of technologies available for current and future collaborators. Pursuant to the ActoGeniX Purchase Agreement, the former members of ActoGeniX received an aggregate of 965,377 shares of the Company's common stock and $32,739 in cash in exchange for all membership interests of ActoGeniX. The results of ActoGeniX's operations subsequent to the acquisition date have been included in the consolidated financial statements.
The fair value of the total consideration transferred was $72,474. The acquisition date fair value of each class of consideration transferred is presented below:
Cash
$
32,739

Common shares
39,735

 
$
72,474


The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock as of the date of the acquisition. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below along with subsequent adjustments during the measurement period to the fair value of assets acquired and liabilities assumed. The adjustments resulted from the difference between estimated and actual accrued expenses.
 
Initial Estimated Fair Value
 
Adjustments
 
Adjusted Fair Value
Cash
$
3,180

 
$
—

 
$
3,180

Other receivables
305

 
—

 
305

Prepaid expenses and other
31

 
—

 
31

Property, plant and equipment
209

 
—

 
209

Intangible assets
68,100

 
—

 
68,100

Other assets
23

 
—

 
23

Total assets acquired
71,848

 
—

 
71,848

Accounts payable
230

 
—

 
230

Accrued compensation and benefits
624

 
(428
)
 
196

Other accrued liabilities
307

 
(54
)
 
253

Deferred revenue
732

 
—

 
732

Deferred tax liabilities
612

 
—

 
612

Total liabilities assumed
2,505

 
(482
)
 
2,023

Net assets acquired
69,343

 
482

 
69,825

Goodwill
3,131

 
(482
)
 
2,649

Total consideration
$
72,474

 
$
—

 
$
72,474


The acquired intangible assets primarily include in-process research and development, and the fair values of the acquired assets were determined using the multi-period excess earnings and with-and-without methods, which are both variations of the income approach that convert future cash flows to single discounted present value amounts. During the three months ended September 30, 2015, the Company re-evaluated the acquired in-process research and development and determined that it was no longer an indefinite-lived intangible asset. The Company assigned it a useful life of eighteen years and began amortization in August 2015. Goodwill, which is not expected to be deductible for tax purposes, represents the assembled workforce and anticipated buyer-specific synergies arising from the combination of the Company's and ActoGeniX's technologies.
The Company incurred $418 of acquisition-related costs, of which $381 is included in selling, general and administrative expenses in the accompanying consolidated statements of operations for the nine months ended September 30, 2015.
Trans Ova Acquisition
In August 2014, the Company acquired 100% of the membership interests of Trans Ova, a provider of bovine reproductive technologies, pursuant to an Amended and Restated Membership Interest Purchase Agreement (the "Trans Ova Purchase Agreement"). The Company and Trans Ova intend to build upon Trans Ova's current platform with new capabilities with a goal of achieving higher levels of delivered value to dairy and beef cattle producers. Pursuant to the Trans Ova Purchase Agreement, the former members of Trans Ova received an aggregate of 1,444,388 shares of the Company's common stock and $63,625 in cash, and will receive deferred cash consideration valued at $20,115 in exchange for all membership interests of Trans Ova. The deferred cash consideration is payable in three equal installments upon the first, second, and third anniversaries of the transaction date. The Trans Ova Purchase Agreement also provides for payment to the former members of Trans Ova a portion of certain cash proceeds in the event there is an award under certain litigation matters pending as of the transaction date to which Trans Ova is a party. The results of Trans Ova's operations subsequent to the acquisition date have been included in the consolidated financial statements, including revenues of $18,283 and $64,743 and net income (loss) of $(3,655) and $530 for the three and nine months ended September 30, 2015, respectively, and revenues of $8,502 and net loss of $481 for the three and nine months ended September 30, 2014.
The fair value of the total consideration transferred, including the noncontrolling interest in a majority-owned subsidiary of Trans Ova, was $127,875. The acquisition date fair value of each class of consideration transferred and noncontrolling interest is presented below:
Cash
$
63,625

Common shares
32,802

Deferred cash consideration
20,115

Total consideration transferred
116,542

Fair value of noncontrolling interest
11,333

Total
$
127,875


The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock as of the date of the acquisition. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown in the table below.
Cash
$
960

Trade receivables
18,693

Related party receivables
1,219

Inventory
18,476

Prepaid expenses and other
590

Property, plant and equipment
21,164

Intangible assets
23,700

Other assets
147

Total assets acquired
84,949

Accounts payable
3,317

Accrued compensation and benefits
913

Other accrued liabilities
271

Deferred revenue
4,458

Lines of credit
4,091

Related party payables
1,246

Long term debt
9,090

Total liabilities assumed
23,386

Net assets acquired
61,563

Goodwill
66,312

Total consideration and fair value of noncontrolling interest
$
127,875


The fair value of acquired inventory was determined using the cost approach, which establishes value based on the cost of reproducing or replacing the asset. The fair value of acquired property, plant and equipment was determined using the cost approach and the market approach. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets. The acquired intangible assets include various developed technologies and know-how, customer relationships, and trademarks, and the fair values of these assets were determined using the relief-from-royalty, multi-period excess earnings, and with-and-without methods, which are all variations of the income approach. The acquired intangible assets are being amortized over useful lives ranging from three to nine years. Goodwill, which will be deductible for tax purposes, represents the assembled workforce, potential future expansion of Trans Ova business lines and anticipated buyer-specific synergies arising from the combination of the Company's and Trans Ova's technologies.
In conjunction with a prior transaction associated with Trans Ova's subsidiary, ViaGen, in September 2012, the Company may be obligated to make certain future contingent payments to the former equity holders of ViaGen, up to a total of $6,000 if certain revenue targets, as defined in the share purchase agreement, are met.  The Company does not expect these revenue targets to be met and accordingly has assigned no value to this liability.
The Company incurred $713 of costs primarily for legal and due diligence services related to this acquisition, of which $372 and $684 is included in selling, general and administrative expenses in the accompanying consolidated statements of operations for the three and nine months ended September 30, 2014, respectively.
In February 2015, the Company acquired, through an exchange offer, the remaining outstanding membership interests of Trans Ova's majority-owned subsidiary, Exemplar, for $1,566 in cash and 307,074 shares of Company common stock.
Medistem Acquisition
In March 2014, the Company acquired 100% of the outstanding common stock and securities convertible into common stock of Medistem, Inc. ("Medistem"), an entity engaged in the development of Endometrial Regenerative Cells ("ERCs"), for a combination of cash and Company common stock. The acquisition allows the Company to employ its synthetic biology platforms to engineer a diverse array of cell-based therapeutic candidates using Medistem's multipotent ERCs. Pursuant to the terms of the merger agreement, Medistem equity holders received 714,144 shares of the Company's common stock and $4,920 in cash in exchange for the outstanding Medistem common stock and securities convertible into common stock. Additionally, Medistem had issued the Company two promissory notes in the amount of $707, including accrued interest, both of which were settled upon closing of the merger. Certain members of Medistem's management surrendered a total of 17,695 shares of their merger consideration to reimburse the Company for required payroll tax withholdings. The results of Medistem's operations subsequent to the acquisition date have been included in the consolidated financial statements.
The fair value of the total consideration transferred was $24,995. The acquisition date fair value of each class of consideration transferred is presented below:
 
Cash
$
4,920

Common shares
19,368

Settlement of promissory notes
707

 
$
24,995


The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock as of the date of the acquisition. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown in the table below.
Cash
$
8

Intangible assets
4,824

Total assets acquired
4,832

Accounts payable
644

Accrued compensation and benefits
67

Other accrued expenses
50

Total liabilities assumed
761

Net assets acquired
4,071

Goodwill
20,924

Total consideration
$
24,995


The fair value of acquired intangible assets was determined using the cost approach. The acquired intangible assets consist of in-process research and development, which is an indefinite-lived intangible asset. The goodwill consists of buyer-specific synergies between the Company's and Medistem's technologies present. The goodwill is not expected to be deductible for tax purposes.
The Company incurred $680 of acquisition-related costs, of which $310 is included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the nine months ended September 30, 2014.
Unaudited Condensed Pro Forma Financial Information
The results of operations of the 2015 acquisitions discussed above are included in the consolidated statements of operations beginning on the day after the acquisition date. The following unaudited condensed pro forma financial information for the three and nine months ended September 30, 2015 and 2014 is presented as if the acquisitions had been consummated on January 1, 2014:
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
 
Pro forma
Revenues
$
53,754

 
$
21,524

 
$
133,060

 
$
41,742

Loss before income taxes
(43,979
)
 
(58,972
)
 
(66,686
)
 
(117,811
)
Net loss
(43,057
)
 
(58,586
)
 
(66,319
)
 
(116,100
)
Net loss attributable to the noncontrolling interests
816

 
1,137

 
2,940

 
2,895

Net loss attributable to Intrexon
(42,241
)
 
(57,449
)
 
(63,379
)
 
(113,205
)

The results of operations of the 2014 acquisitions discussed above are included in the consolidated statements of operations beginning on the day after their respective acquisition dates. The following unaudited condensed pro forma financial information for the three and nine months ended September 30, 2014 is presented as if the acquisitions had been consummated on January 1, 2013:
 
Three Months Ended 
 September 30, 2014
 
Nine Months Ended 
 September 30, 2014
 
Pro forma
Revenues
$
31,507

 
$
88,629

Loss before income taxes
(51,864
)
 
(98,816
)
Net loss
(51,864
)
 
(98,839
)
Net loss attributable to the noncontrolling interests
1,200

 
3,260

Net loss attributable to Intrexon
(50,664
)
 
(95,580
)
XML 90 R58.htm IDEA: XBRL DOCUMENT v3.3.0.814
Inventory - Schedule of Inventory (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Inventory [Line Items]    
Inventory $ 22,338 $ 25,789
Supplies, semen and embryos    
Inventory [Line Items]    
Inventory 1,368 1,184
Work in process    
Inventory [Line Items]    
Inventory 6,135 5,637
Livestock    
Inventory [Line Items]    
Inventory 12,753 16,996
Feed    
Inventory [Line Items]    
Inventory $ 2,082 $ 1,972
XML 91 R69.htm IDEA: XBRL DOCUMENT v3.3.0.814
Shareholders' Equity - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2015
Jun. 30, 2015
Jan. 31, 2015
Mar. 31, 2014
Jun. 30, 2015
Sep. 30, 2015
Sep. 30, 2014
Schedule of Capitalization, Equity [Line Items]              
Shares of common stock issued 5,609,756   4,312,500 972,004      
Price per share of common stock (in usd per share) $ 41.00   $ 27.00 $ 25.72      
Shares issued in public offerings, net of issuance costs $ 218,193   $ 110,041     $ 328,234  
Underwriting discounts and commissions 11,500   6,086        
Offering expenses capitalized by the Company $ 306   $ 311        
Proceeds from issuance of shares in a private placement       $ 25,000   $ 0 $ 25,000
ZIOPHARM Oncology, Inc.              
Schedule of Capitalization, Equity [Line Items]              
Noncash dividend, shares   17,830,305          
Realized gain on equity securities         $ 81,401    
Affiliates of Third Security              
Schedule of Capitalization, Equity [Line Items]              
Shares of common stock issued     555,556 243,001      
Proceeds from issuance of shares in a private placement       $ 6,250      
Overallotment Option Exercise By Underwriters              
Schedule of Capitalization, Equity [Line Items]              
Shares of common stock issued 731,707   562,500        
XML 92 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2015
Accounting Policies [Abstract]  
Principles of Consolidation
Principles of Consolidation
The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.
Unaudited Financial Information
Unaudited Financial Information
The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with U.S. GAAP. Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of September 30, 2015 and results of operations and cash flows for the interim periods ended September 30, 2015 and 2014. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2015, or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014.
Revenue Recognition
Revenue Recognition
The Company generates revenue through contractual agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement, (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement, (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities, and (iv) royalties on sales of products arising from the collaboration or licensing agreement.
The Company's collaboration and licensing agreements typically contain multiple elements, or deliverables, including technology licenses, research and development services, and in certain cases manufacturing services. The Company identifies the deliverables within the agreements and evaluates which deliverables represent separate units of accounting. Analyzing the agreements to identify deliverables requires the use of judgment. A deliverable is considered a separate unit of accounting when the deliverable has value to the collaborator or licensee on a standalone basis based on the consideration of the relevant facts and circumstances for each agreement.
Consideration received is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. When available, the relative selling price for each deliverable is determined using vendor specific objective evidence ("VSOE") of the selling price or third-party evidence of the selling price, if VSOE does not exist. If neither VSOE nor third-party evidence of the selling price exists, the Company uses its best estimate of the selling price ("BESP") for the deliverable. The amount of allocable consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. The Company recognizes the revenue allocated to each unit of accounting as the Company delivers the related goods or services. If the Company determines that certain deliverables should be treated as a single unit of accounting, then the revenue is recognized using either a proportional performance or straight-line method, depending on whether the Company can reasonably estimate the level of effort required to complete its performance obligations under an arrangement and whether such performance obligations are provided on a best-efforts basis. As the Company cannot reasonably estimate its performance obligations related to its collaborators or licensees, the Company recognizes revenue on a straight-line basis over the period it expects to complete its performance obligations.
The terms of the Company's agreements may provide for milestone payments upon achievement of certain defined events. The Company applies the Milestone Method for recognizing milestone payments. Under the Milestone Method, the Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:
(1)
The consideration is commensurate with either the entity's performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the entity's performance to achieve the milestone;
(2)
The consideration relates solely to past performance; and
(3)
The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.
In the event that a milestone is not considered substantive, the Company recognizes the milestone consideration as revenue using the same method applied to upfront payments.
Research and development services are a deliverable satisfied by the Company in accordance with the terms of the collaboration and licensing agreements and the Company considers these services to be inseparable from the license to the core technology; therefore, reimbursements of services performed are recognized as revenue. Because reimbursement (i) is contingent upon performance of the services by the Company, (ii) does not include a profit component, and (iii) does not relate to any future deliverable, the revenue is recognized during the period in which the related services are performed and collection of such amounts is reasonably assured. Payments received for manufacturing services will be recognized when the earnings process related to the manufactured materials has been completed. Royalties to be received under the agreements will be recognized as earned.
From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. When no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue.
The Company also generates products and services revenue through sales of advanced reproductive technologies, including bovine embryos derived from the Company's embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock used in production. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) services have been rendered or delivery has occurred such that risk of loss has passed to the customer, (iii) the price is fixed or determinable, and (iv) collection from the customer is reasonably assured.
Research and Development
Research and Development
The Company considers that regulatory and other uncertainties inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, and the costs of consultants, certain in-licensed technology rights, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Indirect research and development costs include depreciation, amortization and other indirect overhead expenses.
The Company has research and development arrangements with third parties that include upfront and milestone payments and primarily relate to collaborations. At September 30, 2015 and December 31, 2014, the Company had research and development commitments with third parties that had not yet been incurred totaling $6,576 and $2,183, respectively. The commitments are generally cancellable by the Company at any time upon written notice.
Cash and Cash Equivalents
Cash and Cash Equivalents
All highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions with high quality credit ratings. Recoverability of investments is dependent upon the performance of the issuer.
Short-term and Long-term Investments
Short-term and Long-term Investments
At September 30, 2015, investments include short-term and long-term investments in U.S. government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company's written investment policy requires investments to be explicitly rated by two of the three following rating services: Standard & Poor's, Moody's and/or Fitch and to have a minimum rating of A1, P1 and/or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer.
Equity Securities
Equity Securities
The Company holds equity securities received and/or purchased from certain collaborators. Other than investments accounted for using the equity method, the Company elected the fair value option to account for its equity securities held in these collaborators. These equity securities are recorded at fair value at each reporting date and are subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments are reported in the consolidated statement of operations. The fair value of these equity securities is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these collaborators. These equity securities are classified as noncurrent in the consolidated balance sheet since the Company does not intend to sell these equity securities within one year.
The Company records the fair value of securities received on the date the collaboration is consummated or the milestone is achieved using the closing, quoted price of the collaborator's security on that date, assuming the transfer of consideration is considered perfunctory. If the transfer of the consideration is not considered perfunctory, the Company considers the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluates whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concludes that a discount should be applied, the fair value of the securities is adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:
Level 1:
 
Quoted prices in active markets for identical assets and liabilities;
 
 
Level 2:
 
Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and
 
 
Level 3:
 
Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.
Concentrations of Risk
Concentrations of Risk
Due to the Company's mix of fixed and variable rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of September 30, 2015, gross unrealized losses on the Company's short-term and long-term investments were immaterial. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses.
Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of trade receivables. The Company controls credit risk through credit approvals, credit limits and monitoring procedures. The Company performs ongoing credit evaluations of its customers, but generally does not require collateral to support accounts receivable.
Equity Method Investments
Equity Method Investments
The Company is party to three strategic joint ventures (Note 4). The Company accounts for its investments in these joint ventures and for its investment in Thrive Agrobiotics, Inc. ("Thrive Agrobiotics") (Note 5) using the equity method of accounting since the Company has the ability to exercise significant influence, but not control, over the operating activities of these entities.
Variable Interest Entities
Variable Interest Entities
The Company identifies entities that (i) do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIE" or "VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE.
Trade Receivables
Trade Receivables
Trade receivables consist of credit extended to the Company's customers and collaborators in the normal course of business and are reported net of an allowance for doubtful accounts. The Company reviews its customer accounts on a periodic basis and records bad debt expense for specific amounts the Company evaluates as uncollectible. Past due status is determined based upon contractual terms. Amounts are written off at the point when collection attempts have been exhausted. Management estimates uncollectible amounts considering such factors as current economic conditions and historic and anticipated customer performance. This estimate can fluctuate due to changes in economic, industry or specific customer conditions which may require adjustment to the allowance recorded by the Company. Management has included amounts believed to be uncollectible in the allowance for doubtful accounts.
Inventory
Inventory
The Company's inventory primarily includes adult female cows which are used in certain production processes and are recorded at acquisition cost using the first-in, first-out method or at market, whichever is lower. Work-in-process inventory includes allocations of production costs and facility costs for products currently in production and is recorded at the lower of cost or market. Significant declines in the price of cows could result in unfavorable adjustments to inventory balances.
Property, Plant and Equipment
Property, Plant and Equipment
Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are generally expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets are as follows:
 
  
Years
Land improvements
 
4–20
Buildings and building improvements
  
3–23
Furniture and fixtures
  
1–7
Equipment
  
1–10
Computer hardware and software
  
1–7

Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to fourteen years.
Goodwill
Goodwill
Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized (Note 3). Goodwill is reviewed for impairment at least annually. The Company performs a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the two-step goodwill impairment test. If this is the case, the two-step goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the two-step goodwill impairment test is not required.
If the two-step goodwill impairment test is required, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, an indication of goodwill impairment exists for the reporting unit and the entity must perform step two of the impairment test. Under step two, an impairment loss is recognized for any excess of the carrying amount of the reporting unit's goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation and the residual fair value after this allocation is the implied fair value of the reporting unit goodwill. Fair value of the reporting unit is determined using a discounted cash flow analysis. If the fair value of the reporting unit exceeds its carrying amount, step two does not need to be performed.
The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review.
Intangible Assets
Intangible Assets
Intangible assets subject to amortization consist of patents, related technologies and know-how; customer relationships; trademarks; and a covenant not to compete acquired as a result of mergers and acquisitions (Note 3). These intangible assets are subject to amortization, were recorded at fair value at the date of acquisition and are stated net of accumulated amortization. Indefinite-lived intangible assets consist of in-process research and development acquired in mergers and acquisitions (Note 3) and were recorded at fair value at the dates of the respective acquisitions.
The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible assets are expected to be realized. The intangible assets are amortized over their remaining estimated useful lives, ranging from two to eighteen years for the patents, related technologies and know-how; customer relationships; trademarks; and the covenant not to compete.
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets
Long-lived assets to be held and used, including property, plant and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.
Indefinite-lived intangible assets, including in-process research and development, are tested for impairment annually, or more frequently if events or circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of their fair value to carrying value, without consideration of any recoverability test. The Company monitors the progression of its in-process research and development, as the likelihood of success is contingent upon commercial development or regulatory approval.
Foreign Currency Translation
Foreign Currency Translation
The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into United States dollars at the exchange rates in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in the consolidated statement of comprehensive loss. Revenue and expense amounts are translated at average rates during the period.
Income Taxes
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.
Net Loss per Share
Net Loss per Share
Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.
Segment Information
Segment Information
The Company has determined that it operates in one segment. The Company applies its technologies to create products and services which may be either sold directly to customers or developed through collaboration with third parties.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
In September 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-16, Business Combinations: Simplifying the Accounting for Measurement-Period Adjustments ("ASU 2015-16"). ASU 2015-16 eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Rather, the acquirer must recognize adjustments during the period in which the amounts are determined, including the effect on earnings of any amounts that would have been recorded in previous periods. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, with early adoption permitted. The Company elected to early adopt this guidance and there was no significant impact on the Company's consolidated financial statements.
In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330) - Simplifying the Measurement of Inventory ("ASU 2015-11"). The provisions of ASU 2015-11 provide guidance for simplifying the calculation for subsequent measurement of inventory measured using the first-in-first-out or average cost methods. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2016, and is effective for the Company for the year ending December 31, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.
In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810) - Amendments to the Consolidation Analysis ("ASU 2015-02"). The provisions of ASU 2015-02 provide guidance which changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. This guidance is effective for annual periods and interim periods within those annual periods, beginning after December 15, 2015, with early adoption permitted. The Company elected to early adopt this guidance and there was no significant impact on the Company's consolidated financial statements.
In May 2014, the FASB issued ASU 2014-9, Revenue from Contracts with Customers ("ASU 2014-9"). The FASB issued ASU 2014-9 to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance was originally effective for annual periods and interim periods within those annual periods beginning after December 15, 2016 and early adoption was not permitted. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606) - Deferral of the Effective Date ("ASU 2015-14"), which deferred the effective date of the guidance in ASU 2014-9 by one year to December 15, 2017 for interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016, and is effective for the Company for the year ending December 31, 2018. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.
Reclassifications
Reclassifications
Certain insignificant reclassifications have been made to the prior interim period consolidated financial statements to conform to the current interim period presentation.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
XML 93 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 476 431 1 true 130 0 false 11 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.dna.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.dna.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Operations Sheet http://www.dna.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 1003000 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.dna.com/role/ConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 1004000 - Statement - Consolidated Statements of Shareholders' and Total Equity Sheet http://www.dna.com/role/ConsolidatedStatementsOfShareholdersAndTotalEquity Consolidated Statements of Shareholders' and Total Equity Statements 6 false false R7.htm 1005000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.dna.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101100 - Disclosure - Organization and Basis of Presentation Sheet http://www.dna.com/role/OrganizationAndBasisOfPresentation Organization and Basis of Presentation Notes 8 false false R9.htm 2102100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2103100 - Disclosure - Mergers and Acquisitions Sheet http://www.dna.com/role/MergersAndAcquisitions Mergers and Acquisitions Notes 10 false false R11.htm 2111100 - Disclosure - Investments in Joint Ventures Sheet http://www.dna.com/role/InvestmentsInJointVentures Investments in Joint Ventures Notes 11 false false R12.htm 2112100 - Disclosure - Collaboration and Licensing Revenue Sheet http://www.dna.com/role/CollaborationAndLicensingRevenue Collaboration and Licensing Revenue Notes 12 false false R13.htm 2114100 - Disclosure - Short-term and Long-term Investments Sheet http://www.dna.com/role/ShortTermAndLongTermInvestments Short-term and Long-term Investments Notes 13 false false R14.htm 2115100 - Disclosure - Fair Value Measurements Sheet http://www.dna.com/role/FairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 2116100 - Disclosure - Inventory Sheet http://www.dna.com/role/Inventory Inventory Notes 15 false false R16.htm 2117100 - Disclosure - Property, Plant and Equipment, net Sheet http://www.dna.com/role/PropertyPlantAndEquipmentNet Property, Plant and Equipment, net Notes 16 false false R17.htm 2119100 - Disclosure - Goodwill and Intangible Assets, net Sheet http://www.dna.com/role/GoodwillAndIntangibleAssetsNet Goodwill and Intangible Assets, net Notes 17 false false R18.htm 2120100 - Disclosure - Lines of Credit and Long Term Debt Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebt Lines of Credit and Long Term Debt Notes 18 false false R19.htm 2121100 - Disclosure - Income Taxes Sheet http://www.dna.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 2122100 - Disclosure - Shareholders' Equity Sheet http://www.dna.com/role/ShareholdersEquity Shareholders' Equity Notes 20 false false R21.htm 2123100 - Disclosure - Stock Option Plans Sheet http://www.dna.com/role/StockOptionPlans Stock Option Plans Notes 21 false false R22.htm 2124100 - Disclosure - License Agreement Sheet http://www.dna.com/role/LicenseAgreement License Agreement Notes 22 false false R23.htm 2125100 - Disclosure - Commitments and Contingencies Sheet http://www.dna.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 23 false false R24.htm 2126100 - Disclosure - Related Party Transactions Sheet http://www.dna.com/role/RelatedPartyTransactions Related Party Transactions Notes 24 false false R25.htm 2127100 - Disclosure - Net Loss per Share Sheet http://www.dna.com/role/NetLossPerShare Net Loss per Share Notes 25 false false R26.htm 2128100 - Disclosure - Subsequent Events Sheet http://www.dna.com/role/SubsequentEvents Subsequent Events Notes 26 false false R27.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.dna.com/role/SummaryOfSignificantAccountingPolicies 27 false false R28.htm 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.dna.com/role/SummaryOfSignificantAccountingPolicies 28 false false R29.htm 2303301 - Disclosure - Mergers and Acquisitions (Tables) Sheet http://www.dna.com/role/MergersAndAcquisitionsTables Mergers and Acquisitions (Tables) Tables http://www.dna.com/role/MergersAndAcquisitions 29 false false R30.htm 2312301 - Disclosure - Collaboration and Licensing Revenue (Tables) Sheet http://www.dna.com/role/CollaborationAndLicensingRevenueTables Collaboration and Licensing Revenue (Tables) Tables http://www.dna.com/role/CollaborationAndLicensingRevenue 30 false false R31.htm 2314301 - Disclosure - Short-term and Long-term Investments (Tables) Sheet http://www.dna.com/role/ShortTermAndLongTermInvestmentsTables Short-term and Long-term Investments (Tables) Tables http://www.dna.com/role/ShortTermAndLongTermInvestments 31 false false R32.htm 2315301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.dna.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.dna.com/role/FairValueMeasurements 32 false false R33.htm 2316301 - Disclosure - Inventory (Tables) Sheet http://www.dna.com/role/InventoryTables Inventory (Tables) Tables http://www.dna.com/role/Inventory 33 false false R34.htm 2317301 - Disclosure - Property, Plant and Equipment, net (Tables) Sheet http://www.dna.com/role/PropertyPlantAndEquipmentNetTables Property, Plant and Equipment, net (Tables) Tables http://www.dna.com/role/PropertyPlantAndEquipmentNet 34 false false R35.htm 2319301 - Disclosure - Goodwill and Intangible Assets, net (Tables) Sheet http://www.dna.com/role/GoodwillAndIntangibleAssetsNetTables Goodwill and Intangible Assets, net (Tables) Tables http://www.dna.com/role/GoodwillAndIntangibleAssetsNet 35 false false R36.htm 2320301 - Disclosure - Lines of Credit and Long Term Debt (Tables) Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebtTables Lines of Credit and Long Term Debt (Tables) Tables http://www.dna.com/role/LinesOfCreditAndLongTermDebt 36 false false R37.htm 2322301 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.dna.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.dna.com/role/ShareholdersEquity 37 false false R38.htm 2323301 - Disclosure - Stock Option Plans (Tables) Sheet http://www.dna.com/role/StockOptionPlansTables Stock Option Plans (Tables) Tables http://www.dna.com/role/StockOptionPlans 38 false false R39.htm 2325301 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.dna.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.dna.com/role/CommitmentsAndContingencies 39 false false R40.htm 2327301 - Disclosure - Net Loss per Share (Tables) Sheet http://www.dna.com/role/NetLossPerShareTables Net Loss per Share (Tables) Tables http://www.dna.com/role/NetLossPerShare 40 false false R41.htm 2401401 - Disclosure - Organization and Basis of Presentation - Additional Information (Details) Sheet http://www.dna.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails Organization and Basis of Presentation - Additional Information (Details) Details 41 false false R42.htm 2402403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 42 false false R43.htm 2402404 - Disclosure - Summary of Significant Accounting Policies - Summarized Financial Data (Details) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesSummarizedFinancialDataDetails Summary of Significant Accounting Policies - Summarized Financial Data (Details) Details 43 false false R44.htm 2402405 - Disclosure - Summary of Significant Accounting Policies - Trade Receivables - Rollforward of Allowance for Doubtful Accounts (Details) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesTradeReceivablesRollforwardOfAllowanceForDoubtfulAccountsDetails Summary of Significant Accounting Policies - Trade Receivables - Rollforward of Allowance for Doubtful Accounts (Details) Details 44 false false R45.htm 2402406 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details) Details 45 false false R46.htm 2403402 - Disclosure - Mergers and Acquisitions - Additional Information (Details) Sheet http://www.dna.com/role/MergersAndAcquisitionsAdditionalInformationDetails Mergers and Acquisitions - Additional Information (Details) Details 46 false false R47.htm 2403403 - Disclosure - Mergers and Acquisitions - Fair Value of Consideration Transferred (Details) Sheet http://www.dna.com/role/MergersAndAcquisitionsFairValueOfConsiderationTransferredDetails Mergers and Acquisitions - Fair Value of Consideration Transferred (Details) Details 47 false false R48.htm 2403404 - Disclosure - Mergers and Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) Sheet http://www.dna.com/role/MergersAndAcquisitionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails Mergers and Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) Details 48 false false R49.htm 2403405 - Disclosure - Mergers and Acquisitions - Pro Forma Financial Information (Details) Sheet http://www.dna.com/role/MergersAndAcquisitionsProFormaFinancialInformationDetails Mergers and Acquisitions - Pro Forma Financial Information (Details) Details 49 false false R50.htm 2411401 - Disclosure - Investments in Joint Ventures - Additional Information (Details) Sheet http://www.dna.com/role/InvestmentsInJointVenturesAdditionalInformationDetails Investments in Joint Ventures - Additional Information (Details) Details 50 false false R51.htm 2412402 - Disclosure - Collaboration and Licensing Revenue - Summarized Amount of Collaboration and Licensing Revenue Recorded in Consolidated Statements of Operations (Details) Sheet http://www.dna.com/role/CollaborationAndLicensingRevenueSummarizedAmountOfCollaborationAndLicensingRevenueRecordedInConsolidatedStatementsOfOperationsDetails Collaboration and Licensing Revenue - Summarized Amount of Collaboration and Licensing Revenue Recorded in Consolidated Statements of Operations (Details) Details 51 false false R52.htm 2412403 - Disclosure - Collaboration and Licensing Revenue - Additional Information (Details) Sheet http://www.dna.com/role/CollaborationAndLicensingRevenueAdditionalInformationDetails Collaboration and Licensing Revenue - Additional Information (Details) Details 52 false false R53.htm 2412404 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) Sheet http://www.dna.com/role/CollaborationAndLicensingRevenueSummaryOfDeferredRevenueDetails Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) Details 53 false false R54.htm 2414402 - Disclosure - Short-term and Long-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Short-term and Long-term Investments (Details) Sheet http://www.dna.com/role/ShortTermAndLongTermInvestmentsSummaryOfAmortizedCostGrossUnrealizedGainsAndLossesAndFairValueOfShortTermAndLongTermInvestmentsDetails Short-term and Long-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Short-term and Long-term Investments (Details) Details 54 false false R55.htm 2414403 - Disclosure - Short-term and Long-term Investments - Summary of Estimated Fair Value of Available-for-Sale Investments Classified by Contractual Maturities (Details) Sheet http://www.dna.com/role/ShortTermAndLongTermInvestmentsSummaryOfEstimatedFairValueOfAvailableForSaleInvestmentsClassifiedByContractualMaturitiesDetails Short-term and Long-term Investments - Summary of Estimated Fair Value of Available-for-Sale Investments Classified by Contractual Maturities (Details) Details 55 false false R56.htm 2415402 - Disclosure - Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.dna.com/role/FairValueMeasurementsSummaryOfPlacementInFairValueHierarchyOfFinancialAssetsThatAreMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) Details 56 false false R57.htm 2415403 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 57 false false R58.htm 2416402 - Disclosure - Inventory - Schedule of Inventory (Details) Sheet http://www.dna.com/role/InventoryScheduleOfInventoryDetails Inventory - Schedule of Inventory (Details) Details 58 false false R59.htm 2417402 - Disclosure - Property, Plant and Equipment, net - Schedule of Property Plant and Equipment (Details) Sheet http://www.dna.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails Property, Plant and Equipment, net - Schedule of Property Plant and Equipment (Details) Details 59 false false R60.htm 2417403 - Disclosure - Property, Plant and Equipment, net - Additional Information (Details) Sheet http://www.dna.com/role/PropertyPlantAndEquipmentNetAdditionalInformationDetails Property, Plant and Equipment, net - Additional Information (Details) Details 60 false false R61.htm 2419402 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Changes in Carrying Amount of Goodwill (Details) Sheet http://www.dna.com/role/GoodwillAndIntangibleAssetsNetScheduleOfChangesInCarryingAmountOfGoodwillDetails Goodwill and Intangible Assets, net - Schedule of Changes in Carrying Amount of Goodwill (Details) Details 61 false false R62.htm 2419403 - Disclosure - Goodwill and Intangible Assets, net - Additional Information (Details) Sheet http://www.dna.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails Goodwill and Intangible Assets, net - Additional Information (Details) Details 62 false false R63.htm 2419404 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details) Sheet http://www.dna.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details) Details 63 false false R64.htm 2420402 - Disclosure - Lines of Credit and Long Term Debt - Lines of Credit - Additional Information (Details) Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebtLinesOfCreditAdditionalInformationDetails Lines of Credit and Long Term Debt - Lines of Credit - Additional Information (Details) Details 64 false false R65.htm 2420403 - Disclosure - Lines of Credit and Long Term Debt - Components of Long Term Debt (Details) Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebtComponentsOfLongTermDebtDetails Lines of Credit and Long Term Debt - Components of Long Term Debt (Details) Details 65 false false R66.htm 2420404 - Disclosure - Lines of Credit and Long Term Debt - Long Term Debt - Additional Information (Details) Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebtLongTermDebtAdditionalInformationDetails Lines of Credit and Long Term Debt - Long Term Debt - Additional Information (Details) Details 66 false false R67.htm 2420405 - Disclosure - Lines of Credit and Long Term Debt - Schedule of Future Maturities of Long Term Debt (Details) Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails Lines of Credit and Long Term Debt - Schedule of Future Maturities of Long Term Debt (Details) Details 67 false false R68.htm 2421401 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 68 false false R69.htm 2422402 - Disclosure - Shareholders' Equity - Additional Information (Details) Sheet http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails Shareholders' Equity - Additional Information (Details) Details 69 false false R70.htm 2422403 - Disclosure - Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) Sheet http://www.dna.com/role/ShareholdersEquityComponentsOfAccumulatedOtherComprehensiveLossDetails Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) Details 70 false false R71.htm 2423402 - Disclosure - Stock Option Plans - Additional Information (Details) Sheet http://www.dna.com/role/StockOptionPlansAdditionalInformationDetails Stock Option Plans - Additional Information (Details) Details 71 false false R72.htm 2423403 - Disclosure - Stock Option Plans - Stock Compensation Expense (Details) Sheet http://www.dna.com/role/StockOptionPlansStockCompensationExpenseDetails Stock Option Plans - Stock Compensation Expense (Details) Details 72 false false R73.htm 2423404 - Disclosure - Stock Option Plans - Schedule of Stock Option Activity (Details) Sheet http://www.dna.com/role/StockOptionPlansScheduleOfStockOptionActivityDetails Stock Option Plans - Schedule of Stock Option Activity (Details) Details 73 false false R74.htm 2424401 - Disclosure - License Agreement - Additional Information (Details) Sheet http://www.dna.com/role/LicenseAgreementAdditionalInformationDetails License Agreement - Additional Information (Details) Details 74 false false R75.htm 2425402 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments Under Noncancelable Operating Leases (Details) Sheet http://www.dna.com/role/CommitmentsAndContingenciesFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails Commitments and Contingencies - Future Minimum Lease Payments Under Noncancelable Operating Leases (Details) Details 75 false false R76.htm 2425403 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.dna.com/role/CommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 76 false false R77.htm 2426401 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 77 false false R78.htm 2427402 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Sheet http://www.dna.com/role/NetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Details 78 false false R79.htm 2427403 - Disclosure - Net Loss per Share - Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share (Details) Sheet http://www.dna.com/role/NetLossPerSharePotentiallyDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails Net Loss per Share - Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share (Details) Details 79 false false R80.htm 2428401 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://www.dna.com/role/SubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 80 false false All Reports Book All Reports In ''Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Consolidated Statements of Cash Flows'', column(s) 1, 2, 3 are contained in other reports, so were removed by flow through suppression. xon-20150930.xml xon-20150930_cal.xml xon-20150930_def.xml xon-20150930_lab.xml xon-20150930_pre.xml xon-20150930.xsd true true XML 94 R74.htm IDEA: XBRL DOCUMENT v3.3.0.814
License Agreement - Additional Information (Details) - USD ($)
 1 Months Ended 9 Months Ended
Jan. 31, 2015
Sep. 30, 2015
Other Commitments [Line Items]    
Shares issued as consideration of license agreement (in shares) 2,100,085  
Research and development    
Other Commitments [Line Items]    
Payment of license fees $ 59,579,000  
ZIOPHARM Oncology, Inc.    
Other Commitments [Line Items]    
Annual funding commitment, term   3 years
Minimum | ZIOPHARM Oncology, Inc.    
Other Commitments [Line Items]    
Annual funding commitment, amount   $ 15,000,000
Maximum | ZIOPHARM Oncology, Inc.    
Other Commitments [Line Items]    
Annual funding commitment, amount   $ 20,000,000
XML 95 R38.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock Option Plans (Tables)
 9 Months Ended
Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Employee Service Share-based Compensation Allocation
Stock-based compensation costs included in the consolidated statements of operations are presented below:
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Cost of products
$
21

 
$
5

 
$
76

 
$
5

Cost of services
98

 
50

 
301

 
50

Research and development
2,234

 
1,514

 
6,141

 
3,226

Selling, general and administrative
6,032

 
2,681

 
20,006

 
11,591

Total
$
8,385

 
$
4,250

 
$
26,524

 
$
14,872
Schedule of Stock Option Activity
Stock option activity under Intrexon's award plans was as follows:
 
Number of Shares
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2014
8,323,544

 
$
22.59

 
8.64
Granted
4,282,000

 
47.89

 
 
Adjustment due to dividend (Note 13)
312,795

 
25.40

 
 
Exercised
(790,265
)
 
(16.89
)
 
 
Forfeited
(1,467,488
)
 
(25.77
)
 
 
Expired
(546
)
 
(17.72
)
 
 
Balances at September 30, 2015
10,660,040

 
32.07

 
8.53
Exercisable at September 30, 2015
2,502,418

 
18.18

 
6.73
Vested and Expected to Vest at September 30, 2015(1)
8,803,769

 
30.69

 
8.37
(1)
The number of stock options expected to vest takes into account an estimate of expected forfeitures.
XML 96 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814
Shareholders' Equity
 9 Months Ended
Sep. 30, 2015
Equity [Abstract]  
Shareholders' Equity
Shareholders' Equity
Issuances of Common Stock
In August 2015, the Company closed a public offering of 5,609,756 shares of its common stock, inclusive of 731,707 shares of common stock sold by the Company pursuant to the full exercise of an overallotment option granted to the underwriters in connection with the offering, at a public offering price of $41.00 per share. The aggregate proceeds of the offering were $218,193, net of underwriting discounts of $11,500 and offering expenses paid by the Company of approximately $306, all of which were capitalized.
In January 2015, the Company closed a public offering of 4,312,500 shares of its common stock, inclusive of 562,500 shares of common stock sold by the Company pursuant to the full exercise of an overallotment option granted to the underwriters in connection with the offering and 555,556 shares of common stock purchased by affiliates of Third Security (Note 17), at a public offering price of $27.00 per share. The aggregate proceeds of the offering were $110,041, net of underwriting discounts and commissions of $6,086 and offering expenses paid by the Company of approximately $311, all of which were capitalized.
In March 2014 and concurrent with the formation of Intrexon Energy Partners, the Company entered into securities purchase agreements with each of the Investors in Intrexon Energy Partners for the private placement of 972,004 shares of the Company's common stock at a price per share of $25.72 for gross proceeds of $25,000. Each Investor purchased an amount proportionate to its investment in Intrexon Energy Partners, including 243,001 shares, or $6,250, purchased by an affiliate of Third Security (Note 17).
Dividend to Shareholders
In June 2015, the Company distributed to its shareholders 17,830,305 shares of ZIOPHARM common stock, representing all of the equity interests of ZIOPHARM held by the Company and resulting in a realized gain of $81,401. The distribution constituted a dividend to shareholders of record as of June 4, 2015. In connection with the distribution, pursuant to the terms of the Company's equity incentive plans, the conversion terms of all outstanding options for shares of the Company's stock as of June 4, 2015 were adjusted to reflect the value of the distribution with respect to shares of the Company's common stock.
Components of Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive loss were as follows:
 
September 30,
2015
 
December 31,
2014
Unrealized gain on investments
$
291

 
$
42

Foreign currency translation adjustments
(5,486
)
 
(46
)
Total accumulated other comprehensive loss
$
(5,195
)
 
$
(4
)